PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	RIVARA, FP; KOEPSELL, TD; JURKOVICH, GJ; GURNEY, JG; SODERBERG, R				RIVARA, FP; KOEPSELL, TD; JURKOVICH, GJ; GURNEY, JG; SODERBERG, R			THE EFFECTS OF ALCOHOL-ABUSE ON READMISSION FOR TRAUMA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							SCREENING-TEST; INJURIES; INTOXICATION; EMERGENCY; ACCIDENTS	Objective.-To determine the effect of admission for trauma with concurrent acute alcohol intoxication or chronic alcohol abuse on the risk of subsequent recurrence of trauma. Design.-Prospective cohort study. Setting.-Level I regional trauma center. Patients.-A total of 2578 patients 18 years or older admitted with blunt or penetrating trauma within 24 hours of injury and surviving to discharge. All patients had a blood alcohol concentration (BAC) test, a gamma-glutamyltransferase (GGT) test, and the short Michigan Alcohol Screening Test (SMAST) performed on admission. Main Outcome Measurement.-Readmission to the trauma center for new trauma. Average follow-up was 28 months (range, 16 to 40 months). Results.-The overall rate of readmission for new injuries was 1.3 per 1000 patient-months of follow-up. Patients who were intoxicated on the initial admission (BAC >22 mmol/L [100 mg/dL]) were 2.5-fold as likely to be readmitted than those not intoxicated (95% confidence limits, 1.6, 3.9). The relative risks for patients with positive SMAST scores and abnormal GGT values were 2.2 (95% confidence limits, 1.4, 3.5) and 3.5 (95% confidence limits, 2.2, 5.5), respectively. The increased risks remained significant for intoxication and abnormal GGT values after adjustment for gender, race, Medicaid status, and mechanism of injury. Conclusion.-Alcohol abuse is associated with an increased risk of readmission for new trauma. Trauma patients should be screened for alcohol problems; referral of problem drinkers for appropriate care may decrease their risk of admission for subsequent trauma.	UNIV WASHINGTON, DEPT EPIDEMIOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT PEDIAT, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT HLTH SERV, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT SURG, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	RIVARA, FP (corresponding author), HARBORVIEW INJURY PREVENT & RES CTR, 325 9TH AVE, ZX-10, SEATTLE, WA 98104 USA.							BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Baker SP, 1992, THE INJURY FACT BOOK, V2nd; CESARE J, 1990, J TRAUMA, V30, P176, DOI 10.1097/00005373-199002000-00007; CHANG G, 1988, JAMA-J AM MED ASSOC, V260, P2533, DOI 10.1001/jama.260.17.2533; COX DR, 1972, J R STAT SOC B, V34, P187; DEVGUN MS, 1985, ALCOHOL CLIN EXP RES, V9, P235, DOI 10.1111/j.1530-0277.1985.tb05742.x; GENTILELLO LM, 1988, AM J SURG, V156, P558, DOI 10.1016/S0002-9610(88)80553-1; JURKOVICH GJ, 1992, ANN EMERG MED, V21, P704, DOI 10.1016/S0196-0644(05)82783-0; JURKOVICH GJ, 1993, JAMA-J AM MED ASSOC, V270, P51, DOI 10.1001/jama.270.1.51; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LOWENFELS AB, 1984, ANN EMERG MED, V13, P1056, DOI 10.1016/S0196-0644(84)80070-0; MACKENZIE EJ, 1988, ICDMAP DETERMINING I; PAPOZ L, 1986, BRIT MED J, V292, P1234, DOI 10.1136/bmj.292.6530.1234; PATEL S, 1975, J CLIN PATHOL, V28, P414, DOI 10.1136/jcp.28.5.414; POKORNY AD, 1972, AM J PSYCHIAT, V129, P342, DOI 10.1176/ajp.129.3.342; RIVARA FP, 1993, ARCH SURG-CHICAGO, V128, P907; ROSKALI S, 1974, CLIN CHEM, V20, P1121; SELZER ML, 1975, J STUD ALCOHOL, V36, P117, DOI 10.15288/jsa.1975.36.117; SMITH GS, 1988, ANNU REV PUBL HEALTH, V9, P99; SODERSTROM CA, 1987, ARCH SURG-CHICAGO, V122, P1067; SODERSTROM CA, 1989, ADV TRAUMA, V4, P211; Swan KG, 1989, J TRAUMA, V29, P947; WATSON RR, 1986, ALCOHOL CLIN EXP RES, V10, P364, DOI 10.1111/j.1530-0277.1986.tb05108.x; WEISBESKI D, 1989, J TRAUMA, V29, P940, DOI 10.1097/00005373-198907000-00006; 1990, BROADENING BASE TREA; 1985, INJURY AM CONTINUING	26	173	175	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 27	1993	270	16					1962	1964		10.1001/jama.270.16.1962	http://dx.doi.org/10.1001/jama.270.16.1962			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MC513	8105114				2022-12-28	WOS:A1993MC51300028
J	DEBRE, M; BONNET, MC; FRIDMAN, WH; CAROSELLA, E; PHILIPPE, N; REINERT, P; VILMER, E; KAPLAN, C; TEILLAUD, JL; GRISCELLI, C				DEBRE, M; BONNET, MC; FRIDMAN, WH; CAROSELLA, E; PHILIPPE, N; REINERT, P; VILMER, E; KAPLAN, C; TEILLAUD, JL; GRISCELLI, C			INFUSION OF FC-GAMMA-FRAGMENTS FOR TREATMENT OF CHILDREN WITH ACUTE IMMUNE THROMBOCYTOPENIC PURPURA	LANCET			English	Article							IMMUNOGLOBULIN-BINDING FACTORS; INTRAVENOUS IMMUNOGLOBULIN; ANTIBODY-PRODUCTION; GLOBULIN; RECEPTORS; CELLS; IGG; CHILDHOOD	Treatment of acute immune thrombocytopenic purpura (ITP) with intravenous immunoglobulin (IVIG) induces partial or complete responses, shown by transient or persistent increases in platelet count. The clinical benefit could be due to blockade of the Fcgamma receptor (FcgammaR); platelets sensitised by IgG could not be cleared by cells of the reticuloendothelial system if FcgammaR on these cells was blocked with IVIG. To find out whether this putative mechanism is correct, we treated twelve children who had acute ITP with intravenous infusions of Fcgamma fragments. Eleven children showed rapid increases in platelet counts to above the critical value of 50 x 10(9)/L, thereby avoiding major haemorrhagic risk. The response was stable in six patients and transient in five. No adverse reactions were observed. In responders who had detectable platelet-associated IgG before treatment (> 1500 IgG per platelet), platelet IgG fell substantially with treatment. Serum soluble CD16 (sCD16 or sFcgammaRIII) concentrations, measured in five children, showed transient or stable increases that correlated with the rise in platelet count. No sCD16 was detected in the Fcgamma preparation used. We conclude that the infusion of Fcgamma fragments is an efficient treatment of acute ITP in children. The efficacy of Fcgamma fragments strengthens the hypothesis that FcgammaR blockade is the main mechanism of action of IVIG in ITP, although other immunoregulatory mechanisms triggered by the presence of increased sCD16 concentrations in serum could be involved in the clinical benefit observed.	DIRECT MED IMMUNOPROT PASTEUR MERLEUX SERUMS & VAC, MARCY LETOILE, FRANCE; INST CURIE, INSERM, U255, F-75231 PARIS 05, FRANCE; HOP INTERCOMMUNAL CRETEIL, CRETEIL, FRANCE; HOP ROBERT DEBRE, PARIS, FRANCE; HOP ST LOUIS, CTR HAYEM, CEA, DSV, F-75475 PARIS 10, FRANCE; HOP DEBROUSSE, F-69005 LYON, FRANCE; INST NATL TRANSFUS SANGUINE, PARIS, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; CEA; UDICE-French Research Universities; Universite Paris Cite; CHU Lyon	DEBRE, M (corresponding author), HOP NECKER ENFANTS MALAD, UNITE IMMUNOHEMATOL, 149 RUE SEVRES, F-75748 PARIS, FRANCE.			fridman, wolf herman/0000-0002-1332-0973; Teillaud, Jean-Luc/0000-0003-4442-9565				ANDERSON CL, 1989, CHEM IMMUNOL, V47, P1; ASTIER A, IN PRESS J IMMUNOL M; BARANDUN S, 1975, VOX SANG, V28, P157, DOI 10.1111/j.1423-0410.1975.tb02755.x; BEARDSLEY DS, 1993, HEMATOLOGY INFANCY C, P1561; BURDACH SEG, 1986, J PEDIATR-US, V109, P770, DOI 10.1016/S0022-3476(86)80691-6; BUSSEL JB, 1987, VOX SANG, V52, P206, DOI 10.1111/j.1423-0410.1987.tb03029.x; BUSSEL JB, 1989, J ALLERGY CLIN IMMUN, V84, P566, DOI 10.1016/0091-6749(89)90193-0; CLARKSON SB, 1986, NEW ENGL J MED, V314, P1236, DOI 10.1056/NEJM198605083141907; COHN EJ, 1946, J AM CHEM SOC, V68, P459, DOI 10.1021/ja01207a034; FEHR J, 1982, NEW ENGL J MED, V306, P1254, DOI 10.1056/NEJM198205273062102; FLEIT HB, 1982, P NATL ACAD SCI-BIOL, V79, P3275, DOI 10.1073/pnas.79.10.3275; FOLLEA G, 1985, NOUV REV FR HEMATOL, V27, P5; FRIDMAN WH, 1986, MOL IMMUNOL, V23, P1141, DOI 10.1016/0161-5890(86)90144-6; FRIDMAN WH, 1988, NOUV REV FR HEMATOL, V30, P311; FRIDMAN WH, 1974, J IMMUNOL, V113, P1008; HALL WH, 1990, JAMA-J AM MED ASSOC, V264, P3189; HUIZINGA TWJ, 1988, NATURE, V333, P667, DOI 10.1038/333667a0; IMBACH P, 1981, LANCET, V1, P1228; KAVERI SV, 1991, CLIN EXP IMMUNOL, V86, P192; KHAYAT D, 1987, J IMMUNOL METHODS, V100, P235, DOI 10.1016/0022-1759(87)90194-3; LANIER LL, 1989, EUR J IMMUNOL, V19, P775, DOI 10.1002/eji.1830190431; LOWY I, 1983, P NATL ACAD SCI-BIOL, V80, P2323, DOI 10.1073/pnas.80.8.2323; MULLER JY, 1983, REV FR TRANSFUS IMMU, V26, P173, DOI 10.1016/S0338-4535(83)80091-9; ONCLEY JL, 1949, J AM CHEM SOC, V71, P541, DOI 10.1021/ja01170a048; SALAMA A, 1983, LANCET, V2, P193; SOLALCELIGNY P, 1983, SCAND J HAEMATOL, V31, P39; SOUBRANE C, 1993, BLOOD, V81, P15; TEILLAUD JL, 1990, MOL IMMUNOL, V27, P1209, DOI 10.1016/0161-5890(90)90024-T; VARIN N, 1989, EUR J IMMUNOL, V19, P2263, DOI 10.1002/eji.1830191213	29	274	282	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 16	1993	342	8877					945	949		10.1016/0140-6736(93)92000-J	http://dx.doi.org/10.1016/0140-6736(93)92000-J			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MC005	8105212				2022-12-28	WOS:A1993MC00500007
J	KERSCHER, M; VOLKENANDT, M; PLEWIG, G; LEHMANN, P				KERSCHER, M; VOLKENANDT, M; PLEWIG, G; LEHMANN, P			COMBINATION PHOTOTHERAPY OF PSORIASIS WITH CALCIPOTRIOL AND NARROW-BAND UVB	LANCET			English	Letter							RADIATION; VULGARIS				KERSCHER, M (corresponding author), LUDWIG MAXIMILIANS UNIV MUNCHEN,DEPT DERMATOL,D-80337 MUNICH,GERMANY.							Goeckerman W., 1925, NW MED, V24, P229; KRAGBALLE K, 1990, DERMATOLOGICA, V181, P211, DOI 10.1159/000247926; KRAGBALLE K, 1991, LANCET, V337, P193, DOI 10.1016/0140-6736(91)92157-W; VANWEELDEN H, 1988, BRIT J DERMATOL, V119, P11; WULF HC, 1989, PHOTODERMATOLOGY, V6, P44	5	70	70	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 9	1993	342	8876					923	923		10.1016/0140-6736(93)91968-R	http://dx.doi.org/10.1016/0140-6736(93)91968-R			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA963	8105177				2022-12-28	WOS:A1993MA96300030
J	ANDERSEN, G; VESTERGAARD, K; RIIS, JO				ANDERSEN, G; VESTERGAARD, K; RIIS, JO			CITALOPRAM FOR POSTSTROKE PATHOLOGICAL CRYING	LANCET			English	Article							BRAIN-DAMAGE; EMOTIONALISM; LEVODOPA	Post-stroke pathological crying is a distressing condition in which episodes occur in response to minor stimuli without associated mood changes. There is preliminary evidence of disturbed serotoninergic neurotransmission in such cases. We investigated the effect of the selective serotonin reuptake inhibitor citalopram on uncontrolled crying in stroke patients in a double-blind placebo-controlled crossover study. 16 consecutive patients (median age 58.5 years, range 40-83) entered the 9-week study a median of 168 days (range 6-913) post stroke and were treated with citalopram 10-20 mg daily for 3 weeks. Crying history was determined from semistructured interviews and from diaries kept by the patients. Psychiatric assessment was made with the Hamilton depression scale (HDS), and unwanted effects were measured with the UKU side-effect scale. In 13 patients in whom frequency of crying could be assessed, the number of daily crying episodes decreased by at least 50% in all cases during citalopram treatment vs 2 patients during placebo treatment (p < 0.005, McNemar's test), the effect being rapid (1-3 days) and pronounced in 11 (73%). There was a concomitant significant decrease in depression rating from HDS 8.9 to 5.3 (p < 0.005, Wilcoxon's test). Citalopram was well tolerated, the few side-effects being mild and transient. We conclude that serotoninergic neurotransmission plays an important part in post-stroke pathological crying and that citalopram is an effective and well-tolerated treatment.			ANDERSEN, G (corresponding author), AALBORG HOSP,DEPT NEUROL,DK-9000 AALBORG,DENMARK.			Andersen, Grethe/0000-0001-6807-2500				ALLMAN P, 1990, POSTGRAD MED J, V66, P818, DOI 10.1136/pgmj.66.780.818; BECK P, 1986, ACTA PSYCHIATR S326, V74, P7; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HOLBROOK M, 1983, AGE AGEING, V12, P166, DOI 10.1093/ageing/12.2.166; HOUSE A, 1989, BMJ-BRIT MED J, V298, P991, DOI 10.1136/bmj.298.6679.991; Karusu T.B., 1976, GERIATRIC PSYCHIAT, P77; LAWSON IR, 1969, BRIT J PSYCHIAT, V115, P281, DOI 10.1192/bjp.115.520.281; LINGJAERDE O, 1987, Acta Psychiatrica Scandinavica Supplementum, V76, P1, DOI 10.1111/j.1600-0447.1987.tb10566.x; POECK K, 1985, HDB CLIN NEUROLOGY, V1, P219; ROSS ED, 1987, J NERV MENT DIS, V175, P165, DOI 10.1097/00005053-198703000-00007; SCHIFFER RB, 1985, NEW ENGL J MED, V312, P1480, DOI 10.1056/NEJM198506063122303; SELIGER G M, 1992, Brain Injury, V6, P267, DOI 10.3109/02699059209029668; SLOAN R L, 1992, Brain Injury, V6, P315, DOI 10.3109/02699059209034945; UDAKA F, 1984, ARCH NEUROL-CHICAGO, V41, P1095, DOI 10.1001/archneur.1984.04050210093023; WOLF JK, 1979, NEUROLOGY, V29, P1435, DOI 10.1212/WNL.29.10.1435-b	15	176	182	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 2	1993	342	8875					837	839		10.1016/0140-6736(93)92696-Q	http://dx.doi.org/10.1016/0140-6736(93)92696-Q			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA025	8104273				2022-12-28	WOS:A1993MA02500010
J	RIGGS, JE				RIGGS, JE			SMOKING AND ALZHEIMERS-DISEASE - PROTECTIVE EFFECT OR DIFFERENTIAL SURVIVAL BIAS	LANCET			English	Editorial Material							CIGARETTE-SMOKING				RIGGS, JE (corresponding author), W VIRGINIA UNIV,HLTH SCI CTR,DEPT NEUROL,POB 9180,MORGANTOWN,WV 26506, USA.							AU WW, 1991, MUTAT RES, V260, P137, DOI 10.1016/0165-1218(91)90001-3; BARON JA, 1986, NEUROLOGY, V36, P1490, DOI 10.1212/WNL.36.11.1490; BOERRIGTER ME, 1992, J GERONTOL, V47, P177; BRENNER DE, 1993, NEUROLOGY, V43, P293, DOI 10.1212/WNL.43.2.293; CONNEALLY PM, 1991, ADV NEUROL, V56, P233; FARRER LA, 1984, AM J MED GENET, V18, P115, DOI 10.1002/ajmg.1320180115; FIELDING JE, 1985, NEW ENGL J MED, V313, P555, DOI 10.1056/NEJM198508293130906; GRAVES AB, 1991, INT J EPIDEMIOL S2, V20, P48; Gusella J F, 1991, Adv Hum Genet, V20, P125; PINCHEIRA J, 1993, MUTAT RES, V295, P55, DOI 10.1016/0921-8734(93)90001-J; RIGGS JE, 1992, CLIN NEUROPHARMACOL, V15, P88, DOI 10.1097/00002826-199204000-00002; RIGGS JE, 1992, MECH AGEING DEV, V65, P217, DOI 10.1016/0047-6374(92)90037-E; RIGGS JE, 1993, MECH AGEING DEV, V66, P249, DOI 10.1016/0047-6374(93)90012-G; VANDUIJN CM, 1991, BRIT MED J, V302, P1491, DOI 10.1136/bmj.302.6791.1491	14	71	71	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 25	1993	342	8874					793	794		10.1016/0140-6736(93)91547-Y	http://dx.doi.org/10.1016/0140-6736(93)91547-Y			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LY868	8103882				2022-12-28	WOS:A1993LY86800016
J	CAMPBELL, G; WEAVER, T; TOMLINSON, A				CAMPBELL, G; WEAVER, T; TOMLINSON, A			AXIS SPECIFICATION IN THE DEVELOPING DROSOPHILA APPENDAGE - THE ROLE OF WINGLESS, DECAPENTAPLEGIC, AND THE HOMEOBOX GENE ARISTALESS	CELL			English	Article							SEGMENT-POLARITY GENE; IMAGINAL DISKS; XENOPUS EMBRYOS; HALTERE DEVELOPMENT; ECTOPIC EXPRESSION; FROG EMBRYOS; BETA FAMILY; PATTERN; ORGANIZER; WNT	The wingless (wg) and decapentaplegic (dpp) genes of Drosophila encode homologs of secreted growth factors and are required for the correct patterning of the appendages. We show that the presumptive tips of both the leg and wing, the distal extreme of the proximodistal axis, are characterized by the close association of cells expressing wg, dpp, and the homeobox gene aristaless (al). Ectopic expression of wg can induce both ectopic al expression and a duplication of the proximodistal axis (the development of supernumerary legs), but only in regions expressing high levels of dpp. Ectopic al expression can induce a duplication of the proximodistal axis in the wing, suggesting that it may also be directly involved in axis specification. The proximodistal axis may be specified via a mechanism involving a direct interaction between cells expressing wg, dpp, and possibly al.	MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	MRC Laboratory Molecular Biology				Campbell, Gerard/0000-0002-7631-4394				ALTABA AR, 1989, NATURE, V341, P33; ALTABA ARI, 1992, DEVELOPMENT, V116, P81; BAKER NE, 1988, DEVELOPMENT, V102, P489; BAKER NE, 1988, DEV BIOL, V125, P96, DOI 10.1016/0012-1606(88)90062-0; BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; BASLER K, 1990, GENE DEV, V4, P728, DOI 10.1101/gad.4.5.728; BATE M, 1991, DEVELOPMENT, V112, P755; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; BLUMBERG B, 1991, SCIENCE, V253, P194, DOI 10.1126/science.1677215; Bryant P.J., 1978, P230; Bryant PJ, 1987, GENETIC REGULATION D, P339; BRYANT SV, 1981, SCIENCE, V212, P993, DOI 10.1126/science.212.4498.993; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; COHEN B, 1993, DEVELOPMENT, V117, P597; COHEN B, 1991, MECH DEVELOP, V33, P229, DOI 10.1016/0925-4773(91)90030-A; COHEN SM, 1989, NATURE, V338, P432, DOI 10.1038/338432a0; CONDIC ML, 1991, DEVELOPMENT, V111, P23; DAVIS LG, 1986, METHODS MOL BIOL; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FRENCH V, 1976, SCIENCE, V193, P969, DOI 10.1126/science.948762; GELBART WM, 1989, DEVELOPMENT, V107, P65; GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0; Grigliati T., 1986, DROSOPHILA PRACTICAL, P39; KASSIS JA, 1992, P NATL ACAD SCI USA, V89, P1919, DOI 10.1073/pnas.89.5.1919; KLEMENZ R, 1987, NUCLEIC ACIDS RES, V15, P3947, DOI 10.1093/nar/15.10.3947; LEWIS EB, 1945, GENETICS, V30, P137; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; LINDSLEY DL, 1968, CARNEGIE I WASH PUBL, V627; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; MASUCCI JD, 1990, GENE DEV, V4, P2011, DOI 10.1101/gad.4.11.2011; MCMAHON AP, 1992, TRENDS GENET, V8, P236, DOI 10.1016/0168-9525(92)90122-K; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MEINHARDT H, 1982, DEV ORDER ITS ORIGIN, P439; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; POODRY CA, 1970, ROUX ARCH DEV BIOL, V166, P1, DOI 10.1007/BF00576805; POSAKONY LG, 1991, MECH DEVELOP, V33, P69; POSTLETHWAIT JH, 1978, GENETICS BIOL DROS C, V2, P359; RAFTERY LA, 1991, DEVELOPMENT, V113, P27; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; Sambrook J, 1989, MOL CLONING LABORATO; SCHNEITZ K, 1993, GENE DEV, V7, P114, DOI 10.1101/gad.7.1.114; SCHUBIGER G, 1968, ROUX ARCH DEV BIOL, V160, P9; SHARMA RP, 1976, DEV BIOL, V48, P461, DOI 10.1016/0012-1606(76)90108-1; SMITH JC, 1989, DEVELOPMENT, V107, P149; SMITH JC, 1983, J EMBRYOL EXP MORPH, V78, P299; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; SOKOL SY, 1992, DEV BIOL, V154, P348, DOI 10.1016/0012-1606(92)90073-P; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; Stern C, 1926, GENETICS, V11, P503; STJOHNSTON D, 1992, CELL, V68, P201; STJOHNSTON RD, 1987, EMBO J, V6, P2785, DOI 10.1002/j.1460-2075.1987.tb02574.x; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; WILLIAMS JA, 1991, GENE DEV, V5, P2481, DOI 10.1101/gad.5.12b.2481	59	246	247	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 24	1993	74	6					1113	1123		10.1016/0092-8674(93)90732-6	http://dx.doi.org/10.1016/0092-8674(93)90732-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LY493	8104704				2022-12-28	WOS:A1993LY49300017
J	HOWIE, JGR; STOTT, NCH				HOWIE, JGR; STOTT, NCH			THE UNIVERSITIES RESEARCH ASSESSMENT EXERCISE 1992 - A 2ND OPINION	LANCET			English	Editorial Material								We compared assessments of university departments of general practice by the heads of department with those of The UK University Funding Council. There was little difference between them. The departmental heads' assessment was quicker and cheaper. Current means of assessing academic departments may need to be reconsidered.	UNIV WALES COLL CARDIFF,COLL MED,LLANEDYRN HLTH CTR,DEPT GEN PRACTICE,CARDIFF CF3 8PN,WALES; UNIV EDINBURGH,DEPT GEN PRACTICE,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND	Cardiff University; University of Edinburgh								1991, RES HLTH RES DEV STR; 1993, 3RD REPORT STEERING; 1992, 2692 U FUND COUNC RE; 1992, 562 U FUND COUNC RES; 1992, SHARPENING FOCUS RES	5	2	2	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 11	1993	342	8872					665	666		10.1016/0140-6736(93)91765-E	http://dx.doi.org/10.1016/0140-6736(93)91765-E			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX272	8103152				2022-12-28	WOS:A1993LX27200016
J	STEINHOFF, MC				STEINHOFF, MC			DEVELOPING AND DEPLOYING PNEUMOCOCCAL AND HAEMOPHILUS VACCINES	LANCET			English	Editorial Material											STEINHOFF, MC (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,BALTIMORE,MD 21218, USA.							FUNKHOUSER A, 1991, REV INFECT DIS, V13, P542; MASTRO TD, 1991, LANCET, V337, P156, DOI 10.1016/0140-6736(91)90813-5; RILEY ID, 1991, REV INFECT DIS, V13, P535; ROBBINS JB, 1983, J INFECT DIS, V148, P1136, DOI 10.1093/infdis/148.6.1136; STEINHOFF MC, 1992, 32ND INT C ANT AG CH, P325; 1986, NEW VACCINE DEV ESTA, V2, P357	6	23	23	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 11	1993	342	8872					630	631		10.1016/0140-6736(93)91754-A	http://dx.doi.org/10.1016/0140-6736(93)91754-A			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX272	8103141	hybrid			2022-12-28	WOS:A1993LX27200005
J	STANSFIELD, SK; PIERRELOUIS, M; LEREBOURS, G; AUGUSTIN, A				STANSFIELD, SK; PIERRELOUIS, M; LEREBOURS, G; AUGUSTIN, A			VITAMIN-A SUPPLEMENTATION AND INCREASED PREVALENCE OF CHILDHOOD DIARRHEA AND ACUTE RESPIRATORY-INFECTIONS	LANCET			English	Article							MILD VITAMIN; NORTHEASTERN THAILAND; SCHOOL-CHILDREN; IMMUNE-RESPONSE; TRACT DISEASES; DEFICIENCY; MORBIDITY; TRIAL; MORTALITY; RISK	There is uncertainty over whether vitamin A supplementation reduces morbidity among children with subclinical deficiency of the vitamin. Hence a double-blind, placebo-controlled trial of the effect of vitamin A supplementation on childhood morbidity was conducted among 11 124 children aged 6-83 months in the northwest of Haiti. After a random start, children were sequentially assigned by household units to receive either megadose vitamin A or placebo in three distribution cycles 4 months apart. 2 to 8 weeks after each administration of the vitamin A and placebo capsules, indicators of childhood morbidity were reassessed through interviews conducted in the homes of participating families. The vitamin A group was found to have an increased 2-week prevalence of all symptoms and signs of childhood morbidity assessed, including diarrhoea (rate ratio [RR] = 1.09, 95% confidence interval 1.05-1.14), rhinitis (RR = 1.02, 95% confidence interval 1.00-1.04), cold/flu symptoms (RR = 1.04, 95% confidence interval 1.01-1.06), cough (RR = 1.07, 95% confidence interval 1.03-1.11), and rapid breathing (RR = 1.18, 95% confidence interval 1.09-1.27). The study shows an increased 2-week prevalence of diarrhoea and the symptoms of respiratory infections after vitamin A supplementation.	EYE CARE HAITI, PORT AU PRINCE, HAITI; INST HAITEN ENFANCE, PORT AU PRINCE, HAITI		STANSFIELD, SK (corresponding author), MCGILL UNIV, DEPT EPIDEMIOL & BIOSTAT, 1020 PINE AVE W, MONTREAL H3A 1A2, PQ, CANADA.							ABDELJABER MH, 1991, AM J PUBLIC HEALTH, V81, P1654, DOI 10.2105/AJPH.81.12.1654; ARTHUR P, 1992, LANCET, V339, P361, DOI 10.1016/0140-6736(92)91677-Z; BANDRINATH P, 1991, LANCET, V29, P849; BASSETT DC, 1990, RAPID NUTRITION ASSE; BLACK RE, 1984, AM J CLIN NUTR, V39, P87, DOI 10.1093/ajcn/39.1.87; BLOEM MW, 1990, AM J EPIDEMIOL, V131, P332, DOI 10.1093/oxfordjournals.aje.a115502; BRILLIANT LB, 1985, B WORLD HEALTH ORGAN, V63, P375; COUTSOUDIS A, 1991, AM J CLIN NUTR, V54, P890, DOI 10.1093/ajcn/54.5.890; FRIEDMAN A, 1989, J NUTR, V119, P790, DOI 10.1093/jn/119.5.790; FRIEDMAN A, 1991, J NUTR, V121, P395, DOI 10.1093/jn/121.3.395; GERSHOFF SN, 1977, AM J CLIN NUTR, V30, P1185, DOI 10.1093/ajcn/30.7.1185; HUSSEY GD, 1990, NEW ENGL J MED, V323, P160, DOI 10.1056/NEJM199007193230304; Kartasasmita C B, 1991, Paediatr Indones, V31, P41; KEUSCH GT, 1991, REV INFECT DIS    S6, V13, pS468; KJOLHEDE CL, 1991, AM J EPIDEMIOL, V133, P319, DOI 10.1093/oxfordjournals.aje.a115880; KOTHARI G, 1991, J TROP PEDIATRICS, V37, P141, DOI 10.1093/tropej/37.3.141; MILTON RC, 1987, AM J CLIN NUTR, V46, P827, DOI 10.1093/ajcn/46.5.827; PINNOCK CB, 1988, AUST PAEDIATR J, V24, P286; PINNOCK CB, 1986, AUST PAEDIATR J, V22, P95; RAHMATHULLAH L, 1991, AM J CLIN NUTR, V54, P568, DOI 10.1093/ajcn/54.3.568; SOLON FS, 1978, AM J CLIN NUTR, V31, P360, DOI 10.1093/ajcn/31.2.360; SOMMER A, 1990, ANN NY ACAD SCI, V587, P17, DOI 10.1111/j.1749-6632.1990.tb00129.x; SOMMER A, 1984, AM J CLIN NUTR, V40, P1090, DOI 10.1093/ajcn/40.5.1090; STANTON BF, 1986, AM J DIS CHILD, V140, P584, DOI 10.1001/archpedi.1986.02140200094036; STOLL BJ, 1985, J TROP PEDIATRICS, V31, P36, DOI 10.1093/tropej/31.1.36; TARWOTJO I, 1987, AM J CLIN NUTR, V45, P1466, DOI 10.1093/ajcn/45.6.1466; TIELSCH JM, 1986, AM J EPIDEMIOL, V124, P561, DOI 10.1093/oxfordjournals.aje.a114428; VIJAYARAGHAVAN K, 1990, LANCET, V336, P1342, DOI 10.1016/0140-6736(90)92895-O; 1980, DIAGNOSTIC SITUATION; 1988, VITAMIN A SUPPLEMENT; 1987, WKLY EPIDEMIOL REC, V19, P133; 1992, STATE WORLDS CHILDRE	32	84	86	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 4	1993	342	8871					578	582		10.1016/0140-6736(93)91410-N	http://dx.doi.org/10.1016/0140-6736(93)91410-N			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV963	8102720				2022-12-28	WOS:A1993LV96300010
J	XUE, D; TU, Y; CHALFIE, M				XUE, D; TU, Y; CHALFIE, M			COOPERATIVE INTERACTIONS BETWEEN THE CAENORHABDITIS-ELEGANS HOMEOPROTEINS UNC-86 AND MEC-3	SCIENCE			English	Article							DROSOPHILA HOMEODOMAIN PROTEINS; DNA-BINDING SPECIFICITY; TOUCH RECEPTOR NEURONS; POU-DOMAIN PROTEINS; C-ELEGANS; RNA-POLYMERASE; TRANSCRIPTION FACTORS; CELL IDENTITY; GENE; EXPRESSION	The POU-type homeodomain protein UNC-86 and the LIM-type homeodomain protein MEC-3, which specify neuronal cell fate in the nematode Caenorhabditis elegans, bind cooperatively as a heterodimer to the mec-3 promoter. Heterodimer formation increases DNA binding stability and, therefore, increases DNA binding specificity. The in vivo significance of this heterodimer formation in neuronal differentiation is suggested by (i) a loss-of-function mec-3 mutation whose product in vitro binds DNA well but forms heterodimers with UNC-86 poorly and (ii) a mec-3 mutation with wild-type function whose product binds DNA poorly but forms heterodimers well.	COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027	Columbia University				XUE, DING/0000-0002-8429-8136	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030997, R37GM030997] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30997] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHALFIE M, 1981, CELL, V24, P59, DOI 10.1016/0092-8674(81)90501-8; CHALFIE M, 1981, DEV BIOL, V82, P358, DOI 10.1016/0012-1606(81)90459-0; CHALFIE M, 1989, SCIENCE, V243, P1027, DOI 10.1126/science.2646709; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; FINNEY M, 1988, CELL, V55, P757, DOI 10.1016/0092-8674(88)90132-8; FRITSCH EFJ, 1989, MOL CLONING LABORATO; GIBSON G, 1990, CELL, V62, P1087, DOI 10.1016/0092-8674(90)90386-S; GOUTTE C, 1988, CELL, V52, P875, DOI 10.1016/0092-8674(88)90429-1; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HAMELIN M, 1992, EMBO J, V11, P2885, DOI 10.1002/j.1460-2075.1992.tb05357.x; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; HARLOW E, 1988, ANTIBODIES LABORATOR; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUZIORA MA, 1988, CELL, V55, P477, DOI 10.1016/0092-8674(88)90034-7; KUZIORA MA, 1989, CELL, V59, P563, DOI 10.1016/0092-8674(89)90039-1; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LEBOWITZ JH, 1989, GENE DEV, V3, P1625, DOI 10.1101/gad.3.10.1625; MANN RS, 1990, CELL, V60, P597, DOI 10.1016/0092-8674(90)90663-Y; MENDEL DB, 1991, SCIENCE, V254, P1762, DOI 10.1126/science.1763325; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; MITANI S, IN PRESS DEVELOPMENT; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; RUVKUN G, 1991, CELL, V64, P475, DOI 10.1016/0092-8674(91)90227-P; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SHARP PA, 1991, NATURE, V351, P16, DOI 10.1038/351016d0; SMITH DL, 1992, CELL, V68, P133, DOI 10.1016/0092-8674(92)90212-U; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; TREISMAN J, 1989, CELL, V59, P553; VERSHON AK, 1993, CELL, V72, P105, DOI 10.1016/0092-8674(93)90054-T; VOSS JW, 1991, GENE DEV, V5, P1309, DOI 10.1101/gad.5.7.1309; WAY JC, 1991, GENE DEV, V5, P2199, DOI 10.1101/gad.5.12a.2199; WAY JC, 1989, GENE DEV, V3, P1823, DOI 10.1101/gad.3.12a.1823; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WILLIAMS BD, 1992, GENETICS, V131, P609; XUE D, 1992, EMBO J, V11, P4969, DOI 10.1002/j.1460-2075.1992.tb05604.x; XUE DF, UNPUB; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E	51	194	201	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 3	1993	261	5126					1324	1328		10.1126/science.8103239	http://dx.doi.org/10.1126/science.8103239			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LV656	8103239				2022-12-28	WOS:A1993LV65600029
J	LAST, JM				LAST, JM			WAR AND THE DEMOGRAPHIC TRAP	LANCET			English	Editorial Material											LAST, JM (corresponding author), UNIV OTTAWA,FAC MED,OTTAWA K1N 6N5,ONTARIO,CANADA.							ELLIOTT G, 1973, 20TH CENTURY BOOK DE; HOMERDIXON TF, 1991, INT SECURITY, V16, P76, DOI 10.2307/2539061; HOMERDIXON TF, 1993, SCI AM           FEB, P38; KING M, 1993, LANCET, V341, P669, DOI 10.1016/0140-6736(93)90431-F; LAST J, 1991, AM J PREV MED, V7, P253, DOI 10.1016/S0749-3797(18)30924-3; SIVARD R., 1991, WORLD MILITARY SOCIA; Storr Anthony, 1992, HUMAN DESTRUCTIVENES; 1993, WORLD SCI WARNING HU	8	4	5	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 28	1993	342	8870					508	509		10.1016/0140-6736(93)91641-X	http://dx.doi.org/10.1016/0140-6736(93)91641-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LU582	8102662				2022-12-28	WOS:A1993LU58200004
J	FERNANDEZDELCASTILLO, C; RATTNER, DW; WARSHAW, AL				FERNANDEZDELCASTILLO, C; RATTNER, DW; WARSHAW, AL			ACUTE-PANCREATITIS	LANCET			English	Article							COMPUTED-TOMOGRAPHY; GALLSTONE PANCREATITIS; PERITONEAL-LAVAGE; CONTROLLED TRIAL; NECROSIS; MULTICENTER; INFECTION; SEVERITY; SPHINCTEROTOMY; SOMATOSTATIN		MASSACHUSETTS GEN HOSP,DEPT SURG,15 PARKMAN ST,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School			Castillo, Carlos Fenandez-del/AAO-2602-2020					BALTHAZAR EJ, 1985, RADIOLOGY, V156, P767, DOI 10.1148/radiology.156.3.4023241; BEGER HG, 1988, BRIT J SURG, V75, P207, DOI 10.1002/bjs.1800750306; BEGER HG, 1991, HEPATO-GASTROENTEROL, V38, P92; BEGER HG, 1986, GASTROENTEROLOGY, V91, P433, DOI 10.1016/0016-5085(86)90579-2; BRADLEY EL, 1987, ANN SURG, V206, P542, DOI 10.1097/00000658-198710000-00015; BRADLEY EL, 1989, ANN SURG, V210, P495, DOI 10.1097/00000658-198910000-00010; BRADLEY EL, 1991, AM J SURG, V161, P19, DOI 10.1016/0002-9610(91)90355-H; BUCHLER M, 1992, GASTROENTEROLOGY, V103, P1902; BUCHLER M, 1992, GASTROENTEROLOGY, V104, P1165; CHOI TK, 1989, GUT, V30, P223, DOI 10.1136/gut.30.2.223; CRAIG RM, 1975, ANN INTERN MED, V83, P831, DOI 10.7326/0003-4819-83-6-831; DAMICO D, 1990, HEPATO-GASTROENTEROL, V37, P92; DEGIDIO A, 1991, BRIT J SURG, V78, P133, DOI 10.1002/bjs.1800780204; DOMINGUEZMUNOZ JE, 1991, BRIT J SURG, V78, P1230, DOI 10.1002/bjs.1800781027; FAN ST, 1993, NEW ENGL J MED, V328, P228, DOI 10.1056/NEJM199301283280402; FINCH WT, 1976, ANN SURG, V183, P667, DOI 10.1097/00000658-197606000-00008; FOITZIK T, IN PRESS GASTROENTER; GERZOF SG, 1987, GASTROENTEROLOGY, V93, P1315, DOI 10.1016/0016-5085(87)90261-7; GLORUP I, 1992, SURG GYNECOL OBSTET, V175, P397; GUDGEON AM, 1990, LANCET, V335, P4, DOI 10.1016/0140-6736(90)90135-R; HOWES R, 1975, J SURG RES, V80, P94; KARIMGANI I, 1992, GASTROENTEROLOGY, V103, P1636, DOI 10.1016/0016-5085(92)91189-B; KARJALAINEN J, 1992, EUR J SURG, V158, P549; KELLY TR, 1988, SURGERY, V104, P600; KHUROO MS, 1992, BRIT J SURG, V79, P1335, DOI 10.1002/bjs.1800791231; KLAR E, 1993, SURG GYNECOL OBSTET, V174, P144; LONDON NJM, 1989, GUT, V30, P397, DOI 10.1136/gut.30.3.397; LONDON NJM, 1991, BRIT J SURG, V78, P1452, DOI 10.1002/bjs.1800781216; MAYER AD, 1985, NEW ENGL J MED, V312, P399, DOI 10.1056/NEJM198502143120703; NEOPTOLEMOS JP, 1988, LANCET, V2, P979, DOI 10.1016/S0140-6736(88)90740-4; PEDERZOLI P, 1993, SURG GYNECOL OBSTET, V176, P480; RANSON JHC, 1990, ANN SURG, V211, P708, DOI 10.1097/00000658-199006000-00009; RATTNER DW, 1992, AM J SURG, V163, P105, DOI 10.1016/0002-9610(92)90261-O; SCHMIDT J, 1993, AM J SURG, V165, P140; VALDERRAMA R, 1992, DIGESTION, V51, P65, DOI 10.1159/000200877; WILSON C, 1990, BRIT J SURG, V77, P1260, DOI 10.1002/bjs.1800771120; WILSON C, 1989, BRIT J SURG, V76, P177, DOI 10.1002/bjs.1800760224	37	34	34	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 21	1993	342	8869					475	479		10.1016/0140-6736(93)91598-G	http://dx.doi.org/10.1016/0140-6736(93)91598-G			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU075	8102434				2022-12-28	WOS:A1993LU07500015
J	SAVEN, A; PIRO, LD				SAVEN, A; PIRO, LD			COMPLETE REMISSIONS IN HAIRY-CELL LEUKEMIA WITH 2-CHLORODEOXYADENOSINE AFTER FAILURE WITH 2'-DEOXYCOFORMYCIN	ANNALS OF INTERNAL MEDICINE			English	Article						PENTOSTATIN; 2-CHLORODEOXYADENOSINE; LEUKEMIA, HAIRY CELL; DRUG RESISTANCE; DRUG TOLERANCE	PENTOSTATIN 2'-DEOXYCOFORMYCIN; TOXICITY; AGENT	Objective: To determine whether clinical cross-resistance and intolerance exists between the nucleosides 2'-deoxycoformycin (DCF) and 2-chlorodeoxyadenosine (2-CdA) in the treatment of patients with hairy cell leukemia despite similar structures and mechanisms of action. Design: Phase II clinical study. Setting: Referral cancer center. Participants: Five patients with hairy cell leukemia who had been previously treated with DCF. Intervention: Single course of 2-CdA at 0.1 mg/kg body weight per day for 7 days by continuous intravenous infusion. Results: Of five patients, three were resistant to and two were intolerant of (having had life-threatening toxic reactions) DCF therapy. Four patients obtained a complete response with a median follow-up period of more than 11 months. The other patient in whom splenectomy, interferon, and DCF treatments were unsuccessful had a partial response lasting 2 months and subsequently died of Streptococcus pneumoniae bacteremia. Three of the four patients with complete responses remain in unmaintained remission, whereas the fourth has progressive splenic enlargement with stable hematologic parameters. The median leukocyte count increased from 2.0 x 10(9)/L to 3.8 x 10(9)/L, the median absolute neutrophil count increased from 0.56 x 10(9)/L to 2.73 x 10(9)/L, the median hemoglobin level increased from 112 g/L to 140 g/L, and the median platelet count increased from 55 x 10(9)/L to 123 x 10(9)/L. Two patients had culture-negative neutropenic fever associated with treatment. Conclusions: 2-Chlorodeoxyadenosine induced complete responses in patients with hairy cell leukemia resistant to DCF, suggesting a lack of cross-resistance. Also, 2-CdA is not prohibitively toxic in patients intolerant of DCF.			SAVEN, A (corresponding author), SCRIPPS CLIN & RES FDN, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.							BOURONCLE BA, 1958, BLOOD, V13, P609, DOI 10.1182/blood.V13.7.609.609; CARRERA CJ, 1990, BLOOD S, V76, P260; CARRERA CJ, 1987, MOL BASIS BLOOD DISE; CARRERA CJ, 1991, J PURINE PYRIMIDI S1, V2, P15; CARSON DA, 1980, P NATL ACAD SCI-BIOL, V77, P6865, DOI 10.1073/pnas.77.11.6865; CARSON DA, 1983, BLOOD, V62, P737; CASSILETH PA, 1991, J CLIN ONCOL, V9, P243, DOI 10.1200/JCO.1991.9.2.243; GOLOMB HM, 1978, ANN INTERN MED, V89, P677, DOI 10.7326/0003-4819-89-5-677; HO AD, 1989, J CLIN ONCOL, V7, P1533, DOI 10.1200/JCO.1989.7.10.1533; KAY AC, 1992, J CLIN ONCOL, V10, P371, DOI 10.1200/JCO.1992.10.3.371; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; PIRO LD, 1990, NEW ENGL J MED, V322, P1117, DOI 10.1056/NEJM199004193221605; PIRO LD, 1988, BLOOD, V72, P1069; PIRO LD, 1992, P AN M AM SOC CLIN, V11, P846; SAVEN A, 1992, BLOOD, V80, P587; SAVEN A, 1992, BLOOD, V79, P1111; SAVEN A, 1991, LEUKEMIA LYMPHOMA, V5, P133, DOI 10.3109/10428199109103394; SORENSEN JM, 1991, P AN M AM SOC CLIN, V10, P232; SPIERS ASD, 1984, J CLIN ONCOL, V2, P1336, DOI 10.1200/JCO.1984.2.12.1336; SPIERS ASD, 1987, NEW ENGL J MED, V316, P825, DOI 10.1056/NEJM198704023161401; URBA WJ, 1989, BLOOD, V73, P38	21	60	62	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1993	119	4					278	283		10.7326/0003-4819-119-4-199308150-00005	http://dx.doi.org/10.7326/0003-4819-119-4-199308150-00005			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV525	8101069				2022-12-28	WOS:A1993LV52500005
J	CINQUE, P; BRYTTING, M; VAGO, L; CASTAGNA, A; PARRAVICINI, C; ZANCHETTA, N; MONFORTE, AD; WAHREN, B; LAZZARIN, A; LINDE, A				CINQUE, P; BRYTTING, M; VAGO, L; CASTAGNA, A; PARRAVICINI, C; ZANCHETTA, N; MONFORTE, AD; WAHREN, B; LAZZARIN, A; LINDE, A			EPSTEIN-BARR-VIRUS DNA IN CEREBROSPINAL-FLUID FROM PATIENTS WITH AIDS-RELATED PRIMARY LYMPHOMA OF THE CENTRAL-NERVOUS-SYSTEM	LANCET			English	Article							POLYMERASE CHAIN-REACTION; AMPLIFICATION; DIAGNOSIS	Epstein-Barr virus (EBV) is constantly associated with AIDS-related primary lymphomas of the central nervous system (CNS). To assess whether EBV DNA in cerebrospinal fluid (CSF) could be used as a tumour marker, CSF samples that had been taken within 180 days before death from 85 patients with HIV infection and neurological disorders at necropsy were examined retrospectively by nested polymerase chain reaction (PCR) for EBV. Histologically evident primary CNS lymphomas were found in 17 patients, and EBV was shown in tissue by in-situ hybridisation in 16 of the 16 cases examined. All 17 patients with primary CNS lymphoma had EBV DNA in CSF. EBV DNA was found in CSF from 1 of 68 HIV-infected patients without histologically detectable lymphoma at necropsy. PCR for EBV DNA in CSF was 100% sensitive and 98.5% specific for AIDS-associated primary CNS lymphoma, and may be useful as a diagnostic tumour marker.	UNIV MILAN,S RAFFAELE HOSP,DEPT INFECT DIS,I-20122 MILAN,ITALY; NATL BACTERIOL LAB,DEPT VIROL,S-10521 STOCKHOLM,SWEDEN; KAROLINSKA INST,S-10401 STOCKHOLM 60,SWEDEN; UNIV MILAN,L SACCO HOSP,DEPT PATHOL 5,I-20122 MILAN,ITALY; UNIV MILAN,L SACCO HOSP,CENT ANAL LAB,I-20122 MILAN,ITALY; UNIV MILAN,L SACCO HOSP,INFECT DIS CLIN,I-20122 MILAN,ITALY	University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Karolinska Institutet; University of Milan; Luigi Sacco Hospital; University of Milan; Luigi Sacco Hospital; University of Milan; Luigi Sacco Hospital			Castagna, Antonella/K-3280-2018; Cinque, Paola/AAA-1227-2019; LAZZARIN, Adriano/K-3607-2018	Castagna, Antonella/0000-0002-8338-9714; Cinque, Paola/0000-0003-2448-5957; LAZZARIN, Adriano/0000-0003-2551-7754				[Anonymous], 1982, CANCER, V49, P2112; AURELIUS E, 1991, LANCET, V337, P189, DOI 10.1016/0140-6736(91)92155-U; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BRYTTING M, 1992, J CLIN MICROBIOL, V30, P1937, DOI 10.1128/JCM.30.8.1937-1941.1992; CHAPPELL ET, 1992, NEUROSURGERY, V30, P825, DOI 10.1227/00006123-199206000-00001; CINQUE P, 1992, J INFECT DIS, V166, P1408, DOI 10.1093/infdis/166.6.1408; CINQUE P, 1993, 4TH INT C CYT PAR; GULLEY ML, 1992, CANCER, V70, P185, DOI 10.1002/1097-0142(19920701)70:1<185::AID-CNCR2820700129>3.0.CO;2-J; HAMILTONDUTOIT SJ, 1991, AM J PATHOL, V138, P149; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; HSIA K, 1989, J CLIN MICROBIOL, V27, P1802, DOI 10.1128/JCM.27.8.1802-1809.1989; KATZ BZ, 1992, AM J PATHOL, V140, P1247; MACMAHON EME, 1991, LANCET, V338, P969, DOI 10.1016/0140-6736(91)91837-K; Maniatis T., 1982, MOL CLONING; PARRAVICINI CL, 1988, AIDS, V2, P171; SUMAYA CV, 1986, J INFECT DIS, V154, P864, DOI 10.1093/infdis/154.5.864	16	263	272	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 14	1993	342	8868					398	401		10.1016/0140-6736(93)92814-A	http://dx.doi.org/10.1016/0140-6736(93)92814-A			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR900	8101902				2022-12-28	WOS:A1993LR90000010
J	RUSHFORTH, JA; HOY, CM; KITE, P; PUNTIS, JWL				RUSHFORTH, JA; HOY, CM; KITE, P; PUNTIS, JWL			RAPID DIAGNOSIS OF CENTRAL VENOUS CATHETER SEPSIS	LANCET			English	Note								Signs of infection with a central venous access device in situ raise the possibility of catheter sepsis. We evaluated three tests for diagnosis of infection in infants with suspected catheter sepsis. The acridine orange leucocyte cytospin (AOLC) test was 87% sensitive and 94% specific in the diagnosis of catheter-related sepsis defined by quantitative blood culture. The C-reactive protein and nitroblue tetrazolium tests were not as useful. Using the AOLC results, available in an hour, we now remove fewer catheters on suspicion of sepsis alone.	GEN INFIRM,ACAD DEPT PAEDIAT & CHILD HLTH,LEEDS LS2 9NS,ENGLAND; GEN INFIRM,DEPT MICROBIOL,LEEDS LS2 9NS,ENGLAND	Leeds General Infirmary; Leeds General Infirmary								BOZZETTI F, 1985, SURG GYNECOL OBSTET, V161, P293; COOPER GL, 1985, NEW ENGL J MED, V312, P1142, DOI 10.1056/NEJM198505023121802; KITE P, 1988, ARCH DIS CHILD, V63, P639, DOI 10.1136/adc.63.6.639; MAKI DG, 1977, NEW ENGL J MED, V296, P1305, DOI 10.1056/NEJM197706092962301; PADBERG FT, 1981, ANN SURG, V193, P264, DOI 10.1097/00000658-198103000-00002; PRINCE A, 1986, PEDIATR INFECT DIS J, V5, P20, DOI 10.1097/00006454-198601000-00004; RUDERMAN JW, 1988, J PEDIATR-US, V112, P748, DOI 10.1016/S0022-3476(88)80695-4	7	44	48	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 14	1993	342	8868					402	403		10.1016/0140-6736(93)92815-B	http://dx.doi.org/10.1016/0140-6736(93)92815-B			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR900	8101903				2022-12-28	WOS:A1993LR90000011
J	MARKOWITZ, N; HANSEN, NI; WILCOSKY, TC; HOPEWELL, PC; GLASSROTH, J; KVALE, PA; MANGURA, BT; OSMOND, D; WALLACE, JM; ROSEN, MJ; REICHMAN, LB				MARKOWITZ, N; HANSEN, NI; WILCOSKY, TC; HOPEWELL, PC; GLASSROTH, J; KVALE, PA; MANGURA, BT; OSMOND, D; WALLACE, JM; ROSEN, MJ; REICHMAN, LB			TUBERCULIN AND ANERGY TESTING IN HIV-SEROPOSITIVE AND HIV-SERONEGATIVE PERSONS	ANNALS OF INTERNAL MEDICINE			English	Article						TUBERCULIN TEST; HYPERSENSITIVITY, DELAYED; HUMAN IMMUNODEFICIENCY VIRUS SEROPOSITIVITY; SKIN TESTS; HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS	HUMAN-IMMUNODEFICIENCY-VIRUS; INTRAVENOUS-DRUG-USERS; SKIN-TEST; ACTIVE TUBERCULOSIS; INFECTION; HYPERSENSITIVITY; POPULATION; REACTIVITY; EPIDEMIC; OUTBREAK	Objective: To determine the prevalence and predictors of reactivity to tuberculin purified protein derivative (PPD) and skin test anergy in patients with human immunodeficiency virus (HIV) infection and in HIV-seronegative controls. Design: Cross-sectional analysis of baseline data from a prospective, multicenter study of pulmonary complications of HIV infection. Setting: Community-based cohort of persons with and without HIV infection. Patients: A total of 1171 HIV-seropositive patients without AIDS (841 homosexual men, 274 intravenous drug users, and 56 women with heterosexually acquired infection); 182 HIV-seronegative persons (125 homosexual men and 57 intravenous drug users). Measurements: Delayed-type hypersensitivity response to tuberculin PPD, trichophytin, mumps, and Candida antigens; T-lymphocyte subsets. Results: The prevalence of tuberculin PPD reactivity was higher among intravenous drug users than among homosexual men, in both HIV-seronegative (19.1% compared with 6.8%, P = 0.03) and HIV-seropositive persons (15.1% compared with 2.5%, P < 0.001). Among HIV-infected patients, the prevalence of tuberculin reactivity varied directly and that of anergy inversely with the absolute CD4 lymphocyte count. Prevalences were 1% and 72%, respectively, in patients with fewer than 200 CD4 cells/mm3, and 8.4% and 25.5%, respectively, in those with 600 CD4 cells/mm3 (P < 0.001 for both comparisons). Patients with HIV infection and fewer than 400 CD4 lymphocytes/mm3 had a lower prevalence of PPD reactivity than HIV-seronegative controls (2.7% compared with 10.0%, P < 0.001). The strongest predictors of tuberculin reactivity were intravenous drug use, black race, a previous positive PPD test result, and a history of Calmette-Guerin bacillus vaccination. The strongest predictor of anergy was HIV seropositivity. Conclusions: The response to delayed-type hypersensitivity antigens depends on immune status. The value of PPD and anergy testing in HIV-seropositive patients depends on the ability of such testing to predict subsequent tuberculosis, which is imprecisely known. Until more data or better methods are available, these tests should be done as early as possible in the course of HIV infection.	UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94143 USA; NORTHWESTERN UNIV, CHICAGO, IL 60611 USA; BETH ISRAEL MED CTR, NEW YORK, NY 10003 USA; UNIV MED & DENT NEW JERSEY, NEW BRUNSWICK, NJ 08903 USA; UNIV CALIF LOS ANGELES, LOS ANGELES, CA 90024 USA	University of California System; University of California San Francisco; Northwestern University; Harvard University; Beth Israel Deaconess Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of California System; University of California Los Angeles	MARKOWITZ, N (corresponding author), HENRY FORD HOSP, DIV INFECT DIS, 2799 W GRAND BLVD, DETROIT, MI 48202 USA.			Hansen, Nellie/0000-0003-4794-9646	NHLBI NIH HHS [N01-HR7-6031, N01-HR7-6029, N01-HR7-6030] Funding Source: Medline; DIVISION OF LUNG DISEASES [N01HR076030, N01HR076031, N01HR076029] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1992, MMWR Recomm Rep, V41, P1; BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; CANESSA PA, 1989, CHEST, V96, P1215, DOI 10.1378/chest.96.5.1215; COLEBUNDERS RL, 1989, J ACQ IMMUN DEF SYND, V2, P576; COMSTOCK GW, 1982, AM REV RESPIR DIS, V125, P8; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DIPERRI G, 1989, LANCET, V2, P1502; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; Fleiss JL, 1981, STAT METHODS RATES P; GIORGI JV, 1990, CLIN IMMUNOL IMMUNOP, V55, P173, DOI 10.1016/0090-1229(90)90096-9; GRAHAM NMH, 1992, JAMA-J AM MED ASSOC, V267, P369, DOI 10.1001/jama.267.3.369; HOLDEN M, 1971, NEW ENGL J MED, V285, P1506, DOI 10.1056/NEJM197112302852704; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; HUEBNER RE, 1992, JAMA-J AM MED ASSOC, V267, P409, DOI 10.1001/jama.267.3.409; Jereb J A, 1991, MMWR CDC Surveill Summ, V40, P23; JOHNSON MP, 1992, J INFECT DIS, V166, P194, DOI 10.1093/infdis/166.1.194; JORDAN TJ, 1991, JAMA-J AM MED ASSOC, V265, P2987, DOI 10.1001/jama.265.22.2987; KENT DC, 1967, AM REV RESPIR DIS, V95, P411; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; MAAYAN S, 1985, ARCH INTERN MED, V145, P1607, DOI 10.1001/archinte.145.9.1607; MARION SA, 1989, J ACQ IMMUN DEF SYND, V2, P178; NASH DR, 1980, CHEST, V77, P32, DOI 10.1378/chest.77.1.32; PALMER DL, 1974, J INFECT DIS, V130, P132, DOI 10.1093/infdis/130.2.132; PITCHENIK AE, 1984, ANN INTERN MED, V101, P641, DOI 10.7326/0003-4819-101-5-641; RIEDER HL, 1989, JAMA-J AM MED ASSOC, V262, P385, DOI 10.1001/jama.262.3.385; RIEDER HL, 1989, ARCH INTERN MED, V149, P1268, DOI 10.1001/archinte.149.6.1268; ROBERT CF, 1989, NEW ENGL J MED, V321, P1268; SEARS SD, 1987, CLIN IMMUNOL IMMUNOP, V45, P177, DOI 10.1016/0090-1229(87)90032-8; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SELWYN PA, 1992, JAMA-J AM MED ASSOC, V268, P504, DOI 10.1001/jama.268.4.504; SMALL PM, 1991, NEW ENGL J MED, V324, P289, DOI 10.1056/NEJM199101313240503; SMITH DT, 1967, ANN INTERN MED, V67, P919, DOI 10.7326/0003-4819-67-5-919; SNIDER DE, 1982, AM REV RESPIR DIS, V125, P108; 1987, MMWR, V36, pS1; 1987, MMWR, V36, P785; 1991, MMWR, V40, P273; 1991, MMWR, V40, P585; 1990, MMWR, V39, P645; 1987, MMWR, V36, P795; 1990, MMWR, V39, P1; 1990, MMWR, V39, P638; 1991, MMWR, V40, P1291	42	187	191	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1993	119	3					185	193		10.7326/0003-4819-119-3-199308010-00002	http://dx.doi.org/10.7326/0003-4819-119-3-199308010-00002			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU903	8100692				2022-12-28	WOS:A1993LU90300002
J	RAMSAY, MEB; RAO, M; BEGG, NT; REDHEAD, K; ATTWELL, AM				RAMSAY, MEB; RAO, M; BEGG, NT; REDHEAD, K; ATTWELL, AM			ANTIBODY-RESPONSE TO ACCELERATED IMMUNIZATION WITH DIPHTHERIA, TETANUS, PERTUSSIS-VACCINE	LANCET			English	Article							PERFORMANCE; AFFINITY	From May, 1990, a new schedule of immunisation against diphtheria, tetanus, and pertussis (at 2, 3, and 4 months) replaced the previous more widely spaced schedule. A report that children had lower concentrations of diphtheria and tetanus antibodies a month after an accelerated schedule led us to undertake a controlled study to assess antibody response and the persistence of antibodies a year after immunisation in children receiving vaccine according to widely spaced and accelerated schedules. Concentrations of antibodies to diphtheria and tetanus toxoids and to Bordetella pertussis filamentous haemagglutinin (FHA) were measured by solid-phase radioimmunoassay (SP-RIA). We studied 57 children who received accelerated immunisation at median ages of 11, 16, and 21 weeks and two control cohorts (total n = 82) who received vaccine at median ages of 15, 21, and 45 weeks. 6-8 weeks after the third dose the accelerated-schedule group had lower (p<0.0001) geometric mean concentrations of antibody to tetanus (0.522 [95% CI 0.383-0.710] vs 3.43 [2.45-4.81] IU/mL), diphtheria (0.266 [0.179-0.396] vs 2.39 [0.616-3.53] IU/mL), and FHA (0.044 10.030-0.063] vs 0.270 [0.196-0.374] units/mL) than the longer-schedule group. 12 months after the third dose the differences between the groups had narrowed (tetanus 0.197 vs 0.341 IU/mL, p=0.29; diphtheria 0.100 vs 0.131 IU/mL, p=0.64; FHA 0.014 vs 0.016 units/mL, p=0.72). At that time all children had tetanus antibody concentrations above protective levels (0.01 IU/mL); only 2 of 31 in the accelerated-schedule group and 3 of 31 in the longer-schedule group had diphtheria antibody concentrations below the protective level. The use of an accelerated schedule of diphtheria, tetanus, and pertussis vaccination is unlikely to lead to an increase in the proportion of children unprotected against these diseases before the preschool booster.	PHLS,CTR COMMUNICABLE DIS SURVEILLANCE,DIV IMMUNISAT,LONDON,ENGLAND; NE ESSEX HLTH AUTHOR,COLCHESTER,ESSEX,ENGLAND; NATL INST BIOL STAND & CONTROLS,POTTERS BAR,HERTS,ENGLAND	National Institute for Biological Standards & Control			Ramsay, Mary Elizabeth/S-8281-2016	Ramsay, Mary Elizabeth/0000-0002-7156-7640				[Anonymous], 1988, LANCET, Vi, P955; BOOY R, 1992, LANCET, V339, P507, DOI 10.1016/0140-6736(92)90336-2; JOHNSTONE A, 1987, IMMUNOCHEMISTRY PRAC; Miller E, 1992, Commun Dis Rep CDR Rev, V2, pR152; NIMMO GR, 1984, J IMMUNOL METHODS, V72, P177, DOI 10.1016/0022-1759(84)90446-0; RAMSAY MEB, 1991, BRIT MED J, V302, P1489, DOI 10.1136/bmj.302.6791.1489; SESARDIC D, 1992, LANCET, V340, P737, DOI 10.1016/0140-6736(92)92284-M; SMITH JWG, 1969, BRIT MED BULL, V25, P177, DOI 10.1093/oxfordjournals.bmb.a070689; STEWARD MW, 1985, J IMMUNOL METHODS, V78, P173, DOI 10.1016/0022-1759(85)90074-2; WHITE JM, 1992, BRIT MED J, V304, P682, DOI 10.1136/bmj.304.6828.682; 1990, IMMUNISATION INFECTI; 1989, CANADIAN IMMUNIZATIO; 1988, IMMUNISATION INFECTI; 1990, REPORT WHO M COPENHA	14	21	21	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 24	1993	342	8865					203	205		10.1016/0140-6736(93)92298-8	http://dx.doi.org/10.1016/0140-6736(93)92298-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN622	8100929				2022-12-28	WOS:A1993LN62200011
J	ALLEN, CMC				ALLEN, CMC			CONSCIOUS BUT PARALYZED - RELEASING THE LOCKED-IN	LANCET			English	Editorial Material											ALLEN, CMC (corresponding author), ADDENBROOKES HOSP,DEPT NEUROL,CAMBRIDGE CB2 2QQ,ENGLAND.							BERNAT JL, 1993, NEUROLOGY, V43, P224, DOI 10.1212/WNL.43.1_Part_1.224; BRAHAMS D, 1992, LANCET, V340, P1534, DOI 10.1016/0140-6736(92)92777-D; HOWARD RS, 1989, BRAIN, V112, P1155, DOI 10.1093/brain/112.5.1155; MOSS AH, 1993, NEUROLOGY, V43, P438, DOI 10.1212/WNL.43.2.438; PATTERSON JR, 1986, STROKE, V17, P758, DOI 10.1161/01.STR.17.4.758; THADANI VM, 1991, NEUROLOGY, V41, P498, DOI 10.1212/WNL.41.4.498; 1993, NEUROLOGY, V43, P222	7	10	11	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 17	1993	342	8864					130	131		10.1016/0140-6736(93)91340-R	http://dx.doi.org/10.1016/0140-6736(93)91340-R			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN042	8101251				2022-12-28	WOS:A1993LN04200006
J	COATES, A; FORBES, J				COATES, A; FORBES, J			IS CHEMOTHERAPY FOR NONSMALL CELL LUNG-CANCER WORTHWHILE	LANCET			English	Editorial Material							BREAST-CANCER; QUALITY; COSTS		NEWCASTLE MATER MISERICORDIAE HOSP, NEWCASTLE, NSW, AUSTRALIA; AUSTRALIAN NEW ZEALAND BREAST CANC TRIALS GRP, NEWCASTLE, NSW, AUSTRALIA	Calvary Mater Newcastle Hospital	COATES, A (corresponding author), ROYAL PRINCE ALFRED HOSP, CAMPERDOWN, NSW 2050, AUSTRALIA.							COATES A, 1987, NEW ENGL J MED, V317, P1490, DOI 10.1056/NEJM198712103172402; COATES AS, 1993, INTRO NEW TREATMENTS, P447; Early Breast Cancer Trialists' Collaborative Group, 1992, LANCET, V339, P1; GANZ PA, 1989, CANCER, V63, P1271, DOI 10.1002/1097-0142(19890401)63:7<1271::AID-CNCR2820630707>3.0.CO;2-6; GOLDHIRSCH A, 1989, J CLIN ONCOL, V7, P36, DOI 10.1200/JCO.1989.7.1.36; JAAKKIMAINEN L, 1990, J CLIN ONCOL, V8, P1301, DOI 10.1200/JCO.1990.8.8.1301; 1992, LANCET, V339, P71	7	12	12	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 3	1993	342	8862					4	4		10.1016/0140-6736(93)91876-N	http://dx.doi.org/10.1016/0140-6736(93)91876-N			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK985	8100297				2022-12-28	WOS:A1993LK98500005
J	VENDRELL, JP; REYNES, J; HUGUET, MF; NGOU, J; MICHARD, C; ATOUI, N; PRATLONG, F; SEGONDY, M; SERRE, A				VENDRELL, JP; REYNES, J; HUGUET, MF; NGOU, J; MICHARD, C; ATOUI, N; PRATLONG, F; SEGONDY, M; SERRE, A			IN-VITRO SYNTHESIS OF ANTIBODIES TO TOXOPLASMA-GONDII BY LYMPHOCYTES FROM HIV-1-INFECTED PATIENTS	LANCET			English	Note							HIV-1 INFECTION; SECRETION; CELLS	Toxoplasma-specific in-vitro antibody production by peripheral blood lymphocytes (PBL) was investigated in 124 adults infected with human immunodeficiency virus (HIV-1). PBL from 20 of 21 patients with cerebral toxoplasmosis showed spontaneous in-vitro secretion of antibodies to Toxoplasma gondii antigens. Among 103 HIV-1-infected patients without signs or symptoms of toxoplasmosis, PBL from 19 produced toxoplasma-specific antibodies in vitro; 5 of these patients, who discontinued prophylaxis for toxoplasmic encephalitis, showed in-vitro antibody production 3-15 months before the diagnosis of toxoplasmic encephalitis. In-vitro production of toxoplasma-specific antibodies could improve the diagnosis of toxoplasmic encephalitis in HIV-1-infected patients.	CHR MONTPELLIER,DEPT PARASITOL,MONTPELLIER,FRANCE; FAC MED MONTPELLIER,F-34000 MONTPELLIER,FRANCE; CHR MONTPELLIER,DEPT INFECT DIS,MONTPELLIER,FRANCE; FAC MED MONTPELLIER,F-34000 MONTPELLIER,FRANCE; CHR MONTPELLIER,DEPT IMMUNOL,MONTPELLIER,FRANCE; CHR MONTPELLIER,DEPT VIROL,MONTPELLIER,FRANCE	Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; CHU de Montpellier	VENDRELL, JP (corresponding author), INST BIOL,DEPT IMMUNOL,INSERM,U249,4 BLVD HENRI IV,F-34060 MONTPELLIER,FRANCE.							AMADORI A, 1989, J IMMUNOL, V143, P2146; [Anonymous], MMWR; LUFT BJ, 1992, CLIN INFECT DIS, V15, P211, DOI 10.1093/clinids/15.2.211; PAHWA S, 1989, P NATL ACAD SCI USA, V86, P7532, DOI 10.1073/pnas.86.19.7532; PORTER SB, 1992, NEW ENGL J MED, V327, P1643, DOI 10.1056/NEJM199212033272306; RIECKMANN P, 1991, J IMMUNOL, V147, P2922; STEPICKBIEK P, 1990, J INFECT DIS, V162, P270, DOI 10.1093/infdis/162.1.270; STEVENS RH, 1979, J IMMUNOL, V122, P2498; VENDRELL JP, 1992, CLIN EXP IMMUNOL, V89, P126, DOI 10.1111/j.1365-2249.1992.tb06890.x; VENDRELL JP, 1991, CLIN EXP IMMUNOL, V83, P197, DOI 10.1111/j.1365-2249.1991.tb05614.x	10	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 3	1993	342	8862					22	23		10.1016/0140-6736(93)91883-N	http://dx.doi.org/10.1016/0140-6736(93)91883-N			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK985	8100291				2022-12-28	WOS:A1993LK98500012
J	LOWRY, S				LOWRY, S			ONCOLOGY - MOLECULAR-BASIS FOR HORMONE-RELATED CANCER	LANCET			English	Editorial Material											LOWRY, S (corresponding author), BELFAST CITY HOSP,DEPT ONCOL,BELFAST BT9 7AD,ANTRIM,NORTH IRELAND.							FATHALLA MF, 1971, LANCET, V2, P163; FUTREAL PA, 1992, CANCER RES, V52, P2624; JACOBS IJ, 1993, CANCER RES, V53, P1218; LOWRY WS, 1992, OVARIAN CANC, V2, P35; POLYMEROPOULOS MH, 1991, NUCLEIC ACIDS RES, V19, P689, DOI 10.1093/nar/19.3.689; SKOLNICK HM, 1992, AM J HUM GENET, V51, P4; TULINIUS H, 1992, BRIT MED J, V305, P855, DOI 10.1136/bmj.305.6858.855	7	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 26	1993	341	8861					1630	1630		10.1016/0140-6736(93)90767-B	http://dx.doi.org/10.1016/0140-6736(93)90767-B			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ727	8099999				2022-12-28	WOS:A1993LJ72700013
J	SEARS, MR				SEARS, MR			RESPIRATORY-DISEASE - TRANSPLANTATION ASTHMA	LANCET			English	Editorial Material							MARROW TRANSPLANTATION				SEARS, MR (corresponding author), MCMASTER UNIV,DEPT MED,HAMILTON L8S 4L8,ONTARIO,CANADA.							AGOSTI JM, 1988, NEW ENGL J MED, V319, P1623, DOI 10.1056/NEJM198812223192502; ATKINSON K, 1984, TRANSPLANT P, V16, P1030; CORRIS, 1993, LANCET, V341, P1369; HERVE P, 1992, AM REV RESPIR DIS, V145, P1503, DOI 10.1164/ajrccm/145.6.1503; HIGENBOTTAM T, 1989, AM REV RESPIR DIS, V140, P52, DOI 10.1164/ajrccm/140.1.52; SUSTIEL A, 1989, CLIN EXP ALLERGY, V19, P11, DOI 10.1111/j.1365-2222.1989.tb02337.x	6	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 29	1993	341	8857					1377	1378		10.1016/0140-6736(93)90946-E	http://dx.doi.org/10.1016/0140-6736(93)90946-E			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE180	8098795				2022-12-28	WOS:A1993LE18000009
J	LOGAN, A				LOGAN, A			MOLECULAR MEDICINE - MAKING CALCIUM SIGNALS SELECTIVE	LANCET			English	Note											LOGAN, A (corresponding author), UNIV BIRMINGHAM,DEPT CLIN CHEM,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.			Logan, Ann/0000-0003-3215-5042				ALLBRITTON NL, 1992, SCIENCE, V258, P1812, DOI 10.1126/science.1465619; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; NATHANSON MH, 1992, J BIOL CHEM, V267, P18118; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0	4	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 15	1993	341	8855					1248	1248		10.1016/0140-6736(93)91151-B	http://dx.doi.org/10.1016/0140-6736(93)91151-B			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LC497	8098397				2022-12-28	WOS:A1993LC49700009
J	BALL, SG; COWAN, JC; WINTER, C; MACKINTOSH, AF; TAN, LB; CALDICOTT, L; CHANNER, K; HAWLEY, SK; WILSON, A; DEWS, I; KADR, H; STANTON, J; STATUCH, C; STEPHENS, JD; BERKIN, KE; DAVIES, S; RAJ, MVJ; CALLAGHAN, TS; JOSEPH, S; RAO, AC; HAMBLETON, D; HORNUNG, RS; RODRIGUES, E; ROBERTS, H; WALLER, D; WARNER, N; PUGH, SE; RAMAKRISHNAN, N; SEKAR, M; BLACKWOOD, RA; ROBINSON, P; CLARK, M; ROBSON, RH; PICKENS, PT; TILDESLEY, G; WHITE, RWB; KELLY, P; WILSON, JI; JONES, S; KINGDOM, C; PATTERSON, DLH; BENTLEY, A; GUPTA, S; HENDRY, WG; DAVIDSON, C; GLENNON, P; BISHOP, A; KLUTH, D; MOONEY, A; WILKINSON, P; ANTHONY, TP; GHOSH, AK; ROBSON, D; MCALEER, B; VARMA, MPS; LARKIN, H; KADDOURA, S; KNIGHT, C; SUTTON, G; CLARK, RS; BEEN, M; RAMAN, A; BROWN, AK; FOALE, R; SHAHI, J; BORLAND, C; JAYASURIYA, TG; SOMASUNDRAM, U; EKDAHL, S; HANSEN, S; BROQVIST, M; DAHLSTROM, U; KONGSTAD, O; CLINE, C; ERHARDT, L; WILLENHEIMER, R; BERGLUND, H; NYQUIST, O; NYMAN, P; URSING, D; JENSEN, S; GYLAND, F; LINNE, R; RAGNARTZ, T; WATZ, R; FREITAG, M; OLSSON, L; HALLGREN, J; LINDVALL, P; BERGIN, C; CREAN, P; ELGUYLANI, N; MCADAMS, B; MORAIS, D; SHEAHAN, R; MCKENNA, J; MURRAY, D; SULLIVAN, P; FENNELL, W; KEARNEY, P; VAUGHAN, C; GALVIN, J; SUGRUE, D; PEIRCE, T; GHAISAS, N; HARKIN, E; OCALLAGHAN, T; MCHUGH, P; NISAR, S; DALY, K; LAVIN, F; SHAH, P; JUNEJA, R; MCGARRY, K; JUNEJO, S; MACMAHON, B; PILLAY, NP; LONG, D; MAGUIRE, C; MULDOON, BC; SHIELS, P; BANNAN, L; CONNELLY, E; BARTON, J; MCCREERY, C; QUIGLEY, P; CASSIM, S; NAIDOO, DP; MYBURGH, DP; MARX, JD; COMMERFORD, PJ; LAWRENSON, J; THERON, HD; RAJPUT, MC; BENNETT, JM; SARELI, P; ARCE, P; RICCITELLI, MA; RYBA, D; BECK, E; DEMARTINI, A; BORREGA, NG; LAZZARI, J; GONZALEZ, M; LIPRANDI, AS; MARTINEZ, JM; SAMPO, EA; BORTMAN, G; GRANCELLI, H; CARBAJALES, J; GIROTTI, A; MAUTNER, B; GABRIELLI, O; CAGIDE, A; LAPUENTE, A; ESPER, R; TAKENS, LJ; VANDERHEIJDEN, MY; KRAGTEN, JA; RENKENS, R; TANS, AC; GROSFELD, MJW; KRUYSWIJK, HH; DEGROOT, A; LIEM, KL; OLTHOF, H; HAERKENSARENDS, HE; HOOGHOUDT, TEH; KUYPERS, A; NIEMEYER, MG; VANMANTGEM, JP; AELFERS, E; SLEGERS, LC; SCHEFFER, MG; DOEBE, BO; SCHRIJVERS, LEJM; VANWELY, LR; HERWEIJER, AH; DEMYTTENAERE, M; PEERENBOOM, P; BEKAERT, I; SURMONT, P; VANDORPE, A; BEYS, J; CLEMENT, D; BENIT, E; BEYLOOS, M; DURIEUX, C; BAYART, M; HERSSENS, M; CREMERS, S; DEKEYSER, F; VANWALLEGHEM, U; HOPF, R; MOLLER, A; HAUBER, J; HOFGARTNER, F; SIGEL, HA; GRIESHABER, M; NEUBAUER, M; RUDOLPH, K; SEHNERT, W; CARTSBURG, R; KLEINE, P; HENNECKE, TH; KINDLER, J; RAMME, P; HELLMANN, D; HEMMENFUNK, DA; FREYTAG, F; BECKER, HJ; EISENMENGER, A; FACH, WA; BERNHARDT, P; ERNST, BKH; JACOB, H; MALINOWSKI, K; ROTH, H; SIMON, H; BIAS, HJ; BISCHOFF, KO; GERNER, U; TORNOW, P; JENSEN, SG; MELLEMGAARD, K; AMTOFT, A; AXELSEN, A; CHRISTENSEN, C; HAUNSO, S; JORGENSEN, P; RASMUSSEN, S; STRUNGE, P; SVENDSEN, TL; MADSEN, H; NIELSEN, W; EGEDE, F; RASMUSSEN, J; MARKENVARD, J; MOLLERUP, H; SIGURD, B; KIRCHHOFF, M; MCNAIR, A; NIELSEN, PE; NIELSEN, JER; ANDERSEN, MP; BUCHER, E; ELLIOTT, P; SLANY, J; GRISOLD, M; KLEIN, W; ALDOR, E; DORNAUS, C; KAINZ, W; MLCZOCH, J; NOBIS, H; TRINKS, S; POHJOLASINTONEN, S; NAUKKARINEN, V; SIPILA, R; NIKUS, K; WINGREN, PE; HARKONEN, M; JAGERHOLM, S; ELORANTA, M; ISOJARVI, J; SUHONEN, O; KOSKELAINEN, J; DECIAN, F; VOLTA, SD; BERTON, G; CUCCHINI, F; ABELLI, I; GAZZOLA, U; VILLANI, GQ; CENTOFANTE, P; MOSELE, GM; VINCENZI, M; ACCORSI, F; DEITOS, GA; DELAGARDELLE, C; MUNCH, U; VOGELIN, HP				BALL, SG; COWAN, JC; WINTER, C; MACKINTOSH, AF; TAN, LB; CALDICOTT, L; CHANNER, K; HAWLEY, SK; WILSON, A; DEWS, I; KADR, H; STANTON, J; STATUCH, C; STEPHENS, JD; BERKIN, KE; DAVIES, S; RAJ, MVJ; CALLAGHAN, TS; JOSEPH, S; RAO, AC; HAMBLETON, D; HORNUNG, RS; RODRIGUES, E; ROBERTS, H; WALLER, D; WARNER, N; PUGH, SE; RAMAKRISHNAN, N; SEKAR, M; BLACKWOOD, RA; ROBINSON, P; CLARK, M; ROBSON, RH; PICKENS, PT; TILDESLEY, G; WHITE, RWB; KELLY, P; WILSON, JI; JONES, S; KINGDOM, C; PATTERSON, DLH; BENTLEY, A; GUPTA, S; HENDRY, WG; DAVIDSON, C; GLENNON, P; BISHOP, A; KLUTH, D; MOONEY, A; WILKINSON, P; ANTHONY, TP; GHOSH, AK; ROBSON, D; MCALEER, B; VARMA, MPS; LARKIN, H; KADDOURA, S; KNIGHT, C; SUTTON, G; CLARK, RS; BEEN, M; RAMAN, A; BROWN, AK; FOALE, R; SHAHI, J; BORLAND, C; JAYASURIYA, TG; SOMASUNDRAM, U; EKDAHL, S; HANSEN, S; BROQVIST, M; DAHLSTROM, U; KONGSTAD, O; CLINE, C; ERHARDT, L; WILLENHEIMER, R; BERGLUND, H; NYQUIST, O; NYMAN, P; URSING, D; JENSEN, S; GYLAND, F; LINNE, R; RAGNARTZ, T; WATZ, R; FREITAG, M; OLSSON, L; HALLGREN, J; LINDVALL, P; BERGIN, C; CREAN, P; ELGUYLANI, N; MCADAMS, B; MORAIS, D; SHEAHAN, R; MCKENNA, J; MURRAY, D; SULLIVAN, P; FENNELL, W; KEARNEY, P; VAUGHAN, C; GALVIN, J; SUGRUE, D; PEIRCE, T; GHAISAS, N; HARKIN, E; OCALLAGHAN, T; MCHUGH, P; NISAR, S; DALY, K; LAVIN, F; SHAH, P; JUNEJA, R; MCGARRY, K; JUNEJO, S; MACMAHON, B; PILLAY, NP; LONG, D; MAGUIRE, C; MULDOON, BC; SHIELS, P; BANNAN, L; CONNELLY, E; BARTON, J; MCCREERY, C; QUIGLEY, P; CASSIM, S; NAIDOO, DP; MYBURGH, DP; MARX, JD; COMMERFORD, PJ; LAWRENSON, J; THERON, HD; RAJPUT, MC; BENNETT, JM; SARELI, P; ARCE, P; RICCITELLI, MA; RYBA, D; BECK, E; DEMARTINI, A; BORREGA, NG; LAZZARI, J; GONZALEZ, M; LIPRANDI, AS; MARTINEZ, JM; SAMPO, EA; BORTMAN, G; GRANCELLI, H; CARBAJALES, J; GIROTTI, A; MAUTNER, B; GABRIELLI, O; CAGIDE, A; LAPUENTE, A; ESPER, R; TAKENS, LJ; VANDERHEIJDEN, MY; KRAGTEN, JA; RENKENS, R; TANS, AC; GROSFELD, MJW; KRUYSWIJK, HH; DEGROOT, A; LIEM, KL; OLTHOF, H; HAERKENSARENDS, HE; HOOGHOUDT, TEH; KUYPERS, A; NIEMEYER, MG; VANMANTGEM, JP; AELFERS, E; SLEGERS, LC; SCHEFFER, MG; DOEBE, BO; SCHRIJVERS, LEJM; VANWELY, LR; HERWEIJER, AH; DEMYTTENAERE, M; PEERENBOOM, P; BEKAERT, I; SURMONT, P; VANDORPE, A; BEYS, J; CLEMENT, D; BENIT, E; BEYLOOS, M; DURIEUX, C; BAYART, M; HERSSENS, M; CREMERS, S; DEKEYSER, F; VANWALLEGHEM, U; HOPF, R; MOLLER, A; HAUBER, J; HOFGARTNER, F; SIGEL, HA; GRIESHABER, M; NEUBAUER, M; RUDOLPH, K; SEHNERT, W; CARTSBURG, R; KLEINE, P; HENNECKE, TH; KINDLER, J; RAMME, P; HELLMANN, D; HEMMENFUNK, DA; FREYTAG, F; BECKER, HJ; EISENMENGER, A; FACH, WA; BERNHARDT, P; ERNST, BKH; JACOB, H; MALINOWSKI, K; ROTH, H; SIMON, H; BIAS, HJ; BISCHOFF, KO; GERNER, U; TORNOW, P; JENSEN, SG; MELLEMGAARD, K; AMTOFT, A; AXELSEN, A; CHRISTENSEN, C; HAUNSO, S; JORGENSEN, P; RASMUSSEN, S; STRUNGE, P; SVENDSEN, TL; MADSEN, H; NIELSEN, W; EGEDE, F; RASMUSSEN, J; MARKENVARD, J; MOLLERUP, H; SIGURD, B; KIRCHHOFF, M; MCNAIR, A; NIELSEN, PE; NIELSEN, JER; ANDERSEN, MP; BUCHER, E; ELLIOTT, P; SLANY, J; GRISOLD, M; KLEIN, W; ALDOR, E; DORNAUS, C; KAINZ, W; MLCZOCH, J; NOBIS, H; TRINKS, S; POHJOLASINTONEN, S; NAUKKARINEN, V; SIPILA, R; NIKUS, K; WINGREN, PE; HARKONEN, M; JAGERHOLM, S; ELORANTA, M; ISOJARVI, J; SUHONEN, O; KOSKELAINEN, J; DECIAN, F; VOLTA, SD; BERTON, G; CUCCHINI, F; ABELLI, I; GAZZOLA, U; VILLANI, GQ; CENTOFANTE, P; MOSELE, GM; VINCENZI, M; ACCORSI, F; DEITOS, GA; DELAGARDELLE, C; MUNCH, U; VOGELIN, HP			EFFECT OF RAMIPRIL ON MORTALITY AND MORBIDITY OF SURVIVORS OF ACUTE MYOCARDIAL-INFARCTION WITH CLINICAL-EVIDENCE OF HEART-FAILURE	LANCET			English	Article							VENTRICULAR ENLARGEMENT TRIAL; ENALAPRIL; COMPLICATIONS; INHIBITION	Survival after acute myocardial infarction has been enhanced by treatment with thrombolytic agents, aspirin, and beta-adrenoceptor blockade. However, there remains a substantial subgroup of patients who manifest clinical evidence of heart failure despite the first two of these treatments, and for whom beta-adrenoceptor antagonists are relatively or absolutely contraindicated. These patients have a greatly increased risk of fatal and non-fatal ischaemic, arrhythmic, and haemodynamic events. In this selected high-risk subset of patients we investigated the effect of therapy with the angiotensin converting enzyme (ACE) inhibitor ramipril, postulating that it would lengthen survival. 2006 patients who had shown clinical evidence of heart failure at any time after an acute myocardial infarction (AMI) were recruited from 144 centres in 14 countries. Patients were randomly allocated to double-blind treatment with either placebo (992 patients) or ramipril (1014 patients) on day 3 to day 10 after AMI (day 1). Patients with severe heart failure resistant to conventional therapy, in whom the attending physician considered the use of an ACE inhibitor to be mandatory, were excluded. Follow-up was continued for a minimum of 6 months and an average of 15 months. On intention-to-treat analysis mortality from all causes was significantly lower for patients randomised to receive ramipril (170 deaths; 17%) than for those randomised to receive placebo (222 deaths; 23%). The observed risk reduction was 27% (95% CI 11% to 40%; p=0.002). Analysis of prespecified secondary outcomes revealed a risk reduction of 19% for the first validated outcome (ie, first event in an individual patient)-namely, death, severe/resistant heart failure, myocardial infarction, or stroke (95% CI 5% to 31%; p=0.008). Oral administration of ramipril to patients with clinical evidence of either transient or ongoing heart failure, initiated between the second and ninth day after myocardial infarction, resulted in a substantial reduction in premature death from all causes. This benefit was apparent as early as 30 days and was consistent across a range of subgroups.	GEN INFIRM, LEEDS LS1 3EX, W YORKSHIRE, ENGLAND; ST JAMES UNIV HOSP, LEEDS LS9 7TF, W YORKSHIRE, ENGLAND; ROYAL HALLAMSHIRE HOSP, SHEFFIELD S10 2JF, S YORKSHIRE, ENGLAND; OLDCHURCH HOSP, ROMFORD RM7 0BE, ESSEX, ENGLAND; WHARFEDALE GEN HOSP, OTLEY, ENGLAND; GOOD HOPE DIST GEN HOSP, SUTTON COLDFIELD, ENGLAND; STRACATHRO HOSP, BRECHIN, SCOTLAND; MAYDAY HOSP, CROYDON, ENGLAND; WALTON HOSP, LIVERPOOL L9 1AE, MERSEYSIDE, ENGLAND; ROYAL S HANTS HOSP, SOUTHAMPTON SO9 4PE, HANTS, ENGLAND; SOUTHAMPTON GEN HOSP, SOUTHAMPTON SO9 4XY, HANTS, ENGLAND; SUNDERLAND DIST HOSP, SUNDERLAND, ENGLAND; WEXHAM PK HOSP, SLOUGH, ENGLAND; CUMBERLAND INFIRM, CARLISLE, ENGLAND; GEN HOSP, HARTLEPOOL, ENGLAND; PINDERFIELDS GEN HOSP, WAKEFIELD, ENGLAND; WHITTINGTON HOSP, LONDON N19 5NF, ENGLAND; WYCOMBE GEN HOSP, HIGH WYCOMBE, BUCKS, ENGLAND; ROYAL SUSSEX CTY HOSP, BRIGHTON BN2 5BE, E SUSSEX, ENGLAND; ASHFORD HOSP, ASHFORD, ENGLAND; PONTEFRACT DIST GEN HOSP, PONTEFRACT WF8 1PL, W YORKSHIRE, ENGLAND; GREENWICH DIST HOSP, LONDON, ENGLAND; ERNE HOSP, ENNISKILLEN, NORTH IRELAND; HARROGATE DIST HOSP, HARROGATE, ENGLAND; HILLINGDON HOSP, HILLINGDON, ENGLAND; SCARBOROUGH GEN HOSP, SCARBOROUGH, N YORKSHIRE, ENGLAND; WALSGRAVE GEN HOSP, COVENTRY CV2 2DY, W MIDLANDS, ENGLAND; ROYAL LANCASTER INFIRM, LANCASTER, ENGLAND; ST MARKS HOSP, LONDON EC1V 2PS, ENGLAND; HINCHINGBROOKE HOSP, HUNTINGDON, ENGLAND; FRIARAGE HOSP, NORTHALLERTON, ENGLAND; HOGLANDSSJUKHUSET EKSJO, EKSJO, SWEDEN; UNIV SJUKHUSET LINKOPING, LINKOPING, SWEDEN; MALMO GEN HOSP, S-21401 MALMO, SWEDEN; HUDDINGE HOSP, S-14186 HUDDINGE, SWEDEN; SJUKHUSET ANGELHOLM, ANGELHOLM, SWEDEN; LANSLASARETTET, KARLSHAMN, SWEDEN; LANDSKRONA LASARETT, LANDSKRONA, SWEDEN; SJUKHUSET KRISTINEHAMN, KRISTINEHAMN, SWEDEN; CENT LASARETTET, KARLSKRONA, SWEDEN; SIMRISHAMNS SJUKHUS, SIMRISHAMNS, SWEDEN; ST JAMES HOSP, DUBLIN 8, IRELAND; SLIGO GEN HOSP, SLIGO, IRELAND; MALLOW CTY HOSP, MALLOW, IRELAND; CORK REG HOSP, CORK, IRELAND; MATER MISERICORDIAE HOSP, DUBLIN, IRELAND; LIMERICK REG HOSP, LIMERICK, IRELAND; LOUTH CTY HOSP, DUNDALK, IRELAND; CTY HOSP, ROSCOMMON, IRELAND; UNIV COLL HOSP GALWAY, GALWAY, IRELAND; OUR LADYS HOSP, NAVAN, IRELAND; MONAGHAN GEN HOSP, MONAGHAN, IRELAND; OUR LADY LOURDES HOSP, DROGHEDA, IRELAND; LETTERKENNY GEN HOSP, LETTERKENNY, IRELAND; PORTIUNCULA HOSP, BALLINASLOE, IRELAND; ST VINCENTS HOSP, DUBLIN 4, IRELAND; ADDINGTON HOSP, DURBAN, SOUTH AFRICA; HF VERWOERD HOSP, PRETORIA, SOUTH AFRICA; UNIV HOSP BLOEMFONTEIN, BLOEMFONTEIN, SOUTH AFRICA; GROOTE SCHUUR HOSP, CAPE TOWN 7925, SOUTH AFRICA; HYDROMED HOSP, BLOEMFONTEIN, SOUTH AFRICA; RK KHAN HOSP, CHATSWORTH, ZIMBABWE; UNITAS HOSP, VERWOERDBURG, SOUTH AFRICA; BARAGWANATH HOSP, SOWETO, SOUTH AFRICA; HOSP ARGERICH, BUENOS AIRES, ARGENTINA; HOSP SANTOJANNI, BUENOS AIRES, ARGENTINA; HOSP PIROVANO, BUENOS AIRES, ARGENTINA; SANATORIO MITRE, BUENOS AIRES, ARGENTINA; HOSP CLIN JOSE SAN MARTIN, BUENOS AIRES, ARGENTINA; HOSP ESPANOL, BUENOS AIRES, ARGENTINA; HOSP RAMOS MEIJA, BUENOS AIRES, DF, ARGENTINA; HOSP JUAN A FERNANDEZ, BUENOS AIRES, ARGENTINA; HOSP ITALIANO BUENOS AIRES, BUENOS AIRES, ARGENTINA; HOSP INT AGUDOS EVA PERON, BUENOS AIRES, ARGENTINA; POLICLIN BANCARIA, BUENOS AIRES, ARGENTINA; MARTINI ZIEKENHUIS, GRONINGEN, NETHERLANDS; DE WEVER ZIEKENHUIS, HEERLEN, NETHERLANDS; HET NIEUWE SPITTAAL, ZUTPHEN, NETHERLANDS; SPAARNE ZIEKENHUIS, HEEMSTEDE, NETHERLANDS; ST STREEKZIEKENHUIS, HILVERSUM, NETHERLANDS; ELKERLIEK ZIEKENHUIS, HELMOND, NETHERLANDS; CANISIUS WILHELMINA ZIEKENHUIS, NIJMEGEN, NETHERLANDS; MERWEDE ZIEKENHUIS, SLIEDRECHT EN DORDRECHT, NETHERLANDS; ST ZIEKENHUIS AMSTELVEEN, AMSTELVEEN, NETHERLANDS; ST SINT JOSEPH ZIEKENHUIS, VELDHOVEN, NETHERLANDS; ST CLARA HOSP, ROTTERDAM, NETHERLANDS; MARTINI ZIEKENHUIS, GRONINGEN, NETHERLANDS; ST SINT JOSEPH ZIEKENHUIS, VEGHEL, NETHERLANDS; DRECHTSTEDEN ZIEKENHUIS, ZWIJNDRECHT, NETHERLANDS; HOP BRAINE ALLEUD, BRAINE LALLEUD, BELGIUM; ST ANNA HOSP, ST TRUIDEN, BELGIUM; AZ ST JOZEF, TURNHOUT, BELGIUM; ONZE LIEVE VROUW MIDDELARES ZIEKENHUIS, DEURNE, BELGIUM; HEILIG HARTZIEKENHUIS, NEERPELT, BELGIUM; ONZE LIEVE VROUW HOSP, MECHELEN, BELGIUM; HEILIG HARTZIEKENHUIS, ROESELARE, BELGIUM; CLIN DEUX ALICE, BRUSSELS, BELGIUM; KLIN ZWARTE ZUSTERS, IEPER, BELGIUM; ST JOZEFKLIN, BORNEM, BELGIUM; HOP ST THERESE, BASTOGNE, BELGIUM; AZ ST NORBERTUS, DUFFET, BELGIUM; KRANKENHAUS SACHSENHAUSEN, FRANKFURT, GERMANY; KLIN EICHERT, GOPPINGEN, GERMANY; DREIEICH KRANKENHAUS, LANGEN, GERMANY; EVANGEL KRANKENHAUS, HERNE, GERMANY; ALBERT SCHWEITZER KRANKENHAUS, NORTHEIM, GERMANY; KREISKRANKENHAUS, WURSELEN, GERMANY; ST JOSEFS HOSP, CLOPPENBURG, GERMANY; KREISKRANKENHAUS, GUNZENHAUSEN, GERMANY; STADT KRANKENHAUS, HANAU, GERMANY; EVANGEL KRANKENHAUS, ESSEN, GERMANY; STADT KRANKENHAUS, DUREN, GERMANY; KREISKRANKENHAUS, WALDBROL, GERMANY; STADT KLINIKEN, CHEMNITZ, GERMANY; STADT KLINIKEN, OLDBURG, GERMANY; FAC, HILLEROD, DENMARK; BRAEDSTRUP SYGEHUS, BRAEDSTRUP, DENMARK; RIGSHOSP, DK-2100 COPENHAGEN, DENMARK; HORSENS SYGEHUS, HORSENS, DENMARK; NAESTVED CENT SYGEHUS, NAESTVED, DENMARK; SVENDBORG SYGEHUS, SVENDBORG, DENMARK; CENT SYGEHUSET I, NYKOBING, DENMARK; FREDERIKSSUND SYGEHUS, FREDERIKSSUND, DENMARK; KAS GLOSTRUP, COPENHAGEN, DENMARK; SUNDBY HOSP, COPENHAGEN, DENMARK; KRANKENANSTALT RUDOLFSTIFTUNG WIEN, A-1030 VIENNA, AUSTRIA; GRAZ UNIV, MED KLIN, A-8010 GRAZ, AUSTRIA; HANUSCH HOSP, A-1140 VIENNA, AUSTRIA; KRANKENHAUS LAINZ, VIENNA, AUSTRIA; UNIV HELSINKI, CENT HOSP, SF-00100 HELSINKI 10, FINLAND; JORVI HOSP, ESPOO, FINLAND; MALMI DIST HOSP, PIETARSAARI, FINLAND; PROVOO DIST HOSP, PORVOO, FINLAND; LAPPI CENT HOSP, ROVANIEMI, FINLAND; LOHJA DIST HOSP, LOHJA, FINLAND; LOUNAIS HAME DIST HOSP, FORSA, FINLAND; UNIV PADOVA POLICLIN, PADUA, ITALY; OSPED GEN, BASSANO DEL GRAPPA, ITALY; OSPED CIVILE, PIACENZA, ITALY; OSPED GEN PROV, CONEGLIANO, ITALY; CTR HOSP LUXEMBOURG, LUXEMBOURG, LUXEMBOURG; KREISSPITAL, BULACH, SWITZERLAND	Leeds General Infirmary; Saint James's University Hospital; University of Sheffield; Heart of England NHS Foundation Trust; Good Hope Hospital; Croydon University Hospital; Walton Centre; University of Southampton; University Hospital Southampton NHS Foundation Trust; Royal South Hants Hospital; University of Southampton; Pinderfields Hospital; University of London; University College London; University of Brighton; Imperial College London; Linkoping University; Trinity College Dublin; Mater Misericordiae University Hospital; University College Dublin; University of Limerick; Ollscoil na Gaillimhe-University of Galway; University College Dublin; University of Cape Town; University of Buenos Aires; University of Buenos Aires; Hospital de Clinicas Jose de San Martin; University of Buenos Aires; University of Buenos Aires; Hospital Italiano de Buenos Aires; University of Buenos Aires; Martini Hospital; Spaarne Hospital; Canisius-Wilhelmina Hospital; Martini Hospital; Chemnitz Clinic; Rigshospitalet; University of Copenhagen; Aarhus University; Naestved Hospital; Rudolfstiftung Hospital; University of Graz; WGKK - Hanusch Hospital; University of Helsinki; Helsinki University Central Hospital; University of Padua; Luxembourg Hospital Center			Callaghan, Terens V./N-7640-2014; Nikus, Kjell/K-7813-2019; Lima, Thaísa/AAG-6483-2021					[Anonymous], 1989, NEW ENGL J MED, V321, P406; [Anonymous], 1990, LANCET, V336, P65; BIGGER JT, 1984, ANNU REV MED, V35, P127; Bunning P, 1987, J Cardiovasc Pharmacol, V10 Suppl 7, pS31; CLELAND JGF, IN PRESS J CARDIOVAS; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; ERMAN A, 1991, J HYPERTENS, V9, P1057, DOI 10.1097/00004872-199111000-00012; FURBERG CD, 1984, CIRCULATION, V69, P761, DOI 10.1161/01.CIR.69.4.761; GOTTLIEB S, 1992, AM J CARDIOL, V69, P977, DOI 10.1016/0002-9149(92)90850-X; HALL AS, 1991, J CARDIOVASC PHARM, V18, pS105, DOI 10.1097/00005344-199100182-00022; HALL AS, 1989, LANCET, V2, P1527; HALL D, 1992, J AM COLL CARDIOL, V20, P1549, DOI 10.1016/0735-1097(92)90449-W; HUTCHINS GM, 1978, AM J CARDIOL, V41, P1127, DOI 10.1016/0002-9149(78)90869-X; KILLIP T, 1967, AM J CARDIOL, V20, P457, DOI 10.1016/0002-9149(67)90023-9; LINZ W, 1992, J MOL CELL CARDIOL, V24, P909, DOI 10.1016/0022-2828(92)91103-C; LORELL BH, 1993, NEW ENGL J MED, V328, P966; MOSS AJ, 1988, NEW ENGL J MED, V319, P385; MOSS AJ, 1983, NEW ENGL J MED, V309, P331, DOI 10.1056/nejm198308113090602; MOYE LA, 1991, AM J CARDIOL, V68, pD70; NICKLAS JM, 1992, NEW ENGL J MED, V327, P685; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; PFEFFER MA, 1990, CIRCULATION, V81, P1161, DOI 10.1161/01.CIR.81.4.1161; SHARPE N, 1988, LANCET, V1, P255; STEVENSON R, 1993, BMJ-BRIT MED J, V307, P349, DOI 10.1136/bmj.307.6900.349; SWEDBERG K, 1992, NEW ENGL J MED, V327, P678, DOI 10.1056/NEJM199209033271002; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; VANDEWERF F, 1990, LANCET, V336, P71; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; YUSUF S, 1992, LANCET, V340, P1173, DOI 10.1016/0140-6736(92)92889-N	30	1845	1894	3	48	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 2	1993	342	8875					821	828						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA025	8104270				2022-12-28	WOS:A1993MA02500007
J	GENEWEIN, A; TELENTI, A; BERNASCONI, C; MORDASINI, C; WEISS, S; MAURER, AM; RIEDER, HL; SCHOPFER, K; BODMER, T				GENEWEIN, A; TELENTI, A; BERNASCONI, C; MORDASINI, C; WEISS, S; MAURER, AM; RIEDER, HL; SCHOPFER, K; BODMER, T			MOLECULAR APPROACH TO IDENTIFYING ROUTE OF TRANSMISSION OF TUBERCULOSIS IN THE COMMUNITY	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; MYCOBACTERIUM-TUBERCULOSIS; EPIDEMIOLOGY; OUTBREAK; TOOL; ELEMENT; POLYMORPHISMS; INFECTION; COMPLEX; STRAINS	There is growing concern that tuberculosis is spread in Europe in the way that it is in the USA. We have used DNA ''fingerprinting'' in a systematic evaluation of tuberculosis cases notified in our community to uncover foci of transmission. An IS6110 probe was used to test all isolates from culture-confirmed tuberculosis cases (163 patients) notified in 1991-92 in the Canton of Berne. In total, 45 patients (27.6%), potentially linked on the basis of restriction fragment length polymorphism, were investigated edepidemiologically. The largest group (n = 22) included members of a defined social group (drug addicts, homeless persons, alcoholics), from whom tuberculosis spread to the general population. A key patient developed multidrug-resistant tuberculosis during the surveillance period. This population study showed that (i) extensive transmission of Mycobacterium tuberculosis is now taking place in Europe in the same social setting as in the USA; (ii) there is definite ''spillover'' to the general population; (iii) the dimensions of the problem cannot be recognised easily by routine public health service activities because of the complexity of the transmission network; and (iv) multidrug-resistant tuberculosis develops in this setting.	UNIV BERN,INST MED MICROBIOL,FRIEDBUEHLSTR 51,CH-3010 BERN,SWITZERLAND; TIEFENAU HOSP,BERN,SWITZERLAND; CANTONAL LEAGUE AGAINST TB & LUNG DIS,BERN,SWITZERLAND; CANTONAL OFF PUBL HLTH,BERN,SWITZERLAND; FED OFF PUBL HLTH,LIEBEFELD,SWITZERLAND	University of Bern			Telenti, Amalio/AAY-1674-2021					ANNAS GJ, 1993, NEW ENGL J MED, V328, P585, DOI 10.1056/NEJM199302253280825; BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; COHN DL, 1990, ANN INTERN MED, V112, P407, DOI 10.7326/0003-4819-76-3-112-6-407; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; HERMANS PWM, 1990, J CLIN MICROBIOL, V28, P2051, DOI 10.1128/JCM.28.9.2051-2058.1990; ISERMAN MD, 1993, NEW ENGL J MED, V328, P576; LAGUNA F, 1991, J INFECTION, V23, P139, DOI 10.1016/0163-4453(91)92016-X; MCADAM RA, 1990, MOL MICROBIOL, V4, P1607, DOI 10.1111/j.1365-2958.1990.tb02073.x; MULLER M, 1992, ZWANGSMASSNAHMEN INS; NOLAN CM, 1991, AM REV RESPIR DIS, V143, P257, DOI 10.1164/ajrccm/143.2.257; PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191; RAVIGLIONE MC, 1993, B WORLD HEALTH ORGAN, V71, P297; REVES R, 1981, AM J EPIDEMIOL, V113, P423, DOI 10.1093/oxfordjournals.aje.a113110; RIEDER HL, 1992, TUBERCLE LUNG DIS, V73, P181, DOI 10.1016/0962-8479(92)90082-U; RIEDER HL, 1989, EPIDEMIOL REV, V11, P79, DOI 10.1093/oxfordjournals.epirev.a036046; ROSS BC, 1992, J CLIN MICROBIOL, V30, P942, DOI 10.1128/JCM.30.4.942-946.1992; THIERRY D, 1990, NUCLEIC ACIDS RES, V18, P188, DOI 10.1093/nar/18.1.188; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993; VANSOOLINGEN D, 1991, J CLIN MICROBIOL, V29, P2578, DOI 10.1128/JCM.29.11.2578-2586.1991; VANSOOLINGEN D, 1992, RFLP ANAL MYCOBACTER; ZHANG YS, 1992, J CLIN MICROBIOL, V30, P1551, DOI 10.1128/JCM.30.6.1551-1556.1992; 1992, MMWR, V41, P1; 1991, MMWR, V40, P585; 1991, MMWR, V40, P869; 1991, B OFF FED SANTE PUBL, V35, P546	27	203	207	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 2	1993	342	8875					841	844		10.1016/0140-6736(93)92698-S	http://dx.doi.org/10.1016/0140-6736(93)92698-S			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA025	8104275				2022-12-28	WOS:A1993MA02500012
J	CHRISTAKIS, NA; ASCH, DA				CHRISTAKIS, NA; ASCH, DA			BIASES IN HOW PHYSICIANS CHOOSE TO WITHDRAW LIFE-SUPPORT	LANCET			English	Article							SUSTAINING TREATMENT; ADVANCE DIRECTIVES; DECISION-MAKING; CRITICALLY ILL; CARE; PREFERENCES; EUTHANASIA; ATTITUDES	We have investigated biases in physicians' decisions regarding the form of life support to withdraw from critically ill patients in whom the decision to withdraw has already been made. Using a specially designed instrument that solicited both self-reported preferences and also responses to experimentally varied clinical vignettes, we surveyed 862 American internists, of whom 481 (56%) responded. Physicians do have preferences about the form of life support withdrawn. From most likely to least likely the order is: blood products, haemodialysis, intravenous vasopressors, total parenteral nutrition, antibiotics, mechanical ventilation, tube feedings, and intravenous fluids. Four biases in decision making were also identified. Physicians prefer to withdraw forms of therapy supporting organs that failed for natural rather than iatrogenic reasons, to withdraw recently instituted rather than longstanding interventions, to withdraw forms of therapy resulting in immediate death rather than delayed death, and to withdraw forms of therapy resulting in delayed death when confronted with diagnostic uncertainty. Because these biases may have clinical, social, and ethical consequences counter to patient goals, and because they may affect the underlying decision whether to withdraw life support at all, they may represent impediments to rational and compassionate decision making in critical care.	UNIV PENN, LEONARD DAVIS INST HLTH ECON, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DIV FISIOL VEGETAL, PHILADELPHIA, PA 19104 USA; UNIV PENN, DEPT SOCIOL, PHILADELPHIA, PA 19104 USA; VET AFFAIRS MED CTR, PHILADELPHIA, PA USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center			Christakis, Nicholas A/B-6690-2008; Christakis, Nicholas A/C-3205-2009	Asch, David/0000-0002-7970-286X				[Anonymous], 1983, PRESIDENTS COMMISSIO; BOSK CL, 1980, NEW ENGL J MED, V303, P71, DOI 10.1056/NEJM198007103030203; BRETT AS, 1991, JAMA-J AM MED ASSOC, V266, P825, DOI 10.1001/jama.266.6.825; CARALIS PV, 1992, CRIT CARE MED, V20, P683, DOI 10.1097/00003246-199205000-00023; Cassell EJ, 1991, NATURE SUFFERING GOA; CHARLSON ME, 1986, JAMA-J AM MED ASSOC, V255, P1316, DOI 10.1001/jama.255.10.1316; COHEN BJ, 1992, MED DECIS MAKING, V12, P350; CRANE D, 1977, SANCTITY SOCIAL LIFE; DANIS M, 1988, JAMA-J AM MED ASSOC, V260, P797, DOI 10.1001/jama.260.6.797; DANIS M, 1991, NEW ENGL J MED, V324, P882, DOI 10.1056/NEJM199103283241304; EMANUEL EJ, 1988, LANCET, V1, P106; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; FABERLANGENDOEN K, 1992, CRIT CARE MED, V20, P570, DOI 10.1097/00003246-199205000-00005; HOLLANDER M, 1973, NONPARAMETRIC STATIS; LYNN J, 1989, BY NO EXTRAORDINARY; MOWER WR, 1993, ARCH INTERN MED, V153, P375, DOI 10.1001/archinte.153.3.375; NEU S, 1986, NEW ENGL J MED, V314, P14, DOI 10.1056/NEJM198601023140103; NIGHTINGALE SD, 1988, CHEST, V93, P684, DOI 10.1378/chest.93.4.684; PEARLMAN RA, 1982, ANN INTERN MED, V97, P420, DOI 10.7326/0003-4819-97-3-420; RUARK JE, 1988, NEW ENGL J MED, V318, P25, DOI 10.1056/NEJM198801073180106; Samuelson W, 1988, J RISK UNCERTAINTY, V1, P7, DOI 10.1007/BF00055564; SCHNEIDERMAN LJ, 1988, NEW ENGL J MED, V318, P984, DOI 10.1056/NEJM198804143181509; SMEDIRA NG, 1990, NEW ENGL J MED, V322, P309, DOI 10.1056/NEJM199002013220506; SOLOMON MZ, 1993, AM J PUBLIC HEALTH, V83, P14, DOI 10.2105/AJPH.83.1.14; UHLMANN RF, 1991, ARCH INTERN MED, V151, P495, DOI 10.1001/archinte.151.3.495; VONPREYSSFRIEDMAN SM, 1992, J GEN INTERN MED, V7, P46, DOI 10.1007/BF02599102; WEIR RF, 1989, ABATING TREATMENT CR; WILSON W C, 1992, Journal of the American Medical Association, V267, P949, DOI 10.1001/jama.267.7.949; Zussman Robert, 1992, INTENSIVE CARE MED E; 1991, LANCET, V337, P96	30	143	146	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 11	1993	342	8872					642	646		10.1016/0140-6736(93)91759-F	http://dx.doi.org/10.1016/0140-6736(93)91759-F			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX272	8103146	hybrid			2022-12-28	WOS:A1993LX27200010
J	HANSEN, PR; HOVGAARD, D				HANSEN, PR; HOVGAARD, D			GRANULOCYTE AND GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTORS	LANCET			English	Letter							LIPOPROTEINS		UNIV COPENHAGEN,RIGSHOSP,DEPT HAEMATOL,DK-2100 COPENHAGEN,DENMARK	Rigshospitalet; University of Copenhagen	HANSEN, PR (corresponding author), UNIV COPENHAGEN,RIGSHOSP,DEPT MED B2142,DIV CARDIOL,BLEGDAMSVEJ 9,DK-2100 COPENHAGEN,DENMARK.		Hansen, Peter Riis/AAR-7659-2020					ISHIBASHI S, 1990, J BIOL CHEM, V265, P14109; SCANU AM, 1990, J CLIN INVEST, V85, P1709, DOI 10.1172/JCI114625; SHIMANO H, 1990, J BIOL CHEM, V265, P12869; STOUDEMIRE JB, 1991, BLOOD, V77, P750	4	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 11	1993	342	8872					679	679						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX272	8103162				2022-12-28	WOS:A1993LX27200040
J	HERMANN, E; YU, DTY; ZUMBUSCHENFELDE, KHM; FLEISCHER, B				HERMANN, E; YU, DTY; ZUMBUSCHENFELDE, KHM; FLEISCHER, B			HLA-B27-RESTRICTED CD8 T-CELLS DERIVED FROM SYNOVIAL-FLUIDS OF PATIENTS WITH REACTIVE ARTHRITIS AND ANKYLOSING-SPONDYLITIS	LANCET			English	Article							REITERS-SYNDROME; CLONES; HLA-B27; LYMPHOCYTES; DISEASE; SELF	Ankylosing spondylitis and seronegative spondylarthropathies such as Reiter's syndrome and reactive arthritis are strongly associated with HLA-B27. However, the mechanisms by which HLA-B27 is involved in disease susceptibility and pathogenesis are unknown. If the disease association is a consequence of HLA-B27's physiological function in antigen presentation, the disease should be mediated by cytotoxic T lymphocytes (CTLs) that recognise bacterial or self peptides presented by HLA-B27. Proof of this arthritogenic peptide model requires isolation of B27-restricted CD8 T cells from arthritic joints of patients with spondylarthropathies. An important question is whether ''arthritogenic'' bacteria such as yersinia or salmonella can generate HLA-B27-restricted bacteria-specific CTLs. We describe such HLA-B27-restricted CTLs. We tested a panel of 354 alphabeta-TCR CD8 T lymphocyte clones (TLCs) that had been derived from the synovial fluid of 4 patients with reactive arthritis and 2 patients with ankylosing spondylitis. In 1 patient with yersinia-induced arthritis, 2 TLCs were identified that killed specifically yersinia-infected B27 target cells. In another patient with salmonella-induced arthritis, 1 B27-restricted CD8 TLC that recognised both salmonella and yersinia was identified. In 5 of the 6 patients autoreactive CTLs were found, 5 of which showed B27-restricted killing of uninfected cell lines. B27-restricted CTLs with specificity for arthritogenic bacteria or autoantigens provide a missing link in the pathogenesis of the HLA-B27-associated spondylarthropathies.	UNIV CALIF LOS ANGELES,DEPT MED,DIV RHEUMATOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles	HERMANN, E (corresponding author), JOHANNES GUTENBERG UNIV,DEPT MED 1,LANGENBECKSTR 1,D-55101 MAINZ,GERMANY.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR040919] Funding Source: NIH RePORTER; NIAMS NIH HHS [NIAMS P01 AR40919] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ahvonen P, 1969, Acta Rheumatol Scand, V15, P232; BENJAMIN R, 1990, IMMUNOL TODAY, V11, P137, DOI 10.1016/0167-5699(90)90051-A; BENJAMIN R, 1992, RHEUM DIS CLIN N AM, V18, P11; BIJLSMA JWJ, 1988, ANN RHEUM DIS, V47, P350, DOI 10.1136/ard.47.4.350-b; BRANCATO L, 1989, RHEUMATOL INT, V9, P137; BUCHMEIER NA, 1990, SCIENCE, V248, P730, DOI 10.1126/science.1970672; EDWARDS PAW, 1982, EUR J IMMUNOL, V12, P641, DOI 10.1002/eji.1830120804; GAMMON G, 1991, IMMUNOL TODAY, V12, P193, DOI 10.1016/0167-5699(91)90052-U; GUMPEL JM, 1981, ANN RHEUM DIS, V40, P64, DOI 10.1136/ard.40.1.64; HASSELL AB, 1992, CLIN EXP IMMUNOL, V88, P442; HERMANN E, 1992, CLIN EXP IMMUNOL, V89, P427; HERMANN E, 1992, J RHEUMATOL, V19, P1243; HERMANN E, 1990, SCAND J RHEUMATOL, V19, P350, DOI 10.3109/03009749009096790; HERMANN E, 1992, CELL IMMUNOL, V143, P253, DOI 10.1016/0008-8749(92)90023-I; HERMANN E, 1989, CLIN EXP IMMUNOL, V75, P365; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; KAPASI K, 1992, J IMMUNOL, V148, P3554; KEAT A, 1983, NEW ENGL J MED, V309, P1606, DOI 10.1056/NEJM198312293092604; KINGSLEY G, 1992, RHEUM DIS CLIN N AM, V18, P49; MONACO JJ, 1992, IMMUNOL TODAY, V13, P173, DOI 10.1016/0167-5699(92)90122-N; PFEIFER JD, 1993, NATURE, V361, P359, DOI 10.1038/361359a0; SCHLAAK J, 1992, EUR J IMMUNOL, V22, P2771, DOI 10.1002/eji.1830221103; VARTIAINEN J, 1964, ACTA MED SCAND, V175, P771; VINER NJ, 1991, ARTHRITIS RHEUM, V34, P1151, DOI 10.1002/art.1780340911	24	304	309	1	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 11	1993	342	8872					646	650		10.1016/0140-6736(93)91760-J	http://dx.doi.org/10.1016/0140-6736(93)91760-J			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX272	8103147				2022-12-28	WOS:A1993LX27200011
J	MCGRATH, R				MCGRATH, R			TRADING IN DEATH - ANTI-PERSONNEL MINES	LANCET			English	Editorial Material											MCGRATH, R (corresponding author), MINES ADVISORY GRP,COCKERMOUTH,CUMBRIA,ENGLAND.								0	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 11	1993	342	8872					628	629		10.1016/0140-6736(93)91751-7	http://dx.doi.org/10.1016/0140-6736(93)91751-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX272	8103138				2022-12-28	WOS:A1993LX27200002
J	HARRIS, DN; BAILEY, SM; SMITH, PLC; TAYLOR, KM; OATRIDGE, A; BYDDER, GM				HARRIS, DN; BAILEY, SM; SMITH, PLC; TAYLOR, KM; OATRIDGE, A; BYDDER, GM			BRAIN-SWELLING IN 1ST HOUR AFTER CORONARY-ARTERY BYPASS-SURGERY	LANCET			English	Note							RESONANCE	Six patients undergoing routine coronary artery bypass surgery were examined by magnetic resonance imaging of the brain before surgery, immediately afterwards, and 6-18 days later. Brain swelling was visible in all six patients on the immediate postoperative scan. In five patients who had later scans the swelling had subsided. No major neurological deficits were seen, and the patients were extubated successfully within 3 h of the operation. The mechanism of the cerebral swelling is uncertain, but it may provide insight into the cause of neurophysiological deficits seen after coronary artery surgery.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT CARDIAC SURG,LONDON W12 0NN,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT DIAGNOST RADIOL,LONDON W12 0NN,ENGLAND	Imperial College London; Imperial College London	HARRIS, DN (corresponding author), HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT ANAESTHESIA,LONDON W12 0NN,ENGLAND.							BLAUTH CI, 1988, J THORAC CARDIOV SUR, V95, P668; DECOENE B, 1992, AM J NEURORADIOL, V13, P1555; HIS JH, 1991, AJR, V157, P1291; MOODY DM, 1990, ANN NEUROL, V28, P477, DOI 10.1002/ana.410280403; SCHMIDT R, 1993, NEUROLOGY, V43, P775, DOI 10.1212/WNL.43.4.775; SELLMAN M, 1992, ANN THORAC SURG, V53, P807, DOI 10.1016/0003-4975(92)91441-B; SHAW PJ, 1987, Q J MED, V62, P259; SMITH PLC, 1986, LANCET, V1, P823; VIK A, 1991, NEURORADIOLOGY, V33, P396, DOI 10.1007/BF00598610; WHITFIELD A, 1989, BRIT J ANAESTH, V62, P694, DOI 10.1093/bja/62.6.694	10	194	197	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 4	1993	342	8871					586	587		10.1016/0140-6736(93)91412-F	http://dx.doi.org/10.1016/0140-6736(93)91412-F			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV963	8102722				2022-12-28	WOS:A1993LV96300012
J	AOKI, TT; BENBARKA, MM; OKIMURA, MC; ARCANGELI, MA; WALTER, RM; WILSON, LD; TRUONG, MP; BARBER, AR; KUMAGAI, LF				AOKI, TT; BENBARKA, MM; OKIMURA, MC; ARCANGELI, MA; WALTER, RM; WILSON, LD; TRUONG, MP; BARBER, AR; KUMAGAI, LF			LONG-TERM INTERMITTENT INTRAVENOUS INSULIN THERAPY AND TYPE-1 DIABETES-MELLITUS	LANCET			English	Article							CARBOHYDRATE EXCHANGE; GLUCOSE-HOMEOSTASIS; GLYCEMIC INDEX; RESTORATION; INFUSION; MUSCLE; FOODS	An important defect in insulin-dependent diabetes mellitus (IDDM) is that the liver does not meet its full fuel-processing function, because many of the enzymes involved depend on high insulin concentrations in the portal vein. We tried to reactivate the liver by long-term treatment of IDDM patients with intravenous insulin in pulses, with the aim of achieving high portal-vein concentrations during and after a glucose meal. We studied 20 IDDM patients with brittle disease; despite use of a four-injection regimen with manipulation of insulin doses, diet, and physical activity, and frequent clinic visits for at least a year, these patients still had wide swings in blood glucose and frequent hypoglycaemic reactions. The intermittent therapy consisted of 7-10 pulses of intravenous insulin, infused while the patient was ingesting carbohydrate, primarily glucose, during the first hour of a 3 h treatment; three treatments were given in a day. After 2 consecutive days' treatment, patients were treated for 1 day per week. No patient was withdrawn from the study. At the time of this analysis the duration of intermittent treatment ranged from 7 to 71 months (mean 41 [SE 5] months). Haemoglobin A1C concentrations declined from 8.5 (0.4)% at the end of the stabilisation phase to 7.0 (0.2)% at the analysis point (p = 0.0003). During the same time the frequencies of major and minor hypoglycaemic events also fell significantly (major 3.0 [1.1] to 0.1 [0], minor 13.0 [2.6] to 2.4 [0.8] per month; both p < 0.0001). Because the use of saline rather than insulin pulses would have led to unacceptable hyperglycaemia we opted for a historical control design. The absence of a true control group limits the interpretation of these preliminary results, but we believe further studies of hepatic and muscle metabolism before and after long-term intermittent intravenous insulin therapy would be worth while.			AOKI, TT (corresponding author), UNIV CALIF DAVIS,SACRAMENTO MED CTR,DEPT INTERNAL MED,DIV ENDOCRINOL,4301 X ST,BLDG FOLB II-C,SACRAMENTO,CA 95817, USA.							AOKI TT, 1983, J CLIN INVEST, V71, P837, DOI 10.1172/JCI110837; BERGER W, 1973, HORM METAB RES, V5, P4, DOI 10.1055/s-0028-1093991; CAHILL GF, 1959, AM J MED, V26, P264, DOI 10.1016/0002-9343(59)90316-X; FOSS MC, 1982, DIABETES, V31, P46, DOI 10.2337/diabetes.31.1.46; HEINEMANN L, 1989, J INTERN MED, V226, P325, DOI 10.1111/j.1365-2796.1989.tb01403.x; HERS HG, 1982, BIOCHEM J, V206, P2; ISHIDA T, 1984, DIABETES, V33, P984, DOI 10.2337/diabetes.33.10.984; JENKINS DJA, 1983, DIABETOLOGIA, V24, P257, DOI 10.1007/BF00282710; JENKINS DJA, 1981, AM J CLIN NUTR, V34, P362, DOI 10.1093/ajcn/34.3.362; KARAM JH, 1991, BASIC CLIN ENDOCRINO, P592; KELLEY D, 1988, J CLIN INVEST, V81, P1563, DOI 10.1172/JCI113489; MEISTAS MT, 1985, DIABETES, V34, P960, DOI 10.2337/diabetes.34.10.960; PILKIS SJ, 1968, P SOC EXP BIOL MED, V129, P681; RUDERMAN NB, 1968, DIABETES, V17, P611, DOI 10.2337/diab.17.10.611; STORER AC, 1976, BIOCHEM J, V159, P7, DOI 10.1042/bj1590007; WALDHAUSL W, 1982, DIABETOLOGIA, V23, P6, DOI 10.1007/BF00257722; Weinhouse S, 1976, CURRENT TOPICS CELLU, P1; WESSON DE, 1988, JPEN-PARENTER ENTER, V12, P237, DOI 10.1177/0148607188012003237	18	18	27	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 28	1993	342	8870					515	518		10.1016/0140-6736(93)91645-3	http://dx.doi.org/10.1016/0140-6736(93)91645-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU582	8102666				2022-12-28	WOS:A1993LU58200008
J	CREMERS, MJG; BOL, E; DEROOS, F; VANGIJN, J				CREMERS, MJG; BOL, E; DEROOS, F; VANGIJN, J			RISK OF SPORTS ACTIVITIES IN CHILDREN WITH DOWNS-SYNDROME AND ATLANTOAXIAL INSTABILITY	LANCET			English	Article							AXIAL INSTABILITY; CERVICAL-SPINE; SUBLUXATION; INDIVIDUALS; DISLOCATION; TOMOGRAPHY	10-40% of children with Down's syndrome have atlantoaxial instability. These children might run the risk of spinal cord compression if they play sport. The aim of our study was to assess this presumed risk. We obtained 282 radiographs of the cervical spine from a cohort of 400 children and young adults with Down's syndrome who attended special schools and who were between 4 and 20 years old (about 25% of all such children in the Netherlands). The atlantoaxial distance was more than 4 mm in 91 children. These children were randomly assigned to two groups, with the provision that all children at any particular school were assigned to the same group. Children of one group were allowed to continue their habitual sports and exercise activities, whereas those in the other group were advised not to play ''risky'' sports (as defined by a panel of four experts) and not to make ''risky'' movements during physical education lessons. The compliance of the experimental group was good. After a year, there were no differences between the groups in scores on a functional motor scale, the frequency of neurological signs, or changes in the atlantoaxial distance. The motor function of a third group of 44 children with Down's syndrome but normal atlantoaxial distances was similar to that of children in the other two groups, as was the frequency of neurological signs. These findings suggest there is no reason to stop children with Down's syndrome from playing certain sports and no need to screen them by radiography before they take up such sports activities.	UNIV UTRECHT,DEPT NEUROL,UTRECHT,NETHERLANDS	Utrecht University	CREMERS, MJG (corresponding author), UNIV UTRECHT,DEPT PHYSIOL & SPORTS,JANUS JONGBLOED RES CTR,VONDELLAAN 24,3521 GG UTRECHT,NETHERLANDS.							ALVAREZ N, 1986, APPL RES MENT RETARD, V7, P67, DOI 10.1016/0270-3092(86)90019-6; American Academy of Pediatrics Committee on Sports Medicine, 1984, PEDIATRICS, V74, P152; BRAAKHEKKE JP, 1985, CLIN NEUROL NEUROSUR, V87, P173, DOI 10.1016/0303-8467(85)90003-4; CHAUDHRY V, 1987, ANN NEUROL, V21, P606, DOI 10.1002/ana.410210616; Cook T.C., 1979, QUASIEXPERIMENTATION; CREMERS MJG, 1988, HED TIJDSCHR GENEESK, V132, P2328; CREMERS MJG, IN PRESS ARCH DIS CH; DAVIDSON RG, 1988, PEDIATRICS, V81, P857; GREENBERG AD, 1968, BRAIN, V91, P655, DOI 10.1093/brain/91.4.655; GROBOVSCHEK M, 1985, NEURORADIOLOGY, V27, P186, DOI 10.1007/BF00343797; HINCK VC, 1960, AMER J ROENTGENOL RA, V84, P945; HREIDARSSON S, 1982, PEDIATRICS, V69, P568; KOBORI M, 1986, SPINE, V11, P195, DOI 10.1097/00007632-198604000-00003; KRAIJER DW, 1981, SRZ SGZ SMZ SCHALEN; KRAMER J, 1991, RHEUM DIS CLIN N AM, V17, P757; LOCKE GR, 1966, AJR, V87, P135; MILLER JDR, 1986, J COMPUT ASSIST TOMO, V10, P589, DOI 10.1097/00004728-198607000-00007; ORLEBEKE JF, 1990, NEDERLANDS TIJDSCH G, V134, P2062; OYEVAAR AM, 1991, BEWEG HULPVERLENEN, V3, P178; PEUSCHEL SM, 1987, J PEDIATR, V110, P515; POWELL JF, 1990, ANAESTHESIA, V45, P1049, DOI 10.1111/j.1365-2044.1990.tb14886.x; PUESCHEL SM, 1984, J PEDIATR ORTHOPED, V4, P682, DOI 10.1097/01241398-198411000-00005; PUESCHEL SM, 1987, PEDIATRICS, V80, P555; PUESCHEL SM, 1992, SPINE, V17, P735, DOI 10.1097/00007632-199207000-00001; SEEKINS NL, 1984, SPORTS MENTALLY HAND; TISHLER J, 1965, RADIOLOGY, V84, P904, DOI 10.1148/84.5.904; 1989, LANCET, V1, P24	27	36	38	0	12	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 28	1993	342	8870					511	514		10.1016/0140-6736(93)91644-2	http://dx.doi.org/10.1016/0140-6736(93)91644-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU582	8102665				2022-12-28	WOS:A1993LU58200007
J	BARD, H				BARD, H			ASSESSING NEONATAL RISK - CRIB VS SNAP	LANCET			English	Editorial Material											BARD, H (corresponding author), HOP ST JUSTINE, NEONATAL SERV, MONTREAL H3T 1C5, QUEBEC, CANADA.							RICHARDSON DK, 1993, PEDIATRICS, V91, P617; 1993, LANCET, V342, P193; 1992, COMITE ENQUETE MORTA; 1992, NIH922786 PUBL	4	12	12	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 21	1993	342	8869					449	450		10.1016/0140-6736(93)91587-C	http://dx.doi.org/10.1016/0140-6736(93)91587-C			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU075	8102423				2022-12-28	WOS:A1993LU07500004
J	LAWRENCE, R; SORRELL, T				LAWRENCE, R; SORRELL, T			EICOSAPENTAENOIC ACID IN CYSTIC-FIBROSIS - EVIDENCE OF A PATHOGENETIC ROLE FOR LEUKOTRIENE-B(4)	LANCET			English	Article							ALTERNATE-DAY PREDNISONE; TUMOR NECROSIS FACTOR; DIETARY SUPPLEMENTATION; PSEUDOMONAS-AERUGINOSA; RHEUMATOID-ARTHRITIS; CHEMOTACTIC RESPONSE; LIPID MEDIATORS; FISH OIL; GENERATION; IDENTIFICATION	Much of the lung damage that limits the life of young adults with cystic fibrosis is due to proteases and oxygen metabolites generated by neutrophils, which are recruited into the airway by the interaction between Pseudomonas aeruginosa and pulmonary macrophages. Leukotriene B4 (LTB4) has been proposed as a local mediator of this process; its production is susceptible to specific modulation with dietary eicosapentaenoic acid (EPA). We carried out a placebo-controlled trial of EPA (2.7 g daily for 6 weeks) to assess its effects on markers of clinical state, peripheral neutrophil function, and lung inflammation in sixteen patients with cystic fibrosis colonised with P aeruginosa. EPA was well tolerated and resulted in a significant reduction in sputum volume (median change with EPA -10 mL/day, placebo 0; p = 0.015), and improvements in Shwachman score (EPA 5%, placebo 0; p = 0 034), forced expiratory volume in 1 s (EPA 0.25 L, placebo -0.1 L; p = 0.006), and vital capacity (EPA 0.6 L, placebo 0; p = 0.011). Relative chemotaxis of circulating neutrophils to LTB4 increased from a subnormal baseline of 4 (median: range 0-10) mum/30 min before treatment, to a near normal value of 11 (5-18) mum/30 min after EPA. Relative chemotaxis to LTB4 of patients taking placebo did not change: the difference in response was highly significant (p = 0.001). Specific reduction of neutrophil chemotaxis to LTB4 is a sensitive assay of chronic in-vivo exposure to LTB4. Our results suggest that LTB4 has a pathogenetic role in the lung damage of cystic fibrosis. Longer-term clinical trials of EPA are warranted in a larger number of cystic fibrosis patients.			LAWRENCE, R (corresponding author), UNIV SYDNEY,WESTMEAD HOSP,CTR INFECT DIS & MICROBIOL,WESTMEAD,NSW 2145,AUSTRALIA.		Sorrell, Tania/AAZ-5286-2020	Sorrell, Tania/0000-0001-9460-0960				AUERBACH HS, 1985, LANCET, V2, P686; BERGMANN U, 1989, INFECT IMMUN, V57, P2187, DOI 10.1128/IAI.57.7.2187-2195.1989; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BRUCE MC, 1985, AM REV RESPIR DIS, V132, P529; CROMWELL O, 1981, LANCET, V2, P164; DORING G, 1988, CHEST, V94, pS109, DOI 10.1378/chest.94.2.109S; ENDRES S, 1989, NEW ENGL J MED, V320, P265, DOI 10.1056/NEJM198902023200501; FICK RB, 1986, PEDIATR RES, V20, P1258, DOI 10.1203/00006450-198612000-00014; GOLDMAN DW, 1983, BIOCHEM BIOPH RES CO, V117, P282, DOI 10.1016/0006-291X(83)91572-3; GOLDMAN DW, 1984, J EXP MED, V159, P1027, DOI 10.1084/jem.159.4.1027; HENDERSON WR, 1992, PEDIATR PULM, V8, P217; KLICKSTEIN LB, 1980, J CLIN INVEST, V66, P1166, DOI 10.1172/JCI109947; LAWRENCE RH, 1992, CLIN EXP IMMUNOL, V89, P321; LEE TH, 1985, NEW ENGL J MED, V312, P1217, DOI 10.1056/NEJM198505093121903; LEE TH, 1984, J BIOL CHEM, V259, P2383; MAROM Z, 1983, J CLIN INVEST, V72, P122, DOI 10.1172/JCI110949; MAY TB, 1991, CLIN MICROBIOL REV, V4, P191, DOI 10.1128/CMR.4.2.191-206.1991; MULLER M, 1992, INFECT IMMUN, V60, P2536, DOI 10.1128/IAI.60.6.2536-2540.1992; PARKER CW, 1987, ANNU REV IMMUNOL, V5, P65, DOI 10.1146/annurev.iy.05.040187.000433; PENKETH ARL, 1987, THORAX, V42, P526, DOI 10.1136/thx.42.7.526; PRESCOTT SM, 1984, J BIOL CHEM, V259, P7615; ROSENSTEIN BJ, 1991, PEDIATRICS, V87, P245; SHWACHMAN H, 1965, PEDIATRICS, V36, P689; SPERLING RI, 1993, J CLIN INVEST, V91, P651, DOI 10.1172/JCI116245; SPERLING RI, 1987, ARTHRITIS RHEUM, V30, P988, DOI 10.1002/art.1780300905; STENSON WF, 1992, ANN INTERN MED, V116, P609, DOI 10.7326/0003-4819-116-8-609; SUTER S, 1989, AM REV RESPIR DIS, V140, P1640, DOI 10.1164/ajrccm/140.6.1640; ZAKRZEWSKI JT, 1987, AM REV RESPIR DIS, V136, P779, DOI 10.1164/ajrccm/136.3.779	29	94	96	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 21	1993	342	8869					465	469		10.1016/0140-6736(93)91594-C	http://dx.doi.org/10.1016/0140-6736(93)91594-C			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU075	8102430				2022-12-28	WOS:A1993LU07500011
J	JOSHI, GP				JOSHI, GP			PERIPHERAL ANALGESIA	LANCET			English	Editorial Material											JOSHI, GP (corresponding author), SW MED CTR,DEPT ANESTHESIOL & PAIN MANAGEMENT,DALLAS,TX 75235, USA.							APPELBOOM T, 1991, ARTHRITIS RHEUM-US, V34, P1048, DOI 10.1002/art.1780340815; BASBAUM AI, 1991, NEW ENGL J MED, V325, P1168, DOI 10.1056/NEJM199110173251610; BJURHOLM A, 1990, ARTHRITIS RHEUM, V33, P859, DOI 10.1002/art.1780330613; JOSHI GP, 1993, ANESTH ANALG, V76, P333; LAWRENCE AJ, 1992, EUR J CLIN PHARMACOL, V43, P351, DOI 10.1007/BF02220608	5	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 7	1993	342	8867					320	320		10.1016/0140-6736(93)91469-3	http://dx.doi.org/10.1016/0140-6736(93)91469-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ868	8101582				2022-12-28	WOS:A1993LQ86800007
J	RANASINHA, C; ASSOUFI, B; SHAK, S; CHRISTIANSEN, D; FUCHS, H; EMPEY, D; GEDDES, D; HODSON, M				RANASINHA, C; ASSOUFI, B; SHAK, S; CHRISTIANSEN, D; FUCHS, H; EMPEY, D; GEDDES, D; HODSON, M			EFFICACY AND SAFETY OF SHORT-TERM ADMINISTRATION OF AEROSOLIZED RECOMBINANT HUMAN DNASE-I IN ADULTS WITH STABLE STAGE CYSTIC-FIBROSIS	LANCET			English	Article							SPUTUM	Chronic pulmonary infection is the major cause of morbidity and mortality in cystic fibrosis. High levels of DNA in the sputum make the sputum viscous and difficult to expectorate. Recombinant human deoxyribonuclease (rhDNase) in vitro has been shown to reduce the viscoelasticity of the sputum from CF patients. We have done a phase 11 double-blind randomised placebo-controlled trial in which patients received either 2.5 mg rhDNase twice daily or placebo for 10 days. All patients had forced vital capacity (FVC) above 40% predicted and were clinically stable. Patients were followed up for 42 days from the start of drug/placebo administration. All 71 randomised patients, aged 16-55, completed every aspect of the study and baseline characteristics were similar in the two groups. Baseline forced expiratory volume in one second (FEV1) was 46% of predicted for patients randomised to rhDNase, and 48% for those randomised to placebo; and baseline FVC was 76% of predicted for both groups. The mean percentage change in FEV1 from baseline was a 13.3% rise on rhDNase and a 0.2% fall on placebo (p < 0.001). FVC rose 7.2% in the rhDNase group and 2.3% in the placebo group (not significant). There were no life-threatening adverse events and no anaphylactic reactions. There was no significant difference in side-effects between the groups. This study confirms that short-term administration of rhDNase in stable patients with cystic fibrosis is safe and improves lung function.	ROYAL BROMPTON HOSP,DEPT CYST FIBROSIS,LONDON SW3 6NP,ENGLAND; GENENTECH INC,S SAN FRANCISCO,CA; LONDON CHEST HOSP,LONDON,ENGLAND	Royal Brompton Hospital; Roche Holding; Genentech; University of London; Queen Mary University London								AITKEN ML, 1992, JAMA-J AM MED ASSOC, V267, P1947, DOI 10.1001/jama.267.14.1947; ARMSTRONG JB, 1950, LANCET, V2, P739; CHERNICK WS, 1959, PEDIATRICS, V24, P739; CHERNICK WS, 1961, PEDIATRICS, V27, P589; COREY M, 1988, J CLIN EPIDEMIOL, V41, P583, DOI 10.1016/0895-4356(88)90063-7; ELMES PC, 1953, THORAX, V8, P295, DOI 10.1136/thx.8.4.295; GIFT AG, 1989, REHABIL NURS     NOV, P323; HUBBARD RC, 1992, NEW ENGL J MED, V326, P812, DOI 10.1056/NEJM199203193261207; LIEBERMAN J, 1968, J AMER MED ASSOC, V205, P312, DOI 10.1001/jama.205.5.312; MATTHEWS LW, 1963, AM REV RESPIR DIS, V88, P199; MENDELMAN PM, 1985, AM REV RESPIR DIS, V132, P761; PENKETH ARL, 1987, THORAX, V42, P526, DOI 10.1136/thx.42.7.526; PICOT R, 1978, THORAX, V33, P235, DOI 10.1136/thx.33.2.235; POTTER J, 1960, AM J DIS CHILD, V100, P493; POTTER JL, 1965, PEDIATRICS, V36, P714; RASKIN P, 1968, AM REV RESPIR DIS, V98, P597; SALOMON A, 1954, Ann Allergy, V12, P71; SHAK S, 1990, P NATL ACAD SCI USA, V87, P9188, DOI 10.1073/pnas.87.23.9188; SINICROPI D, 1991, PEDIATR PULM S, V6, P300; SPIER R, 1961, JAMA-J AM MED ASSOC, V178, P878, DOI 10.1001/jama.1961.03040480008003; TAUSSIG LM, 1973, J PEDIATR-US, V82, P380, DOI 10.1016/S0022-3476(73)80110-6; VANDAUX P, 1980, J INFECT DIS, V142, P86; 1988, BMJ, V297, P1599	23	151	156	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 24	1993	342	8865					199	202		10.1016/0140-6736(93)92297-7	http://dx.doi.org/10.1016/0140-6736(93)92297-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN622	8100928				2022-12-28	WOS:A1993LN62200010
J	MUKADI, Y; PERRIENS, JH; STLOUIS, ME; BROWN, C; PRIGNOT, J; WILLAME, JC; POUTHIER, F; KABOTO, M; RYDER, RW; PORTAELS, F; PIOT, P				MUKADI, Y; PERRIENS, JH; STLOUIS, ME; BROWN, C; PRIGNOT, J; WILLAME, JC; POUTHIER, F; KABOTO, M; RYDER, RW; PORTAELS, F; PIOT, P			SPECTRUM OF IMMUNODEFICIENCY IN HIV-1-INFECTED PATIENTS WITH PULMONARY TUBERCULOSIS IN ZAIRE	LANCET			English	Article							CLINICAL CASE-DEFINITION; VIRUS-INFECTION; IMMUNE-DEFICIENCY; HIV-INFECTION; AIDS; COHORT; RISK; DISEASE	Tuberculosis (TB) is the most common opportunistic infection in African patients who die from AIDS, yet the stage of immunodeficiency at which TB develops is uncertain. We studied the immune status of HIV-infected outpatients with pulmonary TB in relation to their clinical presentation in a cross-sectional study of 216 HIV-seropositive and 146 HIV-seronegative ambulatory incident cases of smear-positive and culture-positive pulmonary TB in Kinshasa, Zaire. HIV-seropositive and seronegative patients had median CD4 lymphocyte counts of 316.5/muL and 830.5/muL, respectively. Of the HIV-seropositive patients, 32 9% had less than 200 CD4 lymphocytes/muL, 37% between 200 and 499, and 30.1% 500 or more. Clinical AIDS, as defined by the WHO clinical case-definition ora modified version, was of similar limited use as a predictor of immunodeficiency. Among HIV-seropositive patients, oral candidosis, lymphopenia, a negative tuberculin purified protein derivative test, and cutaneous anergy were strongly associated with CD4 counts of less than 200/muL, and seemed to be better markers of immune dysfunction. We conclude that pulmonary TB develops across a broad spectrum of HIV-induced immunodeficiency and that a diagnosis of pulmonary TB is of limited use as a marker of stage of HIV disease in African HIV-infected outpatients.	PROJET SIDA, KINSHASA, DEM REP CONGO; BELGIAN ADM DEV & COOPERAT, BRUSSELS, BELGIUM; UNIV CATHOLIQUE LOUVAIN, MT GODINNE, BELGIUM; BUR NATL TB, KINSHASA, DEM REP CONGO; INST TROP MED PRINCE LEOPOLD, B-2000 ANTWERP, BELGIUM; CDC, NCID, DIV HIV AIDS, ATLANTA, GA USA; CTR DEPISTAGE TB, KINSHASA, DEM REP CONGO	Universite Catholique Louvain; Institute of Tropical Medicine (ITM); Centers for Disease Control & Prevention - USA								[Anonymous], 1990, Wkly Epidemiol Rec, V65, P221; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; BATUNGWANAGO J, 1990, 5TH INT C AIDS AFR K; BRAUN MM, 1991, AM REV RESPIR DIS, V143, P501, DOI 10.1164/ajrccm/143.3.501; BURCHAM J, 1991, AIDS, V5, P365, DOI 10.1097/00002030-199104000-00002; COLEBUNDERS R, 1987, LANCET, V1, P492; COLEBUNDERS RL, 1989, AM REV RESPIR DIS, V139, P1082, DOI 10.1164/ajrccm/139.5.1082; DECOCK KM, 1992, JAMA-J AM MED ASSOC, V268, P1581, DOI 10.1001/jama.1992.03490120095035; JORDAN TJ, 1987, CHEST, V92, P234, DOI 10.1378/chest.92.2.234; KASLOW RA, 1987, ANN INTERN MED, V107, P474, DOI 10.7326/0003-4819-107-4-474; KLEIN NC, 1989, CHEST, V95, P1190, DOI 10.1378/chest.95.6.1190; KLEIN RS, 1984, NEW ENGL J MED, V311, P354, DOI 10.1056/NEJM198408093110602; MODILEVSKY T, 1989, ARCH INTERN MED, V149, P2201, DOI 10.1001/archinte.149.10.2201; Murray C J, 1990, Bull Int Union Tuberc Lung Dis, V65, P6; OKONDA L, 1991, 7 INT C AIDS FLOR; PAPE JW, 1992, 8 INT C AIDS 3 STD W; PITCHENIK AE, 1985, AM REV RESPIR DIS, V131, P393; ROYCE RA, 1991, AIDS, V5, P355, DOI 10.1097/00002030-199104000-00001; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SHAFER RW, 1991, AIDS, V5, P399, DOI 10.1097/00002030-199104000-00007; THEUER CP, 1990, J INFECT DIS, V162, P8, DOI 10.1093/infdis/162.1.8; WADHAWAN D, 1992, 8 INT C AIDS 3 STD W; WALLIS RS, 1993, J INFECT DIS, V167, P43, DOI 10.1093/infdis/167.1.43; WIDYWIRSKI R, 1988, JAMA-J AM MED ASSOC, V260, P3286, DOI 10.1001/jama.260.22.3286; 1963, WHO TB TECH GUIDE, V3; 1986, WKLY EPIDEMIOL REC, V61, P69; 1991, MMWR, V40, P27	27	118	121	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 17	1993	342	8864					143	146		10.1016/0140-6736(93)91346-N	http://dx.doi.org/10.1016/0140-6736(93)91346-N			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN042	8101257				2022-12-28	WOS:A1993LN04200012
J	VICTORA, CG				VICTORA, CG			WHATS THE DENOMINATOR	LANCET			English	Article											VICTORA, CG (corresponding author), UNIV FED PELOTAS,CP 464,BR-96001 PELOTAS,RS,BRAZIL.		Victora, Cesar Gomes/Y-2455-2019; Victora, Cesar G/D-4476-2013	Victora, Cesar Gomes/0000-0002-2465-2180; Victora, Cesar G/0000-0002-2465-2180				[Anonymous], 1985, THEORETICAL EPIDEMIO; KIRKWOOD BR, 1988, ESSENTIALS MED STATI; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; RODRIGUES L, 1990, INT J EPIDEMIOL, V19, P205, DOI 10.1093/ije/19.1.205; ROSE G, 1979, EPIDEMIOLOGY UNINITI; Rothman K, 1986, MODERN EPIDEMIOLOGY; SAMARAS TT, 1992, B WORLD HEALTH ORGAN, V70, P259	7	15	17	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 10	1993	342	8863					97	99		10.1016/0140-6736(93)91291-S	http://dx.doi.org/10.1016/0140-6736(93)91291-S			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LL789	8100918				2022-12-28	WOS:A1993LL78900015
J	COHEN, MV; DOWNEY, JM				COHEN, MV; DOWNEY, JM			ISCHEMIC PRECONDITIONING - CAN THE PROTECTION BE BOTTLED	LANCET			English	Letter							ISCHEMIA				COHEN, MV (corresponding author), UNIV SO ALABAMA,DEPT PHYSIOL,MOBILE,AL 36688, USA.							DEUTSCH E, 1990, CIRCULATION, V82, P2044, DOI 10.1161/01.CIR.82.6.2044; LAWSON CS, 1993, CARDIOVASC RES, V27, P542, DOI 10.1093/cvr/27.4.542; LIU GS, 1991, CIRCULATION, V84, P350, DOI 10.1161/01.CIR.84.1.350; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; THORNTON JD, 1993, J MOL CELL CARDIOL, V25, P311, DOI 10.1006/jmcc.1993.1037; THORNTON JD, IN PRESS CIRC RES; TSUCHIDA A, IN PRESS J MOL CELL; YANG XM, 1993, CARDIOVASC RES, V27, P556, DOI 10.1093/cvr/27.4.556; YTREHUS K, 1993, FASEB J, V7, pA418	9	80	80	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 3	1993	342	8862					6	6		10.1016/0140-6736(93)91878-P	http://dx.doi.org/10.1016/0140-6736(93)91878-P			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK985	8100337				2022-12-28	WOS:A1993LK98500007
J	BONYHADI, ML; RABIN, L; SALIMI, S; BROWN, DA; KOSEK, J; MCCUNE, JM; KANESHIMA, H				BONYHADI, ML; RABIN, L; SALIMI, S; BROWN, DA; KOSEK, J; MCCUNE, JM; KANESHIMA, H			HIV INDUCES THYMUS DEPLETION INVIVO	NATURE			English	Article							SCID-HU MOUSE; HUMAN IMMUNODEFICIENCY VIRUS; T-CELLS; INFECTION; APOPTOSIS; DIFFERENTIATION; MODEL; DEATH	HUMAN immunodeficiency virus (HIV) disease is typified by declining CD4+ T lymphocyte counts in the peripheral circulation, a loss which may be secondary to accelerated destruction, to suppressed differentiation, and/or to sequestration of circulating cells into tissue spaces. As it is hard to distinguish between these possibilities in human subjects, the pathogenic mechanisms associated with HIV infection are unclear. In particular, little is known about the events that occur within infected lymphoid organs in which most CD4 T lymphocytes mature and function1,2. To obtain a better description of HIV pathogenesis in vivo, we have implanted human haematolymphoid organs into the immunodeficient SCID mouse to create the SCID-hu mouse3,4. We have previously shown that these organ systems promote long-term multilineage human haematopoiesis and are permissive for infection with HIV5,6. Here we report that human thymopoiesis is suppressed by HIV infection, thereby precluding regeneration of the peripheral T-cell compartment.	VET ADM MED CTR, PALO ALTO, CA 94304 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA)	BONYHADI, ML (corresponding author), SYSTEMIX INC, DIV NEW ENTERPRISE RES, 3155 PORTER DR, PALO ALTO, CA 94304 USA.							BANDA NK, 1992, J EXP MED, V176, P1099, DOI 10.1084/jem.176.4.1099; BASKIN GB, 1991, LAB INVEST, V65, P400; BENOIST C, 1989, CELL, V58, P1027, DOI 10.1016/0092-8674(89)90501-1; DIVE C, 1992, BIOCHIM BIOPHYS ACTA, V1133, P275, DOI 10.1016/0167-4889(92)90048-G; DIVE C, 1992, J IMMUNOL, V148, P1595; GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331; JOSHI VV, 1986, ARCH PATHOL LAB MED, V110, P837; KOYANAGI Y, 1987, SCIENCE, V236, P819, DOI 10.1126/science.3646751; KROWKA JF, 1991, J IMMUNOL, V146, P3751; LIN YS, 1992, J IMMUNOL, V149, P1156; MCCUNE J, 1991, ANNU REV IMMUNOL, V9, P399, DOI 10.1146/annurev.iy.09.040191.002151; MCCUNE JM, 1988, SCIENCE, V241, P1632, DOI 10.1126/science.2971269; MCCUNE JM, 1991, CELL, V64, P351, DOI 10.1016/0092-8674(91)90644-E; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; MOCARSKI ES, 1993, P NATL ACAD SCI USA, V90, P104, DOI 10.1073/pnas.90.1.104; NAMIKAWA R, 1988, SCIENCE, V242, P1684, DOI 10.1126/science.3201256; NAMIKAWA R, 1990, J EXP MED, V172, P1055, DOI 10.1084/jem.172.4.1055; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NUMAZAKI K, 1989, CLIN IMMUNOL IMMUNOP, V51, P185, DOI 10.1016/0090-1229(89)90018-4; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; PAPIERNIK M, 1992, PEDIATRICS, V89, P297; SCHUURMAN HJ, 1989, AM J PATHOL, V134, P1329; SCHWARTZ LM, 1993, P NATL ACAD SCI USA, V90, P980, DOI 10.1073/pnas.90.3.980; SELLINS KS, 1991, J IMMUNOL, V147, P795; SHI YF, 1991, J IMMUNOL, V146, P3340; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; Steinmann G G, 1986, Curr Top Pathol, V75, P43; TELFORD WG, 1992, CYTOMETRY, V13, P137, DOI 10.1002/cyto.990130205; VANDEKERCKHOVE BAE, 1991, J IMMUNOL, V146, P4173; VANEWIJK W, 1991, ANNU REV IMMUNOL, V9, P591, DOI 10.1146/annurev.iy.09.040191.003111; Wyllie A H, 1980, Int Rev Cytol, V68, P251	31	361	366	0	3	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 24	1993	363	6431					728	732		10.1038/363728a0	http://dx.doi.org/10.1038/363728a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LJ339	8100043				2022-12-28	WOS:A1993LJ33900058
J	BENDAVID, J; ZIPES, DP				BENDAVID, J; ZIPES, DP			TORSADES-DE-POINTES AND PROARRHYTHMIA	LANCET			English	Article							LONG QT SYNDROMES; EARLY AFTERDEPOLARIZATIONS; VENTRICULAR TACHYARRHYTHMIAS; SYMPATHETIC DENERVATION; CARDIAC-ARRHYTHMIA; STIMULATION; SUPPRESSION; CESIUM; DOGS; REPOLARIZATION		ROUDEBUSH VET AFFAIRS MED CTR,INDIANAPOLIS,IN	US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center	BENDAVID, J (corresponding author), KRANNERT CARDIOVASC RES INST,1111 W 10TH ST,INDIANAPOLIS,IN 46201, USA.			Zipes, Douglas/0000-0001-7141-6829	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042370] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-42370, HL-07182] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKHTAR M, 1990, CIRCULATION, V81, P1123, DOI 10.1161/01.CIR.81.3.1123; BAILIE DS, 1988, CIRCULATION, V77, P1395, DOI 10.1161/01.CIR.77.6.1395; BENDAVID J, 1988, CIRCULATION, V78, P1241, DOI 10.1161/01.CIR.78.5.1241; BENDAVID J, 1992, J AM COLL CARDIOL, V20, P1576, DOI 10.1016/0735-1097(92)90453-T; BENDAVID J, 1990, CIRCULATION, V82, P225, DOI 10.1161/01.CIR.82.1.225; BONATTI V, 1985, EUR HEART J, V6, P131, DOI 10.1093/eurheartj/6.suppl_D.131; BRACHMANN J, 1983, CIRCULATION, V68, P846, DOI 10.1161/01.CIR.68.4.846; CALDINS H, 1992, CIRCULATION, V86, P391; CRANFIELD PF, 1988, CARDIAC ARRHYTHMIAS; EGGELING T, 1992, CIRCULATION, V86, P392; ELDAR M, 1992, J AM COLL CARDIOL, V20, P830, DOI 10.1016/0735-1097(92)90180-U; ELSHERIF N, 1989, J AM COLL CARDIOL, V14, P252, DOI 10.1016/0735-1097(89)90082-X; FISH FA, 1990, CIRCULATION, V82, P1362, DOI 10.1161/01.CIR.82.4.1362; HII JTY, 1992, CIRCULATION, V86, P1376, DOI 10.1161/01.CIR.86.5.1376; JACKMAN WM, 1988, PROG CARDIOVASC DIS, V31, P115, DOI 10.1016/0033-0620(88)90014-X; JAMES TN, 1979, ANN INTERN MED, V91, P727, DOI 10.7326/0003-4819-91-5-727; JANUARY C T, 1990, Journal of Cardiovascular Electrophysiology, V1, P161, DOI 10.1111/j.1540-8167.1990.tb01058.x; KEATING M, 1991, SCIENCE, V252, P704, DOI 10.1126/science.1673802; KRAUSE PC, IN PRESS AM HT J; LEENHARDT A, 1992, J CARDIOVASC ELECTR, V3, P281, DOI 10.1111/j.1540-8167.1992.tb00973.x; LEVY MN, 1977, CARDIOVASC RES, V11, P481, DOI 10.1093/cvr/11.6.481; MINARDO JD, 1988, NEW ENGL J MED, V319, P257, DOI 10.1056/NEJM198808043190501; MIYAZAKI T, 1990, J AM COLL CARDIOL, V16, P1287, DOI 10.1016/0735-1097(90)90567-9; PRESSLER GM, 1992, JACC, V20, P504; Randall WC, 1988, NEUROCARDIOLOGY, P3; RODEN DM, 1986, AM HEART J, V111, P1088, DOI 10.1016/0002-8703(86)90010-4; ROSEN MR, 1988, PROGR CARDIOLOGY, P34; RUBART M, IN PRESS CIRCULATION; SCHWARTZ PJ, 1987, CIRCULATION, V75, P677, DOI 10.1161/01.CIR.75.4.677; SCHWARTZ PJ, 1991, CIRCULATION, V84, P503, DOI 10.1161/01.CIR.84.2.503; SCHWARTZ PJ, 1990, CARDIAC ELECTROPHYSI, P589; STANTON MS, 1989, J AM COLL CARDIOL, V14, P1519, DOI 10.1016/0735-1097(89)90391-4; TZIVONI D, 1988, CIRCULATION, V77, P392, DOI 10.1161/01.CIR.77.2.392; VINCENT GM, 1992, J AM COLL CARDIOL, V20, P500, DOI 10.1016/0735-1097(92)90123-5; ZIPES DP, 1991, CIRCULATION, V84, P1414, DOI 10.1161/01.CIR.84.3.1414; ZIPES DP, 1988, AM J CARDIOL, V61, pA70, DOI 10.1016/0002-9149(88)90743-6; ZIPES DP, 1991, PROG CARDIOVASC DIS, V33, P385, DOI 10.1016/0033-0620(91)90004-6; ZIPES DP, 1993, CARDIOL REV, V1, P1	38	82	84	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 19	1993	341	8860					1578	1582		10.1016/0140-6736(93)90708-O	http://dx.doi.org/10.1016/0140-6736(93)90708-O			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH550	8099651				2022-12-28	WOS:A1993LH55000015
J	STEFFEN, R; FUCHS, E; SCHILDKNECHT, J; NAEF, U; FUNK, M; SCHLAGENHAUF, P; PHILLIPSHOWARD, P; NEVILL, C; STURCHLER, D				STEFFEN, R; FUCHS, E; SCHILDKNECHT, J; NAEF, U; FUNK, M; SCHLAGENHAUF, P; PHILLIPSHOWARD, P; NEVILL, C; STURCHLER, D			MEFLOQUINE COMPARED WITH OTHER MALARIA CHEMOPROPHYLACTIC REGIMENS IN TOURISTS VISITING EAST-AFRICA	LANCET			English	Article							ADVERSE REACTIONS; CHLOROQUINE; PROPHYLAXIS	There is much confusion over which malaria chemoprophylaxis should be used in areas such as East Africa. We did two consecutive studies between 1985 and 1991 to assess the efficacy and side-effects of malaria chemoprophylaxis in short-term travellers to East Africa. All passengers returning from Kenya to Europe received an in-flight questionnaire and a second one three months later. Any report of documented malaria or of admission to hospital for possible side-effects was verified with the physician. 145 003 travellers completed questionnaires. Among the 139 164 who stayed in East Africa for less than one year, 296 cases of confirmed malaria were reported (275 due to P falciparum). In people who used no chemoprophylaxis, the incidence of falciparum malaria was 1.2% per month. Prophylactic effectiveness was 91% (95% CI 85 to 94) for mefloquine, 82% (71 to 89) for pyrimethamine and sulfadoxine, 72% (56 to 82) for chloroquine plus proguanil, and 10 to 42% for chloroquine at various doses. Rates of side-effects, which were usually mild, were 18.8% for mefloquine users, 17.1% and 18.6% for chloroquine 300 mg and 600 mg base per week, respectively, 30.1% for chloroquine plus proguanil, and 11.7% for sulfadoxine and pyrimethamine. Mefloquine is significantly more effective than chloroquine plus proguanil for malaria prophylaxis in short-term tourists visiting East Africa and has a tolerance similar to that of chloroquine used alone.	AFRICAN MED & RES FDN, DEPT CLIN, NAIROBI, KENYA; UNIV LONDON LONDON SCH HYG & TROP MED, LONDON WC1E 7HT, ENGLAND; F HOFFMANN LA ROCHE & CO LTD, CH-4002 BASEL, SWITZERLAND	African Medical & Research Foundation (AMREF); University of London; London School of Hygiene & Tropical Medicine; Roche Holding	STEFFEN, R (corresponding author), UNIV ZURICH, INST SOCIAL & PREVENT MED, DIV EPIDEMIOL & PREVENT COMMUNICABLE DIS, SUMATRASTR 30, CH-8006 ZURICH, SWITZERLAND.			Schlagenhauf, Patricia/0000-0002-1075-7010; Phillips-Howard, Penelope A/0000-0003-1018-116X				BEM JL, 1992, J TROP MED HYG, V95, P167; ERIKSSON B, 1991, SCAND J INFECT DIS, V23, P489, DOI 10.3109/00365549109075098; FISH DR, 1988, BRIT MED J, V297, P526, DOI 10.1136/bmj.297.6647.526; HENNEQUIN C, 1991, LANCET, V337, P984, DOI 10.1016/0140-6736(91)91625-5; LOBEL HO, 1990, B WORLD HEALTH ORGAN, V68, P209; LOBEL HO, 1991, JAMA-J AM MED ASSOC, V265, P361, DOI 10.1001/jama.265.3.361; LOBEL HO, 1993, LANCET, V341, P848, DOI 10.1016/0140-6736(93)93058-9; LOVESTONE S, 1991, BRIT J PSYCHIAT, V159, P164, DOI 10.1192/bjp.159.1.164b; MOLINEAUX L, 1989, World Health Statistics Quarterly, V42, P100; Peto R., 1980, LONG TERM SHORT TERM; PHILLIPSHOWARD PA, 1990, J ROY SOC MED, V83, P82, DOI 10.1177/014107689008300208; PHILLIPSHOWARD PA, 1990, BMJ-BRIT MED J, V300, P499, DOI 10.1136/bmj.300.6723.499; PRYCE DI, 1993, J ROY SOC MED, V86, P152; STEFFEN R, 1990, B WORLD HEALTH ORGAN, V68, P313; VANDENENDEN E, 1991, LANCET, V337, P683, DOI 10.1016/0140-6736(91)92509-Z; WEINKE T, 1991, AM J TROP MED HYG, V45, P86, DOI 10.4269/ajtmh.1991.45.86; WITTES R, 1987, CAN FAM PHYSICIAN, V33, P2644; 1990, B EPIDEMIOL HEBD, V51, P219; 1990, B BUNDESAMT GESUN S1, V1, P1; 1991, WHOMAL911063; 1993, INT TRAVEL HLTH VACC; 1989, BMJ, V299, P1087; 1992, CDC928280 US DEP HLT	23	223	224	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 22	1993	341	8856					1299	1303		10.1016/0140-6736(93)90814-W	http://dx.doi.org/10.1016/0140-6736(93)90814-W			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD253	8098447				2022-12-28	WOS:A1993LD25300002
J	WALKER, JM; YELLON, DM; KLONER, RA; DOWNEY, JM; PUGSLEY, WB				WALKER, JM; YELLON, DM; KLONER, RA; DOWNEY, JM; PUGSLEY, WB			UNSTABLE ANGINA - REPORT OF A MEETING OF PHYSICIANS AND SCIENTISTS, UNIVERSITY-COLLEGE-LONDON MEDICAL-SCHOOL	LANCET			English	Discussion							ACUTE MYOCARDIAL-INFARCTION; STUNNED MYOCARDIUM; THROMBOLYTIC THERAPY; VENTRICULAR DYSFUNCTION; HIBERNATING MYOCARDIUM; CORONARY ANGIOPLASTY; ISCHEMIA; RECOVERY; OCCLUSION; TOLERANCE		UCL, SCH MED,DIV CARDIOL, HATTER INST CARDIOVASC STUDIES,GOWER ST, LONDON WC1E 6AU, ENGLAND; UNIV SO ALABAMA, COLL MED, DEPT PHYSIOL, MOBILE, AL 36688 USA; MIDDLESEX HOSP, DEPT CARDIOTHORAC SURG, LONDON W1, ENGLAND; UNIV COLL HOSP LONDON, DEPT CLIN CARDIOL, WC1 LONDON, ENGLAND; UNIV SO CALIF, HOSP GOOD SAMARITAN, HEART INST, LOS ANGELES, CA 90089 USA	University of London; University College London; UCL Medical School; University of South Alabama; University of London; University College London; University College London Hospitals NHS Foundation Trust; University of Southern California			Yellon, Derek M/ABD-5110-2021; Kloner, Robert A/B-2971-2012	Yellon, Derek/0000-0001-7791-9320				AMBROSIO G, 1991, CIRCULATION S11, V84, P1891; BOLLI R, 1991, CARDIOVASC DRUG THER, V5, P877, DOI 10.1007/BF00053548; BOLLI R, 1990, CIRCULATION, V82, P723, DOI 10.1161/01.CIR.82.3.723; BRAUNWALD E, 1982, CIRCULATION, V66, P1146, DOI 10.1161/01.CIR.66.6.1146; BREISBLATT WM, 1990, J AM COLL CARDIOL, V15, P1261, DOI 10.1016/S0735-1097(10)80011-7; CAMICI P, 1986, CIRCULATION, V74, P81, DOI 10.1161/01.CIR.74.1.81; COX TA, 1992, AM J CARD IMAG, V6, P208; CRIBIER A, 1992, J AM COLL CARDIOL, V20, P578, DOI 10.1016/0735-1097(92)90011-B; DENYS B G, 1992, European Heart Journal, V13, P246; DEUTSCH E, 1990, CIRCULATION, V82, P2044, DOI 10.1161/01.CIR.82.6.2044; DOWNEY JM, 1992, TRENDS CARDIOVAS MED, V2, P170, DOI 10.1016/1050-1738(92)90045-T; ELLIS SG, 1983, J AM COLL CARDIOL, V1, P1047, DOI 10.1016/S0735-1097(83)80107-7; FOURNIER C, 1991, AM HEART J, V121, P593, DOI 10.1016/0002-8703(91)90731-V; FRAGASSO G, 1991, J AM COLL CARDIOL, V17, P1251, DOI 10.1016/S0735-1097(10)80131-7; GEFT IL, 1982, CIRCULATION, V66, P1150, DOI 10.1161/01.CIR.66.6.1150; GROSS GJ, 1992, CIRC RES, V70, P223, DOI 10.1161/01.RES.70.2.223; HEIBIG J, 1989, CATHETER CARDIO DIAG, V16, P99, DOI 10.1002/ccd.1810160206; HEYNDRICKX GR, 1975, J CLIN INVEST, V56, P978, DOI 10.1172/JCI108178; HITTINGER L, 1990, CIRC RES, V66, P329, DOI 10.1161/01.RES.66.2.329; HOMANS DC, 1986, J CLIN INVEST, V77, P66, DOI 10.1172/JCI112303; KLONER RA, 1989, AM J MED, V86, P14, DOI 10.1016/0002-9343(89)90005-3; KLONER RA, 1991, AM J CARDIOL, V68, P329, DOI 10.1016/0002-9149(91)90827-8; LIU GS, 1991, CIRCULATION, V84, P350, DOI 10.1161/01.CIR.84.1.350; MATHIAS P, 1987, AM HEART J, V113, P383, DOI 10.1016/0002-8703(87)90282-1; MULLER DWM, 1990, AM HEART J, V119, P224, DOI 10.1016/S0002-8703(05)80008-0; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; NIENABER CA, 1991, J AM COLL CARDIOL, V18, P966, DOI 10.1016/0735-1097(91)90755-X; NISHIMURA T, 1991, JPN CIRC J, V55, P913, DOI 10.1253/jcj.55.913; OLDROYD KG, 1992, BRIT HEART J, V68, P43; RAHIMTOOLA SH, 1989, AM HEART J, V117, P211, DOI 10.1016/0002-8703(89)90685-6; SATLER LF, 1986, AM HEART J, V111, P821, DOI 10.1016/0002-8703(86)90628-9; SHEEHAN FH, 1988, J AM COLL CARDIOL, V12, P289, DOI 10.1016/0735-1097(88)90397-X; TAKATSU F, 1986, AM J CARDIOL, V58, P647, DOI 10.1016/0002-9149(86)90293-6; THORNTON JD, 1993, CIRC RES, V72, P44, DOI 10.1161/01.RES.72.1.44; THORNTON JD, IN PRESS J MOL CELL; WALKER DM, 1992, CARDIOVASC RES, V26, P734, DOI 10.1093/cvr/26.8.734	36	5	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 22	1993	341	8856					1323	1327						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD253	8098457				2022-12-28	WOS:A1993LD25300013
J	MARIAN, AJ; YU, QT; WORKMAN, R; GREVE, G; ROBERTS, R				MARIAN, AJ; YU, QT; WORKMAN, R; GREVE, G; ROBERTS, R			ANGIOTENSIN-CONVERTING ENZYME POLYMORPHISM IN HYPERTROPHIC CARDIOMYOPATHY AND SUDDEN CARDIAC DEATH	LANCET			English	Note							INSERTION DELETION POLYMORPHISM; HEAVY-CHAIN GENE; MUTATION	We determined the distribution frequency of angiotensin converting enzyme (ACE) polymorphism in 100 patients with hypertrophic cardiomyopathy and 106 of their unaffected siblings and offspring. The distribution of ACE genotypes was different in the two groups: allele D frequency of 0.69 in patients and 0 57 in relatives (p = 0.021). The frequency of allele D was also higher in hypertrophic cardiomyopathy families with a high incidence of sudden cardiac death than those with a low incidence (0.74 vs 0.55, p = 0.011). In 25 hypertrophic cardiomyopathy patients with a strong family history of sudden cardiac death the frequency of allele D was 0.82 (p = 0.001 vs normals).	BAYLOR COLL MED,6535 FANNIN,MS F905,HOUSTON,TX 77030	Baylor College of Medicine				Marian, AJ/0000-0002-1252-7120	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042267] Funding Source: NIH RePORTER; NHLBI NIH HHS [P50-HL42267-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANAN R, IN PRESS J CLIN INVE; EPSTEIN ND, 1992, CIRCULATION, V86, P345, DOI 10.1161/01.CIR.86.2.345; HEJTMANCIK JF, 1991, CIRCULATION, V83, P1592, DOI 10.1161/01.CIR.83.5.1592; JACKSON TR, 1988, NATURE, V335, P437, DOI 10.1038/335437a0; MARIAN AJ, 1992, CIRCULATION, V86, P16; NAFTILAN AJ, 1989, J CLIN INVEST, V83, P1419, DOI 10.1172/JCI114032; RIGAT B, 1992, NUCLEIC ACIDS RES, V20, P1433, DOI 10.1093/nar/20.6.1433-a; RIGAT B, 1990, J CLIN INVEST, V86, P1343, DOI 10.1172/JCI114844; SCHUNKERT H, 1993, CIRCULATION, V87, P1328, DOI 10.1161/01.CIR.87.4.1328	9	350	362	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 30	1993	342	8879					1085	1086		10.1016/0140-6736(93)92064-Z	http://dx.doi.org/10.1016/0140-6736(93)92064-Z			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME822	8105312				2022-12-28	WOS:A1993ME82200010
J	PETRICCIANI, JC				PETRICCIANI, JC			ONGOING TRAGEDY OF RABIES	LANCET			English	Editorial Material											PETRICCIANI, JC (corresponding author), GENET INST INC,CAMBRIDGE,MA, USA.							BROWN A, 1974, J VIROL, V14, P840, DOI 10.1128/JVI.14.4.840-845.1974; Grachev V, 1989, Dev Biol Stand, V70, P215; MORGEAUX S, 1993, VACCINE, V11, P82, DOI 10.1016/0264-410X(93)90343-V; NICHOLSON KG, 1990, LANCET, V335, P1201, DOI 10.1016/0140-6736(90)92710-Y; PETRICCIANI JC, 1991, DEV BIOL STAND, V76, P5; PETRICCIANI JC, 1979, CELL SUBSTRATES, P9; SEHGAL S, 1992, GELBEN HELTE, V38, P126; SWADDIWUTHIPONG W, 1988, T ROY SOC TROP MED H, V82, P472, DOI 10.1016/0035-9203(88)90167-8; 1992, WORLD SURVEY RABIES	9	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 30	1993	342	8879					1067	1068		10.1016/0140-6736(93)92058-2	http://dx.doi.org/10.1016/0140-6736(93)92058-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME822	8105306				2022-12-28	WOS:A1993ME82200004
J	TENNANT, F; MOLL, D; DEPAULO, V				TENNANT, F; MOLL, D; DEPAULO, V			TOPICAL MORPHINE FOR PERIPHERAL PAIN	LANCET			English	Letter							INFLAMMATION				TENNANT, F (corresponding author), RES CTR DEPENDENCY DISORDERS & CHRON PAIN,COMMUNITY HLTH PROJECTS,W COVINA,CA 91790, USA.							JORIS JL, 1987, ANESTH ANALG, V66, P1277; JOSHI, 1993, LANCET, V342, P320; JOSHI GP, 1993, ANESTH ANALG, V76, P333; STEIN, 1993, LANCET, V342, P321; STEIN C, 1989, J PHARMACOL EXP THER, V248, P1269	5	15	18	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 23	1993	342	8878					1047	1048		10.1016/0140-6736(93)92900-E	http://dx.doi.org/10.1016/0140-6736(93)92900-E			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD066	8105274				2022-12-28	WOS:A1993MD06600029
J	BRAHAMS, D				BRAHAMS, D			VIDEO SURVEILLANCE AND CHILD-ABUSE	LANCET			English	Editorial Material																		FOREMAN DM, 1993, BMJ-BRIT MED J, V307, P611, DOI 10.1136/bmj.307.6904.611; SAMUELS MP, 1992, ARCH DIS CHILD, V67, P162, DOI 10.1136/adc.67.2.162; SOUTHALL DP, 1993, BRIT MED J, V307, P613, DOI 10.1136/bmj.307.6904.613; 1992, LANCET, V340, P87	4	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 16	1993	342	8877					944	944		10.1016/0140-6736(93)91999-3	http://dx.doi.org/10.1016/0140-6736(93)91999-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MC005	8105211				2022-12-28	WOS:A1993MC00500006
J	ROVNER, J; FIRSHEIN, J; FRANKEL, DH				ROVNER, J; FIRSHEIN, J; FRANKEL, DH			3 VISITS TO CLINTON-CARE	LANCET			English	Article																		1993, LANCET, V342, P732; 1993, LANCET, V342, P797; 1993, LANCET, V341, P694; 1993, LANCET, V341, P231	4	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 2	1993	342	8875					851	854		10.1016/0140-6736(93)92701-T	http://dx.doi.org/10.1016/0140-6736(93)92701-T			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA025	8104278				2022-12-28	WOS:A1993MA02500015
J	HAMPTON, J; WILCOX, R; ARMSTRONG, P; AYLWARD, P; BETT, N; CHARBONNIER, B; GULBA, D; HEIKKILA, J; JENSEN, G; LOPEZBESCOS, L; MOULOPOULOS, S; SEABRAGOMES, R; THEROUX, P; TOPOL, E; VANDEWERF, F				HAMPTON, J; WILCOX, R; ARMSTRONG, P; AYLWARD, P; BETT, N; CHARBONNIER, B; GULBA, D; HEIKKILA, J; JENSEN, G; LOPEZBESCOS, L; MOULOPOULOS, S; SEABRAGOMES, R; THEROUX, P; TOPOL, E; VANDEWERF, F			LATE ASSESSMENT OF THROMBOLYTIC EFFICACY (LATE) STUDY WITH ALTEPLASE 6-24 HOURS AFTER ONSET OF ACUTE MYOCARDIAL-INFARCTION	LANCET			English	Article							TISSUE PLASMINOGEN-ACTIVATOR; THERAPY; REPERFUSION; TRIAL	The effect of late thrombolysis in acute myocardial infarction (AMI)-ie, treatment beginning more than 6 h after the onset of symptoms-remains controversial. The Late Assessment of Thrombolytic Efficacy (LATE) study is a large randomised trial designed to resolve this question. 5711 patients with symptoms and electrocardiographic criteria consistent with AMI were randomised double-blind to intravenous alteplase (100 mg over 3 h) or matching placebo, between 6 and 24 h from symptom onset. Both groups received immediate oral aspirin and for later recruits intravenous heparin for 48 h was recommended. All patients were followed up for at least 6 months and 73% were followed up for 1 year. Intention-to-treat analysis of survival revealed a nonsignificant reduction in the alteplase group (397/2836 deaths) compared with placebo (444/2875). 35-day mortality was 8.86% and 10.31%, respectively, a relative reduction of 14.1% (95% CI 0-28.1%). Pre-specified survival analysis according to treatment within 12 h of symptom onset, however, showed a significant reduction in mortality in favour of alteplase: 35-day mortality was 8.90% versus 11.97% for placebo, a relative reduction of 25.6% (p=0.0229, 95% CI 6.3-45.0%). Rates were 8.7% and 9.2%, respectively, for those treated at 12-24 h but subgroup analysis suggests that some patients may benefit even when treated after 12 h. Although treatment with alteplase resulted in an excess of haemorrhagic strokes, by 6 months the number of disabled survivors was the same in both treatment groups and other clinical events were observed with similar frequency in the two groups. We conclude that the time window for thrombolysis with alteplase should be extended to at least 12 h from symptom onset in patients with AMI.	UNIV NOTTINGHAM HOSP, DIV CARDIOVASC MED, NOTTINGHAM NG7 2UH, ENGLAND; ST MICHAELS HOSP, TORONTO M5B 1W8, ONTARIO, CANADA; FLINDERS UNIV S AUSTRALIA, MED CTR, BEDFORD PK, SA 5042, AUSTRALIA; PRINCE CHARLES HOSP, CHERMSIDE, QLD 4032, AUSTRALIA; CLIN CARDIOL TROUSSEAU, Chambray Les Tours, FRANCE; MED HSCH HANNOVER KLINIKEN, HANNOVER, GERMANY; UNIV HELSINKI, CENT HOSP, SF-00100 HELSINKI 10, FINLAND; HVIDOVRE UNIV HOSP, DK-2650 HVIDOVRE, DENMARK; HOSP GREGORIO MARANON, MADRID, SPAIN; ALEXANDRAS MATERN HOSP, ATHENS, GREECE; HOSP SANTA CRUZ, CARNAXIDE, PORTUGAL; MONTREAL HEART INST, MONTREAL H1T 1C8, QUEBEC, CANADA; CLEVELAND CLIN EDUC FDN, CLEVELAND, OH 44106 USA; UNIV ZIEKENHUIS GASTHUISBERG, LOUVAIN, BELGIUM	University of Nottingham; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; Flinders University South Australia; Prince Charles Hospital; Hannover Medical School; University of Helsinki; Helsinki University Central Hospital; University of Copenhagen; General University Gregorio Maranon Hospital; Alexandra Hospital; Universite de Montreal; Cleveland Clinic Foundation; KU Leuven; University Hospital Leuven								[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, Lancet, V1, P397; BEEK AM, 1991, AM J CARDIOL, V68, P1287, DOI 10.1016/0002-9149(91)90232-A; BLEICH SD, 1990, AM J CARDIOL, V66, P1412, DOI 10.1016/0002-9149(90)90525-6; BONADUCE D, 1990, J AM COLL CARDIOL, V16, P1561, DOI 10.1016/0735-1097(90)90301-5; BROWN EJ, 1991, J AM COLL CARDIOL, V17, P1641, DOI 10.1016/0735-1097(91)90660-2; BRUGADA P, 1986, J AM COLL CARDIOL, V8, P1035, DOI 10.1016/S0735-1097(86)80379-5; CHAMBERLAIN DA, 1988, LANCET, V1, P545; COLLEN D, 1983, J CLIN INVEST, V71, P368, DOI 10.1172/JCI110778; GRIECO A, 1984, HEALTH PSYCHOL, V3, P129, DOI 10.1037/0278-6133.3.2.129; HOCHMAN JS, 1987, CIRCULATION, V75, P299, DOI 10.1161/01.CIR.75.1.299; HSIA J, 1990, NEW ENGL J MED, V323, P1433, DOI 10.1056/NEJM199011223232101; HUNT D, 1992, LANCET, V339, P753; MULLER DWM, 1990, ANN INTERN MED, V113, P949, DOI 10.7326/0003-4819-113-12-949; MURRAY N, 1987, BRIT HEART J, V57, P144; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; RENTROP KP, 1989, J AM COLL CARDIOL, V14, P58, DOI 10.1016/0735-1097(89)90054-5; TOPOL EJ, 1992, CIRCULATION, V85, P2090, DOI 10.1161/01.CIR.85.6.2090; VANDEWERF F, 1990, LANCET, V336, P71; WHITE HD, 1992, LANCET, V340, P221, DOI 10.1016/0140-6736(92)90478-L; WILCOX RG, 1988, LANCET, V2, P525; YATEMAN NA, 1993, STAT MED, V12, P1365, DOI 10.1002/sim.4780121208; 1991, MAR AM COLL CARD 40T	23	361	364	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 25	1993	342	8874					759	766						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LY868	8103874				2022-12-28	WOS:A1993LY86800007
J	WOTHERSPOON, AC; DOGLIONI, C; DISS, TC; PAN, LX; MOSCHINI, A; DEBONI, M; ISAACSON, PG				WOTHERSPOON, AC; DOGLIONI, C; DISS, TC; PAN, LX; MOSCHINI, A; DEBONI, M; ISAACSON, PG			REGRESSION OF PRIMARY LOW-GRADE B-CELL GASTRIC LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID-TISSUE TYPE AFTER ERADICATION OF HELICOBACTER-PYLORI	LANCET			English	Article							CAMPYLOBACTER-PYLORI; IMMUNE-RESPONSE; MONOCLONALITY	Certain features of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue (MALT) suggest the tumour is antigen-responsive. Given the close association between gastric MALT lymphoma and Helicobacter pylori, these organisms might be evoking the immunological response, and eradication of H pylori might inhibit the tumour. 6 patients in whom biopsies showed histological and molecular-genetic evidence of low-grade gastric B-cell MALT lymphoma with H pylori infection were treated with antibiotics. In all cases H pylori was eradicated and in 5, repeated biopsies showed no evidence of lymphoma. These results suggest that eradication of H pylori causes regression of low-grade B-cell gastric MALT lymphoma, and that anti-H-pylori treatment should be given for this lymphoma.	UCL,SCH MED,DEPT HISTOPATHOL,UNIV ST,LONDON WC1E 6JJ,ENGLAND; OSPED CIVILE,FELTRE,ITALY	University of London; University College London; UCL Medical School				DOGLIONI, Claudio/0000-0002-4969-5216				BENAYED F, 1989, CANCER, V63, P1251, DOI 10.1002/1097-0142(19890401)63:7<1251::AID-CNCR2820630704>3.0.CO;2-H; DISS TC, 1993, J PATHOL, V169, P291, DOI 10.1002/path.1711690303; GENTA RM, 1993, HUM PATHOL, V24, P577, DOI 10.1016/0046-8177(93)90235-9; HUSSELL T, 1993, LANCET, V342, P571, DOI 10.1016/0140-6736(93)91408-E; ISAACSON PG, 1991, AM J SURG PATHOL, V15, P819, DOI 10.1097/00000478-199109000-00001; ISAACSON PG, 1987, HISTOPATHOLOGY, V11, P445, DOI 10.1111/j.1365-2559.1987.tb02654.x; Maniatis T., 1982, MOL CLONING; RAMASAMY I, 1992, J CLIN PATHOL, V45, P770, DOI 10.1136/jcp.45.9.770; STOLTE M, 1992, LANCET, V339, P745, DOI 10.1016/0140-6736(92)90645-J; STOLTE M, 1989, J CLIN PATHOL, V42, P1269, DOI 10.1136/jcp.42.12.1269; TRAINOR KJ, 1990, BLOOD, V75, P2220; WAN JH, 1990, J CLIN PATHOL, V43, P888, DOI 10.1136/jcp.43.11.888; WOTHERSPOON AC, 1991, LANCET, V338, P1175, DOI 10.1016/0140-6736(91)92035-Z; WYATT JI, 1988, SCAND J GASTROENTERO, V23, P44, DOI 10.3109/00365528809091712	14	1757	1803	1	33	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 4	1993	342	8871					575	577		10.1016/0140-6736(93)91409-F	http://dx.doi.org/10.1016/0140-6736(93)91409-F			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV963	8102719				2022-12-28	WOS:A1993LV96300009
J	OKA, Y; KATAGIRI, H; YAZAKI, Y; MURASE, T; KOBAYASHI, T				OKA, Y; KATAGIRI, H; YAZAKI, Y; MURASE, T; KOBAYASHI, T			MITOCHONDRIAL GENE MUTATION IN ISLET-CELL-ANTIBODY-POSITIVE PATIENTS WHO WERE INITIALLY NON-INSULIN-DEPENDENT DIABETICS	LANCET			English	Note							MELLITUS	Autoimmunity is thought to lead to islet-cell-antibody (ICA) formation in diabetes mellitus. However, we found a mitochondrial gene mutation at nucleotide pair 3243 in 3 of 27 Japanese ICA-positive, initially non-insulin-dependent diabetic patients. All 3 progressed to insulin-dependency within 13-31 months, whereas 5 of the other 24 are non-insulin-dependent after 54-90 months. ICA, at least in these 3 patients, may follow gradual beta-cell destruction due to mitochondrial gene mutation, although the possibility of beta-cells with the mutation being susceptible to autoimmune destruction cannot be excluded.	TORANOMON GEN HOSP,DEPT ENDOCRINOL & METAB,TOKYO 107,JAPAN	Toranomon Hospital	OKA, Y (corresponding author), UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,TOKYO 113,JAPAN.							GERBITZ KD, 1993, FEBS LETT, V321, P194, DOI 10.1016/0014-5793(93)80106-5; KOBAYASHI T, 1993, DIABETES CARE, V16, P780, DOI 10.2337/diacare.16.5.780; KOBAYASHI T, 1987, DIABETES, V36, P510, DOI 10.2337/diabetes.36.4.510; LOHR M, 1987, DIABETOLOGIA, V30, P757; NAKANISHI K, 1993, METABOLISM, V42, P196, DOI 10.1016/0026-0495(93)90035-M; REARDON W, 1992, LANCET, V340, P1376, DOI 10.1016/0140-6736(92)92560-3; SRIKANTA S, 1983, NEW ENGL J MED, V308, P322, DOI 10.1056/NEJM198302103080607; SRIKANTA S, 1985, NEW ENGL J MED, V313, P4611; VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368; WARRAM JH, 1984, NEW ENGL J MED, V311, P149, DOI 10.1056/NEJM198407193110304	10	109	111	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 28	1993	342	8870					527	528		10.1016/0140-6736(93)91649-7	http://dx.doi.org/10.1016/0140-6736(93)91649-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU582	8102670				2022-12-28	WOS:A1993LU58200012
J	NEVEN, P				NEVEN, P			TAMOXIFEN AND ENDOMETRIAL LESIONS	LANCET			English	Editorial Material							BODY-FAT DISTRIBUTION; BREAST-CANCER				NEVEN, P (corresponding author), ALGEMENE KLIN ST JAN,DEPT OBSTET & GYNAECOL,BRUSSELS,BELGIUM.							COHEN I, 1993, BRIT J OBSTET GYNAEC, V100, P567, DOI 10.1111/j.1471-0528.1993.tb15310.x; COHEN I, 1992, LANCET, V340, P312, DOI 10.1016/0140-6736(92)92409-9; FORNANDER T, 1989, LANCET, V1, P117; LAHTI E, 1993, OBSTET GYNECOL, V81, P660; NEVEN P, 1990, EUR J OBSTET GYN R B, V35, P235, DOI 10.1016/0028-2243(90)90167-Y; SCHAPIRA DV, 1991, CANCER, V67, P523, DOI 10.1002/1097-0142(19910115)67:2<523::AID-CNCR2820670234>3.0.CO;2-O; SCHAPIRA DV, 1991, JAMA-J AM MED ASSOC, V266, P1808, DOI 10.1001/jama.266.13.1808	7	21	21	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 21	1993	342	8869					452	452		10.1016/0140-6736(93)91590-I	http://dx.doi.org/10.1016/0140-6736(93)91590-I			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU075	8102426				2022-12-28	WOS:A1993LU07500007
J	SCHAAD, UB; LIPS, U; GNEHM, HE; BLUMBERG, A; HEINZER, I; WEDGWOOD, J				SCHAAD, UB; LIPS, U; GNEHM, HE; BLUMBERG, A; HEINZER, I; WEDGWOOD, J			DEXAMETHASONE THERAPY FOR BACTERIAL-MENINGITIS IN CHILDREN	LANCET			English	Article							C-REACTIVE PROTEIN; CEREBROSPINAL-FLUID; PNEUMOCOCCAL MENINGITIS; PATHOPHYSIOLOGY; INFANTS; DIAGNOSIS	Routine use of steroids as adjunctive treatment of bacterial meningitis remains controversial. We have carried out a prospective, placebo-controlled, double-blind study of dexamethasone in 115 children with acute bacterial meningitis in Switzerland. The patients were randomly assigned to receive either placebo (n = 55) or dexamethasone (n = 60) in addition to optimum antibiotic treatment (100 mg/kg daily ceftriaxone). Dexamethasone therapy (0.4 mg/kg) was started 10 min before the first dose of ceftriaxone and given every 12 h for 2 days. Baseline demographic, clinical, and laboratory features of the two groups were similar. After 24 h treatment meningeal inflammation as shown by cerebrospinal fluid (CSF) glucose concentration was significantly less with dexamethasone than with placebo (mean increase in glucose 63 [76]vs 40 [75]%, p=0 008). However, other indices of inflammation showed similar changes in both groups. Addition of dexamethasone did not affect the rate at which CSF became sterile. Both groups showed prompt clinical responses and similar frequencies of complications (15 vs 12%). Monitoring for possible adverse effects of dexamethasone revealed no abnormalities. At follow-up examinations 3, 9, and 15 months after hospital discharge, 9 (16%) of 55 placebo recipients and 3 (5%) of 60 dexamethasone recipients had one or more neurological or audiological sequelae (p=0.066); the relative risk of sequelae was 3.27 (95% Cl 0.93-11.47). Our results and those of similarly designed studies lead us to believe that adjunctive dexamethasone therapy improves outcome from bacterial meningitis in infants and children. We recommend its use, preferably in the dose regimen used in this study.	UNIV BERN,DEPT PEDIAT,CH-3000 BERN,SWITZERLAND; UNIV ZURICH,DEPT PEDIAT,CH-8006 ZURICH,SWITZERLAND; KANTONSSPITAL AARAU,DEPT PEDIAT,AARAU,SWITZERLAND; KANTONSSPITAL AARAU,DEPT MED MICROBIOL,AARAU,SWITZERLAND; WILDERMETHSPITAL BLEL,DEPT PEDIAT,BIEL,SWITZERLAND	University of Bern; University of Zurich; Kantonsspital Aarau AG (KSA); Kantonsspital Aarau AG (KSA)								BHATT SM, 1993, J INFECT DIS, V167, P675, DOI 10.1093/infdis/167.3.675; DODGE PR, 1984, NEW ENGL J MED, V311, P869, DOI 10.1056/NEJM198410043111401; FEIGIN RD, 1992, PEDIATR INFECT DIS J, V11, P785, DOI 10.1097/00006454-199209000-00039; GIRGIS NI, 1989, PEDIATR INFECT DIS J, V8, P848, DOI 10.1097/00006454-198912000-00004; HERSON VC, 1977, PEDIATRICS, V59, P35; KAPLAN SL, 1984, PEDIATRICS, V73, P575; KENNEDY WA, 1991, AM J DIS CHILD, V145, P1374, DOI 10.1001/archpedi.1991.02160120042016; Lebel M H, 1992, Antibiot Chemother (1971), V45, P169; LEBEL MH, 1989, AM J DIS CHILD, V143, P301, DOI 10.1001/archpedi.1989.02150150055017; LEBEL MH, 1988, NEW ENGL J MED, V319, P964, DOI 10.1056/NEJM198810133191502; LEBEL MH, 1989, PEDIATRICS, V83, P161; MATTHEWS DE, 1985, USING UNDERSTANDING, P1; MCCRACKEN GH, 1989, AM J DIS CHILD, V143, P287, DOI 10.1001/archpedi.1989.02150150041013; MCCRACKEN GH, 1992, CLIN INFECT DIS, V15, pS182, DOI 10.1093/clind/15.Supplement_1.S182; MUSTAFA MM, 1989, J INFECT DIS, V160, P818, DOI 10.1093/infdis/160.5.818; MUSTAFA MM, 1990, AM J DIS CHILD, V144, P883, DOI 10.1001/archpedi.1990.02150320047024; ODIO CM, 1991, NEW ENGL J MED, V324, P1525, DOI 10.1056/NEJM199105303242201; PELTOLA HO, 1982, LANCET, V1, P980; QUAGLIARELLO V, 1992, NEW ENGL J MED, V327, P864, DOI 10.1056/NEJM199209173271208; RICHTER O, 1983, PEDIATR PHARMACOL, V3, P329; SAEZLLORENS X, 1990, J PEDIATR-US, V116, P671, DOI 10.1016/S0022-3476(05)82647-2; SCHAAD UB, 1990, NEW ENGL J MED, V322, P141, DOI 10.1056/NEJM199001183220301; TAUBER MG, 1987, J INFECT DIS, V156, P456, DOI 10.1093/infdis/156.3.456; TUNKEL AR, 1990, ANN INTERN MED, V112, P610, DOI 10.7326/0003-4819-112-8-610; TUOMANEN E, 1987, J INFECT DIS, V155, P985, DOI 10.1093/infdis/155.5.985; VALMARI P, 1984, LANCET, V1, P741; VIENNY H, 1984, PEDIATRICS, V73, P579; WALD E, 1992, 32ND INT C ANT AG CH; 1992, ARCH DIS CHILD, V67, P14; 1990, M7A2 NCCLS APPR STAN	30	152	155	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 21	1993	342	8869					457	461		10.1016/0140-6736(93)91592-A	http://dx.doi.org/10.1016/0140-6736(93)91592-A			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU075	8102428				2022-12-28	WOS:A1993LU07500009
J	BRODSKY, M; KAMENKER, E; ORLOV, M; ALLEN, B				BRODSKY, M; KAMENKER, E; ORLOV, M; ALLEN, B			CARDIAC EFFECT OF PROLONGED BETA-BLOCKER THERAPY FOR MIGRAINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											BRODSKY, M (corresponding author), UNIV CALIF IRVINE,IRVINE MED CTR,ORANGE,CA 92668, USA.							FRISHMAN WH, 1988, MED CLIN N AM, V72, P37, DOI 10.1016/S0025-7125(16)30786-6; GORDON NF, 1991, MED SCI SPORT EXER, V23, P668; ROSEN JA, 1983, ANN NEUROL, V13, P92, DOI 10.1002/ana.410130119; SABLE DL, 1982, CIRCULATION, V65, P679, DOI 10.1161/01.CIR.65.4.679; WALDEN RJ, 1982, AM HEART J, V104, P515, DOI 10.1016/0002-8703(82)90149-1	5	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	1993	270	7					880	880						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR612	8101882				2022-12-28	WOS:A1993LR61200041
J	OGRADY, JG; SCHALM, SW; WILLIAMS, R				OGRADY, JG; SCHALM, SW; WILLIAMS, R			ACUTE LIVER-FAILURE - REDEFINING THE SYNDROMES	LANCET			English	Article							HEPATIC-FAILURE; FULMINANT; PROGNOSIS	Existing definitions of clinical syndromes in acute liver failure do not accurately reflect important differences in clinical features and prognosis. Based on a large series of patients with acute liver failure treated at King's College Hospital, London between 1972 and 1985, we propose a new terminology. Hyperacute liver failure is our suggested term for cases in which encephalopathy occurs within 7 days of the onset of jaundice; this group includes the sizeable cohort likely to survive with medical management despite the high incidence of cerebral oedema. We suggest the term acute liver failure for cases with an interval of between 8 and 28 days from jaundice to encephalopathy; they also have a high incidence of cerebral oedema, but have a much poorer prognosis without liver transplantation. The term subacute liver failure is suggested to describe cases with encephalopathy that occurs within 5 to 12 weeks of the onset of jaundice; these patients are characterised by a law incidence of cerebral oedema, but have a poor prognosis. Adoption of this terminology should help in the management of these patients, in addition to standardising the structure and interpretation of controlled trials of therapies.	KINGS COLL,SCH MED & DENT,INST LIVER STUDIES,LONDON SE5 8RS,ENGLAND; ST JAMES UNIV HOSP,LIVER UNIT,LEEDS LS9 7TF,W YORKSHIRE,ENGLAND; UNIV HOSP ROTTERDAM,DEPT INTERNAL MED 2,ROTTERDAM,NETHERLANDS	University of London; King's College London; Saint James's University Hospital; Erasmus University Rotterdam; Erasmus MC				opoku, anita/0000-0001-7243-8157				BERNUAU J, 1993, LANCET, V342, P252, DOI 10.1016/0140-6736(93)91809-Z; BERNUAU J, 1986, SEMIN LIVER DIS, V6, P97, DOI 10.1055/s-2008-1040593; GIMSON AES, 1986, HEPATOLOGY, V6, P288, DOI 10.1002/hep.1840060222; LUCKE B, 1946, AM J PATHOL, V22, P867; MATHIESEN LR, 1980, GUT, V21, P72, DOI 10.1136/gut.21.1.72; OGRADY JG, 1989, GASTROENTEROLOGY, V97, P439, DOI 10.1016/0016-5085(89)90081-4; TAKAHASHI Y, 1991, J GASTROEN HEPATOL, V6, P159, DOI 10.1111/j.1440-1746.1991.tb01458.x; Trey C, 1970, Prog Liver Dis, V3, P282; 1989, GUT, V20, P620	9	628	645	1	25	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 31	1993	342	8866					273	275						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ163	8101303				2022-12-28	WOS:A1993LQ16300011
J	COOKE, H				COOKE, H			DNA AND POLICE FILES	LANCET			English	Editorial Material											COOKE, H (corresponding author), WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.								0	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 17	1993	342	8864					130	130		10.1016/0140-6736(93)91339-N	http://dx.doi.org/10.1016/0140-6736(93)91339-N			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LN042	8101250				2022-12-28	WOS:A1993LN04200005
J	WANG, BB; MULLERIMMERGLUCK, MM; AUSTIN, J; ROBINSON, NT; CHISHOLM, A; KENYON, C				WANG, BB; MULLERIMMERGLUCK, MM; AUSTIN, J; ROBINSON, NT; CHISHOLM, A; KENYON, C			A HOMEOTIC GENE-CLUSTER PATTERNS THE ANTEROPOSTERIOR BODY AXIS OF C-ELEGANS	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; DROSOPHILA HEAD DEVELOPMENT; ANTERIOR POSTERIOR AXIS; HOMEOBOX GENES; EMBRYONIC EXPRESSION; BITHORAX COMPLEX; EMPTY SPIRACLES; DISTAL-LESS; HOMEODOMAIN; SEQUENCE	In insects and vertebrates, clusters of Antennapedia class homeobox (HOM-C) genes specify anteroposterior body pattern. The nematode C. elegans also contains a small cluster of HOM-C genes, one of which has been shown to specify positional identity. Here we show that two additional C. elegans HOM-C genes also specify positional identity and that together these three HOM-C genes function along the anteroposterior axis in the same order as their homologs in other organisms. Thus, HOM-C-based pattern formation has been conserved in nematodes despite the many differences in morphology and embryology that distinguish them from other phyla. Each C. elegans HOM-C gene is responsible for a distinct body region; however, where their domains overlap, two HOM-C genes can act together to specify the fates of individual cells.	MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	MRC Laboratory Molecular Biology	WANG, BB (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.			Chisholm, Andrew/0000-0001-5091-0537				AKAM M, 1988, DEVELOPMENT, V104, P123; BRENNER S, 1974, GENETICS, V77, P71; BURGLIN TR, 1991, NATURE, V351, P703, DOI 10.1038/351703a0; BURGLIN TR, 1989, NATURE, V341, P239, DOI 10.1038/341239a0; CELNIKER SE, 1989, GENE DEV, V3, P1424, DOI 10.1101/gad.3.9.1424; CHALFIE M, 1983, SCIENCE, V221, P61, DOI 10.1126/science.6857263; CHISHOLM A, 1991, DEVELOPMENT, V111, P921; CLARK SG, 1993, CELL, V74, P43, DOI 10.1016/0092-8674(93)90293-Y; COSTA M, 1988, CELL, V55, P747, DOI 10.1016/0092-8674(88)90131-6; COWING DW, 1992, DEVELOPMENT, V116, P481; CRIBBS DL, 1992, EMBO J, V11, P1437, DOI 10.1002/j.1460-2075.1992.tb05188.x; DALTON D, 1989, GENE DEV, V3, P1940, DOI 10.1101/gad.3.12a.1940; DIEDERICH RJ, 1989, GENE DEV, V3, P399, DOI 10.1101/gad.3.3.399; ELLIS H, 1985, THESIS MIT CAMBRIDGE; FIBI M, 1988, DEVELOPMENT, V102, P349; FIRE A, 1992, GENET ANAL-BIOMOL E, V9, P151, DOI 10.1016/1050-3862(92)90042-4; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; FRANCIS R, 1991, J CELL BIOL, V114, P465, DOI 10.1083/jcb.114.3.465; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; GALLIOT B, 1989, DEVELOPMENT, V107, P343; GEHRING WJ, 1990, TRENDS GENET, V6, P323, DOI 10.1016/0168-9525(90)90253-3; HAWKINS NC, 1990, NUCLEIC ACIDS RES, V18, P6101, DOI 10.1093/nar/18.20.6101; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HORVITZ HR, 1982, NEUROSCI COMMENT, V1, P56; IZPISUABELMONTE JC, 1991, EMBO J, V10, P2279, DOI 10.1002/j.1460-2075.1991.tb07764.x; KAMB A, 1989, P NATL ACAD SCI USA, V86, P4372, DOI 10.1073/pnas.86.12.4372; KARCH F, 1990, GENE DEV, V4, P1573, DOI 10.1101/gad.4.9.1573; KENYON C, 1986, CELL, V46, P477, DOI 10.1016/0092-8674(86)90668-9; KENYON C, 1991, SCIENCE, V253, P516, DOI 10.1126/science.1677487; KONGSUWAN K, 1989, NUCLEIC ACIDS RES, V17, P1881, DOI 10.1093/nar/17.5.1881; KORNFELD K, 1989, GENE DEV, V3, P243, DOI 10.1101/gad.3.2.243; LAUGHON A, 1986, MOL CELL BIOL, V6, P4676, DOI 10.1128/MCB.6.12.4676; LEMOTTE PK, 1989, EMBO J, V8, P219, DOI 10.1002/j.1460-2075.1989.tb03367.x; LOER CM, 1993, IN PRESS NEUROSCIENC; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MEIJLINK F, 1987, NUCLEIC ACIDS RES, V15, P6773, DOI 10.1093/nar/15.17.6773; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PORTEUS MH, 1991, NEURON, V7, P221, DOI 10.1016/0896-6273(91)90260-7; PRICE M, 1991, NATURE, V351, P748, DOI 10.1038/351748a0; REGULSKI M, 1987, EMBO J, V6, P767, DOI 10.1002/j.1460-2075.1987.tb04819.x; SALSER SJ, 1992, NATURE, V355, P255, DOI 10.1038/355255a0; SCHALLER D, 1990, NUCLEIC ACIDS RES, V18, P2033, DOI 10.1093/nar/18.8.2033; SCHUGHART K, 1988, P NATL ACAD SCI USA, V85, P5582, DOI 10.1073/pnas.85.15.5582; SCOTT MP, 1992, CELL, V71, P551, DOI 10.1016/0092-8674(92)90588-4; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SIMEONE A, 1992, EMBO J, V11, P2541, DOI 10.1002/j.1460-2075.1992.tb05319.x; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; TAN DP, 1992, P NATL ACAD SCI USA, V89, P6280, DOI 10.1073/pnas.89.14.6280; VACHON G, 1992, CELL, V71, P437, DOI 10.1016/0092-8674(92)90513-C; WOOD WB, 1988, NEMATODE CAENORHABDI, P491	50	283	294	1	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 16	1993	74	1					29	42		10.1016/0092-8674(93)90292-X	http://dx.doi.org/10.1016/0092-8674(93)90292-X			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LN625	8101474				2022-12-28	WOS:A1993LN62500005
J	OBRIEN, SJ; BHOPAL, RS				OBRIEN, SJ; BHOPAL, RS			LEGIONNAIRES-DISEASE - THE INFECTIVE DOSE PARADOX	LANCET			English	Editorial Material							LEGIONELLA-PNEUMOPHILA; AEROSOLS; SURVIVAL; EXPOSURE		MED SCH NEWCASTLE UPON TYNE,DEPT EPIDEMIOL & PUBL HLTH,NEWCASTLE TYNE,ENGLAND	Newcastle University - UK	OBRIEN, SJ (corresponding author), UNIV BIRMINGHAM SCH MED,DEPT INFECT,BIRMINGHAM B15 2TJ,W MIDLANDS,ENGLAND.		OBRIEN, STEPHEN/ABD-1346-2020					BASKERVILLE A, 1981, LANCET, V2, P1389; BHOPAL RS, 1993, J INFECTION, V26, P239, DOI 10.1016/0163-4453(93)95215-5; BHOPAL RS, 1991, BRIT MED J, V302, P378, DOI 10.1136/bmj.302.6773.378; BREIMAN RF, 1990, J INFECT DIS, V161, P1257, DOI 10.1093/infdis/161.6.1257; COLBOURNE JS, 1989, J INST WATER ENV MAN, V3, P345; DENNIS PJL, 1984, J HYG-CAMBRIDGE, V93, P349, DOI 10.1017/S0022172400064901; HAMBLETON P, 1983, J HYG-CAMBRIDGE, V90, P451, DOI 10.1017/S0022172400029090; MOFFAT JF, 1992, INFECT IMMUN, V60, P296, DOI 10.1128/IAI.60.1.296-301.1992; TYNDALL RL, 1985, LEGIONNAIRES DISEASE; VICKERS RM, 1992, J CLIN MICROBIOL, V30, P537, DOI 10.1128/JCM.30.3.537-539.1992; YAMAMOTO Y, 1992, J IMMUNOL, V148, P584	11	46	48	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 3	1993	342	8862					5	6		10.1016/0140-6736(93)91877-O	http://dx.doi.org/10.1016/0140-6736(93)91877-O			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK985	8100317				2022-12-28	WOS:A1993LK98500006
J	BUELER, H; AGUZZI, A; SAILER, A; GREINER, RA; AUTENRIED, P; AGUET, M; WEISSMANN, C				BUELER, H; AGUZZI, A; SAILER, A; GREINER, RA; AUTENRIED, P; AGUET, M; WEISSMANN, C			MICE DEVOID OF PRP ARE RESISTANT TO SCRAPIE	CELL			English	Article							CREUTZFELDT-JAKOB DISEASE; PRION PROTEIN; AMYLOID PLAQUES; INFECTIVITY; LINKAGE; VIRUS; GENE; IDENTIFICATION; POLYMORPHISM; PURIFICATION	S. B. Prusiner proposed that the infectious agent of scrapie, the prion, is PrP(Sc), a modified form of the normal host protein PrP(C). Prn-p0/0 mice devoid of PrP(C) showed normal development and behavior. When inoculated with mouse scrapie prions, they remained free of scrapie symptoms for at least 13 months while wild-type controls all died within 6 months. Surprisingly, heterozygous Prn-p0/+ mice also showed enhanced resistance to scrapie. After introduction of Syrian hamster PrP transgenes, Prn-P0/0 mice became highly susceptible to hamster but not to mouse prions. These experiments show that PrP(C), possibly at close to normal levels, is required for the usual susceptibility to scrapie and that lack of homology between incoming prions and the host's PrP genes retards disease.	UNIV HOSP ZURICH,INST NEUROPATHOL,CH-8091 ZURICH,SWITZERLAND; UNIV HOSP ZURICH,BIOL ZENT LAB,CH-8091 ZURICH,SWITZERLAND	University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital	BUELER, H (corresponding author), UNIV ZURICH,INST MOLEK BIOL 1,CH-8093 ZURICH,SWITZERLAND.		Aguzzi, Adriano/A-3351-2008; Büeler, Hansruedi/J-6965-2017; Sailer, Andreas/M-9913-2016	Büeler, Hansruedi/0000-0002-4892-7177; Sailer, Andreas/0000-0002-9015-7946; Aguzzi, Adriano/0000-0002-0344-6708	NINDS NIH HHS [NS22786-07] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS022786] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baker H. F., 1992, Neurodegeneration, V1, P3; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; BOLTON DC, 1988, NOVEL INFECTIOUS AGE, P164; BROWN P, 1990, NEUROLOGY, V40, P887, DOI 10.1212/WNL.40.6.887; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; CAIRNS HJF, 1950, NATURE, V166, P910, DOI 10.1038/166910b0; CARLSON GA, 1989, P NATL ACAD SCI USA, V86, P7475, DOI 10.1073/pnas.86.19.7475; CARLSON GA, 1986, CELL, V46, P503, DOI 10.1016/0092-8674(86)90875-5; CARLSON GA, 1988, MOL CELL BIOL, V8, P5528, DOI 10.1128/MCB.8.12.5528; CHANDLER RL, 1961, LANCET, V1, P1378; DEARMOND SJ, 1985, CELL, V41, P221, DOI 10.1016/0092-8674(85)90076-5; DIRINGER H, 1983, NATURE, V306, P476, DOI 10.1038/306476a0; DIRINGER H, 1988, CIBA F SYMP, V135, P135; EKLUND CM, 1967, J INFECT DIS, V117, P15, DOI 10.1093/infdis/117.1.15; GABIZON R, 1988, P NATL ACAD SCI USA, V85, P6617, DOI 10.1073/pnas.85.18.6617; GAJDUSEK DC, 1991, EUR J EPIDEMIOL, V7, P567, DOI 10.1007/BF00143141; HILMERT H, 1984, BIOSCIENCE REP, V4, P165, DOI 10.1007/BF01120313; HOTCHIN J, 1983, INTERVIROLOGY, V19, P205, DOI 10.1159/000149362; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; HUNTER N, 1987, J GEN VIROL, V68, P2711, DOI 10.1099/0022-1317-68-10-2711; KELLINGS K, 1992, J GEN VIROL, V73, P1025, DOI 10.1099/0022-1317-73-4-1025; Kimberlin R.H., 1990, SE VIROL, V1, P153; KINGSBURY DT, 1990, ANNU REV GENET, V24, P115, DOI 10.1146/annurev.ge.24.120190.000555; KITAMOTO T, 1986, ANN NEUROL, V20, P204, DOI 10.1002/ana.410200205; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANUELIDIS L, 1988, CIBA F SYMP, V135, P117; MEYER N, 1991, J GEN VIROL, V72, P37, DOI 10.1099/0022-1317-72-1-37; MILLSON GC, 1993, VET MICROBIOL 1979, P89; OESCH B, 1988, CIBA F SYMP, V135, P209; PATTISON IH, 1966, RES VET SCI, V7, P207; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1982, BIOCHEMISTRY-US, V21, P6942, DOI 10.1021/bi00269a050; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; RACE RE, 1990, J GEN VIROL, V71, P493, DOI 10.1099/0022-1317-71-2-493; Rohwer R G, 1991, Curr Top Microbiol Immunol, V172, P195; SCOTT M, 1989, CELL, V59, P847, DOI 10.1016/0092-8674(89)90608-9; SERBAN D, 1990, NEUROLOGY, V40, P110, DOI 10.1212/WNL.40.1.110; WEISSMANN C, 1991, NATURE, V352, P679, DOI 10.1038/352679a0	40	1706	1768	2	101	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 2	1993	73	7					1339	1347		10.1016/0092-8674(93)90360-3	http://dx.doi.org/10.1016/0092-8674(93)90360-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology	LL209	8100741	Bronze			2022-12-28	WOS:A1993LL20900009
J	MATONDO, P				MATONDO, P			INFECTIOUS-DISEASE - ANTENATAL INTERVENTIONS AGAINST SEXUALLY-TRANSMITTED DISEASE IN AFRICA	LANCET			English	Editorial Material							PLACEBO-CONTROLLED TRIAL; ERYTHROMYCIN TREATMENT				MATONDO, P (corresponding author), UNIV TEACHING HOSP,LUSAKA,ZAMBIA.							BRADDICK MR, 1990, GENITOURIN MED, V66, P622; ELLIOT G, 1990, J INFECT DIS, V161, P5321; ESCHENBACH DA, 1991, AM J OBSTET GYNECOL, V164, P734, DOI 10.1016/0002-9378(91)90506-M; HIRA SK, 1990, GENITOURIN MED, V66, P159; MATONDO P, 1989, MED J ZAMBIA, V24, P3; MCCORMACK WM, 1987, OBSTET GYNECOL, V69, P202; MCGREGOR JA, 1986, AM J OBSTET GYNECOL, V154, P98, DOI 10.1016/0002-9378(86)90401-1; Ratnam A V, 1980, Med J Zambia, V14, P71; VANDYCK E, 1992, GENITOURIN MED, V68, P111; 1992, WHOMSM92 DOC	10	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 19	1993	341	8860					1565	1566		10.1016/0140-6736(93)90701-H	http://dx.doi.org/10.1016/0140-6736(93)90701-H			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH550	8099644				2022-12-28	WOS:A1993LH55000008
J	THOMPSON, WG				THOMPSON, WG			IRRITABLE-BOWEL-SYNDROME - PATHOGENESIS AND MANAGEMENT	LANCET			English	Article							COLONIC MYOELECTRICAL ACTIVITY; DIETARY FIBER; PROGNOSIS; DISORDERS; SYMPTOMS; DISEASE; ILLNESS; PAIN	An international working team defined the irritable bowel syndrome as distinct from other functional bowel disorders. Symptom criteria for the irritable bowel syndrome are known as the Rome criteria. Since there is no pathophysiological marker for any of these syndromes we must rely on symptoms for their definition and classification. The Rome nosology is a step towards better understanding of functional gastrointestinal disorders because the disparate syndromes are likely to have different causes and treatments.			THOMPSON, WG (corresponding author), OTTAWA CIVIC HOSP,DIV GASTROENTEROL A1,1053 CARLING AVE,OTTAWA K1Y 4E9,ONTARIO,CANADA.							ALMY TP, 1951, AM J MED, V10, P60, DOI 10.1016/0002-9343(51)90219-7; [Anonymous], 1992, GASTROENTEROL INT; BIZHEN KW, 1988, CHIN J EPIDEMIOL, V9, P345; BRODY H, 1982, ANN INTERN MED, V97, P112, DOI 10.7326/0003-4819-97-1-112; BUENO L, 1980, GUT, V21, P480, DOI 10.1136/gut.21.6.480; Burkitt D P, 1972, Lancet, V2, P1408; CREED F, 1988, GUT, V29, P235, DOI 10.1136/gut.29.2.235; DROSSMAN DA, 1990, ANN INTERN MED, V113, P828, DOI 10.7326/0003-4819-113-11-828; DROSSMAN DA, 1992, ANN INTERN MED, V116, P1009, DOI 10.7326/0003-4819-116-12-1009; GUTHRIE E, 1991, GASTROENTEROLOGY, V100, P450, DOI 10.1016/0016-5085(91)90215-7; GUTHRIE EA, 1992, GUT, V33, P361, DOI 10.1136/gut.33.3.361; HARVEY RF, 1973, LANCET, V1, P1; HARVEY RF, 1987, LANCET, V1, P963; HEATON KW, 1985, IRRITABLE BOWEL SYND, P203; KELLOW JE, 1988, GUT, V29, P1236, DOI 10.1136/gut.29.9.1236; KLEIN KB, 1988, GASTROENTEROLOGY, V95, P232, DOI 10.1016/0016-5085(88)90319-8; KRUIS W, 1984, GASTROENTEROLOGY, V87, P1; LASSER RB, 1975, NEW ENGL J MED, V293, P544; MANNING AP, 1978, BRIT MED J, V2, P653, DOI 10.1136/bmj.2.6138.653; MCINTOSH D, 1992, AM J GASTROENTEROL, V87, P1407; ODONNELL LJD, 1990, BMJ-BRIT MED J, V300, P439, DOI 10.1136/bmj.300.6722.439; SULLIVAN MA, 1978, NEW ENGL J MED, V298, P878, DOI 10.1056/NEJM197804202981604; SWARBRICK ET, 1980, LANCET, V2, P443; SWEDLUND J, 1983, LANCET, V2, P589; THOMPSON WG, 1986, CAN MED ASSOC J, V134, P111; TUCKER DM, 1981, GASTROENTEROLOGY, V81, P879; VALORI RM, 1986, GASTROENTEROLOGY, V90, P1890, DOI 10.1016/0016-5085(86)90258-1; WANGEL AG, 1965, GASTROENTEROLOGY, V48, P69; WHITEHEAD WE, 1990, GASTROENTEROLOGY, V98, P1187, DOI 10.1016/0016-5085(90)90332-U; WHITEHEAD WE, 1988, GASTROENTEROLOGY, V95, P709, DOI 10.1016/S0016-5085(88)80018-0; WHITEHEAD WE, 1982, DIGEST DIS SCI, V27, P202, DOI 10.1007/BF01296915	31	69	82	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 19	1993	341	8860					1569	1572		10.1016/0140-6736(93)90705-L	http://dx.doi.org/10.1016/0140-6736(93)90705-L			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH550	8099648				2022-12-28	WOS:A1993LH55000012
J	BRODIE, MJ				BRODIE, MJ			EPILEPSY - FELBAMATE - A NEW ANTIEPILEPTIC DRUG	LANCET			English	Editorial Material							PARTIAL SEIZURES; CLINICAL-TRIAL; CARBAMAZEPINE				BRODIE, MJ (corresponding author), WESTERN INFIRM & ASSOCIATED HOSP,EPILEPSY RES UNIT,GLASGOW G11 6NT,SCOTLAND.							ALBANI F, 1991, EPILEPSIA, V32, P130, DOI 10.1111/j.1528-1157.1991.tb05624.x; FAUGHT E, IN PRESS NEUROLOGY; FUERST RH, 1988, EPILEPSIA, V29, P448; GRAVES NM, 1989, EPILEPSIA, V30, P225, DOI 10.1111/j.1528-1157.1989.tb05458.x; LEPPIK I E, 1990, Neurology, V40, P158; LEPPIK IE, 1991, NEUROLOGY, V41, P1785, DOI 10.1212/WNL.41.11.1785; PALMER KJ, IN PRESS DRUGS; SACHDEO R, 1992, ANN NEUROL, V32, P386, DOI 10.1002/ana.410320313; THEODORE WH, 1991, EPILEPSIA, V32, P392, DOI 10.1111/j.1528-1157.1991.tb04668.x; WAGNER M L, 1991, Epilepsia, V32, P15; WAGNER ML, 1990, EPILEPSIA, V31, P642; WARD D L, 1991, Epilepsia, V32, P8; 1992, SCRIP           1222, P26; 1993, NEW ENGL J MED, V328, P29	14	24	25	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 5	1993	341	8858					1445	1446		10.1016/0140-6736(93)90888-N	http://dx.doi.org/10.1016/0140-6736(93)90888-N			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF841	8099147				2022-12-28	WOS:A1993LF84100010
J	PARKINSON, JS				PARKINSON, JS			SIGNAL-TRANSDUCTION SCHEMES OF BACTERIA	CELL			English	Review							2 REGULATORY COMPONENTS; DIRECTED CROSS-LINKING; PORIN GENE-EXPRESSION; ESCHERICHIA-COLI; ACTIVATOR PROTEIN; SENSORY RECEPTOR; TRANSCRIPTIONAL ACTIVATOR; RESPONSE REGULATOR; DNA-BINDING; OMPC GENES				PARKINSON, JS (corresponding author), UNIV UTAH, DEPT BIOL, SALT LAKE CITY, UT 84112 USA.			Parkinson, John/0000-0001-8788-7844				AIBA H, 1989, J BIOL CHEM, V264, P14090; AIBA H, 1989, J BIOL CHEM, V264, P8563; AIBA H, 1989, J BIOCHEM-TOKYO, V106, P5, DOI 10.1093/oxfordjournals.jbchem.a122817; AMES P, 1988, CELL, V55, P817, DOI 10.1016/0092-8674(88)90137-7; ARTYMIUK PJ, 1990, PROTEIN ENG, V4, P39, DOI 10.1093/protein/4.1.39; BARAK R, 1992, BIOCHEMISTRY-US, V31, P1821, DOI 10.1021/bi00121a034; BERG HC, 1988, COLD SPRING HARB SYM, V53, P1, DOI 10.1101/SQB.1988.053.01.003; BLISKA JB, 1993, CELL, V73, P903, DOI 10.1016/0092-8674(93)90270-Z; BORKOVICH KA, 1992, P NATL ACAD SCI USA, V89, P6756, DOI 10.1073/pnas.89.15.6756; BORKOVICH KA, 1989, P NATL ACAD SCI USA, V86, P1208, DOI 10.1073/pnas.86.4.1208; BORKOVICH KA, 1990, CELL, V63, P1339, DOI 10.1016/0092-8674(90)90429-I; BOURRET RB, 1990, P NATL ACAD SCI USA, V87, P41, DOI 10.1073/pnas.87.1.41; BOURRET RB, 1993, J BACTERIOL, V175, P2097, DOI 10.1128/JB.175.7.2097-2101.1993; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; BRISSETTE RE, 1991, J BACTERIOL, V173, P601, DOI 10.1128/jb.173.2.601-608.1991; BURROWS GG, 1991, THESIS WASHINGTON ST; CHEN J, 1992, THESIS U UTAH SALT L; CHEN JM, 1990, INT J PEPT PROT RES, V36, P1; DUNTEN P, 1991, J BIOL CHEM, V266, P1491; EISENBACH M, 1991, SENSORY RECEPTORS SI, P131; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; FALKE JJ, 1988, J BIOL CHEM, V263, P14850; FENG JL, 1992, J BACTERIOL, V174, P6061, DOI 10.1128/JB.174.19.6061-6070.1992; FORST S, 1990, J BACTERIOL, V172, P3473, DOI 10.1128/jb.172.6.3473-3477.1990; FORST S, 1987, J BIOL CHEM, V262, P16433; FORST S, 1989, P NATL ACAD SCI USA, V86, P6052, DOI 10.1073/pnas.86.16.6052; GEGNER JA, 1992, CELL, V70, P975, DOI 10.1016/0092-8674(92)90247-A; HAZELBAUER GL, 1993, CELL, V73, P15, DOI 10.1016/0092-8674(93)90156-K; HAZELBAUER GL, 1989, P NATL ACAD SCI USA, V86, P1448, DOI 10.1073/pnas.86.5.1448; Hazelbauer GL, 1992, CURR OPIN STRUC BIOL, V2, P505; HAZELBAUER GL, 1990, SOC GENERAL MICROBIO, V46, P107; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; HESS JF, 1988, NATURE, V336, P139, DOI 10.1038/336139a0; IGO M M, 1990, New Biologist, V2, P5; IGO MM, 1989, GENE DEV, V3, P1725, DOI 10.1101/gad.3.11.1725; JONES CJ, 1991, ADV MICROB PHYSIOL, V32, P109, DOI 10.1016/S0065-2911(08)60007-7; KAISER D, 1993, CELL, V73, P873, DOI 10.1016/0092-8674(93)90268-U; KEENER J, 1988, P NATL ACAD SCI USA, V85, P4976, DOI 10.1073/pnas.85.14.4976; KEHRY MR, 1984, J BIOL CHEM, V259, P1828; KEHRY MR, 1983, P NATL ACAD SCI-BIOL, V80, P3599, DOI 10.1073/pnas.80.12.3599; LEE L, 1990, J BACTERIOL, V172, P377, DOI 10.1128/JB.172.1.377-382.1990; LIU J, 1990, THESIS U UTAH SALT L; LIU JD, 1991, J BACTERIOL, V173, P4941, DOI 10.1128/jb.173.16.4941-4951.1991; LONG DG, 1992, BIOCHEMISTRY-US, V31, P9904, DOI 10.1021/bi00156a007; LONG SR, 1993, CELL, V73, P921, DOI 10.1016/0092-8674(93)90271-Q; LUKAT GS, 1991, J BIOL CHEM, V266, P8348; LUKAT GS, 1992, P NATL ACAD SCI USA, V89, P718, DOI 10.1073/pnas.89.2.718; LUPAS A, 1989, J BIOL CHEM, V264, P17337; LYNCH BA, 1991, P NATL ACAD SCI USA, V88, P10402, DOI 10.1073/pnas.88.23.10402; LYNCH BA, 1992, FEBS LETT, V307, P3, DOI 10.1016/0014-5793(92)80891-J; MACNAB RM, 1992, ANNU REV GENET, V26, P131, DOI 10.1146/annurev.ge.26.120192.001023; MADDOCK JR, 1993, SCIENCE, V259, P1717; MAEDA S, 1990, J BACTERIOL, V172, P501, DOI 10.1128/JB.172.1.501-503.1990; MANSON MD, 1992, ADV MICROB PHYSIOL, V33, P277, DOI 10.1016/S0065-2911(08)60219-2; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; MILLIGAN DL, 1991, SCIENCE, V254, P1651, DOI 10.1126/science.1661030; MIZUNO T, 1990, MOL MICROBIOL, V4, P1077, DOI 10.1111/j.1365-2958.1990.tb00681.x; MORGAN DG, 1993, J BACTERIOL, V175, P133, DOI 10.1128/JB.175.1.133-140.1993; MUTOH N, 1986, J BACTERIOL, V167, P992, DOI 10.1128/jb.167.3.992-998.1986; NAKASHIMA K, 1991, J BIOL CHEM, V266, P10775; NINFA AJ, 1991, J BIOL CHEM, V266, P6888; NINFA AJ, 1987, CELL, V50, P1039, DOI 10.1016/0092-8674(87)90170-X; NINFA AJ, 1986, P NATL ACAD SCI USA, V83, P5909, DOI 10.1073/pnas.83.16.5909; NINFA EG, 1991, J BIOL CHEM, V266, P9764; NOWLIN DM, 1988, PROTEINS, V3, P102, DOI 10.1002/prot.340030205; OOSAWA K, 1988, CELL, V53, P89, DOI 10.1016/0092-8674(88)90490-4; PAKULA AA, 1992, P NATL ACAD SCI USA, V89, P4144, DOI 10.1073/pnas.89.9.4144; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; RAMPERSAUD A, 1989, J BIOL CHEM, V264, P18693; RAMPERSAUD A, 1991, J BACTERIOL, V173, P6882, DOI 10.1128/jb.173.21.6882-6888.1991; ROMAN SJ, 1992, J BACTERIOL, V174, P6247, DOI 10.1128/JB.174.19.6247-6255.1992; RUSSELL CB, 1989, J BACTERIOL, V171, P3609, DOI 10.1128/jb.171.7.3609-3618.1989; RUSSO FD, 1991, J MOL BIOL, V222, P567, DOI 10.1016/0022-2836(91)90497-T; SANDERS DA, 1988, P NATL ACAD SCI USA, V85, P8425, DOI 10.1073/pnas.85.22.8425; SANDERS DA, 1992, J BACTERIOL, V174, P5117, DOI 10.1128/JB.174.15.5117-5122.1992; SANDERS DA, 1989, J BIOL CHEM, V264, P21770; SASSEDWIGHT S, 1988, P NATL ACAD SCI USA, V85, P8934, DOI 10.1073/pnas.85.23.8934; SEGALL JE, 1982, NATURE, V296, P855, DOI 10.1038/296855a0; SEGALL JE, 1986, P NATL ACAD SCI USA, V83, P8987, DOI 10.1073/pnas.83.23.8987; SEGALL JE, 1985, J BACTERIOL, V161, P51, DOI 10.1128/JB.161.1.51-59.1985; SHAPIRO L, 1993, CELL, V73, P841, DOI 10.1016/0092-8674(93)90266-S; SLAUCH JM, 1991, J BACTERIOL, V173, P7501, DOI 10.1128/jb.173.23.7501-7510.1991; SLAUCH JM, 1989, J MOL BIOL, V210, P281, DOI 10.1016/0022-2836(89)90330-6; STEWART RC, 1993, J BIOL CHEM, V268, P1921; STEWART RC, 1990, J BACTERIOL, V172, P3388, DOI 10.1128/jb.172.6.3388-3399.1990; STOCK AM, 1989, NATURE, V337, P745, DOI 10.1038/337745a0; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; STOCK JB, 1991, ANNU REV BIOPHYS BIO, V20, P109, DOI 10.1146/annurev.bb.20.060191.000545; STOCK JB, 1990, NATURE, V344, P395, DOI 10.1038/344395a0; STODDARD BL, 1992, BIOCHEMISTRY-US, V31, P11978, DOI 10.1021/bi00163a004; SU W, 1990, P NATL ACAD SCI USA, V87, P5504, DOI 10.1073/pnas.87.14.5504; SWANSON RV, 1993, IN PRESS MOL MICROBI; TOKISHITA S, 1992, J BIOCHEM-TOKYO, V111, P707, DOI 10.1093/oxfordjournals.jbchem.a123823; TOKISHITA S, 1991, J BIOL CHEM, V266, P6780; UTSUMI R, 1989, SCIENCE, V245, P1246, DOI 10.1126/science.2476847; VOLZ K, 1991, J BIOL CHEM, V266, P15511; WANNER BL, 1992, J BACTERIOL, V174, P2053, DOI 10.1128/JB.174.7.2053-2058.1992; WEDEL A, 1990, SCIENCE, V248, P486, DOI 10.1126/science.1970441; WEISS DS, 1991, CELL, V67, P155, DOI 10.1016/0092-8674(91)90579-N; WEISS V, 1992, P NATL ACAD SCI USA, V89, P5088, DOI 10.1073/pnas.89.11.5088; WEISS V, 1988, P NATL ACAD SCI USA, V85, P8919, DOI 10.1073/pnas.85.23.8919; WOLFE AJ, 1993, P NATL ACAD SCI USA, V90, P1518, DOI 10.1073/pnas.90.4.1518; WOLFF C, 1988, J BACTERIOL, V170, P4509, DOI 10.1128/jb.170.10.4509-4515.1988; WOOTTON JC, 1989, PROTEIN ENG, V2, P535, DOI 10.1093/protein/2.7.535; WYLIE D, 1988, BIOCHEM BIOPH RES CO, V151, P891, DOI 10.1016/S0006-291X(88)80365-6; YANG Y, 1991, P NATL ACAD SCI USA, V88, P11057, DOI 10.1073/pnas.88.24.11057	108	638	651	0	30	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 4	1993	73	5					857	871		10.1016/0092-8674(93)90267-T	http://dx.doi.org/10.1016/0092-8674(93)90267-T			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LF061	8098993				2022-12-28	WOS:A1993LF06100005
J	WEAVER, LT; BECKERLEG, S				WEAVER, LT; BECKERLEG, S			IS HEALTH A SUSTAINABLE STATE - A VILLAGE STUDY IN THE GAMBIA	LANCET			English	Article											WEAVER, LT (corresponding author), MRC, DUNN NUTR UNIT, MILTON RD, CAMBRIDGE CB4 1XJ, ENGLAND.							BARRETT HR, 1991, GAMBIA STUDIES SOC P, P16; BILLEWICZ WZ, 1981, J BIOSOC SCI, V13, P219, DOI 10.1017/S0021932000013390; FA F, 1990, P INT CONFEDERATION, P39; GAMBLE DP, 1955, EC CONDITIONS 2 MAND; JABANG S, 1990, SUMMARY METEOROLOGIC; KING M, 1990, LANCET, V336, P664, DOI 10.1016/0140-6736(90)92156-C; KING M, 1993, LANCET, V341, P669, DOI 10.1016/0140-6736(93)90431-F; LAMB WH, 1984, LANCET, V2, P912; LAMB WH, 1985, LANCET, V1, P334; LUNN PG, 1984, AM J CLIN NUTR, V39, P227, DOI 10.1093/ajcn/39.2.227; MCGREGOR IA, 1952, T ROY SOC TROP MED H, V46, P403, DOI 10.1016/0035-9203(52)90058-8; MCGREGOR IA, 1961, BRIT MED J, V2, P1161; MCNICOLL G, 1988, MICROAPPROACHES DEMO, P10; MORLEY DC, 1963, T R SOC TROP MED HYG, V57, P80; OPPONG C, 1987, SEX ROLES POPULATION; PARKHURST GP, 1991, THESIS U OXFORD; ROWLAND MGM, 1977, BRIT J NUTR, V37, P441, DOI 10.1079/BJN19770047; SWINDELL K, 1991, BIRMINGHAM U AFRICAN, V3, P6; THOMPSON B, 1965, THESIS U ABERDEEN; WEAVER LT, 1990, NUTRITION DEV WORLD; Weil Peter, 1986, CULTURE REPRODUCTION, P294	21	26	26	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 22	1993	341	8856					1327	1330		10.1016/0140-6736(93)90827-4	http://dx.doi.org/10.1016/0140-6736(93)90827-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD253	8098458				2022-12-28	WOS:A1993LD25300014
J	HEAD, A; KENDALL, MJ; EAGLES, C				HEAD, A; KENDALL, MJ; EAGLES, C			CARDIAC REHABILITATION	BRITISH MEDICAL JOURNAL			English	Letter											HEAD, A (corresponding author), QUEEN ELIZABETH HOSP,DEPT MED,CLIN INVEST UNIT,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND.							CHUA TP, 1993, BRIT MED J, V306, P731, DOI 10.1136/bmj.306.6880.731; HEAD A, 1993, POSTGRAD MED J, V69, P197, DOI 10.1136/pgmj.69.809.197; McNair D., 1971, MANUAL PROFILE MOOD; OLSSON G, 1992, EUR HEART J, V13, P28, DOI 10.1093/oxfordjournals.eurheartj.a060043	4	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 8	1993	306	6887					1271	1271		10.1136/bmj.306.6887.1271-a	http://dx.doi.org/10.1136/bmj.306.6887.1271-a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB804	8098973	Green Published			2022-12-28	WOS:A1993LB80400051
J	MYERS, MG; BAIGRIE, RS; CHARLAT, ML; MORGAN, CD				MYERS, MG; BAIGRIE, RS; CHARLAT, ML; MORGAN, CD			ARE ROUTINE NONINVASIVE TESTS USEFUL IN PREDICTION OF OUTCOME AFTER MYOCARDIAL-INFARCTION IN ELDERLY PEOPLE	LANCET			English	Article							PATIENTS OLDER; CLINICAL-VARIABLES; CHEST PAIN; PROGNOSIS; YOUNGER; RISK; AGE; RADIONUCLIDE; MANAGEMENT; DISCHARGE	Many patients with acute myocardial infarction undergo tests to identify ischaemia, left-ventricular dysfunction, and arrhythmias. We examined the usefulness of these tests in clinical practice by comparing the ability of a cardiologist to predict outcome at 1 year after infarction with and without knowledge of the results of an exercise test, radionuclide angiogram, and 24 h Holter electrocardiographic (ECG) recording. The study was limited to patients older than 65 years, who have a greater risk of cardiovascular sequelae and undergo fewer interventional procedures. The patient's own cardiologist predicted outcome on a standard rating scale, based on clinical findings and routine hospital tests. He then made a second prediction after seeing the non-invasive test results. Two other cardiologists not involved in the care of the patient independently made similar predictions. Success in predicting outcome was assessed by comparison of differences between the first and second predictions in the area under receiver operating characteristic curves. During 1 year's follow-up there were 24 cardiovascular deaths and 3 recurrent myocardial infarctions among the 147 patients. There were no significant differences in mean curve areas between the first and second predictions for the patients' own cardiologist (0.62 [SE 0.06] vs 0.60 [0.06]) or the other cardiologists (0.63 [0.06] vs 0.64 [0.06] and 0.61 [0.06] vs 0.65 [0.06]). All predictions were significantly (p < 0.05) better than chance. Prediction of outcome in older patients after myocardial infarction is not improved by knowledge of the results of an exercise test, radionuclide angiogram, or 24 h Holter ECG recording.	UNIV TORONTO,DEPT MED,TORONTO M5S 1A1,ONTARIO,CANADA	University of Toronto	MYERS, MG (corresponding author), SUNNYBROOK HLTH SCI CTR,DIV CARDIOL,A-222,2075 BAYVIEW AVE,TORONTO M4N 3M5,ON,CANADA.							CAIRNS JA, 1989, CAN J CARDIOL, V5, P239; CROW RS, 1975, CIRCULATION, V51, P211; DEBUSK RF, 1989, ANN INTERN MED, V110, P470, DOI 10.7326/0003-4819-110-6-470; DEBUSK RF, 1983, AM J CARDIOL, V52, P1161, DOI 10.1016/0002-9149(83)90567-2; DECKERS JW, 1984, EUR HEART J, V5, P97, DOI 10.1093/eurheartj/5.suppl_E.97; DIAMOND GA, 1989, J AM COLL CARDIOL, V14, pA12, DOI 10.1016/0735-1097(89)90157-5; FALLEN EL, 1991, CAN MED ASSOC J, V144, P1015; FIORETTI P, 1985, AM J CARDIOL, V55, P1313, DOI 10.1016/0002-9149(85)90495-3; FIORETTI P, 1986, J AM COLL CARDIOL, V8, P40, DOI 10.1016/S0735-1097(86)80089-4; GRIFFIN BP, 1991, AM J CARDIOL, V68, P707, DOI 10.1016/0002-9149(91)90640-7; HLATKY M, 1982, AM J CARDIOL, V49, P1927, DOI 10.1016/0002-9149(82)90211-9; HOIT BD, 1986, CIRCULATION, V74, P712, DOI 10.1161/01.CIR.74.4.712; MCNEIL BJ, 1984, MED DECIS MAKING, V4, P137, DOI 10.1177/0272989X8400400203; MONTAGUE TJ, 1991, AM J CARDIOL, V68, P843, DOI 10.1016/0002-9149(91)90397-4; MONTAGUE TJ, 1992, CAN J CARDIOL, V8, P596; MOSS AJ, 1990, NEW ENGL J MED, V322, P743, DOI 10.1056/NEJM199003153221107; OLMSTED WL, 1987, AM J CARDIOL, V60, P971, DOI 10.1016/0002-9149(87)90335-3; POLLOCK SG, 1992, CIRCULATION, V85, P237, DOI 10.1161/01.CIR.85.1.237; SOLOMON CG, 1989, AM J CARDIOL, V63, P772, DOI 10.1016/0002-9149(89)90040-4; WILLIAMS WL, 1984, J AM COLL CARDIOL, V4, P477, DOI 10.1016/S0735-1097(84)80090-X; 1989, ANN INTERN MED, V110, P485	21	16	16	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 30	1993	342	8879					1069	1072		10.1016/0140-6736(93)92060-7	http://dx.doi.org/10.1016/0140-6736(93)92060-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME822	8105308				2022-12-28	WOS:A1993ME82200006
J	MARLOW, N; WEINDLING, M; SHAW, B				MARLOW, N; WEINDLING, M; SHAW, B			OPIATES, CATECHOLAMINE CONCENTRATIONS, AND VENTILATED PRETERM BABIES	LANCET			English	Letter									UNIV LIVERPOOL,DEPT CHILD HLTH,LIVERPOOL L69 3BX,ENGLAND	University of Liverpool	MARLOW, N (corresponding author), UNIV BRISTOL,ST MICHAELS HOSP,DEPT CHILD HLTH,BRISTOL BS2 8EG,ENGLAND.		Marlow, Neil/D-2918-2009	Marlow, Neil/0000-0001-5890-2953				MARLOW N, 1990, ARCH DIS CHILD-FETAL, V65, P349, DOI 10.1136/adc.65.4_Spec_No.349; QUINN, 1993, LANCET, V342, P324	2	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 16	1993	342	8877					997	998		10.1016/0140-6736(93)92048-X	http://dx.doi.org/10.1016/0140-6736(93)92048-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MC005	8105252				2022-12-28	WOS:A1993MC00500063
J	ABRAHAMSON, S				ABRAHAMSON, S			UNIVERSITY-STUDENT ATTITUDES TO A CAREER IN MEDICINE	LANCET			English	Editorial Material											ABRAHAMSON, S (corresponding author), UNIV SO CALIF,SCH MED,DEPT MED EDUC,LOS ANGELES,CA 90033, USA.							BARONDESS JA, 1993, ACAD MED, V68, P323, DOI 10.1097/00001888-199305000-00002	1	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 25	1993	342	8874					757	758		10.1016/0140-6736(93)91536-U	http://dx.doi.org/10.1016/0140-6736(93)91536-U			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LY868	8103872				2022-12-28	WOS:A1993LY86800005
J	MIKO, TL; LEMAITRE, C; KINFU, Y				MIKO, TL; LEMAITRE, C; KINFU, Y			DAMAGE AND REGENERATION OF PERIPHERAL-NERVES IN ADVANCED TREATED LEPROSY	LANCET			English	Article							REPAIR; GRAFT	Despite the rapidly falling prevalence of leprosy, the disability and handicap resulting from loss of protective sensation, due to irreversible nerve damage, will remain a huge medical problem for many years. To elucidate the location and consequences of permanent nerve damage in treated leprosy, a prospective study involving nine patients who underwent leg amputation was conducted. Full-length nerves dissected from amputated legs were studied with histological and immunohistochemical methods. Our main findings were that: in both lepromatous and tuberculoid leprosy nerve damage increased distally, culminating in total destruction of dermal nerves and sensory nerve endings; after the therapy-related decrease of inflammation large-scale nerve regeneration took place; and that regenerating axons persisted for decades and in tuberculoid leprosy they might reach the subcutaneous fat of the plantar skin. We conclude that nerve regeneration was blocked by fibrous replacement of the distal-most nerves and nerve endings, and that the theoretical basis of nerve grafting in leprosy is in need of further clarification. In some patients, autologous transplantation of skin flaps, probably irrespective of the duration of loss of sensation, might help in regaining protective sensation.	ALL AFRICA LEPROSY & REHABIL TRAINING CTR,ARMAUER HANSEN RES INST,ADDIS ABABA,ETHIOPIA; UNIV ADDIS ABABA,FAC MED,DEPT ANAT,ADDIS ABABA,ETHIOPIA	Addis Ababa University								ADEYMO O, 1957, TRANSPLAN B, V4, P152; Carayon A, 1970, J Chir (Paris), V99, P235; Dastur D K, 1970, Int J Lepr Other Mycobact Dis, V38, P30; Dastur D K, 1983, Neurosurg Rev, V6, P139, DOI 10.1007/BF01742765; DASTUR DK, 1955, BRAIN, V78, P615, DOI 10.1093/brain/78.4.615; DAYAN AD, 1970, J NEUROL NEUROSUR PS, V33, P586, DOI 10.1136/jnnp.33.5.586; ERMAKOVA NINA, 1936, INTERNAL JOUR LEPROSY, V4, P325; FAWCETT JW, 1986, J NEUROSURG, V65, P354, DOI 10.3171/jns.1986.65.3.0354; HASTINGS R C, 1968, Leprosy Review, V39, P71; Job C K, 1968, Int J Lepr Other Mycobact Dis, V36, P257; KARANTH SS, 1989, J PATHOL, V157, P15, DOI 10.1002/path.1711570104; MACKINNON SE, 1988, SURGERY PERIPHERAL N; MANNERFELT L, 1962, Br J Plast Surg, V15, P136, DOI 10.1016/S0007-1226(62)80019-8; MIKO TL, IN PRESS BIOTECHNIC; MIKO TL, IN PRESS LEPR REV; NOORDEEN SK, 1992, B WORLD HEALTH ORGAN, V70, P7; NORRIS RW, 1988, J BONE JOINT SURG BR, V70, P530, DOI 10.1302/0301-620X.70B4.3403592; PEREIRA JH, 1991, LANCET, V338, P1239, DOI 10.1016/0140-6736(91)92105-B; PFALTZGRAFF RE, 1985, LEPROSY; REDDY DG, 1962, INDIAN J MED RES, V50, P692; Ridley DS., 1988, PATHOGENESIS LEPROSY; SABIN TD, 1969, ARCH NEUROL-CHICAGO, V20, P257, DOI 10.1001/archneur.1969.00480090045006; SABIN TD, 1984, PERIPHERAL NEUROPATH; SMITH WCS, 1993, LANCET, V341, P89, DOI 10.1016/0140-6736(93)92563-9; SMITH WCS, 1992, LEPROSY REV, V63, P23; SUNDERLAND S, 1973, BRAIN, V96, P865, DOI 10.1093/brain/96.4.865; VIEREGGE P, 1985, LEPROSY REV, V56, P5; WATERS MFR, 1993, LANCET, V341, P489, DOI 10.1016/0140-6736(93)90238-C; 1991, ELIMINATION LEPROSY	29	22	22	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 28	1993	342	8870					521	525		10.1016/0140-6736(93)91647-5	http://dx.doi.org/10.1016/0140-6736(93)91647-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU582	8102668				2022-12-28	WOS:A1993LU58200010
J	VERKUYL, DAA				VERKUYL, DAA			2 WORLD RELIGIONS AND FAMILY-PLANNING	LANCET			English	Editorial Material											VERKUYL, DAA (corresponding author), UNITED BULAWAYO HOSP,POB 958,BULAWAYO,ZIMBABWE.							Edwards S., 1992, INT FAMILY PLANNING, V18, P116; FAUVEAU V, 1990, INT FAM PLANNING PER, V16, P3; HARRISON KA, 1985, BR J OBSTET GYNAEC S, V5; KING M, 1990, LANCET, V336, P664, DOI 10.1016/0140-6736(90)92156-C; LOGIE D, 1992, BRIT MED J, V304, P1423, DOI 10.1136/bmj.304.6839.1423; MAY JF, 1990, STUD FAMILY PLANN, V21, P20, DOI 10.2307/1966588; Rukanuddin A. R., 1992, International Family Planning Perspectives, V18, P109, DOI 10.2307/2133410; SCHEPERHUGHES N, 1991, LANCET, V337, P1144, DOI 10.1016/0140-6736(91)92800-H; VERKUYL DAA, 1991, CENT AFR J MED, V37, P308; Weis P., 1992, IPPF Medical Bulletin, V26, P1; WESTHOFF CF, 1991, DEMOGR HLTH SURV COM; 1992, LANCET, V340, P603; 1992, POPULATIONS REPORT S, V20	13	19	19	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 21	1993	342	8869					473	475		10.1016/0140-6736(93)91597-F	http://dx.doi.org/10.1016/0140-6736(93)91597-F			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LU075	8102433				2022-12-28	WOS:A1993LU07500014
J	FELICIELLO, A; PORCELLINI, A; CIULLO, I; BONAVOLONTA, G; AVVEDIMENTO, EV; FENZI, G				FELICIELLO, A; PORCELLINI, A; CIULLO, I; BONAVOLONTA, G; AVVEDIMENTO, EV; FENZI, G			EXPRESSION OF THYROTROPIN-RECEPTOR MESSENGER-RNA IN HEALTHY AND GRAVES-DISEASE RETRO-ORBITAL TISSUE	LANCET			English	Note							MOLECULAR-CLONING; OPHTHALMOPATHY; FIBROBLASTS	It is not clear whether the ophthalmopathy present in Graves' disease is related to autoimmune reactions to common thyroid/orbit components or is due to specific ocular antigens unrelated to the thyroid. In Graves' disease, serum antibodies to the thyrotropin receptor (TSH-R) can stimulate thyroid function, but no link between the TSH-R and ocular tissues has been found. We have shown, by polymerase chain reaction amplification of specific cDNA, that mature TSH-R mRNA is expressed in the retro-orbital tissue of both healthy subjects and patients with Graves' disease. Of other tissues and cells tested (fibroblasts, lymphocytes, muscle, and thyroid), only thyroid tissue expressed the TSH-R mRNA.	UNIV NAPLES,FAC MED,CATTEDRA ENDOCRINOL,VIA S PANSINI 5,I-80131 NAPLES,ITALY; UNIV NAPLES,FAC MED,CATTEDRA PATOL ORBITARIA,I-80131 NAPLES,ITALY; UNIV NAPLES,FAC MED,DIPARTIMENTO BIOL & PATOL MOLEC & CELLULARE,I-80131 NAPLES,ITALY; UNIV REGGIO CALABRIA,FAC MED CATANZARO,DIPARTIMENTO MED SPERIMENTALE & CLIN,CATANZARO,ITALY	University of Naples Federico II; University of Naples Federico II; University of Naples Federico II; Magna Graecia University of Catanzaro; Universita Mediterranea di Reggio Calabria			Porcellini, Antonio/E-1900-2011; Porcellini, Antonio/AAC-6097-2019	Porcellini, Antonio/0000-0001-6882-9518; Feliciello, Antonio/0000-0002-7932-2170				ATKINSON S, 1984, LANCET, V2, P374; Francis T, 1991, Thyroid, V1, P223, DOI 10.1089/thy.1991.1.223; HEUFELDER AE, 1991, J CLIN ENDOCR METAB, V73, P307, DOI 10.1210/jcem-73-2-307; NAGAYAMA Y, 1992, MOL ENDOCRINOL, V6, P145, DOI 10.1210/me.6.2.145; PARMENTIER M, 1989, SCIENCE, V246, P1620, DOI 10.1126/science.2556796; SMITH TJ, 1989, J CLIN ENDOCR METAB, V69, P1019, DOI 10.1210/jcem-69-5-1019; WEETMAN AP, 1991, LANCET, V338, P25, DOI 10.1016/0140-6736(91)90013-F	7	241	249	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 7	1993	342	8867					337	338		10.1016/0140-6736(93)91475-2	http://dx.doi.org/10.1016/0140-6736(93)91475-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ868	8101586				2022-12-28	WOS:A1993LQ86800013
J	HENDERSON, AH; JONES, CJH				HENDERSON, AH; JONES, CJH			REVERSIBLE ENDOTHELIAL DYSFUNCTION IN EPICARDIAL CORONARY-ARTERIES	LANCET			English	Editorial Material							RESISTANCE VESSELS; MICROCIRCULATION; ATHEROSCLEROSIS				HENDERSON, AH (corresponding author), UNIV WALES COLL MED,DEPT CARDIOL,CARDIFF CF4 4XN,S GLAM,WALES.							CHILIAN WM, 1990, AM J PHYSIOL, V258, pH529, DOI 10.1152/ajpheart.1990.258.2.H529; CREAGER MA, 1990, J CLIN INVEST, V86, P228, DOI 10.1172/JCI114688; DREXLER H, 1991, LANCET, V338, P1546, DOI 10.1016/0140-6736(91)92372-9; GRIFFITH TM, 1987, NATURE, V329, P442, DOI 10.1038/329442a0; HARRISON DG, 1987, J CLIN INVEST, V80, P1808, DOI 10.1172/JCI113276; HENDERSON AH, 1991, BRIT HEART J, V65, P116; LEUNG WH, 1993, LANCET, V341, P1496, DOI 10.1016/0140-6736(93)90634-S; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0	8	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 31	1993	342	8866					253	253		10.1016/0140-6736(93)91810-9	http://dx.doi.org/10.1016/0140-6736(93)91810-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ163	8101295				2022-12-28	WOS:A1993LQ16300003
J	KROOK, A; BRUETON, L; ORAHILLY, S				KROOK, A; BRUETON, L; ORAHILLY, S			HOMOZYGOUS NONSENSE MUTATION IN THE INSULIN-RECEPTOR GENE IN INFANT WITH LEPRECHAUNISM	LANCET			English	Note							TARGETED INACTIVATION; GROWTH	Mutations in the insulin receptor gene have been detected in patients with severe insulin resistance, but the absence of insulin receptors has not been recorded. We report a severely insulin resistant newborn baby, the offspring of consainguineous parents, who was homozygous for a nonsense mutation (Lys 121-Amber) in this gene. Translation of this very truncated N-terminal fragment would not be expected to result in a functional insulin receptor. The infant had all the typical features of the syndrome of leprechaunism. The baby probably represents the null phenotype with respect to the insulin receptor. Because insulin receptors are expressed very early in the developing embryo, the absence of functional insulin receptors is thought to be incompatible with fetal viability: the normal organogenesis in this infant who survived beyond term implies that this assumption is probably incorrect.	UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT MED,CAMBRIDGE CB2 2QR,ENGLAND; NORTHWICK PK HOSP & CLIN RES CTR,CLIN RES CTR,KENNEDY GALTON CTR,HARROW HA1 3UJ,MIDDX,ENGLAND; UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT CLIN BIOCHEM,CAMBRIDGE CB2 2QR,ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Imperial College London; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge			Krook, Anna/K-1192-2015; O'Rahilly, Stephen/ABF-6509-2020	Krook, Anna/0000-0002-0891-0258; O'Rahilly, Stephen/0000-0003-2199-4449	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ACCILI D, 1991, P NATL ACAD SCI USA, V88, P4708, DOI 10.1073/pnas.88.11.4708; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; DIETZ HC, 1993, SCIENCE, V259, P680, DOI 10.1126/science.8430317; GIRBAU M, 1992, MOL CELL ENDOCRINOL, V90, P69, DOI 10.1016/0303-7207(92)90103-D; ORAHILLY S, 1991, DIABETES, V40, P777, DOI 10.2337/diabetes.40.6.777; PABLO FD, 1990, ENDOCR REV, V11, P558; SEINO S, 1990, DIABETES, V39, P123, DOI 10.2337/diabetes.39.1.123; TAYLOR SI, 1992, ENDOCR REV, V13, P566, DOI 10.1210/er.13.3.566; TRAVERS JP, 1989, DIABETES, V38, P773, DOI 10.2337/diabetes.38.6.773	9	75	77	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 31	1993	342	8866					277	278		10.1016/0140-6736(93)91820-C	http://dx.doi.org/10.1016/0140-6736(93)91820-C			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ163	8101305				2022-12-28	WOS:A1993LQ16300013
J	LOGAN, S; STANTON, A				LOGAN, S; STANTON, A			SCREENING FOR BILIARY ATRESIA	LANCET			English	Editorial Material									MARSTON GREEN HOSP,COMMUNITY MENTAL HLTH SERV UNIT,BIRMINGHAM,ENGLAND		LOGAN, S (corresponding author), INST CHILD HLTH,DIV PUBL HLTH,BIRMINGHAM B16 8ET,W MIDLANDS,ENGLAND.			Logan, Stuart/0000-0002-9279-261X				DICK MC, 1985, ARCH DIS CHILD, V60, P512, DOI 10.1136/adc.60.6.512; HENRIKSEN NT, 1981, ARCH DIS CHILD, V56, P622, DOI 10.1136/adc.56.8.622; KIVLAHAN C, 1984, PEDIATRICS, V74, P364; MACKINLAY GA, 1993, BRIT MED J, V306, P1426, DOI 10.1136/bmj.306.6890.1426; MATTHEW PM, 1981, ARCH DIS CHILD, V56, P949; MIELIVERGANI G, 1989, LANCET, V1, P421; WILSON JMG, 1968, 34 PUBL HLTH PAP	7	10	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 31	1993	342	8866					256	256		10.1016/0140-6736(93)91814-3	http://dx.doi.org/10.1016/0140-6736(93)91814-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ163	8101299				2022-12-28	WOS:A1993LQ16300007
J	RICHMOND, CE; BROMLEY, LM; WOOLF, CJ				RICHMOND, CE; BROMLEY, LM; WOOLF, CJ			PREOPERATIVE MORPHINE PREEMPTS POSTOPERATIVE PAIN	LANCET			English	Article								Postoperative analgesia is usually inadequate, perhaps because conventional approaches to pain relief do not take account of underlying mechanisms. Pre-emptive analgesia may prevent nociceptive inputs generated during surgery from sensitising central neurons and, therefore, may reduce postoperative pain. In a randomised, double-blind study, we compared the effect of parenteral morphine when given before or after total abdominal hysterectomy in 60 patients. 10 mg of morphine were given intramuscularly 1 hour before operation (im pre), intravenously at induction of anaesthesia (iv pre), or intravenously at closure of the peritoneum (iv post). Response was assessed by morphine consumption from patient-controlled analgesia machines which was found to be significantly reduced in the iv pre group for 24 hours after operation compared with the iv post group. Pain sensitivity around the wound was reduced in both preoperative treatment groups compared with the iv post group. We conclude that pre-emptive analgesia with intravenous morphine, by preventing the establishment of central sensitisation during surgery, reduces postoperative pain, analgesic requirements, and secondary hyperalgesia.	UNIV LONDON UNIV COLL, SCH MED, ACAD DEPT ANAESTHESIA, LONDON WC1E 6BT, ENGLAND; UNIV LONDON UNIV COLL, DEPT ANAT & DEV BIOL, LONDON WC1E 6BT, ENGLAND	University of London; University College London; UCL Medical School; University of London; University College London			Woolf, Clifford/A-9784-2010					DAHL JB, 1992, BRIT J ANAESTH, V69, P4, DOI 10.1093/bja/69.1.4; DIERKING GW, 1992, BRIT J ANAESTH, V68, P344, DOI 10.1093/bja/68.4.344; EJLERSEN E, 1992, ANESTH ANALG, V74, P495; JEBELES JA, 1991, PAIN, V47, P305, DOI 10.1016/0304-3959(91)90220-R; KATZ J, 1992, ANESTHESIOLOGY, V77, P439, DOI 10.1097/00000542-199209000-00006; KISS IE, 1992, PAIN, V48, P157, DOI 10.1016/0304-3959(92)90051-C; MCQUAY HJ, 1988, PAIN, V33, P291, DOI 10.1016/0304-3959(88)90287-4; MCQUAY HJ, 1992, BRIT J ANAESTH, V69, P1, DOI 10.1093/bja/69.1.1; PRYLE BJ, 1993, ANAESTHESIA, V48, P120; RINGROSE NH, 1984, AM J SPORT MED, V12, P398, DOI 10.1177/036354658401200512; TVERSKOY M, 1990, ANESTH ANALG, V70, P29, DOI 10.1213/00000539-199001000-00006; WOOLF CJ, 1986, NEUROSCI LETT, V64, P221, DOI 10.1016/0304-3940(86)90104-7; WOOLF CJ, 1983, NATURE, V306, P686, DOI 10.1038/306686a0; WOOLF CJ, IN PRESS ANESTH ANAL; 1990, REPORT WORKING PARTY	15	231	235	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 10	1993	342	8863					73	75		10.1016/0140-6736(93)91284-S	http://dx.doi.org/10.1016/0140-6736(93)91284-S			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LL789	8100911				2022-12-28	WOS:A1993LL78900008
J	JOLLEY, D				JOLLEY, D			THE GLITTER OF THE T-TABLE	LANCET			English	Article											JOLLEY, D (corresponding author), ANTI CANC COUNCIL VICTORIA,CTR CANC EPIDEMIOL,CARLTON,VIC 3053,AUSTRALIA.							Becker R, 1988, COMPUTER SCI SERIES; Chambers J.M., 1992, STAT MODELS S, DOI 10.1201/9780203738535; Gardner MJ, 1989, BRIT MED J LONDON; Giles GG., 1990, P NUTR AUST, V15, P94; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; HIRSCHOWITZ I, 1992, BMJ, V304, P1209; KIRKWOOD BR, 1988, ESSENTIALS MED STATI; RIPLEY BD, 1992, INTRO GUIDE S PLUS; ROSE G, 1986, BRIT MED J LONDON; ROTHMAN KJ, 1990, AM J EPIDEMIOL, V132, pS6, DOI 10.1093/oxfordjournals.aje.a115790; Tukey J. W., 1977, EXPLORATORY DATA ANA; Uniform requirements for manuscripts submitted to biomedical journals, 1991, BMJ, V302, P338, DOI DOI 10.1136/bmj.302.6772.338; WILSON APR, 1993, LANCET, V341, P282; 1992, EGRET COMPUTER PROGR	15	16	16	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 3	1993	342	8862					27	29		10.1016/0140-6736(93)91886-Q	http://dx.doi.org/10.1016/0140-6736(93)91886-Q			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK985	8100294				2022-12-28	WOS:A1993LK98500015
J	SOUQUET, PJ; CHAUVIN, F; BOISSEL, JP; CELLERINO, R; CORMIER, Y; GANZ, PA; KAASA, S; PATER, JL; QUOIX, E; RAPP, E; TUMARELLO, D; WILLIAMS, J; WOODS, BL; BERNARD, JP				SOUQUET, PJ; CHAUVIN, F; BOISSEL, JP; CELLERINO, R; CORMIER, Y; GANZ, PA; KAASA, S; PATER, JL; QUOIX, E; RAPP, E; TUMARELLO, D; WILLIAMS, J; WOODS, BL; BERNARD, JP			POLYCHEMOTHERAPY IN ADVANCED NON-SMALL-CELL LUNG-CANCER - A METAANALYSIS	LANCET			English	Article							RANDOMIZED TRIAL; COMBINATION CHEMOTHERAPY; SUPPORTIVE CARE; CARCINOMA; CISPLATIN; VINDESINE	We did a meta-analysis of all published polychemotherapy vs supportive care clinical trials in patients with non-resectable non small cell lung cancer. 7 studies with more than 700 patients were selected. We used the number of deaths at 3, 6, 9, 12, and 18 months as the endpoints because we were unable to obtain all the individual data. Our analysis showed a reduction in mortality during the first 6 months with polychemotherapy. Although small, this increase in survival, together with an improved quality of life, suggests that polychemotherapy should be recommended for patients with non-resectable non small cell lung cancer.	UNITE PHARMACOL CLIN, LYON, FRANCE; HOP LAVAL, CTR PNEUMOL, QUEBEC CITY, PQ, CANADA; UNIV CALIF LOS ANGELES, DEPT MED, LOS ANGELES, CA USA; CTR HOSP STRASBOURG, SERV PNEUMOL, STRASBOURG, FRANCE; ROYAL N SHORE HOSP, DEPT CLIN ONCOL, SYDNEY, AUSTRALIA; TOM BAKER CANC CLIN, CALGARY, AB, CANADA; SOUTHAMPTON GEN HOSP, CRC, SOUTHAMPTON SO9 4XY, HANTS, ENGLAND; UNIV ANCONA, ONCOL CLIN, I-60100 ANCONA, ITALY; NORWEGIAN RADIUM HOSP, OSLO 3, NORWAY; QUEENS UNIV, NCI, CANADA CLIN TRIALS GRP, KINGSTON K7L 3N6, ONTARIO, CANADA	Laval University; University of California System; University of California Los Angeles; CHU Strasbourg; Royal North Shore Hospital; University of Sydney; Tom Baker Cancer Clinic; University of Calgary; University of Southampton; Marche Polytechnic University; University of Oslo; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Queens University - Canada	SOUQUET, PJ (corresponding author), CTR HOSP LYON SUD, SERV PNEUMOL, F-69310 PIERRE BENITE, FRANCE.							ANDERSON G, 1984, SEMIN ONCOL, V12, P21; CELLERINO R, 1988, EUR J CANCER CLIN ON, V24, P1839, DOI 10.1016/0277-5379(88)90095-8; CELLERINO R, 1991, J CLIN ONCOL, V9, P1453, DOI 10.1200/JCO.1991.9.8.1453; CORMIER Y, 1982, CANCER, V50, P845, DOI 10.1002/1097-0142(19820901)50:5<845::AID-CNCR2820500507>3.0.CO;2-S; DURRANT KR, 1971, LANCET, V1, P715; FERNANDEZ C, 1989, ACTA ONCOL, V28, P129; GANZ PA, 1989, CANCER, V63, P1271, DOI 10.1002/1097-0142(19890401)63:7<1271::AID-CNCR2820630707>3.0.CO;2-6; GANZ PA, 1988, CANCER, V61, P849, DOI 10.1002/1097-0142(19880215)61:4<849::AID-CNCR2820610435>3.0.CO;2-B; GLASS GV, 1984, META ANAL SOCIAL RES; GRALLA RJ, 1981, ANN INTERN MED, V95, P414, DOI 10.7326/0003-4819-95-4-414; Hedges L, 1985, STATISTICAL METHODS; JAAKINIMAINEN L, 1989, P ASCO, V8, P221; KAASA S, 1991, CANCER, V67, P2443, DOI 10.1002/1097-0142(19910515)67:10<2443::AID-CNCR2820671008>3.0.CO;2-K; LAING AH, 1975, LANCET, V2, P1161; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; QUOIX E, 1988, LUNG CANCER, V4, pA181; RAPP E, 1988, J CLIN ONCOL, V6, P633, DOI 10.1200/JCO.1988.6.4.633; REGAN J, 1991, BRIT J CANCER, V64, P396, DOI 10.1038/bjc.1991.316; WOODS RL, 1990, BRIT J CANCER, V61, P608, DOI 10.1038/bjc.1990.135	19	490	502	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 3	1993	342	8862					19	21						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK985	8100290				2022-12-28	WOS:A1993LK98500011
J	BERTHJONES, J; GRAHAMBROWN, RAC				BERTHJONES, J; GRAHAMBROWN, RAC			PLACEBO-CONTROLLED TRIAL OF ESSENTIAL FATTY-ACID SUPPLEMENTATION IN ATOPIC-DERMATITIS	LANCET			English	Article							EVENING PRIMROSE OIL; EICOSAPENTAENOIC ACID; ECZEMA; SKIN	Treatment of atopic dermatitis with essential fatty acids remains controversial. A double-blind, placebo-controlled, parallel-group study was done to investigate the response of patients with atopic dermatitis to essential fatty acid supplements. Patients with atopic dermatitis were randomised to receive evening primrose oil, evening primrose oil and fish oil, or placebo for 16 weeks. Disease activity was monitored by clinical severity scores recorded by the investigator, topical steroid requirement, and symptom scores recorded by subjects. Of 123 subjects recruited, 102 completed the treatment period. No improvement with active treatment was demonstrated. Our study, which avoided the methodological and analytical problems of previous studies, found no effect of essential fatty acid supplementation in atopic dermatitis.			BERTHJONES, J (corresponding author), LEICESTER ROYAL INFIRM,DEPT DERMATOL,LEICESTER LE1 5WW,ENGLAND.							BAMFORD JTM, 1985, J AM ACAD DERMATOL, V13, P959, DOI 10.1016/S0190-9622(85)70245-9; BJORNEBOE A, 1987, BRIT J DERMATOL, V117, P463, DOI 10.1111/j.1365-2133.1987.tb04926.x; BORDONI A, 1987, DRUGS EXPT CLIN RES, V14, P291; BURTON JL, 1989, LANCET, V1, P27; COSTA C, 1989, ACTA DERM-VENEREOL, V69, P41; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HORROBIN DF, 1990, LANCET, V335, P864, DOI 10.1016/0140-6736(90)90987-G; KUNZ B, 1989, J ALLERGY CLIN IMMUN, V83, P196; LOVELL CR, 1981, LANCET, V1, P278; MORSE PF, 1989, BRIT J DERMATOL, V121, P75, DOI 10.1111/j.1365-2133.1989.tb01403.x; RILLIET A, 1988, DERMATOLOGICA, V177, P257; SCHALINKARRILA M, 1987, BRIT J DERMATOL, V117, P11, DOI 10.1111/j.1365-2133.1987.tb04085.x; SHARPE GR, 1990, LANCET, V335, P667, DOI 10.1016/0140-6736(90)90459-I; SHARPE GR, 1990, LANCET, V335, P1283, DOI 10.1016/0140-6736(90)91350-J; WRIGHT S, 1991, BRIT J DERMATOL, V125, P503, DOI 10.1111/j.1365-2133.1991.tb14786.x; WRIGHT S, 1982, LANCET, V2, P1120	16	95	97	1	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 19	1993	341	8860					1557	1560		10.1016/0140-6736(93)90697-F	http://dx.doi.org/10.1016/0140-6736(93)90697-F			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH550	8099640				2022-12-28	WOS:A1993LH55000004
J	BOYD, O; GROUNDS, RM				BOYD, O; GROUNDS, RM			PHYSIOLOGICAL SCORING SYSTEMS AND AUDIT	LANCET			English	Article							INTENSIVE-CARE; DISEASE	Scoring systems designed to rate the severity of an illness are being used for comparison of hospital units to identify different standards of care and to allocate resources. One such scoring system is the Acute Physiology and Chronic Health Evaluation (APACHE) system which is designed to assess the severity of illness of patients in intensive care units (ICUs). It is widely assumed that different ICUs can be compared by the ratio of actual mortality to that predicted by the APACHE score. However, we suggest that the use of physiological data that can be influenced by medical and nursing intervention should not be used for audit. For example, by good care a patient may be made less severely ill and, therefore, may have a lower actual mortality while, at the same time, accumulating only a low APACHE score with low predicted mortality. This patient could have, therefore, the same mortality ratio as a patient treated inappropriately, who may have a higher actual mortality and a high APACHE score with greater predicted mortality. Paradoxically, the very accuracy of these scoring systems for assessing the severity of illness precludes their use for comparison and audit.	ST GEORGE HOSP,DEPT ANAESTHESIA,LONDON SW17 0QT,ENGLAND; ST GEORGE HOSP,GEN INTENS CARE UNIT,LONDON SW17 0QT,ENGLAND	St Georges University London; St Georges University London	BOYD, O (corresponding author), ST GEORGE HOSP,DEPT MED,LONDON SW17 0QT,ENGLAND.							APGAR V, 1953, ANESTH ANALG CLEVE, V32, P260, DOI DOI 10.1213/00000539-195301000-00041; BION JF, 1985, BRIT MED J, V291, P432, DOI 10.1136/bmj.291.6493.432; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; DRAGSTED L, 1989, CRIT CARE MED, V17, P418, DOI 10.1097/00003246-198905000-00008; DUBOIS RW, 1987, NEW ENGL J MED, V317, P1674, DOI 10.1056/NEJM198712243172626; KANUS WA, 1992, CARE CRITICALLY ILL, P1275; KNAUS WA, 1982, LANCET, V2, P642; KNAUS WA, 1986, ANN INTERN MED, V104, P410, DOI 10.7326/0003-4819-104-3-410; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LYONS C, 1990, BRIT MED J, V300, P1563, DOI 10.1136/bmj.300.6739.1563; TEASDALE G, 1974, LANCET, V2, P81; WAGNER DP, 1986, ARCH INTERN MED, V146, P1389, DOI 10.1001/archinte.146.7.1389; ZIMMERMAN JE, 1988, CRIT CARE MED, V16, P318, DOI 10.1097/00003246-198804000-00003	13	47	47	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 19	1993	341	8860					1573	1574		10.1016/0140-6736(93)90706-M	http://dx.doi.org/10.1016/0140-6736(93)90706-M			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH550	8099649				2022-12-28	WOS:A1993LH55000013
J	SHENASA, M; BORGGREFE, M; HAVERKAMP, W; HINDRICKS, G; BREITHARDT, G				SHENASA, M; BORGGREFE, M; HAVERKAMP, W; HINDRICKS, G; BREITHARDT, G			VENTRICULAR-TACHYCARDIA	LANCET			English	Article							CATHETER ABLATION; HYPERTROPHIC CARDIOMYOPATHY; MYOCARDIAL-INFARCTION; COMPLEX TACHYCARDIA; ARRHYTHMIAS; REVASCULARIZATION; REAPPRAISAL; CONDUCTION; MANAGEMENT; DIAGNOSIS		WESTFAL WILHELMS UNIV MUNSTER HOSP,DEPT CARDIOL & ANGIOL,MUNSTER,GERMANY; INST RES ARTERIOSCLEROSIS,MUNSTER,GERMANY	University of Munster								AKHTAR M, 1988, ANN INTERN MED, V109, P905, DOI 10.7326/0003-4819-109-11-905; [Anonymous], 1989, CIRCULATION, V79, P1354; BORGGREFE M, 1991, INTERVENTIONAL ELECTROPHYSIOLOGY, P301; CARDINAL R, 1988, CIRCULATION, V77, P1162, DOI 10.1161/01.CIR.77.5.1162; CRIPPS TR, 1990, J AM COLL CARDIOL, V15, P956, DOI 10.1016/0735-1097(90)90223-C; DONGAS J, 1985, AM J CARDIOL, V55, P717, DOI 10.1016/0002-9149(85)90143-2; FANANAPAZIR L, 1989, CIRCULATION, V80, P1259, DOI 10.1161/01.CIR.80.5.1259; FITZGERALD DM, 1988, CIRCULATION, V77, P806, DOI 10.1161/01.CIR.77.4.806; FROMER M, 1987, AM HEART J, V114, P1537, DOI 10.1016/0002-8703(87)90582-5; GARAN H, 1983, AM J CARDIOL, V51, P519, DOI 10.1016/S0002-9149(83)80091-5; JOSEPHSON ME, 1982, AM J CARDIOL, V49, P207, DOI 10.1016/0002-9149(82)90295-8; KALTENBRUNNER W, 1991, CIRCULATION, V84, P1058, DOI 10.1161/01.CIR.84.3.1058; KELLY P, 1990, J AM COLL CARDIOL, V15, P267, DOI 10.1016/S0735-1097(10)80046-4; KLEIN LS, 1992, CIRCULATION, V85, P1666, DOI 10.1161/01.CIR.85.5.1666; Lewis T, 1909, LANCET, V1, P382; MORADY F, 1988, J AM COLL CARDIOL, V11, P775, DOI 10.1016/0735-1097(88)90211-2; MORADY F, 1987, CIRCULATION, V75, P1037, DOI 10.1161/01.CIR.75.5.1037; MORGANROTH J, 1990, AM J CARDIOL, V65, P1497, DOI 10.1016/0002-9149(90)91362-A; OHE T, 1988, CIRCULATION, V77, P560, DOI 10.1161/01.CIR.77.3.560; OKUMURA K, 1987, CIRCULATION, V75, P369, DOI 10.1161/01.CIR.75.2.369; OSTERMEYER J, 1987, J THORAC CARDIOV SUR, V94, P848; POGWIZD SM, 1992, CIRCULATION, V86, P1872, DOI 10.1161/01.CIR.86.6.1872; SAUMAREZ RC, 1992, CIRCULATION, V86, P467, DOI 10.1161/01.CIR.86.2.467; SHENASA M, 1990, CIRCULATION, V82, P580; STEWART RB, 1986, ANN INTERN MED, V104, P766, DOI 10.7326/0003-4819-104-6-766; SUNG RJ, 1988, J CLIN INVEST, V81, P688, DOI 10.1172/JCI113374; TCHOU P, 1988, AM J MED, V84, P53, DOI 10.1016/0002-9343(88)90008-3; WELLENS HJJ, 1986, PROG CARDIOVASC DIS, V24, P165; WICHTER T, 1992, CIRCULATION, V86, P29, DOI 10.1161/01.CIR.86.1.29; 1993, CIRCULATION, V87, P323; 1992, JACC, V19, pA387	31	18	18	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 12	1993	341	8859					1512	1519		10.1016/0140-6736(93)90642-T	http://dx.doi.org/10.1016/0140-6736(93)90642-T			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LG242	8099387				2022-12-28	WOS:A1993LG24200011
J	CHAUHAN, A; PETCH, MC; SCHOFIELD, PM				CHAUHAN, A; PETCH, MC; SCHOFIELD, PM			EFFECT OF ESOPHAGEAL ACID INSTILLATION ON CORONARY BLOOD-FLOW	LANCET			English	Note							RESERVE	To assess whether gastrointestinal factors can cause chest pain (''linked angina''), we studied the effect of oesophageal stimulation with acid on coronary blood flow in 20 syndrome X patients. Coronary blood flow velocity (CBFV) was measured with an intracoronary doppler catheter positioned in the proximal left anterior descending coronary artery. Acid stimulation produced typical anginal, pain in 11 patients. Mean CBFV was significantly reduced from 7.3 (SD 4.0) to 4.4 (2.8) cm/s. Gastro-oesophageal reflux leading to reduced coronary blood flow may be a mechanism to explain linked angina.			CHAUHAN, A (corresponding author), PAPWORTH HOSP, CARDIAC UNIT, CAMBRIDGE CB3 8RE, ENGLAND.							BENNETT JR, 1966, LANCET, V2, P1150; CHAUHAN A, 1992, European Heart Journal, V13, P266; DAVIES HA, 1985, LANCET, V1, P1011; Gilbert NC, 1940, AM HEART J, V20, P519, DOI 10.1016/S0002-8703(40)90930-9; MCGINN AL, 1990, CIRCULATION, V81, P1319, DOI 10.1161/01.CIR.81.4.1319; MELLOW MH, 1983, GASTROENTEROLOGY, V85, P306; MULLINS PA, 1992, BRIT HEART J, V68, P253; SMITH KS, 1962, BRIT MED J, P1425, DOI 10.1136/bmj.2.5317.1425; THORPE A, 1984, CARDIOLOGY PRACTICE, V2, P35; von Bergmann G, 1932, DEUT MED WOCHENSCHR, V58, P605; WILSON RF, 1985, CIRCULATION, V72, P82, DOI 10.1161/01.CIR.72.1.82	11	57	58	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 22	1993	341	8856					1309	1310		10.1016/0140-6736(93)90817-Z	http://dx.doi.org/10.1016/0140-6736(93)90817-Z			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD253	8098450				2022-12-28	WOS:A1993LD25300005
J	RAYNOLDS, MV; BRISTOW, MR; BUSH, EW; ABRAHAM, WT; LOWES, BD; ZISMAN, LS; TAFT, CS; PERRYMAN, MB				RAYNOLDS, MV; BRISTOW, MR; BUSH, EW; ABRAHAM, WT; LOWES, BD; ZISMAN, LS; TAFT, CS; PERRYMAN, MB			ANGIOTENSIN-CONVERTING ENZYME-DD GENOTYPE IN PATIENTS WITH ISCHEMIC OR IDIOPATHIC DILATED CARDIOMYOPATHY	LANCET			English	Article							MYOCARDIAL-INFARCTION; MESSENGER-RNA; PROLIFERATION; GENE	Polymorphism in the angiotensin-converting enzyme (ACE) gene has been shown to correlate with circulating ACE concentrations, and also to be an independent risk factor for the development of myocardial infarction, particularly in men thought to be at low risk by standard criteria. We determined the genotypes of individuals with end-stage heart failure due to either ischaemic dilated cardiomyopathy (102) or idiopathic dilated cardiomyopathy (112) and compared these to organ donors with normally functioning hearts (79). Genotypes were determined by the polymerase chain reaction with oligonucleotide primers flanking the polymorphic region in intron 16 of the ACE gene to amplify template DNA isolated from patients. Compared with the DD frequency in the control population, the frequency of the ACE DD genotype was 48% higher in individuals with idiopathic dilated cardiomyopathy (p=0.008) and 63% higher in subjects with ischaemic cardiomyopathy (p=0.008), suggesting that an ACE gene variant may contribute to the pathogenesis of both types of cardiomyopathy.			RAYNOLDS, MV (corresponding author), UNIV COLORADO,HLTH SCI CTR,TEMPLE HOYNE BUELL HEART CTR,DEPT MED,DIV CARDIOL,4200 E 9TH AVE,DENVER,CO 80262, USA.		bristow, michael r/G-7850-2011; Lowes, Brian/M-9020-2017	Lowes, Brian/0000-0002-5919-2540				CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0; DAEMEN MJAP, 1991, CIRC RES, V68, P450, DOI 10.1161/01.RES.68.2.450; GAUDRON P, 1993, CIRCULATION, V87, P755, DOI 10.1161/01.CIR.87.3.755; KUNAPULI SP, 1987, CIRC RES, V60, P786, DOI 10.1161/01.RES.60.5.786; LAMAS GA, 1991, AM HEART J, V121, P1194, DOI 10.1016/0002-8703(91)90682-8; LINDPAINTNER K, 1992, J CARDIOVASC PHARM, V20, P41; MCCABE ERB, 1987, HUM GENET, V75, P213, DOI 10.1007/BF00281061; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; POWELL JS, 1989, SCIENCE, V245, P186, DOI 10.1126/science.2526370; SCHUNKERT H, 1990, J CLIN INVEST, V86, P1913, DOI 10.1172/JCI114924; TIRET L, 1992, AM J HUM GENET, V51, P197; TIRET L, 1993, LANCET, V341, P991, DOI 10.1016/0140-6736(93)91075-W; 1991, NEW ENGL J MED, V325, P293	13	416	428	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 30	1993	342	8879					1073	1075		10.1016/0140-6736(93)92061-W	http://dx.doi.org/10.1016/0140-6736(93)92061-W			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME822	8105309				2022-12-28	WOS:A1993ME82200007
J	GREENWOOD, D				GREENWOOD, D			LACKING BLOOD FOR CULTURE	LANCET			English	Editorial Material							BACTEREMIA				GREENWOOD, D (corresponding author), UNIV NOTTINGHAM HOSP,DEPT MICROBIOL,NOTTINGHAM NG7 2UH,ENGLAND.							ISPAHANI P, 1989, MED LAB SCI, V46, P295; ISPAHANI P, 1987, Q J MED, V63, P427; MERMEL LA, 1993, ANN INTERN MED, V119, P270, DOI 10.7326/0003-4819-119-4-199308150-00003; Pulvertaft RJV, 1930, LANCET, V1, P821; SHANSON DC, 1984, J CLIN PATHOL, V37, P568, DOI 10.1136/jcp.37.5.568; SHANSON DC, 1989, SEPTICAEMIA ENDOCARD; WEINSTEIN MP, 1983, REV INFECT DIS, V5, P54	7	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 23	1993	342	8878					1006	1006		10.1016/0140-6736(93)92875-T	http://dx.doi.org/10.1016/0140-6736(93)92875-T			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD066	8105261				2022-12-28	WOS:A1993MD06600006
J	MITCHELL, JD; GATT, JA; PHILLIPS, TM; HOUGHTON, E; ROSTRON, G; WIGNALL, C; WHITTINGTON, J; SHAW, IC				MITCHELL, JD; GATT, JA; PHILLIPS, TM; HOUGHTON, E; ROSTRON, G; WIGNALL, C; WHITTINGTON, J; SHAW, IC			CU/ZN SUPEROXIDE-DISMUTASE FREE-RADICALS, AND MOTONEURON DISEASE	LANCET			English	Letter									ROYAL PRESTON HOSP,DEPT CLIN CHEM,PRESTON PR2 4HT,ENGLAND; ROYAL PRESTON HOSP,DEPT PHARM,PRESTON PR2 4HT,ENGLAND; MEDISCIENCE LTD,BUCKINGHAM,ENGLAND; UNIV CENT LANCASHIRE,CTR TOXICOL,PRESTON,ENGLAND	Royal Preston Hospital; Royal Preston Hospital; University of Central Lancashire	MITCHELL, JD (corresponding author), ROYAL PRESTON HOSP,DEPT NEUROL,PRESTON PR2 4HT,ENGLAND.							BRACCO F, 1991, P SOC EXP BIOL MED, V196, P36; MCMASTER D, 1990, CLIN CHEM, V36, P211; MITCHELL JD, 1992, HDB AMYOTROPHIC LATE, P533; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0	4	35	37	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 23	1993	342	8878					1051	1052		10.1016/0140-6736(93)92906-A	http://dx.doi.org/10.1016/0140-6736(93)92906-A			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD066	8105281				2022-12-28	WOS:A1993MD06600036
J	MACMILLAN, JC; SNELL, RG; TYLER, A; HOULIHAN, GD; FENTON, I; CHEADLE, JP; LAZAROU, LP; SHAW, DJ; HARPER, PS				MACMILLAN, JC; SNELL, RG; TYLER, A; HOULIHAN, GD; FENTON, I; CHEADLE, JP; LAZAROU, LP; SHAW, DJ; HARPER, PS			MOLECULAR ANALYSIS AND CLINICAL CORRELATIONS OF THE HUNTINGTONS-DISEASE MUTATION	LANCET			English	Article							MYOTONIC-DYSTROPHY; ANTICIPATION; REPEAT	The genetic mutation underlying Huntington's disease (HD) has been identified as an expansion and instability of a specific CAG repeat sequence in a gene (IT15) on chromosome 4. We have investigated the relation of the phenotype of HD to this molecular defect and assessed the feasibility of HD mutation analysis in diagnosis and prediction. Analysis of DNA from 449 HD patients (351 familial and 98 apparently isolated cases) revealed the mutation in more than 95% of patients from both groups. No molecular difference was found between patients presenting with psychiatric symptoms and those in whom chorea or other motor defects were the principal features; additionally, there was a wide range of age at onset for any specific repeat number, though the small group with juvenile onset and presenting with rigidity showed the largest expansions. The findings suggest that molecular analysis will be an accurate and specific diagnostic test for HD and valuable in presymptomatic detection in individuals at risk. However, such testing will require considerable caution to avoid serious difficulties; the well-established guidelines developed for the use of linked markers in relation to the prediction of HD should continue to be followed, though they will require reassessment in relation to use in diagnosis.	UNIV WALES COLL MED, INST MED GENET, HEATH PK, CARDIFF CF4 4XN, S GLAM, WALES	Cardiff University			MacMillan, John C/C-9591-2011	Snell, Russell/0000-0002-8166-4014	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; CRAUFURD D, 1992, J MED GENET, V29, P915, DOI 10.1136/jmg.29.12.915; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; GUSELLA JF, 1983, NATURE, V306, P234, DOI 10.1038/306234a0; HARLEY HG, 1992, LANCET, V339, P1125, DOI 10.1016/0140-6736(92)90729-M; HARPER PS, 1992, AM J HUM GENET, V51, P10; Harper PS, 1991, HUNTINGTONS DISEASE; HOWELER CJ, 1989, BRAIN, V112, P779, DOI 10.1093/brain/112.3.779; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; QUARRELL OWJ, 1988, J MED GENET, V25, P191, DOI 10.1136/jmg.25.3.191; QUARRELL OWJ, 1986, CLIN GENET, V30, P433; RIDLEY RM, 1991, J MED GENET, V28, P224, DOI 10.1136/jmg.28.4.224; SHAW DJ, 1992, NEUROMUSCULAR DISORD, V2, P241, DOI 10.1016/0960-8966(92)90055-B; SNELL RG, 1993, NAT GENET, V4, P393, DOI 10.1038/ng0893-393; VANDIJK JG, 1986, HUM GENET, V73, P235, DOI 10.1007/BF00401235; WENT L, 1990, J MED GENET, V27, P34, DOI 10.1136/jmg.27.1.34	16	84	89	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 16	1993	342	8877					954	958		10.1016/0140-6736(93)92002-B	http://dx.doi.org/10.1016/0140-6736(93)92002-B			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MC005	8105214				2022-12-28	WOS:A1993MC00500009
J	ALMIND, K; BJORBAEK, C; VESTERGAARD, H; HANSEN, T; ECHWALD, S; PEDERSEN, O				ALMIND, K; BJORBAEK, C; VESTERGAARD, H; HANSEN, T; ECHWALD, S; PEDERSEN, O			AMINO-ACID POLYMORPHISMS OF INSULIN-RECEPTOR SUBSTRATE-1 IN NON-INSULIN-DEPENDENT DIABETES-MELLITUS	LANCET			English	Article							C-PEPTIDE; PROTEIN; GLUCOSE; EXPRESSION; GENETICS; MUSCLE; NIDDM; SERUM; RNA	Since relative or absolute insulin deficiency and insulin insensitivity are involved in the aetiology of non-insulin-dependent diabetes mellitus (NIDDM), we examined whether patients with NIDDM exhibit genetic variability in the coding region of insulin receptor substrate-1 (IRS-1), a candidate gene that is ubiquitous in insulin-sensitive and insulin-like growth factor 1 (IGF1) sensitive tissues, including those that determine glucose production and clearance and those with regulatory effects on pancreatic beta-cell function. IRS-1 has a central role as an adaptor molecule that links the insulin-receptor and IGF1-receptor kinases with enzymes that regulate cellular metabolism and growth. Single-stranded conformation polymorphism analysis and direct nucleotide sequencing were applied to genomic DNA from 86 unrelated patients with NIDDM and 76 normoglycaemic controls. 10 of the patients with NIDDM and 3 of the controls were heterozygous at codon 972 for a polymorphism in which glycine was substituted with arginine. Moreover, at codon 513, 6 patients with NIDDM and 2 controls had a heterozygous polymorphism with a transition from alanine to proline. None of the polymorphism carriers had both aminoacid variants and the total allelic frequency of IRS-1 polymorphisms was about three times higher in patients with NIDDM than in controls (p=0.02). Both aminoacid substitutions were located close to tyrosine phosphorylation motifs that are putative recognition sites for insulin and IGF1 signal transmission proteins. Analysis of the phenotypes showed that patients with NIDDM who had IRS-1 variants did not differ in their degree of insulin resistance compared with patients without known IRS-1 polymorphisms. However, carriers of the codon 972 variant had significantly lower plasma levels of fasting insulin and C-peptide. Our results suggest that aminoacid polymorphisms in IRS-1 may be involved in the aetiology of a subset of late-onset NIDDM.	STENO DIABET CTR,DK-2820 GENTOFTE,DENMARK; HAGEDORN RES INST,DK-2820 GENTOFTE,DENMARK	Steno Diabetes Center; Novo Nordisk; Hagedorn Research Institute			Pedersen, Oluf/AAG-8015-2020; Bjorbaek, Christian/S-4727-2019; Pedersen, Oluf/Z-1731-2019	Pedersen, Oluf/0000-0002-3321-3972; Vestergaard, Henrik/0000-0003-3090-269X; Hansen, Torben/0000-0001-8748-3831				CERASI E, 1972, DIABETES, V21, P224, DOI 10.2337/diab.21.4.224; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAMSGAARD EM, 1987, DIABETES CARE, V10, P26, DOI 10.2337/diacare.10.1.26; DEFRONZO RA, 1979, AM J PHYSIOL, V237, pE214; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; HEDING LG, 1975, DIABETOLOGIA, V11, P541, DOI 10.1007/BF01222104; HEDING LG, 1972, DIABETOLOGIA, V8, P260, DOI 10.1007/BF01225569; HITMAN GA, 1991, BAILLIERE CLIN ENDOC, V5, P455, DOI 10.1016/S0950-351X(05)80142-9; HOLLENBECK C, 1987, J CLIN ENDOCR METAB, V64, P1169, DOI 10.1210/jcem-64-6-1169; KAHN CR, 1988, J CLIN INVEST, V82, P1151, DOI 10.1172/JCI113711; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1993, DIABETES, V42, P643, DOI 10.2337/diabetes.42.5.643; NISHIYAMA M, 1992, BIOCHEM BIOPH RES CO, V183, P280, DOI 10.1016/0006-291X(92)91640-C; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; STEELE R, 1959, ANN NY ACAD SCI, V82, P420, DOI 10.1111/j.1749-6632.1959.tb44923.x; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAYLOR SI, 1991, J CLIN ENDOCR METAB, V73, P1158, DOI 10.1210/jcem-73-6-1158; VESTERGAARD H, 1991, DIABETES, V40, P1740, DOI 10.2337/diabetes.40.12.1740; 1979, DIABETES, V28, P1039	22	302	316	0	14	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 2	1993	342	8875					828	832		10.1016/0140-6736(93)92694-O	http://dx.doi.org/10.1016/0140-6736(93)92694-O			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA025	8104271				2022-12-28	WOS:A1993MA02500008
J	KOHLI, V; PANDE, GK; DEV, V; REDDY, KS; KAUL, U; NUNDY, S				KOHLI, V; PANDE, GK; DEV, V; REDDY, KS; KAUL, U; NUNDY, S			MANAGEMENT OF HEPATIC VENOUS OUTFLOW OBSTRUCTION	LANCET			English	Article							BUDD-CHIARI SYNDROME; INFERIOR VENA-CAVA; SIDE PORTACAVAL-SHUNT; MEMBRANOUS OBSTRUCTION; HEPATOCELLULAR-CARCINOMA; PORTAL DECOMPRESSION; CLINICAL SPECTRUM; TRANSPLANTATION; COARCTATION; THROMBOSIS	Hepatic venous outflow obstruction (HVOO) is a rare cause of portal hypertension and conservative treatment is usually ineffective. A large series of patients gave us an opportunity to devise a management protocol for this disorder. Between 1978 and 1992, we prospectively studied 75 patients with HVOO. The obstruction was in the hepatic vein in 24, in the inferior vena cava (IVC) in 44, and in both in 7. For hepatic vein obstruction proximal splenorenal shunts were done in 7 (2 died postoperatively); 4 shunts blocked and only 1 patient became completely symptom free. In 2 patients with partial obstruction we performed balloon dilatation of the right hepatic veins but within 6 months the obstruction recurred. In the next 6 patients we constructed a side-to-side portocaval shunt; 2 died of encephalopathy after discharge and 4 are alive and well. For IVC obstruction, after surgical procedures had yielded poor results in 14 patients, we changed to balloon angioplasty which was successful in 28 of the 30 other patients; restenosis occurred in 4. Of the 7 patients with a combined block, 3 have had balloon angioplasty followed by a side-to-side portocaval shunt; 1 died, 2 are well, and the remainder have not completed treatment. Of our 75 patients, 22 have died (5 in hospital and 17 after discharge), 7 have not completed treatment, and 2 have been lost to follow-up. However, 44 are symptom free. We did not encounter any case of hepatocellular carcinoma. We suggest that patients with HVOO should be actively managed with a side-to-side portocaval shunt for hepatic vein obstruction, balloon angioplasty for inferior vena caval obstruction, and perhaps both procedures for those with combined obstructions.	ALL INDIA INST MED SCI, DEPT GASTROINTESTINAL SURG, ROOM 1005, PC BLOCK, NEW DELHI 110029, INDIA; ALL INDIA INST MED SCI, DEPT CARDIOL, NEW DELHI 110029, INDIA	All India Institute of Medical Sciences (AIIMS) New Delhi; All India Institute of Medical Sciences (AIIMS) New Delhi				Nundy, Samiran/0000-0002-1757-3919				AHN SS, 1987, J VASC SURG, V5, P28, DOI 10.1067/mva.1987.avs0050028; CAMERON JL, 1978, ANN SURG, V187, P402, DOI 10.1097/00000658-197804000-00010; CAMPBELL DA, 1988, SURG GYNECOL OBSTET, V166, P511; COON HO, 1989, ASAIO T, V35, P163; DATTA DV, 1972, INDIAN J MED RES, V60, P385; HAIMOVICI H, 1970, SURG GYNECOL OBSTETR, V131, P1173; HALFF G, 1990, ANN SURG, V211, P43, DOI 10.1097/00000658-199001000-00007; HUGUET C, 1984, SURGERY, V95, P108; KEW MC, 1989, HEPATOLOGY, V9, P121, DOI 10.1002/hep.1840090121; KIMURA C, 1972, SURGERY, V72, P551; MADANAGOPALAN N, 1986, J GASTROEN HEPATOL, V1, P359, DOI 10.1111/j.1440-1746.1986.tb00776.x; MADDREY WC, 1984, HEPATOLOGY, V4, pS44, DOI 10.1002/hep.1840040713; MILLIKAN WJ, 1985, AM J SURG, V149, P167, DOI 10.1016/S0002-9610(85)80028-3; MITCHELL MC, 1982, MEDICINE, V61, P199, DOI 10.1097/00005792-198207000-00001; NAKAMURA T, 1968, ANGIOLOGY, V19, P479, DOI 10.1177/000331976801900805; NUNDY S, 1983, IDIOPATHIC PORTAL HY, P535; ORLOFF MJ, 1989, SURG GYNECOL OBSTET, V168, P33; ORLOFF MJ, 1992, ARCH SURG-CHICAGO, V127, P1182; ORLOFF MJ, 1978, ANN SURG, V188, P494, DOI 10.1097/00000658-197810000-00007; PANDE G, 1987, BMJ-BRIT MED J, V297, P1115; PEZZUOLI G, 1985, SURGERY, V98, P319; POWELLJACKSON PR, 1982, Q J MED, V51, P79; RECTOR WG, 1985, MEDICINE, V64, P134, DOI 10.1097/00005792-198503000-00005; SANFEY H, 1984, WORLD J SURG, V8, P706, DOI 10.1007/BF01655767; SELTMAN HJ, 1983, GASTROENTEROLOGY, V84, P640; SIMSON IW, 1982, GASTROENTEROLOGY, V82, P171; TAKEUCHI J, 1971, AM J MED, V51, P11, DOI 10.1016/0002-9343(71)90319-6; TAVILL AS, 1975, GASTROENTEROLOGY, V68, P509; VALLA D, 1985, ANN INTERN MED, V103, P329, DOI 10.7326/0003-4819-103-3-329; VICTOR S, 1986, J THORAC CARDIOV SUR, V91, P99; VONS C, 1986, ANN SURG, V203, P366, DOI 10.1097/00000658-198604000-00005; WANG ZG, 1989, J VASC SURG, V10, P149, DOI 10.1067/mva.1989.vs0100149	32	79	80	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 18	1993	342	8873					718	722		10.1016/0140-6736(93)91712-U	http://dx.doi.org/10.1016/0140-6736(93)91712-U			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX469	8103826				2022-12-28	WOS:A1993LX46900013
J	HAMILTON, JA				HAMILTON, JA			RHEUMATOID-ARTHRITIS - OPPOSING ACTIONS OF HEMATOPOIETIC GROWTH-FACTORS AND SLOW-ACTING ANTIRHEUMATIC DRUGS	LANCET			English	Article							COLONY-STIMULATING FACTOR; CHRONIC INFLAMMATORY ARTHRITIS; TUMOR-NECROSIS-FACTOR; BONE-MARROW ADJACENT; D-PENICILLAMINE; GM-CSF; FACTOR-ALPHA; GOLD SALTS; CELLS; INTERLEUKIN-1	The pathogenesis of rheumatoid arthritis and the mode of action of anti-rheumatic drugs are unknown. This hypothesis proposes that haemopoietic growth factors (colony stimulating factors [CSFs]) have an important role in rheumatoid arthritis as regulators of myelopoiesis and as activators of inflammatory leucocytes. It also suggests that slow-acting anti-rheumatic drugs may work by inhibiting myelopoiesis. This opposition to one of the actions of the CSFs would result in fewer inflammatory cells in the inflamed joints.			HAMILTON, JA (corresponding author), UNIV MELBOURNE, ROYAL MELBOURNE HOSP, DEPT MED, PARKVILLE, VIC 3050, AUSTRALIA.			Hamilton, John A/0000-0002-9493-9224				ABD AHA, 1991, LYMPHOKINE CYTOK RES, V10, P43; ALLISON AC, IN PRESS AG ACT; ALVAROGRACIA JM, 1991, J IMMUNOL, V146, P3365; BRANDES ME, 1991, J CLIN INVEST, V87, P1108, DOI 10.1172/JCI115073; BUCHAN GS, 1985, J LEUKOCYTE BIOL, V37, P221, DOI 10.1002/jlb.37.2.221; CAMPBELL IK, 1991, J IMMUNOL, V147, P1238; CAMPBELL IK, IN PRESS BIOCH BIOPH; DINARELLO CA, 1989, ADV IMMUNOL, V44, P153, DOI [10.1016/s0065-2776(08)60642-2, 10.1016/S0065-2776(08)60642-2, DOI 10.1016/S0065-2776(08)60642-2]; DREHER R, 1986, IMMUN INFEKT, V14, P100; FIRESTEIN GS, 1988, J EXP MED, V168, P1573, DOI 10.1084/jem.168.5.1573; FIRESTEIN GS, 1990, ARTHRITIS RHEUM, V33, P768, DOI 10.1002/art.1780330602; GERATZ JD, 1988, ARTHRITIS RHEUM, V31, P1156; HAMILTON JA, 1993, IMMUNOL TODAY, V14, P18, DOI 10.1016/0167-5699(93)90319-G; HAMILTON JA, 1991, J RHEUMATOL, V18, P106; HAMILTON JA, 1985, J RHEUMATOL, V12, P892; HAMILTON JA, 1987, J RHEUMATOL, V14, P216; HAMILTON JA, IN PRESS GROWTH FACT; HAYASHIDA K, 1992, ARTHRITIS RHEUM, V35, P241, DOI 10.1002/art.1780350219; HAZENBERG BPC, 1989, BLOOD, V74, P2769, DOI 10.1182/blood.V74.8.2769.2769; HOWELL A, 1975, BRIT MED J, V1, P432, DOI 10.1136/bmj.1.5955.432; KAY AGL, 1979, ANN RHEUM DIS, V38, P232, DOI 10.1136/ard.38.3.232; KAY AGL, 1976, BRIT MED J, V1, P1266, DOI 10.1136/bmj.1.6020.1266; KOTAKE S, 1992, J RHEUMATOL, V19, P1511; KUIPERS EJ, 1992, J RHEUMATOL, V19, P621; LEIZER T, 1990, BLOOD, V76, P1989, DOI 10.1182/blood.V76.10.1989.1989; LIPSKY PE, 1989, SPRINGER SEMIN IMMUN, V11, P123; LIPSKY PE, 1982, ADV INFLAMMAT RES, V3, P219; LOWENTHAL RM, 1993, J RHEUMATOL, V20, P137; METCALF D, 1987, EXP HEMATOL, V15, P1; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; OCHI T, 1988, J RHEUMATOL, V15, P1609; OWAKI H, 1989, J RHEUMATOL, V16, P572; SEITZ M, 1982, CLIN IMMUNOL IMMUNOP, V25, P405, DOI 10.1016/0090-1229(82)90205-7; SEITZ M, 1992, J RHEUMATOL, V19, P1038; THOMAS D, 1984, ANN RHEUM DIS, V43, P402, DOI 10.1136/ard.43.3.402; VERNONROBERTS B, 1979, J RHEUMATOL, V6, P120; WIKTORJEDRZEJCZAK W, 1991, EXP HEMATOL, V19, P1049; XU WD, 1989, J CLIN INVEST, V83, P876, DOI 10.1172/JCI113971; YANNI G, 1992, ARTHRITIS RHEUM, V35, pS108; ZSEBO KM, 1988, BLOOD, V71, P99	40	93	98	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 28	1993	342	8870					536	539		10.1016/0140-6736(93)91653-4	http://dx.doi.org/10.1016/0140-6736(93)91653-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU582	8102674				2022-12-28	WOS:A1993LU58200016
J	HARRISON, P				HARRISON, P			ANTISENSE - INTO THE BRAIN	LANCET			English	Editorial Material							EXPRESSION; INVIVO		RADCLIFFE INFIRM,DEPT NEUROPATHOL,OXFORD OX2 6HE,ENGLAND	Radcliffe Infirmary	HARRISON, P (corresponding author), UNIV OXFORD,WARNEFORD HOSP,DEPT PSYCHIAT,OXFORD OX3 7J,ENGLAND.			Harrison, Paul/0000-0002-6719-1126				Akhtar S, 1992, Trends Cell Biol, V2, P139, DOI 10.1016/0962-8924(92)90100-2; CHIASSON BJ, 1992, EUR J PHARM-MOLEC PH, V227, P451, DOI 10.1016/0922-4106(92)90167-T; HELENE C, 1990, BIOCHIM BIOPHYS ACTA, V1049, P99, DOI 10.1016/0167-4781(90)90031-V; JIRIKOWSKI GF, 1992, SCIENCE, V255, P996, DOI 10.1126/science.1546298; PRUSINER SB, 1992, CURR OPINION NEUROBI, V5, P638; SIMONS M, 1992, NATURE, V359, P67, DOI 10.1038/359067a0; WAGNER RW, 1993, SCIENCE, V260, P1510, DOI 10.1126/science.7684856; WAHLESTEDT C, 1993, NATURE, V363, P260, DOI 10.1038/363260a0; WAHLESTEDT C, 1993, SCIENCE, V259, P528, DOI 10.1126/science.8380941; WHITESELL L, 1993, P NATL ACAD SCI USA, V90, P4665, DOI 10.1073/pnas.90.10.4665; 1991, LANCET, V338, P1427	11	9	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 31	1993	342	8866					254	255		10.1016/0140-6736(93)91812-Z	http://dx.doi.org/10.1016/0140-6736(93)91812-Z			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ163	8101297				2022-12-28	WOS:A1993LQ16300005
J	DURANDZALESKI, I; RYMER, JC; ROUDOTTHORAVAL, F; REVUZ, J; ROSA, J				DURANDZALESKI, I; RYMER, JC; ROUDOTTHORAVAL, F; REVUZ, J; ROSA, J			REDUCING UNNECESSARY LABORATORY USE WITH NEW TEST REQUEST FORM - EXAMPLE OF TUMOR-MARKERS	LANCET			English	Article							CLINICAL DECISION-MAKING; TEST-ORDERING BEHAVIOR; CONTROLLED TRIAL; COST; STRATEGIES; EDUCATION; PHYSICIANS; FAILURE; MODIFY	To limit the ordering of serum tumour marker tests that are clinically irrelevant, we designed a new request form. This is a matrix of boxes, rows being individual markers and columns body organs. The box at the intersection of line and column is colour-coded to indicate whether the test is appropriate or not. These ratings were allocated on the basis of published data and local consensus. This new form replaced the form in use at our hospital at the beginning of 1992, and resulted in a 25% decrease in the ordering of tumour markers. Adapting the design of the test request form is a low-cost intervention that combines both economic and clinical requirements in reducing the prescription of tests that are useless in a given clinical situation.	HOP HENRI MONDOR,DEPT BIOCHEM,F-94010 CRETEIL,FRANCE; HOP HENRI MONDOR,DERMATOL SERV,F-94010 CRETEIL,FRANCE	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP	DURANDZALESKI, I (corresponding author), HOP HENRI MONDOR,PUBL HLTH SERV,51 AVE MARECHAL DE LATTRE DE TASSIGNY,F-94010 CRETEIL,FRANCE.							BATES SE, 1991, ANN INTERN MED, V115, P623, DOI 10.7326/0003-4819-115-8-623; BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; DAVIDOFF F, 1989, MED CARE, V27, P45, DOI 10.1097/00005650-198901000-00005; DEVINE GW, 1989, J GEN INTERN MED, V7, P623; EVERITT DE, 1990, INFECT CONT HOSP EP, V11, P578; FOWKES FGR, 1986, BRIT MED J, V292, P883, DOI 10.1136/bmj.292.6524.883; FRASER CG, 1987, ANN CLIN BIOCHEM, V24, P223, DOI 10.1177/000456328702400301; GOLDMAN L, 1990, NEW ENGL J MED, V322, P1524, DOI 10.1056/NEJM199005243222110; GORTMAKER SL, 1988, MED CARE, V26, P631, DOI 10.1097/00005650-198806000-00011; GRINER PF, 1982, NEW ENGL J MED, V307, P1336, DOI 10.1056/NEJM198211183072109; GRINER PF, 1979, ANN INTERN MED, V90, P243, DOI 10.7326/0003-4819-90-2-243; GROSSMAN RM, 1983, MED CARE, V21, P783, DOI 10.1097/00005650-198308000-00003; HARRINGTON JT, 1985, NEW ENGL J MED, V312, P785; HENDERSON AR, 1982, J CLIN PATHOL, V35, P986, DOI 10.1136/jcp.35.9.986; HERSHEY JC, 1987, MED DECIS MAKING, V7, P212, DOI 10.1177/0272989X8700700403; KASSIRER JP, 1986, JAMA-J AM MED ASSOC, V256, P256, DOI 10.1001/jama.256.2.256; LEPAGE EF, 1992, TRANSFUSION, V32, P253, DOI 10.1046/j.1537-2995.1992.32392213810.x; MARTIN AR, 1980, NEW ENGL J MED, V303, P1330, DOI 10.1056/NEJM198012043032304; PAUKER SG, 1980, NEW ENGL J MED, V302, P1109, DOI 10.1056/NEJM198005153022003; SCHROEDER S, 1973, JAMA-J AM MED ASSOC, V225, P996; SCHROEDER SA, 1984, JAMA-J AM MED ASSOC, V252, P225, DOI 10.1001/jama.252.2.225; SILVER H, 1992, TRANSFUSION, V32, P260, DOI 10.1046/j.1537-2995.1992.32392213811.x; SOMERAI SB, 1990, QUAL ASSUR HLTH CARE, V2, P37; SOUMERAI SB, 1990, JAMA-J AM MED ASSOC, V263, P549, DOI 10.1001/jama.263.4.549; TIERNEY WM, 1990, NEW ENGL J MED, V322, P1499, DOI 10.1056/NEJM199005243222105; WICKENNS R, 1992, BMJ, V304, P1093; WONES RG, 1987, MED CARE, V25, P78, DOI 10.1097/00005650-198701000-00009; WONG ET, 1983, JAMA-J AM MED ASSOC, V249, P3076, DOI 10.1001/jama.249.22.3076; WONG ET, 1983, JAMA-J AM MED ASSOC, V250, P2510, DOI 10.1001/jama.250.18.2510; YOUNG D, 1981, BMJ, V282, P1610; ZAAT JOM, 1992, MED CARE, V30, P189, DOI 10.1097/00005650-199203000-00001	31	56	56	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 17	1993	342	8864					150	153		10.1016/0140-6736(93)91349-Q	http://dx.doi.org/10.1016/0140-6736(93)91349-Q			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN042	8101259				2022-12-28	WOS:A1993LN04200015
J	EITAN, S; SCHWARTZ, M				EITAN, S; SCHWARTZ, M			A TRANSGLUTAMINASE THAT CONVERTS INTERLEUKIN-2 INTO A FACTOR CYTOTOXIC TO OLIGODENDROCYTES	SCIENCE			English	Article							HAIR FOLLICLE TRANSGLUTAMINASES; CROSS-LINKING; CELL-LINE; GROWTH; REGENERATION; ENZYMES; CULTURE; INVITRO; INJURY; MYELIN	Regenerating optic nerves from fish produce a factor that is cytotoxic to oligodendrocytes. The cytotoxic factor is recognized by antibodies to interleukin-2 (IL-2) and has the apparent molecular size of a dimer of IL-2. An enzyme, identified as a nerve transglutaminase, was purified from regenerating optic nerves of fish and was found to catalyze dimerization of human IL-2. The dimerized IL-2, unlike monomeric IL-2, is cytotoxic to oligodendrocytes from rat brain in culture. The results suggest that posttranslational modification of a cytokine can alter its activity. Under conditions in which oligodendrocytes inhibit neuronal regeneration, dimerization of IL-2 might provide a mechanism to permit nerve growth.	WEIZMANN INST SCI, DEPT NEUROBIOL, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science								Aguayo A., 1979, ADV CELL NEUROBIOL, V3, P215; BASTMEYER M, 1991, J NEUROSCI, V11, P626; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BYRD JC, 1987, J BIOL CHEM, V262, P11699; CAJAL SRY, 1954, DEGENERATION REGENER, V1; CARBONETTO S, 1987, J NEUROSCI, V7, P610; CHAKRABORTY G, 1987, J NEUROCHEM, V48, P669, DOI 10.1111/j.1471-4159.1987.tb05567.x; COHEN A, 1990, BRAIN RES, V537, P24, DOI 10.1016/0006-8993(90)90335-9; EITAN S, 1992, P NATL ACAD SCI USA, V89, P5442, DOI 10.1073/pnas.89.12.5442; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; GILAD GM, 1985, J NEUROCHEM, V44, P1385, DOI 10.1111/j.1471-4159.1985.tb08774.x; GILLIS S, 1982, IMMUNOL REV, V63, P167, DOI 10.1111/j.1600-065X.1982.tb00415.x; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; KIERNAN JA, 1979, BIOL REV, V54, P155, DOI 10.1111/j.1469-185X.1979.tb00871.x; LORAND L, 1981, METHOD ENZYMOL, V80, P333; MARTINET N, 1988, J BIOL CHEM, V263, P4236; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MELINO G, 1988, EXP CELL RES, V179, P429, DOI 10.1016/0014-4827(88)90281-9; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; PAONESSA G, 1984, SCIENCE, V226, P852, DOI 10.1126/science.6149619; PETERSON LL, 1984, MOL CELL BIOCHEM, V58, P99, DOI 10.1007/BF00240609; SAVIO T, 1989, J NEUROSCI, V9, P1126; SCHWAB ME, 1990, EXP NEUROL, V109, P2, DOI 10.1016/S0014-4886(05)80003-2; SCHWARTZ M, 1989, FASEB J, V3, P2371, DOI 10.1096/fasebj.3.12.2676680; SCHWARTZ M, 1985, SCIENCE, V228, P601; SIMON M, 1985, CELL, V40, P677, DOI 10.1016/0092-8674(85)90216-8; SIVRON T, 1991, GLIA, V4, P591, DOI 10.1002/glia.440040606; SIVRON T, UNPUB; TETZLAFF W, 1988, BRAIN RES, V445, P142, DOI 10.1016/0006-8993(88)91083-9; WATSON J, 1979, J EXP MED, V150, P1510, DOI 10.1084/jem.150.6.1510	31	131	137	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 2	1993	261	5117					106	108		10.1126/science.8100369	http://dx.doi.org/10.1126/science.8100369			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LK434	8100369				2022-12-28	WOS:A1993LK43400044
J	BAIRD, KS; ALWAN, WH; CROSSAN, JF; WOJCIAK, B				BAIRD, KS; ALWAN, WH; CROSSAN, JF; WOJCIAK, B			T-CELL-MEDIATED RESPONSE IN DUPUYTRENS DISEASE	LANCET			English	Note								The cause of Dupuytren's disease is unknown, but inflammatory cells might have a role. Enzymatic digestion of diseased tissue permits identification and immunofluorescent labelling of a cell subset displaying inflammatory cell morphology. Cytofluorimetry of this cell population demonstrated the presence of CD3-positive lymphocytes and expression of major histocompatibility complex (MHC) class II proteins. These results raise the possibility that Dupuytren's disease is a T-cell-mediated autoimmune disorder. The development of medical treatment on this basis may reduce the need for surgery, with its associated morbidity and high recurrence rates.	UNIV GLASGOW,DEPT ORTHOPAED SURG,GLASGOW G11 6NT,SCOTLAND; UNIV GLASGOW,DEPT IMMUNOL,GLASGOW G11 6NT,SCOTLAND; UNIV GLASGOW,DEPT CELL BIOL,GLASGOW G11 6NT,SCOTLAND	University of Glasgow; University of Glasgow; University of Glasgow					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDREW JG, 1991, J HAND SURG-BRIT EUR, V16B, P267, DOI 10.1016/0266-7681(91)90051-O; BAIRD KS, IN PRESS J CLIN PATH; BOWER M, 1990, BRIT MED J, V300, P164, DOI 10.1136/bmj.300.6718.164; GIDDENS WE, 1985, AM J PATHOL, V119, P253; HURST LC, 1990, DUPUYTRENS DIS BIOL, P253; Jupiter JB, 1991, FLYNNS HAND SURG, P864; LING RSM, 1963, J BONE JOINT SURG BR, V45, P709, DOI 10.1302/0301-620X.45B4.709; McFarlane R.M., 1990, DUPUYTRENS DIS BIOL, P265; MILLWARDSADLER GH, 1985, LIVER BILIARY DISEAS, P844; SPENCER JD, 1984, J HAND SURG-BRIT EUR, V9B, P276, DOI 10.1016/0266-7681(84)90041-X	10	33	33	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 26	1993	341	8861					1622	1623		10.1016/0140-6736(93)90760-E	http://dx.doi.org/10.1016/0140-6736(93)90760-E			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ727	8099992				2022-12-28	WOS:A1993LJ72700006
J	MELDRUM, BS				MELDRUM, BS			EPILEPSY - INTRACEREBRAL MICRODIALYSIS AND SEIZURE INITIATION	LANCET			English	Editorial Material							DIALYTRODE; BRAIN				MELDRUM, BS (corresponding author), INST PSYCHIAT,DEPT NEUROL,LONDON SE5 8AF,ENGLAND.							BENVENISTE H, 1990, PROG NEUROBIOL, V35, P195, DOI 10.1016/0301-0082(90)90027-E; CARLSON H, 1992, NEUROSCI LETT, V140, P30, DOI 10.1016/0304-3940(92)90674-V; DELGADO JMR, 1972, ARCH INT PHARMACOD T, V198, P9; DELGADO JMR, 1984, J NEUROCHEM, V42, P1218, DOI 10.1111/j.1471-4159.1984.tb02775.x; DO KQ, 1991, FID RES FDN, V5, P677; DURING MJ, 1992, ANN NEUROL, V32, P618, DOI 10.1002/ana.410320504; MEYERSON BA, 1990, LIFE SCI, V46, P301, DOI 10.1016/0024-3205(90)90037-R; MILLAN H, 1993, EPILEPSY RES, V14, P139; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072	9	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 26	1993	341	8861					1627	1627		10.1016/0140-6736(93)90764-8	http://dx.doi.org/10.1016/0140-6736(93)90764-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ727	8099996				2022-12-28	WOS:A1993LJ72700010
J	MUMMERT, E; GRIMM, R; SPETH, V; ECKERSKORN, C; SCHILTZ, E; GATENBY, AA; SCHAFER, E				MUMMERT, E; GRIMM, R; SPETH, V; ECKERSKORN, C; SCHILTZ, E; GATENBY, AA; SCHAFER, E			A TCP1-RELATED MOLECULAR CHAPERONE FROM PLANTS REFOLDS PHYTOCHROME TO ITS PHOTOREVERSIBLE FORM	NATURE			English	Article							RIBULOSEBISPHOSPHATE CARBOXYLASE; MITOCHONDRIAL PROTEIN; PURIFICATION; BACTERIAL; GROEL	FOLDING of the major cytoskeletal components in the cytosol of mammalian cells is mediated by interactions with t-complex polypeptide-1 (TCP1) molecular chaperones1-6, a situation analogous to the chaperonin 60-aided folding of polypeptides in bacteria7,8, chloroplasts9,10 and mitochondria11-13. We have purified a TCP1-related molecular chaperone from etiolated oat seedlings that has a unique structure. Although immunologically related to TCP1, and having amino-acid sequence similarity, its quaternary structure is different from animal TCP1 proteins5,6,14. Electron microscopy and image analysis reveals that the chaperone has two stacked rings of six subunits each, and is distinct in size and configuration. The chaperone copurifies with the soluble cytosolic photoreceptor phytochrome15, and can stimulate refolding of denatured phytochrome to a photoactive form in the presence of Mg-ATP. We propose that this protein is the cytosolic chaperone involved in phytochrome biogenesis in plant cells.	MAX PLANCK INST BIOCHEM,GENZENTRUM,W-8033 MARTINSRIED,GERMANY; INST BIOL 2,W-7800 FREIBURG,GERMANY; INST ORGAN CHEM & BIOCHEM,W-7800 FREIBURG,GERMANY; DUPONT CO INC,CENT RES & DEV,DIV MOLEC BIOL,WILMINGTON,DE 19880	Max Planck Society; DuPont								ECKERSKORN C, 1988, EUR J BIOCHEM, V176, P509, DOI 10.1111/j.1432-1033.1988.tb14308.x; ELLIS RJ, 1990, SCIENCE, V250, P954, DOI 10.1126/science.250.4983.954; ELLIS RJ, 1991, REV BIOCH, V60, P321; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; Furuya M, 1989, Adv Biophys, V25, P133, DOI 10.1016/0065-227X(89)90006-3; GATENBY AA, 1990, ANNU REV CELL BIOL, V6, P125; GILMARTIN PM, 1990, PLANT CELL, V2, P369, DOI 10.1105/tpc.2.5.369; GORG A, 1988, ELECTROPHORESIS, V9, P531, DOI 10.1002/elps.1150090913; GRIMM R, 1993, J BIOL CHEM, V268, P5220; GRIMM R, 1986, Z NATURFORSCH C, V41, P988; Gross J, 1984, TECHNIQUES PHOTOMORP, P131; GUPTA RS, 1990, BIOCHEM INT, V20, P833; Hallberg R L, 1990, Semin Cell Biol, V1, P37; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HEMMINGSEN SM, 1986, PLANT PHYSIOL, V80, P269, DOI 10.1104/pp.80.1.269; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; JACKSON JF, 1985, MOD METHOD PLANT, V1, P301; JINDAL S, 1989, MOL CELL BIOL, V9, P2279, DOI 10.1128/MCB.9.5.2279; KUBOTA H, 1992, GENE, V120, P207, DOI 10.1016/0378-1119(92)90095-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS VA, 1992, NATURE, V358, P249, DOI 10.1038/358249a0; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; MARKHAM R, 1963, VIROLOGY, V20, P88, DOI 10.1016/0042-6822(63)90143-0; MCMULLIN TW, 1988, MOL CELL BIOL, V8, P371, DOI 10.1128/MCB.8.1.371; MORI M, 1992, GENE, V122, P381, DOI 10.1016/0378-1119(92)90231-D; NORTH G, 1991, NATURE, V354, P434, DOI 10.1038/354434a0; PHIPPS BM, 1993, NATURE, V361, P475, DOI 10.1038/361475a0; PILWAT G, 1980, PLANTA, V147, P396, DOI 10.1007/BF00380179; RUDIGER W, 1983, P NATL ACAD SCI-BIOL, V80, P6244, DOI 10.1073/pnas.80.20.6244; TRENT JD, 1991, NATURE, V354, P490, DOI 10.1038/354490a0; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; WILLISON K, 1989, CELL, V57, P631; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0	33	44	44	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 17	1993	363	6430					644	648		10.1038/363644a0	http://dx.doi.org/10.1038/363644a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LH139	8099715				2022-12-28	WOS:A1993LH13900061
J	BOLINDER, J; UNGERSTEDT, U; ARNER, P				BOLINDER, J; UNGERSTEDT, U; ARNER, P			LONG-TERM CONTINUOUS GLUCOSE MONITORING WITH MICRODIALYSIS IN AMBULATORY INSULIN-DEPENDENT DIABETIC-PATIENTS	LANCET			English	Article							BLOOD-GLUCOSE; SUBCUTANEOUS TISSUE; ADIPOSE-TISSUE; INSTABILITY; GLYCEMIA; INVIVO	The glucose concentration in the extracellular space of subcutaneous adipose tissue closely mirrors the blood glucose concentration. With a microdialysis technique, we undertook continuous ambulatory monitoring of adipose tissue glucose in 17 insulin-dependent diabetic patients with labile glycaemic control. The aims of the study were to investigate performance of the microdialysis device and to evaluate whether consecutive 24 h glucose profiles could be used to adjust insulin therapy. A microdialysis probe was implanted subcutaneously, perfused by a portable microinfusion pump, and dialysate fractions were collected every 1 or 2 h for 75 h. The mean (SE) tissue dialysate glucose concentration was 93 (3)% of the concentration in venous plasma, and variations in adipose tissue glucose closely paralleled changes in plasma glucose. Mean 24 h tissue glucose concentration correlated significantly with glycosylated haemoglobin (HbA1c; r=0.62, p < 0.01). Most patients had a reproducible daily pattern of glucose swings, and in more than half the patients consecutive ambulatory glucose profiles were almost superimposed. When patients' insulin therapy was adjusted on the basis of ambulatory glucose monitoring, HbA1c decreased by almost 2% (p < 0.01), and this decrease lasted for at least 9 months. Microdialysis of adipose tissue can be used for continuous long-term monitoring of glucose concentrations in diabetic patients during ordinary daily life. Daily glucose profiles are often reproducible and the recordings may thus be used for individual tailoring of insulin therapy to improve glycaemic control.	HUDDINGE UNIV HOSP,DEPT MED,S-14186 HUDDINGE,SWEDEN; HUDDINGE UNIV HOSP,RES CTR,S-14186 HUDDINGE,SWEDEN; KAROLINSKA INST,DEPT PHARMACOL,S-10401 STOCKHOLM 60,SWEDEN	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet				Bolinder, Jan/0000-0003-0035-0142				ALBISSER AM, 1990, DIABETES CARE, V13, P393, DOI 10.2337/diacare.13.4.393; ARNER P, 1991, J INTERN MED, V230, P381, DOI 10.1111/j.1365-2796.1991.tb00461.x; BOLINDER J, 1992, DIABETOLOGIA, V35, P1177, DOI 10.1007/BF00401374; FISCHER U, 1987, DIABETOLOGIA, V30, P940, DOI 10.1007/BF00295878; JANSSON PA, 1988, AM J PHYSIOL, V255, pE218, DOI 10.1152/ajpendo.1988.255.2.E218; KADDISH AH, 1968, CLIN CHEM, V14, P116; LONNROTH P, 1987, AM J PHYSIOL, V253, pE3228; MAZZE RS, 1987, DIABETES CARE, V10, P111, DOI 10.2337/diacare.10.1.111; MEYERHOFF C, 1992, DIABETOLOGIA, V35, P1087, DOI 10.1007/BF02221686; MOATTISIRAT D, 1992, DIABETOLOGIA, V35, P224, DOI 10.1007/BF00400921; MOLNAR GD, 1972, DIABETOLOGIA, V8, P342, DOI 10.1007/BF01218495; PERNICK NL, 1986, DIABETES CARE, V9, P61, DOI 10.2337/diacare.9.1.61; PICKUP JC, 1985, LANCET, V2, P817; SCHIFFRIN A, 1982, DIABETES CARE, V5, P479, DOI 10.2337/diacare.5.5.479; SCHLICHTKRULL J, 1965, ACTA MED SCAND, V177, P95; SERVICE FJ, 1970, DIABETES, V19, P644, DOI 10.2337/diab.19.9.644; TOSSMAN U, 1986, ACTA PHYSIOL SCAND, V128, P9, DOI 10.1111/j.1748-1716.1986.tb07943.x; UNGERSTEDT U, 1991, J INTERN MED, V230, P365, DOI 10.1111/j.1365-2796.1991.tb00459.x; WATFORD M, 1991, TRENDS BIOCHEM SCI, V16, P201, DOI 10.1016/0968-0004(91)90082-7; WILSON DE, 1983, DIABETES CARE, V6, P604, DOI 10.2337/diacare.6.6.604; WORTH R, 1982, BRIT MED J, V285, P1233, DOI 10.1136/bmj.285.6350.1233; 1992, LANCET, V339, P1326	22	103	104	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 30	1993	342	8879					1080	1085		10.1016/0140-6736(93)92063-Y	http://dx.doi.org/10.1016/0140-6736(93)92063-Y			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME822	8105311				2022-12-28	WOS:A1993ME82200009
J	BERGER, J; MANZ, A				BERGER, J; MANZ, A			WHEN IS A CLUSTER	LANCET			English	Editorial Material							DISEASE		BERATUNGSSTELLE CHEM ARBETER,HAMBURG,GERMANY		BERGER, J (corresponding author), INST MATH & DATENVERABEITUNG,HAMBURG,GERMANY.							CLAYTON D, 1987, BIOMETRICS, V43, P671, DOI 10.2307/2532003; Cliff A, 1973, SPATIAL AUTOCORRELAT; Geary R.C., 1954, INC STAT, V5, P115, DOI [10.2307/2986645, DOI 10.2307/2986645]; HILLS M, 1989, J ROY STAT SOC A STA, V152, P353, DOI 10.2307/2983132; Johnson N.L., 1977, URN MODELS THEIR APP; KING WD, 1993, EUR J CANCER A, V29, P1418; MORAN PAP, 1948, J ROY STAT SOC B, V10, P243; OHNO Y, 1979, INT J EPIDEMIOL, V8, P273, DOI 10.1093/ije/8.3.273	8	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 2	1993	342	8875					818	818		10.1016/0140-6736(93)92690-U	http://dx.doi.org/10.1016/0140-6736(93)92690-U			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA025	8104267				2022-12-28	WOS:A1993MA02500004
J	MURGATROYD, F				MURGATROYD, F			MALIGNANT ARRHYTHMIAS - TRIBULATIONS POST ESVEM	LANCET			English	Editorial Material							SURVIVAL				MURGATROYD, F (corresponding author), ST GEORGE HOSP,SCH MED,DEPT CARDIOL SCI,LONDON,ENGLAND.							[Anonymous], 1989, CIRCULATION, V79, P1354; GRABOYS TB, 1982, AM J CARDIOL, V50, P437, DOI 10.1016/0002-9149(82)90307-1; MASON JW, 1993, NEW ENGL J MED, V329, P452, DOI 10.1056/NEJM199308123290702; MASON JW, 1993, NEW ENGL J MED, V329, P445, DOI 10.1056/NEJM199308123290701; SHENASA M, 1993, LANCET, V341, P1512, DOI 10.1016/0140-6736(93)90642-T; SWERDLOW CD, 1983, NEW ENGL J MED, V308, P1436, DOI 10.1056/NEJM198306163082402; WARD DE, 1993, NEW ENGL J MED, V329, P498, DOI 10.1056/NEJM199308123290710	7	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 4	1993	342	8871					569	569		10.1016/0140-6736(93)91405-B	http://dx.doi.org/10.1016/0140-6736(93)91405-B			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV963	8102715				2022-12-28	WOS:A1993LV96300005
J	YOUNG, ID				YOUNG, ID			PREGNANCY SCREENING FOR CYSTIC-FIBROSIS	LANCET			English	Editorial Material											YOUNG, ID (corresponding author), CITY HOSP NOTTINGHAM,DEPT CLIN GENET,NOTTINGHAM NG5 1PD,ENGLAND.							BEKKER H, 1993, BRIT MED J, V306, P1584, DOI 10.1136/bmj.306.6892.1584; HARRIS H, 1993, BRIT MED J, V306, P1580, DOI 10.1136/bmj.306.6892.1580; MENNIE ME, 1992, LANCET, V340, P214, DOI 10.1016/0140-6736(92)90476-J; WATSON EK, 1991, BRIT MED J, V303, P504, DOI 10.1136/bmj.303.6801.504; 1992, LANCET, V340, P209	5	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 4	1993	342	8871					569	570		10.1016/0140-6736(93)91406-C	http://dx.doi.org/10.1016/0140-6736(93)91406-C			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV963	8102716				2022-12-28	WOS:A1993LV96300006
J	TOMOTSUNE, D; SHOJI, H; WAKAMATSU, Y; KONDOH, H; TAKAHASHI, N				TOMOTSUNE, D; SHOJI, H; WAKAMATSU, Y; KONDOH, H; TAKAHASHI, N			A MOUSE HOMOLOG OF THE DROSOPHILA TUMOR-SUPPRESSOR GENE L(2)GL CONTROLLED BY HOX-C8 IN-VIVO	NATURE			English	Article							HOMEOTIC GENES; EXPRESSION; PROTEIN; ULTRABITHORAX; ORGANIZATION; MELANOGASTER; CAPACITIES; DISRUPTION; POLYMERASE; SEQUENCE	THE homeobox is a 183-base-pair DNA sequence originally found in Drosophila segmentation and homeotic genes1,2. In Drosophila, homeotic genes are clustered in the Antennapedia and Bithorax complexes, collectively called the homeotic gene complex (HOM-C)3. In the mouse genome, about 40 homeobox genes (Hox) are clustered in four chromosomal regions (Hox A to D). The Hox genes are arranged in the same order and have the same antero-posterior pattern of expression as their structural homologue in the HOM-C4,5, suggesting that they control mouse pattern formation in the same way that HOM-C members do in Drosophila. Homeobox gene products are believed to be transcription factors that regulate expression of target genes. A few candidate target genes have been identified in Drosophila by various approaches6 but the Hox gene targets are poorly understood, mostly because of limitations in the available approaches. Here we identify several candidate Hox gene targets, including a mouse homologue of the Drosophila tumour-suppressor gene l(2)gl, by immunopurification of DNA sequences bound to a Hox protein in native chromatin.	NAGOYA UNIV,SCH SCI,DEPT MOLEC BIOL,NAGOYA,AICHI 464,JAPAN	Nagoya University								AKAM M, 1989, CELL, V57, P347, DOI 10.1016/0092-8674(89)90909-4; ANDREW DJ, 1992, NEW BIOL, V4, P5; ARCIONI L, 1992, EMBO J, V11, P265, DOI 10.1002/j.1460-2075.1992.tb05049.x; AWGULEWITSCH A, 1990, DEVELOPMENT, V108, P411; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; GATEFF E, 1974, ROUX ARCH DEV BIOL, V176, P23, DOI 10.1007/BF00577830; GOULD AP, 1990, NATURE, V348, P308, DOI 10.1038/348308a0; GRABA Y, 1992, EMBO J, V11, P3375, DOI 10.1002/j.1460-2075.1992.tb05416.x; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; HARLOW E, 1988, ANTIBODIES LABORATOR; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; JACKSON V, 1974, BIOCHEMISTRY-US, V19, P3952; JACOB L, 1987, CELL, V50, P215, DOI 10.1016/0092-8674(87)90217-0; KENNISON JA, 1992, NEW BIOL, V4, P91; KLAMBT C, 1989, DEV BIOL, V133, P425, DOI 10.1016/0012-1606(89)90046-8; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; MCGINNIS W, 1984, CELL, V37, P403, DOI 10.1016/0092-8674(84)90370-2; MECHLER BM, 1985, EMBO J, V4, P1551, DOI 10.1002/j.1460-2075.1985.tb03816.x; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT MP, 1984, P NATL ACAD SCI-BIOL, V81, P4115, DOI 10.1073/pnas.81.13.4115; WAKAMATSU Y, 1990, ACTA HISTOCHEM CYTOC, V23, P367, DOI 10.1267/ahc.23.367; WAKAMATSU Y, 1993, NEURON, V10, P1, DOI 10.1016/0896-6273(93)90236-K; ZAPPAVIGNA V, 1991, EMBO J, V10, P4177, DOI 10.1002/j.1460-2075.1991.tb04996.x	29	105	108	1	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 2	1993	365	6441					69	72		10.1038/365069a0	http://dx.doi.org/10.1038/365069a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LV646	8103190				2022-12-28	WOS:A1993LV64600056
J	DEFRANCISCO, A; CHAKRABORTY, J; CHOWDHURY, HR; YUNUS, M; BAQUI, AH; SIDDIQUE, AK; SACK, RB				DEFRANCISCO, A; CHAKRABORTY, J; CHOWDHURY, HR; YUNUS, M; BAQUI, AH; SIDDIQUE, AK; SACK, RB			ACUTE TOXICITY OF VITAMIN-A GIVEN WITH VACCINES IN INFANCY	LANCET			English	Note								A double-blind, randomised, placebo-controlled trial was conducted to evaluate the safety and toxicity of vitamin A supplementation within the Expanded Programme on Immunisation (EPI) in rural Bangladesh. 191 infants received 3 doses of either 50 000 IU of vitamin A or placebo at about 1.5, 2.5, and 3.5 months and were examined on days 1, 2,3, and 8 after supplementation. 11 infants (11.5%) supplemented with vitamin A had episodes of bulging of the fontanelle as opposed to 1 (1%) in the placebo group. 16 of the 17 events occurred in the vitamin A supplemented group. No other side effects were noted. There was a tendency towards a cumulative effect of toxicity with increasing doses.			DEFRANCISCO, A (corresponding author), INT CTR DIARRHOEAL DIS RES,GPO BOX 128,DHAKA 1000,BANGLADESH.							BAUERNFEIN JC, 1980, SAFE USE VITAMIN A R; GEUBEL AP, 1991, GASTROENTEROLOGY, V100, P1701, DOI 10.1016/0016-5085(91)90672-8; GREEN M, 1986, PEDIATRIC DIAGNOSIS; HATHCOCK JN, 1990, AM J CLIN NUTR, V52, P183, DOI 10.1093/ajcn/52.2.183; Miller D.R., 1982, NUTRITIONAL TOXICOLO, V1, P81; OLSON JA, 1987, AM J CLIN NUTR, V45, P704, DOI 10.1093/ajcn/45.4.704; VARNA RN, 1972, CAN J PHYSL PHARM, V50, P1026; VAUGHAN VC, 1987, NELSON TXB PEDIATRIC; 1992, VITAMIN A DEFICIENCY; 1988, VITAMIN A SUPPLEMENT	10	54	54	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 28	1993	342	8870					526	527		10.1016/0140-6736(93)91648-6	http://dx.doi.org/10.1016/0140-6736(93)91648-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU582	8102669				2022-12-28	WOS:A1993LU58200011
J	DUBOW, MS				DUBOW, MS			ANTITUBERCULOSIS DRUG SCREENING	LANCET			English	Editorial Material											DUBOW, MS (corresponding author), MCGILL UNIV,DEPT MICROBIOL & IMMUNOL,MONTREAL H3A 2T5,QUEBEC,CANADA.							GUZZO J, 1992, TOXICOL LETT, V64-5, P687, DOI 10.1016/0378-4274(92)90248-I; JACOBS WR, 1993, SCIENCE, V260, P819, DOI 10.1126/science.8484123; MEIGHEN EA, 1991, MICROBIOL REV, V55, P123, DOI 10.1128/MMBR.55.1.123-142.1991; OWENHUGHES TA, 1992, CELL, V71, P255, DOI 10.1016/0092-8674(92)90354-F; RAMSAY S, 1993, LANCET, V341, P1340, DOI 10.1016/0140-6736(93)90843-6; STEWART GSA, 1909, ASM NEWS, V59, P241; ULITZUR S, 1987, BIOLUMINESCENCE CHEM, P463	7	3	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 21	1993	342	8869					448	449		10.1016/0140-6736(93)91586-B	http://dx.doi.org/10.1016/0140-6736(93)91586-B			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU075	8102422				2022-12-28	WOS:A1993LU07500003
J	HENGGE, UR; BROCKMEYER, NH; BAUMANN, M; REIMANN, G; GOOS, M				HENGGE, UR; BROCKMEYER, NH; BAUMANN, M; REIMANN, G; GOOS, M			LIPOSOMAL DOXORUBICIN IN AIDS-RELATED KAPOSIS-SARCOMA	LANCET			English	Letter									UNIV ESSEN GESAMTHSCH,DEPT DERMATOL & VENEREOL,W-4300 ESSEN 1,GERMANY	University of Duisburg Essen	HENGGE, UR (corresponding author), NCI,DERMATOL BRANCH,BETHESDA,MD 20892, USA.							CHACHOUA A, 1989, J CLIN ONCOL, V7, P745; FISCHL MA, 1993, AIDS, V6, P259; Gelmann E P, 1987, Am J Med, V82, P456, DOI 10.1016/0002-9343(87)90445-1; GILL PS, 1991, AM J MED, V90, P427, DOI 10.1016/0002-9343(91)80081-V; HENGGE UR, 1993, LANCET, V341, P383, DOI 10.1016/0140-6736(93)90198-P; PRESANT CA, 1993, LANCET, V341, P1242, DOI 10.1016/0140-6736(93)91147-E	6	36	36	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 21	1993	342	8869					497	497		10.1016/0140-6736(93)91624-U	http://dx.doi.org/10.1016/0140-6736(93)91624-U			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU075	8102452				2022-12-28	WOS:A1993LU07500042
J	STEIN, C; HASSAN, AHS; LEHRBERGER, K; GIEFING, J; YASSOURIDIS, A				STEIN, C; HASSAN, AHS; LEHRBERGER, K; GIEFING, J; YASSOURIDIS, A			LOCAL ANALGESIC EFFECT OF ENDOGENOUS OPIOID-PEPTIDES	LANCET			English	Article							MCGILL PAIN QUESTIONNAIRE; INTRAARTICULAR MORPHINE; INFLAMED TISSUE; IMMUNE CELLS; RECEPTORS; INFLAMMATION; ANTINOCICEPTION	Opioids produce analgesia by interacting with local opioid receptors in peripheral inflamed tissue. This study investigated whether endogenous ligands of these receptors are present in synovia and whether such opioid peptides can inhibit pain by activation of intra-articular opioid receptors. Samples of synovium from 8 patients undergoing arthroscopic knee surgery were examined by immunohistochemistry for the presence of beta-endorphin, met-encephalin, and dynorphin. All tissue samples showed synovitis. Inflammatory cells stained strongly for beta-endorphin and met-encephalin but not for dynorphin. To find out whether blockade of intra-articular opioid receptors affected pain, we randomly assigned 22 patients undergoing arthroscopic knee surgery to receive naloxone (0.04 mg) intra-articularly (n = 10) or intravenously (n = 12); each patient received a placebo injection into the other site. Postoperative pain was assessed by visual analogue scale, a numerical rating scale, the McGill pain questionnaire, and supplementary analgesic consumption during the next 24 h. All pain scores were higher in the intra-articular naloxone group than in the intravenous naloxone group. The differences were significant (p < 0.05) during the first 4 h. Supplementary analgesic consumption was significantly higher in the intra-articular group (52.5 [14.0] vs 15.6 [8.0] mg diclofenac, p < 0.05). Opioid peptides are present in inflamed synovial tissue and can inhibit pain after knee surgery through an action specific to intra-articular opioid receptors, These findings expand the gate control theory of pain and suggest new approaches such as the development of peripherally acting opioid analgesics without central side-effects.	MAX PLANCK INST PSYCHIAT,DEPT BIOSTAT,W-8000 MUNICH 40,GERMANY; MAX PLANCK INST PSYCHIAT,DEPT NEUROPHARMACOL,W-8033 MARTINSRIED,GERMANY; JOHNS HOPKINS UNIV,DEPT ANESTHESIOL & CRIT CARE MED,BALTIMORE,MD 21218; PRAXIS & BELEGKLINIKEN SPEZIELLE ORTHOPAD CHIRURG,MUNICH,GERMANY; UNIV MUNICH,DEPT ANESTHESIOL,W-8000 MUNICH 2,GERMANY	Max Planck Society; Max Planck Society; Johns Hopkins University; University of Munich				Stein, Christoph/0000-0001-5240-6836				AMAND MS, 1992, ANESTHESIOLOGY, V77, pA817; BARBER A, 1992, MED RES REV, V12, P525, DOI 10.1002/med.2610120505; BARTHO L, 1990, N-S ARCH PHARMACOL, V342, P666, DOI 10.1007/BF00175710; CHAPMAN CR, 1985, PAIN, V22, P1, DOI 10.1016/0304-3959(85)90145-9; HASSAN AHS, 1992, NEUROSCI LETT, V140, P85, DOI 10.1016/0304-3940(92)90688-4; HASSAN AHS, 1993, NEUROSCIENCE, V55, P185, DOI 10.1016/0306-4522(93)90465-R; HEJINEN CJ, 1991, IMMUNOL REV, V119, P41; HOLLT V, 1986, ANNU REV PHARMACOL, V26, P59, DOI 10.1146/annurev.pa.26.040186.000423; JOSHI GP, 1993, BRIT J ANAESTH, V70, P87, DOI 10.1093/bja/70.1.87; JOSHI GP, 1992, J BONE JOINT SURG BR, V74, P749, DOI 10.1302/0301-620X.74B5.1527127; KHOURY GF, 1992, ANESTHESIOLOGY, V77, P263, DOI 10.1097/00000542-199208000-00007; LAWRENCE AJ, 1992, EUR J CLIN PHARMACOL, V43, P351, DOI 10.1007/BF02220608; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; MELZACK R, 1965, SCIENCE, V150, P971, DOI 10.1126/science.150.3699.971; MILLAN MJ, 1986, PAIN, V27, P303, DOI 10.1016/0304-3959(86)90158-2; PRZEWLOCKI R, 1992, NEUROSCIENCE, V48, P491, DOI 10.1016/0306-4522(92)90509-Z; ROQUES BP, 1990, TRENDS PHARMACOL SCI, V11, P245; SIBINGA NES, 1988, ANNU REV IMMUNOL, V6, P219; STEIN C, 1990, P NATL ACAD SCI USA, V87, P5935, DOI 10.1073/pnas.87.15.5935; STEIN C, 1990, J NEUROSCI, V10, P1292; STEIN C, 1993, ANESTH ANALG, V76, P182; STEIN C, 1988, PAIN, V32, P251, DOI 10.1016/0304-3959(88)90074-7; STEIN C, 1991, NEW ENGL J MED, V325, P1168; YOSHINO S, 1992, J RHEUMATOL, V19, P660; ZAR JH, 1984, BIOSTAT ANAL, P138	25	251	262	0	17	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 7	1993	342	8867					321	324		10.1016/0140-6736(93)91471-W	http://dx.doi.org/10.1016/0140-6736(93)91471-W			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ868	8101583	hybrid			2022-12-28	WOS:A1993LQ86800009
J	KOCOVA, M; SIEGEL, SF; WENGER, SL; LEE, PA; TRUCCO, M				KOCOVA, M; SIEGEL, SF; WENGER, SL; LEE, PA; TRUCCO, M			DETECTION OF Y-CHROMOSOME SEQUENCES IN TURNERS-SYNDROME BY SOUTHERN BLOT ANALYSIS OF AMPLIFIED DNA	LANCET			English	Article							MARKER CHROMOSOMES; MOSAICISM; GONADOBLASTOMA; GROWTH	Only about half of all patients with Turner's syndrome are monosomy 45,X on karyotyping and there are grounds for supposing that cryptic mosaicism for at least part of the Y chromosome may be present in some patients. If so this would be clinically important because of the risk to patients of gonadal neoplasms and virilisation. We have used a very sensitive method to detect Y chromosomal segments in eighteen patients with Turner's syndrome, none of whom had evidence of Y chromosomal material by cytogenetic analysis. In DNA from peripheral blood lymphocytes and/or fibroblasts we looked for specific nucleotide sequences from the sex-determining region of the Y chromosome (SRY gene) and repetitive sequences located at the centromeric region (DYZ3). By polymerase chain amplification (PCR) one patient had a definite positive signal and two patients had faintly positive signals for the SRY gene. Southern blot analysis of PCR material with a SRY-specific probe confirmed that these patients were positive for SRY and revealed another three. No patient was positive for DYZ3, suggesting that only a small portion of Y was present. These results suggest that ''pure'' 45,X monosomy is less frequent than previously supposed. Long-term follow-up of patients with Y sequences is needed to determine their risk for subsequent gonadal neoplasms and virilisation.	UNIV PITTSBURGH,CHILDRENS HOSP PITTSBURGH,DEPT PEDIAT,PITTSBURGH,PA 15213; UNIV PITTSBURGH,CHILDRENS HOSP PITTSBURG,RANGOES RES CTR,DIV ENDOCRINOL,PITTSBURGH,PA 15213; UNIV PITTSBURGH,CHILDRENS HOSP PITTSBURGH,RANGOES CTR,DIV MED GENET,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh								ARANOFF GS, 1988, J ADOLESCENT HEALTH, V9, P501, DOI 10.1016/S0197-0070(88)80011-1; BONAKDAR MI, 1980, OBSTET GYNECOL, V56, P748; BOSZE P, 1989, GYNECOL OBSTET INVES, V28, P113, DOI 10.1159/000293544; DEARCE MA, 1992, CLIN GENET, V41, P28; DOMINGUEZ CJ, 1962, AM J OBSTET GYNECOL, V83, P674, DOI 10.1016/S0002-9378(16)35898-7; GEMMILL RM, 1987, AM J HUM GENET, V41, P157; HASSOLD T, 1988, AM J HUM GENET, V42, P534; HELD KR, 1992, HUM GENET, V88, P288; HOOK EB, 1983, HUM GENET, V64, P24, DOI 10.1007/BF00289473; JACOBS PA, 1990, ANN HUM GENET, V54, P209, DOI 10.1111/j.1469-1809.1990.tb00379.x; LIN CC, 1990, AM J MED GENET, V37, P71, DOI 10.1002/ajmg.1320370117; LINDSAY AN, 1981, AM J MED GENET, V10, P21, DOI 10.1002/ajmg.1320100104; MAGENIS RE, 1984, J PEDIATR-US, V105, P916, DOI 10.1016/S0022-3476(84)80077-3; MAGENIS RE, 1980, AM J HUM GENET, V32, pA79; MEDLEJ R, 1922, J CLIN ENDOCR METAB, V75, P1289; MULLER U, 1987, HUM GENET, V75, P109, DOI 10.1007/BF00591069; NAKAGOME Y, 1991, AM J MED GENET, V41, P112, DOI 10.1002/ajmg.1320410127; PAGE DC, 1987, DEVELOPMENT, V101, P151; PARK E, 1983, PEDIATR RES, V17, P1; RANKE MB, 1983, EUR J PEDIATR, V141, P81, DOI 10.1007/BF00496795; ROSEN GF, 1988, OBSTET GYNECOL, V71, P677; SHAH KD, 1988, AM J CLIN PATHOL, V90, P622, DOI 10.1093/ajcp/90.5.622; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; SINISI AA, 1988, CLIN ENDOCRINOL, V28, P187, DOI 10.1111/j.1365-2265.1988.tb03655.x; STARZL TE, 1992, LANCET, V340, P876, DOI 10.1016/0140-6736(92)93286-V; WARBURTON PE, 1991, GENOMICS, V11, P325	26	53	53	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 17	1993	342	8864					140	143		10.1016/0140-6736(93)91345-M	http://dx.doi.org/10.1016/0140-6736(93)91345-M			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN042	8101256				2022-12-28	WOS:A1993LN04200011
J	OSULLIVAN, C; LEWIS, CE; HARRIS, AL; MCGEE, JO				OSULLIVAN, C; LEWIS, CE; HARRIS, AL; MCGEE, JO			SECRETION OF EPIDERMAL GROWTH-FACTOR BY MACROPHAGES ASSOCIATED WITH BREAST-CARCINOMA	LANCET			English	Note							CANCER; CELLS	By means of a cytokine release assay we have shown that in cell populations derived from primary breast carcinoma, epidermal growth factor (EGF) is secreted by cells with the characteristic morphological and immunophenotypic profile of activated macrophages (positive for CD68, CD16, CD25). EGF secretion was observed in 11 (31%) of 35 primary tumours. Secretion of EGF by normal or malignant epithelial cells was not observed. We found no association between EGF secretion by the primary tumour and recognised clinical indices of prognosis.	JOHN RADCLIFFE HOSP,INST MOLEC MED,ICRF,CLIN ONCOL UNIT,OXFORD OX3 9DU,ENGLAND	University of Oxford	OSULLIVAN, C (corresponding author), JOHN RADCLIFFE HOSP,DEPT PATHOL & BACTERIOL,LEVEL 4,OXFORD OX3 9DU,ENGLAND.		Sroka, Isis C/A-2949-2009; Harris, Adrian L/ABA-3343-2020	Harris, Adrian L/0000-0003-1376-8409				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BURGESS AW, 1989, BRIT MED BULL, V45, P401, DOI 10.1093/oxfordjournals.bmb.a072331; DOTZLAW H, 1990, CANCER RES, V50, P4204; Harris A L, 1989, Recent Results Cancer Res, V113, P70; LEWIS CE, 1990, J IMMUNOL METHODS, V127, P51, DOI 10.1016/0022-1759(90)90340-2; MANTOVANI A, 1992, IMMUNOL TODAY, V13, P265, DOI 10.1016/0167-5699(92)90008-U; MIZUKAMI Y, 1991, ANTICANCER RES, V11, P1485; WHALEN GF, 1990, LANCET, V336, P1489, DOI 10.1016/0140-6736(90)93188-U	8	117	120	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 17	1993	342	8864					148	149		10.1016/0140-6736(93)91348-P	http://dx.doi.org/10.1016/0140-6736(93)91348-P			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN042	8101258				2022-12-28	WOS:A1993LN04200014
J	ERNST, E				ERNST, E			COMPLEMENTARY MEDICINE - SCRUTINIZING THE ALTERNATIVES	LANCET			English	Editorial Material											ERNST, E (corresponding author), UNIV VIENNA,SCH MED,DEPT PHYS MED & REHABIL,A-1010 VIENNA,AUSTRIA.							DELUZE C, 1992, BRIT MED J, V305, P1249, DOI 10.1136/bmj.305.6864.1249; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; ERNST E, 1990, BRIT J CLIN PHARMACO, V30, P173, DOI 10.1111/j.1365-2125.1990.tb03761.x; ERNST E, 1992, PHLEBOLOGY, V7, P154, DOI 10.1177/026835559200700407; Ernst E, 1990, PHYSIOTHERAPY, V76, P207; FULDER SJ, 1985, LANCET, V2, P542; KLEIJNEN J, 1992, LANCET, V340, P1236; SHEKELLE PG, 1992, ANN INTERN MED, V117, P590, DOI 10.7326/0003-4819-117-7-590	8	26	26	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 26	1993	341	8861					1626	1626		10.1016/0140-6736(93)90763-7	http://dx.doi.org/10.1016/0140-6736(93)90763-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ727	8099995				2022-12-28	WOS:A1993LJ72700009
J	TAYLORROBINSON, AW; PHILLIPS, RS; SEVERN, A; MONCADA, S; LIEW, FY				TAYLORROBINSON, AW; PHILLIPS, RS; SEVERN, A; MONCADA, S; LIEW, FY			THE ROLE OF T(H)1 AND T(H)2 CELLS IN A RODENT MALARIA INFECTION	SCIENCE			English	Article							NITRIC-OXIDE; PLASMODIUM-CHABAUDI; L-ARGININE; RECRUDESCENT PARASITEMIAS; MODULATION; MICE	CD4+ T cells play a major role in protective immunity against the blood stage of malaria, but the mechanism of protection is unclear. By adoptive transfer of cloned T cell lines, direct evidence is provided that both T(H)1 and T(H)2 subsets of CD4+ T cells can protect mice against Plasmodium chabaudi chabaudi infection. T(H)1 cells protect by a nitric oxide-dependent mechanism, whereas T(H)2 cells protect by the enhancement and accelerated production of specific immunoglobulin G1 antibody.	UNIV GLASGOW,DEPT IMMUNOL,GLASGOW G11 6NT,SCOTLAND; WELLCOME RES LABS,BECKENHAM BR3 3BS,KENT,ENGLAND	University of Glasgow; GlaxoSmithKline; Wellcome Research Laboratories	TAYLORROBINSON, AW (corresponding author), UNIV GLASGOW,WELLCOME LABS EXPTL PARASITOL,GLASGOW G61 1QH,SCOTLAND.		Taylor-Robinson, Andrew/R-2805-2019	Taylor-Robinson, Andrew/0000-0001-7342-8348	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		COBBOLD SP, 1984, NATURE, V312, P548, DOI 10.1038/312548a0; KNOWLES RG, 1992, TRENDS BIOCHEM SCI, V17, P399, DOI 10.1016/0968-0004(92)90008-W; LANGHORNE J, 1989, PARASITOL TODAY, V5, P362, DOI 10.1016/0169-4758(89)90113-0; LEIST TP, 1984, J IMMUNOL, V138, P548; LIEW FY, 1991, EUR J IMMUNOL, V21, P2489, DOI 10.1002/eji.1830211027; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; MCLEAN SA, 1982, EXP PARASITOL, V54, P296, DOI 10.1016/0014-4894(82)90038-8; MCLEAN SA, 1982, EXP PARASITOL, V54, P213, DOI 10.1016/0014-4894(82)90129-1; MELLOUK S, 1991, J IMMUNOL, V146, P3971; MONACO AP, 1966, ANN NY ACAD SCI, V129, P190, DOI 10.1111/j.1749-6632.1966.tb12851.x; MONCADA S, 1991, PHARMACOL REV, V43, P109; MOSMANN TR, 1987, IMMUNOL TODAY, V8, P223, DOI 10.1016/0167-5699(87)90171-X; NUSSLER A, 1991, EUR J IMMUNOL, V21, P227, DOI 10.1002/eji.1830210134; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PHILLIPS RS, 1992, IMMUNOBIOLOGY, V184, P240, DOI 10.1016/S0171-2985(11)80478-X; ROCKETT KA, 1991, INFECT IMMUN, V59, P3280, DOI 10.1128/IAI.59.9.3280-3283.1991; ROCKETT KA, 1992, INFECT IMMUN, V60, P3725, DOI 10.1128/IAI.60.9.3725-3730.1992; SEPPALA I, 1981, SCAND J IMMUNOL, V14, P335, DOI 10.1111/j.1365-3083.1981.tb00573.x; STEVENSON MM, 1986, INFECT IMMUN, V54, P600, DOI 10.1128/IAI.54.2.600-602.1986; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; TAYLOR DW, 1990, MALARIA HOST RESPONS, P1; TAYLORROBINSON AW, 1992, IMMUNOLOGY, V77, P99	22	348	360	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 25	1993	260	5116					1931	1934		10.1126/science.8100366	http://dx.doi.org/10.1126/science.8100366			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LJ349	8100366				2022-12-28	WOS:A1993LJ34900040
J	LIMOUSIN, P; POLLAK, P; GERVASONTOURNIER, CL; HOMMEL, M; PERRET, JE				LIMOUSIN, P; POLLAK, P; GERVASONTOURNIER, CL; HOMMEL, M; PERRET, JE			RO-40-7592, A COMT INHIBITOR, PLUS LEVODOPA IN PARKINSONS-DISEASE	LANCET			English	Letter											LIMOUSIN, P (corresponding author), JOSEPH FOURIER UNIV GRENOBLE,DEPT CLIN & BIOL NEUROSCI,F-38043 GRENOBLE,FRANCE.							BRANNAN T, 1992, NEUROLOGY, V42, P683, DOI 10.1212/WNL.42.3.683; ZURCHER G, 1993, ADV NEUROL, V60, P641	2	40	40	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 19	1993	341	8860					1605	1605		10.1016/0140-6736(93)90750-B	http://dx.doi.org/10.1016/0140-6736(93)90750-B			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH550	8099689				2022-12-28	WOS:A1993LH55000058
J	BOURGUIGNON, JP; PIERARD, GE; ERNOULD, C; HEINRICHS, C; CRAEN, M; ROCHICCIOLI, P; ARRESE, JE; FRANCHIMONT, C				BOURGUIGNON, JP; PIERARD, GE; ERNOULD, C; HEINRICHS, C; CRAEN, M; ROCHICCIOLI, P; ARRESE, JE; FRANCHIMONT, C			EFFECTS OF HUMAN GROWTH-HORMONE THERAPY ON MELANOCYTIC NEVI	LANCET			English	Note							MONOCLONAL-ANTIBODY; HMB-45; MELANOMA; RECOGNIZES; TUMORS; NEVI	Melanocytic naevi may grow more rapidly during human growth hormone (hGH) therapy. With standardised skin photographs, the growth rate of the naevi was two-fold greater in 14 hypopituitary and 5 Turner's syndrome girls treated with hGH than in untreated patients or controls. HMB-45 immunoreactivity, a marker of stimulated melanocytes, was absent in naevi from 18 of 19 individuals not treated with hGH, including 5 Turner's syndrome patients studied 2-43 months after stopping hGH. In naevi from 39 hGH-treated patients, 22 showed unusual HMB-45 reactivity in dermal naevocytes. During administration of hGH, melanocytic naevi grow faster and there is reversible stimulation of naevocytes.	STATE UNIV LIEGE,CHU SART TILMAN,DERMATOPATHOL LAB,B-4000 SART,BELGIUM; UNIV BRUSSELS,DEPT PAEDIAT,GHENT,BELGIUM	University of Liege	BOURGUIGNON, JP (corresponding author), STATE UNIV LIEGE,CHR CITADELLE,DEPT PAEDIAT,B-4000 LIEGE,BELGIUM.							COOKE KR, 1988, MELANOMA NAEVI INCID, P8; GOWN AM, 1986, AM J PATHOL, V123, P195; NIKKELS A, 1991, ANAL QUANT CYTOL, V13, P23; OAKES SR, 1992, J CLIN ENDOCR METAB, V75, P1366; PALAZZO JP, 1988, J CUTAN PATHOL, V15, P166, DOI 10.1111/j.1600-0560.1988.tb00537.x; PALMER CG, 1976, HUM GENET, V35, P35, DOI 10.1007/BF00295617; SMOLLER BR, 1989, J CUTAN PATHOL, V16, P49, DOI 10.1111/j.1600-0560.1989.tb00010.x; SMOLLER BR, 1989, AM J SURG PATHOL, V13, P680, DOI 10.1097/00000478-198908000-00006; SMOLLER BR, 1991, J CUTAN PATHOL, V18, P315, DOI 10.1111/j.1600-0560.1991.tb01542.x; WICK MR, 1988, J CUTAN PATHOL, V15, P201, DOI 10.1111/j.1600-0560.1988.tb00544.x	10	68	70	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 12	1993	341	8859					1505	1506		10.1016/0140-6736(93)90636-U	http://dx.doi.org/10.1016/0140-6736(93)90636-U			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LG242	8099381	Green Submitted			2022-12-28	WOS:A1993LG24200005
J	LAU, JYN; DAVIS, GL; KNIFFEN, J; QIAN, KP; URDEA, MS; CHAN, CS; MIZOKAMI, M; NEUWALD, PD; WILBER, JC				LAU, JYN; DAVIS, GL; KNIFFEN, J; QIAN, KP; URDEA, MS; CHAN, CS; MIZOKAMI, M; NEUWALD, PD; WILBER, JC			SIGNIFICANCE OF SERUM HEPATITIS-C VIRUS-RNA LEVELS IN CHRONIC HEPATITIS-C	LANCET			English	Article							NON-B-HEPATITIS; RECOMBINANT INTERFERON-ALFA; NON-A-HEPATITIS; CONTROLLED TRIAL; ANTIBODIES; THERAPY; GENOME	Hepatitis C virus (HCV) is the main cause of parenteral non-A, non-B hepatitis and serum can be tested for the virus itself by reverse-transcription polymerase chain amplificaton. What of the level of this viraemia? To find out if quantitative study of HCV RNA might be useful clinically we took advantage of participation in trials of interferon-alpha in patients with chronic HCV infection and applied a new assay, branched DNA (bDNA) signal amplification. Paired serum and liver biopsy specimens from 47 patients with confirmed chronic HCV infection and evidence of HCV RNA in their serum were studied. The quantitative bDNA assay (detection limit 350 000 equivalents/mL [eq/mL]) was positive in 34 sera (sensitivity 72%). Patients who acquired HCV infection by blood transfusion had a higher viraemia (median 2701 000 eq/mL, n = 29) than health workers and intravenous drug users (635 000 eq/mL, n = 13; p < 0.01). Patients with a sustained complete response to interferon-alpha therapy had lower pre-treatment viraemia levels (median at bDNA cut-off, n = 11) than complete responders who relapsed after the drug was stopped (1613 000 eq/mL, n = 15; p < 0.01) and non-responders (3066 000 eq/mL, n = 20; p < 0.01). High viraemia levels were not related to the histological diagnosis but were associated with lobular inflammation, lymphoid aggregates, and bileduct lesions. These findings indicate that mode of acquisition is an important determinant of HCV viraemia and that patients with low HCV viraemia levels are more likely to respond to interferon in a sustained fashion.	CHIRON CORP,EMERYVILLE,CA; NAGOYA CITY UNIV,SCH MED,DEPT MED 2,NAGOYA,AICHI 467,JAPAN	Novartis; Nagoya City University	LAU, JYN (corresponding author), UNIV FLORIDA,DEPT MED,DIV GASTROENTEROL HEPATOL & NUTR,HEPATOBILIARY DIS SECT,GAINESVILLE,FL 32610, USA.		Yang, Chen/G-1379-2010		NCRR NIH HHS [5M01RR 82] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; BUSCH MP, 1992, TRANSFUSION, V32, P420, DOI 10.1046/j.1537-2995.1992.32592327714.x; CHA TA, 1992, P NATL ACAD SCI USA, V89, P7144, DOI 10.1073/pnas.89.15.7144; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DAVIS GL, 1992, HEPATOLOGY, V16, P4; DIBISCEGLIE AM, 1989, NEW ENGL J MED, V321, P1506, DOI 10.1056/NEJM198911303212204; ESTEBAN JI, 1989, LANCET, V2, P294; GUNJI T, 1992, INT J CANCER, V52, P726, DOI 10.1002/ijc.2910520510; KATO N, 1990, P NATL ACAD SCI USA, V87, P9524, DOI 10.1073/pnas.87.24.9524; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; KRAWCZYNSKI K, 1992, GASTROENTEROLOGY, V103, P622, DOI 10.1016/0016-5085(92)90856-T; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; LAU JYN, 1993, J HEPATOL, V17, P253, DOI 10.1016/S0168-8278(05)80047-9; LAU JYN, 1992, HEPATOLOGY S, V16; LIN HJ, 1987, J VIROL METHODS, V15, P139, DOI 10.1016/0166-0934(87)90057-7; LIN HJ, IN PRESS VIRUS RES; LIN HJ, 1992, J MED VIROL, V3, P220; MISHIRO S, 1990, LANCET, V336, P1400, DOI 10.1016/0140-6736(90)93101-T; OKADA S, 1992, HEPATOLOGY, V16, P619, DOI 10.1002/hep.1840160302; SANCHEZPESCADOR R, 1992, HEPATOLOGY, V16, P588; SHINDO M, 1991, ANN INTERN MED, V115, P700, DOI 10.7326/0003-4819-115-9-700; Urdea M S, 1991, Nucleic Acids Symp Ser, P197; URDEA MS, 1990, LUMINESCENCE IMMUNOA, P275; WEINER AJ, 1990, LANCET, V335, P1, DOI 10.1016/0140-6736(90)90134-Q; YOSHIOKA K, 1992, HEPATOLOGY, V16, P293, DOI 10.1002/hep.1840160203; 1977, LANCET, V2, P914	29	827	832	1	12	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 12	1993	341	8859					1501	1504		10.1016/0140-6736(93)90635-T	http://dx.doi.org/10.1016/0140-6736(93)90635-T			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LG242	8099380				2022-12-28	WOS:A1993LG24200004
J	ROTHENBERG, LS				ROTHENBERG, LS			HEALTH-CARE - MOLECULAR MEDICINE IN THE UNITED-STATES - CAN 3 PARADIGMS SHIFT SIMULTANEOUSLY	LANCET			English	Editorial Material											ROTHENBERG, LS (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, LOS ANGELES, CA USA.							BOSK CL, 1992, ALL GODS MISTAKES GE, P154; Dowling J J, 1991, Hawaii Med J, V50, P416; FLETCHER RH, 1989, J GEN INTERN MED, V4, P357, DOI 10.1007/BF02597412; FREYMANN JG, 1989, J GEN INTERN MED, V4, P313, DOI 10.1007/BF02597404; GREENFIELD S, 1992, MED CARE, V30, pMS23, DOI 10.1097/00005650-199205001-00003; KATZ AM, 1991, J MOL CELL CARDIOL, V23, P403, DOI 10.1016/0022-2828(91)90164-H; Kuhn T.S., 1970, STRUCTURE SCI REVOLU, P174; Muller-Smith P A, 1992, J Post Anesth Nurs, V7, P278; 1989, BUS HEALTH, V7, P8	9	2	2	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 29	1993	341	8857					1379	1380		10.1016/0140-6736(93)90948-G	http://dx.doi.org/10.1016/0140-6736(93)90948-G			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE180	8098797				2022-12-28	WOS:A1993LE18000011
J	VERMYLEN, J; BRIET, E				VERMYLEN, J; BRIET, E			FACTOR-VIII PREPARATIONS - NEED FOR PROSPECTIVE PHARMACOVIGILANCE	LANCET			English	Editorial Material							FACTOR-IX INHIBITORS; HEMOPHILIACS; CONCENTRATE		LEIDEN UNIV,DEPT HAEMATOL,2300 RA LEIDEN,NETHERLANDS; LEIDEN UNIV,DIV BLEEDING & VASC DISORDERS,2300 RA LEIDEN,NETHERLANDS	Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC	VERMYLEN, J (corresponding author), LEIDEN UNIV,CTR MOLEC & VASC BIOL,2300 RA LEIDEN,NETHERLANDS.							ADDIEGO J, 1993, LANCET, V342, P462, DOI 10.1016/0140-6736(93)91593-B; ADDIEGO JE, 1992, THROMB HAEMOSTASIS, V67, P19; BRAY GL, 1993, THROMB HAEMOSTASIS, V69, P1205; DEBIASI R, 1991, BLOOD, V78, P1919; EHRENFORTH S, 1992, LANCET, V339, P594, DOI 10.1016/0140-6736(92)90874-3; GUEROIS C, 1993, THROMB HAEMOSTASIS, V69, P852; LUSHER JM, 1993, NEW ENGL J MED, V328, P453, DOI 10.1056/NEJM199302183280701; MANNUCCI PM, 1993, THROMB HAEMOSTASIS, V70, P17; PASI KJ, 1987, LANCET, V1, P689; PEERLINCK K, 1993, THROMB HAEMOSTASIS, V69, P115; PEERLINCK K, 1993, BLOOD, V81, P3332; ROSENDAAL FR, 1993, BLOOD, V81, P2180	12	15	15	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 18	1993	342	8873					693	694		10.1016/0140-6736(93)91702-N	http://dx.doi.org/10.1016/0140-6736(93)91702-N			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX469	8103816				2022-12-28	WOS:A1993LX46900003
J	WADDINGTON, JL				WADDINGTON, JL			SIGHT AND INSIGHT - VISUALIZATION OF AUDITORY HALLUCINATIONS IN SCHIZOPHRENIA	LANCET			English	Editorial Material											WADDINGTON, JL (corresponding author), ROYAL COLL SURGEONS IRELAND,DEPT CLIN PHARMACOL,DUBLIN 2,IRELAND.							CLEGHORN JM, 1992, AM J PSYCHIAT, V149, P1062; DAVID AS, 1993, NEUROPSYCHOLOGY SCHI, P269; HINKE RM, 1993, NEUROREPORT, V4, P675, DOI 10.1097/00001756-199306000-00018; LIDDLE PF, 1992, BRIT J PSYCHIAT, V160, P179, DOI 10.1192/bjp.160.2.179; MCCARTHY G, 1993, P NATL ACAD SCI USA, V90, P4952, DOI 10.1073/pnas.90.11.4952; PAULESU E, 1993, NATURE, V362, P342, DOI 10.1038/362342a0; SUZUKI M, 1993, EUR ARCH PSY CLIN N, V242, P257, DOI 10.1007/BF02190383; TAMMINGA CA, 1992, ARCH GEN PSYCHIAT, V49, P522; WADDINGTON JL, 1993, LANCET, V341, P531, DOI 10.1016/0140-6736(93)90288-R	9	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 18	1993	342	8873					692	693		10.1016/0140-6736(93)91701-M	http://dx.doi.org/10.1016/0140-6736(93)91701-M			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LX469	8103815				2022-12-28	WOS:A1993LX46900002
J	INMAN, W; PEARCE, G				INMAN, W; PEARCE, G			PRESCRIBER PROFILE AND POSTMARKETING SURVEILLANCE	LANCET			English	Article								The response rate to requests to general practitioners (GPs) to supply post-marketing data on new drugs has been falling within the prescription-event monitoring (PEM) system organised by the Drug Safety Research Unit in Southampton, UK. To find out why, we looked at the characteristics of prescribers and the pattern of their prescribing for twenty seven PEM drugs and 543 788 treatments dispensed in England between September, 1984, and June, 1991. 28 402 GPs identified during PEM studies were divided into six groups according to the largest number of prescriptions for one or more of the drugs, ranging from group 1 (none of the drugs prescribed) to group 6 (one or more drugs for over 60 patients). From group 1 to group 6 the proportion of the GPs who were women decreased from 46% to 9%, and the proportion of overseas-qualified doctors increased from 13% to 47%. 10% of doctors who had prescribed most heavily accounted for 42% of total prescribing. 19 doctors had each prescribed a drug for more than 120 patients during the early post-marketing period. There was a consistent inverse relation between the number of prescriptions and the resonse to requests for post-marketing information. The overall response was 53% but the heaviest 10% of prescribers returned only 44% and the heaviest 1% returned only 34% of questionnaires. No differences in medical need can account for such variations in prescribing practice. Heavy prescribing by a minority of doctors during the period immediately following licensing for marketing may be placing patients at unnecessary risk. These doctors also affect the success of attempts to monitor the safety of new drugs.			INMAN, W (corresponding author), DRUG SAFETY RES UNIT,BURLESDON HALL,SOUTHAMPTON SO3 8BA,ENGLAND.							FINNEY DJ, 1965, J CHRON DIS, V18, P77, DOI 10.1016/0021-9681(65)90054-8; INMAN WHW, 1986, MONITORING DRUG SAFE, P213; INMAN WHW, 1977, DRUG MONITORING, P65; RAWSON NSB, 1990, J CLIN EPIDEMIOL, V43, P509, DOI 10.1016/0895-4356(90)90140-K; WALLER PC, 1992, BRIT MED J, V304, P1470, DOI 10.1136/bmj.304.6840.1470; WRIGHT P, 1975, BRIT MED J, V1, P595, DOI 10.1136/bmj.1.5958.595	6	63	64	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 11	1993	342	8872					658	661		10.1016/0140-6736(93)91763-C	http://dx.doi.org/10.1016/0140-6736(93)91763-C			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX272	8103150				2022-12-28	WOS:A1993LX27200014
J	TOVO, PA				TOVO, PA			CESAREAN-SECTION AND PERINATAL HIV TRANSMISSION - WHAT NEXT	LANCET			English	Editorial Material							IMMUNODEFICIENCY-VIRUS TYPE-1; INFECTION				TOVO, PA (corresponding author), UNIV TURIN,DEPT PAEDIAT,I-10124 TURIN,ITALY.			Tovo, Pier Angelo/0000-0002-0192-3240				BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; GABIANO C, 1992, PEDIATRICS, V90, P362; GOEDERT JJ, 1991, LANCET, V338, P1471, DOI 10.1016/0140-6736(91)92297-F; HUTTO C, 1991, J PEDIATR-US, V118, P347, DOI 10.1016/S0022-3476(05)82145-6; KIND C, 1992, EUR J PEDIATR, V151, P442, DOI 10.1007/BF01959360; LINDGREN S, 1991, AIDS, V5, P1111, DOI 10.1097/00002030-199109000-00009; NAIR P, 1993, J ACQ IMMUN DEF SYND, V6, P298; VILLARI P, 1993, ONLINE J CURR C 0708; 1992, LANCET, V339, P1007	9	15	15	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 11	1993	342	8872					630	630		10.1016/0140-6736(93)91753-9	http://dx.doi.org/10.1016/0140-6736(93)91753-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX272	8103140				2022-12-28	WOS:A1993LX27200004
J	ELTUMI, M; TRIVEDI, P; HOBBS, JR; PORTMANN, B; CHEESEMAN, P; DOWNIE, C; RISTELI, J; RISTELI, L; MOWAT, AP				ELTUMI, M; TRIVEDI, P; HOBBS, JR; PORTMANN, B; CHEESEMAN, P; DOWNIE, C; RISTELI, J; RISTELI, L; MOWAT, AP			MONITORING OF VENOOCCLUSIVE DISEASE AFTER BONE-MARROW TRANSPLANTATION BY SERUM AMINOPROPEPTIDE OF TYPE-III PROCOLLAGEN	LANCET			English	Article							AMINO-TERMINAL PROPEPTIDE; LIVER; CHILDREN; MARKERS	Differential diagnosis of hepatic complications after bone marrow transplantation (BMT) is often difficult. To assess whether serum concentrations of the aminopropeptide of type III procollagen (PIIINP) could facilitate diagnosis,we measured serum PIIINP, corrected for age by conversion to standard deviation scores (SDS), serially after BMT in 27 children. A preliminary study of 11 patients showed that a PNIIINP-SDS cutoff of 8.0 was an optimum for diagnosis of veno-occlusive disease (VOD). PIIINP-SDS was increased above cut-off 1-25 days before the onset of clinical signs in the 12 patients (4 from the preliminary group, the others from a group of 16 studied prospectively) who developed VOD, with subsequent changes in PIIINP-SDS mirroring the course of VOD. By contrast, PIIINP-SDS remained below cut-off in all other patients, including 7 with liver graft-versus-host disease and 3 with drug hepatotoxicity. PIIINP-SDS values greater than 8.0 predict, diagnose, and monitor VOD after BMT.	WESTMINSTER MED SCH & HOSP,BONE MARROW TRANSPLANT UNIT,LONDON,ENGLAND; UNIV LONDON KINGS COLL HOSP,INST LIVER STUDIES,LONDON SE5 8RX,ENGLAND; UNIV OULU,DEPT CLIN CHEM,SF-90100 OULU 10,FINLAND; UNIV OULU,DEPT MED BIOCHEM,SF-90100 OULU 10,FINLAND; UNIV LONDON KINGS COLL HOSP,DEPT CHILD HLTH,LONDON SE5 8RX,ENGLAND	Imperial College London; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; University of Oulu; University of Oulu; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London				Risteli, Leila/0000-0002-5532-5895				EL-TUMI M, 1990, Bone Marrow Transplantation, V5, P116; HERSHKO C, 1980, BIOL BONE MARROW TRA, P56; HOBBS JR, 1986, BONE MARROW TRANSPL, V1, P201; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; MCDONALD GB, 1984, HEPATOLOGY, V4, P116, DOI 10.1002/hep.1840040121; MCDONALD GB, 1987, SEMIN LIVER DIS, V7, P210, DOI 10.1055/s-2008-1040578; PLEBANI M, 1991, CLIN BIOCHEM, V24, P219, DOI 10.1016/0009-9120(91)80013-S; RISTELI J, 1988, CLIN CHEM, V34, P715; SHULMAN HM, 1992, BONE MARROW TRANSPL, V10, P197; SMEDSROD B, 1988, COLLAGEN REL RES, V8, P375; TRIVEDI P, 1985, EUR J CLIN INVEST, V15, P69, DOI 10.1111/j.1365-2362.1985.tb00147.x; TRIVEDI P, 1987, HEPATOLOGY, V7, P1249, DOI 10.1002/hep.1840070612; TRIVEDI P, 1989, J PEDIATR-US, V114, P225, DOI 10.1016/S0022-3476(89)80787-5	13	39	39	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 28	1993	342	8870					518	521		10.1016/0140-6736(93)91646-4	http://dx.doi.org/10.1016/0140-6736(93)91646-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU582	8102667				2022-12-28	WOS:A1993LU58200009
J	OU, WJ; CAMERON, PH; THOMAS, DY; BERGERON, JJM				OU, WJ; CAMERON, PH; THOMAS, DY; BERGERON, JJM			ASSOCIATION OF FOLDING INTERMEDIATES OF GLYCOPROTEINS WITH CALNEXIN DURING PROTEIN MATURATION	NATURE			English	Article							ROUGH ENDOPLASMIC-RETICULUM; NEWLY SYNTHESIZED PROTEINS; INFLUENZA HEMAGGLUTININ; INTRACELLULAR-TRANSPORT; LINKED OLIGOSACCHARIDES; MOLECULAR CHAPERONE; ALPHA-SUBUNIT; COMPLEX; GLYCOSYLATION; SECRETION	Calnexin, an endoplasmic reticulum transmembrane protein, represents a new type of molecular chaperone that selectively associates in a transient fashion with newly synthesized monomeric glycoproteins in HepG2 cells. Calnexin only recognizes glycoproteins when they are incompletely folded. Dissociation of glycoproteins from calnexin occurs at different rates and is related to the time taken for their folding, which may then initiate their differential transport rates from the endoplasmic reticulum.	MCGILL UNIV,DEPT BIOL,MONTREAL H3A 2B2,QUEBEC,CANADA; NATL RES COUNCIL CANADA,BIOTECHNOL RES INST,EUKARYOT GENET GRP,MONTREAL H4P 2R2,PQ,CANADA	McGill University; National Research Council Canada	OU, WJ (corresponding author), MCGILL UNIV,DEPT ANAT & CELL BIOL,MONTREAL H3A 2B2,QUEBEC,CANADA.		Bergeron, John/AAW-1893-2021; Thomas, David/M-7661-2017	Thomas, David/0000-0002-8854-762X				AHLUWALIA N, 1992, J BIOL CHEM, V267, P10914; Amara J F, 1992, Trends Cell Biol, V2, P145, DOI 10.1016/0962-8924(92)90101-R; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; BROWN CR, 1993, J CELL BIOL, V120, P1101, DOI 10.1083/jcb.120.5.1101; CALLEA F, 1992, LIVER, V12, P357; DAVID V, 1993, J BIOL CHEM, V268, P9585; DEGEN E, 1992, J EXP MED, V175, P1653, DOI 10.1084/jem.175.6.1653; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; DORNER AJ, 1987, J CELL BIOL, V105, P2665, DOI 10.1083/jcb.105.6.2665; GALVIN K, 1992, P NATL ACAD SCI USA, V89, P8452, DOI 10.1073/pnas.89.18.8452; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Helenius Ari, 1992, Trends in Cell Biology, V2, P227, DOI 10.1016/0962-8924(92)90309-B; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; HURTLEY SM, 1989, J CELL BIOL, V108, P2117, DOI 10.1083/jcb.108.6.2117; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KIM PS, 1992, J CELL BIOL, V118, P541, DOI 10.1083/jcb.118.3.541; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LAW SW, 1981, NATURE, V291, P201, DOI 10.1038/291201a0; LODISH HF, 1991, J BIOL CHEM, V266, P14835; LODISH HF, 1988, J BIOL CHEM, V263, P2107; LODISH HF, 1983, NATURE, V304, P80, DOI 10.1038/304080a0; LODISH HF, 1984, J CELL BIOL, V98, P1720, DOI 10.1083/jcb.98.5.1720; MACHAMER CE, 1990, J BIOL CHEM, V265, P6879; MACHAMER CE, 1988, J BIOL CHEM, V263, P5955; MANNINGKRIEG UC, 1991, EMBO J, V10, P3273, DOI 10.1002/j.1460-2075.1991.tb04891.x; MARQUARDT T, 1992, J CELL BIOL, V117, P505, DOI 10.1083/jcb.117.3.505; MATZUK MM, 1988, J CELL BIOL, V106, P1049, DOI 10.1083/jcb.106.4.1049; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; REDMAN CM, 1972, J CELL BIOL, V52, P231, DOI 10.1083/jcb.52.2.231; WADA I, 1991, J BIOL CHEM, V266, P19599; WEITZ G, 1992, J BIOL CHEM, V267, P10039	35	520	531	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 26	1993	364	6440					771	776		10.1038/364771a0	http://dx.doi.org/10.1038/364771a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU581	8102790				2022-12-28	WOS:A1993LU58100046
J	BAILEY, RL; ARULLENDRAN, P; WHITTLE, HC; MABEY, DCW				BAILEY, RL; ARULLENDRAN, P; WHITTLE, HC; MABEY, DCW			RANDOMIZED CONTROLLED TRIAL OF SINGLE-DOSE AZITHROMYCIN IN TREATMENT OF TRACHOMA	LANCET			English	Article							CHLAMYDIA-TRACHOMATIS; ENDEMIC TRACHOMA; INVITRO ACTIVITY	Blindness due to trachoma is a serious public health issue world wide. The currently recommended treatment of active trachoma with repeated doses of tetracycline eye ointment has many disadvantages. The new azalide antibiotic azithromycin is effective as a single oral dose in the chemotherapy of genital Chlamydia trachomatis infections, and we have assessed its efficacy for trachoma treatment. We carried out a randomised single-blind comparison of azithromycin (a single oral dose of 20 mg/kg) with conventional treatment (6 weeks of topical tetracycline plus erythromycin for severe cases) in two villages with endemic trachoma in The Gambia. The patients were followed up for 26 weeks from the start of treatment by an observer unaware of treatment allocation. By 6 months' follow-up, trachoma had resolved in 76 (78%) of 97 subjects who received azithromycin compared with 70 (72%) of 97 who were treated conventionally (95% Cl for difference -6% to 18%). Compliance with both treatments was good, but that for conventional treatment could probably not be achieved outside the research setting. There were no significant differences in treatment effect, baseline characteristics, or re-emergent disease between the treatment groups. Azithromycin was well tolerated. As a systemic treatment effective in a single dose it has important potential for trachoma control.	UNIV LONDON LONDON SCH HYG & TROP MED, DEPT CLIN SCI, LONDON WC1E 7HT, ENGLAND; MRC LABS, FAJARA, SENEGAMBIA	University of London; London School of Hygiene & Tropical Medicine				Mabey, David/0000-0002-0031-8276				CHUMBLEY LC, 1988, EYE, V2, P471, DOI 10.1038/eye.1988.94; DAROUGAR S, 1980, BRIT J OPHTHALMOL, V64, P37, DOI 10.1136/bjo.64.1.37; Dawson CR, 1981, GUIDE TRACHOMA CONTR; MABEY D, 1993, LANCET, V341, P153, DOI 10.1016/0140-6736(93)90011-5; MABEY DCW, 1991, ANN TROP PAEDIATR, V11, P295, DOI 10.1080/02724936.1991.11747518; MALATY R, 1981, J INFECT DIS, V143, P853, DOI 10.1093/infdis/143.6.853; MARTIN DH, 1992, NEW ENGL J MED, V327, P921, DOI 10.1056/NEJM199209243271304; MARX R, 1988, ACTA OPHTHALMOL S183, V66, P8; SCHACHTER J, 1990, SCAND J INFECT DIS, P55; SCIEUX C, 1990, J ANTIMICROB CHEMOTH, V25, P7, DOI 10.1093/jac/25.suppl_A.7; SLANEY L, 1990, J ANTIMICROB CHEMOTH, V25, P1; STEINGRIMSSON O, 1990, J ANTIMICROB CHEMOTH, V25, P109, DOI 10.1093/jac/25.suppl_A.109; TAYLOR HR, 1989, ARCH OPHTHALMOL-CHIC, V107, P1821, DOI 10.1001/archopht.1989.01070020903037; WARD M, 1990, SCAND J INFECT DIS, P137; WEST S, 1989, B WORLD HEALTH ORGAN, V67, P71; WOOLRIDGE RL, 1967, AM J OPHTHALMOL, V63, P1577; 1984, STRATEIGES PREVENTIO	17	165	167	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 21	1993	342	8869					453	456		10.1016/0140-6736(93)91591-9	http://dx.doi.org/10.1016/0140-6736(93)91591-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU075	8102427				2022-12-28	WOS:A1993LU07500008
J	GIMSON, AES; RAMAGE, JK; PANOS, MZ; HAYLLAR, K; HARRISON, PM; WILLIAMS, R; WESTABY, D				GIMSON, AES; RAMAGE, JK; PANOS, MZ; HAYLLAR, K; HARRISON, PM; WILLIAMS, R; WESTABY, D			RANDOMIZED TRIAL OF VARICEAL BANDING LIGATION VERSUS INJECTION SCLEROTHERAPY FOR BLEEDING ESOPHAGEAL-VARICES	LANCET			English	Article							CONTROLLED CLINICAL-TRIAL; ESOPHAGEAL-VARICES; ENDOSCOPIC SCLEROTHERAPY; LIVER-TRANSPLANTATION; MANAGEMENT; HEMORRHAGE; SURVIVAL	Injection sclerotherapy of bleeding oesophageal varices is undoubtedly beneficial but it is associated with a substantial complication rate, and variceal rebleeding is common during the treatment period before variceal obliteration is achieved. We aimed to find out whether endoscopic variceal banding ligation is safer and more effective. The two methods were compared in a randomised controlled trial of 103 patients (54 assigned to banding ligation, and 49 to injection sclerotherapy) of whom 21 (39%) and 23 (47%), respectively, had active bleeding at index endoscopy. Both treatments were highly effective in controlling active haemorrhage (91% and 92% respectively). Variceal obliteration was not achieved for 22 patients in each group, but among those whose varices were eradicated, banding ligation achieved obliteration more quickly than did sclerotherapy (mean 39 [SD 4] vs 72 [7] days, p = 0.004) and in fewer endoscopy sessions (3.4 [2.2] vs 4.9 [3.5], p = 0.006). Rebleeding was less common in the banding ligation group than in the sclerotherapy group (16 [30%] vs 26 [53%], p < 0.05). There was no difference in outcome between the groups, but 14 sclerotherapy patients were withdrawn from the trial (7 for orthotopic liver transplantation) compared with only 5 (1 for liver transplantation) in the banding ligation group (p < 0.05). Complication rates were similar in the two groups. Variceal banding ligation is a safe and effective technique, which obliterates varices more quickly and with a lower rebleeding rate than injection sclerotherapy.	UNIV LONDON KINGS COLL HOSP,INST LIVER STUDIES,DENMARK HILL,LONDON SE5 9RS,ENGLAND; UNIV LONDON KINGS COLL,SCH MED & DENT,LONDON WC2R 2LS,ENGLAND	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; University of London; King's College London			Harrison, Phillip M/D-5374-2009; Ramage, John/ABG-4603-2020	Ramage, John/0000-0003-4824-6600; opoku, anita/0000-0001-7243-8157				BURROUGHS AK, 1990, GASTROENTEROLOGY, V99, P1388, DOI 10.1016/0016-5085(90)91166-4; CRASS RA, 1989, AM J SURG, V157, P476, DOI 10.1016/0002-9610(89)90638-7; GARRETT KO, 1988, SURGERY, V104, P819; GIMSON A, 1990, GASTROENTEROLOGY, V99, P1829, DOI 10.1016/0016-5085(90)90495-M; GIMSON AES, 1991, J HEPATOL, V13, P274, DOI 10.1016/0168-8278(91)90068-M; GRAHAM DY, 1981, GASTROENTEROLOGY, V80, P800; GUADY H, 1989, GASTROINTEST ENDOSC, V35, P377; INFANTERIVARD C, 1989, GASTROENTEROLOGY, V96, P1087, DOI 10.1016/0016-5085(89)91627-2; IWATSUKI S, 1988, SURGERY, V104, P697; KAHN D, 1989, SURGERY, V105, P160; KORULA J, 1985, HEPATOLOGY, V5, P584, DOI 10.1002/hep.1840050410; POLSON R, 1989, HEPATOLOGY, V109, P279; SINGAL A, 1990, J CLIN GASTROENTEROL, V12, P250, DOI 10.1097/00004836-199006000-00003; STIEGMANN GV, 1988, AM SURGEON, V54, P105; STIEGMANN GV, 1992, NEW ENGL J MED, V326, P1527, DOI 10.1056/NEJM199206043262304; TERBLANCHE J, 1983, LANCET, V2, P1328; WESTABY D, 1984, GUT, V25, P129, DOI 10.1136/gut.25.2.129; WESTABY D, 1985, HEPATOLOGY, V5, P827, DOI 10.1002/hep.1840050520; WESTABY D, 1989, HEPATOLOGY, V9, P274, DOI 10.1002/hep.1840090219; 1986, NEW ENGL J MED, V311, P11	20	263	267	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 14	1993	342	8868					391	394		10.1016/0140-6736(93)92812-8	http://dx.doi.org/10.1016/0140-6736(93)92812-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR900	8101900				2022-12-28	WOS:A1993LR90000008
J	VANMEERWIJK, JPM; GERMAIN, RN				VANMEERWIJK, JPM; GERMAIN, RN			DEVELOPMENT OF MATURE CD8+ THYMOCYTES - SELECTION RATHER THAN INSTRUCTION	SCIENCE			English	Article							T-CELL RECEPTOR; THYMIC SELECTION; SEQUENTIAL APPEARANCE; SUBLETHAL IRRADIATION; NEGATIVE SELECTION; PRECURSOR CELLS; LYMPHOCYTES-T; MOUSE THYMUS; STEM-CELLS; CD4	The role of major histocompatibility complex (MHC) molecules in T cell differentiation was investigated by comparison of thymocyte subpopulations in wild-type mice and beta2-microglobulin (beta2M) mutant mice deficient in MHC class I expression and mature CD8+ cells. On the basis of surface markers, glucocorticoid resistance, in vitro differentiation capacity, and absence in beta2M-/- mice, CD4(intermediate)CD8hi cells with high expression of alphabeta T cell receptor (TCRalphabeta) were identified as having been positively selected by MHC class I for development into mature CD8+ T cells. Activated CD4(int)CD8hi cells bearing intermediate rather than high amounts of TCR were present in both wild-type and beta2M-/- animals. These data suggest that recognition of MHC class I molecules is required for full maturation to CD8+ T cells, but not for receptor-initiated commitment to the CD8+ lineage, consistent with a stochastic (selection) model of thymocyte development.	NIAID,IMMUNOL LAB,LYMPHOCYTE BIOL SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Germain, Ronald N./Z-1945-2019; van Meerwijk, Joost P.M./K-1345-2014; Germain, Ronald/ABE-7090-2020	van Meerwijk, Joost P.M./0000-0001-8231-1897; 				ARASE H, 1992, P NATL ACAD SCI USA, V89, P6506, DOI 10.1073/pnas.89.14.6506; ARASE H, 1993, EUR J IMMUNOL, V23, P307, DOI 10.1002/eji.1830230151; BENDELAC A, 1992, J EXP MED, V175, P731, DOI 10.1084/jem.175.3.731; BORGULYA P, 1991, EMBO J, V10, P913, DOI 10.1002/j.1460-2075.1991.tb08024.x; BOYD RL, 1991, IMMUNOL TODAY, V12, P71, DOI 10.1016/0167-5699(91)90161-L; CHAN SH, 1993, CELL, V73, P225, DOI 10.1016/0092-8674(93)90225-F; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; CRISPE IN, 1987, NATURE, V329, P336, DOI 10.1038/329336a0; DAVIS CB, 1993, CELL, V73, P237, DOI 10.1016/0092-8674(93)90226-G; ECKHARDT LA, 1980, IMMUNOGENETICS, V11, P275, DOI 10.1007/BF01567794; FOWLKES BJ, 1985, J EXP MED, V162, P802, DOI 10.1084/jem.162.3.802; GUIDOS CJ, 1990, J EXP MED, V172, P835, DOI 10.1084/jem.172.3.835; GUIDOS CJ, 1989, P NATL ACAD SCI USA, V86, P7542, DOI 10.1073/pnas.86.19.7542; HAYAKAWA K, 1992, J EXP MED, V176, P269, DOI 10.1084/jem.176.1.269; HUGO P, 1991, INT IMMUNOL, V3, P265, DOI 10.1093/intimm/3.3.265; HUGO P, 1991, EUR J IMMUNOL, V21, P2655, DOI 10.1002/eji.1830211103; HUGO P, 1990, INT IMMUNOL, V2, P209, DOI 10.1093/intimm/2.3.209; HUISKAMP R, 1985, J IMMUNOL, V134, P2161; KADISH JL, 1975, J IMMUNOL, V114, P452; KARIV I, 1993, J EXP MED, V177, P1429, DOI 10.1084/jem.177.5.1429; KISIELOW P, 1991, IMMUNOL REV, V122, P69, DOI 10.1111/j.1600-065X.1991.tb00597.x; KISIELOW P, 1984, J IMMUNOL, V133, P1117; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; KRUISBEEK AM, 1985, J EXP MED, V161, P1029, DOI 10.1084/jem.161.5.1029; MACDONALD HR, 1988, EUR J IMMUNOL, V18, P519, DOI 10.1002/eji.1830180405; MARUSICGALESIC S, 1988, NATURE, V333, P180, DOI 10.1038/333180a0; NIKOLICZUGIC J, 1991, IMMUNOL TODAY, V12, P65, DOI 10.1016/0167-5699(91)90160-U; OHASHI PS, 1990, NATURE, V346, P861, DOI 10.1038/346861a0; RAMSDELL F, 1991, J IMMUNOL, V147, P1779; Robey E A, 1990, Semin Immunol, V2, P25; ROBEY EA, 1991, CELL, V64, P99, DOI 10.1016/0092-8674(91)90212-H; SCOLLAY R, 1984, IMMUNOL REV, V82, P79, DOI 10.1111/j.1600-065X.1984.tb01118.x; SCOLLAY R, 1988, IMMUNOL REV, V104, P81, DOI 10.1111/j.1600-065X.1988.tb00760.x; SCOLLAY R, 1985, J IMMUNOL, V134, P3632; SEONG RH, 1992, NATURE, V356, P718, DOI 10.1038/356718a0; SHORTMAN K, 1991, J EXP MED, V173, P323, DOI 10.1084/jem.173.2.323; TAKAHAMA Y, 1992, SCIENCE, V258, P653, DOI 10.1126/science.1357752; TAKAHAMA Y, 1991, J IMMUNOL, V146, P1134; TOMOOKA S, 1987, J IMMUNOL, V139, P3986; VANEWIJK W, 1991, ANNU REV IMMUNOL, V9, P591, DOI 10.1146/annurev.iy.09.040191.003111; VONBOEHMER H, 1986, IMMUNOL TODAY, V7, P333; VONBOEHMER H, 1992, IMMUNOL TODAY, V13, P454, DOI 10.1016/0167-5699(92)90075-I; YOKOYAMA WM, 1988, J IMMUNOL, V141, P369; ZIJLSTRA M, 1989, NATURE, V342, P435, DOI 10.1038/342435a0; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0; ZUNIGAPFLUCKER JC, 1990, J IMMUNOL, V144, P3736; ZUNIGAPFLUCKER JC, 1989, J EXP MED, V169, P2085, DOI 10.1084/jem.169.6.2085	47	99	99	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 13	1993	261	5123					911	915		10.1126/science.8102208	http://dx.doi.org/10.1126/science.8102208			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR897	8102208				2022-12-28	WOS:A1993LR89700038
J	BLACK, J				BLACK, J			DEEP-VEIN THROMBOSIS AND PULMONARY-EMBOLISM	LANCET			English	Editorial Material																		BERGQVIST D, 1986, BRIT MED J, V292, P658, DOI 10.1136/bmj.292.6521.658-a; JULIAN DG, 1989, DISEASES HEART, P515; OGSTRON D, 1987, VENOUS THROMBOSIS CA, P52; SASAHARA AA, 1987, VENOUS THROMBOSIS PU, P128	4	20	20	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 7	1993	342	8867					352	353		10.1016/0140-6736(93)91480-A	http://dx.doi.org/10.1016/0140-6736(93)91480-A			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ868	8101590				2022-12-28	WOS:A1993LQ86800018
J	TOOLE, MJ				TOOLE, MJ			MILITARY ROLE IN HUMANITARIAN RELIEF IN SOMALIA	LANCET			English	Editorial Material											TOOLE, MJ (corresponding author), CTR DIS CONTROL & PREVENT,INT HLTH PROGRAM OFF,ATLANTA,GA 30333, USA.							Africa Rights, 1993, SOMALIA OPERATION RE; [Anonymous], MMWR; MOORE PS, 1993, LANCET, V341, P935, DOI 10.1016/0140-6736(93)91223-9; 1993, MMWR, V42, P304	4	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 24	1993	342	8865					190	191		10.1016/0140-6736(93)92292-2	http://dx.doi.org/10.1016/0140-6736(93)92292-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LN622	8100924				2022-12-28	WOS:A1993LN62200005
J	POPOV, SV; POO, MM				POPOV, SV; POO, MM			SYNAPTOTAGMIN - A CALCIUM-SENSITIVE INHIBITOR OF EXOCYTOSIS	CELL			English	Review											POPOV, SV (corresponding author), COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027, USA.							BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; DAN Y, 1992, NATURE, V359, P733, DOI 10.1038/359733a0; DIANTONIO A, 1993, CELL, V73, P1281, DOI 10.1016/0092-8674(93)90356-U; ELFERINK LA, 1993, CELL, V72, P153, DOI 10.1016/0092-8674(93)90059-Y; Holtzman E, 1992, Curr Opin Neurobiol, V2, P607, DOI 10.1016/0959-4388(92)90026-H; KELLY RB, 1993, CELL, V72, P43, DOI 10.1016/S0092-8674(05)80027-3; LEVEQUE C, 1992, P NATL ACAD SCI USA, V89, P3625, DOI 10.1073/pnas.89.8.3625; MATTHEW WD, 1981, J CELL BIOL, V91, P257, DOI 10.1083/jcb.91.1.257; NEHER E, 1993, NEURON, V10, P21, DOI 10.1016/0896-6273(93)90238-M; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; SHOJIKASAI Y, 1992, SCIENCE, V256, P1820, DOI 10.1126/science.256.5065.1820; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094	17	102	103	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 2	1993	73	7					1247	1249		10.1016/0092-8674(93)90352-Q	http://dx.doi.org/10.1016/0092-8674(93)90352-Q			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology	LL209	8100739	Bronze			2022-12-28	WOS:A1993LL20900001
J	MONCADA, S; MARTIN, JF				MONCADA, S; MARTIN, JF			VASODILATION - EVOLUTION OF NITRIC-OXIDE	LANCET			English	Editorial Material									UNIV LONDON KINGS COLL,SCH MED,LONDON WC2R 2LS,ENGLAND	University of London; King's College London	MONCADA, S (corresponding author), WELLCOME RES LABS,BECKENHAM BR3 3BS,KENT,ENGLAND.							MARKWARDT F, 1991, THROMB HAEMOSTASIS, V66, P141; MONCADA S, 1992, ACTA PHYSIOL SCAND, V145, P201, DOI 10.1111/j.1748-1716.1992.tb09359.x; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; RADOMSKI MW, 1991, PHILOS T ROY SOC B, V334, P129, DOI 10.1098/rstb.1991.0102; RIBEIRO JMC, 1990, BRIT J PHARMACOL, V101, P932, DOI 10.1111/j.1476-5381.1990.tb14183.x; RIBEIRO JMC, 1993, SCIENCE, V260, P539, DOI 10.1126/science.8386393	6	31	31	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 12	1993	341	8859					1511	1511		10.1016/0140-6736(93)90641-S	http://dx.doi.org/10.1016/0140-6736(93)90641-S			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LG242	8099386				2022-12-28	WOS:A1993LG24200010
J	RAMSAY, LE				RAMSAY, LE			CARDIOVASCULAR-DISEASE - WARFARIN IN CHRONIC ATRIAL-FIBRILLATION	LANCET			English	Editorial Material											RAMSAY, LE (corresponding author), UNIV SHEFFIELD,ROYAL HALLAMSHIRE HOSP,DEPT MED & PHARMACOL,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND.							CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; KOPECKY SL, 1987, NEW ENGL J MED, V317, P669, DOI 10.1056/NEJM198709103171104; PETERSEN P, 1989, LANCET, V1, P175; SINGER DE, 1992, NEW ENGL J MED, V327, P1451, DOI 10.1056/NEJM199211123272009; WOLF PA, 1991, STROKE, V22, P953; 1991, CIRCULATION, V84, P527; 1990, NEW ENGL J MED, V323, P1505	8	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 29	1993	341	8857					1376	1377		10.1016/0140-6736(93)90945-D	http://dx.doi.org/10.1016/0140-6736(93)90945-D			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE180	8098794				2022-12-28	WOS:A1993LE18000008
J	COSTA, SH; VESSEY, MP				COSTA, SH; VESSEY, MP			MISOPROSTOL AND ILLEGAL ABORTION IN RIO-DE-JANEIRO, BRAZIL	LANCET			English	Article							TRIMESTER	We report on the determinants and consequences of induced abortion among 803 women admitted to hospital with abortion complications in Rio de Janeiro, Brazil, in 1991. 458 (57%) women reported using misoprostol to induce abortion, 74% in the first 4 months of pregnancy. Doses of 200-16 800 mug were reported, with a median of 800 mug. 65% of the women took the drug orally, 29% used a combination of oral and vaginal routes, and 6% administered it intravaginally. Vaginal bleeding and uterine cramps were the commonest reasons for seeking hospital care. Only 8% of women reported gastrointestinal side-effects. Misoprostol induced vaginal bleeding within 12 h of administration in 52% of the women, but 16% waited 10 days or more for onset of bleeding. 4% were admitted to hospital with complete abortion. The likelihood of bleeding starting within 12 h increased with duration of gestation and it was greater when the drug was used both orally and intravaginally. A significantly smaller proportion of women taking misoprostol than of those who induced abortion by catheter insertion presented signs of infection or physical injuries or required blood transfusion (<0.0005). Among 803 women interviewed at delivery as controls, 6% had taken misoprostol but abortion had not ensued. Misoprostol has an important role as an abortifacient among the women studied.	OSWALDO CRUZ FDN,NATL SCH PUBL HLTH,DEPT EPIDEMIOL & QUANTITAT METHODS,RIO JANEIRO,BRAZIL; UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,OXFORD,ENGLAND	Fundacao Oswaldo Cruz; University of Oxford								ARMITAGE P, 1971, STATISTICAL METHODS; BYGDEMAN M, 1984, CLIN OBSTET GYNAECOL, V11, P573; COELHO LT, 1991, CIENCIA HOJE, V13, P60; COSTA S, 1990, INT FAMILY PLANNING, V16, P16; FONSECA W, 1991, LANCET, V338, P56, DOI 10.1016/0140-6736(91)90046-R; HILL NCW, 1989, BRIT J OBSTET GYNAEC, V96, P1424, DOI 10.1111/j.1471-0528.1989.tb06307.x; MACKENZIE IZ, 1978, LANCET, V1, P1223; MERCUCCI VL, 1991, MARKERING FERTILIDAD, P113; NORMAN JE, 1991, LANCET, V338, P1233, DOI 10.1016/0140-6736(91)92102-8; RABE T, 1987, GEBURTSH FRAUENHEILK, V47, P324, DOI 10.1055/s-2008-1035830; Schonhofar P S, 1991, Lancet, V337, P1534, DOI 10.1016/0140-6736(91)93212-R; SONTAG SJ, 1985, DIGEST DIS SCI, V30, pS159, DOI 10.1007/BF01309403	12	132	137	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 15	1993	341	8855					1258	1261		10.1016/0140-6736(93)91156-G	http://dx.doi.org/10.1016/0140-6736(93)91156-G			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LC497	8098402				2022-12-28	WOS:A1993LC49700014
J	BUSCHARD, K; JOSEFSEN, K; HORN, T; FREDMAN, P				BUSCHARD, K; JOSEFSEN, K; HORN, T; FREDMAN, P			SULFATIDE AND SULFATIDE ANTIBODIES IN INSULIN-DEPENDENT DIABETES-MELLITUS	LANCET			English	Note							SULFATIDE	Insulin-dependent diabetes mellitus (IDDM) is associated with neurological disorders. Sulph I, a monoclonal antibody to sulphatide (a neural epitope), stained secretory granules in alpha and beta cells of rat islets of Langerhans, but not exocrine tissue. Sera from 88% of 57 newly diagnosed IDDM patients was anti-sulphatide positive, and 76% were positive 6 months later. All 135 healthy controls were negative. Sulphatide antibody may be an IDDM marker.	MOLNDALS SJUKHUS,DEPT CLIN NEUROSCI,PSYCHIAT & NEUROCHEM SECT,MOLNDAL,SWEDEN; HERLEV HOSP,DEPT PATHOL,DK-2730 HERLEV,DENMARK	University of Copenhagen; Herlev & Gentofte Hospital	BUSCHARD, K (corresponding author), KOMMUNE HOSP COPENHAGEN,BARTHOLIN INST,DK-1399 COPENHAGEN K,DENMARK.			Buschard, Karsten/0000-0002-0126-7423				BUSCHARD K, 1983, DIABETOLOGIA, V24, P42; DEAN BM, 1986, DIABETOLOGIA, V29, P339, DOI 10.1007/BF00452073; FREDMAN P, 1991, J NEUROL, V238, P75, DOI 10.1007/BF00315684; FREDMAN P, 1988, BIOCHEM J, V251, P17, DOI 10.1042/bj2510017; FREDMAN P, 1993, J NEUROL, V240, P382; GLEICHMANN H, 1987, DIABETES, V36, P578, DOI 10.2337/diabetes.36.5.578; MARSHALL MO, 1992, J IMMUNOL METHODS, V149, P63, DOI 10.1016/S0022-1759(12)80049-4; RABINOWE SL, 1990, DIABETES METAB REV, V6, P169, DOI 10.1002/dmr.5610060304	8	53	55	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 2	1993	342	8875					840	840		10.1016/0140-6736(93)92697-R	http://dx.doi.org/10.1016/0140-6736(93)92697-R			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA025	8104274				2022-12-28	WOS:A1993MA02500011
J	JUDICE, JK; GAMBLE, TR; MURPHY, EC; DEVOS, AM; SCHULTZ, PG				JUDICE, JK; GAMBLE, TR; MURPHY, EC; DEVOS, AM; SCHULTZ, PG			PROBING THE MECHANISM OF STAPHYLOCOCCAL NUCLEASE WITH UNNATURAL AMINO-ACIDS - KINETIC AND STRUCTURAL STUDIES	SCIENCE			English	Article							ACTIVE-SITE; MAGNETIC-RESONANCE; CRYSTAL-STRUCTURE; DOUBLE MUTANT; SUBSTITUTIONS; RESOLUTION; CATALYSIS; PROTEINS; COMPLEX	Staphylococcal nuclease is an enzyme with enormous catalytic power, accelerating phosphodiester bond hydrolysis by a factor of 10(16) over the spontaneous rate. The mechanistic basis for this rate acceleration was investigated by substitution of the active site residues Glu43, Arg35, and Arg87 With unnatural amino acid analogs. Two Glu43 mutants, one containing the nitro analog of glutamate and the other containing homoglutamate, retained high catalytic activity at pH 9.9, but were less active than the wild-type enzyme at lower pH values. The x-ray crystal structure of the homoglutamate mutant revealed that the carboxylate side chain of this residue occupies a position and orientation similar to that of Glu43 in the wild-type enzyme. The increase in steric bulk is accommodated by a backbone shift and altered torsion angles. The nitro and the homoglutamate mutants display similar pH versus rate profiles, which differ from that of the wild-type enzyme. Taken together, these studies suggest that Glu43 may not act as a general base, as previously thought, but may play a more complex structural role during catalysis.	UNIV CALIF BERKELEY, DEPT CHEM, BERKELEY, CA 94720 USA; UNIV CALIF SAN FRANCISCO, GRAD GRP BIOPHYS, SAN FRANCISCO, CA 94143 USA; GENENTECH INC, DEPT PROT ENGN, S SAN FRANCISCO, CA 94080 USA	University of California System; University of California Berkeley; University of California System; University of California San Francisco; Roche Holding; Genentech					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014012, T32GM008388, R01GM049220] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 14012-02S1, R01 GM49220, T32GM-08388] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNETT EM, 1963, PROG PHYS ORG CHEM, V1, P223, DOI 10.1002/9780470171806.ch5; BRUNGER AT, 1992, XPLOR MANUAL; COTTON FA, 1979, P NATL ACAD SCI USA, V76, P2551, DOI 10.1073/pnas.76.6.2551; CUATRECA.P, 1967, J BIOL CHEM, V242, P1541; DUNN BM, 1973, J BIOL CHEM, V248, P4769; ELLMAN J, 1991, METHOD ENZYMOL, V202, P301; HALE SP, IN PRESS BIOCHEMISTR; HERMANN P, 1968, H-S Z PHYSIOL CHEM, V349, P390, DOI 10.1515/bchm2.1968.349.1.390; HIBLER DW, 1987, BIOCHEMISTRY-US, V26, P6278, DOI 10.1021/bi00393a048; HYNES TR, 1991, PROTEINS, V10, P92, DOI 10.1002/prot.340100203; JOESTEN MD, 1974, HYDROGEN BONDING, P309; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; LESLEY SA, UNPUB; LOLL PJ, 1990, BIOCHEMISTRY-US, V29, P6866, DOI 10.1021/bi00481a016; LOLL PJ, 1989, PROTEINS, V5, P183, DOI 10.1002/prot.340050302; MEHDI S, 1982, J AM CHEM SOC, V104, P3223, DOI 10.1021/ja00375a053; NOREN CJ, 1989, SCIENCE, V244, P182, DOI 10.1126/science.2649980; POURMOTABBED T, 1990, BIOCHEMISTRY-US, V29, P3677, DOI 10.1021/bi00467a013; SAMPSON NS, 1992, BIOCHEMISTRY-US, V31, P8488, DOI 10.1021/bi00151a015; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; Schowen R. L., 1977, ISOTOPE EFFECTS ENZY, P64; SERPERSU EH, 1987, BIOCHEMISTRY-US, V26, P1289, DOI 10.1021/bi00379a014; SERPERSU EH, 1986, BIOCHEMISTRY-US, V25, P68, DOI 10.1021/bi00349a011; SHORTLE D, 1983, GENE, V22, P181, DOI 10.1016/0378-1119(83)90102-6; SLATER CD, 1981, J ORG CHEM, V46, P2173, DOI 10.1021/jo00323a041; SUICH DJ, 1993, THESIS U CALIFORNIA; TAKAHARA M, 1985, J BIOL CHEM, V260, P2670; WEBER DJ, 1990, BIOCHEMISTRY-US, V29, P8632, DOI 10.1021/bi00489a020; WEBER DJ, 1991, BIOCHEMISTRY-US, V30, P6103, DOI 10.1021/bi00239a004; WEBER DJ, 1992, PROTEINS, V13, P275, DOI 10.1002/prot.340130402; WILDE JA, 1988, BIOCHEMISTRY-US, V27, P4127, DOI 10.1021/bi00411a033	31	80	81	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 17	1993	261	5128					1578	1581		10.1126/science.8103944	http://dx.doi.org/10.1126/science.8103944			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LX474	8103944				2022-12-28	WOS:A1993LX47400030
J	FREI, E				FREI, E			GENE DELETION - A NEW TARGET FOR CANCER-CHEMOTHERAPY	LANCET			English	Article							CELL LUNG-CANCER; RETINOBLASTOMA; 5-FLUOROURACIL; INACTIVATION; TOXICITY				FREI, E (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT MED,44 BINNEY ST,BOSTON,MA 02115, USA.							BERTINO JR, 1993, CANC MED, P698; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BRENT TP, 1985, P NATL ACAD SCI USA, V82, P2985, DOI 10.1073/pnas.82.9.2985; DIASIO RB, 1989, CLIN PHARMACOKINET, V16, P215, DOI 10.2165/00003088-198916040-00002; FREI E, 1993, CANCER MED, P631; GELEHRTER TD, 1990, PRINCIPLERS MED GENE, P255; HARRIS BE, 1991, CANCER, V68, P499, DOI 10.1002/1097-0142(19910801)68:3<499::AID-CNCR2820680309>3.0.CO;2-F; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LEBEAU MM, 1986, J CLIN ONCOL, V4, P325, DOI 10.1200/JCO.1986.4.3.325; LEE WH, 1987, HUM GENET, V76, P33; LILENBAUM RC, 1992, P AM SOC CLIN ONCOL, V33, P11; Meyer U A, 1990, Prog Liver Dis, V9, P307; MILLER YE, 1989, J CLIN INVEST, V83, P2120, DOI 10.1172/JCI114125; OWENS TK, 1992, CANCER RES, V82, P2389; PINKEL D, 1988, P NATL ACAD SCI USA, V85, P9138, DOI 10.1073/pnas.85.23.9138; REMICK SC, 1990, CANCER RES, V50, P2667; SAGER R, 1984, CANCER SURV, V3, P321; TUCHMAN M, 1985, NEW ENGL J MED, V313, P245, DOI 10.1056/NEJM198507253130407; WAXMAN DJ, 1990, CANCER RES, V50, P6449; WHANGPENG J, 1991, GENE CHROMOSOME CANC, V3, P168, DOI 10.1002/gcc.2870030303; WOLFENDEN R, 1975, BIOCHEMISTRY-US, V14, P599; 1987, CYTOGENET CELL GENET, V46, P1	23	17	18	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 11	1993	342	8872					662	664		10.1016/0140-6736(93)91764-D	http://dx.doi.org/10.1016/0140-6736(93)91764-D			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX272	8103151				2022-12-28	WOS:A1993LX27200015
J	HANAUER, SB				HANAUER, SB			MEDICAL THERAPY OF ULCERATIVE-COLITIS	LANCET			English	Article							INFLAMMATORY BOWEL-DISEASE; RANDOMIZED CONTROLLED TRIAL; 5-AMINOSALICYLIC ACID; INTRAVENOUS TREATMENT; DRUG-THERAPY; SULPHASALAZINE; AZATHIOPRINE; SULFASALAZINE; METRONIDAZOLE; SURVEILLANCE				HANAUER, SB (corresponding author), UNIV CHICAGO,MED CTR,GASTROENTEROL SECT,5941 S MARYLAND AVE,CHICAGO,IL 60637, USA.							ADLER DJ, 1990, AM J GASTROENTEROL, V85, P717; ALSTEAD EM, 1990, GASTROENTEROLOGY, V99, P443, DOI 10.1016/0016-5085(90)91027-4; Asicura H, 1991, GASTROENTEROLOGY, V100, pA194; AZADKHAN AK, 1977, LANCET, V2, P892; BIRNIE GG, 1981, GUT, V22, P452, DOI 10.1136/gut.22.6.452; BJORCK S, 1992, 3RD P M SID EFF ANT, pC60; CANN PA, 1984, LANCET, V1, P1119; CHAPMAN RW, 1986, GUT, V27, P1210, DOI 10.1136/gut.27.10.1210; EKBOM A, 1992, GASTROENTEROLOGY, V103, P954, DOI 10.1016/0016-5085(92)90029-X; EMMRICH J, 1991, LANCET, V338, P570, DOI 10.1016/0140-6736(91)91133-F; GEMLO BT, 1993, PROBL GEN SURG, V10, P109; GILAT T, 1989, J CLIN GASTROENTEROL, V11, P392, DOI 10.1097/00004836-198908000-00008; HANAN IM, 1991, INTENS CARE MED, P917; HANAUER S, 1992, GASTROENTEROLOGY, V102, pA634; HANAUER SB, 1990, SCAND J GASTROENTERO, V25, P97, DOI 10.3109/00365529009093133; HANAUER SB, 1992, INFLAMMATORY BOWEL D, P297; HANAUER SB, 1990, MANAGEMENT INFLAMMAT, P65; HAWTHORNE AB, 1992, BRIT MED J, V305, P20, DOI 10.1136/bmj.305.6844.20; HAWTHORNE AB, 1992, GUT, V33, P922, DOI 10.1136/gut.33.7.922; HAWTHORNE AB, 1989, DRUGS, V38, P267, DOI 10.2165/00003495-198938020-00007; HODGSON HJF, 1991, ALIMENT PHARM THERAP, V5, P555; IRELAND A, 1992, GUT, V33, P1343, DOI 10.1136/gut.33.10.1343; IRELAND A, 1990, CLIN SCI, V78, P119, DOI 10.1042/cs0780119; JARNEROT G, 1985, GASTROENTEROLOGY, V89, P1005; KAUFMANN HJ, 1987, ANN INTERN MED, V107, P513, DOI 10.7326/0003-4819-107-4-513; KOHLER LW, 1991, GASTROENTEROLOGY, V101, P679; KOZAREK RA, 1989, ANN INTERN MED, V110, P353, DOI 10.7326/0003-4819-110-5-353; LAURITSEN K, 1988, GUT, V29, P1316, DOI 10.1136/gut.29.10.1316; LAURSEN LS, 1990, LANCET, V335, P683; LEVIN B, 1991, B WORLD HEALTH ORGAN, V69, P121; LICHTIGER S, 1993, GASTROENTEROLOGY, V104, pA732; MANTZARIS GJ, 1993, GASTROENTEROLOGY, V104, pA736; MARGOLIN ML, 1988, AM J GASTROENTEROL, V83, P27; MCINTYRE PB, 1986, GUT, V27, P481, DOI 10.1136/gut.27.5.481; MEYERS S, 1983, GASTROENTEROLOGY, V85, P351; MULDER CJJ, 1993, ALIMENT PHARM THERAP, V7, P125; PEPPERCORN MA, 1990, ANN INTERN MED, V112, P50, DOI 10.7326/0003-4819-112-1-50; PERRAULT J, 1993, PROBLEMS GENERAL SUR, V10, P187; PULLAN RD, 1993, GASTROENTEROLOGY, V104, pA764; RAO SS, 1987, SCAND J GASTROENTERO, V22, P332, DOI 10.3109/00365528709078600; RILEY SA, 1991, GUT, V32, P174, DOI 10.1136/gut.32.2.174; ROEDIGER WEW, 1980, LANCET, V2, P712; SANDBORN WJ, 1992, MAYO CLIN PROC, V67, P981, DOI 10.1016/S0025-6196(12)60930-6; SCHEPPACH W, 1992, GASTROENTEROLOGY, V103, P51, DOI 10.1016/0016-5085(92)91094-K; SVARTZ N, 1988, AM J GASTROENTEROL, V83, P497; TRUELOVE SC, 1955, BRIT MED J, V2, P1041, DOI 10.1136/bmj.2.4947.1041; VERHAVE M, 1990, J PEDIATR-US, V117, P809, DOI 10.1016/S0022-3476(05)83349-9; VILASECA J, 1990, GASTROENTEROLOGY, V98, P269, DOI 10.1016/0016-5085(90)90814-H; WOOLRICH AJ, 1992, GASTROENTEROLOGY, V103, P431, DOI 10.1016/0016-5085(92)90831-I	49	58	65	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 14	1993	342	8868					412	417		10.1016/0140-6736(93)92819-F	http://dx.doi.org/10.1016/0140-6736(93)92819-F			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR900	8101907				2022-12-28	WOS:A1993LR90000015
J	SWERDLOW, DL; RIES, AA				SWERDLOW, DL; RIES, AA			VIBRIO-CHOLERAE NON-01 - THE 8TH PANDEMIC	LANCET			English	Editorial Material									CTR DIS CONTROL & PREVENT,ATLANTA,GA	Centers for Disease Control & Prevention - USA	SWERDLOW, DL (corresponding author), MASSACHUSETTS GEN HOSP,INFECT DIS UNIT,BOSTON,MA 02114, USA.							ALBERT MJ, 1993, LANCET, V342, P387, DOI 10.1016/0140-6736(93)92811-7; CHONGSANGUAN M, 1993, LANCET, V342, P430, DOI 10.1016/0140-6736(93)92841-G; GOODGAME RW, 1975, ANN INTERN MED, V82, P101, DOI 10.7326/0003-4819-82-1-101; HALL RH, 1993, LANCET, V342, P430, DOI 10.1016/0140-6736(93)92839-L; ISLAM MS, 1993, LANCET, V342, P430, DOI 10.1016/0140-6736(93)92840-P; Lederberg J., 1992, EMERGING INFECTIONS; MORRIS JG, 1981, ANN INTERN MED, V94, P656, DOI 10.7326/0003-4819-94-5-656; SHIMADA T, 1993, LANCET, V341, P1346; SWERDLOW DL, 1992, LANCET, V340, P28, DOI 10.1016/0140-6736(92)92432-F; SWERDLOW DL, 1992, JAMA-J AM MED ASSOC, V267, P1495, DOI 10.1001/jama.267.11.1495; 1993, WKLY EPIDEMIOL REC, V68, P141; 1991, EPIDEMIOL B, V12, P5	12	60	62	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 14	1993	342	8868					382	383						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR900	8101894				2022-12-28	WOS:A1993LR90000002
J	DATTA, M				DATTA, M			YOU CANNOT EXCLUDE THE EXPLANATION YOU HAVE NOT CONSIDERED	LANCET			English	Editorial Material							DEATHS				DATTA, M (corresponding author), TB RES CTR,EPIDEMIOL UNIT,MADRAS 600031,INDIA.							BHASKARAM P, 1992, Indian Pediatrics, V29, P39; CHOI BCK, 1984, INT J EPIDEMIOL, V13, P229, DOI 10.1093/ije/13.2.229; DOLL R, 1976, BRIT MED J, V2, P1525, DOI 10.1136/bmj.2.6051.1525; Hennekens C.H., 1987, EPIDEMIOLOGY MED; KALACHE A, 1993, LANCET, V341, P33, DOI 10.1016/0140-6736(93)92497-H; MIETTINEN OS, 1981, AM J EPIDEMIOL, V114, P593, DOI 10.1093/oxfordjournals.aje.a113225; NEWMAN TB, 1988, DESIGNING CLIN RES, P98; VICTORA CG, 1989, AM J EPIDEMIOL, V129, P1032, DOI 10.1093/oxfordjournals.aje.a115207; VICTORA CG, 1989, INT J EPIDEMIOL, V18, P918, DOI 10.1093/ije/18.4.918; ZARKOVIC G, 1972, INT J EPIDEMIOL, V1, P167, DOI 10.1093/ije/1.2.167	10	37	37	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 7	1993	342	8867					345	347		10.1016/0140-6736(93)91478-5	http://dx.doi.org/10.1016/0140-6736(93)91478-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ868	8101588				2022-12-28	WOS:A1993LQ86800016
J	DIXON, RA				DIXON, RA			COST-EFFECTIVENESS OF GROWTH MONITORING AND PROMOTION	LANCET			English	Editorial Material											DIXON, RA (corresponding author), UNIV SHEFFIELD,DEPT PUBL HLTH MED,SHEFFIELD S10 2TN,S YORKSHIRE,ENGLAND.			Dixon, Robert Arthur/0000-0001-5295-8112				DIXON RA, 1991, ANN TROP PAEDIATR, V11, P3, DOI 10.1080/02724936.1991.11747471; ETTYANG GA, 1993, P NYEREI C GROWTH PR; GEORGE SM, 1993, P NYERI C GROWTH PRO; GRANT JP, 1987, STATE WORLDS CHILDRE; GREEN N, 1993, P NYERI C GROWTH PRO; KIELMANN AA, 1993, P NYERI C GROWTH PRO	6	5	6	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 7	1993	342	8867					317	317		10.1016/0140-6736(93)91465-X	http://dx.doi.org/10.1016/0140-6736(93)91465-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ868	8101577				2022-12-28	WOS:A1993LQ86800003
J	GEORGE, SM; LATHAM, MC; ABEL, R; ETHIRAJAN, N; FRONGILLO, EA				GEORGE, SM; LATHAM, MC; ABEL, R; ETHIRAJAN, N; FRONGILLO, EA			EVALUATION OF EFFECTIVENESS OF GOOD GROWTH MONITORING IN SOUTH INDIAN VILLAGES	LANCET			English	Article								We conducted a community intervention trial in 12 villages in Tamil Nadu, India to evaluate the benefits of growth monitoring. The villages were divided into 6 ''growth-monitoring package'' of intervention villages (GMP) and 6 ''non-growth-monitoring package'' of intervention villages (NGM). A functioning primary health care system was in place in all 12 villages. One village nutrition worker in each of the 12 villages implemented a set of interventions including health and nutritional education. About 550 children under the age of 60 months were studied over 4 years in GMP villages and a similar number of children in NGM villages. The interventions were identical in the two sets of villages except for the use of growth charts in education in the 6 GMP villages. The nutrition worker in the NGM villages had the same contact time as in the GMP villages but advised mothers without the benefit of growth charts. The research team, independently of the nutrition worker, did anthropometric studies on children in all villages every 4 to 5 months. Comparisons were done by calculating monthly gains in stature, and weight, and the significance of differences observed was adjusted for age and sex. After 30 months of interventions, similar improvements in growth were seen in GMP and NGM children. The interventions seemed to have improved the nutritional status of young children in both groups of villages. In view of the lack of additional benefit from growth monitoring over other educational interventions, we question its use as part of child survival programmes in India.	CORNELL UNIV,DIV NUTR SCI,PROGRAM INT NUTR,ITHACA,NY 14853; DEPT CHRISTIAN MED COLL & HOSP,RURAL UNIT HLTH & SOCIAL AFFAIRS,VELLORE,INDIA	Cornell University; Christian Medical College & Hospital (CMCH) Vellore								BALACHANDER J, 1991, STATE ART ART SERIES, V8, P97; CHATTERJEE M, 1989, JUL WORKSH TAM NAD I; DIBLEY MJ, 1987, AM J CLIN NUTR, V46, P749, DOI 10.1093/ajcn/46.5.749; GEORGE SM, 1993, P C GROWTH PROMOTION, P150; GEORGE SM, 1993, THESIS CORNELL U NEW; GOPALAN C, 1992, NFI B, V13, P1; GOPALAN C, 1985, SPEC PUBL SER, V2; GRANT JP, 1985, STATE WORLDS CHILDRE, P3; LIDDLE J, 1986, DAUGHTERS INDEPENDEN; Miller B. D., 1992, SANCTIONS SANCTUARY, P173; MORLEY D, 1968, T ROY SOC TROP MED H, V62, P200, DOI 10.1016/0035-9203(68)90157-0; MORLEY D, 1993, P NYERI C GROWTH PRO, P188; NABARRO D, 1988, SOC SCI MED, V26, P941, DOI 10.1016/0277-9536(88)90414-5; NABARRO D, NESTLE NUTRITION WOR, V14, P165; Rohde J., 1983, Practising health for all., P252; ROHDE JE, 1988, INDIAN J PEDIATR, V55, pS1; SHEKAR M, 1992, Indian Journal of Pediatrics, V59, P5, DOI 10.1007/BF02760889; 1985, LANCET, V2, P1337; 1992, LANCET, V340, P149	19	36	36	1	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 7	1993	342	8867					348	352		10.1016/0140-6736(93)91479-6	http://dx.doi.org/10.1016/0140-6736(93)91479-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ868	8101589				2022-12-28	WOS:A1993LQ86800017
J	GOUDEMAND, M; MANIEZMONTREUIL, M; DUPRESSOIRBURLET, MV				GOUDEMAND, M; MANIEZMONTREUIL, M; DUPRESSOIRBURLET, MV			SPECIFIC ANTI-HAV IMMUNOGLOBULIN	LANCET			English	Letter							HEPATITIS-A				GOUDEMAND, M (corresponding author), CTR REG TRANSFUS SANGUINE,F-59012 LILLE,FRANCE.							BEHRENS RH, 1993, LANCET, V341, P972, DOI 10.1016/0140-6736(93)91274-P; MANIEZMONTREUIL M, 1993, REV FR TRANSFUS IMMU, V26, P531; MANIEZMONTREUIL M, 1986, CONCOURS MED, V108, P1151; SORENSEN PG, 1983, DAN MED BULL, V30, P421; THORPE R, 1991, LANCET, V337, P497, DOI 10.1016/0140-6736(91)93437-E	5	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 24	1993	342	8865					239	239		10.1016/0140-6736(93)92328-Q	http://dx.doi.org/10.1016/0140-6736(93)92328-Q			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN622	8100956				2022-12-28	WOS:A1993LN62200038
J	KAMEOKA, J; TANAKA, T; NOJIMA, Y; SCHLOSSMAN, SF; MORIMOTO, C				KAMEOKA, J; TANAKA, T; NOJIMA, Y; SCHLOSSMAN, SF; MORIMOTO, C			DIRECT ASSOCIATION OF ADENOSINE-DEAMINASE WITH A T-CELL ACTIVATION ANTIGEN, CD26	SCIENCE			English	Article							DIPEPTIDYL PEPTIDASE-IV; AMINO-ACID-SEQUENCE; COMPLEXING PROTEIN; MONOCLONAL-ANTIBODIES; BINDING-PROTEIN; SURFACE; EXPRESSION; 1F7; CHROMOSOME-2; ASSIGNMENT	CD26, the T cell activation molecule dipeptidyl peptidase IV (DPPIV), associates with a 43-kilodalton protein. Amino acid sequence analysis and immunoprecipitation studies demonstrated that this 43-kilodalton protein was adenosine deaminase (ADA). ADA was coexpressed with CD26 on the Jurkat T cell lines, and an in vitro binding assay showed that the binding was through the extracellular domain of CD26. ADA deficiency causes severe combined immunodeficiency disease (SCID) in humans. Thus, ADA and CD26 (DPPIV) interact on the T cell surface, and this interaction may provide a clue to the pathophysiology of SCID caused by ADA deficiency.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR IMMUNOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI012069, R37AI012069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR033713] Funding Source: NIH RePORTER; NIAID NIH HHS [AI29530, AI12069] Funding Source: Medline; NIAMS NIH HHS [AR33713] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDY RJ, 1982, J BIOL CHEM, V257, P7922; ARAN JM, 1991, J HISTOCHEM CYTOCHEM, V39, P1001, DOI 10.1177/39.8.1856451; BARANKIEWICZ J, 1988, J BIOL CHEM, V263, P7094; BLAESE RM, 1993, PEDIATR RES, V33, pS49, DOI 10.1203/00006450-199304001-00010; BUC HA, 1990, EUR J IMMUNOL, V20, P611, DOI 10.1002/eji.1830200322; CAMM AJ, 1991, NEW ENGL J MED, V325, P1621, DOI 10.1056/NEJM199112053252306; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DADDONA PE, 1984, J BIOL CHEM, V259, P2101; DANG NH, 1991, J IMMUNOL, V147, P2825; DANG NH, 1990, J IMMUNOL, V145, P3963; DANG NH, 1990, J EXP MED, V172, P649, DOI 10.1084/jem.172.2.649; DANG NH, 1990, J IMMUNOL, V144, P4092; DARMOUL D, 1990, ANN HUM GENET, V54, P191, DOI 10.1111/j.1469-1809.1990.tb00377.x; DARMOUL D, 1992, J BIOL CHEM, V267, P4824; DINJENS WNM, 1989, J BIOL CHEM, V264, P19215; FLEISCHER B, 1987, J IMMUNOL, V138, P1346; FOX DA, 1984, J IMMUNOL, V133, P1250; HEGEN M, 1990, J IMMUNOL, V144, P2908; HERBSCHLEBVOOGT E, 1981, HUM GENET, V59, P317, DOI 10.1007/BF00295464; HIRSCHHORN R, 1993, PEDIATR RES, V33, pS35; HIRSCHHORN R, 1990, Immunodeficiency Reviews, V2, P175; KAMEOKA J, UNPUB; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; MOORE KA, 1990, BLOOD, V75, P2085; MORIMOTO C, 1989, J IMMUNOL, V143, P3430; MORRISON ME, 1993, J EXP MED, V177, P1135, DOI 10.1084/jem.177.4.1135; SCHARENBERG JGM, 1990, INT J IMMUNOPHARMACO, V12, P113, DOI 10.1016/0192-0561(90)90074-W; SCHRADER WP, 1988, J HISTOCHEM CYTOCHEM, V36, P1481, DOI 10.1177/36.12.2461411; SCHRADER WP, 1990, J BIOL CHEM, V265, P19312; TANAKA T, 1993, P NATL ACAD SCI USA, V90, P4586, DOI 10.1073/pnas.90.10.4586; TANAKA T, 1992, J IMMUNOL, V149, P481; Tanaka T., UNPUB; TORIMOTO Y, 1991, J IMMUNOL, V147, P2514; TORIMOTO Y, 1992, MOL IMMUNOL, V29, P183, DOI 10.1016/0161-5890(92)90099-J; ULMER AJ, 1990, SCAND J IMMUNOL, V31, P429, DOI 10.1111/j.1365-3083.1990.tb02789.x	35	458	477	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 23	1993	261	5120					466	469		10.1126/science.8101391	http://dx.doi.org/10.1126/science.8101391			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN623	8101391				2022-12-28	WOS:A1993LN62300034
J	WATTERSON, A				WATTERSON, A			CHEMICAL HAZARDS AND PUBLIC CONFIDENCE	LANCET			English	Editorial Material											WATTERSON, A (corresponding author), NOTTINGHAM TRENT UNIV,CTR OCCUPAT SAFETY & HLTH,NOTTINGHAM,ENGLAND.							[Anonymous], 1992, RISK ANAL PERCEPTION; Avery N., 1993, CRACKING CODEX ANAL; KRAUS N, 1992, RISK ANAL, V12, P215, DOI 10.1111/j.1539-6924.1992.tb00669.x; 1976, ENV HLTH CRITERIA, V1; 1993, DRAFT ENV HLTH CRITE; 1991, ENV HLTH CRITERIA, V126	6	7	7	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 17	1993	342	8864					131	132		10.1016/0140-6736(93)91341-I	http://dx.doi.org/10.1016/0140-6736(93)91341-I			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN042	8101252				2022-12-28	WOS:A1993LN04200007
J	WILLIAMS, JK				WILLIAMS, JK			ESTROGEN THERAPY FOR MYOCARDIAL-ISCHEMIA IN WOMEN	LANCET			English	Editorial Material											WILLIAMS, JK (corresponding author), WAKE FOREST UNIV,BOWMAN GRAY SCH MED,WINSTON SALEM,NC 27103, USA.							ROSANO GMC, 1993, LANCET, V342, P133, DOI 10.1016/0140-6736(93)91343-K	1	3	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 17	1993	342	8864					128	128						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN042	8101247				2022-12-28	WOS:A1993LN04200002
J	VONROENN, JH; CLEELAND, CS; GONIN, R; HATFIELD, AK; PANDYA, KJ				VONROENN, JH; CLEELAND, CS; GONIN, R; HATFIELD, AK; PANDYA, KJ			PHYSICIAN ATTITUDES AND PRACTICE IN CANCER PAIN MANAGEMENT - A SURVEY FROM THE EASTERN-COOPERATIVE-ONCOLOGY-GROUP	ANNALS OF INTERNAL MEDICINE			English	Article						PAIN; PAIN MEASUREMENT; ANALGESICS, ADDICTIVE; ONCOLOGY SERVICE, HOSPITAL; PHYSICIANS PRACTICE PATTERNS	CONTROL REGIMENS; EDUCATION; PREVALENCE; PATIENT	Objective: The Eastern Cooperative Oncology Group (ECOG) conducted a groupwide survey to determine the amount of knowledge about cancer pain and its treatment among physicians practicing in ECOG-affiliated institutions and to determine the methods of pain control being used by these physicians. Design: Survey. Setting. A questionnaire was sent to all ECOG physicians with patient care responsibilities (medical oncologists, hematologists, surgeons, and radiation therapists), practicing in university institutions, Community Clinical Oncology Program (CCOP) institutions, and Cooperative Group Outreach Programs (CGOP) institutions. Measurements: A physician cancer pain questionnaire developed by the Pain Research Group at the University of Wisconsin was used. The questionnaire was designed to assess physicians' estimates of the magnitude of pain as a specific problem for cancer patients, their perceptions of the adequacy of cancer pain management, and their report of how they manage pain in their own practice setting. Results: The study analyzed responses to 897 of 1800 surveys. In regard to the use of analgesics for cancer pain in the United States, 86% felt that the majority of patients with pain were undermedicated. Only 51% believed pain control in their own practice setting was good or very good; 31% would wait until the patient's prognosis was 6 months or less before they would start maximal analgesia. Adjuvants and prophylactic side-effect management should have been used more frequently in the treatment plan. Concerns about side-effect management and tolerance were reported as limiting analgesic prescribing. Poor pain assessment was rated by 76% of physicians as the single most important barrier to adequate pain management. Other barriers included patient reluctance to report pain and patient reluctance to take analgesics (both by 62%) as well as physician reluctance to prescribe opioids (61%). Conclusions. Professional education needs to focus on the proper assessment of pain, focus on the management of side effects, and focus on the use of adjuvant medications. A better understanding of the pharmacology of opioid analgesics is also needed. Physicians also need to educate patients to report pain and to effectively use the medications that are prescribed for pain management.			CLEELAND, CS (corresponding author), PAIN RES GRP, DEPT NEUROL, 600 HIGHLAND AVE, MADISON, WI 53792 USA.				NATIONAL CANCER INSTITUTE [R01CA026582, U10CA021115, R18CA026582, U10CA017145] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21115, CA 26582, CA 17145, R01 CA026582] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Austin C, 1986, Cancer Nurs, V9, P58; AVORN J, 1988, ARCH INTERN MED, V148, P1720, DOI 10.1001/archinte.148.8.1720; Bonica J. J., 1980, PAIN, P335; BONICA JJ, 1985, ADV PAIN RES THER, V9, P589; Cleeland C., 1989, ISSUES PAIN MEASUREM; CLEELAND C, 1991, ADV PAIN RES THER, P631; CLEELAND CS, 1986, CANCER, V58, P796, DOI 10.1002/1097-0142(19860801)58:3<796::AID-CNCR2820580331>3.0.CO;2-#; CLEELAND CS, 1984, CANCER, V53, P2264; DAUT RL, 1982, CANCER-AM CANCER SOC, V50, P1913, DOI 10.1002/1097-0142(19821101)50:9<1913::AID-CNCR2820500944>3.0.CO;2-R; DONOVAN M, 1987, PAIN, V30, P69, DOI 10.1016/0304-3959(87)90084-4; FISHMAN B, 1987, CANCER-AM CANCER SOC, V60, P1151, DOI 10.1002/1097-0142(19870901)60:5<1151::AID-CNCR2820600538>3.0.CO;2-G; FOLEY KM, 1985, NEW ENGL J MED, V313, P84, DOI 10.1056/NEJM198507113130205; GREENWALD HP, 1987, CANCER, V60, P2563, DOI 10.1002/1097-0142(19871115)60:10<2563::AID-CNCR2820601036>3.0.CO;2-L; GROSSMAN SA, 1991, J PAIN SYMPTOM MANAG, V6, P53, DOI 10.1016/0885-3924(91)90518-9; HODES R, 1989, ADV PAIN RES THER, P91; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; JONES WL, 1984, PATIENT EDUC COUNS, V5, P159, DOI 10.1016/0738-3991(84)90175-7; MAX MB, 1990, ANN INTERN MED, V113, P885, DOI 10.7326/0003-4819-113-11-885; MCGIVNEY WT, 1984, JAMA-J AM MED ASSOC, V251, P1182; MELZACK R, 1976, CAN MED ASSOC J, V115, P125; RAY WA, 1985, MED CARE, V23, P1307, DOI 10.1097/00005650-198511000-00009; RIMER B, 1987, PATIENT EDUC COUNS, V10, P267, DOI 10.1016/0738-3991(87)90128-5; SAUNDERS CM, 1981, THERAPY PAIN, P215; TROTTER JM, 1981, BMJ-BRIT MED J, V10, P122; TWYCROSS RG, 1984, CLIN ONCOLO, V3, P5; TWYCROSS RG, 1982, PAIN, V14, P303, DOI 10.1016/0304-3959(82)90137-3; Weissman D E, 1991, Wis Med J, V90, P671; Zar J.H., 1999, ZAR KUHR 5 2019, V4th; 1983, ANN INTERN MED, V99, P870; 1992, PHS920032 US DEP HLT; 1986, CANCER PAIN RELIEF; 1989, PRINCIPLES ANALGESIC	32	537	544	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1993	119	2					121	126		10.7326/0003-4819-119-2-199307150-00005	http://dx.doi.org/10.7326/0003-4819-119-2-199307150-00005			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU902	8099769				2022-12-28	WOS:A1993LU90200005
J	COLSTON, KW				COLSTON, KW			NEW CONCEPTS IN HORMONE-RECEPTOR ACTION	LANCET			English	Editorial Material							THYROID-HORMONE; RETINOIC ACID				COLSTON, KW (corresponding author), ST GEORGE HOSP,SCH MED,DEPT CLIN BIOCHEM,LONDON,ENGLAND.							CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E	6	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 10	1993	342	8863					67	68		10.1016/0140-6736(93)91281-P	http://dx.doi.org/10.1016/0140-6736(93)91281-P			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LL789	8100908				2022-12-28	WOS:A1993LL78900005
J	BODNARENKO, SR; CHALUPA, LM				BODNARENKO, SR; CHALUPA, LM			STRATIFICATION OF ON AND OFF GANGLION-CELL DENDRITES DEPENDS ON GLUTAMATE-MEDIATED AFFERENT ACTIVITY IN THE DEVELOPING RETINA	NATURE			English	Article							ACTION-POTENTIAL ACTIVITY; INNER PLEXIFORM LAYER; CAT RETINA; PHARMACOLOGICAL MODULATION; MAMMALIAN RETINA; ON-CENTER; MORPHOLOGY; BIPOLAR; BETA; ROD	A FUNDAMENTAL attribute of the vertebrate visual system is the segregation of ON and OFF pathways signalling increments and decrements of light1-4. In the mature retina, dendrites of ON- and OFF-centre retinal ganglion cells (RGCs) stratify in different sublaminae of the inner plexiform layer (IPL), and are differentially innervated by two types of bipolar cells which depolarize and hyperpolarize on exposure to light5-10. This stratification of ON and OFF RGCs is achieved by the gradual restriction of their dendrites which ramify throughout the IPL early in development11-14. The factors underlying this regressive event are unknown. Dendritic stratification occurs around the time that bipolar cells form synapses in the IPL15,16, which raises the possibility that synaptic activity is involved in this process. Here we test this hypothesis by treating the developing cat retina with the glutamate analogue 2-amino-4-phosphonobutyric acid (APB), which hyperpolarizes ON cone bipolar and rod bipolar cells, thereby preventing their release of glutamate17-19. We report that intraocular injection of APB during the period when dendritic stratification normally occurs prevents the formation of structurally segregated ON and OFF retinal pathways. These results provide evidence that glutamate-mediated afferent activity regulates the remodelling of RGC dendrites during development.	UNIV CALIF DAVIS,CTR NEUROSCI,DAVIS,CA 95616	University of California System; University of California Davis	BODNARENKO, SR (corresponding author), UNIV CALIF DAVIS,DEPT PSYCHOL,DAVIS,CA 95616, USA.							BARLOW HB, 1953, J PHYSIOL-LONDON, V119, P69, DOI 10.1113/jphysiol.1953.sp004829; BOLZ J, 1984, NEUROSCIENCE, V12, P875, DOI 10.1016/0306-4522(84)90176-3; DANN JF, 1988, J NEUROSCI, V8, P1485; DUBIN MW, 1986, J NEUROSCI, V6, P1021; FAMIGLIETTI EV, 1975, BRAIN RES, V84, P293, DOI 10.1016/0006-8993(75)90983-X; FAMIGLIETTI EV, 1976, SCIENCE, V194, P193, DOI 10.1126/science.959847; HAHM JO, 1991, NATURE, V351, P568, DOI 10.1038/351568a0; Hartline HK, 1938, AM J PHYSIOL, V121, P400, DOI 10.1152/ajplegacy.1938.121.2.400; KOLB H, 1974, SCIENCE, V186, P47, DOI 10.1126/science.186.4158.47; KUFFLER SW, 1953, J NEUROPHYSIOL, V16, P37, DOI 10.1152/jn.1953.16.1.37; LAU KC, 1990, J COMP NEUROL, V300, P583, DOI 10.1002/cne.903000411; LEVENTHAL AG, 1983, J NEUROSCI, V3, P332; MASLIM J, 1988, DEV BRAIN RES, V44, P87, DOI 10.1016/0165-3806(88)90120-4; MASLIM J, 1986, BRAIN RES, V373, P35, DOI 10.1016/0006-8993(86)90313-6; MASLIM J, 1986, J COMP NEUROL, V254, P382, DOI 10.1002/cne.902540310; MCGUIRE BA, 1984, J NEUROSCI, V4, P2920; MCGUIRE BA, 1986, J NEUROSCI, V6, P907; MOVSHON JA, 1981, ANNU REV PSYCHOL, V32, P477, DOI 10.1146/annurev.ps.32.020181.002401; MULLER F, 1988, J NEUROPHYSIOL, V59, P1657, DOI 10.1152/jn.1988.59.6.1657; NELSON R, 1983, VISION RES, V23, P1183, DOI 10.1016/0042-6989(83)90032-9; NELSON R, 1978, J NEUROPHYSIOL, V41, P472, DOI 10.1152/jn.1978.41.2.472; RAMOA AS, 1988, J NEUROSCI, V8, P4239; SCHILLER PH, 1992, TRENDS NEUROSCI, V15, P86, DOI 10.1016/0166-2236(92)90017-3; SHATZ CJ, 1988, SCIENCE, V242, P87, DOI 10.1126/science.3175636; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; SHERMAN SM, 1982, PHYSIOL REV, V62, P740; SLAUGHTER MM, 1981, SCIENCE, V211, P182, DOI 10.1126/science.6255566; SRETAVAN DW, 1988, NATURE, V336, P468, DOI 10.1038/336468a0; WASSLE H, 1991, VISUAL NEUROSCI, V7, P99, DOI 10.1017/S095252380001097X; WASSLE H, 1991, PHYSIOL REV, V71, P447, DOI 10.1152/physrev.1991.71.2.447; WASSLE H, 1981, PROC R SOC SER B-BIO, V212, P177, DOI 10.1098/rspb.1981.0033; WONG ROL, 1991, J NEUROBIOL, V22, P685, DOI 10.1002/neu.480220704	32	185	187	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 8	1993	364	6433					144	146		10.1038/364144a0	http://dx.doi.org/10.1038/364144a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LL367	8100613				2022-12-28	WOS:A1993LL36700048
J	WILDLING, E; WINKLER, S; BRANDTS, C; JENNE, L; GRANINGER, W; WERNSDORFER, WH; BIENZLE, U; KREMSNER, PG				WILDLING, E; WINKLER, S; BRANDTS, C; JENNE, L; GRANINGER, W; WERNSDORFER, WH; BIENZLE, U; KREMSNER, PG			HALOFANTRINE SENSITIVITY	LANCET			English	Letter									UNIV VIENNA,INST SPECIF PROPHYLAXIS & TROP MED,A-1010 VIENNA,AUSTRIA; LANDESINST TROPENMED,BERLIN,GERMANY; UNIV VIENNA,DEPT INFECT DIS,A-1010 VIENNA,AUSTRIA	University of Vienna; University of Vienna	WILDLING, E (corresponding author), ALBERT SCHWEITZER HOSP,INT RES LAB,BP 118,LAMBARENE,GABON.		Graninger, Winfried/AAI-7192-2020	Brandts, Christian H./0000-0003-1732-2535				BRASSEUR, 1993, LANCET, V341, P901; RICHARDLENOBLE D, 1989, PARASITOL TODAY, P59	2	8	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 3	1993	342	8862					55	55		10.1016/0140-6736(93)91922-9	http://dx.doi.org/10.1016/0140-6736(93)91922-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK985	8100329				2022-12-28	WOS:A1993LK98500051
J	MILLER, JD				MILLER, JD			NEUROSURGERY - SURGICAL EXCISION FOR SINGLE CEREBRAL METASTASIS	LANCET			English	Editorial Material							BRAIN				MILLER, JD (corresponding author), WESTERN GEN HOSP,DEPT CLIN NEUROSCI,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.							BLACK P, 1979, NEUROSURGERY, V5, P617, DOI 10.1227/00006123-197911000-00015; CAIRNCROSS JG, 1980, ANN NEUROL, V7, P529, DOI 10.1002/ana.410070606; PATCHELL RA, 1990, NEW ENGL J MED, V322, P494, DOI 10.1056/NEJM199002223220802; Thomas D G, 1989, Br J Neurosurg, V3, P321, DOI 10.3109/02688698909002810; TODD NV, 1987, LANCET, V1, P611; VECHT CJ, 1993, ANN NEUROL, V33, P583, DOI 10.1002/ana.410330605	6	8	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 19	1993	341	8860					1566	1566		10.1016/0140-6736(93)90702-I	http://dx.doi.org/10.1016/0140-6736(93)90702-I			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH550	8099645				2022-12-28	WOS:A1993LH55000009
J	TALLIS, R				TALLIS, R			GERIATRICS - HOW LONG SHOULD ELDERLY PATIENTS TAKE ANTIDEPRESSANTS	LANCET			English	Editorial Material											TALLIS, R (corresponding author), UNIV MANCHESTER,DEPT GERIATR MED,MANCHESTER M13 9PL,LANCS,ENGLAND.							Angst J., 1992, LONG TERM TREATMENT, P1; Cartwright A, 1988, ELDERLY PEOPLE THEIR; COLE MG, 1990, CAN MED ASSOC J, V143, P633; FRANK E, 1992, LONG TERM TREATMENT, P197; HOEPER EW, 1984, LANCET, V1, P33; LINDLEY CM, 1992, AGE AGEING, V21, P294, DOI 10.1093/ageing/21.4.294; MEYER RB, 1992, OXFORD TXB GERIATRIC, P105; SONG FJ, 1993, BMJ-BRIT MED J, V306, P683, DOI 10.1136/bmj.306.6879.683; WILLIAMSON J, 1980, AGE AGEING, V9, P73, DOI 10.1093/ageing/9.2.73; 1993, BRIT J PSYCHIAT, V162, P175	10	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 5	1993	341	8858					1444	1445		10.1016/0140-6736(93)90887-M	http://dx.doi.org/10.1016/0140-6736(93)90887-M			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF841	8099146				2022-12-28	WOS:A1993LF84100009
J	SALK, J; BRETSCHER, PA; SALK, PL; CLERICI, M; SHEARER, GM				SALK, J; BRETSCHER, PA; SALK, PL; CLERICI, M; SHEARER, GM			A STRATEGY FOR PROPHYLACTIC VACCINATION AGAINST HIV	SCIENCE			English	Editorial Material							CELL-MEDIATED-IMMUNITY; CYTOTOXIC T-CELLS; SUBSETS; HELPER; LEISHMANIASIS; RESPONSES; INFECTION; IMMUNIZATION; INDUCTION; ENVELOPE		UNIV SASKATCHEWAN, DEPT MICROBIOL, SASKATOON S7N 0X0, SK, CANADA; JONAS SALK FDN, LA JOLLA, CA 92037 USA; NCI, EXPTL IMMUNOL BRANCH, BETHESDA, MD 20892 USA	University of Saskatchewan; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	SALK, J (corresponding author), SALK INST BIOL STUDIES, POB 85800, SAN DIEGO, CA 92138 USA.			Clerici, Mario/0000-0001-5920-6191				ALDOVINI A, 1991, NATURE, V351, P479, DOI 10.1038/351479a0; ASHERSON GL, 1965, IMMUNOLOGY, V9, P205; BLOOM BR, 1992, IMMUNOL TODAY, V13, P131, DOI 10.1016/0167-5699(92)90110-S; BORKOWSKY W, 1990, AIDS RES HUM RETROV, V6, P673, DOI 10.1089/aid.1990.6.673; BRETSCHER PA, 1974, CELL IMMUNOL, V13, P171, DOI 10.1016/0008-8749(74)90237-8; BRETSCHER PA, 1992, IMMUNOL TODAY, V13, P342, DOI 10.1016/0167-5699(92)90168-7; BRETSCHER PA, 1991, RES IMMUNOL, V142, P45, DOI 10.1016/0923-2494(91)90011-7; BRETSCHER PA, 1981, FED PROC, V40, P1473; BRETSCHER PA, 1992, SCIENCE, V257, P539, DOI 10.1126/science.1636090; BRETSCHER PA, UNPUB; CHEYNIER R, 1992, EUR J IMMUNOL, V22, P2211, DOI 10.1002/eji.1830220905; CLERICI M, 1991, J INFECT DIS, V164, P178, DOI 10.1093/infdis/164.1.178; CLERICI M, 1992, J INFECT DIS, V165, P1012, DOI 10.1093/infdis/165.6.1012; CLERICI M, 1993, IMMUNOL TODAY, V14, P107, DOI 10.1016/0167-5699(93)90208-3; CLERICI M, 1993, J CLIN INVEST, V91, P759, DOI 10.1172/JCI116294; CLERICI M, 1993, IN PRESS 9 INT C AID; DELPRETE GF, 1991, J CLIN INVEST, V88, P346, DOI 10.1172/JCI115300; DOLAN MJ, 1993, IN PRESS 9 INT C AID; ELLNER JJ, 1990, MICROBIAL DETERMINANTS OF VIRULENCE AND HOST RESPONSE, P77; EMINI EA, 1990, J VIROL, V64, P3674, DOI 10.1128/JVI.64.8.3674-3678.1990; FITZGERALD TJ, 1992, INFECT IMMUN, V60, P3475, DOI 10.1128/IAI.60.9.3475-3479.1992; GAZZINELLI RT, 1992, J IMMUNOL, V148, P182; Gervais Francine, 1992, Immunology and Infectious Diseases (Oxford), V2, P179; HAMMOND SA, 1992, J EXP MED, V176, P1531, DOI 10.1084/jem.176.6.1531; HART MK, 1991, P NATL ACAD SCI USA, V88, P9448, DOI 10.1073/pnas.88.21.9448; HOM RC, 1991, J VIROL, V65, P220, DOI 10.1128/JVI.65.1.220-224.1991; HOWARD JG, 1986, INT REV EXP PATHOL, V28, P79; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; KELKER HC, 1992, AIDS RES HUM RETROV, V8, P1355, DOI 10.1089/aid.1992.8.1355; KOUP RA, 1993, FRONTIERS HIV PATHOG, P220; LAGRANGE PH, 1974, J EXP MED, V139, P528, DOI 10.1084/jem.139.3.528; LASARTE JJ, 1992, CELL IMMUNOL, V141, P211, DOI 10.1016/0008-8749(92)90140-K; LEVIN J, 1992, pA35; LEVY JA, 1989, JAMA-J AM MED ASSOC, V261, P2997, DOI 10.1001/jama.261.20.2997; LEVY JA, 1988, JAMA-J AM MED ASSOC, V259, P3037, DOI 10.1001/jama.259.20.3037; LOCKSLEY RM, 1991, IMMUNOPARASITOL TOD, pA58, DOI 10.1016/S0167-5699(05)80017-9; MOSMANN T, 1991, IMMUNOL TODAY, V12, P257, DOI 10.1016/0167-5699(91)90121-9; MOSMANN TR, 1989, ADV IMMUNOL, V46, P111, DOI 10.1016/S0065-2776(08)60652-5; PARISH CR, 1972, TRANSPLANT REV-DENMA, V13, P35; PEARSON RD, 1983, REV INFECT DIS, V5, P907; Plotkin SA, 1988, VACCINES-BASEL; PRINCE AM, 1991, AIDS RES HUM RETROV, V7, P971, DOI 10.1089/aid.1991.7.971; PUTKONEN P, 1991, NATURE, V352, P436, DOI 10.1038/352436a0; RAMSHAW I, 1992, IMMUNOL REV, V127, P157, DOI 10.1111/j.1600-065X.1992.tb01413.x; RAMSHAW IA, 1977, EUR J IMMUNOL, V7, P180, DOI 10.1002/eji.1830070313; RAMSHAW IA, 1976, EUR J IMMUNOL, V6, P674, DOI 10.1002/eji.1830061003; RAMSHAW IA, 1977, CELL IMMUNOL, V31, P364, DOI 10.1016/0008-8749(77)90038-7; RANKI A, 1989, AIDS, V3, P63, DOI 10.1097/00002030-198902000-00002; ROMAGNANI S, 1991, IMMUNOL TODAY, V12, P256, DOI 10.1016/0167-5699(91)90120-I; ROWLANDJONES SL, 1993, LANCET, V341, P860, DOI 10.1016/0140-6736(93)93063-7; SALGAME P, 1991, SCIENCE, V254, P279, DOI 10.1126/science.1681588; SALK J, 1969, ANN NY ACAD SCI, V164, P365, DOI 10.1111/j.1749-6632.1969.tb14051.x; SASTRY KJ, 1992, VIROLOGY, V188, P502, DOI 10.1016/0042-6822(92)90504-I; SCOTT P, 1988, J EXP MED, V168, P1675, DOI 10.1084/jem.168.5.1675; SCOTT P, 1991, IMMUNOL TODAY, V12, P346, DOI 10.1016/0167-5699(91)90063-Y; SCOTT P, 1993, SCIENCE, V260, P496, DOI 10.1126/science.8097337; SHEARER GM, 1992, CHEM IMMUNOL, V54, P21; SHEARER GM, 1992, J CELL BIOCH E S, V16, P112; SHEARER GM, 1993, IN PRESS 9 INT C AID; SHER A, 1992, ANNU REV IMMUNOL, V127, P183; STOVER CK, 1991, NATURE, V351, P456, DOI 10.1038/351456a0; TAKAHASHI H, 1990, NATURE, V344, P873, DOI 10.1038/344873a0; Turk J L, 1971, Adv Immunol, V13, P209, DOI 10.1016/S0065-2776(08)60185-6; TUTTOSI S, 1992, J IMMUNOL, V148, P397; VENET A, IN PRESS AIDS; WEISS SH, IN PRESS 9 INT C AID; WORTIS HH, 1968, IMMUNOLOGY, V14, P69; YASUTOMI Y, 1993, J VIROL, V67, P1707, DOI 10.1128/JVI.67.3.1707-1711.1993; YSSEL H, 1991, J EXP MED, V174, P593, DOI 10.1084/jem.174.3.593	69	193	211	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 28	1993	260	5112					1270	1272		10.1126/science.8098553	http://dx.doi.org/10.1126/science.8098553			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LE025	8098553				2022-12-28	WOS:A1993LE02500032
J	HEDRICK, MH; JENNINGS, RW; MACGILLIVRAY, TE; RICE, HE; FLAKE, AW; ADZICK, NS; HARRISON, MR				HEDRICK, MH; JENNINGS, RW; MACGILLIVRAY, TE; RICE, HE; FLAKE, AW; ADZICK, NS; HARRISON, MR			CHRONIC FETAL VASCULAR ACCESS	LANCET			English	Note							DIAPHRAGMATIC-HERNIA; MANAGEMENT	Intensive management of the fetus is limited by our inability to achieve access to the fetal circulation. Using laparoscopic surgery, we can maintain long-term access to the fetal circulation by extra-amniotic catheterisation of chorionic vessels in third-trimester monkeys and early-gestation sheep. We can sample fetal blood, continuously measure blood pressure, and infuse drugs without complications. Safe vascular access will permit assessment of fetal status during fetal surgical procedures and improve postoperative monitoring.			HEDRICK, MH (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT SURG,CTR FETAL TREATMENT,ROOM 1601-HSW,BOX 0570,SAN FRANCISCO,CA 94143, USA.		Harrison, Michael/GYD-8608-2022					HARRISON MR, 1982, J PEDIATR SURG, V17, P115, DOI 10.1016/S0022-3468(82)80193-0; HARRISON MR, 1990, NEW ENGL J MED, V322, P1582, DOI 10.1056/NEJM199005313222207; HARRISON MR, 1980, SURGERY, V88, P174; HARRISON MR, 1982, J PEDIATR SURG, V17, P728, DOI 10.1016/S0022-3468(82)80437-5; HARRISON MR, 1990, LANCET, V336, P965, DOI 10.1016/0140-6736(90)92420-M; HEDRICK MH, 1993, TRANSPLANT SCI, V3, P23; HEDRICK MH, 1992, SURG FORUM, P504; JENNINGS R W, 1991, Surgical Forum (Chicago), V42, P575; RICE HE, IN PRESS SURG FORUM	9	14	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 30	1993	342	8879					1086	1087		10.1016/0140-6736(93)92065-2	http://dx.doi.org/10.1016/0140-6736(93)92065-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME822	8105313				2022-12-28	WOS:A1993ME82200011
J	MEADE, TW; RUDDOCK, V; STIRLING, Y; CHAKRABARTI, R; MILLER, GJ				MEADE, TW; RUDDOCK, V; STIRLING, Y; CHAKRABARTI, R; MILLER, GJ			FIBRINOLYTIC-ACTIVITY, CLOTTING FACTORS, AND LONG-TERM INCIDENCE OF ISCHEMIC-HEART-DISEASE IN THE NORTHWICK-PARK-HEART-STUDY	LANCET			English	Article							MYOCARDIAL-INFARCTION; HEMOSTATIC FUNCTION; IMPAIRED FIBRINOLYSIS; PLASMINOGEN-ACTIVATOR; CORRELATED EXPOSURES; RISK FACTOR; PLASMA; FIBRINOGEN; DEATH	Fibrinolytic activity (FA) was measured by dilute blood clot lysis time at entry to the Northwick Park Heart Study in 1382 white men aged 40-64, of whom 179 subsequently experienced episodes of ischaemic heart disease during a mean follow-up period of 16.1 years. There was a significant interaction between age and low FA (p = 0.02) with respect to ischaemic heart disease: a difference of one standard deviation in FA was associated with a difference of about 40% in ischaemic heart disease risk (p = 0.002) in those aged 40-54 at entry. The FA association remained after adjusting for plasma fibrinogen. High fibrinogen concentrations themselves were also associated with ischaemic heart disease, as was high factor VII activity with fatal events. Low FA in younger men may exert a long-term influence by impairing the removal of fibrin deposits that contribute to atherogenesis. Low FA appears to be a leading determinant of ischaemic heart disease in younger men and methods of enhancing fibrinolytic activity, whether by life-style changes or pharmacologically, should be considered.			MEADE, TW (corresponding author), ST BARTHOLOMEWS HOSP,COLL MED,WOLFSON INST PREVENT MED,MRC,EPIDEMIOL & MED CARE UNIT,LONDON EC1M 6BQ,ENGLAND.							ASHFORD TP, 1968, AM J PATHOL, V53, P599; CHAKRABARTI R, 1968, LANCET, V1, P987; CHAKRABARTI R, 1978, THROMB HAEMOSTASIS, V39, P450; CHAKRABARTI R, 1962, J CLIN PATHOL, V15, P228, DOI 10.1136/jcp.15.3.228; FOLSOM AR, 1993, ARTERIOSCLER THROMB, V13, P162, DOI 10.1161/01.ATV.13.2.162; FRANCIS RB, 1988, AM HEART J, V115, P776, DOI 10.1016/0002-8703(88)90878-2; HAMSTEN A, 1986, BRIT HEART J, V55, P58; HAMSTEN A, 1987, LANCET, V2, P3; HEINRICH J, IN PRESS ARTERIOSCLE; HICKMAN JA, 1973, J CLIN PATHOL, V26, P189, DOI 10.1136/jcp.26.3.189; JANSSON JH, 1991, EUR HEART J, V12, P157, DOI 10.1093/oxfordjournals.eurheartj.a059862; MEADE TW, 1987, LANCET, V2, P986; MEADE TW, 1977, BRIT MED BULL, V33, P283, DOI 10.1093/oxfordjournals.bmb.a071448; MEADE TW, 1979, BMJ-BRIT MED J, V1, P153, DOI 10.1136/bmj.1.6157.153; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; MEADE TW, 1980, LANCET, V1, P1050; MILLER GJ, 1991, LANCET, V338, P1079, DOI 10.1016/0140-6736(91)91936-O; MILLER GJ, IN PRESS THROMB HAEM; MUSSONI L, 1992, ARTERIOSCLER THROMB, V12, P19, DOI 10.1161/01.ATV.12.1.19; PEDERSEN OD, 1993, EUR HEART J, V14, P785, DOI 10.1093/eurheartj/14.6.785; PHILLIPS AN, 1992, STAT MED, V11, P953, DOI 10.1002/sim.4780110712; PHILLIPS AN, 1991, J CLIN EPIDEMIOL, V44, P1223, DOI 10.1016/0895-4356(91)90155-3; PRINS MH, 1991, AM HEART J, V122, P545, DOI 10.1016/0002-8703(91)91014-E; RIDKER PM, 1993, LANCET, V341, P1165, DOI 10.1016/0140-6736(93)90998-V; ROSE G, 1986, BRIT MED J, V293, P306, DOI 10.1136/bmj.293.6542.306; SMITH EB, 1987, FIBRINOGEN, V2, P115; TORBJORN K, 1987, THROMB RES, V48, P621; WALMSLEY D, 1991, DIABETIC MED, V8, P954, DOI 10.1111/j.1464-5491.1991.tb01536.x; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804; 1976, WHO5 REG OFF EUR	30	704	714	1	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 30	1993	342	8879					1076	1079		10.1016/0140-6736(93)92062-X	http://dx.doi.org/10.1016/0140-6736(93)92062-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME822	8105310				2022-12-28	WOS:A1993ME82200008
J	PICKUP, JC				PICKUP, JC			SAMPLING AND SENSING BLOOD-GLUCOSE	LANCET			English	Editorial Material											PICKUP, JC (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,DIV CHEM PATHOL,LONDON,ENGLAND.							FISCHER U, 1987, DIABETOLOGIA, V30, P940, DOI 10.1007/BF00295878; HASHIGUCHI Y, 1993, DIABETES, V42, pA138; MEYERHOFF C, 1992, DIABETOLOGIA, V35, P1087, DOI 10.1007/BF02221686; PICKUP JC, 1993, DIABETES CARE, V16, P535, DOI 10.2337/diacare.16.2.535; POITOUT V, 1993, DIABETOLOGIA, V36, P658, DOI 10.1007/BF00404077; ROBINSON MR, 1992, CLIN CHEM, V38, P1618; WANG PH, 1993, LANCET, V342, P129, DOI 10.1016/0140-6736(93)91338-M; WANG PH, 1993, NEW ENGL J MED, V329, P977	8	6	6	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 30	1993	342	8879					1068	1068		10.1016/0140-6736(93)92059-3	http://dx.doi.org/10.1016/0140-6736(93)92059-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME822	8105307				2022-12-28	WOS:A1993ME82200005
J	CARPENTER, RHS				CARPENTER, RHS			BEYOND THE DARROW-YANNET DIAGRAM - AN ENHANCED PLOT FOR BODY-FLUID SPACES AND OSMOLALITY	LANCET			English	Article								The C-plot is a new method of plotting the volumes and osmolality of extracellular and intracellular body fluids, which in many circumstances is an improvement on the classical Darrow-Yannet diagram. The C-plot allows natural perturbations to be seen easily, and enables the relation between threats to fluid homoeostasis and the physiological mechanisms that counter those threats to be appreciated. The course of such events can also be shown in a single diagram.			CARPENTER, RHS (corresponding author), UNIV CAMBRIDGE,PHYSIOL LAB,CAMBRIDGE CB2 3EG,ENGLAND.			Carpenter, Roger/0000-0003-2572-1448				Darrow DC, 1935, J CLIN INVEST, V14, P266, DOI 10.1172/JCI100674; Kindig N B, 1983, Physiologist, V26, P304; SIGAARDANDERSEN O, 1971, SCAND J LAB INVEST, V27, P239	3	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 16	1993	342	8877					968	970		10.1016/0140-6736(93)92007-G	http://dx.doi.org/10.1016/0140-6736(93)92007-G			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MC005	8105219				2022-12-28	WOS:A1993MC00500014
J	BENSON, JR; BAUM, M				BENSON, JR; BAUM, M			BREAST-CANCER, DESMOID TUMORS, AND FAMILIAL ADENOMATOUS POLYPOSIS - A UNIFYING HYPOTHESIS	LANCET			English	Article							GROWTH; FIBROBLASTS; FETAL; CARCINOMA; INVITRO; INVIVO; CELLS; BETA	There is widespread agreement that epithelial tumours develop as a consequence of primary events within epithelial cells. According to the monoclonal theory, a tumour is caused by genetic change within a single cell, which imparts a selective growth advantage. This simple theory fails to take into account two important concepts. First, tumour generation is likely to involve multiple genetic events, some of which initiate a tumour, and others promote its growth.1 Second, tumours are usually composed of several tissue components, although they are known by the dominant proliferative cell type. This convention has tended to obscure the importance of ''secondary'' tissue components in carcinogenesis, despite evidence for the involvement of mesenchymal elements both in the induction and maintenance of transformation. To shift emphasis from the monoclonal theory, we propose a unifying hypothesis accounting for the effect of adjuvant tamoxifen in early breast cancer and the association between gastrointestinal polyps and desmoid tumours.	ROYAL MARSDEN HOSP,LONDON SW3 1JJ,ENGLAND	Royal Marsden NHS Foundation Trust	BENSON, JR (corresponding author), INST CANC RES,ACAD SECT SURG,HARTWELL LAB,FULHAM RD,LONDON SW3 1JJ,ENGLAND.							ADAMS EF, 1988, BREAST CANCER RES TR, V11, P165, DOI 10.1007/BF01805840; BAUM M, 1991, BRIT J CANCER, V64, P205, DOI 10.1038/bjc.1991.276; BROOKS MD, 1992, EUR J CANCER, V28A, P1014, DOI 10.1016/0959-8049(92)90445-8; BULOW S, 1987, SEMIN SURG ONCOL, V3, P84, DOI 10.1002/ssu.2980030207; BUTTA A, 1992, CANCER RES, V52, P4261; COLLETTA AA, 1990, BRIT J CANCER, V62, P405, DOI 10.1038/bjc.1990.307; COOPER M, 1977, CANCER RES, V37, P2544; Cunha G R, 1987, Prog Clin Biol Res, V239, P251; CUNHA GR, 1985, CELL DIFFER DEV, V17, P137, DOI 10.1016/0045-6039(85)90481-6; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; GORSCH SM, 1992, CANCER RES, V52, P6949; GREY AM, 1989, P NATL ACAD SCI USA, V86, P2438, DOI 10.1073/pnas.86.7.2438; HAGGIE JA, 1987, LANCET, V1, P1455; HERRERA L, 1986, AM J MED GENET, V25, P269; HORGAN K, 1987, BRIT J SURG, V74, P227, DOI 10.1002/bjs.1800740326; HUYNH HT, 1993, CANCER RES, V53, P1727; KNUDSON AG, 1986, ANNU REV GENET, V20, P231; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LIVINGSTONE DM, 1992 WINT M BACR ABP; LONGAKER MT, 1991, PLAST RECONSTR SURG, V87, P788, DOI 10.1097/00006534-199104000-00032; MANNING AM, 1991, ONCOGENE, V6, P1471; NAYLOR EW, 1979, ARCH SURG-CHICAGO, V114, P1181; NISWANDER L, 1993, NATURE, V361, P68, DOI 10.1038/361068a0; PFEFFER L, 1976, J CELL PHYSIOL, V89, P29, DOI 10.1002/jcp.1040890104; RICHMAN PI, 1988, J PATHOL, V156, P197, DOI 10.1002/path.1711560305; SOLOMON E, 1987, NATURE, V328, P616, DOI 10.1038/328616a0; WILLIAMS AC, 1990, CANCER RES, V50, P4724; 1992, LANCET, V339, P11; 1992, LANCET, V339, P71	29	34	35	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 2	1993	342	8875					848	850		10.1016/0140-6736(93)92700-4	http://dx.doi.org/10.1016/0140-6736(93)92700-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA025	8104277				2022-12-28	WOS:A1993MA02500014
J	SIMONS, FER; PERSAUD, MP; GILLESPIE, CA; CHEANG, M; SHUCKETT, EP				SIMONS, FER; PERSAUD, MP; GILLESPIE, CA; CHEANG, M; SHUCKETT, EP			ABSENCE OF POSTERIOR SUBCAPSULAR CATARACTS IN YOUNG-PATIENTS TREATED WITH INHALED GLUCOCORTICOIDS	LANCET			English	Article							ASTHMATIC-CHILDREN; STEROID AEROSOLS; BECLOMETHASONE; THERAPY	The prevalence of posterior subcapsular cataracts in young patients receiving inhaled glucocorticoids for treatment of chronic asthma is unknown. In a cross-sectional study, slit-lamp examinations were done on 95 consecutive young patients who were taking inhaled beclomethasone or budesonide. No posterior subcapsular cataracts were found. The median age of the patients was 13 8 (range 5.8-24.8). The median dose of inhaled beclomethasone or budesonide was 750 mug/day (range 300-2000), or 12.9 mug/kg per day (range 7.5-34.2). The median duration of treatment was 5 years (range 1-15). 77% of the patients had not used oral glucocorticoids in the year preceding the examination. This. study suggests that routine screening for posterior subcapsular cataracts in this patient population is not warranted.	UNIV MANITOBA,DEPT PEDIAT & CHILD HLTH,ALLERGY & CLIN IMMUNOL SECT,WINNIPEG R3T 2N2,MANITOBA,CANADA; UNIV MANITOBA,BIOSTAT CONSULTING UNIT,WINNIPEG R3T 2N2,MANITOBA,CANADA; UNIV MANITOBA,FAC MED,DEPT OPHTHALMOL,WINNIPEG R3T 2N2,MANITOBA,CANADA	University of Manitoba; University of Manitoba; University of Manitoba								ALLEN MB, 1989, BRIT MED J, V299, P432, DOI 10.1136/bmj.299.6696.432; AMEMIYA T, 1980, OPHTHALMOLOGICA, V180, P129, DOI 10.1159/000308965; BHAGAT RG, 1984, PEDIATRICS, V73, P626; CASTROW FF, 1981, J AM ACAD DERMATOL, V5, P64, DOI 10.1016/S0190-9622(81)70079-3; COUTTS JAP, 1992, ARCH DIS CHILD, V67, P332, DOI 10.1136/adc.67.3.332; DUNAND P, 1975, J ALLERGY CLIN IMMUN, V55, P123; KARIM AKA, 1989, BRIT MED J, V299, P918, DOI 10.1136/bmj.299.6704.918; KERREBIJN KF, 1990, AM REV RESPIR DIS, V141, pS77; KEWLEY GD, 1980, AUST PAEDIATR J, V16, P117; NASSIF E, 1987, J ALLERGY CLIN IMMUN, V80, P518, DOI 10.1016/0091-6749(87)90002-9; ROOKLIN AR, 1979, J ALLERGY CLIN IMMUN, V63, P383, DOI 10.1016/0091-6749(79)90210-0; SEVEL D, 1977, J ALLERGY CLIN IMMUN, V60, P215, DOI 10.1016/0091-6749(77)90132-4; SHAPIRO GG, 1976, J ALLERGY CLIN IMMUN, V57, P430, DOI 10.1016/0091-6749(76)90058-0; SHUNSHIN GA, 1989, BRIT J OPHTHALMOL, V73, P522, DOI 10.1136/bjo.73.7.522; TOOGOOD JH, 1993, J ALLERGY CLIN IMMUN, V91, P571, DOI 10.1016/0091-6749(93)90263-F; TURPEINEN M, 1991, J ALLERGY CLIN IMMUN, V88, P384, DOI 10.1016/0091-6749(91)90101-S	16	75	76	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 25	1993	342	8874					776	778		10.1016/0140-6736(93)91541-S	http://dx.doi.org/10.1016/0140-6736(93)91541-S			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LY868	8103877				2022-12-28	WOS:A1993LY86800010
J	SUTRISNA, B; REINGOLD, A; KRESNO, S; HARRISON, G; UTOMO, B				SUTRISNA, B; REINGOLD, A; KRESNO, S; HARRISON, G; UTOMO, B			CARE-SEEKING FOR FATAL ILLNESSES IN YOUNG-CHILDREN IN INDRAMAYU, WEST JAVA, INDONESIA	LANCET			English	Article							CHILDHOOD	To examine patterns of seeking care for gravely ill infants and children, we studied all deaths in children under 5 in 10 000 households in Indramayu, West Java, Indonesia, between July 1, 1991, and Dec 31, 1992. 141 deaths were identified (mortality rate 80 7 per 1000), of which 139 were due to causes other than trauma. No treatment of any kind was sought outside the home for 30 (22%) of the children who died from natural causes, and for 59 (42%) others only a traditional healer or other source of non-western medical advice was consulted. Whether or not a mother sought western medical care was strongly associated with the age of the child, the duration of the terminal illness, the previous attendance of the mother at a community-based maternal-and-child-health facility, and the mother's response to a prospectively asked question about what care should be sought for a hypothetical 1-month-old baby with signs of severe pneumonia. Household income, maternal age, and education, and distance between home and government health post were not associated with whether or not western medical care was sought.	UNIV CALIF BERKELEY,SCH PUBL HLTH,DEPT BIOMED & ENVIRONM HLTH SCI,EARL WARREN HALL,BERKELEY,CA 94720; UNIV INDONESIA,FAC PUBL HLTH,JAKARTA,INDONESIA; UNIV CALIF LOS ANGELES,SCH PUBL HLTH,LOS ANGELES,CA 90024; UNIV INDONESIA,CTR CHILD SURVIVAL,JAKARTA,INDONESIA	University of California System; University of California Berkeley; University of Indonesia; University of California System; University of California Los Angeles; University of Indonesia				Sutrisna, Bambang/0000-0002-5277-3879				BANG AT, 1992, B WORLD HEALTH ORGAN, V70, P499; CHERNICHOVSKY D, 1986, SOC SCI MED, V23, P611, DOI 10.1016/0277-9536(86)90155-3; COLSON A, 1971, J HLTH SOC BEHAV SEP, P226; GREEN EC, 1985, SOC SCI MED, V20, P277, DOI 10.1016/0277-9536(85)90242-4; PRAJITNO A, 1979, INT J HLTH ED, V2, P30; SUDARTI D, IN PRESS MED ANTHR	6	44	46	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 25	1993	342	8874					787	789		10.1016/0140-6736(93)91545-W	http://dx.doi.org/10.1016/0140-6736(93)91545-W			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LY868	8103880				2022-12-28	WOS:A1993LY86800014
J	DEDERA, DA; WALLER, EK; LEBRUN, DP; SENMAJUMDAR, A; STEVENS, ME; BARSH, GS; CLEARY, ML				DEDERA, DA; WALLER, EK; LEBRUN, DP; SENMAJUMDAR, A; STEVENS, ME; BARSH, GS; CLEARY, ML			CHIMERIC HOMEOBOX GENE E2A-PBX1 INDUCES PROLIFERATION, APOPTOSIS, AND MALIGNANT-LYMPHOMAS IN TRANSGENIC MICE	CELL			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; C-MYC EXPRESSION; PRE-B; CELL-DEATH; TRANSCRIPTION FACTORS; NEGATIVE SELECTION; ENHANCER BINDING; DNA-BINDING; N-MYC; BCL-2	Expression of the homeobox fusion gene E2A-PBX1 under control of the immunoglobulin heavy chain enhancer efficiently induced malignancies in transgenic mice. All animals died before 5 months of age with lymphomas that demonstrated phenotypes consistent with transitional intermediate thymocytes (CD4+/CD8+/CD3med). E2A-PBX1 also markedly altered lymphoid development in pretumorous animals, reducing the number of thymocytes and bone marrow B lineage progenitors to 20% of normal levels. In spite of the observed reductions in lymphoid cells, premalignant animals contained significantly increased numbers of cycling thymocytes, but a higher proportion was also undergoing apoptosis, suggesting that increased cell death resulted in the marked lymphopenias. These data indicate that the chimeric homeodomain protein E2A-PBX1 paradoxically induces both proliferation and apoptosis in lymphoid cells, suggesting an in vivo association between nuclear oncogene-induced cell cycle progression and programed cell death.	STANFORD UNIV,MED CTR,SCH MED,DEPT MED,STANFORD,CA 94305; STANFORD UNIV,MED CTR,SCH MED,DEPT RADIAT ONCOL,STANFORD,CA 94305; STANFORD UNIV,MED CTR,SCH MED,DEPT DEV BIOL,STANFORD,CA 94305; STANFORD UNIV,MED CTR,SCH MED,HOWARD HUGHES MED INST,STANFORD,CA 94305	Stanford University; Stanford University; Stanford University; Howard Hughes Medical Institute; Stanford University	DEDERA, DA (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT PATHOL,EXPTL ONCOL LAB,STANFORD,CA 94305, USA.		Waller, Edmund K/AAP-3055-2020		NATIONAL CANCER INSTITUTE [R01CA042971, R37CA042971] Funding Source: NIH RePORTER; NCI NIH HHS [CA42971] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; ASKEW DS, 1991, ONCOGENE, V6, P1915; BINDL JM, 1986, AM J CLIN PATHOL, V85, P490, DOI 10.1093/ajcp/85.4.490; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BLANKENSTEIN T, 1988, NUCLEIC ACIDS RES, V16, P10939, DOI 10.1093/nar/16.22.10939; BOROWITZ MJ, 1993, BLOOD, V82, P1086; CARROLL AJ, 1984, BLOOD, V63, P721; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DILDROP R, 1989, EMBO J, V8, P1121, DOI 10.1002/j.1460-2075.1989.tb03482.x; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FISCH P, 1992, ONCOGENE, V7, P2389; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; GROSSCHEDL R, 1984, CELL, V38, P647, DOI 10.1016/0092-8674(84)90259-9; GUIDOS CJ, 1990, J EXP MED, V172, P835, DOI 10.1084/jem.172.3.835; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HOGAN B, 1986, MANIPULATING MOUSE E; HOLLANDER Z, 1988, CYTOMETRY, V9, P485, DOI 10.1002/cyto.990090513; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MCGUIRE EA, 1992, MOL CELL BIOL, V12, P4186, DOI 10.1128/MCB.12.9.4186; MELLENTIN JD, 1990, GENE CHROMOSOME CANC, V2, P239, DOI 10.1002/gcc.2870020313; MELLENTIN JD, 1989, SCIENCE, V246, P379, DOI 10.1126/science.2799390; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; MOROY T, 1990, EMBO J, V9, P3659, DOI 10.1002/j.1460-2075.1990.tb07577.x; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PRIVITERA E, 1992, BLOOD, V79, P1781; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SENMAJUMDAR A, 1990, J IMMUNOL, V144, P111; SENMAJUMDAR A, 1992, J EXP MED, V176, P543, DOI 10.1084/jem.176.2.543; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; TILLY JL, 1992, MOL ENDOCRINOL, V6, P1942, DOI 10.1210/me.6.11.1942; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251	52	184	188	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 10	1993	74	5					833	843		10.1016/0092-8674(93)90463-Z	http://dx.doi.org/10.1016/0092-8674(93)90463-Z			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LX292	8104101				2022-12-28	WOS:A1993LX29200009
J	HUSSELL, T; ISAACSON, PG; CRABTREE, JE; SPENCER, J				HUSSELL, T; ISAACSON, PG; CRABTREE, JE; SPENCER, J			THE RESPONSE OF CELLS FROM LOW-GRADE B-CELL GASTRIC LYMPHOMAS OF MUCOSA-ASSOCIATED LYMPHOID-TISSUE TO HELICOBACTER-PYLORI	LANCET			English	Article							PROLIFERATION; ANTIGEN; MICE	An association has been shown between colonisation of gastric mucosa by Helicobacter pylori, acquisition of mucosa-associated lymphoid tissue (MALT), and occurrence of primary B-cell gastric MALT lymphoma. We investigated the immunological response of cells from 3 low-grade primary B-cell gastric MALT lymphomas to H pylori type NCTC 11637 and 12 isolates of H pylori from patients without lymphomas. After co-culture of tumour cells with bacteria, cells were examined for phenotypic evidence of activation and proliferation, and supernatant assayed to detect tumour-derived immunoglobulin and interleukin-2 (IL-2). Neoplastic B cells and non-neoplastic T cells proliferated, and IL-2-receptor expression by most cells in the cultures was increased with stimulating strains of H pylori. There were also increases in tumour immunoglobulin and IL-2 release when activation and proliferation were seen in response to stimulating bacteria. Removal of T cells from the tumour cell suspension reduced proliferation and IL-2-receptor expression. In comparison, no responses were seen in cells from high-grade gastric MALT lymphomas or low-grade B-cell MALT lymphomas of other sites. The response of low-grade B-cell gastric MALT lymphomas to stimulating strains of H pylori is dependent on H-pylori-specific T cells and their products, rather than the bacteria themselves.	UCL,SCH MED,DEPT HISTOPATHOL,UNIV ST,LONDON WC1E 6JJ,ENGLAND; ST JAMES HOSP,DEPT CLIN MED,LEEDS,ENGLAND	University of London; University College London; UCL Medical School; Saint James's University Hospital			Hussell, Tracy/O-4630-2014; Crabtree, Jean E/A-3549-2010	Hussell, Tracy/0000-0001-7186-6141; Spencer, Jo/0000-0002-7202-2431				AKOPYANZ N, 1992, NUCLEIC ACIDS RES, V20, P6221, DOI 10.1093/nar/20.23.6221; BEVERLEY PCL, 1981, EUR J IMMUNOL, V126, P2117; CARACCI A, 1993, P NATL ACAD SCI USA, V90, P5791; COGLIATTI SB, 1991, GASTROENTEROLOGY, V101, P1159, DOI 10.1016/0016-5085(91)90063-Q; CRABTREE JE, 1991, LANCET, V338, P332, DOI 10.1016/0140-6736(91)90477-7; FIGURA N, 1989, J CLIN MICROBIOL, V27, P225, DOI 10.1128/JCM.27.1.225-226.1989; GERDES J, 1984, J IMMUNOL, V133, P1710; GREEN JE, 1989, NATURE, V341, P72, DOI 10.1038/341072a0; HUSSELL T, 1993, AM J PATHOL, V142, P285; HUSSELL T, 1993, J PATHOL, V169, P221, DOI 10.1002/path.1711690208; ISAACSON PG, 1987, HISTOPATHOLOGY, V11, P445, DOI 10.1111/j.1365-2559.1987.tb02654.x; MASON DY, 1990, AM J PATHOL, V136, P1215; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; SMITH KA, 1988, SCIENCE, V240, P1164; SPENCER J, 1990, J PATHOL, V160, P231, DOI 10.1002/path.1711600309; THOMAS JE, 1992, LANCET, V340, P1194, DOI 10.1016/0140-6736(92)92894-L; UMETSU DT, 1990, J IMMUNOL, V144, P2550; VERONESE ML, 1992, J EXP MED, V176, P1763, DOI 10.1084/jem.176.6.1763; WOTHERSPOON AC, 1993, LANCET, V342, P575, DOI 10.1016/0140-6736(93)91409-F; WOTHERSPOON AC, 1991, LANCET, V338, P1175, DOI 10.1016/0140-6736(91)92035-Z	20	719	745	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 4	1993	342	8871					571	574		10.1016/0140-6736(93)91408-E	http://dx.doi.org/10.1016/0140-6736(93)91408-E			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV963	8102718				2022-12-28	WOS:A1993LV96300008
J	TUCKEY, JA; PARRY, BR; MCCALL, JL				TUCKEY, JA; PARRY, BR; MCCALL, JL			PENTOXIFYLLINE AND WELL-BEING IN CANCER	LANCET			English	Letter							VALIDATION							McCall, John/0000-0001-8667-3449				BUXTON LS, 1992, EUR J SURG, V158, P393; DEZUBE BJ, 1990, LANCET, V335, P662, DOI 10.1016/0140-6736(90)90450-J; MCCALL JL, 1990, AUST NZ J SURG, V60, P503, DOI 10.1111/j.1445-2197.1990.tb07415.x; SCHIPPER H, 1984, J CLIN ONCOL, V2, P472, DOI 10.1200/JCO.1984.2.5.472	4	5	5	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 4	1993	342	8871					617	617		10.1016/0140-6736(93)91441-N	http://dx.doi.org/10.1016/0140-6736(93)91441-N			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV963	8102744				2022-12-28	WOS:A1993LV96300046
J	FRANKLYN, JA				FRANKLYN, JA			GRAVES OPHTHALMOPATHY AND THE TSH RECEPTOR	LANCET			English	Editorial Material							THYROTROPIN RECEPTOR				FRANKLYN, JA (corresponding author), UNIV BIRMINGHAM,DEPT MED,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.							BAHN RS, 1993, J ENDOCRINOL INVE S2, V16, P42; ENDO T, 1993, J ENDOCRINOL INVE S2, V16, P158; Francis T, 1991, Thyroid, V1, P223, DOI 10.1089/thy.1991.1.223; HELDIN NE, 1991, J CLIN ENDOCR METAB, V73, P1374, DOI 10.1210/jcem-73-6-1374; HEUFELDER AE, 1993, 75TH P M END SOC; MURAKAMI M, 1990, BIOCHEM BIOPH RES CO, V171, P512, DOI 10.1016/0006-291X(90)91423-P; ROSELLIREHFUS L, 1992, ENDOCRINOLOGY, V10, P1857; ROTELLA CM, 1986, J CLIN ENDOCR METAB, V62, P357, DOI 10.1210/jcem-62-2-357	8	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 7	1993	342	8867					318	319		10.1016/0140-6736(93)91467-Z	http://dx.doi.org/10.1016/0140-6736(93)91467-Z			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ868	8101579				2022-12-28	WOS:A1993LQ86800005
J	HASIBEDER, W; HAISJACKI, M; GERMANN, R; VERGEINER, R; SEYR, M; SPARR, H				HASIBEDER, W; HAISJACKI, M; GERMANN, R; VERGEINER, R; SEYR, M; SPARR, H			PHYSIOLOGICAL SCORING SYSTEMS AND AUDIT	LANCET			English	Letter											HASIBEDER, W (corresponding author), UNIV INNSBRUCK, ANAESTHESIA & GEN INTENS CARE MED CLIN, A-6020 INNSBRUCK, AUSTRIA.							Cullen D J, 1974, Crit Care Med, V2, P57, DOI 10.1097/00003246-197403000-00001; GUTIERREZ G, 1992, LANCET, V339, P195, DOI 10.1016/0140-6736(92)90002-K	2	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 31	1993	342	8866					307	307						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ163	8101333				2022-12-28	WOS:A1993LQ16300051
J	VANDERMEER, J; HILLEGE, HL; KOOTSTRA, GJ; ASCOOP, CAPL; PFISTERER, M; VANGILST, WH; LIE, KI				VANDERMEER, J; HILLEGE, HL; KOOTSTRA, GJ; ASCOOP, CAPL; PFISTERER, M; VANGILST, WH; LIE, KI			PREVENTION OF ONE-YEAR VEIN-GRAFT OCCLUSION AFTER AORTOCORONARY-BYPASS SURGERY - A COMPARISON OF LOW-DOSE ASPIRIN, LOW-DOSE ASPIRIN PLUS DIPYRIDAMOLE, AND ORAL ANTICOAGULANTS	LANCET			English	Article							CORONARY-ARTERY BYPASS; ANTI-COAGULANT THERAPY; ANTIPLATELET THERAPY; PATENCY; PLATELET; TRIAL; OPERATIONS; INHIBITION; AGENTS; RATIO	Aspirin, alone or in combination with dipyridamole, is known to prevent occlusion of aortocoronary vein grafts. The benefit of dipyridamole in addition to aspirin remains controversial, and the efficacy and safety of oral anticoagulants for prevention of vein-graft occlusion have not been established. We assessed one-year angiographic vein-graft patency after aortocoronary-bypass surgery in 948 patients assigned to receive aspirin, aspirin plus dipyridamole, or oral anticoagulants in a prospective, randomised trial. The design was double-blind and placebo-controlled for the aspirin groups, but open for oral anticoagulant treatment. Dipyridamole (5 mg/kg per 24 h intravenously for 28 h, followed by 200 mg twice daily) and oral anticoagulants (desired prothrombin time range 2.8-4.8 international normalised ratio) were started before surgery, and aspirin (50 mg per day) was started after surgery. Clinical outcome was assessed by the incidence of myocardial infarction, thrombosis, major bleeding, or death. Occlusion rate of distal anastomoses was 11% in the aspirin plus dipyridamole group versus 15% in the aspirin group (relative risk 0.76, 95% CI 0.54-1.05) and 13% in the oral anticoagulants group. Clinical events occurred in 20.3% of patients receiving aspirin plus dipyridamole compared with 13.9% of the aspirin group (relative risk 1.46, 95% CI 1.02-2.08) and 16.9% of the oral anticoagulants group. Our data provide no convincing evidence that addition of dipyridamole to 50 mg aspirin per day improves aortocoronary vein-graft patency. Moreover, there is evidence that the combination increases the overall clinical-event rate. Compared with aspirin, oral anticoagulants provided no benefit.	MED CTR DE KLOKKENBERG,BREDA,SWITZERLAND; UNIV HOSP BASEL,CH-4031 BASEL,SWITZERLAND; ST ANTONIUS HOSP,NIEUWEGEIN,SWITZERLAND	University of Basel	VANDERMEER, J (corresponding author), UNIV GRONINGEN HOSP,THORAXCTR,9713 EZ GRONINGEN,NETHERLANDS.		van Gilst, Wiek/R-1806-2019; van Gilst, Wiek H/C-3828-2008	van Gilst, Wiek/0000-0003-2968-8585; 				BAR FW, 1984, J AM COLL CARDIOL, V4, P17; BROWN BG, 1985, CIRCULATION, V72, P138, DOI 10.1161/01.CIR.72.1.138; CHESEBRO JH, 1982, NEW ENGL J MED, V307, P73, DOI 10.1056/NEJM198207083070201; CHESEBRO JH, 1984, NEW ENGL J MED, V310, P209, DOI 10.1056/NEJM198401263100401; EKESTROM SA, 1990, SCAND J THORAC CARD, V24, P191, DOI 10.3109/14017439009098068; FITZGERALD GA, 1987, NEW ENGL J MED, V316, P1247; Fuster V., 1987, THROMB DIATH HAEMO, P349; GAVAGHAN TP, 1991, CIRCULATION, V83, P1526, DOI 10.1161/01.CIR.83.5.1526; GOHLKE H, 1981, CIRCULATION, V64, P22; GOLDMAN S, 1989, CIRCULATION, V80, P1190, DOI 10.1161/01.CIR.80.5.1190; GOLDMAN S, 1991, CIRCULATION, V84, P520, DOI 10.1161/01.CIR.84.2.520; GOLDMAN S, 1988, CIRCULATION, V77, P1324, DOI 10.1161/01.CIR.77.6.1324; HENDERSON WG, 1989, ANN INTERN MED, V111, P743, DOI 10.7326/0003-4819-111-9-743; HENDERSON WG, 1988, CONTROL CLIN TRIALS, V9, P189, DOI 10.1016/0197-2456(88)90060-8; LORENZ RL, 1984, LANCET, V1, P1261; MCENANY MT, 1982, J THORAC CARDIOV SUR, V83, P81; MIETTINEN OS, 1974, AM J EPIDEMIOL, V100, P515; PANTELY GA, 1979, NEW ENGL J MED, V301, P962, DOI 10.1056/NEJM197911013011803; PATRIGNANI P, 1982, J CLIN INVEST, V69, P1366, DOI 10.1172/JCI110576; PFISTERER M, 1989, LANCET, V2, P1; SANZ G, 1990, CIRCULATION, V82, P765, DOI 10.1161/01.CIR.82.3.765; TEOH KH, 1988, J THORAC CARDIOV SUR, V96, P332; VANDENBESSELAAR AMHP, 1988, AM J CLIN PATHOL, V90, P685, DOI 10.1093/ajcp/90.6.685; VERSTRAETE M, 1986, EUR HEART J, V7, P4, DOI 10.1093/oxfordjournals.eurheartj.a061955; WEKSLER BB, 1983, NEW ENGL J MED, V308, P800, DOI 10.1056/NEJM198304073081402; 1991, NEW ENGL J MED, V325, P1261; 1990, LANCET, V336, P827	27	89	89	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 31	1993	342	8866					257	264		10.1016/0140-6736(93)91815-4	http://dx.doi.org/10.1016/0140-6736(93)91815-4			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ163	8101300				2022-12-28	WOS:A1993LQ16300008
J	EDWARDSON, JA; MOORE, PB; FERRIER, IN; LILLEY, JS; NEWTON, GWA; BARKER, J; TEMPLAR, J; DAY, JP				EDWARDSON, JA; MOORE, PB; FERRIER, IN; LILLEY, JS; NEWTON, GWA; BARKER, J; TEMPLAR, J; DAY, JP			EFFECT OF SILICON ON GASTROINTESTINAL ABSORPTION OF ALUMINUM	LANCET			English	Note							ALZHEIMERS-DISEASE; CITRATE	The reported geographical association between Alzheimer's disease and levels of aluminium (Al) in water supplies may reflect the inverse relation between Al and silicon (Si) concentrations in water, and the potential for Si to reduce the bioavailability of the metal. We tested this hypothesis using isotopic Al-26 tracer administered orally to five healthy volunteers in the presence and absence of Si. Dissolved Si, at a concentration found in some water suplies (100 mumol/L), reduced the peak plasma Al-26 concentration to 15% of the value obtained in the absence of Si. The results indicate that dissolved Si is an important factor in limiting the absorption of dietary Al.	SERC, DARESBURY LAB, NUCL STRUCT FACIL, WARRINGTON WA4 4AD, CHESHIRE, ENGLAND; UNIV MANCHESTER, DEPT CHEM, MANCHESTER M13 9PL, LANCS, ENGLAND	STFC Daresbury Laboratory; University of Manchester	EDWARDSON, JA (corresponding author), NEWCASTLE GEN HOSP, MRC, NEUROCHEM PATHOL UNIT, NEWCASTLE UPON TYNE NE4 6BE, TYNE & WEAR, ENGLAND.		Barker, James/A-5103-2018	Barker, James/0000-0002-5863-9400				BARKER J, 1990, NUCL INSTRUM METH B, V52, P540, DOI 10.1016/0168-583X(90)90473-8; BIRCHALL JD, 1989, LANCET, V1, P953; Birchall JD, 1991, ALUMINIUM CHEM BIOL, P53; DAY JP, 1991, LANCET, V337, P1345, DOI 10.1016/0140-6736(91)93016-3; EDWARDSON JA, 1992, ALUMINIUM CHEM BIOL, P85; GREGER JL, 1992, CIBA F SYMP, V169, P26; Martyn C N, 1992, Ciba Found Symp, V169, P69; MOORE PB, 1992, ANN M ROYAL COLLEGE; SLANINA P, 1984, FOOD CHEM TOXICOL, V22, P391, DOI 10.1016/0278-6915(84)90369-7; TAYLOR GA, 1992, AGE AGEING, V21, P81, DOI 10.1093/ageing/21.2.81	10	134	138	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 24	1993	342	8865					211	212		10.1016/0140-6736(93)92301-9	http://dx.doi.org/10.1016/0140-6736(93)92301-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN622	8100932				2022-12-28	WOS:A1993LN62200014
J	SERNERI, GGN; GENSINI, GF; COMEGLIO, M				SERNERI, GGN; GENSINI, GF; COMEGLIO, M			LONG-TERM FOLLOW-UP OF HEPARIN TO PREVENT MYOCARDIAL-INFARCTION	LANCET			English	Letter											SERNERI, GGN (corresponding author), UNIV FLORENCE,ITALIAN STUDY GRP PREVENT MYOCARDIAL REINFARCT LOW DOSE HEPARIN,I-50134 FLORENCE,ITALY.							SERNERI GGN, 1987, LANCET, V1, P937	1	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 3	1993	342	8862					48	48		10.1016/0140-6736(93)91908-5	http://dx.doi.org/10.1016/0140-6736(93)91908-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK985	8100312				2022-12-28	WOS:A1993LK98500036
J	CRAIG, EA				CRAIG, EA			CHAPERONES - HELPERS ALONG THE PATHWAYS TO PROTEIN-FOLDING	SCIENCE			English	Editorial Material							PRECURSOR PROTEINS; YEAST MITOCHONDRIA; TRANSLOCATION; MATRIX; IMPORT; HSP70				CRAIG, EA (corresponding author), UNIV WISCONSIN,DEPT BIOMOLEC CHEM,MADISON,WI 53706, USA.							BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BERTSCH U, 1992, P NATL ACAD SCI USA, V89, P8696, DOI 10.1073/pnas.89.18.8696; CHEN WJ, 1987, J BIOL CHEM, V262, P15605; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CRAIG EA, 1993, MICROBIOL REV, V57, P293; EPSTEIN CJ, 1963, COLD SPRING HARB SYM, V28, P439, DOI 10.1101/SQB.1963.028.01.060; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LINDQUIST S, 1988, ANNU REV GENET, V22, P316; MANNINGKRIEG UC, 1991, EMBO J, V10, P3273, DOI 10.1002/j.1460-2075.1991.tb04891.x; NELSON R J, 1992, Current Biology, V2, P487, DOI 10.1016/0960-9822(92)90673-X; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; OSTERMANN J, 1990, FEBS LETT, V277, P281, DOI 10.1016/0014-5793(90)80865-G; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885	17	167	197	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 25	1993	260	5116					1902	1903		10.1126/science.8100364	http://dx.doi.org/10.1126/science.8100364			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LJ349	8100364				2022-12-28	WOS:A1993LJ34900030
J	POTTS, M; CARSWELL, W				POTTS, M; CARSWELL, W			INFECTION - AIDS - LOSING THE BATTLE AND THE WAR	LANCET			English	Editorial Material									UNIV CALIF BERKELEY,SCH PUBL HLTH,BERKELEY,CA 94720	University of California System; University of California Berkeley	POTTS, M (corresponding author), INT FAMILY HLTH,LONDON,ENGLAND.							SHELTON JD, 1992, LANCET, V340, P1334, DOI 10.1016/0140-6736(92)92505-A; 1992, AIDS ASSESSMENT PLAN	2	2	2	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 5	1993	341	8858					1442	1443		10.1016/0140-6736(93)90885-K	http://dx.doi.org/10.1016/0140-6736(93)90885-K			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF841	8099144				2022-12-28	WOS:A1993LF84100007
J	REDMAN, CWG; ROBERTS, JM				REDMAN, CWG; ROBERTS, JM			MANAGEMENT OF PREECLAMPSIA	LANCET			English	Article							ANTIHYPERTENSIVE TREATMENT; SEVERE PREECLAMPSIA; CONTROLLED TRIAL; PREGNANCY; HYPERTENSION; ATENOLOL; TOXEMIA; CALCIUM; ASPIRIN		UNIV PITTSBURGH, MAGEE WOMENS HOSP, DEPT OBSTET GYNECOL & REPROD SCI, PITTSBURGH, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	REDMAN, CWG (corresponding author), JOHN RADCLIFFE HOSP, NUFFIELD DEPT OBSTET & GYNAECOL, OXFORD OX3 9DU, ENGLAND.		Roberts, James/AAI-3283-2020	Roberts, James/0000-0002-2671-3207				[Anonymous], 1993, Lancet, V341, P396; BEAUFILS M, 1985, LANCET, V1, P840, DOI 10.1016/S0140-6736(85)92207-X; BELFORT MA, 1992, AM J OBSTET GYNECOL, V167, P661, DOI 10.1016/S0002-9378(11)91567-1; BELIZAN JM, 1991, NEW ENGL J MED, V325, P1399, DOI 10.1056/NEJM199111143252002; BLAKE S, 1991, BRIT J OBSTET GYNAEC, V98, P244, DOI 10.1111/j.1471-0528.1991.tb13387.x; BUTTERS L, 1990, BMJ-BRIT MED J, V301, P587, DOI 10.1136/bmj.301.6752.587; CHUA S, 1991, LANCET, V337, P250, DOI 10.1016/0140-6736(91)92227-S; COLLINS R, 1991, OXFORD DATABASE PERI; DEKKER GA, 1993, AM J OBSTET GYNECOL, V168, P214, DOI 10.1016/S0002-9378(12)90917-5; DOMMISSE J, 1990, BRIT J OBSTET GYNAEC, V97, P104, DOI 10.1111/j.1471-0528.1990.tb01734.x; DULEY L, 1992, OXFORD DATABASE PERI; FENAKEL K, 1991, OBSTET GYNECOL, V77, P331; GOODLIN RC, 1978, LANCET, V2, P51; HALL MH, 1980, LANCET, V2, P78; HUTTON JD, 1992, BRIT J OBSTET GYNAEC, V99, P554, DOI 10.1111/j.1471-0528.1992.tb13819.x; IMPERIALE TF, 1991, JAMA-J AM MED ASSOC, V266, P261; MCCARRON DA, 1982, NEW ENGL J MED, V307, P226, DOI 10.1056/NEJM198207223070405; OLSEN SF, 1990, BRIT J NUTR, V64, P599, DOI 10.1079/BJN19900063; PRITCHARD JA, 1984, AM J OBSTET GYNECOL, V148, P951, DOI 10.1016/0002-9378(84)90538-6; REDMAN CWG, 1976, LANCET, V2, P753; REDMAN CWG, 1978, BRIT MED J, V1, P467, DOI 10.1136/bmj.1.6111.467; REDMAN CWG, 1989, TXB OBSTETRICS, P515; ROBINSON M, 1958, LANCET, V1, P178; RUBIN PC, 1983, LANCET, V1, P431; RYAN G, 1989, AM J OBSTET GYNECOL, V161, P1297, DOI 10.1016/0002-9378(89)90687-X; SCHWARTZ ML, 1985, OBSTET GYNECOL, V66, pS19; SIBAI BM, 1981, OBSTET GYNECOL, V58, P609; TUFFNELL DJ, 1992, LANCET, V339, P224, DOI 10.1016/0140-6736(92)90017-W; WALLENBURG HCS, 1986, LANCET, V1, P1; WEINSTEIN L, 1982, AM J OBSTET GYNECOL, V142, P159, DOI 10.1016/S0002-9378(16)32330-4; 1992, LANCET, V339, P1023; 1946, J OBSTET GYN BR COMM, V53, P498; 1989, LANCET, V2, P482	33	89	91	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 5	1993	341	8858					1451	1454		10.1016/0140-6736(93)90890-S	http://dx.doi.org/10.1016/0140-6736(93)90890-S			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF841	8099149				2022-12-28	WOS:A1993LF84100012
J	BECKINGHAM, IJ; OROURKE, JS; BISHOP, MC; BLAMEY, RW				BECKINGHAM, IJ; OROURKE, JS; BISHOP, MC; BLAMEY, RW			ARE BACKUP ARTERIOVENOUS-FISTULAS NECESSARY FOR PATIENTS ON CONTINUOUS AMBULATORY PERITONEAL-DIALYSIS	LANCET			English	Article							VASCULAR ACCESS; HEMODIALYSIS	The rationale for backup fistulae for patients on continuous ambulatory peritoneal dialysis (CAPD) is that many will require emergency haemodialysis and, subsequently, permanent haemodialysis. 42% of renal units in the UK have a policy of providing CAPD patients with backup arteriovenous fistulae. We have investigated whether this policy is justified. In our unit, of 176 patients who started CAPD between 1986 and 1989, most (73%) did not require haemodialysis over a median follow-up period of 4 years. Of the 153 backup fistulae created in 114 patients, only 10 were ever used for emergency haemodialysis. 23 other patients required emergency haemodialysis, but when required their fistulae were no longer functioning. The mean fistula patency times among patients in this study compared very favourably with those in other published work. This finding indicates that most fistulae are not available for emergency haemodialysis when required. 94% of fistulae were never used for haemodialysis. Hence it is no longer justifiable to create backup fistulae in CAPD patients.			BECKINGHAM, IJ (corresponding author), CITY HOSP,DEPT TRANSPLANT SURG,PROF SURG UNIT,NOTTINGHAM NG5 1PB,ENGLAND.							BERNARDINI J, 1991, CLIN NEPHROL, V36, P29; BRESCIA MJ, 1966, NEW ENGL J MED, V275, P1089, DOI 10.1056/NEJM196611172752002; DEPIN EAS, 1976, AM J SURG, V132, P373; FARRINGTON K, 1991, NEPHRON, V59, P323, DOI 10.1159/000186576; HAIMOV M, 1975, SURG GYNECOL OBSTET, V141, P619; HAKIM RM, 1986, KIDNEY, P1795; JOFFE P, 1986, PERITON DIALYSIS INT, V6, P193; LAWTON L, 1979, INT J ARTIF ORGANS, V2, P9; PALDER SB, 1985, ANN SURG, V202, P235, DOI 10.1097/00000658-198508000-00015; ROHR MS, 1978, ARCH SURG-CHICAGO, V113, P153	10	19	20	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 29	1993	341	8857					1384	1386		10.1016/0140-6736(93)90951-C	http://dx.doi.org/10.1016/0140-6736(93)90951-C			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE180	8098800				2022-12-28	WOS:A1993LE18000014
J	CARO, JJ; GROOME, PA; FLEGEL, KM				CARO, JJ; GROOME, PA; FLEGEL, KM			ATRIAL-FIBRILLATION AND ANTICOAGULATION - FROM RANDOMIZED TRIALS TO PRACTICE	LANCET			English	Article							STROKE; FRAMINGHAM; WARFARIN; THERAPY; COMPLICATIONS; PREVENTION; RISK	Randomised trials confirm that anticoagulants reduce the risk of emboli in atrial fibrillation. To apply this evidence to practice, we developed an expression relating all relevant factors. Trial-based estimates of the risks of emboli and haemorrhage, and of the effects of anticoagulants on these risks were used to derive the extent to which haemorrhage has to be seen to be more detrimental than emboli to justify not using anticoagulants. Information from other studies was used to assess the risks for the types of patients not included in the trials. Haemorrhage needs to be assessed as being at least six times more detrimental than emboli to warrant withholding anticoagulants from patients like those in the trials. Only in patients with lone atrial fibrillation and in those with features suggesting a bleeding risk six times higher than the trials' average would a perception of equal detriment risk justify not giving anticoagulation.	MCGILL UNIV,ROYAL VICTORIA HOSP,DIV GEN INTERNAL MED,MONTREAL H3A 1A1,QUEBEC,CANADA; MCGILL UNIV,ROYAL VICTORIA HOSP,DIV CLIN EPIDEMIOL,MONTREAL H3A 1A1,QUEBEC,CANADA	McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital				Caro, Jaime/0000-0001-5470-3754				BRAND FN, 1985, JAMA-J AM MED ASSOC, V254, P3449, DOI 10.1001/jama.254.24.3449; CHANG HJ, 1990, ARCH INTERN MED, V150, P81; CONOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; EZEKOWITZ MD, 1991, CIRCULATION S2, V84, P450; FLEGEL KM, 1991, J CLIN EPIDEMIOL, V44, P551, DOI 10.1016/0895-4356(91)90219-Y; FLEGEL KM, 1989, STROKE, V20, P1000, DOI 10.1161/01.STR.20.8.1000; HULL R, 1982, NEW ENGL J MED, V307, P1676, DOI 10.1056/NEJM198212303072704; KOPECKY SL, 1987, NEW ENGL J MED, V317, P669, DOI 10.1056/NEJM198709103171104; KUTNER M, 1991, ARCH INTERN MED, V151, P1950, DOI 10.1001/archinte.151.10.1950; LANCASTER TR, 1991, ARCH INTERN MED, V151, P1944, DOI 10.1001/archinte.151.10.1944; LANDEFELD CS, 1987, AM J MED, V82, P703, DOI 10.1016/0002-9343(87)90004-0; PAUKER SG, 1989, CHEST, V95, pS161; PETERSEN P, 1986, STROKE, V17, P622, DOI 10.1161/01.STR.17.4.622; PETERSEN P, 1989, LANCET, V1, P175; SELZER A, 1982, NEW ENGL J MED, V306, P1044, DOI 10.1056/NEJM198204293061709; Sox HC, 1988, MED DECISION MAKING; TSEVAT J, 1989, MED DECIS MAKING, V9, P162, DOI 10.1177/0272989X8900900303; WOLF PA, 1987, ARCH INTERN MED, V147, P1561, DOI 10.1001/archinte.147.9.1561; WOLF PA, 1978, NEUROLOGY, V28, P973, DOI 10.1212/WNL.28.10.973; 1992, ANN INTERN MED, V116, P6; 1991, CIRCULATION, V84, P527; 1990, NEW ENGL J MED, V323, P1505	23	32	33	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 29	1993	341	8857					1381	1384		10.1016/0140-6736(93)90950-L	http://dx.doi.org/10.1016/0140-6736(93)90950-L			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE180	8098799				2022-12-28	WOS:A1993LE18000013
J	ARROLL, B; BEAGLEHOLE, R				ARROLL, B; BEAGLEHOLE, R			HYPERTENSION - EXERCISE FOR HYPERTENSION	LANCET			English	Note							PHYSICAL-ACTIVITY		UNIV AUCKLAND,DEPT GEN PRACTICE,AUCKLAND,NEW ZEALAND	University of Auckland	ARROLL, B (corresponding author), UNIV AUCKLAND,DEPT COMMUNITY HLTH,AUCKLAND,NEW ZEALAND.							BLAIR SN, 1992, ANNU REV PUBL HEALTH, V13, P99, DOI 10.1146/annurev.pu.13.050192.000531; Bouchard C, 1988, EXERCISE FITNESS HLT, P147; HAGBERG JM, 1989, AM J CARDIOL, V64, P348, DOI 10.1016/0002-9149(89)90533-X; HARRIS KA, 1987, MED SCI SPORT EXER, V19, P246; HURLEY BF, 1984, MED SCI SPORT EXER, V16, P483, DOI 10.1249/00005768-198410000-00011; JHURLEY BF, 1988, MED SCI SPORTS EXERC, V20, P150; MEREDITH IT, 1990, J HYPERTENS, V8, P859, DOI 10.1097/00004872-199009000-00010; NELSON L, 1986, LANCET, V2, P473, DOI 10.1016/S0140-6736(86)90354-5; PAFFENBARGER RS, 1986, NEW ENGL J MED, V314, P605, DOI 10.1056/NEJM198603063141003; SEALS DR, 1984, MED SCI SPORT EXER, V16, P207; SISCOVICK DS, 1984, NEW ENGL J MED, V311, P874, DOI 10.1056/NEJM198410043111402	11	14	15	2	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 15	1993	341	8855					1248	1249		10.1016/0140-6736(93)91152-C	http://dx.doi.org/10.1016/0140-6736(93)91152-C			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LC497	8098398				2022-12-28	WOS:A1993LC49700010
J	PSATY, BM; SAVAGE, PJ; TELL, GS; POLAK, JF; HIRSCH, CH; GARDIN, JM; MCDONALD, RH				PSATY, BM; SAVAGE, PJ; TELL, GS; POLAK, JF; HIRSCH, CH; GARDIN, JM; MCDONALD, RH			TEMPORAL PATTERNS OF ANTIHYPERTENSIVE MEDICATION USE AMONG ELDERLY PATIENTS - THE CARDIOVASCULAR HEALTH STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BLOOD-PRESSURE; HYPERTENSION; EXPERIENCE; GLUCOSE; THERAPY; TRIAL	Objectives.-To estimate the incidence of newly treated hypertension and to describe the patterns of antihypertensive medication use among those aged 65 years and older. Design.-Medicare eligibility lists from four US communities (Forsyth County, North Carolina; Washington County, Maryland; Sacramento County, California; and Pittsburgh, Pa) were used to obtain a representative sample of 5201 community-dwelling elderly for the Cardiovascular Health Study, a prospective cohort study of risk factors for coronary heart disease and stroke. Participants were examined at baseline and again 1 year later. The two examinations included standardized questionnaires, blood pressure measurements, and the assessment of medication use by medication inventory. In this cohort analysis, we excluded 231 subjects (4.4%) who did not return for follow-up, 69 (1.3%) who had missing data for medications, and another 495 (9.5%) who were taking ''antihypertensive'' medications for an indication other than high blood pressure. Interventions.-None. Results.-Among the 4406 participants, 1613 used antihypertensive medications at both visits. Between the two visits, 144 started and 115 stopped antihypertensive therapy. Among nonusers at baseline, the annual incidence of newly treated hypertension was 5.2% in women and 5.6% in men. Due to the number of participants who stopped therapy, the overall prevalence of antihypertensive treatment increased only slightly, from 40.7% to 41.1% in women and from 37.1% to 38.2% in men, during 1 year of follow-up. After adjustment for age, systolic blood pressure, number of antihypertensive drugs, diabetes, and cardiovascular disease, the newly treated hypertensives were about half as likely as the previously treated hypertensives to receive diuretics (odds ratio [OR], 0.59; P=.008) or beta-blockers (OR, 0.52; P=.01); and they were about twice as likely to receive calcium channel blockers (OR, 1.88; P<.004) or angiotensin converting enzyme inhibitors (OR, 2.40; P<.001). A similar pattern of within-person changes over time was apparent among the continuous users. Conclusions.-Between June 1990 and June 1991, physicians were increasingly prescribing angiotensin converting enzyme inhibitors and calcium channel blockers in place of diuretics and beta-blockers for the treatment of hypertension in elderly patients, especially for those just starting therapy.	UNIV WASHINGTON, DEPT MED, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT EPIDEMIOL, SEATTLE, WA 98195 USA; UNIV PITTSBURGH, DEPT EPIDEMIOL, PITTSBURGH, PA 15260 USA; UNIV WASHINGTON, DEPT HLTH SERV, SEATTLE, WA 98195 USA; NHLBI, DIV EPIDEMIOL & CLIN APPLICAT, EPIDEMIOL & BIOMETRY PROGRAM, BETHESDA, MD 20892 USA; WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT PUBL HLTH SCI, WINSTON SALEM, NC 27103 USA; BRIGHAM & WOMENS HOSP, DEPT RADIOL, BOSTON, MA 02115 USA; UNIV CALIF DAVIS, SACRAMENTO MED CTR, DEPT MED, SACRAMENTO, CA 95817 USA; UNIV CALIF IRVINE, DEPT MED, IRVINE, CA 92717 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Wake Forest University; Wake Forest Baptist Medical Center; Harvard University; Brigham & Women's Hospital; University of California System; University of California Davis; University of California System; University of California Irvine	PSATY, BM (corresponding author), CARDIOVASC HLTH STUDY, CTR COORDINATING, CENTURY SQ, SUITE 2025, 1501 4TH AVE, SEATTLE, WA 98101 USA.		Tell, Grethe/G-5639-2015	Tell, Grethe/0000-0003-1386-1638	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC085086, N01HC085079] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043201] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-43201, N01-HC-85086, N01-HC-85079] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1988, ARCH INTERN MED, V148, P1023; APPLEGATE WB, 1989, ANN INTERN MED, V110, P901, DOI 10.7326/0003-4819-110-11-901; AVANZINI F, 1989, CLIN CARDIOL, V12, P283; Cochran W.G, 1957, STAT METHODS, V6th ed; CORNONIHUNTLEY J, 1989, ARCH INTERN MED, V149, P780, DOI 10.1001/archinte.149.4.780; CROOG SH, 1986, NEW ENGL J MED, V314, P1657, DOI 10.1056/NEJM198606263142602; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; DANNENBERG AL, 1988, AM J PUBLIC HEALTH, V78, P676, DOI 10.2105/AJPH.78.6.676; DANNENBERG AL, 1987, JAMA-J AM MED ASSOC, V257, P1477, DOI 10.1001/jama.257.11.1477; DAVIDSON RA, 1989, J AM GERIATR SOC, V37, P861, DOI 10.1111/j.1532-5415.1989.tb02267.x; FARNETT L, 1991, JAMA-J AM MED ASSOC, V265, P489, DOI 10.1001/jama.265.4.489; Fried Linda P., 1991, Annals of Epidemiology, V1, P263; HARRIS MI, 1985, DIABETES CARE, V8, P562, DOI 10.2337/diacare.8.6.562; MCCLOSKEY LW, 1992, ARCH INTERN MED, V152, P513, DOI 10.1001/archinte.152.3.513; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; MITTELMARK MB, 1993, AM J EPIDEMIOL, V137, P311, DOI 10.1093/oxfordjournals.aje.a116678; MOSER M, 1993, ARCH INTERN MED, V153, P1843, DOI 10.1001/archinte.153.15.1843; POLLARE T, 1989, NEW ENGL J MED, V321, P868, DOI 10.1056/NEJM198909283211305; PSATY BM, 1992, JAMA-J AM MED ASSOC, V268, P1287, DOI 10.1001/jama.268.10.1287; PSATY BM, 1992, J CLIN EPIDEMIOL, V45, P683, DOI 10.1016/0895-4356(92)90143-B; PSATY BM, IN PRESS PRIMER HYPE; ROCCELLA EJ, 1985, HYPERTENSION, V7, P457; STAMLER R, 1987, JAMA-J AM MED ASSOC, V257, P1484, DOI 10.1001/jama.257.11.1484; Tell G S, 1993, Ann Epidemiol, V3, P358, DOI 10.1016/1047-2797(93)90062-9; WEBER MA, 1993, ARCH INTERN MED, V153, P149, DOI 10.1001/archinte.153.2.149; WEISSFELD JL, 1985, J CHRON DIS, V38, P915, DOI 10.1016/0021-9681(85)90127-4; 1993, ARCH INTERN MED, V153, P1023	28	61	61	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 20	1993	270	15					1837	1841		10.1001/jama.270.15.1837	http://dx.doi.org/10.1001/jama.270.15.1837			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB464	8105112				2022-12-28	WOS:A1993MB46400027
J	COLEBUNDERS, R; NDUMBE, P				COLEBUNDERS, R; NDUMBE, P			PRIORITIES FOR HIV TESTING IN DEVELOPING-COUNTRIES	LANCET			English	Editorial Material							COUNSELING-CENTER; ZAIRE; AIDS; SURVEILLANCE; SEROCONVERSION; EXPERIENCE; INFECTION; KINSHASA; BEHAVIOR; COUPLES		UNIV YAOUNDE,FAC MED & BIOMED SCI,VIRUS IMMUNOL UNIT,YAOUNDE,CAMEROON	University of Yaounde I	COLEBUNDERS, R (corresponding author), INST TROP MED,NATL STR 155,B-2000 ANTWERP,BELGIUM.							ALLAN S, 1992, JAMA-J AM MED ASSOC, V268, P3338; ALLEN S, 1992, BRIT MED J, V304, P1605, DOI 10.1136/bmj.304.6842.1605; ALLWOOD CW, 1992, S AFR MED J, V82, P98; CHIN J, 1990, B WORLD HEALTH ORGAN, V68, P529; COLEBUNDERS R, 1987, AM J GASTROENTEROL, V82, P859; COLEBUNDERS RL, 1990, HEALTH POLICY, V15, P1, DOI 10.1016/0168-8510(90)90413-8; FOSTER S, 1991, LONDON SCH HYGIENE T, V3, P14; FRERICHS RR, 1992, LANCET, V340, P1496, DOI 10.1016/0140-6736(92)92755-5; GOODGAME RW, 1990, NEW ENGL J MED, V323, P383, DOI 10.1056/NEJM199008093230605; KAMENGA M, 1991, AIDS, V5, P61, DOI 10.1097/00002030-199101000-00009; MITCHELL S, 1990, HDB AIDS PREVENTION, P20; MULLER O, 1992, AIDS, V6, P869, DOI 10.1097/00002030-199208000-00016; NTITA I, 1991, AIDS, V5, P437, DOI 10.1097/00002030-199104000-00013; RYDER RW, 1991, AIDS, V5, P1521, DOI 10.1097/00002030-199112000-00016; SOW S, 1992, 7TH C AIDS YAOUND, P113; TEMMERMAN M, 1990, AIDS Care, V2, P247, DOI 10.1080/09540129008257737; TEMMERMAN M, 1992, NEW ENGL J MED, V327, P1102; TOMASEVSKI K, 1992, GLOBAL REPORT AIDS W, P537; WADHAWAN D, 1990, 6 INT C AIDS SAN FRA; ZHANG X, 1992, LANCET, V340, P1541, DOI 10.1016/0140-6736(92)92789-I; 1992, WEEKLY EPIDEMIOL REC, V67, P145	21	28	28	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 4	1993	342	8871					601	602		10.1016/0140-6736(93)91417-K	http://dx.doi.org/10.1016/0140-6736(93)91417-K			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV963	8102727				2022-12-28	WOS:A1993LV96300017
J	LANGHORNE, P; WILLIAMS, BO; GILCHRIST, W; HOWIE, K				LANGHORNE, P; WILLIAMS, BO; GILCHRIST, W; HOWIE, K			DO STROKE UNITS SAVE LIVES	LANCET			English	Article							RANDOMIZED CONTROLLED TRIAL; REHABILITATION; MANAGEMENT; THERAPY; NEED	Management of stroke patients in specialist stroke units hastens recovery but is not believed to influence mortality. We did a statistical overview of randomised controlled trials reported between 1962 and 1993 in which the management of stroke patients in a specialist unit was compared with that in general wards. We identified 10 trials, 8 of which used a strict randomisation procedure. 1586 stroke patients were included; 766 were allocated to a stroke unit and 820 to general wards. The odds ratio (stroke unit vs general wards) for mortality within the first 4 months (median follow-up 3 months) after the stroke was 0.72 (95% CI 0.56-0.92), consistent with a reduction in mortality of 28% (2p < 0.01). This reduction persisted (odds ratio 0.79, 95% CI 0.63-0.99, 2p < 0.05) when calculated for mortality during the first 12 months. The findings were not significantly altered if the analysis was limited to studies that used a formal randomisation procedure. We conclude that management of stroke patients in a stroke unit is associated with a sustained reduction in mortality.	UNIV GLASGOW,WESTERN INFIRM,GARDINER INST,DEPT MED,GLASGOW G11 6NT,SCOTLAND; GARTNAVEL ROYAL HOSP,DEPT GERIATR MED,GLASGOW G12 0YN,SCOTLAND	University of Glasgow; Gartnavel Royal Hospital								Aitken PD, 1993, AGE AGEING S2, V22, P4; ASPLUND K, 1991, CEREBROVASC DIS, V1, P129, DOI 10.1159/000108908; DEPEDROCUESTA J, 1992, ACTA NEUROL SCAND, V86, P433; Ebrahim S., 1990, CLIN EPIDEMIOLOGY ST; ERILA T, 1990, STROKE S1, V21, pI53; FELDMAN DJ, 1962, J CHRON DIS, V15, P297, DOI 10.1016/0021-9681(62)90013-9; GARRAWAY M, 1985, STROKE, V16, P178, DOI 10.1161/01.STR.16.2.178; GARRAWAY WM, 1980, BRIT MED J, V280, P1040, DOI 10.1136/bmj.280.6220.1040; GARRAWAY WM, 1980, BRIT MED J, V281, P827, DOI 10.1136/bmj.281.6244.827; GELMERS HJ, 1990, STROKE, V21, P81; GORDON EE, 1966, J CHRON DIS, V19, P3, DOI 10.1016/0021-9681(66)90148-2; HAMRIN E, 1982, SCAND J REHABIL MED, V14, P101; HAMRIN E, 1982, SCAND J REHABIL MED, V14, P111; INDREDAVIK B, 1991, STROKE, V22, P1026, DOI 10.1161/01.STR.22.8.1026; MILLIKAN CH, 1979, STROKE, V10, P235, DOI 10.1161/01.STR.10.3.235; PEACOCK PB, 1972, TRENDS EPIDEMIOLOGY, P231; PETO R, 1987, STAT MED, V6, P233, DOI 10.1002/sim.4780060306; ROGVIHANSEN BA, 1992, CEREBROVASC DIS, V2, P11; ROSENTHAL R, 1979, PSYCHOL BULL, V86, P638, DOI 10.1037/0033-2909.86.3.638; SANDERCOCK P, 1992, LANCET, V339, P537, DOI 10.1016/0140-6736(92)90348-7; SANDERCOCK PAG, 1993, J NEUROL NEUROSUR PS, V56, P17, DOI 10.1136/jnnp.56.1.17; SIVENIUS J, 1985, STROKE, V16, P928, DOI 10.1161/01.STR.16.6.928; SMITH DS, 1981, BMJ-BRIT MED J, V282, P517, DOI 10.1136/bmj.282.6263.517; STEVENS RS, 1984, AGE AGEING, V13, P65, DOI 10.1093/ageing/13.2.65; STRAND T, 1985, STROKE, V16, P29, DOI 10.1161/01.STR.16.1.29; SUNDERLAND A, 1992, J NEUROL NEUROSUR PS, V55, P530, DOI 10.1136/jnnp.55.7.530; WADE DT, 1985, LANCET, V1, P323; WADE DT, 1992, BRIT MED J, V304, P609, DOI 10.1136/bmj.304.6827.609; WOODDAUPHINEE S, 1984, STROKE, V5, P864; YOUNG JB, 1992, BRIT MED J, V304, P1085, DOI 10.1136/bmj.304.6834.1085	30	479	486	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 14	1993	342	8868					395	398		10.1016/0140-6736(93)92813-9	http://dx.doi.org/10.1016/0140-6736(93)92813-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR900	8101901				2022-12-28	WOS:A1993LR90000009
J	ROYSTON, D				ROYSTON, D			PERIOPERATIVE BLEEDING - DRUGS FOR SURGICAL BLOOD-LOSS	LANCET			English	Editorial Material							TRANEXAMIC ACID				ROYSTON, D (corresponding author), HAREFIELD HOSP,DEPT ANAESTHESIA,HAREFIELD,MIDDX,ENGLAND.							COSGROVE DM, 1992, ANN THORAC SURG, V54, P1031, DOI 10.1016/0003-4975(92)90066-D; HERSCHLEIN H. J., 1964, MED WELT, V24, P1314; HORROW JC, 1991, CIRCULATION, V84, P2063, DOI 10.1161/01.CIR.84.5.2063; Kojima M, 1983, Bibl Haematol, P95; LORD RA, 1992, BRIT J SURG, V79, P517, DOI 10.1002/bjs.1800790614; MALLETT SV, 1990, LANCET, V336, P886, DOI 10.1016/0140-6736(90)92404-6; OVRUM E, 1993, J THORAC CARDIOV SUR, V105, P78; Royston D, 1992, J Cardiothorac Vasc Anesth, V6, P76, DOI 10.1016/1053-0770(91)90052-U; WHITTEN C W, 1992, Anesthesiology (Hagerstown), V77, pA266, DOI 10.1097/00000542-199209001-00266; WIJDICKS EFM, 1989, STROKE, V20, P1674, DOI 10.1161/01.STR.20.12.1674	10	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 26	1993	341	8861					1629	1629		10.1016/0140-6736(93)90766-A	http://dx.doi.org/10.1016/0140-6736(93)90766-A			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ727	8099998				2022-12-28	WOS:A1993LJ72700012
J	CORDNER, SM				CORDNER, SM			DECIDING THE CAUSE OF DEATH AFTER NECROPSY	LANCET			English	Editorial Material											CORDNER, SM (corresponding author), MONASH UNIV,VICTORIAN INST FORENS PATHOL,57-83 KAVANAGH ST,S MELBORNE,VIC 3205,AUSTRALIA.								0	16	17	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 5	1993	341	8858					1458	1460		10.1016/0140-6736(93)90892-K	http://dx.doi.org/10.1016/0140-6736(93)90892-K			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF841	8099151				2022-12-28	WOS:A1993LF84100014
J	VANDERMEER, JWM; WEENING, RS; SCHELLEKENS, PTA; VANMUNSTER, IP; NAGENGAST, FM				VANDERMEER, JWM; WEENING, RS; SCHELLEKENS, PTA; VANMUNSTER, IP; NAGENGAST, FM			COLORECTAL-CANCER IN PATIENTS WITH X-LINKED AGAMMAGLOBULINEMIA	LANCET			English	Note							HYPOGAMMAGLOBULINEMIA	Primary immunodeficiency disorders can predispose to certain malignancies but hitherto no such relation has been established for X-linked agammaglobulinaemia (XLA). We have diagnosed rapidly progressive colorectal cancer in 3 unrelated young adults with XLA. We could find no explanation for. the tumours. Since the calculated incidence of rectosigmoid cancer is increased 30-fold in patients with XLA, we advise the screening of these individuals, and perhaps people with other agammaglobulinaemias, for colorectal cancer.	UNIV HOSP NIJMEGEN,DEPT GASTROENTEROL & HEPATOL,6500 HB NIJMEGEN,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT PAEDIAT,1105 AZ AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT INTERNAL MED,1105 AZ AMSTERDAM,NETHERLANDS	Radboud University Nijmegen; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	VANDERMEER, JWM (corresponding author), UNIV HOSP NIJMEGEN,DEPT GEN INTERNAL MED,POSTBOX 9101,6500 HB NIJMEGEN,NETHERLANDS.		van der Meer, Jos W.M./C-8521-2013	van der Meer, Jos W.M./0000-0001-5120-3690				ADACHI Y, 1992, DIS COLON RECTUM, V35, P197, DOI 10.1007/BF02050679; [Anonymous], DIAGNOSIS TREATMENT; DENHARTOG G, 1988, NEW ENGL J MED, V318, P1563; HERMASZEWSKI RA, 1993, Q J MED, V86, P31; KERSTENS PJSM, 1992, EUR J CLIN MICROBIOL, V11, P842, DOI 10.1007/BF01960888; KINLEN LJ, 1985, LANCET, V1, P263; LEDERMAN HM, 1985, MEDICINE, V64, P145, DOI 10.1097/00005792-198505000-00001; MELAMED I, 1983, AM J DIS CHILD, V137, P752, DOI 10.1001/archpedi.1983.02140340036009; MENSINK EJBM, 1986, HUM GENET, V73, P327, DOI 10.1007/BF00279095; MENSINK EJBM, 1984, HUM GENET, V68, P303, DOI 10.1007/BF00292589; SPECTOR BD, 1978, CLIN IMMUNOL IMMUNOP, V11, P12, DOI 10.1016/0090-1229(78)90200-3; VANDERMEER JWM, 1986, J INFECTION, V12, P235, DOI 10.1016/S0163-4453(86)94190-3	12	64	64	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 5	1993	341	8858					1439	1440		10.1016/0140-6736(93)90883-I	http://dx.doi.org/10.1016/0140-6736(93)90883-I			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF841	8099142	Green Submitted			2022-12-28	WOS:A1993LF84100005
J	HERNANDEZ, CA; LERCH, MM				HERNANDEZ, CA; LERCH, MM			SPHINCTER STENOSIS AND GALLSTONE MIGRATION THROUGH THE BILIARY-TRACT	LANCET			English	Note							PANCREATITIS	We have investigated whether stenosis or insufficiency at the duodenal papilla results from the passage of a gallstone through the biliary tract. In three groups of patients after cholecystectomy we studied meal-stimulated pancreatic enzyme activity in T-drain bile from the common bileduct. Group A had gallbladder stones only; group B had gallbladder stones and bileduct stones; and group C had an episode of acute gallstone-induced pancreatitis, which was taken as direct evidence for gallstone migration into the duodenum. Reflux of pancreatic juice into the common bileduct was absent in group A, was occasionally found in group B, and was strikingly increased in group C. We conclude that passage of a gallstone through the biliary tract causes functional stenosis of the sphincter of Oddi and allows for a common channel between the pancreatic duct and the common bileduct. It does not cause sphincter insufficiency as previously assumed.	UNIV ULM,DEPT MED 1,ROBERT KOCH ST 8,W-7900 ULM,GERMANY; UNIV NACL CORDOBA,CORDOBA UNIV HOSP,DEPT SURG 1,CORDOBA,ARGENTINA	Ulm University; Hospital Privado - Universitario de Cordoba; National University of Cordoba			Lerch, Markus M./E-2206-2016	Lerch, Markus M./0000-0002-9643-8263				ACOSTA JM, 1974, NEW ENGL J MED, V290, P484, DOI 10.1056/NEJM197402282900904; BERNFELD P, 1955, METHOD ENZYMOL, V1, P149, DOI 10.1016/0076-6879(55)01021-5; DIMAGNO EP, 1982, CANCER, V49, P361, DOI 10.1002/1097-0142(19820115)49:2<361::AID-CNCR2820490225>3.0.CO;2-O; KELLY TR, 1988, SURGERY, V104, P600; LERCH MM, 1993, GASTROENTEROLOGY, V104, P853, DOI 10.1016/0016-5085(93)91022-A; MCCUTCHEON AD, 1962, ANN SURG, V155, P523, DOI 10.1097/00000658-196204000-00007; Opie EL, 1901, B JOHNS HOPKINS HOSP, V12, P182; RINKERKNECHT H, 1978, GASTROENTEROLOGY, V75, P1083; STONE HH, 1981, ANN SURG, V194, P305, DOI 10.1097/00000658-198109000-00008	9	79	81	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 29	1993	341	8857					1371	1373		10.1016/0140-6736(93)90942-A	http://dx.doi.org/10.1016/0140-6736(93)90942-A			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE180	8098791				2022-12-28	WOS:A1993LE18000005
J	WANG, PH; LAU, J; CHALMERS, TC				WANG, PH; LAU, J; CHALMERS, TC			METAANALYSIS OF EFFECTS OF INTENSIVE BLOOD-GLUCOSE CONTROL ON LATE COMPLICATIONS OF TYPE-I DIABETES	LANCET			English	Article							SUBCUTANEOUS INSULIN INFUSION; CLINICAL-TRIALS; RETINOPATHY; PROGRESSION; EXPERIENCE; MELLITUS; THERAPY; IDDM	Tight blood glucose control has been speculated to reduce late complications in insulin-dependent diabetics but results from individual studies have been inconsistent. We have done a meta-analysis of sixteen randomised trials of intensive therapy to estimate its impact on the progression of diabetic retinopathy and nephropathy and the risks of severe side-effects. In the intensive therapy group, the risk of retinopathy progression was insignificantly higher after 6.12 months of intensive control (odds ratio [OR] 2.11). After more than two years of intensive therapy the risk of retinopathy progression was lower (OR 0.49 [95% confidence interval 0.28-0.85], p = 0.011). The risk of nephropathy progression was also decreased significantly (OR 0.34 [0.20-0.58], p<0.001). The incidence of severe hypoglycaemia increased by 9.1 episodes per 100 person-years (95% CI -1.4 to +19.6) in the intensively treated patients. The incidence of diabetic ketoacidosis increased by 12.6 episodes per 100 person-years (95% CI, 8.7-16.5) in the patients on continuous subcutaneous insulin infusion. Long-term intensive blood glucose control significantly reduces the risk of diabetic retinopathy and nephropathy progression but long-term continuous subcutaneous insulin infusion was associated with an increased incidence of diabetic ketoacidosis, and intensive therapy may cause more severe hypoglycaemic reactions.	BRIGHAM & WOMENS HOSP, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; NEW ENGLAND MED CTR, CTR CARDIOVASC HLTH RES SERV, BOSTON, MA 02111 USA; TECHNOL ASSESSMENT GRP, BOSTON, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Tufts Medical Center	WANG, PH (corresponding author), JOSLIN DIABET CTR, 1 JOSLIN PL, BOSTON, MA 02115 USA.				AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS005936] Funding Source: NIH RePORTER; AHRQ HHS [R01 HS-05936] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BECKNIELSEN H, 1985, DIABETES CARE, V8, P585, DOI 10.2337/diacare.8.6.585; BERLIN JA, 1989, STAT MED, V8, P141, DOI 10.1002/sim.4780080202; BRINCHMANNHANSEN O, 1988, ARCH OPHTHALMOL-CHIC, V106, P1242; Christensen C K, 1987, J Diabet Complications, V1, P91, DOI 10.1016/S0891-6632(87)80063-6; DAHLJORGENSEN K, 1988, ACTA ENDOCRINOL-COP, V117, P19, DOI 10.1530/acta.0.1170019; DCCT Res Grp, 1987, DIABETES CARE, V10, P1; Deckert T, 1984, DIAB NEPHROPATHY, V3, P6; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; ESCHWEGE E, 1979, DIABETOLOGIA, V16, P13, DOI 10.1007/BF00423144; FELDTRASMUSSEN B, 1986, LANCET, V2, P1300; FLEISS JL, 1986, CONTROL CLIN TRIALS, V7, P267, DOI 10.1016/0197-2456(86)90034-6; HELVE E, 1987, ACTA ENDOCRINOL-COP, V115, P313, DOI 10.1530/acta.0.1150313; HOLMAN RR, 1983, LANCET, V1, P204; KLEIN R, 1992, DIABETES CARE, V15, P1875, DOI 10.2337/diacare.15.12.1875; LAATIKAINEN L, 1987, ACTA MED SCAND, V221, P367; LAURITZEN T, 1985, DIABETES, V34, P74, DOI 10.2337/diab.34.3.S74; LOCK DR, 1981, DIABETES CARE, V4, P389, DOI 10.2337/diacare.4.3.389; MECKLENBURG RS, 1984, JAMA-J AM MED ASSOC, V252, P3265, DOI 10.1001/jama.252.23.3265; OLSEN T, 1987, ACTA OPHTHALMOL, V65, P185; REICHARD P, 1991, J INTERN MED, V230, P101, DOI 10.1111/j.1365-2796.1991.tb00415.x; ROSENTHAL R, 1979, PSYCHOL BULL, V86, P638, DOI 10.1037/0033-2909.86.3.638; SHIFFRIN AD, 1984, DIABETES CARE, V7, P107; VERRILLO A, 1988, DIABETES RES CLIN EX, V8, P71; WISEMAN MJ, 1985, NEW ENGL J MED, V312, P617, DOI 10.1056/NEJM198503073121004; 1984, NEW ENGL J MED, V311, P365; 1988, JAMA-J AM MED ASSOC, V260, P37	26	403	411	0	12	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 22	1993	341	8856					1306	1309		10.1016/0140-6736(93)90816-Y	http://dx.doi.org/10.1016/0140-6736(93)90816-Y			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD253	8098449				2022-12-28	WOS:A1993LD25300004
J	AMIEL, S				AMIEL, S			METABOLISM - AMYLIN AND DIABETES	LANCET			English	Note							ISLET-AMYLOID POLYPEPTIDE; MELLITUS; RAT				AMIEL, S (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,DIV MED,LONDON,ENGLAND.			Logan, Ann/0000-0003-3215-5042				BRETHERTONWATT D, 1992, J CLIN ENDOCR METAB, V74, P1032, DOI 10.1210/jc.74.5.1032; CLARK A, 1990, DIABETOLOGIA, V33, P285, DOI 10.1007/BF00403322; COOPER GJS, 1988, P NATL ACAD SCI USA, V85, P7763, DOI 10.1073/pnas.85.20.7763; EDWARDS BJA, 1992, LIFE SCI, V51, P1899, DOI 10.1016/0024-3205(92)90106-Y; FEHMANN HC, 1990, BIOCHEM BIOPH RES CO, V167, P1102, DOI 10.1016/0006-291X(90)90636-2; GHATEI MA, 1990, J ENDOCRINOL, V124, pR9, DOI 10.1677/joe.0.124R009; HARTTER E, 1990, LANCET, V335, P854, DOI 10.1016/0140-6736(90)90966-9; STRIDSBERG M, 1992, SCAND J GASTROENTERO, V27, P381, DOI 10.3109/00365529209000092; VANJAARSVELD BC, 1990, LANCET, V335, P60, DOI 10.1016/0140-6736(90)90197-D; WESTERMARK P, 1987, P NATL ACAD SCI USA, V84, P3881, DOI 10.1073/pnas.84.11.3881; YOUNG AA, 1991, J PHYSIOL-LONDON, V438, pP250	11	10	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 15	1993	341	8855					1249	1250		10.1016/0140-6736(93)91153-D	http://dx.doi.org/10.1016/0140-6736(93)91153-D			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LC497	8098399				2022-12-28	WOS:A1993LC49700011
J	PANCHOLI, P; MIRZA, A; BHARDWAJ, N; STEINMAN, RM				PANCHOLI, P; MIRZA, A; BHARDWAJ, N; STEINMAN, RM			SEQUESTRATION FROM IMMUNE CD4+ T-CELLS OF MYCOBACTERIA GROWING IN HUMAN MACROPHAGES	SCIENCE			English	Article							HUMAN-MONOCYTES; TUBERCULOSIS; ANTIGENS; INFECTION; MICE; ACIDIFICATION; PHAGOSOME; LINES	CD4+ helper T cells mediate resistance to tuberculosis, presumably by enhancing the antimicrobial activity of macrophages within which the Mycobacterium tuberculosis organism grows. A first step in resistance should be the presentation of mycobacterial antigens by macrophages to CD4+ T cells. However, when the antigenic stimulus is limited to organisms growing in human monocytes, the organisms become sequestered from immune CD4+ T cells. This block in presentation is selective for growing mycobacteria and not for other stimuli. Sequestration would allow replicating organisms to persist in infected individuals and may contribute to virulence.			PANCHOLI, P (corresponding author), ROCKEFELLER UNIV,CELLULAR PHYSIOL & IMMUNOL LAB,NEW YORK,NY 10021, USA.		Steinman, Ralph/F-7729-2012		NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI024775] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR039552] Funding Source: NIH RePORTER; NCRR NIH HHS [MOI-RR00102] Funding Source: Medline; NIAID NIH HHS [AI24775] Funding Source: Medline; NIAMS NIH HHS [AR39552] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BAHR GM, 1981, IMMUNOLOGY, V44, P593; BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; BHARDWAJ V, 1988, EUR J IMMUNOL, V18, P691, DOI 10.1002/eji.1830180506; BRODSKY FM, 1991, ANNU REV IMMUNOL, V9, P707; CROWLE AJ, 1991, INFECT IMMUN, V59, P1823, DOI 10.1128/IAI.59.5.1823-1831.1991; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DANNENBERG AM, 1984, MYCOBACTERIA SOURCEB, P721; ELLNER JJ, 1978, J IMMUNOL, V121, P2573; ELLNER JJ, 1989, REV INFECT DIS, V11, pS455; FUJIWARA H, 1991, IMMUNOLOGY, V72, P194; HORWITZ MA, 1984, J CELL BIOL, V99, P1936, DOI 10.1083/jcb.99.6.1936; IZZO AA, 1992, J EXP MED, V176, P581, DOI 10.1084/jem.176.2.581; KINDLER V, 1989, CELL, V56, P731, DOI 10.1016/0092-8674(89)90676-4; LAGRANGE PH, 1988, MYCOBACTERIUM TUBERC, P171; LAMB JR, 1989, REV INFECT DIS, V11, pS443; LEVETON C, 1989, INFECT IMMUN, V57, P390, DOI 10.1128/IAI.57.2.390-395.1989; NAKAMURA RM, 1988, MYCOBACTERIUM TUBERC, P227; PANCHOLI P, 1992, IMMUNOLOGY, V76, P217; PANCHOLI P, 1991, CLIN EXP IMMUNOL, V85, P349; PANCHOLI P, UNPUB; PEDRAZZINI T, 1987, J IMMUNOL, V139, P2032; ROOK GAW, 1986, CLIN EXP IMMUNOL, V63, P105; SIBLEY LD, 1985, NATURE, V315, P416, DOI 10.1038/315416a0; TURCOTTE R, 1981, INFECT IMMUN, V34, P315, DOI 10.1128/IAI.34.2.315-322.1981	24	169	171	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 14	1993	260	5110					984	986		10.1126/science.8098550	http://dx.doi.org/10.1126/science.8098550			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LB791	8098550				2022-12-28	WOS:A1993LB79100043
J	NITTI, VW				NITTI, VW			ICE-WATER TEST IN URODYNAMIC ASSESSMENT	LANCET			English	Editorial Material							BLADDER				NITTI, VW (corresponding author), SUNY HLTH SCI CTR,DEPT UROL,BROOKLYN,NY 11203, USA.			Nitti, Victor/0000-0002-1390-7053				BALMASEDA MT, 1988, AM J PHYS MED REHAB, V67, P225, DOI 10.1097/00002060-198810000-00008; BORS EH, 1957, ARCH NEURO PSYCHIATR, V78, P339, DOI 10.1001/archneurpsyc.1957.02330400013002; FALL M, 1989, BRIT J UROL, V64, P368, DOI 10.1111/j.1464-410X.1989.tb06045.x; GEIRSSON G, 1993, BRIT J UROL, V71, P681, DOI 10.1111/j.1464-410X.1993.tb16065.x; GEIRSSON G, 1993, J UROLOGY, V150, P427, DOI 10.1016/S0022-5347(17)35501-5; HELLSTROM PA, 1991, BRIT J UROL, V67, P275, DOI 10.1111/j.1464-410X.1991.tb15134.x; LINDSTROM S, 1990, NEUROUROL URODYNAM, V9, P365; RAZ S, 1973, J UROLOGY, V109, P603, DOI 10.1016/S0022-5347(17)60491-9; SUSSET JG, 1985, NEUROUROL URODYNAM, V4, P157, DOI 10.1002/nau.1930040303	9	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 30	1993	342	8879					1066	1067		10.1016/0140-6736(93)92057-Z	http://dx.doi.org/10.1016/0140-6736(93)92057-Z			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME822	8105305				2022-12-28	WOS:A1993ME82200003
J	GILKS, CF				GILKS, CF			THE CLINICAL CHALLENGE OF THE HIV EPIDEMIC IN THE DEVELOPING-WORLD	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; INFECTION; DISEASE; NAIROBI; AIDS; TUBERCULOSIS; AFRICA; ADULTS; COHORT; KENYA				GILKS, CF (corresponding author), UNIV LIVERPOOL,LIVERPOOL SCH TROP MED,LIVERPOOL L3 5QA,ENGLAND.		Gilks, Charles/B-4184-2012	Gilks, Charles/0000-0002-8953-3123				DECOCK KM, 1990, SCIENCE, V249, P793, DOI 10.1126/science.2167515; DECOCK KM, 1992, JAMA-J AM MED ASSOC, V268, P1581, DOI 10.1001/jama.1992.03490120095035; FARIZO KM, 1992, JAMA-J AM MED ASSOC, V267, P1798, DOI 10.1001/jama.267.13.1798; GILKS CF, 1990, LANCET, V336, P545, DOI 10.1016/0140-6736(90)92096-Z; GILKS CF, 1992, Q J MED, V82, P25; GILKS CF, 1991, TROP DOCT, V21, P90, DOI 10.1177/004947559102100302; GILKS CF, 1992, 8TH INT C AIDS; GILKS CF, 1993, 9TH INT C AIDS; KARSTAEDT AS, 1992, S AFR MED J, V82, P95; LUCAS SB, 1990, T ROY SOC TROP MED H, V84, P34, DOI 10.1016/0035-9203(90)90453-L; NAGELKERKE NJD, 1990, AIDS, V4, P743, DOI 10.1097/00002030-199008000-00005; NUNN P, 1992, AM REV RESPIR DIS, V146, P849, DOI 10.1164/ajrccm/146.4.849; POTTS M, 1991, LANCET, V338, P608, DOI 10.1016/0140-6736(91)90614-U; SELWYN PA, 1992, NEW ENGL J MED, V327, P1697, DOI 10.1056/NEJM199212103272401; STANFORD JL, 1991, LANCET, V338, P557, DOI 10.1016/0140-6736(91)91113-9	15	66	66	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 23	1993	342	8878					1037	1039		10.1016/0140-6736(93)92885-W	http://dx.doi.org/10.1016/0140-6736(93)92885-W			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD066	8105270				2022-12-28	WOS:A1993MD06600016
J	PRUMMEL, MF; MOURITS, MP; BLANK, L; BERGHOUT, A; KOORNNEEF, L; WIERSINGA, WM				PRUMMEL, MF; MOURITS, MP; BLANK, L; BERGHOUT, A; KOORNNEEF, L; WIERSINGA, WM			RANDOMIZED DOUBLE-BLIND TRIAL OF PREDNISONE VERSUS RADIOTHERAPY IN GRAVES OPHTHALMOPATHY	LANCET			English	Article							ORBITAL IRRADIATION; RADIATION RETINOPATHY; CRITERIA; THERAPY; DISEASE	Corticosteroids are usually given for management of Graves' ophthalmopathy, but they have many and serious side-effects. By comparison, retrobulbar irradiation is well tolerated, although its efficacy has been evaluated only in uncontrolled studies. Therefore, we did a double-blind randomised trial, in which 28 patients with moderately severe Graves' ophthalmopathy were treated with a 3-month course of oral prednisone and sham irradiation, and 28 received retrobulbar irradiation (20 Gy) and placebo capsules. Therapeutic outcome, assessed twenty-four weeks after the start of treatment, was determined by the change in the highest NOSPECS class. A successful outcome was observed in 14 prednisone-treated and in 13 irradiated patients. Responders to treatment (but not nonresponders) in both groups showed improvements in total and subjective eye score and a decrease in eye-muscle volume. Response to either treatment was due largely to changes in soft-tissue involvement and eye-muscle motility. Mean elevation in responders to radiotherapy increased from 18.5-degrees (95% CI 14.8-22.2) at baseline to 21.8-degrees (18.6-25.0) at week twenty-four (p=0.003), but did not change in prednisone responders. Side-effects were more frequent and severe during prednisone than during radiotherapy. Radiotherapy and oral prednisone appear to be equally effective as initial treatment in patients with moderately severe Graves' ophthalmopathy. In view of its better tolerability, radiotherapy should be considered the treatment of first choice.	UNIV AMSTERDAM,ACAD MED CTR,CTR ORBITAL,1105 AZ AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT RADIOTHERAPY,1105 AZ AMSTERDAM,NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	PRUMMEL, MF (corresponding author), UNIV AMSTERDAM,ACAD MED CTR,DEPT ENDOCRINOL,MEIBERGDREEF 9,1105 AZ AMSTERDAM,NETHERLANDS.							BAHN RS, 1987, ENDOCRIN METAB CLIN, V16, P391, DOI 10.1016/S0889-8529(18)30485-7; BARTALENA L, 1983, J CLIN ENDOCR METAB, V56, P1139, DOI 10.1210/jcem-56-6-1139; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; COLTON T, 1974, STAT MED, P151; CRONE RA, 1973, DIPLOPIA, P350; DONALDSON SS, 1973, J CLIN ENDOCR METAB, V37, P276, DOI 10.1210/jcem-37-2-276; DUKEELDER S, 1962, SYSTEM OPHTHALMOLOGY, V7, P370; HALES IB, 1960, Q J MED, V113, P113; HURBLI T, 1985, AM J OPHTHALMOL, V99, P633, DOI 10.1016/S0002-9394(14)76027-1; JACOBSON DH, 1984, ENDOCR REV, V5, P200, DOI 10.1210/edrv-5-2-200; KINYOUN JL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1473; MOURITS MP, 1989, BRIT J OPHTHALMOL, V73, P639, DOI 10.1136/bjo.73.8.639; MOURITS MP, 1991, AUG INT S GRAV OPHTH; Naffziger HC, 1933, ARCH OPHTHALMOL-CHIC, V9, P1; OLIVOTTO IA, 1985, INT J RADIAT ONCOL, V11, P2085, DOI 10.1016/0360-3016(85)90088-4; PETERSEN IA, 1990, INT J RADIAT ONCOL, V19, P259, DOI 10.1016/0360-3016(90)90532-O; PRUMMEL MF, 1990, ARCH INTERN MED, V150, P1098, DOI 10.1001/archinte.150.5.1098; PRUMMEL MF, 1993, OPHTHALMOLOGY, V100, P556; PRUMMEL MF, 1989, NEW ENGL J MED, V321, P1353, DOI 10.1056/NEJM198911163212002; SANDLER HM, 1989, INT J RADIAT ONCOL, V17, P823, DOI 10.1016/0360-3016(89)90073-4; SAUTTERBIHL ML, 1990, GRAVES OPHTHALMOPATH, P145; SERGOTT RC, 1981, SURV OPHTHALMOL, V26, P1, DOI 10.1016/0039-6257(81)90120-X; TENG CS, 1980, CLIN ENDOCRINOL, V13, P545, DOI 10.1111/j.1365-2265.1980.tb03422.x; VIEBAHN M, 1991, BRIT J OPHTHALMOL, V75, P629, DOI 10.1136/bjo.75.10.629; WEETMAN AP, 1991, LANCET, V338, P25, DOI 10.1016/0140-6736(91)90013-F; WERNER SC, 1977, J CLIN ENDOCR METAB, V44, P203, DOI 10.1210/jcem-44-1-203; WIERSINGA WM, 1988, OPHTHALMOLOGICA, V197, P75, DOI 10.1159/000309924; WIERSINGA WM, 1982, METHOD ENZYMOL, V84, P272; WILKINSON L, 1987, SYSTAT SYSTEM STATIS; 1992, THYROID, V2, P235	30	258	268	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 16	1993	342	8877					949	954		10.1016/0140-6736(93)92001-A	http://dx.doi.org/10.1016/0140-6736(93)92001-A			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MC005	8105213				2022-12-28	WOS:A1993MC00500008
J	SMITH, GCM; KENNA, JG; HARRISON, DJ; TEW, D; WOLF, CR				SMITH, GCM; KENNA, JG; HARRISON, DJ; TEW, D; WOLF, CR			AUTOANTIBODIES TO HEPATIC-MICROSOMAL CARBOXYLESTERASE IN HALOTHANE HEPATITIS	LANCET			English	Note							ANTIBODIES; LIVER; SERA; NEOANTIGENS	Halothane hepatitis can be life-threatening, and this severe adverse reaction may arise via an immune process. We have detected autoantibodies to purified human liver microsomal carboxylesterase in sera of 17 out of 20 patients with halothane hepatitis (85%) but not in 9 halothane-exposed controls and in only 2 (at low levels) of 33 patients with liver disease due to other causes. Immunohistochemical studies localised the carboxylesterase predominantly to the centrilobular region of liver sections, which is consistent with the area affected by halothane hepatitis. Human hepatic microsomal carboxylesterase is a target antigen in halothane hepatitis, and an immune response to this protein may be involved in the liver damage observed.	UNIV DUNDEE,NINEWELLS HOSP & MED SCH,BIOMED RES CTR,IMPERIAL CANC RES UNIT,MOLEC PHARMACOL UNIT,DUNDEE DD1 9SY,SCOTLAND; IMPERIAL COLL SCI TECHNOL & MED,ST MARYS HOSP,SCH MED,DEPT PHARMACOL & TOXICOL,LONDON W2,ENGLAND; UNIV EDINBURGH,SCH MED,DEPT PATHOL,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND; SMITHKLINE BEECHAM RES,WELWYN GARDEN CIT,ENGLAND	University of Dundee; Imperial College London; University of Edinburgh; GlaxoSmithKline			Kenna, J Gerry/H-9929-2012	Wolf, Charles Roland/0000-0002-6969-0113; Smith, Gillian/0000-0001-9288-7566				CHRIST DD, 1988, ANESTHESIOLOGY, V69, P833, DOI 10.1097/00000542-198812000-00006; HARRISON DJ, 1989, J CLIN PATHOL, V42, P624, DOI 10.1136/jcp.42.6.624; KENNA JG, 1988, J PHARMACOL EXP THER, V245, P1103; KENNA JG, 1988, HEPATOLOGY, V8, P1635, DOI 10.1002/hep.1840080627; KENNA JG, 1993, ANN NY ACAD SCI, V685, P646, DOI 10.1111/j.1749-6632.1993.tb35930.x; KENNA JG, 1984, J IMMUNOL METHODS, V75, P3, DOI 10.1016/0022-1759(84)90219-9; RAY DC, 1991, BRIT J ANAESTH, V67, P84, DOI 10.1093/bja/67.1.84; SATOH H, 1985, J PHARMACOL EXP THER, V233, P857; SATOH H, 1989, P NATL ACAD SCI USA, V86, P322, DOI 10.1073/pnas.86.1.322	9	41	41	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 16	1993	342	8877					963	964		10.1016/0140-6736(93)92005-E	http://dx.doi.org/10.1016/0140-6736(93)92005-E			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MC005	8105217				2022-12-28	WOS:A1993MC00500012
J	HARPER, G				HARPER, G			BREAKING TABOOS AND STEADYING THE SELF IN MEDICAL-SCHOOL	LANCET			English	Editorial Material									HARVARD UNIV, CHILDRENS HOSP, SCH MED, DEPT MED, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School	HARPER, G (corresponding author), HARVARD UNIV, CHILDRENS HOSP, SCH MED, DEPT PSYCHIAT, 295 LONGWOOD AVE, BOSTON, MA 02115 USA.							Armstrong EG, 1991, CHALLENGE PROBLEM BA; BRANCH W, 1991, J GEN INTERN MED, V6, P573, DOI 10.1007/BF02598231; COLERIDGE ST, 1796, COMMUNICATION   1114; DEBALZAC H, 1962, P GORIOT, P254; Douglas Mary, 1966, PURITY DANGER; Erikson E.H., 1968, IDENTITY YOUTH CRISI; GRIGGS EL, 1966, COLLECTED LETT ST CO, V2, P256; LEBARON C, 1982, GENTAL VENGEANCE; Levitt L P, 1966, Chic Med Sch Q, V25, P201; LINN BS, 1982, J MED EDUC, V57, P684; SACKS MH, 1980, AM J PSYCHIAT, V137, P822; SHAKESPEARE W, KING LEAR, V3, pR4; Williams W. C., 1984, DOCTOR STORIES	13	12	12	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 9	1993	342	8876					913	915		10.1016/0140-6736(93)91952-I	http://dx.doi.org/10.1016/0140-6736(93)91952-I			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA963	8105173				2022-12-28	WOS:A1993MA96300016
J	LITTLETON, JT; STERN, M; SCHULZE, K; PERIN, M; BELLEN, HJ				LITTLETON, JT; STERN, M; SCHULZE, K; PERIN, M; BELLEN, HJ			MUTATIONAL ANALYSIS OF DROSOPHILA SYNAPTOTAGMIN DEMONSTRATES ITS ESSENTIAL ROLE IN CA(2+)-ACTIVATED NEUROTRANSMITTER RELEASE	CELL			English	Article							SYNAPTIC TRANSMITTER RELEASE; ALPHA-LATROTOXIN RECEPTOR; PROTEIN KINASE-C; NEUROMUSCULAR-JUNCTION; VESICLE EXOCYTOSIS; NERVE TERMINALS; ACTIVE ZONES; CALCIUM-IONS; BINDING; MELANOGASTER	Synaptotagmin (syt), a synaptic vesicle-specific protein known to bind Call in the presence of phospholipids, has been proposed to mediate Ca2+-dependent neurotransmitter release. We have addressed the role of syt in neurotransmitter release in vivo by generating mutations in synaptotagmin (syt) in the fruitfly and assaying the subsequent effects on neurotransmission. Most embryos that lack syt fall to hatch and exhibit very reduced, uncoordinated muscle contractions. Larvae with partial lack-of-function mutations show almost no evoked excitatory junctional potentials (EJPs) in 0.4 mM Ca2+ and a 15-fold reduction in EJP amplitude in 1.0 mM Ca2+ when compared with heterozygous controls. In contrast, we observe an increase in the frequency of spontaneous miniature EJPs in the mutants. These results provide in vivo evidence that syt plays a key role in Ca2+ activation of neurotransmitter release and indicate the existence of separate pathways for evoked and spontaneous neurotransmitter release.	BAYLOR COLL MED, HOWARD HUGHES MED INST, HOUSTON, TX 77030 USA; BAYLOR COLL MED, INST MOLEC GENET, HOUSTON, TX 77030 USA; RICE UNIV, DEPT BIOCHEM & CELL BIOL, HOUSTON, TX 77251 USA	Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Rice University	LITTLETON, JT (corresponding author), BAYLOR COLL MED, DIV NEUROSCI, HOUSTON, TX 77030 USA.			Littleton, J. Troy/0000-0001-5576-2887; Bellen, Hugo/0000-0001-5992-5989				AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; BELLEN HJ, 1992, GENE DEV, V6, P2125, DOI 10.1101/gad.6.11.2125; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; BROADIE KS, 1993, J NEUROSCI, V13, P144; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; CECCARELLI B, 1980, PHYSIOL REV, V60, P396, DOI 10.1152/physrev.1980.60.2.396; COHEN MW, 1991, J NEUROSCI, V11, P1032; COPE TC, 1982, J NEUROPHYSIOL, V47, P469, DOI 10.1152/jn.1982.47.3.469; DELCASTILLO J, 1956, PROG BIOPHYS MOL BIO, V6, P122, DOI 10.1016/S0096-4174(18)30106-9; DIANTONIO A, 1993, CELL, V73, P1281, DOI 10.1016/0092-8674(93)90356-U; DODGE FA, 1967, J PHYSIOL-LONDON, V193, P419, DOI 10.1113/jphysiol.1967.sp008367; ELFERINK LA, 1993, CELL, V72, P153, DOI 10.1016/0092-8674(93)90059-Y; GANETZKY B, 1982, J NEUROPHYSIOL, V47, P501, DOI 10.1152/jn.1982.47.3.501; HEUSER JE, 1979, J CELL BIOL, V81, P275, DOI 10.1083/jcb.81.2.275; JAN LY, 1976, J PHYSIOL-LONDON, V262, P189, DOI 10.1113/jphysiol.1976.sp011592; JAN YN, 1978, P NATL ACAD SCI USA, V75, P515, DOI 10.1073/pnas.75.1.515; KAISER K, 1990, P NATL ACAD SCI USA, V87, P1686, DOI 10.1073/pnas.87.5.1686; KATZ B, 1967, PROC R SOC SER B-BIO, V167, P23, DOI 10.1098/rspb.1967.0011; KUFFLER SW, 1984, NEURON BRAIN; LEVEQUE C, 1992, P NATL ACAD SCI USA, V89, P3625, DOI 10.1073/pnas.89.8.3625; LEWIS EB, 1968, DROSOPHILA INFORM SE, V43, P193; LINK E, 1992, BIOCHEM BIOPH RES CO, V189, P1017, DOI 10.1016/0006-291X(92)92305-H; LITTLETON JT, 1993, DEVELOPMENT, V118, P1077; LLINAS R, 1981, BIOPHYS J, V33, P289, DOI 10.1016/S0006-3495(81)84898-9; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; MATTEOLI M, 1988, P NATL ACAD SCI USA, V85, P7366, DOI 10.1073/pnas.85.19.7366; MILEDI R, 1973, PROC R SOC SER B-BIO, V183, P421, DOI 10.1098/rspb.1973.0026; MULKEY RM, 1991, NATURE, V350, P153, DOI 10.1038/350153a0; NISHIZUKA Y, 1989, JAMA-J AM MED ASSOC, V262, P1826, DOI 10.1001/jama.262.13.1826; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; PERIN MS, 1991, J BIOL CHEM, V266, P615; PERIN MS, 1991, J BIOL CHEM, V266, P623; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; PETRENKO AG, 1991, NATURE, V353, P65, DOI 10.1038/353065a0; POPOV SV, 1993, CELL, V73, P1247, DOI 10.1016/0092-8674(93)90352-Q; Sambrook J, 1989, MOL CLONING LABORATO; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SHOJIKASAI Y, 1992, SCIENCE, V256, P1820, DOI 10.1126/science.256.5065.1820; SIMON SM, 1985, BIOPHYS J, V48, P485, DOI 10.1016/S0006-3495(85)83804-2; SMITH SJ, 1988, TRENDS NEUROSCI, V11, P458, DOI 10.1016/0166-2236(88)90199-3; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; STERN M, 1989, J NEUROGENET, V5, P215, DOI 10.3109/01677068909066209; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TOWER J, 1993, GENETICS, V133, P347; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; Walch-Solimena C, 1993, Curr Opin Neurobiol, V3, P329, DOI 10.1016/0959-4388(93)90125-I; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0	52	384	390	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 24	1993	74	6					1125	1134		10.1016/0092-8674(93)90733-7	http://dx.doi.org/10.1016/0092-8674(93)90733-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LY493	8104705				2022-12-28	WOS:A1993LY49300018
J	FELDMAN, RD; BIERBRIER, GS				FELDMAN, RD; BIERBRIER, GS			INSULIN-MEDIATED VASODILATION - IMPAIRMENT WITH INCREASED BLOOD-PRESSURE AND BODY-MASS	LANCET			English	Article							LOW-SODIUM DIET; BETA-ADRENERGIC RESPONSE; ESSENTIAL-HYPERTENSION; SKELETAL-MUSCLE; RESISTANCE; CORRECTS; RESPONSIVENESS; PATHOGENESIS; DISORDERS; HUMANS	Insulin resistance is associated with hypertension although it is not known if this relationship is casual. Studies have shown that insulin increases skeletal-muscle blood flow despite also increasing sympathetic activity. To determine whether insulin may act as a direct vasodilator and whether insulin-mediated vascular effects are altered in hypertension, we studied insulin-mediated alterations in dorsal-hand-vein compliance in normotensive and mild and borderline hypertensive subjects. In phenylephrine pre-constricted vessels, insulin caused a dose-dependent increase in venous distensibility. Insulin-mediated venodilation was significantly impaired in hypertensive subjects. The vasodilator potency of insulin was significantly correlated with both blood pressure and body mass index. Insulin may be an endogenous vasodilator. Further, in hypertensive and obese subjects, impairment of insulin-mediated vasodilation may contribute to the increase in peripheral resistance characteristic of hypertension.	UNIV WESTERN ONTARIO,DEPT MED,LONDON N6A 3K7,ONTARIO,CANADA; UNIV WESTERN ONTARIO,DEPT PHARMACOL & TOXICOL,LONDON N6A 3K7,ONTARIO,CANADA	Western University (University of Western Ontario); Western University (University of Western Ontario)			Feldman, Ross/G-3293-2011					AELLIG WH, 1981, BRIT J CLIN PHARMACO, V11, P237, DOI 10.1111/j.1365-2125.1981.tb00527.x; ANDERSON EA, 1993, HYPERTENSION, V21, P136, DOI 10.1161/01.HYP.21.2.136; ANDERSON EA, 1992, HYPERTENSION, V19, P621, DOI 10.1161/01.HYP.19.6.621; ANDERSON EA, 1991, J CLIN INVEST, V87, P2246, DOI 10.1172/JCI115260; CAPALDO B, 1991, METABOLISM, V40, P1320, DOI 10.1016/0026-0495(91)90036-V; CREAGER MA, 1985, J PHARMACOL EXP THER, V235, P709; FELDMAN RD, 1992, CIRCULATION, V85, P612, DOI 10.1161/01.CIR.85.2.612; FELDMAN RD, 1987, J CLIN INVEST, V79, P290, DOI 10.1172/JCI112797; FELDMAN RD, 1990, J CLIN INVEST, V85, P647, DOI 10.1172/JCI114487; FERRANNINI E, 1991, AM HEART J, V121, P1274, DOI 10.1016/0002-8703(91)90433-I; FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605; KORNER PI, 1984, CLIN EXP HYPERTENS A, V6, P565, DOI 10.3109/10641968409062584; KUZYA H, 1977, DIABETES, V26, P22; LAAKSO M, 1990, J CLIN INVEST, V85, P1844, DOI 10.1172/JCI114644; LEE A, 1992, DIABETES, V41, P759; NASLUND T, 1990, CLIN PHARMACOL THER, V48, P87, DOI 10.1038/clpt.1990.121; NATALI A, 1991, HYPERTENSION, V17, P170, DOI 10.1161/01.HYP.17.2.170; PAN HYM, 1986, J PHARMACOL EXP THER, V239, P802; STROZZI C, 1979, GERONTOLOGY, V25, P24, DOI 10.1159/000212317; THORBURN AW, 1986, BRIT MED J, V292, P1697, DOI 10.1136/bmj.292.6537.1697; VANBRUMMELEN P, 1981, CLIN SCI, V60, P571, DOI 10.1042/cs0600571; WEBB RC, 1981, AM HEART J, V102, P251	22	133	133	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 18	1993	342	8873					707	709		10.1016/0140-6736(93)91708-T	http://dx.doi.org/10.1016/0140-6736(93)91708-T			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX469	8103822				2022-12-28	WOS:A1993LX46900009
J	SCHLAGGAR, BL; FOX, K; OLEARY, DDM				SCHLAGGAR, BL; FOX, K; OLEARY, DDM			POSTSYNAPTIC CONTROL OF PLASTICITY IN DEVELOPING SOMATOSENSORY CORTEX	NATURE			English	Article							RECEPTOR ANTAGONISTS DISRUPT; STRIATE CORTEX; BLOCKADE PREVENTS; CORTICAL ACTIVITY; NMDA RECEPTORS; VISUAL-CORTEX; RAT; ACETYLCHOLINESTERASE; PERIOD; AXONS	THE rearrangement of synaptic connections during normal and deprived development is thought to be controlled by correlations in afferent impulse activity1. A favoured model is based on postsynaptic detection of synchronously active afferents; synapses are stabilized when pre- and postsynaptic activity is correlated and weakened or eliminated when their activity is uncorrelated2,3. Most evidence for this model comes from demonstrations that correlated afferent input is necessary for the segregation of eye-dominant inputs in the developing vertebrate visual system1,4,5 and that critical period plasticity of ocular dominance columns in cat visual cortex is disrupted by blockade of postsynaptic transmission6-8. We tested whether the developmental plasticity of somatosensory columns, known as 'barrels', in rodent primary somatosensory cortex (S1)9-13 is similar to that of ocular dominance columns. We report here that the selective disruption of postsynaptic activation in rat S1 by application of a glutamate receptor antagonist inhibits rearrangements in the somatotopic patterning of thalamocortical afferents induced by manipulations of the sensory periphery during the critical period. These findings show that postsynaptic activation has a prominent role in critical period plasticity in S1 cortex.	SALK INST BIOL STUDIES,MOLEC NEUROBIOL LAB,10010 N TORREY PINES RD,LA JOLLA,CA 92037; UNIV MINNESOTA,DEPT PHYSIOL,MINNEAPOLIS,MN 55455	Salk Institute; University of Minnesota System; University of Minnesota Twin Cities			Schlaggar, Bradley/AAZ-4153-2020; Fox, Kevin/E-8836-2010	Fox, Kevin/0000-0002-2563-112X				AGMON A, 1992, J NEUROPHYSIOL, V68, P345, DOI 10.1152/jn.1992.68.1.345; BEAR MF, 1985, J COMP NEUROL, V234, P411, DOI 10.1002/cne.902340402; BEAR MF, 1990, J NEUROSCI, V10, P909; BELFORD GR, 1980, J COMP NEUROL, V193, P335, DOI 10.1002/cne.901930203; CHIAIA NL, 1992, DEV BRAIN RES, V66, P244, DOI 10.1016/0165-3806(92)90086-C; CLINE HT, 1989, NEURON, V3, P413, DOI 10.1016/0896-6273(89)90201-8; CLINE HT, 1987, P NATL ACAD SCI USA, V84, P4342, DOI 10.1073/pnas.84.12.4342; CONSTAINTINEPAT.M, 1991, A REV NEUROSCI, V13, P129; ERZURUMLU RS, 1990, DEV BRAIN RES, V56, P229; FOX K, 1992, J NEUROSCI, V12, P1826; HAHM JO, 1991, NATURE, V351, P568, DOI 10.1038/351568a0; HEBB DO, 1949, ORG BEHAVIOR; HENDERSON TA, 1992, DEV BRAIN RES, V66, P146, DOI 10.1016/0165-3806(92)90152-M; HONORE T, 1988, SCIENCE, V214, P1701; KILLACKEY HP, 1975, BRAIN RES, V86, P469, DOI 10.1016/0006-8993(75)90897-5; KLEINSCHMIDT A, 1987, SCIENCE, V238, P355, DOI 10.1126/science.2443978; LEVAY S, 1980, J COMP NEUROL, V91, P1; MCCASLAND JS, 1992, P NATL ACAD SCI USA, V89, P1832, DOI 10.1073/pnas.89.5.1832; REITER HO, 1986, EXP BRAIN RES, V65, P182; REITER HO, 1988, P NATL ACAD SCI USA, V85, P3623, DOI 10.1073/pnas.85.10.3623; ROBERTSON RT, 1987, NEUROSCI LETT, V75, P259, DOI 10.1016/0304-3940(87)90531-3; Schlaggar B L, 1993, Perspect Dev Neurobiol, V1, P81; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; SIMON DK, 1992, P NATL ACAD SCI USA, V89, P10593, DOI 10.1073/pnas.89.22.10593; STENT GS, 1973, P NATL ACAD SCI USA, V70, P997, DOI 10.1073/pnas.70.4.997; STRYKER MP, 1986, J NEUROSCI, V6, P2117; VANDERLO.H, 1973, SCIENCE, V179, P395, DOI 10.1126/science.179.4071.395; WIESEL TN, 1965, J NEUROPHYSIOL, V28, P1029, DOI 10.1152/jn.1965.28.6.1029; WOOLSEY TA, 1976, J COMP NEUROL, V170, P53, DOI 10.1002/cne.901700105; WOOLSEY TA, 1970, BRAIN RES, V1, P205	30	279	280	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 12	1993	364	6438					623	626		10.1038/364623a0	http://dx.doi.org/10.1038/364623a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR771	8102476				2022-12-28	WOS:A1993LR77100052
J	RAMPLING, A				RAMPLING, A			SALMONELLA-ENTERITIDIS 5 YEARS ON	LANCET			English	Editorial Material							INFECTED HENS; PHAGE TYPE-4; EGGS				RAMPLING, A (corresponding author), PUBL HLTH LAB,DORCHESTER,ENGLAND.							BARROW PA, 1991, AVIAN PATHOL, V20, P335, DOI 10.1080/03079459108418769; BINKIN N, 1993, EPIDEMIOL INFECT, V110, P227, DOI 10.1017/S095026880006814X; COOPER GL, 1993, VET REC, V133, P31, DOI 10.1136/vr.133.2.31; GALBRAITH NS, 1988, BRIT MED J, V297, P704; GAST RK, 1990, AVIAN DIS, V34, P438, DOI 10.2307/1591433; HUMPHREY TJ, 1989, EPIDEMIOL INFECT, V103, P415, DOI 10.1017/S0950268800030818; PERALES I, 1989, INT J FOOD MICROBIOL, V8, P175, DOI 10.1016/0168-1605(89)90072-X; ROBERTS D, 1991, LANCET, V337, P984, DOI 10.1016/0140-6736(91)91626-6; RODRIGUE DC, 1990, EPIDEMIOL INFECT, V105, P21, DOI 10.1017/S0950268800047609; STLOUIS ME, 1988, JAMA-J AM MED ASSOC, V259, P2103, DOI 10.1001/jama.259.14.2103; VANDEGIESSEN AW, 1992, EPIDEMIOL INFECT, V109, P405, DOI 10.1017/S0950268800050391; 1993, CDR WKLY, V3, P47; 1993, REPORT SALMONELLA EG; 1988, LANCET, V2, P720	14	41	41	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 7	1993	342	8867					317	318		10.1016/0140-6736(93)91466-Y	http://dx.doi.org/10.1016/0140-6736(93)91466-Y			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ868	8101578				2022-12-28	WOS:A1993LQ86800004
J	PAPE, JW; JEAN, SS; HO, JL; HAFNER, A; JOHNSON, WD				PAPE, JW; JEAN, SS; HO, JL; HAFNER, A; JOHNSON, WD			EFFECT OF ISONIAZID PROPHYLAXIS ON INCIDENCE OF ACTIVE TUBERCULOSIS AND PROGRESSION OF HIV-INFECTION	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TUMOR-NECROSIS-FACTOR; AIDS; IMPACT; HAITI	Tuberculosis occurring with human immunodeficiency virus (HIV) infection is a serious and growing public health problem. We have carried out a randomised clinical trial of a 12-month course of isoniazid plus vitamin B6 versus vitamin B6 alone in Port-au-Prince, Haiti, to assess the efficacy of isoniazid in preventing active tuberculosis in symptom-free HIV-infected individuals. The effect of prophylaxis on the development of HIV disease, AIDS, and death was also investigated. 118 subjects were assigned treatment with isoniazid plus B6 (n=58) or B6 alone (n=60) between 1986 and 1989. The treatment groups were similar at study entry in demographic, clinical, and immunological characteristics. Interim analysis in 1990 revealed no significant difference in tuberculosis outcome measures. Follow-up was continued until 1992, at which time significant protection by isoniazid against the development of tuberculosis was apparent, both for the whole study population and for subjects positive for purified protein derivative of tuberculin (PPD). The incidence of tuberculosis was lower in isoniazid recipients than in patients who received B6 alone (2.2 vs 7.5 per 100 person-years). The relative risk of tuberculosis was 3.4 (95% CI 1.1-10.6) for B6 alone versus isoniazid plus B6 (p<0.05). Isoniazid also delayed progression to HIV disease and AIDS and death. Thus isoniazid effectively decreases the incidence of tuberculosis and delays the onset of HIV-related disease in symptom-free HIV-seropositive individuals. Isoniazid prophylaxis should be considered for HIV-seropositive, PPD-positive subjects, and may also be appropriate for PPD-negative patients in areas where tuberculosis is highly endemic.	CORNELL UNIV,MED CTR,COLL MED,DEPT MED,DIV INT MED,A-431,1300 YORK AVE,NEW YORK,NY 10021; HAITIAN STUDY GRP KAPOSIS SARCOMA & OPPORTUNIST INFECT,PORT AU PRINCE,HAITI	Cornell University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI033877, R37AI022624] Funding Source: NIH RePORTER; FIC NIH HHS [TW00018] Funding Source: Medline; NIAID NIH HHS [R21AI 33877, R37 AI 22624] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; BAUM MK, 1991, J ACQ IMMUN DEF SYND, V4, P1122; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; HOPEWELL PC, 1992, CLIN INFECT DIS, V15, P540, DOI 10.1093/clind/15.3.540; HUEBNER RE, 1992, JAMA-J AM MED ASSOC, V267, P409, DOI 10.1001/jama.267.3.409; JOHNSON MP, 1992, J INFECT DIS, V166, P194, DOI 10.1093/infdis/166.1.194; KINDLER V, 1989, CELL, V56, P731, DOI 10.1016/0092-8674(89)90676-4; LIFSON AR, 1992, LANCET, V339, P1436, DOI 10.1016/0140-6736(92)92030-J; LONG R, 1991, AM REV RESPIR DIS, V143, P69, DOI 10.1164/ajrccm/143.1.69; MATSUYAMA T, 1991, AIDS, V5, P1405, DOI 10.1097/00002030-199112000-00001; PAPE JW, 1983, NEW ENGL J MED, V309, P945, DOI 10.1056/NEJM198310203091603; PAPE JW, 1990, J ACQ IMMUN DEF SYND, V3, P995; REDFIELD RR, 1986, NEW ENGL J MED, V314, P131, DOI 10.1056/NEJM198601093140232; SACKETT DL, 1979, NEW ENGL J MED, V301, P1420; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; 1991, MMWR, V40, P27; 1990, EB874 WHO TUB CONTR; 1982, B WORLD HEALTH ORGAN, V60, P555; 1989, MMWR, V38, P236; 1990, AM REV RESPIR DIS, V142, P725; 1987, ANN INTERN MED, V106, P254; 1987, MMWR S1, V36, pS3; [No title captured]	23	403	409	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 31	1993	342	8866					268	272		10.1016/0140-6736(93)91817-6	http://dx.doi.org/10.1016/0140-6736(93)91817-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ163	8101302	hybrid			2022-12-28	WOS:A1993LQ16300010
J	YELLON, DM; ALKHULAIFI, AM; PUGSLEY, WB				YELLON, DM; ALKHULAIFI, AM; PUGSLEY, WB			PRECONDITIONING THE HUMAN MYOCARDIUM	LANCET			English	Note							CELL INJURY; ISCHEMIA	Ischaemic preconditioning (short periods of ischaemia with intermittent reperfusion) has been shown paradoxically to protect the myocardium from a subsequent longer ischaemic insult. The protection associated with preconditioning is one of the most powerful mechanisms of protection known and has been shown in every animal species investigated. However, there is no direct evidence that ischaemic preconditioning occurs in the human heart. We studied whether it was possible to precondition the human heart in a setting of coronary artery bypass surgery. The measurement of adenosine triphosphate in biopsy specimens was used as our endpoint. We believe that our results are the first to show that it may be possible to precondition and protect the human myocardium with short controlled periods of intermittent ischaemia and reperfusion.	MIDDLESEX HOSP,DEPT CARDIOTHORAC SURG,LONDON W1,ENGLAND	University of London; University College London	YELLON, DM (corresponding author), UNIV COLL HOSP LONDON,HATTER INST CARDIOVASC STUDIES,DIV CARDIOL,LONDON WC1E 6AU,ENGLAND.		Yellon, Derek M/ABD-5110-2021; Alkhulaifi, Abdulaziz/AAX-8617-2020	Yellon, Derek/0000-0001-7791-9320				ASIMAKIS G, 1992, AM J PHYSIOL, V32, pH887; KIDA M, 1992, J MOL CELL CARDI S11, V24, P1; LIU GS, 1991, CIRCULATION, V84, P350, DOI 10.1161/01.CIR.84.1.350; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; MURRY CE, 1990, CIRC RES, V66, P913, DOI 10.1161/01.RES.66.4.913; STEENBERGEN C, 1993, CIRC RES, V72, P112, DOI 10.1161/01.RES.72.1.112; VANDERHEIDE RS, IN PRESS J MOL CELL; WALKER DM, 1992, CARDIOVASC RES, V26, P734, DOI 10.1093/cvr/26.8.734; YELLON DM, 1983, J AM COLL CARDIOL, V2, P661, DOI 10.1016/S0735-1097(83)80306-4; YELLON DM, 1990, CARDIOSCIENCE, V1, P89	10	581	622	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 31	1993	342	8866					276	277		10.1016/0140-6736(93)91819-8	http://dx.doi.org/10.1016/0140-6736(93)91819-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ163	8101304				2022-12-28	WOS:A1993LQ16300012
J	HOCKLEY, AD				HOCKLEY, AD			CRANIOSYNOSTOSIS	LANCET			English	Editorial Material											HOCKLEY, AD (corresponding author), QUEEN ELIZABETH HOSP,DEPT NEUROSURG,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND.							CHAR F, 1978, JUN BIRTH DEF ANN M; Cohen, 1986, CRANIOSYNOSTOSIS DIA; GOLDIN H, 1986, BR J HOSP MED, V37, P368; HUNT L, 1993, INDEPENDENT     0707, P2; KIRBY PJG, 1993, LANCET, V341, P1412, DOI 10.1016/0140-6736(93)90979-Q; MUNRO IR, 1975, PLAST RECONSTR SURG, V55, P170, DOI 10.1097/00006534-197502000-00006; RENIER D, 1982, J NEUROSURG, V57, P370, DOI 10.3171/jns.1982.57.3.0370; TESSIER P, 1971, 5TH T INT C PLAST RE, P903; VINKEN PJ, 1977, HDB CLIN NEUROLOGY 1, V30, P1	9	2	2	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 24	1993	342	8865					189	190		10.1016/0140-6736(93)92291-Z	http://dx.doi.org/10.1016/0140-6736(93)92291-Z			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN622	8100923				2022-12-28	WOS:A1993LN62200004
J	BRUERA, E; DESTOUTZ, N; VELASCOLEIVA, A; SCHOELLER, T; HANSON, J				BRUERA, E; DESTOUTZ, N; VELASCOLEIVA, A; SCHOELLER, T; HANSON, J			EFFECTS OF OXYGEN ON DYSPNEA IN HYPOXEMIC TERMINAL-CANCER PATIENTS	LANCET			English	Article							BREATHLESSNESS; DISEASE	Dyspnoea is a frequent and devastating symptom of advanced cancer. The purpose of this prospective, double-blind, crossover trial was to assess the effects of supplemental oxygen on the intensity of dyspnoea. 14 patients with hypoxaemic dyspnoea due to advanced cancer were randomised to receive either oxygen or air; the gases were delivered at 5 L/min by mask. After 5 min of stable oxygen saturation (pulse oximetry), patients were crossed over to receive the other treatment. The crossover was repeated twice. Dyspnoea was assessed with a visual analogue scale (0 = no dyspnoea, 100 = worst dyspnoea). Mean difference in dyspnoea visual analogue scale between air and oxygen treatment was 20.5 (95% confidence interval 13.5 to 27.6). 12 patients consistently preferred oxygen to air; similarly, the investigator consistently chose oxygen for the same 12 patients. In a global rating questionnaire, patients reported little or no benefit during the air phase compared with moderate to much benefit during the oxygen phase. We conclude that oxygen is beneficial to patients with hypoxia and dyspnoea at rest.			BRUERA, E (corresponding author), EDMONTON GEN HOSP,PALLIAT CARE PROGRAM,11111 JASPER AVE,EDMONTON,ALBERTA,CANADA.		Bruera, Eduardo/AAA-1550-2022					BANNISTER RG, 1954, J PHYSIOL-LONDON, V125, P118, DOI 10.1113/jphysiol.1954.sp005145; BILLINGS JA, 1985, OUT PATIENT MANAGEME, V41, P80; CAMPBELL EJ, 1963, BRIT MED BULL, V19, P36, DOI 10.1093/oxfordjournals.bmb.a070002; CHRONOS N, 1988, CLIN SCI, V74, P531, DOI 10.1042/cs0740531; CM Saunders, 1978, MANAGEMENT TERMINAL, P99; Enck R E, 1989, Am J Hosp Care, V6, P11, DOI 10.1177/104990918900600403; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; HILLS M, 1979, BRIT J CLIN PHARMACO, V8, P7, DOI 10.1111/j.1365-2125.1979.tb05903.x; JAESCHKE R, 1991, EFFECT CANCER QUALIT, P65; LISS HP, 1988, AM REV RESPIR DIS, V137, P1285, DOI 10.1164/ajrccm/137.6.1285; MOORE DP, 1992, LANCET, V339, P850, DOI 10.1016/0140-6736(92)90288-E; RESTRICK LJ, 1992, LANCET, V340, P1192, DOI 10.1016/0140-6736(92)92893-K; REUBEN DB, 1986, CHEST, V89, P234, DOI 10.1378/chest.89.2.234; SIMON PM, 1990, AM REV RESPIR DIS, V142, P1009, DOI 10.1164/ajrccm/142.5.1009; STARK RD, 1988, EUR RESPIR J, V1, P280; SWINBURN CR, 1991, AM REV RESPIR DIS, V143, P913, DOI 10.1164/ajrccm/143.5_Pt_1.913; WASSERMAN K, 1988, ANNU REV MED, V39, P503, DOI 10.1146/annurev.med.39.1.503	17	131	133	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 3	1993	342	8862					13	14		10.1016/0140-6736(93)91880-U	http://dx.doi.org/10.1016/0140-6736(93)91880-U			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK985	8100289				2022-12-28	WOS:A1993LK98500009
J	ONUNAIN, S; RUSKIN, J				ONUNAIN, S; RUSKIN, J			CARDIAC-ARREST	LANCET			English	Article							IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR; SUSTAINED VENTRICULAR TACHYARRHYTHMIAS; CORONARY-ARTERY DISEASE; MYOCARDIAL-INFARCTION; ARRHYTHMIAS; PREDICTION; SURVIVORS; DEATH; RISK		HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT MED,BOSTON,MA 02114	Harvard University; Harvard Medical School; Massachusetts General Hospital								[Anonymous], 1989, CIRCULATION, V79, P1354; BARDY GH, 1992, CIRCULATION, V85, P1689, DOI 10.1161/01.CIR.85.5.1689; BIGGER JT, 1984, CIRCULATION, V69, P250, DOI 10.1161/01.CIR.69.2.250; BIGGER JT, 1991, PACE, V14, P883; BOURKE JP, 1991, J AM COLL CARDIOL, V18, P780, DOI 10.1016/0735-1097(91)90802-G; BROWN CG, 1992, NEW ENGL J MED, V327, P1051, DOI 10.1056/NEJM199210083271503; CHAMBERLAIN DA, 1989, BRIT MED J, V299, P446, DOI 10.1136/bmj.299.6696.446; COBB LA, 1992, CIRCULATION, V85, P98; CUMMINS RO, 1991, CIRCULATION, V84, P930; CUPPLES LA, 1992, CIRCULATION, V85, P11; DAVIES MJ, 1989, EUR HEART J, V10, P203, DOI 10.1093/oxfordjournals.eurheartj.a059467; DELUNA AB, 1989, AM HEART J, V117, P151, DOI 10.1016/0002-8703(89)90670-4; EISENBERG MS, 1990, ANN EMERG MED, V19, P1248; FARRELL TG, 1991, J AM COLL CARDIOL, V18, P687, DOI 10.1016/0735-1097(91)90791-7; FURUKAWA T, 1989, CIRCULATION, V80, P599, DOI 10.1161/01.CIR.80.3.599; FUSTER V, 1992, NEW ENGL J MED, V326, P310; GREENE HL, 1992, CIRCULATION S1, V65, pK656; HOLMES DR, 1986, CIRCULATION, V73, P1254, DOI 10.1161/01.CIR.73.6.1254; HOROWITZ LN, 1985, AM J CARDIOL, V55, P367, DOI 10.1016/0002-9149(85)90377-7; KELLY P, 1990, J AM COLL CARDIOL, V15, P267, DOI 10.1016/S0735-1097(10)80046-4; KELLY PA, 1988, J AM COLL CARDIOL, V11, P1278, DOI 10.1016/0735-1097(88)90292-6; KUCHAR DL, 1988, J AM COLL CARDIOL, V12, P982, DOI 10.1016/0735-1097(88)90465-2; MARSDEN AK, 1989, BRIT MED J, V299, P442, DOI 10.1136/bmj.299.6696.442; MIROWSKI M, 1980, NEW ENGL J MED, V303, P322, DOI 10.1056/NEJM198008073030607; MYERBURG RJ, 1992, J CARDIOVASC ELECTR, V3, P626, DOI 10.1111/j.1540-8167.1992.tb01941.x; NIEMANN JT, 1992, NEW ENGL J MED, V327, P1075; SACK JB, 1992, CIRCULATION, V86, P1692, DOI 10.1161/01.CIR.86.6.1692; SCHWARTZ PJ, 1992, CIRCULATION, V85, P77; STIELL IG, 1992, NEW ENGL J MED, V327, P1045, DOI 10.1056/NEJM199210083271502; VARNAUSKAS E, 1985, CIRCULATION, V72, P90; WILBER DJ, 1988, NEW ENGL J MED, V318, P19, DOI 10.1056/NEJM198801073180105; WINKLE RA, 1991, CIRCULATION S2, V84, P426; WOODS KL, 1992, LANCET, V339, P1553, DOI 10.1016/0140-6736(92)91828-V; 1992, JAMA-J AM MED ASSOC, V268, P2172; 1982, JAMA-J AM MED ASSOC, V247, P1254	35	14	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 26	1993	341	8861					1641	1647		10.1016/0140-6736(93)90770-H	http://dx.doi.org/10.1016/0140-6736(93)90770-H			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ727	8100002				2022-12-28	WOS:A1993LJ72700016
J	BRAHAMS, D				BRAHAMS, D			COURT AWARD FOR PERTUSSIS-VACCINE DAMAGE	LANCET			English	Editorial Material																			0	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 22	1993	341	8856					1338	1339		10.1016/0140-6736(93)90837-7	http://dx.doi.org/10.1016/0140-6736(93)90837-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD253	8098462				2022-12-28	WOS:A1993LD25300017
J	STUCK, AE; SIU, AL; WIELAND, GD; ADAMS, J; RUBENSTEIN, LZ				STUCK, AE; SIU, AL; WIELAND, GD; ADAMS, J; RUBENSTEIN, LZ			COMPREHENSIVE GERIATRIC ASSESSMENT - A METAANALYSIS OF CONTROLLED TRIALS	LANCET			English	Article								There is disagreement on the usefulness of comprehensive geriatric assessment (CGA) due to conflicting results from individual trials. We did a meta-analysis on 28 controlled trials comprising 4959 subjects allocated to one of five CGA types and 4912 controls. Published data were supplemented with reanalysed data provided by the original investigators. We calculated combined odds ratios of important outcomes by pooling data from individual trials with multivariate logistic regression. Combined odds ratio (95% confidence interval) of living at home at follow-up was 1.68 (1.17-2.41) for geriatric evaluation and management units, 1.49 (1.12-1.98) for hospital-home assessment services, and 1.22 (1.05-1.37) for home assessment services. Covariate analysis showed that programmes with control over medical recommendations and extended ambulatory follow-up were more likely to be effective. Our analysis suggests that CGA programmes linking geriatric evaluation with strong long-term management are effective for improving survival and function in older persons.	DEPT GERIATR & REHABIL, BERN, SWITZERLAND; VET AFFAIRS MED CTR, CTR GERIATR RES EDUC & CLIN, SEPULVEDA, CA USA; NEW YORK STATE DEPT HLTH, ALBANY, NY 12201 USA; UNIV CALIF LOS ANGELES, SCH MED, MULTICAMPUS PROGRAM GERIATR & GERONTOL, LOS ANGELES, CA 90024 USA	Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); State University of New York (SUNY) System; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA				Rubenstein, Laurence/0000-0001-5910-0266				ALLEN CM, 1986, JAMA-J AM MED ASSOC, V255, P2617, DOI 10.1001/jama.255.19.2617; ALTMAN DG, 1990, LANCET, V335, P149, DOI 10.1016/0140-6736(90)90014-V; APPLEGATE WB, 1990, NEW ENGL J MED, V322, P1572, DOI 10.1056/NEJM199005313222205; CARPENTER GI, 1990, BMJ-BRIT MED J, V300, P1253, DOI 10.1136/bmj.300.6734.1253; COHEN HJ, 1989, J GERONTOL, V44, pM175, DOI 10.1093/geronj/44.6.M175; DICKERSIN K, 1992, EPIDEMIOL REV, V14, P154, DOI 10.1093/oxfordjournals.epirev.a036084; EPSTEIN AM, 1987, ANN INTERN MED, V106, P299, DOI 10.7326/0003-4819-106-2-299; EPSTEIN AM, 1990, JAMA-J AM MED ASSOC, V263, P538, DOI 10.1001/jama.263.4.538; FRETWELL MD, 1990, J AM GERIATR SOC, V38, P1073, DOI 10.1111/j.1532-5415.1990.tb01368.x; GAYTON D, 1987, J AM GERIATR SOC, V35, P726, DOI 10.1111/j.1532-5415.1987.tb06350.x; GILCHRIST WJ, 1988, BRIT MED J, V297, P1116, DOI 10.1136/bmj.297.6656.1116; HANSEN FR, 1992, AGE AGEING, V21, P445, DOI 10.1093/ageing/21.6.445; HARRIS RD, 1991, AUST NZ J MED, V21, P230, DOI 10.1111/j.1445-5994.1991.tb00448.x; HENDRIKSEN C, 1984, BMJ-BRIT MED J, V289, P1522, DOI 10.1136/bmj.289.6457.1522; HOGAN DB, 1987, CAN MED ASSOC J, V136, P713; HOGAN DB, 1990, AGE AGEING, V19, P107, DOI 10.1093/ageing/19.2.107; KENNIE DC, 1988, BRIT MED J, V297, P1083, DOI 10.1136/bmj.297.6656.1083; MELIN AL, 1992, MED CARE, V30, P1004, DOI 10.1097/00005650-199211000-00004; PATHY MSJ, 1992, LANCET, V340, P890, DOI 10.1016/0140-6736(92)93294-W; POWELL C, 1990, AGE AGEING, V19, P21; RUBENSTEIN LZ, 1984, NEW ENGL J MED, V311, P1664, DOI 10.1056/NEJM198412273112604; Rubenstein LZ, 1991, J AM GERIATR SOC S, V39, p8S; RUBIN CD, 1992, J AM GERIATR SOC, V40, P989, DOI 10.1111/j.1532-5415.1992.tb04474.x; Sorensen K H, 1988, Compr Gerontol B, V2, P85; STEWART LA, 1993, LANCET, V341, P418, DOI 10.1016/0140-6736(93)93004-K; TEASDALE TA, 1983, J AM GERIATR SOC, V31, P529, DOI 10.1111/j.1532-5415.1983.tb02196.x; THOMAS DR, 1993, J AM GERIATR SOC, V41, P101, DOI 10.1111/j.1532-5415.1993.tb02040.x; THOMPSON SG, 1991, LANCET, V338, P1127, DOI 10.1016/0140-6736(91)91975-Z; Tulloch A J, 1979, J R Coll Gen Pract, V29, P733; VETTER NJ, 1984, BRIT MED J, V288, P369, DOI 10.1136/bmj.288.6414.369; VETTER NJ, 1992, BMJ-BRIT MED J, V304, P888, DOI 10.1136/bmj.304.6831.888; WILLIAMS ME, 1987, J AM GERIATR SOC, V35, P1071, DOI 10.1111/j.1532-5415.1987.tb04923.x; WILLIAMSON J, 1964, LANCET, V1, P1117; WINOGRAD C, 1991, J AM GERIATR SOC, V39, pA13; YEO G, 1987, J GERONTOL, V42, P252, DOI 10.1093/geronj/42.3.252; 1987, LANCET, V1, P602	36	1299	1313	1	58	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 23	1993	342	8878					1032	1036		10.1016/0140-6736(93)92884-V	http://dx.doi.org/10.1016/0140-6736(93)92884-V			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MD066	8105269				2022-12-28	WOS:A1993MD06600015
J	NEWNHAM, JP; EVANS, SF; MICHAEL, CA; STANLEY, FJ; LANDAU, LI				NEWNHAM, JP; EVANS, SF; MICHAEL, CA; STANLEY, FJ; LANDAU, LI			EFFECTS OF FREQUENT ULTRASOUND DURING PREGNANCY - A RANDOMIZED CONTROLLED TRIAL	LANCET			English	Article							DOPPLER ULTRASOUND	Despite widespread application of ultrasound imaging and Doppler blood flow studies, the effects of their frequent and repeated use in pregnancy have not been evaluated in controlled trials. From 2834 women with single pregnancies at 16-20 weeks gestation, 1415 were selected at random to receive ultrasound imaging and continuous-wave Doppler flow studies at 18, 24, 28, 34, and 38 weeks gestation (the intensive group) and 1419 to receive single ultrasound imaging at 18 weeks (the regular group). Outcome data was obtained from 99% of women who entered the study. The only difference between the two groups was significantly higher intrauterine growth restriction in the intensive group, when expressed both as birthweight <10th centile (relative risk 1.35; 95% confidence interval 1.09 to 1.67; p = 0.006) and birthweight <3rd centile (relative risk 1.65; 95% confidence intervals 1.09 to 2.49; p=0.020). While it is possible that this finding was a chance effect, it is also plausible that frequent exposure to ultrasound may have influenced fetal growth. Repeated prenatal ultrasound imaging and Doppler flow examinations should be restricted to those women to whom the information is likely to be of clinical benefit.	WESTERN AUSTRALIA INST CHILD HLTH,PERTH,AUSTRALIA; UNIV WESTERN AUSTRALIA,PRINCESS MARGARET HOSP,DEPT PAEDIAT,PERTH,WA,AUSTRALIA	University of Western Australia	NEWNHAM, JP (corresponding author), UNIV WESTERN AUSTRALIA,KING EDWARD MEM HOSP,DEPT OBSTET & GYNAECOL,374 BAGOT RD,SUBIACO 6008,WA,AUSTRALIA.		Study, Raine/K-4517-2013	Newnham, John/0000-0001-9983-7457				BAKKETEIG LS, 1984, LANCET, V2, P207; BENNETT MJ, 1982, BRIT J OBSTET GYNAEC, V89, P388; BLAIR E, 1985, BIRTH WEIGHT CHARTS; DAVIES JA, 1992, LANCET, V340, P1299, DOI 10.1016/0140-6736(92)92490-7; EIKNES SH, 1984, LANCET, V1, P1347; MOLE R, 1986, BIRTH-ISS PERINAT C, V13, P29, DOI 10.1111/j.1523-536X.1986.tb00999.x; NEWNHAM JP, 1990, AM J OBSTET GYNECOL, V162, P403, DOI 10.1016/0002-9378(90)90396-O; NIELSON JP, 1984, BRIT MED J, V289, P1179; OBRIEN WD, 1983, J ULTRAS MED, V2, P1; PIZZARELLO DJ, 1978, EXP CELL BIOL, V46, P179; PREGIBON D, 1981, ANN STAT, V9, P705, DOI 10.1214/aos/1176345513; REECE EA, 1990, OBSTET GYNECOL, V76, P139; REUWER PJH, 1987, LANCET, V1, P415; SAARIKEMPPAINEN A, 1975, BRIT J OBSTET GYNAEC, V82, P702; SABBAGHA RE, 1978, OBSTET GYNECOL, V52, P402; TARANTAL AF, 1993, TERATOLOGY, V47, P159, DOI 10.1002/tera.1420470208; TARANTAL AF, 1989, TERATOLOGY, V39, P137, DOI 10.1002/tera.1420390206; TRUDINGER BJ, 1985, BRIT J OBSTET GYNAEC, V92, P23, DOI 10.1111/j.1471-0528.1985.tb01044.x; WALDENSTROM U, 1988, LANCET, V2, P585; WLADIMIROFF JW, 1980, ACTA OBSTET GYN SCAN, V59, P177, DOI 10.3109/00016348009154637; 1984, DHHS NIH86667 PUBL	21	502	504	0	29	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 9	1993	342	8876					887	891		10.1016/0140-6736(93)91944-H	http://dx.doi.org/10.1016/0140-6736(93)91944-H			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA963	8105165				2022-12-28	WOS:A1993MA96300008
J	KASS, DA; WOLFF, MR; TING, CT; LIU, CP; CHANG, MS; LAWRENCE, W; MAUGHAN, WL				KASS, DA; WOLFF, MR; TING, CT; LIU, CP; CHANG, MS; LAWRENCE, W; MAUGHAN, WL			DIASTOLIC COMPLIANCE OF HYPERTROPHIED VENTRICLE IS NOT ACUTELY ALTERED BY PHARMACOLOGICAL AGENTS INFLUENCING ACTIVE PROCESSES	ANNALS OF INTERNAL MEDICINE			English	Article						VENTRICULAR FUNCTION, LEFT; HYPERTROPHY, LEFT VENTRICULAR; VERAPAMIL; ESMOLOL; COMPLIANCE	PRESSURE-VOLUME RELATIONS; CONDUCTANCE CATHETER; HEART-FAILURE; SHORT-TERM; CARDIOMYOPATHY; VERAPAMIL; RELAXATION; DYSFUNCTION; NIFEDIPINE; DETERMINANTS	Objective: To test, by studying the acute effects of drugs that influence active processes, the hypothesis that in humans with marked ventricular hypertrophy, reduced chamber compliance is primarily caused by passive structural changes. Design: An uncontrolled (before-after) study. Setting: University Medical Center. Patients: Fourteen patients with ventricular hypertrophy (19 +/- 4.5-mm diastolic-wall thickness) and normal resting systolic function were studied while they had invasive cardiac catheterization. Intervention: Intravenous beta-blocker (esmolol) or calcium channel blocker (verapamil) or both. Measurements: Left ventricular function was determined by pressure-volume relations. Volume was measured using conductance catheter, providing a continuous voltage signal proportional to chamber volume. Pressure was measured by micromanometer. Cardiac-specific assessment of change in chamber contractility and diastolic compliance due to each drug was determined. Results: Both drugs lowered contractility by approximately 30% (P < 0.01). Esmolol slowed relaxation and reduced early peak filling rate, whereas verapamil delayed the time to peak filling (all P < 0.05). In contrast to the effects of both drugs on active contraction and early diastole, late-diastolic compliance was unaltered, and end-diastolic pressure-volume relations were almost identical. Conclusion: Neither beta-receptor nor calcium channel blockade acutely alters left ventricular compliance despite substantial active effects manifest in systole and early diastole. This supports the notion that chamber compliance is principally determined by passive structural elements in the heart rather than by active processes.	JOHNS HOPKINS MED INST, BALTIMORE, MD 21205 USA; VET GEN HOSP, TAIPEI, TAIWAN	Johns Hopkins University; Johns Hopkins Medicine					NHLBI NIH HHS [HL-33243, HL-01610, HL-01820] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033243, K11HL001820] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		APPLEGATE RJ, 1990, CIRCULATION, V81, P638, DOI 10.1161/01.CIR.81.2.638; BAAN J, 1984, CIRCULATION, V70, P812, DOI 10.1161/01.CIR.70.5.812; BETOCCHI S, 1986, J AM COLL CARDIOL, V7, P74, DOI 10.1016/S0735-1097(86)80262-5; BONOW RO, 1985, CIRCULATION, V72, P853, DOI 10.1161/01.CIR.72.4.853; BONOW RO, 1983, CIRCULATION, V68, P1062, DOI 10.1161/01.CIR.68.5.1062; BONOW RO, 1981, CIRCULATION, V64, P787, DOI 10.1161/01.CIR.64.4.787; BURKHOFF D, 1985, CIRCULATION, V72, P440, DOI 10.1161/01.CIR.72.2.440; COHEN LS, 1967, CIRCULATION, V35, P847, DOI 10.1161/01.CIR.35.5.847; EPSTEIN SE, 1965, J CLIN INVEST, V44, P1745, DOI 10.1172/JCI105282; GILBERT JC, 1989, CIRC RES, V64, P827, DOI 10.1161/01.RES.64.5.827; Glantz SA, 1990, PRIMER APPL REGRESSI, P381; GROSSMAN W, 1991, NEW ENGL J MED, V325, P1557; GWATHMEY JK, 1991, J CLIN INVEST, V87, P1023, DOI 10.1172/JCI115061; HESS OM, 1986, CIRCULATION, V74, P530, DOI 10.1161/01.CIR.74.3.530; KASS DA, 1988, CIRCULATION, V77, P1203, DOI 10.1161/01.CIR.77.6.1203; KASS DA, 1988, CATHETER CARDIO DIAG, V15, P192, DOI 10.1002/ccd.1810150314; KASS DA, 1990, CIRCULATION, V81, P447, DOI 10.1161/01.CIR.81.2.447; LIU CP, 1992, CIRCULATION, V85, P1447, DOI 10.1161/01.CIR.85.4.1447; LORELL BH, 1987, J AM COLL CARDIOL, V9, P1189, DOI 10.1016/S0735-1097(87)80326-1; LORELL BH, 1980, NEW ENGL J MED, V303, P801, DOI 10.1056/NEJM198010023031407; LORELL BH, 1982, CIRCULATION, V65, P499, DOI 10.1161/01.CIR.65.3.499; LUDBROOK PA, 1977, CIRCULATION, V56, P937, DOI 10.1161/01.CIR.56.6.937; MARON BJ, 1987, NEW ENGL J MED, V316, P780, DOI 10.1056/NEJM198703263161305; MORGAN JP, 1990, CIRCULATION, V81, P21; PAULUS WJ, 1983, J AM COLL CARDIOL, V2, P879, DOI 10.1016/S0735-1097(83)80235-6; REFSUM H, 1981, CIRCULATION, V64, P997, DOI 10.1161/01.CIR.64.5.997; SCHULMAN SP, 1990, NEW ENGL J MED, V322, P1350, DOI 10.1056/NEJM199005103221904; Speiser K W, 1981, Eur Heart J, V2, P21; STEWART S, 1968, CIRCULATION, V37, P8, DOI 10.1161/01.CIR.37.1.8; SUGA H, 1974, CIRC RES, V35, P117, DOI 10.1161/01.RES.35.1.117; SWANTON RH, 1977, EUR J CARDIOL, V5, P327; TENCATE FJ, 1983, CIRCULATION, V68, P1274, DOI 10.1161/01.CIR.68.6.1274; WEBER KT, 1987, CIRCULATION, V75, P40; WEBER KT, 1989, AM J HYPERTENS, V2, P931, DOI 10.1093/ajh/2.12.931; WEISS JL, 1976, J CLIN INVEST, V58, P751, DOI 10.1172/JCI108522	35	58	60	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1993	119	6					466	473		10.7326/0003-4819-119-6-199309150-00004	http://dx.doi.org/10.7326/0003-4819-119-6-199309150-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ275	8102838				2022-12-28	WOS:A1993LZ27500004
J	BU, XD; ROTTER, JI				BU, XD; ROTTER, JI			WOLFRAM-SYNDROME - A MITOCHONDRIAL-MEDIATED DISORDER	LANCET			English	Article							PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; HEREDITARY OPTIC NEUROPATHY; KEARNS-SAYRE SYNDROME; DIABETES-MELLITUS; DNA MUTATION; DELETIONS; DEAFNESS; PEDIGREE; GENES	Mitochondrial DNA mutations cause several human diseases, (eg, Leber's hereditary optic neuropathy). Wolfram syndrome (characterised by diabetes insipidus, diabetes mellitus, optic atrophy, and deafness) also has, in some cases, a mitochondrial origin. The disease, often familial, has been well documented as an autosomal recessive disorder, and most of the clinical phenotypes are consistent with an ATP supply defect that is often seen in mitochondrial-mediated disorders. We propose a dual genome defect model for Wolfram syndrome in which nuclear genetic defects or mitochondrial genetic defects can independently lead to the disease. This model suggests that besides a mitochondrial gene defect alone, a nuclear gene defect, which interferes with the normal function of mitochondria (probably with a normal mitochondrial genome), can also be the underlying explanation for the pleiotropic features of Wolfram syndrome. This hypothesis explains how an autosomal recessive disorder can result in mitochondrial dysfunction, and has a general application in the identification of candidate genes for the various important phenotypes (eg, deafness and diabetes mellitus) seen in mitochondrial disorders.	CEDARS SINAI MED CTR, DEPT PEDIAT, LOS ANGELES, CA 90048 USA; UNIV CALIF LOS ANGELES, SCH MED, LOS ANGELES, CA USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	BU, XD (corresponding author), CEDARS SINAI MED CTR, DEPT MED, DIV MED GENET, SSB-3, 8700 W BEVERLY BLVD, LOS ANGELES, CA 90048 USA.				NHLBI NIH HHS [HL28481] Funding Source: Medline; NIDCD NIH HHS [DCO1402] Funding Source: Medline; NIDDK NIH HHS [DK07426] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL028481] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007426] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC001402] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ALCOLADO JC, 1991, BRIT MED J, V302, P1178, DOI 10.1136/bmj.302.6786.1178; BALLINGER SW, 1992, NAT GENET, V1, P11, DOI 10.1038/ng0492-11; BELCOUR L, 1991, P NATL ACAD SCI USA, V88, P3579, DOI 10.1073/pnas.88.9.3579; BU XD, 1993, GENET EPIDEMIOL, V10, P3, DOI 10.1002/gepi.1370100102; BU XD, 1991, P NATL ACAD SCI USA, V88, P8198, DOI 10.1073/pnas.88.18.8198; BU XD, 1992, GENET EPIDEMIOL, V9, P27, DOI 10.1002/gepi.1370090105; BUNDEY S, 1992, J INHERIT METAB DIS, V15, P315, DOI 10.1007/BF02435965; CAVELIER L, 1993, CLIN GENET, V43, P69, DOI 10.1111/j.1399-0004.1993.tb04429.x; CORMIER V, 1991, AM J HUM GENET, V48, P643; GERBITZ KD, 1992, DIABETOLOGIA, V35, P1181, DOI 10.1007/BF00401375; JABER L, 1992, J MED GENET, V29, P86, DOI 10.1136/jmg.29.2.86; MCKUSICK VA, 1992, MENDELIAN INHERITANC, P1333; MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001; PREZANT TR, 1992, AM J MED GENET, V44, P465, DOI 10.1002/ajmg.1320440416; PREZANT TR, 1993, NAT GENET, V4, P289, DOI 10.1038/ng0793-289; REARDON W, 1992, LANCET, V340, P1376, DOI 10.1016/0140-6736(92)92560-3; ROTIG A, 1993, J CLIN INVEST, V91, P1095, DOI 10.1172/JCI116267; SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N; SINGH G, 1989, NEW ENGL J MED, V320, P1300, DOI 10.1056/NEJM198905183202002; SWIFT RG, 1990, LANCET, V336, P667, DOI 10.1016/0140-6736(90)92157-D; VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368; VANDENOUWELAND JMW, 1992, NUCLEIC ACIDS RES, V20, P679, DOI 10.1093/nar/20.4.679; VILKKI J, 1991, American Journal of Human Genetics, V48, P486; WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; ZEVIANI M, 1988, NEUROLOGY, V38, P1339; ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0	27	55	56	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 4	1993	342	8871					598	600		10.1016/0140-6736(93)91416-J	http://dx.doi.org/10.1016/0140-6736(93)91416-J			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV963	8102726				2022-12-28	WOS:A1993LV96300016
J	STOLTE, M; EIDT, S				STOLTE, M; EIDT, S			HEALING GASTRIC MALT LYMPHOMAS BY ERADICATING HELICOBACTER-PYLORI	LANCET			English	Editorial Material							CAMPYLOBACTER-PYLORI; HELICOBACTER-PYLORI; IMMUNE-RESPONSE; MUCOSA		UNIV COLOGNE,INST PATHOL,W-5000 COLOGNE 41,GERMANY	University of Cologne	STOLTE, M (corresponding author), INST PATHOL,BAYREUTH,GERMANY.							BAYERDORFFER E, 1992, EUR J GASTROEN HEPAT, V4, P697; DISS TC, 1993, NEW ENGL J MED, V329, P173; STOLTE M, 1992, LANCET, V339, P745, DOI 10.1016/0140-6736(92)90645-J; STOLTE M, 1989, J CLIN PATHOL, V42, P1269, DOI 10.1136/jcp.42.12.1269; STOLTE M, 1992, Z GASTROENTEROL, V29, P6; WYATT JI, 1988, SCAND J GASTROENTERO, V23, P44, DOI 10.3109/00365528809091712	6	127	129	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 4	1993	342	8871					568	568		10.1016/0140-6736(93)91404-A	http://dx.doi.org/10.1016/0140-6736(93)91404-A			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV963	8102714				2022-12-28	WOS:A1993LV96300004
J	COLLIER, J; VALLANCE, P				COLLIER, J; VALLANCE, P			ORIGINALITY - WHO IS TO JUDGE	LANCET			English	Editorial Material											COLLIER, J (corresponding author), ST GEORGE HOSP,SCH MED,CLIN PHARMACOL UNIT,LONDON,ENGLAND.								0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 28	1993	342	8870					510	510		10.1016/0140-6736(93)91643-Z	http://dx.doi.org/10.1016/0140-6736(93)91643-Z			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU582	8102664				2022-12-28	WOS:A1993LU58200006
J	DONNAN, GA				DONNAN, GA			LIFESAVING FOR STROKE	LANCET			English	Editorial Material											DONNAN, GA (corresponding author), AUSTIN HOSP,DEPT NEUROL,MELBOURNE,AUSTRALIA.		DONNAN, GEOFFREY A/A-9947-2008					Barnett H. J. M., 1992, STROKE PATHOPHYSIOLO; KENNEDY FB, 1970, AM HEART J, V80, P188, DOI 10.1016/0002-8703(70)90166-3; LANGHORNE P, 1993, LANCET, V342, P395, DOI 10.1016/0140-6736(93)92813-9; NORRIS JW, 1986, STROKE, V7, P360; SCHEINBERG P, 1991, NEUROLOGY, V41, P1867, DOI 10.1212/WNL.41.12.1867	5	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 14	1993	342	8868					383	384						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR900	8101895				2022-12-28	WOS:A1993LR90000003
J	QUINN, MW; WILD, J; DEAN, HG; HARTLEY, R; RUSHFORTH, JA; PUNTIS, JWL; LEVENE, MI				QUINN, MW; WILD, J; DEAN, HG; HARTLEY, R; RUSHFORTH, JA; PUNTIS, JWL; LEVENE, MI			RANDOMIZED DOUBLE-BLIND CONTROLLED TRIAL OF EFFECT OF MORPHINE ON CATECHOLAMINE CONCENTRATIONS IN VENTILATED PRETERM BABIES	LANCET			English	Article							STRESS RESPONSE; INFANTS; PRETERM; PANCURONIUM; ANESTHESIA; ANALGESIA; FENTANYL; SURGERY; BIRTH	A sick premature baby who requires intensive care will undergo many uncomfortable procedures. It is now accepted that such babies perceive pain and need adequate analgesia, but little is known about the effects of sedation in these patients. We investigated the use of morphine to provide analgesia and sedation for ventilated preterm babies in a randomised, double-blind, placebo-controlled trial. 41 mechanically ventilated babies who had been treated with surfactant (Curosurf) for hyaline membrane disease were randomly assigned morphine in 5% dextrose (100 mug/kg per h for 2 h followed by 25 mug/kg per h continuous infusion) or 5% dextrose (placebo). Plasma catecholamine concentrations were measured 1 h after the first dose of surfactant and 24 h later. Blood pressure was measured at study entry and after 6 h. The morphine and placebo groups showed no differences in method of delivery, Apgar scores, birthweight, gestation, or catecholamine concentrations at baseline. Morphine-treated babies showed a significant reduction in adrenaline concentrations during the first 24 h (median change -0.4 [95% CI -1.1 to -0.3] nmol/L, p<0.001), which was not seen in the placebo group (median change 0.2 [-0.6 to 0.6] nmol/L, p=0.79). There was a non-significant reduction in noradrenaline concentration in the morphine group. Blood pressure showed a slight but non-significant fall (median -4 mm Hg) in morphine-treated babies. The incidence of intraventricular haemorrhage, patent ductus arteriosus, and pneumothorax, the number of ventilator days, and the numbers of deaths did not differ significantly between the groups. Morphine, in the dose regimen we used, is safe and effective in reducing adrenaline concentrations in preterm ventilated babies.	GEN INFIRM,DEPT CLIN MED,ACAD UNIT PAEDIAT & CHILD HLTH,D FLOOR,CLARENDON WING,LEEDS LS2 9NS,ENGLAND	Leeds General Infirmary								ANAND KJS, 1992, NEW ENGL J MED, V326, P1, DOI 10.1056/NEJM199201023260101; ANAND KJS, 1987, LANCET, V1, P243; ANAND KJS, 1987, NEW ENGL J MED, V317, P1321, DOI 10.1056/NEJM198711193172105; ARNOLD JH, 1990, ANESTHESIOLOGY, V73, P1136, DOI 10.1097/00000542-199012000-00011; CABAL LA, 1985, PEDIATRICS, V75, P284; COMLINE RS, 1965, J PHYSIOL-LONDON, V178, P211, DOI 10.1113/jphysiol.1965.sp007624; DAHLSTROM B, 1979, CLIN PHARMACOL THER, V26, P354; DAPRADA M, 1976, LIFE SCI, V19, P1161, DOI 10.1016/0024-3205(76)90251-4; EKBLAD H, 1992, BIOL NEOATE, V6, P294; FAXELIUS G, 1984, J PEDIATR-US, V105, P144, DOI 10.1016/S0022-3476(84)80381-9; HALLIDAY H, IN PRESS ARCH DIS CH; HARTLEY R, 1993, BRIT J CLIN PHARMACO, V35, P314; HARTLEY R, 1993, BIOMED CHROMATOGR, V7, P34, DOI 10.1002/bmc.1130070109; LEVENE MI, 1992, ARCH DIS CHILD-FETAL, V67, P870, DOI 10.1136/adc.67.7_Spec_No.870; MORRISON JFJ, 1988, BRIT MED J, V296, P1427, DOI 10.1136/bmj.296.6634.1427; QUINN MW, 1992, EARLY HUM DEV, V30, P241, DOI 10.1016/0378-3782(92)90073-P; STOPFKUCHEN H, 1991, EUR J PEDIATR, V150, P503, DOI 10.1007/BF01958433; SURY MRJ, 1990, ANN ROY COLL SURG, V72, P324; TEMPEL A, 1991, DEV BRAIN RES, V64, P19, DOI 10.1016/0165-3806(91)90204-V; WATKINS AMC, 1989, EARLY HUM DEV, V19, P103, DOI 10.1016/0378-3782(89)90120-5; WAY WL, 1965, CLIN PHARMACOL THER, V6, P454	21	105	109	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 7	1993	342	8867					324	327		10.1016/0140-6736(93)91472-X	http://dx.doi.org/10.1016/0140-6736(93)91472-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ868	8101584				2022-12-28	WOS:A1993LQ86800010
J	KATZ, J				KATZ, J			PREOP ANALGESIA FOR POSTOP PAIN	LANCET			English	Editorial Material									UNIV TORONTO,DEPT BEHAV SCI,TORONTO M5S 1A1,ONTARIO,CANADA; UNIV TORONTO,DEPT ANAESTHESIA,TORONTO M5S 1A1,ONTARIO,CANADA	University of Toronto; University of Toronto	KATZ, J (corresponding author), UNIV TORONTO,TORONTO GEN HOSP,DEPT PSYCHOL,TORONTO M5G 1L7,ONTARIO,CANADA.		Katz, Joel/HDO-1635-2022; Katz, Joel/J-7015-2014	Katz, Joel/0000-0002-8686-447X				CODERRE TJ, 1993, PAIN, V52, P259, DOI 10.1016/0304-3959(93)90161-H; DAHL JB, 1992, BRIT J ANAESTH, V69, P4, DOI 10.1093/bja/69.1.4; DAHL JB, 1993, ANESTHESIOLOGY, V78, P801, DOI 10.1097/00000542-199304000-00044; DIERKING GW, 1992, BRIT J ANAESTH, V68, P344, DOI 10.1093/bja/68.4.344; KATZ J, 1992, ANESTHESIOLOGY, V77, P439, DOI 10.1097/00000542-199209000-00006; PRYLE BJ, 1993, ANAESTHESIA, V48, P120; WOOLF CJ, 1986, NEUROSCI LETT, V64, P221, DOI 10.1016/0304-3940(86)90104-7	7	9	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 10	1993	342	8863					65	66		10.1016/0140-6736(93)91279-U	http://dx.doi.org/10.1016/0140-6736(93)91279-U			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LL789	8100906	Green Submitted			2022-12-28	WOS:A1993LL78900003
J	DURING, MJ; SPENCER, DD				DURING, MJ; SPENCER, DD			EXTRACELLULAR HIPPOCAMPAL GLUTAMATE AND SPONTANEOUS SEIZURE IN THE CONSCIOUS HUMAN BRAIN	LANCET			English	Article							GAMMA-AMINOBUTYRIC ACID; EXCITATORY AMINO-ACIDS; PRIMARY CULTURE; NEURONS; INVIVO; ANTAGONISTS; INJECTION; AMYGDALA; EPILEPSY; DIALYSIS	An alteration in excitatory and inhibitory influences may underlie epilepsy. We used bilateral intrahippocampal microdialysis to test the hypothesis that an increase in extracellular glutamate may trigger spontaneous seizures. The concentrations of glutamate and gamma-aminobutyric acid (GABA), the brain's major inhibitory neutrotransmitter, were measured in microdialysates before and during seizures in 6 patients with complex partial epilepsy investigated before surgery. Before seizures, concentrations of glutamate were higher in the epileptogenic hippocampus, whereas GABA concentrations were lower. During seizures, there was a sustained increase in extracellular glutamate to potentially neurotoxic concentrations in the epileptogenic hippocampus. Moreover, the increase preceded seizure. GABA concentrations were unchanged before seizures, but increased during them, with a greater rise in the non-epileptogenic hippocampus, suggesting that a rise in extracellular glutamate may precipitate seizures and that the concentrations reached may cause cell death.	YALE UNIV, SCH MED, DEPT INTERNAL MED, NEUROENDOCRINE PROGRAM, NEW HAVEN, CT 06510 USA	Yale University	DURING, MJ (corresponding author), YALE UNIV, SCH MED,DEPT SURG,NEUROL SURG SECT,NEUROCHEM LAB, 333 CEDAR ST, NEW HAVEN, CT 06510 USA.		During, Matthew/AAC-1388-2020		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS006208, R29NS028227] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 28227, NS06208] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMBERG G, 1989, J PHARMACOL METHOD, V22, P157, DOI 10.1016/0160-5402(89)90012-0; BISCOE TJ, 1966, J PHYSIOL-LONDON, V183, P341, DOI 10.1113/jphysiol.1966.sp007869; CARLSON H, 1992, NEUROSCI LETT, V140, P30, DOI 10.1016/0304-3940(92)90674-V; CHAMBERLIN NL, 1990, J NEUROPHYSIOL, V64, P1000, DOI 10.1152/jn.1990.64.3.1000; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CORNELLBELL A, 1992, EXCITATORY AMINO ACI, V9, P273; CROUCHER MJ, 1982, SCIENCE, V216, P899, DOI 10.1126/science.7079744; DELANEROLLE NC, 1989, BRAIN RES, V495, P387, DOI 10.1016/0006-8993(89)90234-5; DO KQ, 1991, FID RES FDN, V5, P677; DODD PR, 1980, BRAIN RES, V193, P505, DOI 10.1016/0006-8993(80)90180-8; DURING M J, 1989, Society for Neuroscience Abstracts, V15, P340; FRANDSEN A, 1987, NEUROCHEM INT, V10, P583, DOI 10.1016/0197-0186(87)90088-X; IVES AE, 1990, NEUROSCI LETT, V112, P239, DOI 10.1016/0304-3940(90)90210-Z; LEHMANN A, 1987, NEUROSCIENCE, V22, P573, DOI 10.1016/0306-4522(87)90354-X; LEHMANN A, 1985, BRAIN RES, V359, P147, DOI 10.1016/0006-8993(85)91422-2; LENCZ T, 1992, ANN NEUROL, V31, P629, DOI 10.1002/ana.410310610; MCCARTHY G, 1991, SURGERY EPILEPSY, P385; Meldrum B S, 1983, Adv Neurol, V34, P261; MILLAN MH, 1991, EPILEPSY RES, V9, P86, DOI 10.1016/0920-1211(91)90017-A; PETERSON DW, 1983, BRAIN RES, V275, P169, DOI 10.1016/0006-8993(83)90431-6; PIN JP, 1989, J NEUROSCI, V9, P648; SAJI M, 1987, SCIENCE, V235, P66, DOI 10.1126/science.3798095; SHEA PA, 1989, CURR SEP, V9, P53; SLOVITER RS, 1987, SCIENCE, V235, P73, DOI 10.1126/science.2879352; SPENCER SS, 1990, SEMIN NEUROL, V10, P422, DOI 10.1055/s-2008-1063987; STERNAU LL, 1989, STROKE, V20, P281, DOI 10.1161/01.STR.20.2.281; STORMMATHISEN J, 1977, BRAIN RES, V120, P379, DOI 10.1016/0006-8993(77)90918-0; VEZZANI A, 1985, J NEUROCHEM, V45, P335, DOI 10.1111/j.1471-4159.1985.tb03993.x; WADE JV, 1987, J NEUROCHEM, V49, P645, DOI 10.1111/j.1471-4159.1987.tb02912.x	29	725	766	0	28	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 26	1993	341	8861					1607	1610						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ727	8099987				2022-12-28	WOS:A1993LJ72700001
J	GARNER, DM				GARNER, DM			PATHOGENESIS OF ANOREXIA-NERVOSA	LANCET			English	Article							EATING DISORDERS; ILLNESS; HISTORY; WOMEN; CARE				GARNER, DM (corresponding author), MICHIGAN STATE UNIV,DEPT PSYCHIAT,W FEE HALL,E LANSING,MI 48824, USA.							BAKAN R, 1991, INT J EAT DISORDER, V10, P631, DOI 10.1002/1098-108X(199111)10:6&lt;631::AID-EAT2260100603&gt;3.0.CO;2-4; BEAUMONT PJV, 1991, CLIN APPLIED NUTRITI, V1, P9; BOURKE MP, 1992, BRIT J PSYCHIAT, V161, P240, DOI 10.1192/bjp.161.2.240; BRUCH H, 1962, PSYCHOSOM MED, V24, P187, DOI 10.1097/00006842-196203000-00009; CRISP AH, 1967, J PSYCHOSOM RES, V11, P117, DOI 10.1016/0022-3999(67)90064-5; DSM-IV. A.P.A.T.F.o, 1993, DSM 4 DRAFT CRITERIA; ECKERT ED, 1987, PSYCHOL MED, V17, P891, DOI 10.1017/S0033291700000696; FAHY T, 1993, BRIT J PSYCHIAT, V162, P193, DOI 10.1192/bjp.162.2.193; Garfinkel P. E., 1982, ANOREXIA NERVOSA MUL; GARNER DM, 1980, PSYCHOL MED, V10, P647, DOI 10.1017/S0033291700054945; GARNER DM, 1993, INT J EAT DISORDER, V13, P171, DOI 10.1002/1098-108X(199303)13:2&lt;171::AID-EAT2260130205&gt;3.0.CO;2-L; GARNER DM, 1991, CLIN PSYCHOL REV, V11, P729, DOI 10.1016/0272-7358(91)90128-H; GARNER DM, 1982, COGNITIVE THER RES, V6, P123, DOI 10.1007/BF01183887; GARNER DM, 1991, J APPL SPORT SCI RES, V5, P100; GOWERS S, 1989, INT J EAT DISORDER, V8, P105, DOI 10.1002/1098-108X(198901)8:1<105::AID-EAT2260080112>3.0.CO;2-U; HALL RCW, 1989, PSYCHOSOMATICS, V30, P174, DOI 10.1016/S0033-3182(89)72299-4; HALMI KA, 1991, ARCH GEN PSYCHIAT, V48, P712; HERZOG DB, 1992, J AM ACAD CHILD PSY, V31, P810, DOI 10.1097/00004583-199209000-00006; HOEK HW, 1991, PSYCHOL MED, V21, P455, DOI 10.1017/S0033291700020560; HOLLAND AJ, 1988, J PSYCHOSOM RES, V32, P561, DOI 10.1016/0022-3999(88)90004-9; HSU LKG, 1988, PSYCHOL MED, V18, P807, DOI 10.1017/S0033291700009739; HSU LKG, 1991, INT J EAT DISORDER, V10, P15, DOI 10.1002/1098-108X(199101)10:1&lt;15::AID-EAT2260100103&gt;3.0.CO;2-I; HUON GF, 1988, INT J EAT DISORDER, V7, P239, DOI 10.1002/1098-108X(198803)7:2<239::AID-EAT2260070210>3.0.CO;2-L; KASVIKIS YG, 1986, INT J EAT DISORDER, V5, P1069, DOI 10.1002/1098-108X(198609)5:6<1069::AID-EAT2260050610>3.0.CO;2-U; KAYE WH, 1991, ARCH GEN PSYCHIAT, V48, P556; KING MB, 1991, INT J EAT DISORDER, V10, P379, DOI 10.1002/1098-108X(199107)10:4&lt;379::AID-EAT2260100402&gt;3.0.CO;2-I; LUCAS AR, 1991, AM J PSYCHIAT, V148, P917; MUMFORD DB, 1991, BRIT J PSYCHIAT, V158, P222, DOI 10.1192/bjp.158.2.222; MYNORSWALLIS L, 1992, INT J EAT DISORDER, V11, P369, DOI 10.1002/1098-108X(199205)11:4&lt;369::AID-EAT2260110411&gt;3.0.CO;2-M; NIELSEN S, 1992, INT J EAT DISORDER, V11, P25, DOI 10.1002/1098-108X(199201)11:1&lt;25::AID-EAT2260110105&gt;3.0.CO;2-2; PALMER RL, 1990, BRIT J PSYCHIAT, V156, P699, DOI 10.1192/bjp.156.5.699; PALMER RL, 1992, INT J EAT DISORDER, V12, P359, DOI 10.1002/1098-108X(199212)12:4&lt;359::AID-EAT2260120403&gt;3.0.CO;2-O; PATTON GC, 1988, PSYCHOL MED, V18, P947, DOI 10.1017/S0033291700009879; PIRAN N, 1988, INT J EAT DISORDER, V7, P589, DOI 10.1002/1098-108X(198809)7:5<589::AID-EAT2260070502>3.0.CO;2-H; PIRKE KM, 1984, PSYCHOBIOLOGY ANOREX, P46; POPE HG, 1989, INT J EAT DISORDER, V8, P1; RASTAM M, 1992, J AM ACAD CHILD PSY, V31, P819, DOI 10.1097/00004583-199209000-00007; RATHNER G, 1993, PSYCHOL MED, V23, P175, DOI 10.1017/S0033291700038964; ROTHENBERG A, 1988, COMPR PSYCHIAT, V29, P427, DOI 10.1016/0010-440X(88)90024-7; Russell G.F.M., 1970, MODERN TRENDS PSYCHO, V2, P131; RUSSELL GFM, 1988, DIAGNOSTIC ISSUES AN, P3; STACHER G, 1992, INT J EAT DISORDER, V11, P163, DOI 10.1002/1098-108X(199203)11:2&lt;163::AID-EAT2260110207&gt;3.0.CO;2-R; STROBER M, 1990, INT J EAT DISORDER, V9, P239, DOI 10.1002/1098-108X(199005)9:3&lt;239::AID-EAT2260090302&gt;3.0.CO;2-7; VANDEREYCKEN W, 1989, PSYCHOL MED, V19, P837, DOI 10.1017/S0033291700005559; VANDEREYCKEN W, 1989, FAMILY APPROACH EATI; WATERS BGH, 1990, INT J EAT DISORDER, V9, P265, DOI 10.1002/1098-108X(199005)9:3&lt;265::AID-EAT2260090304&gt;3.0.CO;2-X	46	132	136	0	21	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 26	1993	341	8861					1631	1635		10.1016/0140-6736(93)90768-C	http://dx.doi.org/10.1016/0140-6736(93)90768-C			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LJ727	8100000				2022-12-28	WOS:A1993LJ72700014
J	KUCK, KH; SCHLUTER, M				KUCK, KH; SCHLUTER, M			JUNCTIONAL TACHYCARDIA AND THE ROLE OF CATHETER ABLATION	LANCET			English	Article							PARKINSON-WHITE SYNDROME; ACCESSORY ATRIOVENTRICULAR PATHWAYS; NODAL REENTRANT TACHYCARDIA; CLOSED-CHEST ABLATION; RADIOFREQUENCY CURRENT; VENTRICULAR MYOCARDIUM; CONDUCTION; ARRHYTHMIAS; TEMPERATURE; EXPERIENCE				KUCK, KH (corresponding author), UNIV HOSP EPPENDORF,DEPT CARDIOL,MARTINISTR 52,W-2000 HAMBURG 20,GERMANY.							BECKER AE, 1978, CONDUCTION SYSTEM HE, P263; CALKINS H, 1991, NEW ENGL J MED, V324, P1612, DOI 10.1056/NEJM199106063242302; COX JL, 1985, J THORAC CARDIOV SUR, V90, P490; GALLAGHER JJ, 1982, NEW ENGL J MED, V306, P194, DOI 10.1056/NEJM198201283060402; GUIRAUDON GM, 1986, ANN THORAC SURG, V42, P651, DOI 10.1016/S0003-4975(10)64600-0; HAINES DE, 1990, CIRCULATION, V82, P1034, DOI 10.1161/01.CIR.82.3.1034; HAISSAGUERRE M, 1989, NEW ENGL J MED, V320, P426, DOI 10.1056/NEJM198902163200704; HAISSAGUERRE M, 1992, CIRCULATION, V85, P2162, DOI 10.1161/01.CIR.85.6.2162; HEBE J, 1992, CIRCULATION, V86, P202; HINDRICKS G, 1989, EUR HEART J, V10, P972, DOI 10.1093/oxfordjournals.eurheartj.a059422; HUANG SK, 1987, J AM COLL CARDIOL, V9, P349, DOI 10.1016/S0735-1097(87)80388-1; JACKMAN WM, 1991, NEW ENGL J MED, V324, P1605, DOI 10.1056/NEJM199106063242301; JACKMAN WM, 1983, CIRCULATION, V68, P906, DOI 10.1161/01.CIR.68.5.906; JACKMAN WM, 1992, NEW ENGL J MED, V327, P313, DOI 10.1056/NEJM199207303270504; JANSE MJ, 1971, CIRC RES, V28, P403, DOI 10.1161/01.RES.28.4.403; JAZAYERI MR, 1992, CIRCULATION, V85, P1318, DOI 10.1161/01.CIR.85.4.1318; KAY GN, 1992, CIRCULATION, V85, P1675, DOI 10.1161/01.CIR.85.5.1675; KUCK KH, 1992, CIRCULATION, V86, P1743, DOI 10.1161/01.CIR.86.6.1743; KUCK KH, 1991, CIRCULATION, V84, P2366, DOI 10.1161/01.CIR.84.6.2366; KUCK KH, 1991, LANCET, V337, P1557, DOI 10.1016/0140-6736(91)93258-B; KUCK KH, 1990, CIRCULATION, V82, P407, DOI 10.1161/01.CIR.82.2.407; KUCK KH, 1986, PACE, V9, P287; LANGBERG JJ, 1990, PACE, V13, P1242, DOI 10.1111/j.1540-8159.1990.tb02022.x; LEE MA, 1991, CIRCULATION, V83, P827, DOI 10.1161/01.CIR.83.3.827; MCGUIRE MA, 1991, CIRCULATION, V83, P1232, DOI 10.1161/01.CIR.83.4.1232; MOE GK, 1956, CIRC RES, V4, P357, DOI 10.1161/01.RES.4.4.357; OKISHIGE K, 1991, Journal of Cardiovascular Electrophysiology, V2, P465, DOI 10.1111/j.1540-8167.1991.tb01349.x; ROSEN KM, 1974, AM J CARDIOL, V33, P291, DOI 10.1016/0002-9149(74)90292-6; ROSS DL, 1985, J AM COLL CARDIOL, V6, P1383, DOI 10.1016/S0735-1097(85)80229-1; SCHEINMAN MM, 1982, JAMA-J AM MED ASSOC, V248, P851, DOI 10.1001/jama.248.7.851; SCHERF D., 1926, WIENER ARCH INN MED, V12, P501; SCHLUTER M, 1992, J AM COLL CARDIOL, V19, P663, DOI 10.1016/S0735-1097(10)80289-X; SCHLUTER M, 1991, CIRCULATION, V84, P1644, DOI 10.1161/01.CIR.84.4.1644; SCHLUTER M, 1992, PEDIATRICS, V89, P930; VANHARE GF, 1991, J AM COLL CARDIOL, V17, P1613, DOI 10.1016/0735-1097(91)90656-T; WATHEN M, 1992, AM J CARDIOL, V70, P886, DOI 10.1016/0002-9149(92)90732-E; WIT AL, 1971, CIRCULATION, V43, P862, DOI 10.1161/01.CIR.43.6.862; WU DL, 1992, J AM COLL CARDIOL, V20, P884, DOI 10.1016/0735-1097(92)90189-T	38	9	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 29	1993	341	8857					1386	1391		10.1016/0140-6736(93)90952-D	http://dx.doi.org/10.1016/0140-6736(93)90952-D			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE180	8098801				2022-12-28	WOS:A1993LE18000015
J	BRUGADA, P; GURSOY, S; BRUGADA, J; ANDRIES, E				BRUGADA, P; GURSOY, S; BRUGADA, J; ANDRIES, E			INVESTIGATION OF PALPITATIONS	LANCET			English	Article							VENTRICULAR-TACHYCARDIA; DIFFERENTIAL-DIAGNOSIS; QRS COMPLEX; FIBRILLATION; PROGNOSIS; SHORTER; HEART		BAYINDIR MED CTR,ANKARA,TURKEY; UNIV BARCELONA,HOSP CLIN,DEPT CARDIOL,ARRHYTHMIA UNIT,BARCELONA 7,SPAIN	Bayindir Hastanesi; University of Barcelona; Hospital Clinic de Barcelona	BRUGADA, P (corresponding author), ONZE LIEVE VROUW HOSP,CTR CARDIOVASC,MOORSELBAAN 164,B-9300 AALST,BELGIUM.			BRUGADA, JOSEP/0000-0002-5662-8302				AKHTAR M, 1987, CARDIAC ARRHYTHMIAS, P233; BAR FW, 1984, AM J CARDIOL, V54, P555, DOI 10.1016/0002-9149(84)90247-9; BRUGADA P, 1991, CIRCULATION, V83, P1649, DOI 10.1161/01.CIR.83.5.1649; BRUGADA P, 1981, AM J CARDIOL, V48, P611, DOI 10.1016/0002-9149(81)90138-7; BRUGADA P, 1984, AM HEART J, V107, P556, DOI 10.1016/0002-8703(84)90100-5; BRUGADA P, 1989, EUR HEART J, V10, P747, DOI 10.1093/oxfordjournals.eurheartj.a059559; CALKINS H, 1992, CIRCULATION, V85, P1337, DOI 10.1161/01.CIR.85.4.1337; FRANK R, 1978, ARCH MAL COEUR VAISS, V71, P963; GURSOY S, 1992, NEW ENGL J MED, V327, P772, DOI 10.1056/NEJM199209103271105; LEMERY R, 1989, CIRCULATION, V79, P990, DOI 10.1161/01.CIR.79.5.990; LEVY MN, 1971, CIRC RES, V29, P437, DOI 10.1161/01.RES.29.5.437; MALLIANI A, 1980, AM HEART J, V100, P705, DOI 10.1016/0002-8703(80)90238-0; Marriott H. J. L., 1966, PROG CARDIOVASC DIS, V9, P18; SCHERF D, 1942, ELECTROCARDIOGRAFIA, P278; SCHERF D, 1942, ELECTROCARDIOGRAFIA, P290; TORNER P, 1991, EUR HEART J, V12, P144; TRAPPE HJ, 1988, J AM COLL CARDIOL, V12, P166, DOI 10.1016/0735-1097(88)90370-1; WELLENS HJJ, 1978, AM J MED, V64, P27, DOI 10.1016/0002-9343(78)90176-6; 1993, CIRCULATION, V87, P323	19	40	43	1	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 15	1993	341	8855					1254	1258		10.1016/0140-6736(93)91155-F	http://dx.doi.org/10.1016/0140-6736(93)91155-F			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LC497	8098401				2022-12-28	WOS:A1993LC49700013
J	MILNER, SM; HODGETTS, TJ; RYLAH, LTA				MILNER, SM; HODGETTS, TJ; RYLAH, LTA			THE BURNS-CALCULATOR - A SIMPLE PROPOSED GUIDE FOR FLUID RESUSCITATION	LANCET			English	Article							CHILDREN	Most burn casualties will receive their primary care in an emergency department. These departments are staffed by doctors with a varying degree of supervision, and their experience of the treatment of burns is often very modest. Evidently there is a need for a simple method to calculate the fluid requirements of these patients. The Burns Calculator is designed for use during the first eight hours post-injury and is based upon the Parkland resuscitation formula, using only Hartmann's solution BP. It is expected that the patient will have received expert aid by the end of this time. Values for children have been predetermined using body surface area nomograms. The calculator will assist the non-specialist to determine the correct amount of fluid needed to resuscitate a burned patient, and perhaps decrease morbidity and mortality associated with this injury.	ST ANDREWS HOSP,REG BURNS UNIT,BILLERICAY,ESSEX,ENGLAND; ROYAL ARMY MED COLL,LONDON SW1P 4RJ,ENGLAND		MILNER, SM (corresponding author), CHEM & BIOL DEF ESTAB,SALISBURY,WILTS,ENGLAND.							Baxter C R, 1974, Clin Plast Surg, V1, P693; BAXTER CR, 1981, J TRAUMA, V21, P687, DOI 10.1097/00005373-198108001-00016; GRAVES TA, 1988, J TRAUMA, V28, P1656, DOI 10.1097/00005373-198812000-00007; HAMMOND JS, 1987, J TRAUMA, V27, P1161, DOI 10.1097/00005373-198710000-00011; HERNDON DN, 1985, PEDIATR CLIN N AM, V32, P1311; HERNDON DN, 1987, CURR PROB SURG, P347; Lund CC., SURG GYNECOL OBSTET, V79, P352; MILNER SM, 1993, BRIT J HOSP MED, V50, P163; MONAFO WW, 1993, CRITICAL CARE BURNED; Muir IFK, 1987, BURNS THEIR TREATMEN; OAKLEY P, 1993, BRIT MED J, V306, P1613, DOI 10.1136/bmj.306.6892.1613; PRUITT BA, 1987, CLIN SURG, P2823; RYLAH LTA, 1991, ANESTHESIOLOGY, V5, P35; 1988, ADV TRAUMA LIFE SUPP, P206; 1993, ADV PAEDIATRIC LIFE	15	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 30	1993	342	8879					1089	1091		10.1016/0140-6736(93)92067-4	http://dx.doi.org/10.1016/0140-6736(93)92067-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME822	8105315				2022-12-28	WOS:A1993ME82200013
J	SCHEPERHUGHES, N				SCHEPERHUGHES, N			AIDS, PUBLIC-HEALTH, AND HUMAN-RIGHTS IN CUBA	LANCET			English	Article									UNIV CALIF BERKELEY,DEPT ANTHROPOL,BERKELEY,CA 94720	University of California System; University of California Berkeley									0	36	38	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 16	1993	342	8877					965	967		10.1016/0140-6736(93)92006-F	http://dx.doi.org/10.1016/0140-6736(93)92006-F			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MC005	8105218				2022-12-28	WOS:A1993MC00500013
J	COCKCROFT, DW; MCPARLAND, CP; BRITTO, SA; SWYSTUN, VA; RUTHERFORD, BC				COCKCROFT, DW; MCPARLAND, CP; BRITTO, SA; SWYSTUN, VA; RUTHERFORD, BC			REGULAR INHALED SALBUTAMOL AND AIRWAY RESPONSIVENESS TO ALLERGEN	LANCET			English	Article							LATE ASTHMATIC RESPONSE; BRONCHIAL RESPONSIVENESS; BETA-AGONISTS; INDUCED INCREASE; HISTAMINE; TERBUTALINE; BRONCHOCONSTRICTION; SENSITIVITY; REACTIVITY; TOLERANCE	Regular inhaled beta2 agonist causes tolerance to the acute protective effect of beta2 agonist against bronchoconstriction induced by chemical stimuli such as AMP, histamine, and methacholine. We examined a more clinically relevant stimulus, inhaled allergen, in a double-blind, cross-over, random-order trial in 13 mild atopic asthmatics, who had not used beta1 agonist for at least 4 weeks. We compared regular inhaled salbutamol (200 mug four times daily for 2 weeks) with placebo (2 weeks) for effects on bronchodilator response, baseline methacholine, and allergen airway responsiveness, and on the acute protective effect of salbutamol against both stimuli. Baseline forced expiratory volume in 1 s (FEV1), bronchodilator response, and methacholine responsiveness were the same during both treatment periods. After regular salbutamol, the allergen PC20 (provocation concentration producing a 20% FEV1 decrease) fell by 0.91 (SD 0.66) (p = 0.0009) doubling doses, and the protective effects of salbutamol on methacholine and allergen were both significantly reduced (p = 0.026 and 0.025, respectively). Taking into account the reduced baseline allergen PC20, the post-salbutamol allergen PC20 was almost 2 doubling doses (1.94 [1.43], p < 0.01) lower during salbutamol treatment. Thus, 2 weeks of regular inhaled salbutamol increased airway responsiveness to allergen but not to methacholine, and caused tolerance to the protective effect of salbutamol on bronchoconstriction induced by both stimuli. These effects of inhaled beta2 agonist provide further evidence to support detrimental effects of their regular use.			COCKCROFT, DW (corresponding author), UNIV SASKATCHEWAN,ROYAL UNIV HOSP,DEPT MED,DIV RESP MED,ELLIS HALL,5TH FLOOR,SASKATOON S7N 0X0,SK,CANADA.							BEL EH, 1991, THORAX, V46, P9, DOI 10.1136/thx.46.1.9; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; CHEUNG D, 1992, NEW ENGL J MED, V327, P1198, DOI 10.1056/NEJM199210223271703; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1983, CHEST, V84, P505, DOI 10.1378/chest.84.4.505; COCKCROFT DW, 1987, AM REV RESPIR DIS, V135, P264; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; CUSHLEY MJ, 1985, J ALLERGY CLIN IMMUN, V75, P272, DOI 10.1016/0091-6749(85)90057-0; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; FLINT KC, 1985, BRIT MED J, V291, P923, DOI 10.1136/bmj.291.6500.923; GIBSON GJ, 1978, BRIT J DIS CHEST, V72, P199, DOI 10.1016/0007-0971(78)90042-6; KERREBIJN KF, 1987, J ALLERGY CLIN IMMUN, V79, P653, DOI 10.1016/S0091-6749(87)80163-X; KIRBY JG, 1986, CLIN ALLERGY, V16, P191, DOI 10.1111/j.1365-2222.1986.tb00765.x; KRAAN J, 1985, J ALLERGY CLIN IMMUN, V76, P628, DOI 10.1016/0091-6749(85)90786-9; LAI CKW, 1989, AM REV RESPIR DIS, V140, P917, DOI 10.1164/ajrccm/140.4.917; LARSSON K, 1992, CHEST, V101, P953, DOI 10.1378/chest.101.4.953; MITCHELL EA, 1989, THORAX, V44, P81, DOI 10.1136/thx.44.2.81; OCONNOR BJ, 1992, NEW ENGL J MED, V327, P1204, DOI 10.1056/NEJM199210223271704; PARKER CW, 1973, J CLIN INVEST, V52, P48, DOI 10.1172/JCI107173; PEEL ET, 1980, AM REV RESPIR DIS, V121, P973; ROBERTSON DG, 1974, J ALLERGY CLIN IMMUN, V54, P244, DOI 10.1016/0091-6749(74)90067-0; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; TATTERSFIELD AE, 1985, B EUR PHYSIOPATH RES, V21, pS1; VANSCHAYCK CP, 1990, J ALLERGY CLIN IMMUN, V86, P793, DOI 10.1016/S0091-6749(05)80185-X; VATHENEN AS, 1988, LANCET, V1, P554; WONG C S, 1992, American Review of Respiratory Disease, V145, pA54	27	296	297	1	15	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 2	1993	342	8875					833	837		10.1016/0140-6736(93)92695-P	http://dx.doi.org/10.1016/0140-6736(93)92695-P			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA025	8104272				2022-12-28	WOS:A1993MA02500009
J	BANG, A				BANG, A			TOWARDS BETTER ORAL REHYDRATION	LANCET			English	Editorial Material											BANG, A (corresponding author), SEARCH,GANDCHOROLI 442605,INDIA.							BARI A, 1989, Journal of Diarrhoeal Diseases Research, V7, P1; BRYANT J, 1980, CEREAL BASED ORAL RE; GORE SM, 1992, BMJ-BRIT MED J, V304, P287, DOI 10.1136/bmj.304.6822.287; KHIN MU, 1986, HUM NUJTR CLIN NUTR, V40, P249; MATHURAM S, 1990, J PEDIATR, V116, P868; MOLLA AM, 1989, J PEDIATR GASTR NUTR, V8, P81, DOI 10.1097/00005176-198901000-00015; WILSON R, 1990, CEREAL BASED ORAL RE, P13; 1992, PROGRAMME CONTROL DI, P36	8	1	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 25	1993	342	8874					755	756		10.1016/0140-6736(93)91534-S	http://dx.doi.org/10.1016/0140-6736(93)91534-S			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LY868	8103870				2022-12-28	WOS:A1993LY86800003
J	BREWER, C				BREWER, C			PREVENTION OF POSTABORTION INFECTION	LANCET			English	Letter											BREWER, C (corresponding author), STAPLEFORD CTR,25A ECCLESTON ST,LONDON SW1W 9NP,ENGLAND.							BLACKWELL, 1993, LANCET, V342, P206; BREWER C, 1980, BRIT MED J, V281, P780, DOI 10.1136/bmj.281.6243.780-a; 1992, ABORTION MONITORS AB	3	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 25	1993	342	8874					802	802		10.1016/0140-6736(93)91566-5	http://dx.doi.org/10.1016/0140-6736(93)91566-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LY868	8103887				2022-12-28	WOS:A1993LY86800032
J	STEEL, M				STEEL, M			CANCER GENES - COMPLEXES AND COMPLEXITIES	LANCET			English	Editorial Material							NM23 GENE				STEEL, M (corresponding author), WESTERN GEN HOSP, MRC, HUMAN GENET UNIT, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND.							BASERGA R, 1993, CANCER SURV, V16, P201; BLACK DM, 1993, AM J HUM GENET, V52, P702; COHN KH, 1991, LANCET, V338, P722, DOI 10.1016/0140-6736(91)91444-Y; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; HAUT M, 1991, J NATL CANCER I, V83, P712, DOI 10.1093/jnci/83.10.712; LEONE A, 1993, ONCOGENE, V8, P2325; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; STAHL JA, 1991, CANCER RES, V51, P445; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; STEEL CM, 1989, J R COLL PHYSICIANS, V19, P413; ZHOU M, 1993, BRIT J CANCER, V68, P385, DOI 10.1038/bjc.1993.345	11	8	8	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 25	1993	342	8874					754	755		10.1016/0140-6736(93)91533-R	http://dx.doi.org/10.1016/0140-6736(93)91533-R			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LY868	8103869				2022-12-28	WOS:A1993LY86800002
J	SAUNDERS, AM; SCHMADER, K; BREITNER, JCS; BENSON, MD; BROWN, WT; GOLDFARB, L; GOLDGABER, D; MANWARING, MG; SZYMANSKI, MH; MCCOWN, N; DOLE, KC; SCHMECHEL, DE; STRITTMATTER, WJ; PERICAKVANCE, MA; ROSES, AD				SAUNDERS, AM; SCHMADER, K; BREITNER, JCS; BENSON, MD; BROWN, WT; GOLDFARB, L; GOLDGABER, D; MANWARING, MG; SZYMANSKI, MH; MCCOWN, N; DOLE, KC; SCHMECHEL, DE; STRITTMATTER, WJ; PERICAKVANCE, MA; ROSES, AD			APOLIPOPROTEIN-E-EPSILON-4 ALLELE DISTRIBUTIONS IN LATE-ONSET ALZHEIMERS-DISEASE AND IN OTHER AMYLOID-FORMING DISEASES	LANCET			English	Note								The frequency of the allele for apolipoprotein E type 4 (epsilon4) is increased in late-onset familial and sporadic Alzheimer's disease (AD). We have examined epsilon4 frequencies in. four distinct, normal, elderly control groups and, most importantly, in patients with amyloid-forming diseases whose epsilon4 distributions were not previously known (Creutzfeldt-Jakob disease, familial amyloidotic polyneuropathy, Down's syndrome). There were no differences between any of these controls and published control series, cementing the relevance of epsilon4 for late-onset AD. The increase in late-onset AD was confirmed in two new series.	DUKE UNIV,MED CTR,BRYAN ALZHEIMERS DIS RES CTR,DIV NEUROL,DURHAM,NC 27710; SUNY,DEPT PSYCHIAT,STONY BROOK,NY 11794; INDIANA UNIV,SCH MED,INDIANAPOLIS,IN 46202; NIH,BETHESDA,MD 20892; NEW YORK STATE INST BASIC RES DEV DISABIL,STATEN ISL,NY 10314	Duke University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; SUNY Maritime College; Indiana University System; Indiana University-Purdue University Indianapolis; National Institutes of Health (NIH) - USA; Institute for Basic Research in Developmental Disabilities			Brown, William/GXN-2777-2022		NCRR NIH HHS [M01-RR-30] Funding Source: Medline; NIA NIH HHS [AG05128, U24 AG021886, AGO7922] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R35AG007922, U24AG021886] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		LIDDELL M, IN PRESS J MED GENET; MAYEAX R, IN PRESS ANN NEUROL; Robinette C. D., 1990, Dementia and Geriatric Cognitive Disorders,, V1, P297, DOI [10.1159/000107157, DOI 10.1159/000107157]; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C	6	481	492	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 18	1993	342	8873					710	711		10.1016/0140-6736(93)91709-U	http://dx.doi.org/10.1016/0140-6736(93)91709-U			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX469	8103823				2022-12-28	WOS:A1993LX46900010
J	HORNER, PJ; GILROY, CB; THOMAS, BJ; NAIDOO, ROM; TAYLORROBINSON, D				HORNER, PJ; GILROY, CB; THOMAS, BJ; NAIDOO, ROM; TAYLORROBINSON, D			ASSOCIATION OF MYCOPLASMA-GENITALIUM WITH ACUTE NONGONOCOCCAL URETHRITIS	LANCET			English	Article							POLYMERASE CHAIN-REACTION; HUMAN UROGENITAL TRACT; DISCOVERED MYCOPLASMA; CHLAMYDIA-TRACHOMATIS; DNA PROBES; PNEUMONIAE; SPECIMENS; INFECTION	Chlamydia trachomatis is known to be a cause of acute non-gonococcal urethritis (NGU), though the aetiology of this disorder is not fully understood. Mycoplasma genitalium has been isolated from a few men with NGU, but culture has remained difficult and reliable detection became possible only with a specific polymerase chain reaction (PCR). We have used the PCR to examine the role of M genitalium in NGU. M genitalium was detected in urethral samples from 24 (23%) of 103 men with symptoms, signs, or both, of acute NGU, but from only 3 (6%) of 53 men without NGU (p < 0.006). This association was independent of the presence of C trachomatis and could not be explained by differences in age, ethnic origin, lifetime number of sexual partners or a change in sexual partner during the previous 3 months. The clinical response of the mycoplasma-positive men to doxycycline treatment was at least as satisfactory as that of the chlamydia-positive men. These findings suggest that the association of M genitalium with NGU is likely to be causal, a notion consistent with the known virulence characteristics of this microorganism and its ability to cause urethritis in male sub-human primates.	CLIN RES CTR,DIV SEXUALLY TRANSMITTED DIS,WATFORD RD,HARROW HA1 3UJ,MIDDX,ENGLAND; ST MARYS HOSP,LONDON,ENGLAND	Imperial College London				Horner, Paddy/0000-0003-0411-8332				BOWIE WR, 1981, ANN INTERN MED, V95, P306, DOI 10.7326/0003-4819-95-3-306; DALLO SF, 1989, INFECT IMMUN, V57, P1059, DOI 10.1128/IAI.57.4.1059-1065.1989; HAWKINS DA, 1986, MICROBIAL DISEASES N, P47; HAY PE, 1992, INT J STD AIDS, V3, P191, DOI 10.1177/095646249200300307; HOOTON TM, 1988, LANCET, V1, P266; HYMAN HC, 1987, J CLIN MICROBIOL, V25, P726, DOI 10.1128/JCM.25.4.726-728.1987; JENSEN JS, 1991, J CLIN MICROBIOL, V29, P46, DOI 10.1128/JCM.29.1.46-50.1991; KIRCHHOFF H, 1984, ISRAEL J MED SCI, V20, P848; MUNDAY PE, 1985, CLIN PROBLEMS SEXUAL, P15; Palmer H M, 1991, Int J STD AIDS, V2, P261; PALMER HM, 1991, FEMS MICROBIOL LETT, V77, P199, DOI 10.1016/0378-1097(91)90551-K; ROBERTS MC, 1987, ISRAEL J MED SCI, V23, P618; SAMRA Z, 1988, EUR J CLIN MICROBIOL, V7, P49, DOI 10.1007/BF01962172; TAYLORROBINSON D, 1987, ISRAEL J MED SCI, V23, P561; TAYLORROBINSON D, 1980, J CLIN PATHOL, V33, P205, DOI 10.1136/jcp.33.3.205; TAYLORROBINSON D, 1981, ISRAEL J MED SCI, V17, P524; TAYLORROBINSON D, 1985, GENITOURIN MED, V61, P319; TAYLORROBINSON D, 1993, CLIN INFECT DIS   S1, V17, P66; THOMAS BJ, 1984, J CLIN PATHOL, V37, P812, DOI 10.1136/jcp.37.7.812; TULLY JG, 1981, LANCET, V1, P1288; TULLY JG, 1983, INT J SYST BACTERIOL, V33, P387, DOI 10.1099/00207713-33-2-387; TULLY JG, 1986, J INFECT DIS, V153, P1046, DOI 10.1093/infdis/153.6.1046; WILSON K, 1987, CUURRENT PROTOCOLS M, V1	23	173	182	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 4	1993	342	8871					582	585		10.1016/0140-6736(93)91411-E	http://dx.doi.org/10.1016/0140-6736(93)91411-E			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV963	8102721				2022-12-28	WOS:A1993LV96300011
J	WILLIAMS, LL; ROONEY, CM; CONLEY, ME; BRENNER, MK; KRANCE, RA; HESLOP, HE				WILLIAMS, LL; ROONEY, CM; CONLEY, ME; BRENNER, MK; KRANCE, RA; HESLOP, HE			CORRECTION OF DUNCAN SYNDROME BY ALLOGENEIC BONE-MARROW TRANSPLANTATION	LANCET			English	Note							LINKED LYMPHOPROLIFERATIVE SYNDROME; DISEASE	Duncan's syndrome (X-linked lymphoproliferative disorder) is a fatal immunodeficiency syndrome of unknown aetiology and without cure. We show that allogeneic bone marrow transplantation can correct the lethal immune deficits in a patient with this syndrome, We suggest that the primary abnormality in Duncan's syndrome is in bone-marrow derived cells.	ST JUDE CHILDRENS RES HOSP, DEPT VIROL & MOLEC BIOL, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT IMMUNOL, MEMPHIS, TN 38105 USA; UNIV TENNESSEE CTR HLTH SCI, DEPT PEDIAT, MEMPHIS, TN 38104 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	WILLIAMS, LL (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, DIV BONE MARROW TRANSPLANTAT, MEMPHIS, TN 38105 USA.		Heslop, Helen/AAC-9500-2020; Brenner, Malcolm/Y-2509-2019		NATIONAL CANCER INSTITUTE [P01CA020180, P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [CA 20180, CA 21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON JP, 1991, SCAND J INFECT DIS S, V78, P94; CONLEY ME, 1990, CLIN IMMUNOL IMMUNOP, V55, P486, DOI 10.1016/0090-1229(90)90133-B; FILIPOVICH AH, 1986, TRANSPLANTATION, V42, P222; FISCHER A, 1991, NEW ENGL J MED, V324, P1451, DOI 10.1056/NEJM199105233242102; GRIERSON HL, 1991, AM J MED GENET, V40, P294, DOI 10.1002/ajmg.1320400309; PURTILO D T, 1975, Lancet, V1, P935; REITTIE JE, 1989, BLOOD, V73, P1351; SMALL TN, 1990, BLOOD, V76, P1647; YASUDA N, 1991, CLIN EXP IMMUNOL, V83, P10	9	38	38	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 4	1993	342	8871					587	588		10.1016/0140-6736(93)91413-G	http://dx.doi.org/10.1016/0140-6736(93)91413-G			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV963	8102723				2022-12-28	WOS:A1993LV96300013
J	ADDIEGO, J; KASPER, C; ABILDGAARD, C; HILGARTNER, M; LUSHER, J; GLADER, B; ALEDORT, L				ADDIEGO, J; KASPER, C; ABILDGAARD, C; HILGARTNER, M; LUSHER, J; GLADER, B; ALEDORT, L			FREQUENCY OF INHIBITOR DEVELOPMENT IN HEMOPHILIACS TREATED WITH LOW-PURITY FACTOR-VIII	LANCET			English	Article							HEPATITIS-C VIRUS; HEMOPHILIA-A; ANTIHEMOPHILIC-FACTOR; CONCENTRATE; ANTIBODY	Clinical studies evaluating highly purified monoclonal-antibody-derived and recombinant-DNA-derived clotting factor concentrates in previously untreated (PUPS) severe factor VIII (FVIII) deficient haemophilia patients, have documented an increased frequency of inhibitors compared with that seen in patients who have received less pure products. However, a valid comparison of inhibitor frequency in patients treated with pure and less pure products has not been possible because appropriate studies have not been done in PUPS treated with the less pure products. To determine the frequency of inhibitor development in PUPS treated solely with less pure plasma-derived products (specific activities <5 FVIII U/mg protein), we reviewed the records of all haemophilia patients born between 1975 and 1985 and treated with such products at any of seven centres. 89 patients with severe FVIII deficiency (< 1%) were observed and tested for inhibitors from birth to 5 years old or until 30 bleeding episodes had been treated. 25 of the 89 patients developed inhibitors (28%), and 21 of these 25 were high-titre responders (> 5 Bethesda units). This frequency of inhibitor development is greater than that reported in patients treated with monoclonal FVIII products, but the latter patients may not have been followed as long as the patients in our report. Our data may make possible a meaningful comparison with the frequency of inhibitor development in PUPS treated solely with recombinant-DNA-derived FVIII.	ORTHOPED HOSP, CTR HEMOPHILLA TREATMENT, LOS ANGELES, CA 90007 USA; UNIV CALIF DAVIS, DIV HEMATOL ONCOL, DAVIS, CA 95616 USA; CORNELL UNIV, MED CTR, DIV PEDIAT HEMATOL ONCOL, NEW YORK, NY 10021 USA; CHILDRENS HOSP MICHIGAN, DETROIT, MI 48201 USA; PACKARD CHILDRENS HOSP, STANFORD, CA USA; MT SINAI MED CTR, NEW YORK, NY 10029 USA	University of California System; University of California Davis; Cornell University; Children's Hospital of Michigan; Lucile Packard Children's Hospital (LPCH); Icahn School of Medicine at Mount Sinai	ADDIEGO, J (corresponding author), CHILDRENS HOSP OAKLAND, DEPT HEMATOL ONCOL, OAKLAND, CA 94609 USA.							ADDIEGO JE, 1992, THROMB HAEMOSTASIS, V67, P19; BERNTORP E, 1990, LANCET, V335, P1531, DOI 10.1016/0140-6736(90)93075-Z; BRAY GL, 1992, NOV ANN NAT HEM F M; EHRENFORTH S, 1992, LANCET, V339, P594, DOI 10.1016/0140-6736(92)90874-3; Gill FM, 1984, FACTOR 8 INHIBITORS, P19; GITSCHIER J, 1984, NATURE, V312, P326, DOI 10.1038/312326a0; GOMPERTS E, 1991, OCT ANN NAT HEM F M; HOYER LW, 1987, HUM PATHOL, V18, P153, DOI 10.1016/S0046-8177(87)80333-7; KASPER CK, 1991, ANN NY ACAD SCI, V614, P97; LUSHER J, 1992, BLOOD, V10, pA231; LUSHER JM, 1993, NEW ENGL J MED, V328, P453, DOI 10.1056/NEJM199302183280701; LUSHER JM, 1990, SEMIN HEMATOL, V27, P1; LUSHER JM, 1991, BLOOD, V78, pA57; LYON DJ, 1989, LANCET, V1, P1085; MANNUCCI PM, 1990, THROMB HAEMOSTASIS, V64, P232; SCHWARTZ RS, 1990, NEW ENGL J MED, V323, P1800, DOI 10.1056/NEJM199012273232604; WHITE GC, 1989, NEW ENGL J MED, V320, P166, DOI 10.1056/NEJM198901193200307	17	167	172	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 21	1993	342	8869					462	464		10.1016/0140-6736(93)91593-B	http://dx.doi.org/10.1016/0140-6736(93)91593-B			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU075	8102429				2022-12-28	WOS:A1993LU07500010
J	IMAMURA, K				IMAMURA, K			A CRITICAL-LOOK AT HEALTH RESEARCH IN JAPAN	LANCET			English	Editorial Material											IMAMURA, K (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT PUBL HLTH & POLICY,HLTH SERV RES UNIT,LONDON WC1E 7HT,ENGLAND.							HAYASHI C, 1992, GAN TO KAGAKU R 0219, P143; HEATON KW, 1993, INDEPENDENT     0403; SMITH R, 1988, BRIT MED J, V296, P409, DOI 10.1136/bmj.296.6619.409; TANIDA N, 1991, LANCET, V337, P242, DOI 10.1016/0140-6736(91)92211-J; 1993, LANCET, V341, P467; 1991, LANCET, V337, P19; 1990, WORLD HLTH STATISTIC; 1992, COMPENDIUM HLTH STAT; 1993, MAINICHI SHENBU 0611; 1992, KOKUMIN EISEI NO DO; 1990, LANCET, V336, P1309	11	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 31	1993	342	8866					279	282		10.1016/0140-6736(93)91821-3	http://dx.doi.org/10.1016/0140-6736(93)91821-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ163	8101306				2022-12-28	WOS:A1993LQ16300014
J	SITTHIAMORN, C; POSHYACHINDA, V				SITTHIAMORN, C; POSHYACHINDA, V			BIAS	LANCET			English	Article							THAILAND				SITTHIAMORN, C (corresponding author), CHULALONGKORN UNIV, COLL PUBL HLTH,FAC MED,INST BLDG 3,10TH FLOOR, CHULA SOIL 62, BANGKOK 10330, THAILAND.							ACKETT DL, 1975, PLATELETS DRUGS THRO, P306; AQUILINO WS, 1992, INT J ADDICT, V27, P71; BRAMEL D, 1981, AM PSYCHOL, V36, P867, DOI 10.1037/0003-066X.36.8.867; CANNER PL, 1980, NEW ENGL J MED, V303, P1038; CHOI BCK, 1992, J OCCUP ENVIRON MED, V34, P265, DOI 10.1097/00043764-199203000-00010; COATS AJS, 1992, J HYPERTENS, V10, P385, DOI 10.1097/00004872-199204000-00011; FOX AJ, 1976, LANCET, V1, P1009, DOI 10.1016/S0140-6736(76)91874-2; Haynes R. B., 1979, COMPLIANCE HLTH CARE; HEIM FG, 1983, WORK FARMERS MANUAL; Hennekens C.H., 1987, EPIDEMIOLOGY MED; IMON KG, 1989, GENITOURIN MED, V65, P143; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; MORROW R, 1981, INT J EPIDEMIOL, V10, P73, DOI 10.1093/ije/10.1.73; MOTULSKY AG, 1978, NEW ENGL J MED, V298, P1196, DOI 10.1056/NEJM197805252982111; NEWELL DJ, 1992, INT J EPIDEMIOL, V21, P837, DOI 10.1093/ije/21.5.837; PETERSON GM, 1984, EPILEPSIA, V25, P412, DOI 10.1111/j.1528-1157.1984.tb03436.x; PHANTHUMCHINDA K, 1991, INT J GERIATR PSYCH, V6, P639, DOI 10.1002/gps.930060905; POSHYACHINDA V, 1991, ASSESSMENT PSYCHOACT; Rothman K, 1986, MODERN EPIDEMIOLOGY; SACKETT DL, 1979, J CHRON DIS, V32, P51, DOI 10.1016/0021-9681(79)90012-2; SARTWELL PE, 1974, ANN INTERN MED, V81, P381, DOI 10.7326/0003-4819-81-3-381; SITTHIAMORN C, 1986, INT J EPIDEMIOL, V15, P263, DOI 10.1093/ije/15.2.263; VANTHOF MA, 1991, EUR J CLIN NUTR, V45, P5	24	24	27	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 31	1993	342	8866					286	288		10.1016/0140-6736(93)91823-5	http://dx.doi.org/10.1016/0140-6736(93)91823-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ163	8101308				2022-12-28	WOS:A1993LQ16300016
J	BEUMONT, PJV; RUSSELL, JD; TOUYZ, SW				BEUMONT, PJV; RUSSELL, JD; TOUYZ, SW			TREATMENT OF ANOREXIA-NERVOSA	LANCET			English	Article							EATING DISORDERS; SUDDEN-DEATH; BULIMIA; WOMEN; MASS				BEUMONT, PJV (corresponding author), UNIV SYDNEY, DEPT PSYCHIAT, SYDNEY, NSW 2006, AUSTRALIA.			touyz, stephen/0000-0002-1290-6243				ANDERSEN AE, 1985, PRACTICAL COMPREHENS; [Anonymous], 1993, AM J PSYCHIAT, V150, P207; BEAUMONT P, 1988, INT J EAT DISORDER, V7, P399; BEAUMONT PJV, 1991, CLIN APPLIED NUTRITI, V1, P9; BEAUMONT PJV, IN PRESS INT J EATIN; BEAUMONT PJV, 1987, HDB EATING DISORDE 1, P349; BEUMONT PJV, 1981, J HUM NUTR, V35, P265; BEUMONT PJV, 1976, PSYCHOL MED, V6, P617, DOI 10.1017/S0033291700018250; BEUMONT PJV, 1972, PSYCHOL MED, V2, P216, DOI 10.1017/S0033291700042513; BEUMONT PJV, 1991, MED J AUSTRALIA, V155, P519, DOI 10.5694/j.1326-5377.1991.tb93887.x; Bhanji S, 1988, MED ASPECTS ANOREXIA; BRINCH M, 1988, ACTA PSYCHIAT SCAND, V77, P98, DOI 10.1111/j.1600-0447.1988.tb05084.x; Casper R, 1987, HDB EATING DISORDE 1, P255; CRISP AH, 1992, BRIT J PSYCHIAT, V161, P104, DOI 10.1192/bjp.161.1.104; ENRIGHT AB, 1985, HDB PSYCHOTHERAPY AN, P491; FAIRBURN CG, 1991, BRIT MED J, V303, P17, DOI 10.1136/bmj.303.6793.17; Garner D. M., 1985, HDB PSYCHOTHERAPY AN, P513; GARNER DM, 1985, HDB PSYCHOTHERAPY AN, P107; GOODSITT A, 1985, HDB PSYCHOTHERAPY AN, P55; HALL RCW, 1989, PSYCHOSOMATICS, V30, P174, DOI 10.1016/S0033-3182(89)72299-4; HERZOG DB, 1985, NEW ENGL J MED, V313, P295, DOI 10.1056/NEJM198508013130505; HERZOG W, 1992, COURSE EATING DISORD, P85; ISNER JM, 1985, ANN INTERN MED, V102, P49, DOI 10.7326/0003-4819-102-1-49; KAPLAN AS, 1991, EATING DISORDERS REV, V2, P1; LUCAS AR, 1991, AM J PSYCHIAT, V148, P917; MCKENZIE JM, 1992, INT J EAT DISORDER, V11, P235, DOI 10.1002/1098-108X(199204)11:3&lt;235::AID-EAT2260110306&gt;3.0.CO;2-T; McManus M A, 1986, Semin Adolesc Med, V2, P89; MIRA M, 1992, INT J EAT DISORDER, V11, P403, DOI 10.1002/1098-108X(199205)11:4&lt;403::AID-EAT2260110415&gt;3.0.CO;2-X; MORGAN HG, 1983, BRIT J PSYCHIAT, V143, P282, DOI 10.1192/bjp.143.3.282; RATCLIFFE PJ, 1985, PSYCHOL MED, V15, P679, DOI 10.1017/S0033291700031536; RATNASURIYA RH, 1991, BRIT J PSYCHIAT, V158, P495, DOI 10.1192/bjp.158.4.495; RIGOTTI NA, 1991, JAMA-J AM MED ASSOC, V265, P1133, DOI 10.1001/jama.265.9.1133; RUSSELL GFM, 1977, ANOREXIA NERV, P277; RUSSELL J, 1987, HDB EATING DISORDE 1, P201; SCHOCKEN DD, 1989, ARCH INTERN MED, V149, P877, DOI 10.1001/archinte.149.4.877; SILBER TJ, 1989, J ADOLESCENT HEALTH, V10, P122, DOI 10.1016/0197-0070(89)90101-0; STEEL JM, 1987, BRIT MED J, V294, P859, DOI 10.1136/bmj.294.6576.859; THEANDER S, 1985, J PSYCHIATR RES, V19, P493, DOI 10.1016/0022-3956(85)90059-7; TOUYZ SW, 1984, BRIT J PSYCHIAT, V144, P517, DOI 10.1192/bjp.144.5.517; VANDEREYCKEN W, 1987, HDB EATING DISORDE 1, P235; WELLS LA, 1987, PSYCHOSOMATICS, V28, P470, DOI 10.1016/S0033-3182(87)72478-5; WINDAUER U, IN PRESS BR J PSYCHI; WOODSIDE DB, 1990, INT J EAT DISORDER, V9, P303, DOI 10.1002/1098-108X(199005)9:3<303::AID-EAT2260090308>3.0.CO;2-3	43	94	96	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 26	1993	341	8861					1635	1640		10.1016/0140-6736(93)90769-D	http://dx.doi.org/10.1016/0140-6736(93)90769-D			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ727	8100001				2022-12-28	WOS:A1993LJ72700015
J	LEUNG, WH; LAU, CP; WONG, CK				LEUNG, WH; LAU, CP; WONG, CK			BENEFICIAL EFFECT OF CHOLESTEROL-LOWERING THERAPY ON CORONARY ENDOTHELIUM-DEPENDENT RELAXATION IN HYPERCHOLESTEROLEMIC PATIENTS	LANCET			English	Article							LOW-DENSITY LIPOPROTEINS; ARTERY DISEASE; EXPERIMENTAL ATHEROSCLEROSIS; RABBIT AORTA; L-ARGININE; ACETYLCHOLINE; DYSFUNCTION; RESPONSES; VASOCONSTRICTION; REGRESSION	Since hypercholesterolaemia is associated with impaired endothelium-dependent vasodilation, a study was conducted to find out whether cholesterol reduction will improve endothelial function in patients with hypercholesterolaemia and normal coronary arteries. 25 men (mean age 51 [SD 8] years) with total serum cholesterol >6.2 mmol/L) and angiographically normal coronary arteries had their coronary vasomotor responses to intracoronary acetylcholine and nitroglycerin assessed by computer-assisted quantitative angiography at baseline and after 6 months of cholesterol-reducing diet and cholestyramine. Between baseline and follow-up mean total serum cholesterol level fell by 28.7 (SD 5.6)% (p <0.001); mean low-density lipoprotein (LDL) cholesterol level by 35.6 (8.7)% (p <0.001); and mean total cholesterol to high-density lipoprotein (HDL) cholesterol ratio by 29.4 (10.6)% (p <0.001). Acetylcholine significantly reduced the mean segment diameter at baseline, by 21.7 (14.0)% (p <0.01), but it increased the diameter at follow-up, by 6.16 (13.3)% (p < 0.01), the difference between the two occasions being significant (p < 0.001). Nitroglycerin significantly increased the mean segment diameter, both at baseline, by 18.7 (11.5)% (p < 0.01), and at follow-up, by 19.3 (12.1)% (p < 0.01), the difference between the two responses being not significant. At baseline total cholesterol and LDL cholesterol did not correlate with acetylcholine response, but they did at follow-up (total cholesterol, r = 0.67, p < 0.01; LDL cholesterol, r = 0.64, p < 0.01). Impairment of endothelium-dependent (acetylcholine-induced) dilation of the epicardial coronary arteries in hypercholesterolaemic patients with angiographically normal coronary arteries is thus reversible by reducing serum cholesterol. In addition, the degree of impairment of acetylcholine-induced vasomotor response is related to the cholesterol concentrations after therapy.			LEUNG, WH (corresponding author), UNIV HONG KONG,QUEEN MARY HOSP,DEPT MED,DIV CARDIOL,HONG KONG,HONG KONG.							ANDREWS HE, 1987, NATURE, V327, P237, DOI 10.1038/327237a0; ARNETT EN, 1979, ANN INTERN MED, V91, P350, DOI 10.7326/0003-4819-91-3-350; BASSENGE E, 1988, PROG CARDIOVASC DIS, V30, P249; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; CHAPPELL SP, 1987, CARDIOVASC RES, V21, P34, DOI 10.1093/cvr/21.1.34; COCKS TM, 1983, NATURE, V305, P627, DOI 10.1038/305627a0; DREXLER H, 1991, LANCET, V338, P1546, DOI 10.1016/0140-6736(91)92372-9; DREXLER H, 1991, HYPERTENSION, V18, P1190; Farmer JA, 1988, HEART DISEASE TXB CA, P1153; FISH RD, 1988, J CLIN INVEST, V81, P21, DOI 10.1172/JCI113297; FREIMAN PC, 1986, CIRC RES, V58, P783, DOI 10.1161/01.RES.58.6.783; FURCHGOTT RF, 1983, CIRC RES, V53, P557, DOI 10.1161/01.RES.53.5.557; GALLE J, 1991, ARTERIOSCLER THROMB, V11, P198, DOI 10.1161/01.ATV.11.1.198; HARRISON DG, 1987, J CLIN INVEST, V80, P1808, DOI 10.1172/JCI113276; HENDERSON AH, 1991, BRIT HEART J, V65, P116; HODGSON JM, 1989, CIRCULATION, V79, P1043, DOI 10.1161/01.CIR.79.5.1043; HOLTZ J, 1984, J CARDIOVASC PHARM, V6, P1161; JAYAKODY L, 1987, CIRC RES, V60, P251, DOI 10.1161/01.RES.60.2.251; LEUNG W-H, 1991, Journal of the American College of Cardiology, V17, p230A; LEUNG WH, 1991, CATHETER CARDIO DIAG, V24, P121, DOI 10.1002/ccd.1810240211; LEUNG WH, 1990, CATHETER CARDIO DIAG, V21, P148, DOI 10.1002/ccd.1810210305; LEUNG WH, 1992, J AM COLL CARDIOL, V20, P307, DOI 10.1016/0735-1097(92)90095-5; LEUNG WH, 1991, CIRCULATION, V84, P2294, DOI 10.1161/01.CIR.84.6.2294; LEUNG WH, 1991, AM J CARDIOL, V67, P1061, DOI 10.1016/0002-9149(91)90866-J; LUDMER PL, 1986, NEW ENGL J MED, V315, P1046, DOI 10.1056/NEJM198610233151702; MCPHERSON DD, 1987, NEW ENGL J MED, V316, P304, DOI 10.1056/NEJM198702053160604; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; RUBANYI GM, 1991, CIRCULATION, V83, P1118, DOI 10.1161/01.CIR.83.3.1118; SHIMOKAWA H, 1989, CIRC RES, V64, P900, DOI 10.1161/01.RES.64.5.900; SREEHARAN N, 1986, CAN J PHYSIOL PHARM, V64, P1451, DOI 10.1139/y86-246; VANHOUTTE PM, 1988, NEW ENGL J MED, V319, P349; VERHEUREN TJ, 1986, CIRC RES, V58, P783; VITA JA, 1990, CIRCULATION, V81, P491, DOI 10.1161/01.CIR.81.2.491; WATERS D, 1991, AM J MED, V91, pS10, DOI 10.1016/0002-9343(91)90051-X; WATTS GF, 1992, LANCET, V339, P563, DOI 10.1016/0140-6736(92)90863-X; WERNS SW, 1989, CIRCULATION, V79, P287, DOI 10.1161/01.CIR.79.2.287; YASUE H, 1990, CIRCULATION, V81, P482, DOI 10.1161/01.CIR.81.2.482; ZEIHER AM, 1991, CIRCULATION, V83, P391, DOI 10.1161/01.CIR.83.2.391	38	447	449	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 12	1993	341	8859					1496	1500		10.1016/0140-6736(93)90634-S	http://dx.doi.org/10.1016/0140-6736(93)90634-S			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LG242	8099379				2022-12-28	WOS:A1993LG24200003
J	CAMPBELL, RWF				CAMPBELL, RWF			VENTRICULAR ECTOPIC BEATS AND NONSUSTAINED VENTRICULAR-TACHYCARDIA	LANCET			English	Article							ACUTE MYOCARDIAL-INFARCTION; SEVERE HEART-FAILURE; CONTROLLED TRIAL; HEALTHY-SUBJECTS; DOUBLE-BLIND; ARRHYTHMIAS; FREQUENT; PREVENTION; MORTALITY; THERAPY				CAMPBELL, RWF (corresponding author), UNIV NEWCASTLE UPON TYNE, NEW MED SCH, FRAMLINGTON PL, NEWCASTLE UPON TYNE NE2 4HH, ENGLAND.							[Anonymous], 1989, NEW ENGL J MED, V321, P406; BIGGER JT, 1984, CIRCULATION, V69, P250, DOI 10.1161/01.CIR.69.2.250; BRODSKY M, 1977, AM J CARDIOL, V39, P390, DOI 10.1016/S0002-9149(77)80094-5; BUXTON AE, 1984, AM J CARDIOL, V53, P1275, DOI 10.1016/0002-9149(84)90078-X; CAMPBELL RWF, 1981, BRIT HEART J, V46, P351; CHAKKO CS, 1985, AM HEART J, V109, P497, DOI 10.1016/0002-8703(85)90554-X; CLELAND JGF, 1984, BRIT HEART J, V52, P530; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; CULLEN K, 1982, BRIT HEART J, V47, P209; HUGENHOLTZ PG, 1978, MANAGEMENT VENTRICUL, P572; KENNEDY HL, 1985, NEW ENGL J MED, V312, P193, DOI 10.1056/NEJM198501243120401; KENNEDY HL, 1980, ANN INTERN MED, V92, P179, DOI 10.7326/0003-4819-92-2-179; KOSTER RW, 1985, NEW ENGL J MED, V313, P1105, DOI 10.1056/NEJM198510313131801; LOWN B, 1967, J AMER MED ASSOC, V199, P188, DOI 10.1001/jama.199.3.188; MAY GS, 1982, PROG CARDIOVASC DIS, V24, P331, DOI 10.1016/0033-0620(82)90010-X; ROGERS WJ, 1992, NEW ENGL J MED, V327, P227; STEWART RA, 1989, BRIT HEART J, V61, P459; SULPIZI AM, 1987, AM J CARDIOL, V59, P841, DOI 10.1016/0002-9149(87)91103-9; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; WILBER DJ, 1990, CIRCULATION, V82, P350, DOI 10.1161/01.CIR.82.2.350; WREN C, 1987, EUR HEART J, V8, P647, DOI 10.1093/oxfordjournals.eurheartj.a062336; WYMAN MG, 1968, DIS CHEST, V53, P584	22	5	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 5	1993	341	8858					1454	1458		10.1016/0140-6736(93)90891-J	http://dx.doi.org/10.1016/0140-6736(93)90891-J			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF841	8099150				2022-12-28	WOS:A1993LF84100013
J	RUTGEERTS, P; GEBOES, K				RUTGEERTS, P; GEBOES, K			INFLAMMATORY BOWEL-DISEASE - CROHNS-DISEASE AND PRE-APHTHOID LESIONS	LANCET			English	Editorial Material							CELLS				RUTGEERTS, P (corresponding author), UNIV HOSP LEUVEN,DEPT GASTROENTEROL,LOUVAIN,BELGIUM.							GEBOES K, 1992, GASTROENTEROLOGY, V103, P439, DOI 10.1016/0016-5085(92)90832-J; KATZ KD, 1989, GASTROENTEROLOGY, V97, P927, DOI 10.1016/0016-5085(89)91499-6; MASUYAMA J, 1986, J CLIN INVEST, V77, P1596, DOI 10.1172/JCI112475; MAYER L, 1990, J CLIN INVEST, V86, P1255, DOI 10.1172/JCI114832; RIDDELL RM, 1991, EFFECTS IMMUNE CELLS, P11; RUTGEERTS P, 1990, GASTROENTEROLOGY, V99, P956, DOI 10.1016/0016-5085(90)90613-6; RUTGEERTS P, 1991, LANCET, V338, P771, DOI 10.1016/0140-6736(91)90663-A; SANKEY EA, 1993, GUT, V34, P375, DOI 10.1136/gut.34.3.375; WAKEFIELD AJ, 1989, LANCET, V2, P1057	9	9	10	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 5	1993	341	8858					1443	1444		10.1016/0140-6736(93)90886-L	http://dx.doi.org/10.1016/0140-6736(93)90886-L			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF841	8099145				2022-12-28	WOS:A1993LF84100008
J	VELDMAN, PHJM; REYNEN, HM; ARNTZ, IE; GORIS, RJA				VELDMAN, PHJM; REYNEN, HM; ARNTZ, IE; GORIS, RJA			SIGNS AND SYMPTOMS OF REFLEX SYMPATHETIC DYSTROPHY - PROSPECTIVE-STUDY OF 829 PATIENTS	LANCET			English	Article							CORTICOSTEROIDS; CAUSALGIA; TRIAL	The pathogenesis of reflex sympathetic dystrophy-variously known as Sudeck's atrophy, causalgia, algodystrophy, and peripheral trophoneurosis-is not yet understood, and diagnosing and treating patients is difficult. We have prospectively studied 829 patients, paying particular attention to early signs and symptoms. In its early phase, reflex sympathetic dystrophy is characterised by regional inflammation, which increases after muscular exercise. Pain was present in 93% of patients, and hypoaesthesia and hyperpathy were present in 69% and 75% respectively. With time, tissue atrophy may occur as well as involuntary movements, muscle spasms, or pseudoparalysis. Tremor was found in 49% and muscular incoordination in 54% of patients. Sympathetic signs such as hyperhidrosis are infrequent and therefore have no diagnostic value. We found no evidence consistent with the presence of three consecutive phases of the disease. Early symptoms are those of an inflammatory reaction and not of a disturbance of the sympathetic nervous system. These data support the concept of an exaggerated regional inflammatory response to injury or operation in reflex sympathetic dystrophy.			VELDMAN, PHJM (corresponding author), UNIV HOSP NIJMEGEN,DEPT SURG,6500 HB NIJMEGEN,NETHERLANDS.							ACQUAVIVA P, 1982, REV RHUM, V49, P761; ADLER E., 1959, PSYCHIAT ET NEUROL, V138, P256; ATKINS RM, 1990, J BONE JOINT SURG BR, V72, P105, DOI 10.1302/0301-620X.72B1.2298766; BABINSKY J, 1917, HYSTERIE PITHIATISME; Bohm E., 1985, HEFTE UNFALLHEILKD, V174, P241; BONNET J, 1953, THESIS LEIDEN; CHRISTENSEN K, 1982, ACTA CHIR SCAND, V148, P653; EVANS JA, 1947, ANN INTERN MED, V26, P417, DOI 10.7326/0003-4819-26-3-417; GORIS RJA, 1990, LETSELS ENKEL VOET E, P435; Goris RJA, 1991, TISSUE OXYGEN UTILIZ, P350; HADDOX JD, 1990, PAIN SYMPATHETIC NER, P207; HANNA MH, 1989, PAIN, V38, P145, DOI 10.1016/0304-3959(89)90232-7; HEERSCHAP A, 1993, MUSCLE NERVE, V16, P367, DOI 10.1002/mus.880160405; HOLDER LE, 1984, RADIOLOGY, V152, P517, DOI 10.1148/radiology.152.2.6739825; Johnson AC, 1943, ANN INTERN MED, V19, P433, DOI 10.7326/0003-4819-19-3-433; Kleinert H E, 1973, Orthop Clin North Am, V4, P917; KOZIN F, 1976, AM J MED, V60, P321, DOI 10.1016/0002-9343(76)90747-6; KOZIN F, 1981, RADIOLOGY, V138, P437, DOI 10.1148/radiology.138.2.7455127; MARSDEN CD, 1984, BRIT MED J, V288, P173, DOI 10.1136/bmj.288.6412.173; MAURER G, 1940, ERG CHIR, V33, P476; MILLER DS, 1942, SURG GYNECOL OBSTET, V75, P558; Mitchell SW., 1864, GUNSHOT WOUNDS OTHER; MOESKER A, 1985, PAIN CLINIC, V1, P171; Omer G, 1971, Tex Med, V67, P93; OYEN WJG, 1993, IN PRESS PAIN; Pak T J, 1970, Minn Med, V53, P507; PLEWES LW, 1956, J BONE JOINT SURG BR, V38, P195, DOI 10.1302/0301-620X.38B1.195; PROUGH DS, 1985, ANESTHESIOLOGY, V62, P796, DOI 10.1097/00000542-198506000-00017; ROSEN P S, 1957, Can Med Assoc J, V77, P86; ROUMEN RMH, 1991, J BONE JOINT SURG BR, V73, P307, DOI 10.1302/0301-620X.73B2.2005162; SAUNDERS PR, 1988, BRIT MED J, V297, P1635, DOI 10.1136/bmj.297.6664.1635-b; SCHUTZER SF, 1984, J BONE JOINT SURG AM, V66A, P625, DOI 10.2106/00004623-198466040-00025; SHAW RS, 1964, NEW ENGL J MED, V271, P22, DOI 10.1056/NEJM196407022710104; SHUMACKER HB, 1948, SURG GYNECOL OBSTET, V86, P452; STEINBROCKER O, 1947, AM J MED, V3, P402, DOI 10.1016/0002-9343(47)90170-8; Subarrao J, 1981, ARCH PHYS MED REHAB, V62, P549; Sudeck P, 1942, CHIRURG, V15, P449; SUDECK P, 1900, ARCH KLIN CHIR, V62, P147; TAHMOUSH AJ, 1983, NEUROLOGY, V33, P1483, DOI 10.1212/WNL.33.11.1483; TILMAN P B J, 1990, Micron and Microscopica Acta, V21, P271, DOI 10.1016/0739-6260(90)90143-4; WILDER RT, 1992, J BONE JOINT SURG AM, V74A, P910, DOI 10.2106/00004623-199274060-00013	41	801	819	0	18	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 23	1993	342	8878					1012	1016		10.1016/0140-6736(93)92877-V	http://dx.doi.org/10.1016/0140-6736(93)92877-V			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD066	8105263				2022-12-28	WOS:A1993MD06600008
J	VANGIJN, J				VANGIJN, J			TREATING UNCONTROLLED CRYING AFTER STROKE	LANCET			English	Editorial Material							BRAIN-DAMAGE; EMOTIONALISM				VANGIJN, J (corresponding author), UNIV UTRECHT,DEPT NEUROL,UTRECHT,NETHERLANDS.							ALLMAN P, 1990, POSTGRAD MED J, V66, P818, DOI 10.1136/pgmj.66.780.818; GALLAGHER JP, 1989, ACTA NEUROL SCAND, V80, P114, DOI 10.1111/j.1600-0404.1989.tb03851.x; HOUSE A, 1989, BMJ-BRIT MED J, V298, P991, DOI 10.1136/bmj.298.6679.991; ROBINSON RG, 1993, AM J PSYCHIAT, V150, P286; ROSS ED, 1987, J NERV MENT DIS, V175, P165, DOI 10.1097/00005053-198703000-00007; SCHIFFER RB, 1985, NEW ENGL J MED, V312, P1480, DOI 10.1056/NEJM198506063122303; VANHILTEN JJ, 1988, ARCH NEUROL-CHICAGO, V45, P936, DOI 10.1001/archneur.1988.00520330010001; WULFF HR, 1981, RATIONAL DIAGNOSIS T, P12	8	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 2	1993	342	8875					816	817		10.1016/0140-6736(93)92688-P	http://dx.doi.org/10.1016/0140-6736(93)92688-P			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA025	8104265				2022-12-28	WOS:A1993MA02500002
J	BLAU, JN				BLAU, JN			BEHAVIOR DURING A CLUSTER HEADACHE	LANCET			English	Article								Because cluster headache is short-lasting and tends to occur during the early morning hours, physicians rarely witness an attack. Accurate diagnosis is important because effective treatments are available. The diagnosis is made from the history of temporal pattern, reddening and tearing of the affected eye, and ipsilateral nasal congestion. An additional diagnostic aid is to invite patients to demonstrate how they respond to attacks. The pain, one of the worst known, causes extreme restlessness. 50 patients showed how they walk around, sit (or kneel) and rock, and clutch the affected side of the head. Diagnostic value apart, the patient will often be relieved to learn that bizarre behavioural responses are not a mark of insanity.			BLAU, JN (corresponding author), UCL NATL HOSP NEUROL & NEUROSURG, QUEEN SQ, LONDON WC1N 3BG, ENGLAND.							EKBOM K, 1970, ACTA NEUROL SCAND, V46, P1; EKBOM K, 1968, BRAIN MIND PROBLEMS, P482; HORTON BT, 1956, JAMA-J AM MED ASSOC, V160, P468, DOI 10.1001/jama.1956.02960410044011; KUDROW L, 1980, CLUSTER HEADACHE, P35; LANCE JW, NEUROL SCI, V13, P401; LEVI P, 1986, MOMENTS REPRIEVE, P100; MCKINNEY AS, 1983, HEADACHE, V23, P305, DOI 10.1111/j.1526-4610.1983.hed2306305.x; NAPPI G, 1992, CEPHALALGIA, V12, P165, DOI 10.1046/j.1468-2982.1992.1203165.x; SAKAI F, 1990, HEADACHE Q-CURR TREA, V1, P71; SJAASTAD O, 1992, CLUSTER HEADACHE SYN, P206; SOLZHENITSYN A, 1969, CANCER WARD, P454	11	31	34	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 18	1993	342	8873					723	725		10.1016/0140-6736(93)91713-V	http://dx.doi.org/10.1016/0140-6736(93)91713-V			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX469	8103827				2022-12-28	WOS:A1993LX46900014
J	GLYNN, JR				GLYNN, JR			A QUESTION OF ATTRIBUTION	LANCET			English	Article							MORTALITY; MEASLES; CANCER; RISK				GLYNN, JR (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED, DEPT EPIDEMIOL & POPULAT SCI, LONDON WC1E 7HT, ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AABY P, 1989, DAN MED BULL, V36, P93; CHEN LC, 1980, AM J CLIN NUTR, V33, P1836, DOI 10.1093/ajcn/33.8.1836; COHEN D, 1991, LANCET, V337, P993, DOI 10.1016/0140-6736(91)92657-N; DOLL R, 1976, BRIT MED J, V2, P1525, DOI 10.1136/bmj.2.6051.1525; EVANS RJ, 1987, DEATH HAMBURG SOC PO, P265; HACHINSKI V, 1992, LANCET, V340, P645; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; KOSTER FT, 1981, B WORLD HEALTH ORGAN, V59, P901; LEWIS SJ, 1992, BMJ-BRIT MED J, V305, P741, DOI 10.1136/bmj.305.6856.741; Manson P, 1900, Br Med J, V2, P949; MERTENS TE, 1990, AIDS, V4, P57, DOI 10.1097/00002030-199001000-00008; MORLEY D, 1969, BMJ-BRIT MED J, V1, P297, DOI 10.1136/bmj.1.5639.297; PETO R, 1991, BRIT MED J, V302, P906, DOI 10.1136/bmj.302.6781.906; ROSE G, 1974, LANCET, V1, P181, DOI 10.1016/S0140-6736(74)92492-1; ROSE G, 1980, LANCET, V1, P523; SCHOENTHALER SJ, 1991, PERS INDIV DIFFER, V12, P351, DOI 10.1016/0191-8869(91)90287-L; SMITH PG, 1980, BRIT J CANCER, V41, P422, DOI 10.1038/bjc.1980.66; Snow J., 1855, MODE COMMUNICATION C; VANTVEER P, 1990, INT J EPIDEMIOL, V19, P12, DOI 10.1093/ije/19.1.12; WALSH JA, 1983, REV INFECT DIS, V5, P330	20	24	32	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 28	1993	342	8870					530	532		10.1016/0140-6736(93)91651-2	http://dx.doi.org/10.1016/0140-6736(93)91651-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU582	8102672				2022-12-28	WOS:A1993LU58200014
J	GELBER, RD; GOLDHIRSCH, A; CASTIGLIONE, M; RUDENSTRAM, CM; COLLINS, J; SENN, HJ				GELBER, RD; GOLDHIRSCH, A; CASTIGLIONE, M; RUDENSTRAM, CM; COLLINS, J; SENN, HJ			PREMENOPAUSAL OOPHORECTOMY VERSUS CMF CHEMOTHERAPY IN STAGE-II BREAST-CARCINOMA	LANCET			English	Letter											GELBER, RD (corresponding author), IBCSG,KONSUMSTR 13,CH-3010 BERN,SWITZERLAND.							BUDMAN DR, 1992, MAY P ASCO, V29, P51; Early Breast Cancer Trialists' Collaborative Group, 1992, LANCET, V339, P1; ENGELSMAN E, 1991, EUR J CANCER, V27, P966, DOI 10.1016/0277-5379(91)90259-G; MEAKIN JW, 1979, CAN MED ASSOC J, V120, P1221; 1990, ANN ONCOL, V1, P30; 1993, LANCET, V341, P1293; 1992, LANCET, V339, P71; 1985, CANCER RES, V45, P4454	8	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 31	1993	342	8866					305	305		10.1016/0140-6736(93)91853-E	http://dx.doi.org/10.1016/0140-6736(93)91853-E			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ163	8101330				2022-12-28	WOS:A1993LQ16300048
J	CARPENTER, LM				CARPENTER, LM			IS THE STUDY WORTH DOING	LANCET			English	Article							SELLAFIELD NUCLEAR-PLANT; YOUNG-PEOPLE; WEST CUMBRIA; LEUKEMIA; LYMPHOMA; TRIALS				CARPENTER, LM (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,DEPT PUBL HLTH & PRIMARY CARE,GIBSON BLDG,OXFORD OX2 6HE,ENGLAND.							Altman DG., 1982, STATISTICS PRACTICE, P6; ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; CHALMERS I, 1991, BRIT MED J, P127; CHEW F, 1993, LANCET, V41, P194; ENKIN M, 1989, EFFECTIVE CARE PREGN, P1246; GARDNER MJ, 1990, BRIT MED J, V300, P429, DOI 10.1136/bmj.300.6722.429; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; GARDNER MJ, 1989, BRIT MED J; GORE SM, 1982, STATISTICS PRACTICE, P30; MULROW CD, 1987, ANN INTERN MED, V106, P485, DOI 10.7326/0003-4819-106-3-485; SIMES RJ, 1986, J CLIN ONCOL, V4, P1529, DOI 10.1200/JCO.1986.4.10.1529; THOMPSON SG, 1991, LANCET, V338, P1127, DOI 10.1016/0140-6736(91)91975-Z; 1992, LANCET, V339, P753	13	9	9	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 24	1993	342	8865					221	223		10.1016/0140-6736(93)92304-C	http://dx.doi.org/10.1016/0140-6736(93)92304-C			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN622	8100935				2022-12-28	WOS:A1993LN62200017
J	GRECH, ED; RAMSDALE, DR				GRECH, ED; RAMSDALE, DR			ANGIOPLASTY AND ACUTE MYOCARDIAL-INFARCTION	LANCET			English	Editorial Material											GRECH, ED (corresponding author), DEPT CARDIOL,CTR CARDIOTHORAC,LIVERPOOL,ENGLAND.							GIBBONS RJ, 1993, NEW ENGL J MED, V328, P685, DOI 10.1056/NEJM199303113281003; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; KAHN JK, 1990, CIRCULATION, V82, P1910, DOI 10.1161/01.CIR.82.6.1910; KHAN JK, 1990, JACC, V16, P1089; MEIER B, 1990, CIRCULATION, V82, P2243, DOI 10.1161/01.CIR.82.6.2243; STONE GW, 1990, J AM COLL CARDIOL, V15, P534, DOI 10.1016/0735-1097(90)90621-U; TOPOL EJ, 1990, TXB INTERVENTIONAL C, P269; VERSTRAETE M, 1985, LANCET, V1, P842, DOI 10.1016/S0140-6736(85)92208-1; ZIJLSTRA F, 1993, NEW ENGL J MED, V328, P680, DOI 10.1056/NEJM199303113281002	9	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 24	1993	342	8865					191	192		10.1016/0140-6736(93)92293-3	http://dx.doi.org/10.1016/0140-6736(93)92293-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN622	8100925				2022-12-28	WOS:A1993LN62200006
J	CHOCAIR, P; DULEY, J; SIMMONDS, HA; CAMERON, JS; IANHEZ, L; ARAP, S; SABBAGA, E				CHOCAIR, P; DULEY, J; SIMMONDS, HA; CAMERON, JS; IANHEZ, L; ARAP, S; SABBAGA, E			LOW-DOSE ALLOPURINOL PLUS AZATHIOPRINE CYCLOSPORINE PREDNISOLONE, A NOVEL IMMUNOSUPPRESSIVE REGIMEN	LANCET			English	Note								Early rejection can still complicate renal transplantation even with cyclosporin. We added low-dose allopurinol (25 mg on alternative days) to ''triple'' immunosuppression with cyclosporin, prednisolone, and azathioprine for twelve recipients of cadaver renal grafts. The controls were fifteen patients on triple therapy alone. Only one rejection episode occurred among the allopurinol-treated patients, whereas eleven controls had rejections (seven with more than one episode). Allopurinol may be toxic when combined with azathioprine, yet the bone marrow tolerated the new regimen well. As expected, reduction of the azathioprine dose was necessary in the treated group.	UMDS,GUYS HOSP,PURINE RES LAB,LONDON,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	CHOCAIR, P (corresponding author), UNIV SAO PAULO,HOSP CLIN,RENAL TRANSPLANT UNIT,CAIXA POSTAL 8091,SAO PAULO,BRAZIL.		Duley, John/B-1806-2013					CHALMERS AH, 1969, AUST J EXP BIOL MED, V47, P263, DOI 10.1038/icb.1969.27; CHOCAIR PR, 1992, TRANSPLANTATION, V53, P1051, DOI 10.1097/00007890-199205000-00016; HILLEBRAND G, 1991, INTERNIST, V32, P226; KELLEY WN, 1967, J CLIN INVEST, V46, P1518, DOI 10.1172/JCI105643; LENNARD L, 1989, CLIN PHARMACOL THER, V46, P149, DOI 10.1038/clpt.1989.119; NATH KA, 1991, INT YEARBOOK NEPHROL, P47; RAMAN VG, 1990, J INTERN MED, V228, P69	7	61	64	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 10	1993	342	8863					83	84		10.1016/0140-6736(93)91287-V	http://dx.doi.org/10.1016/0140-6736(93)91287-V			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LL789	8100914				2022-12-28	WOS:A1993LL78900011
J	FRIEDEN, TR; MUNSIFF, SS; LOW, DE; WILLEY, BM; WILLIAMS, G; FAUR, Y; EISNER, W; WARREN, S; KREISWIRTH, B				FRIEDEN, TR; MUNSIFF, SS; LOW, DE; WILLEY, BM; WILLIAMS, G; FAUR, Y; EISNER, W; WARREN, S; KREISWIRTH, B			EMERGENCE OF VANCOMYCIN-RESISTANT ENTEROCOCCI IN NEW-YORK-CITY	LANCET			English	Article							GENTAMICIN; SUSCEPTIBILITY; EPIDEMIOLOGY; TEICOPLANIN; INFECTION; FAECIUM	Enterococci, a common cause of nosocomial infection, are intrinsically resistant to most antimicrobials and readily acquire additional resistance. Vancomycin-resistant enterococci (VRE) have caused clusters of nosocomial infections since 1988. In April, 1991, the New York City Department of Health asked all city laboratories to submit suspected VRE isolates for confirmation. Clinical and epidemiological characteristics of the first 100 patients with VRE were identified, and antimicrobial susceptibilty testing, restriction enzyme analysis, and DNA-DNA hybridisation with the vanA gene probe were done. From September, 1989, to October, 1991, 361 patients with VRE were identified at 38 hospitals. The number of hospitals reporting VRE increased from 1 in 1989 to 38 by October, 1991. 98% of 100 VRE infections were nosocomially acquired and 83% patients had received vancomycin and/or a cephalosporin in the 30 days before isolation of VRE. Of 23 isolates from 21 of the first 100 patients, 19 (83%) were resistant to all available antimicrobials. Four vanA probing patterns were noted, and restriction enzyme analysis of the 23 isolates revealed 14 strains. VRE have emerged rapidly in New York City. Molecular analyses suggest that a highly mobile genetic element-eg, a transposon-is responsible for the rapid spread of vancomycin resistance.	PRINCESS MARGARET HOSP, DEPT MICROBIOL, TORONTO M4X 1K9, ONTARIO, CANADA; MT SINAI HOSP, DEPT MICROBIOL, TORONTO M5G 1X5, ONTARIO, CANADA; CTR DIS CONTROL, EPIDEMIOL PROGRAM OFF, DIV FIELD EPIDEMIOL, ATLANTA, GA 30333 USA; COLUMBIA UNIV COLL PHYS & SURG, NEW YORK, NY 10032 USA; PUBL HLTH RES INST CITY NEW YORK INC, NEW YORK, NY 10016 USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Centers for Disease Control & Prevention - USA; Columbia University	FRIEDEN, TR (corresponding author), NEW YORK CITY DEPT HLTH, DIV DIS INTERVENT, 125 WORTH ST, NEW YORK, NY 10013 USA.		Low, Donald/B-1726-2012					AXELROD P, 1989, ARCH INTERN MED, V149, P1397, DOI 10.1001/archinte.149.6.1397; DUTKAMALEN S, 1990, MOL GEN GENET, V224, P364, DOI 10.1007/BF00262430; ELIOPOULOS GM, 1988, ANTIMICROB AGENTS CH, V32, P1528, DOI 10.1128/AAC.32.10.1528; GEORGE RC, 1989, EPIDEMIOL INFECT, V103, P403, DOI 10.1017/S0950268800030806; LECLERCQ R, 1992, CLIN INFECT DIS, V15, P495, DOI 10.1093/clind/15.3.495; LECLERCQ R, 1989, ANTIMICROB AGENTS CH, V33, P10, DOI 10.1128/AAC.33.1.10; LECLERCQ R, 1988, NEW ENGL J MED, V319, P157, DOI 10.1056/NEJM198807213190307; MEDERSKISAMORAJ BD, 1983, J INFECT DIS, V147, P751, DOI 10.1093/infdis/147.4.751; MOELLERING RC, 1982, T AM CLIN CLIMAT ASS, V94, P55; MURRAY BE, 1991, J INFECT DIS, V163, P1185, DOI 10.1093/infdis/163.6.1185; MURRAY BE, 1990, CLIN MICROBIOL REV, V3, P46, DOI 10.1128/CMR.3.1.46-65.1990; NOBLE WC, 1992, FEMS MICROBIOL LETT, V93, P195; PATTERSON JE, 1990, REV INFECT DIS, V12, P644; SCHABERG DR, 1991, AM J MED, V91, pS72, DOI 10.1016/0002-9343(91)90346-Y; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SZETO S, 1991, J CLIN MICROBIOL, V29, P1258, DOI 10.1128/JCM.29.6.1258-1259.1991; TERPENNING MS, 1988, INFECT CONT HOSP EP, V9, P457, DOI 10.1086/645743; TOALA P, 1969, AM J MED SCI, V258, P416, DOI 10.1097/00000441-196912000-00006; 1991, M7A2 NAT COMM CLIN L	19	262	265	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 10	1993	342	8863					76	79		10.1016/0140-6736(93)91285-T	http://dx.doi.org/10.1016/0140-6736(93)91285-T			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LL789	8100912				2022-12-28	WOS:A1993LL78900009
J	BRANCATI, FL; CHOW, JW; WAGENER, MM; VACARELLO, SJ; YU, VL				BRANCATI, FL; CHOW, JW; WAGENER, MM; VACARELLO, SJ; YU, VL			IS PNEUMONIA REALLY THE OLD MANS FRIEND - 2-YEAR PROGNOSIS AFTER COMMUNITY-ACQUIRED PNEUMONIA	LANCET			English	Article							ETIOLOGY; MORTALITY; FEATURES; AGE	Is pneumonia ''the old man's friend''-a terminal event for patients who will otherwise die soon of underlying chronic disease? If so, chronological age might influence treatment policy. We investigated the predictors of 2-year mortality after patients' admission to hospital for community-acquired pneumonia, and focused on the predictive value of age. In a prospective cohort study 141 consecutive patients were admitted to hospital with community-acquired pneumonia. Clinical, laboratory, and sociodemographic data were collected on admission. Comorbidity was categorised as mild, moderate, or severe by a physician based on the patient's medical history. Survival was assessed at 24 months after discharge. 22 (16%) patients died in hospital. Of the remaining 119, 38 (32%) died over the next 24 months. In a Cox model, 2-year mortality was independently related to severe comorbidity (relative risk [RR] = 9.4) or moderate comorbidity (RR = 3.1), and to haematocrit less than 35% (RR = 2.9) (all p less-than-or-equal-to 0.005). However, compared with patients aged 18-44 years, patients aged 45-64 (RR = 0.84), 65-74 (RR = 1.28), and 75-92 (RR = 1.99) were not significantly more likely to die during the 24 months after discharge (all p greater-than-or-equal-to 0.2). Old age should not be a sole criterion for withholding aggressive treatment of community-acquired pneumonia.	JOHNS HOPKINS MED INST,WELCH CTR PREVENT EPIDEMIOL & CLIN RES,BALTIMORE,MD 21205; WAYNE STATE UNIV,SCH MED,DIV INFECT DIS,DETROIT,MI 48201; UNIV PITTSBURGH,SCH MED,DIV INFECT DIS,PITTSBURGH,PA 15261	Johns Hopkins University; Johns Hopkins Medicine; Wayne State University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh			Chow, Joseph W/W-4164-2017	Chow, Joseph W/0000-0002-5934-5877	NHLBI NIH HHS [HL07024, HL07180] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BURNS MW, 1976, MED J AUSTRALIA, V2, P787, DOI 10.5694/j.1326-5377.1976.tb115356.x; COX DR, 1972, J R STAT SOC B, V34, P187; DALEY J, 1988, JAMA-J AM MED ASSOC, V260, P3617, DOI 10.1001/jama.260.24.3617; DORFF GJ, 1973, AM J MED SCI, V266, P349, DOI 10.1097/00000441-197311000-00002; EBRIGHT JR, 1980, J AM GERIATR SOC, V28, P220, DOI 10.1111/j.1532-5415.1980.tb00523.x; FALK RH, 1987, AM J MED, V83, P1134, DOI 10.1016/0002-9343(87)90954-5; FARR BM, 1991, ANN INTERN MED, V115, P428, DOI 10.7326/0003-4819-115-6-428; FEDULLO AJ, 1985, J GERONTOL, V40, P29, DOI 10.1093/geronj/40.1.29; FILICE GA, 1980, AM J EPIDEMIOL, V112, P828, DOI 10.1093/oxfordjournals.aje.a113055; FINE MJ, 1990, AM J MED, V88, pN1; GOLDBERG AI, 1988, CHEST, V94, P1277, DOI 10.1378/chest.94.6.1277; HASLEY PB, IN PRESS MED CARE; JECKER NS, 1991, JAMA-J AM MED ASSOC, V266, P3012, DOI 10.1001/jama.266.21.3012; KILNER JF, 1989, ARCH INTERN MED, V149, P2342; MACFARLANE JT, 1982, LANCET, V2, P255; MANOLIO TA, 1992, AM J MED, V92, P1, DOI 10.1016/0002-9343(92)90007-X; MCNABB WR, 1984, J ROY SOC MED, V77, P550, DOI 10.1177/014107688407700705; MOORE MA, 1977, JOHNS HOPKINS MED J, V140, P9; ORTQVIST A, 1985, SCAND J INFECT DIS, V17, P377; Osler W, 1998, PRINCIPLES PRACTICE, P109; PACHON J, 1990, AM REV RESPIR DIS, V142, P369, DOI 10.1164/ajrccm/142.2.369; SULLIVAN P, 1989, CAN MED ASSOC J, V141, P720; SULLIVAN RJ, 1972, ARCH INTERN MED, V129, P935, DOI 10.1001/archinte.129.6.935; TORRES A, 1991, AM REV RESPIR DIS, V144, P312, DOI 10.1164/ajrccm/144.2.312; VENKATASEN P, 1990, THORAX, V43, P234; WOODHEAD MA, 1987, LANCET, V1, P671; WOODHEAD MA, 1985, J INFECTION, V10, P204, DOI 10.1016/S0163-4453(85)92463-6; ZWEIG S, 1990, J FAM PRACTICE, V30, P153; 1991, HEALTH; 1987, Q J MED, V239, P195	30	119	123	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 3	1993	342	8862					30	33		10.1016/0140-6736(93)91887-R	http://dx.doi.org/10.1016/0140-6736(93)91887-R			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK985	8100295				2022-12-28	WOS:A1993LK98500016
J	STEPHENSON, PA; WAGNER, MG				STEPHENSON, PA; WAGNER, MG			WHO RECOMMENDATIONS FOR IVF - DO THEY FIT WITH HEALTH FOR ALL	LANCET			English	Editorial Material											STEPHENSON, PA (corresponding author), CTR PUBL HLTH RES,LANDSTINGET & VARMLAND,S-65182 KARLSTAD,SWEDEN.							WAGNER MG, 1989, LANCET, V2, P1027; 1992, WHO TECHNICAL REPORT, V82; 1990, CONSULTATION PLACE I	3	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 26	1993	341	8861					1648	1649		10.1016/0140-6736(93)90771-8	http://dx.doi.org/10.1016/0140-6736(93)90771-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ727	8100003				2022-12-28	WOS:A1993LJ72700017
J	CAINE, SB; KOOB, GF				CAINE, SB; KOOB, GF			MODULATION OF COCAINE SELF-ADMINISTRATION IN THE RAT THROUGH D-3 DOPAMINE-RECEPTORS	SCIENCE			English	Article							MOLECULAR-CLONING; NUCLEUS ACCUMBENS; RHESUS-MONKEYS; D1; EXPRESSION; GENE; AMPHETAMINE; ANTAGONISTS; MECHANISMS; LESIONS	The reinforcing properties of cocaine are probably mediated by the mesocorticolimbic dopamine pathways in the central nervous system, but not all of the dopamine receptor subtypes involved in cocaine's reinforcing actions have been clearly identified. Recently, the D-3 receptor has been cloned, and its distribution in the brain has been found to be relatively restricted to limbic projections of the midbrain dopamine system. The D-3-selective compounds 7-hydroxy-N,N-di-n-propyl-2-aminotetralin (7-OHDPAT) and quinpirole potently decreased cocaine self-administration in the rat at doses that were not by themselves reinforcing. Moreover, three dopamine receptor agonists had affinities for binding to the D-3 receptor that correlated highly with their relative potencies in decreasing cocaine self-administration. The D-3 receptor may be involved in the reinforcing effects of cocaine and may be a useful target for the development of new pharmacotherapies for cocaine abuse.			CAINE, SB (corresponding author), SCRIPPS RES INST, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA.				NATIONAL INSTITUTE ON DRUG ABUSE [F31DA005478, R01DA004398] Funding Source: NIH RePORTER; NIDA NIH HHS [NIDA DA04398, NIDA DA05478] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Bergman J., 1990, Behav Pharmacol, V1, P355; BERGMAN J, 1988, FASEB J, V2, pA1137; BRITTON DR, 1991, PHARMACOL BIOCHEM BE, V39, P911, DOI 10.1016/0091-3057(91)90052-4; BUNZOW JR, 1988, NATURE, V336, P783, DOI 10.1038/336783a0; CAINE SB, UNPUB; CAINE SB, IN PRESS BEHAVIORAL; CALLAHAN PM, 1992, PSYCHOPHARMACOLOGY, V107, P73, DOI 10.1007/BF02244968; CEDARBAUM JM, 1990, PHARMACOL BASIS THER, P470; CREESE I, 1975, BRAIN RES, V83, P419, DOI 10.1016/0006-8993(75)90834-3; DAVIS WM, 1977, LIFE SCI, V20, P483; DEARRY A, 1990, NATURE, V347, P72, DOI 10.1038/347072a0; GAWIN FH, 1991, SCIENCE, V251, P1580, DOI 10.1126/science.2011738; GILL CA, 1978, 10TH P C COLL INT NE, P1477; HERLING S, 1979, PSYCHOPHARMACOLOGY, V64, P261, DOI 10.1007/BF00427508; HUBNER CB, 1991, PSYCHOPHARMACOLOGY, V105, P151, DOI 10.1007/BF02244301; HUBNER CB, 1990, NEUROPSYCHOPHARMACOL, V3, P101; KELLY PH, 1975, BRAIN RES, V94, P507, DOI 10.1016/0006-8993(75)90233-4; KOOB GF, 1988, SCIENCE, V242, P715, DOI 10.1126/science.2903550; KOOB GF, 1987, NEUROSCI LETT, V79, P315, DOI 10.1016/0304-3940(87)90451-4; KOOB GF, 1987, BRAIN REWARD SYSTEMS, P35; LEVESQUE D, 1992, P NATL ACAD SCI USA, V89, P8155, DOI 10.1073/pnas.89.17.8155; MONSMA FJ, 1990, P NATL ACAD SCI USA, V87, P6723, DOI 10.1073/pnas.87.17.6723; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; ROBERTS DCS, 1977, PHARMACOL BIOCHEM BE, V6, P615, DOI 10.1016/0091-3057(77)90084-3; ROBERTS DCS, 1980, PHARMACOL BIOCHEM BE, V12, P781, DOI 10.1016/0091-3057(80)90166-5; Schwartz J-C, 1992, SEMIN NEUROSCI, V4, P99, DOI 10.1016/1044-5765(92)90008-P; SOKOLOFF P, 1990, NATURE, V347, P146, DOI 10.1038/347146a0; SUNAHARA RK, 1990, NATURE, V347, P80, DOI 10.1038/347080a0; SUNAHARA RK, 1991, NATURE, V350, P614, DOI 10.1038/350614a0; SVENSSON K, 1986, N-S ARCH PHARMACOL, V334, P234, DOI 10.1007/BF00508777; TALLARIDA RJ, 1987, MANUAL PHARM CALCULA, P35; TIBERI M, 1991, P NATL ACAD SCI USA, V88, P7491, DOI 10.1073/pnas.88.17.7491; WOLF ME, 1987, DOPAMINE RECEPTORS, V8, P45; WOOLVERTON WL, 1984, J PHARMACOL EXP THER, V230, P678	34	431	441	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 18	1993	260	5115					1814	1816		10.1126/science.8099761	http://dx.doi.org/10.1126/science.8099761			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LH205	8099761				2022-12-28	WOS:A1993LH20500053
J	BONITA, R; BEAGLEHOLE, R				BONITA, R; BEAGLEHOLE, R			CEREBROVASCULAR-DISEASE - EXPLAINING STROKE MORTALITY TRENDS	LANCET			English	Editorial Material									UNIV AUCKLAND,DEPT COMMUNITY HLTH,AUCKLAND,NEW ZEALAND	University of Auckland	BONITA, R (corresponding author), UNIV AUCKLAND,DEPT MED,AUCKLAND,NEW ZEALAND.							ANDERSON CS, 1993, MED J AUSTRALIA, V158, P80, DOI 10.5694/j.1326-5377.1993.tb137528.x; BONITA R, 1990, STROKE, V21, P989, DOI 10.1161/01.STR.21.7.989; Bonita R, 1989, HYPERTENSION S1, V3; BRODERICK JP, 1989, STROKE, V20, P577, DOI 10.1161/01.STR.20.5.577; HARMSEN P, 1992, STROKE, V23, P1410, DOI 10.1161/01.STR.23.10.1410; JACOBS DR, 1992, AM J PUBLIC HEALTH, V82, P1596, DOI 10.2105/AJPH.82.12.1596; JORGENSEN HS, 1992, STROKE, V23, P1701, DOI 10.1161/01.STR.23.12.1701; LINDENSTROM E, 1992, STROKE, V23, P28, DOI 10.1161/01.STR.23.1.28; WOLF PA, 1992, STROKE, V23, P1551, DOI 10.1161/01.STR.23.11.1551	9	30	30	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 12	1993	341	8859					1510	1511		10.1016/0140-6736(93)90640-3	http://dx.doi.org/10.1016/0140-6736(93)90640-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LG242	8099385				2022-12-28	WOS:A1993LG24200009
J	SWALES, JD				SWALES, JD			ACE GENE - THE PLOT THICKENS	LANCET			English	Editorial Material							ANGIOTENSIN-CONVERTING ENZYME; DELETION POLYMORPHISM; MYOCARDIAL-INFARCTION; RISK; RAT				SWALES, JD (corresponding author), UNIV LEICESTER,DEPT MED,LEICESTER LE1 7RH,ENGLAND.							ALDERMAN MH, 1991, NEW ENGL J MED, V324, P1098, DOI 10.1056/NEJM199104183241605; CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0; MALIK KU, 1976, CIRC RES, V38, P26, DOI 10.1161/01.RES.38.1.26; RIGAT B, 1990, J CLIN INVEST, V86, P1343, DOI 10.1172/JCI114844; SAMANI NJ, 1988, BIOCHEM J, V253, P907, DOI 10.1042/bj2530907; SCHELLING P, 1991, J HYPERTENS, V9, P3; TIRET L, 1993, LANCET, V341, P991, DOI 10.1016/0140-6736(93)91075-W; UNGER T, 1992, HYPERTENSION, V20, P478, DOI 10.1161/01.HYP.20.4.478; 1988, ARCH INTERN MED, V148, P36	9	9	9	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 30	1993	342	8879					1065	1066		10.1016/0140-6736(93)92056-Y	http://dx.doi.org/10.1016/0140-6736(93)92056-Y			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME822	8105304				2022-12-28	WOS:A1993ME82200002
J	GIESECKE, J				GIESECKE, J			AIDS AND THE PUBLIC-HEALTH	LANCET			English	Editorial Material											GIESECKE, J (corresponding author), HUDDINGE HOSP,DEPT INFECT DIS,STOCKHOLM,SWEDEN.								0	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 16	1993	342	8877					942	942		10.1016/0140-6736(93)91997-Z	http://dx.doi.org/10.1016/0140-6736(93)91997-Z			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MC005	8105209				2022-12-28	WOS:A1993MC00500004
J	BOUDJEMA, K; JAECK, D; SIMEONI, U; BIENTZ, J; CHENARD, MP; BRUNOT, P				BOUDJEMA, K; JAECK, D; SIMEONI, U; BIENTZ, J; CHENARD, MP; BRUNOT, P			TEMPORARY AUXILIARY LIVER-TRANSPLANTATION FOR SUBACUTE LIVER-FAILURE IN A CHILD	LANCET			English	Note							FULMINANT HEPATIC-FAILURE; RECOVERY	A 4-year-old boy with subacute liver failure due to hepatitis A virus underwent temporary auxiliary liver transplantation. The graft, an adult reduced liver, was implanted othotopically after a left hepatectomy had been carried out on the recipient's liver. Good liver function was immediately restored. The remaining native liver, which was 90% necrotic at the time of transplantation, regained normal histological features within 3 months. The auxiliary graft was then removed and immunosuppressive therapy stopped.	HOP UNIV HAUTPIERRE,SERV PEDIAT,F-67098 STRASBOURG,FRANCE; HOP UNIV HAUTPIERRE,SERV CHIRURG INFANTILE,F-67098 STRASBOURG,FRANCE; HOP UNIV HAUTPIERRE,SERV ANAT PATHOL,F-67098 STRASBOURG,FRANCE; HOP UNIV HAUTPIERRE,SERV MED NUCL,F-67098 STRASBOURG,FRANCE	CHU Strasbourg; CHU Strasbourg; CHU Strasbourg; CHU Strasbourg	BOUDJEMA, K (corresponding author), HOP UNIV HAUTEPIERRE,CTR CHIRURG VISCERALE & TRANSPLANTAT,F-67098 STRASBOURG,FRANCE.		Simeoni, Umberto/GRO-6971-2022; SIMEONI, Umberto/AAQ-1870-2021; Chenard, Marie-Pierre/O-2373-2016	Simeoni, Umberto/0000-0003-0730-9337; SIMEONI, Umberto/0000-0003-0730-9337; Boudjema, Karim/0000-0002-3894-8767				FAGAN E, 1990, J MED VIROL, V30, P131, DOI 10.1002/jmv.1890300210; GUBERNATIS G, 1991, WORLD J SURG, V15, P660, DOI 10.1007/BF01789221; GUGENHEIM J, 1981, TRANSPLANTATION, V32, P445; Letoublon C, 1989, Chirurgie, V115, P30; METSELAAR HJ, 1990, LANCET, V335, P1156, DOI 10.1016/0140-6736(90)91158-7; MORITZ MJ, 1990, TRANSPLANTATION, V50, P524, DOI 10.1097/00007890-199009000-00036; STAMPFL DA, 1990, GASTROENTEROLOGY, V99, P1834, DOI 10.1016/0016-5085(90)90497-O; TERPSTRA OT, 1988, TRANSPLANTATION, V45, P1003, DOI 10.1097/00007890-198806000-00001	8	44	45	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 25	1993	342	8874					778	779		10.1016/0140-6736(93)91542-T	http://dx.doi.org/10.1016/0140-6736(93)91542-T			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LY868	8103878				2022-12-28	WOS:A1993LY86800011
J	FLETCHER, A; SPIEGELHALTER, D; STAESSEN, J; THIJS, L; BULPITT, C				FLETCHER, A; SPIEGELHALTER, D; STAESSEN, J; THIJS, L; BULPITT, C			IMPLICATIONS FOR TRIALS IN PROGRESS OF PUBLICATION OF POSITIVE RESULTS	LANCET			English	Article							IMMUNODEFICIENCY-VIRUS INFECTION; ISOLATED SYSTOLIC HYPERTENSION; HORMONE REPLACEMENT THERAPY; PLACEBO-CONTROLLED TRIAL; EUROPEAN WORKING PARTY; HIGH BLOOD-PRESSURE; CLINICAL-TRIAL; BREAST-CANCER; ZIDOVUDINE; MORTALITY	It is not easy to decide, when results from similar trials appear, whether a trial still underway should be stopped or not. The weight of the other evidence has to be taken into account-as indeed it has to be for decisions by clinicians and by health service managers outside the settings of a trial. Taking the Systolic Hypertension in the Elderly Trial (SHEP) as an example, we show how its results are not unequivocal (ie, there is no proof beyond reasonable doubt). This verdict justifies the continuation of similar trials in progress. More generally-but again for individual clinicians and for trial organisers and again with SHEP as the example-we illustrate a bayesian approach to trial-termination decisions.	UNIV CAMBRIDGE,INST PUBL HLTH,MRC,BIOSTAT UNIT,CAMBRIDGE,ENGLAND; CATHOLIC UNIV LEUVEN,DEPT PATHOPHYSIOL,HYPERTENS & CARDIOVASC REHABIL UNIT,B-3000 LOUVAIN,BELGIUM; ROYAL POSTGRAD MED SCH,DIV GERIATR MED,LONDON W12 0HS,ENGLAND	MRC Biostatistics Unit; University of Cambridge; KU Leuven; Imperial College London	FLETCHER, A (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,LONDON WC1E 7HT,ENGLAND.		Staessen, Jan A/A-1065-2011	Staessen, Jan A/0000-0002-3026-1637; Thijs, Lutgarde/0000-0002-8108-2356				ABOULKER JP, 1993, LANCET, V341, P889, DOI 10.1016/0140-6736(93)93096-J; AMERY A, 1985, LANCET, V1, P1349; Amery A, 1991, Aging (Milano), V3, P287; [Anonymous], 1986, Lancet, V1, P397; BEEVERS DG, 1988, BMJ, V297, P1227; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; COOPE J, 1986, BRIT MED J, V293, P1145, DOI 10.1136/bmj.293.6555.1145; CRUICKSHANK JM, 1988, BMJ, V297, P694; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FLETCHER A, 1991, J HYPERTENS, V9, P225, DOI 10.1097/00004872-199103000-00005; FLETCHER AE, 1992, NEW ENGL J MED, V326, P251; FREEDMAN LS, 1992, STAT MED, V11, P23, DOI 10.1002/sim.4780110105; HAMILTON JD, 1992, NEW ENGL J MED, V326, P437, DOI 10.1056/NEJM199202133260703; MATTERSON BJ, 1991, JAGS, V39, P1237; MEADE TW, 1992, BRIT MED BULL, V48, P276, DOI 10.1093/oxfordjournals.bmb.a072548; MERIGAN TC, 1991, BLOOD, V78, P900; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; POCOCK SJ, 1992, BMJ-BRIT MED J, V305, P235, DOI 10.1136/bmj.305.6847.235; POCOCK SJ, 1989, CONTROL CLIN TRIALS, V10, pS209; POCOCK SJ, 1992, BMJ-BRIT MED J, V305, P1015, DOI 10.1136/bmj.305.6860.1015; ROBERTS MM, 1990, LANCET, V335, P241; SIMBERKOFF MS, 1993, CONTROL CLIN TRIALS, V14, P6, DOI 10.1016/0197-2456(93)90046-G; STAESSEN J, 1990, J HYPERTENS, V8, P393, DOI 10.1097/00004872-199005000-00001; STAESSEN J, 1991, J HUM HYPERTENS, V5, P469; STAMPFER MJ, 1982, NEW ENGL J MED, V307, P1180, DOI 10.1056/NEJM198211043071904; STRASSER T, 1986, BLUTHOCHDRUCK PRAVEN; SWALES JD, 1989, BMJ-BRIT MED J, V298, P694; TABAR L, 1985, LANCET, V1, P829, DOI 10.1016/S0140-6736(85)92204-4; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WILKES HC, 1991, BRIT MED J, V302, P1317, DOI 10.1136/bmj.302.6788.1317; WINKER MA, 1991, JAMA-J AM MED ASSOC, V265, P3301, DOI 10.1001/jama.265.24.3301; 1992, BMJ, V304, P405; 1990, WORLD HLTH ORG STATI; 1991, JAMA-J AM MED ASSOC, V265, P3255; 1989, ADJUVANT XRAY 5 FU I; 1987, LANCET, V1, P502; 1992, CHIN J CARDIOL, V20, P270	38	23	23	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 11	1993	342	8872					653	657		10.1016/0140-6736(93)91762-B	http://dx.doi.org/10.1016/0140-6736(93)91762-B			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX272	8103149				2022-12-28	WOS:A1993LX27200013
J	THOROGOOD, M				THOROGOOD, M			LOSING HEART	LANCET			English	Editorial Material											THOROGOOD, M (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,HLTH PROMOT SCI UNIT,LONDON WC1E 7HT,ENGLAND.							ANDA R, 1993, EPIDEMIOLOGY, V4, P285, DOI 10.1097/00001648-199307000-00003	1	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 4	1993	342	8871					570	570		10.1016/0140-6736(93)91407-D	http://dx.doi.org/10.1016/0140-6736(93)91407-D			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV963	8102717				2022-12-28	WOS:A1993LV96300007
J	BRINDLE, P; LINKE, S; MONTMINY, M				BRINDLE, P; LINKE, S; MONTMINY, M			PROTEIN-KINASE-A-DEPENDENT ACTIVATOR IN TRANSCRIPTION FACTOR CREB REVEALS NEW ROLE FOR CREM REPRESSORS	NATURE			English	Article							MAMMALIAN-CELLS; GENE; CAMP; PHOSPHORYLATION; EXPRESSION; PROMOTER	HORMONALLY induced increases in cyclic AMP levels induce phosphorylation of the transcription factor CREB at a serine residue at position 133 by protein kinase A (ref. 1), enhancing its ability to activate transcription without affecting its intracellular location or DNA-binding activity. This effect is dependent on a 60-amino-acid region of CREB that contains Ser 133 and is termed the kinase-inducible domain (KID)2, which also occurs in the CREB-related CREM-alpha and -beta proteins, although these are transcriptional repressors3 . Here we show that the KID domain confers a cAMP-inducible increase on the activity of the Q2 activation domain from CREB and the acidic activation domains from the yeast proteins GAL4 and GCN4. Remarkably, it retains this ability even when attached to a separate polypeptide bound to an adjacent site in the promoter. KID may therefore be the first of a new class of conditional activators that work through other promoter-bound factors to stimulate gene expression in response to hormonal stimuli.			BRINDLE, P (corresponding author), SALK INST BIOL STUDIES,CLAYTON FDN LABS PEPTIDE BIOL,LA JOLLA,CA 92037, USA.			Brindle, Paul/0000-0001-7172-8478; Linke, Steven/0000-0001-8584-4947				CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HUGGENVIK JI, 1991, MOL ENDOCRINOL, V5, P921, DOI 10.1210/mend-5-7-921; LAOIDE BM, 1993, EMBO J, V12, P1179, DOI 10.1002/j.1460-2075.1993.tb05759.x; MEDCALF RL, 1990, J BIOL CHEM, V265, P14618; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; OHLSSON M, 1993, MOL CELL BIOL, V13, P266, DOI 10.1128/MCB.13.1.266; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; WINDLE JJ, 1990, MOL ENDOCRINOL, V4, P597, DOI 10.1210/mend-4-4-597	16	151	153	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 26	1993	364	6440					821	824		10.1038/364821a0	http://dx.doi.org/10.1038/364821a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU581	8102791				2022-12-28	WOS:A1993LU58100061
J	POWELLTUCK, J				POWELLTUCK, J			GLUTAMINE, PARENTERAL-FEEDING, AND INTESTINAL NUTRITION	LANCET			English	Editorial Material							METABOLISM; MUSCLE				POWELLTUCK, J (corresponding author), ROYAL LONDON HOSP,DEPT MED,LONDON,ENGLAND.							ADIBI SA, 1987, DIPEPTIDES NEW SUBST; DEUTZ NEP, 1992, CLIN SCI, V83, P607, DOI 10.1042/cs0830607; HAUSSINGER D, 1993, LANCET, V341, P1330, DOI 10.1016/0140-6736(93)90828-5; HAUSSINGER D, 1989, METABOLISM, V38, P14, DOI 10.1016/0026-0495(89)90133-9; RENNIE MJ, 1986, LANCET, V2, P1008; SOUBA WW, 1985, JPEN-PARENTER ENTER, V9, P608, DOI 10.1177/0148607185009005608; TAMARAPPOO BK, 1990, MINER ELECTROL METAB, V16, P322; VANDERHULST RRWJ, 1993, LANCET, V341, P1363, DOI 10.1016/0140-6736(93)90939-E; WINDMUELLER HG, 1980, J BIOL CHEM, V255, P107	9	6	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 21	1993	342	8869					451	452		10.1016/0140-6736(93)91589-E	http://dx.doi.org/10.1016/0140-6736(93)91589-E			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU075	8102425				2022-12-28	WOS:A1993LU07500006
J	NICOLAOU, KC; RIEMER, C; KERR, MA; RIDEOUT, D; WRASIDLO, W				NICOLAOU, KC; RIEMER, C; KERR, MA; RIDEOUT, D; WRASIDLO, W			DESIGN, SYNTHESIS AND BIOLOGICAL-ACTIVITY OF PROTAXOLS	NATURE			English	Article							WATER-SOLUBLE PRODRUGS; ANTITUMOR-ACTIVITY; TAXOL; CELLS; MICROTUBULES; AGENTS; ASSAY	TAXOL1-6 is a product isolated from the Pacific yew tree (Taxus brevifolia) and is a potent microtubule-stabilizing agent which has recently been approved for treatment of otherwise intractable ovarian cancer. Despite taxol's therapeutic promise, its aqueous insolubility (<0.004 mg ml-1) hampers its clinical application. Here we report the design, synthesis and biological activity of a series of taxol-releasing compounds (protaxols) with improved pharmacological properties. These prodrugs were designed to increase their aqueous solubility and allow for taxol release under basic or physiological conditions. We demonstrate the stability of these prodrugs at pH less-than-or-equal-to 7 and their ability to release taxol in a basic medium. Taxol-like microtubule-stabilizing activity7-9 appears after the release of taxol. In vitro these prodrugs have cytotoxic properties against tumour cell lines comparable to those of taxol; moreover, human plasma catalyses the release of active taxol. These protaxols have greater potential as anticancer agents than the parent compounds taxol and taxotere (Fig. 1a).	UNIV CALIF SAN DIEGO, DEPT CHEM, LA JOLLA, CA 92093 USA; SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, DRUG DISCOVERY UNIT, LA JOLLA, CA 92037 USA	University of California System; University of California San Diego; Scripps Research Institute; Scripps Research Institute	NICOLAOU, KC (corresponding author), SCRIPPS RES INST, DEPT CHEM, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.							DEBRABANDER M, 1981, P NATL ACAD SCI-BIOL, V78, P5608; DEUTSCH HM, 1989, J MED CHEM, V32, P788, DOI 10.1021/jm00124a011; KEIZER HG, 1989, J NATL CANCER I, V81, P706, DOI 10.1093/jnci/81.9.706; KINGSTON DGI, 1991, PHARMACOL THERAPEUT, V52, P1, DOI 10.1016/0163-7258(91)90085-Z; LONGNECKER SM, 1987, CANCER TREAT REP, V71, P53; MATHEW AE, 1992, J MED CHEM, V35, P145, DOI 10.1021/jm00079a019; MERLOCK R, IN PRESS ANAL BIOCH; NICOLAOU KC, IN PRESS ANGEW CHEM; POITIER P, 1992, CHEM SOC REV, V21, P113; ROWINSKY EK, 1991, PHARMACOL THERAPEUT, V52, P35, DOI 10.1016/0163-7258(91)90086-2; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; SWINDELL CS, 1991, ORG PREP PROCED INT, V23, P465, DOI 10.1080/00304949109458240; SWINDELL CS, 1991, J MED CHEM, V34, P1176, DOI 10.1021/jm00107a042; WANI MC, 1971, J AM CHEM SOC, V93, P2325, DOI 10.1021/ja00738a045; ZHAO ZY, 1991, J NAT PROD, V54, P1607, DOI 10.1021/np50078a018	17	118	157	3	34	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 29	1993	364	6436					464	466		10.1038/364464a0	http://dx.doi.org/10.1038/364464a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	LP640	8101355				2022-12-28	WOS:A1993LP64000061
J	COLLEN, D				COLLEN, D			TOWARDS IMPROVED THROMBOLYTIC THERAPY	LANCET			English	Review							UROKINASE				COLLEN, D (corresponding author), CATHOLIC UNIV LEUVEN,CTR MOLEC & VASC BIOL,B-3000 LOUVAIN,BELGIUM.							[Anonymous], 1986, Lancet, V1, P397; BODE C, 1985, SCIENCE, V229, P765, DOI 10.1126/science.4023710; BRAUNWALD E, 1989, CIRCULATION, V79, P441, DOI 10.1161/01.CIR.79.2.441; COLLEN D, 1991, CIRCULATION, V84, P1216, DOI 10.1161/01.CIR.84.3.1216; COLLEN D, 1993, CIRCULATION, V87, P996, DOI 10.1161/01.CIR.87.3.996; COLLEN D, 1991, BLOOD, V78, P3114; COLLEN D, IN PRESS CIRCULATION; COLLEN D, IN PRESS THROMB HAEM; DAVIES MJ, 1985, BRIT HEART J, V53, P363; DEWOOD MA, 1980, NEW ENGL J MED, V303, P897, DOI 10.1056/NEJM198010163031601; GARDELL SJ, 1989, J BIOL CHEM, V264, P17947; GOLD HK, 1990, NEW ENGL J MED, V323, P1483, DOI 10.1056/NEJM199011223232110; HOLVOET P, 1993, BLOOD, V81, P696; HORTON R, 1993, LANCET, V341, P1188, DOI 10.1016/0140-6736(93)91011-A; LIJNEN HR, 1990, BIOTECHNOL THER, V1, P273; NEUHAUS KL, 1992, J AM COLL CARDIOL, V19, P885, DOI 10.1016/0735-1097(92)90265-O; RUNGE MS, 1990, CIRCULATION, V82, P655, DOI 10.1161/01.CIR.82.2.655; SOBEL BE, 1990, CORONARY ARTERY DIS, V1, P3, DOI 10.1097/00019501-199001000-00002; SOBEL BE, 1992, AM J CARDIOL, V70, P385, DOI 10.1016/0002-9149(92)90624-8; 1992, CIRCULATION, V86, P15; 1992, LANCET, V339, P753; 1990, LANCET, V336, P71; 1992, CIRCULATION, V86, P455	23	44	47	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 3	1993	342	8862					34	36		10.1016/0140-6736(93)91888-S	http://dx.doi.org/10.1016/0140-6736(93)91888-S			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK985	8100296				2022-12-28	WOS:A1993LK98500017
J	MICOSSI, P; CARBONE, M; STANCANELLI, G; FORTINO, A				MICOSSI, P; CARBONE, M; STANCANELLI, G; FORTINO, A			HEALTH-CARE - MEASURING PRODUCTS OF HEALTH-CARE SYSTEMS	LANCET			English	Editorial Material											MICOSSI, P (corresponding author), UNIV MILAN,SCH MED,SCI INST S RAFFAELE,I-20122 MILAN,ITALY.							BARALDI G, 1992, IL SISTEMA DRG, P22; BERWICK DM, 1987, HCFA03258 ANN SUPPL; DONABEDIAN A, 1990, QUALITY ASSURANCE HO, P14; FETTER RB, 1985, CASES HLTH POLICY MA, P229; FREEMAN JL, 1991, 7TH P INT PCS E WORK, V2, P22; LEATHARD A, 1990, HLTH CARE PROVISION, P126; WILSON CRM, 1992, STRATEGIES HLTH CARE	7	6	6	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 19	1993	341	8860					1566	1567		10.1016/0140-6736(93)90703-J	http://dx.doi.org/10.1016/0140-6736(93)90703-J			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH550	8099646				2022-12-28	WOS:A1993LH55000010
J	MULLIGAN, LM; KWOK, JBJ; HEALEY, CS; ELSDON, MJ; ENG, C; GARDNER, E; LOVE, DR; MOLE, SE; MOORE, JK; PAPI, L; PONDER, MA; TELENIUS, H; TUNNACLIFFE, A; PONDER, BAJ				MULLIGAN, LM; KWOK, JBJ; HEALEY, CS; ELSDON, MJ; ENG, C; GARDNER, E; LOVE, DR; MOLE, SE; MOORE, JK; PAPI, L; PONDER, MA; TELENIUS, H; TUNNACLIFFE, A; PONDER, BAJ			GERM-LINE MUTATIONS OF THE RET PROTOONCOGENE IN MULTIPLE ENDOCRINE NEOPLASIA TYPE-2A	NATURE			English	Article							POINT MUTATION; TYROSINE KINASE; PROTOONCOGENE; DOMAIN; CHROMOSOME-10; CARCINOMAS	MULTIPLE endocrine neoplasia type 2A (MEN 2A) is a dominantly inherited cancer syndrome that affects tissues derived from neural ectoderm. It is characterized by medullary thyroid carcinoma (MTC) and phaeochromocytoma1. The MEN2A gene has recently been localized by a combination of genetic and physical mapping techniques to a 480-kilobase region in chromosome 10q11.2 (refs 2,3). The DNA segment encompasses the RET proto-oncogene, a receptor tyrosine kinase gene expressed in MTC and phaeochromocytoma and at lower levels in normal human thyroid4. This suggested RET as a candidate for the MEN2A gene. We have identified missense mutations of the RET proto-oncogene in 20 of 23 apparently distinct MEN 2A families, but not in 23 normal controls. Further, 19 of these 20 mutations affect the same conserved cysteine residue at the boundary of the RET extracellular and transmembrane domains.	UNIV CAMBRIDGE,DEPT PATHOL,CANC RES CAMPAIGN,HUMAN CANC GENET GRP,TENNIS COURT RD,CAMBRIDGE CB2 1QP,ENGLAND	CRUK Cambridge Institute; University of Cambridge			Mole, Sara/C-2024-2008	Mole, Sara/0000-0003-4385-4957; Papi, Laura/0000-0003-4552-9517; Love, Donald/0000-0003-4669-8769; Kwok, John/0000-0001-9574-6195; Eng, Charis/0000-0002-3693-5145; Tunnacliffe, Alan/0000-0001-8570-125X				BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; COTTON RGH, 1988, P NATL ACAD SCI USA, V85, P4397, DOI 10.1073/pnas.85.12.4397; COULIER F, 1990, MOL CELL BIOL, V10, P4202, DOI 10.1128/MCB.10.8.4202; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; GARDNER E, 1993, HUM MOL GENET, V2, P241, DOI 10.1093/hmg/2.3.241; ISHIZAKA Y, 1989, ONCOGENE, V4, P1519; IWAMOTO T, 1993, ONCOGENE, V8, P1087; LANDSVATER RM, 1989, GENOMICS, V4, P246, DOI 10.1016/0888-7543(89)90327-3; MOLE SE, 1993, HUM MOL GENET, V2, P247, DOI 10.1093/hmg/2.3.247; MULLIGAN LM, 1993, GENE CHROMOSOME CANC, V6, P166, DOI 10.1002/gcc.2870060307; MULLIGAN LM, 1991, NUCLEIC ACIDS RES, V19, P5795, DOI 10.1093/nar/19.20.5795; NELKIN BD, 1989, CANCER RES, V49, P4114; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; SANTORO M, 1990, ONCOGENE, V5, P1595; SCHIMKE RN, 1984, ANNU REV MED, V35, P25, DOI 10.1146/annurev.me.35.020184.000325; TAHIRA T, 1991, NUCLEIC ACIDS RES, V18, P7472; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571; YAMAMOTO M, 1991, JPN J CLIN ONCOL, V21, P149	20	1612	1652	1	28	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 3	1993	363	6428					458	460		10.1038/363458a0	http://dx.doi.org/10.1038/363458a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LE938	8099202				2022-12-28	WOS:A1993LE93800061
J	ANDREOTTI, F; KLUFT, C; HACKETT, DR; DAVIES, GJ; MASERI, A				ANDREOTTI, F; KLUFT, C; HACKETT, DR; DAVIES, GJ; MASERI, A			THROMBIN GENERATION AFTER FAST OR PROLONGED REGIMENS OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR	LANCET			English	Letter									ROYAL POSTGRAD MED SCH, LONDON W12 0HS, ENGLAND; TNO, IVVO, GAUBIUS LAB, 2313 AD LEIDEN, NETHERLANDS	Imperial College London; Netherlands Organization Applied Science Research	ANDREOTTI, F (corresponding author), UNIV CATTOLICA SACRO CUORE, IST CARDIOL, I-00168 ROME, ITALY.		Andreotti, Felicita/A-9962-2019	Andreotti, Felicita/0000-0002-1456-6430				GENSER N, 1993, LANCET, V341, P1038, DOI 10.1016/0140-6736(93)91141-8; HASKEL EJ, 1991, CIRCULATION, V83, P1048, DOI 10.1161/01.CIR.83.3.1048; KHAN MI, 1990, AM J CARDIOL, V65, P1051, DOI 10.1016/0002-9149(90)90313-P; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001	4	14	14	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 9	1993	342	8876					937	938		10.1016/0140-6736(93)91991-T	http://dx.doi.org/10.1016/0140-6736(93)91991-T			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA963	8105201				2022-12-28	WOS:A1993MA96300057
J	YIP, J; MATTOCK, MB; MOROCUTTI, A; SETHI, M; TREVISAN, R; VIBERTI, GC				YIP, J; MATTOCK, MB; MOROCUTTI, A; SETHI, M; TREVISAN, R; VIBERTI, GC			INSULIN-RESISTANCE IN INSULIN-DEPENDENT DIABETIC-PATIENTS WITH MICROALBUMINURIA	LANCET			English	Article							SODIUM-LITHIUM COUNTERTRANSPORT; AMBULATORY BLOOD-PRESSURE; ESCAPE RATE; MELLITUS; DISEASE; HYPERINSULINEMIA; HYPERTENSION; SENSITIVITY; MORTALITY; ALBUMIN	In insulin-dependent diabetes, microalbuminuria increases the risk of cardiovascular and renal disease. By means of a euglycaemic hyperinsulinaemic clamp method, we measured total-body glucose utilisation rate and studied the interaction of this measure of insulin sensitivity with known risk factors for cardiovascular disease in 14 diabetic patients with microalbuminuria and 14 with normal albumin excretion (median albumin excretion rate [AER] 56.2 [range 39.2-80.6] vs 8.8 [7.4-10.7] mug per min). The two groups were of similar age, duration of diabetes, and body-mass index. Total-body glucose disposal rate was significantly lower in the patients with microalbuminuria than in those without (mean 7.86 [SD 1.40] vs 9.04 [0.90] mg/kg per min; p<0.05). There were also significant differences between the groups in the daily insulin dose needed for equivalent glucose control (0.76 [0.20] vs 0.65 [0.10] U/kg, p<0.05), mean systolic blood pressure over 24 h ambulatory monitoring (134 [7] vs 127 [7] mm Hg; p<0.05), and various plasma lipid concentrations, contributing to a more atherogenic profile in the microalbuminuric group. Total-body glucose disposal rate was inversely correlated with body-mass index and log10 AER. The insulin sensitivity of the microalbuminuric group remained impaired after adjustment for blood pressure and body-mass index. Impaired insulin sensitivity is a feature of insulin-dependent diabetic patients with microalbuminuria, which adds, with other factors, to the increased risks of renal and cardiovascular disease in these patients.	UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,METAB MED UNIT,LONDON,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London			TREVISAN, ROBERTO/Q-8706-2016	TREVISAN, ROBERTO/0000-0003-0420-4468				COLLINS ACG, 1985, DIABETIC MED, V2, P456, DOI 10.1111/j.1464-5491.1985.tb00682.x; DEFARIA JBL, 1992, DIABETES, V41, P610, DOI 10.2337/diab.41.5.610; DEFRONZO RA, 1982, DIABETES, V31, P795, DOI 10.2337/diab.31.9.795; DEFRONZO RA, 1979, AM J PHYSIOL, V237, pE214; DUCIMETIERE P, 1980, DIABETOLOGIA, V19, P205, DOI 10.1007/BF00275270; ERIKSSON J, 1989, NEW ENGL J MED, V321, P337, DOI 10.1056/NEJM198908103210601; FELDTRASMUSSEN B, 1986, DIABETOLOGIA, V29, P282, DOI 10.1007/BF00452063; FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605; FERRARI P, 1991, AM J MED, V91, P589, DOI 10.1016/0002-9343(91)90211-F; HAFFNER SM, 1993, J CLIN ENDOCR METAB, V76, P541, DOI 10.1210/jc.76.3.541; HANSEN KW, 1992, KIDNEY INT, V41, P847, DOI 10.1038/ki.1992.130; JONES SL, 1989, BRIT MED J, V298, P487, DOI 10.1136/bmj.298.6672.487; LAGER I, 1983, BRIT MED J, V287, P1661, DOI 10.1136/bmj.287.6406.1661; MARTIN FIR, 1987, DIABETOLOGIA, V30, P149, DOI 10.1007/BF00274219; MESSENT JWC, 1992, KIDNEY INT, V41, P836, DOI 10.1038/ki.1992.128; MOGENSEN CE, 1984, NEW ENGL J MED, V310, P356, DOI 10.1056/NEJM198402093100605; MONTINI G, 1989, PAEDIATR NEPHROL, V3, pA2010; MOORE WV, 1992, DIABETES, V41, P1035, DOI 10.2337/diabetes.41.9.1035; NESTLER JE, 1990, DIABETES, V39, P1212, DOI 10.2337/diabetes.39.10.1212; PYORALA K, 1985, ACTA MED SCAND S, V701, P38; REAVEN GM, 1967, J CLIN INVEST, V46, P1756, DOI 10.1172/JCI105666; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; TREVISAN R, 1992, KIDNEY INT, V41, P855, DOI 10.1038/ki.1992.131; VIBERTI GC, 1982, LANCET, V1, P32; Welborn T A, 1979, Diabetes Care, V2, P154, DOI 10.2337/diacare.2.2.154; WHITE WB, 1989, AM HEART J, V118, P782, DOI 10.1016/0002-8703(89)90593-0; WHITE WB, 1992, J HYPERTENS, V10, pS35, DOI 10.1097/00004872-199204001-00008; WISEMAN MJ, 1984, DIABETOLOGIA, V2, P401; YIP J, 1993, LANCET, V341, P369, DOI 10.1016/0140-6736(93)90167-F; 1993, BMJ, V306, P1235	30	226	228	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 9	1993	342	8876					883	887		10.1016/0140-6736(93)91943-G	http://dx.doi.org/10.1016/0140-6736(93)91943-G			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA963	8105164				2022-12-28	WOS:A1993MA96300007
J	MCGUIRE, PK; SHAH, GMS; MURRAY, RM				MCGUIRE, PK; SHAH, GMS; MURRAY, RM			INCREASED BLOOD-FLOW IN BROCA AREA DURING AUDITORY HALLUCINATIONS IN SCHIZOPHRENIA	LANCET			English	Article							TEMPORAL-LOBE EPILEPSY; PSYCHOSIS	Verbal auditory hallucinations are common in schizophrenia but little is known about how they arise. We have used single photon emission tomography (SPET) to measure regional cerebral blood flow with the aim of identifying brain areas that are especially active during auditory hallucinations. We scanned twelve men with schizophrenia while they were experiencing hallucinations. The subjects were rescanned under identical conditions when their hallucinations had resolved (mean 19 weeks later). Blood flow was significantly greater during hallucinations than in the non-hallucinating state in Broca's area (mean count density on SPET 1.18 [SD 0.04] vs 1.13 [0.06]; p<0.001); flow was also higher during hallucinations in the left anterior cingulate cortex and regions in the left temporal lobe, but these differences did not achieve significance. The increased flow in Broca's area was not accounted for by changes in other clinical variables nor by changes in the dose of neuroleptic drugs. These findings suggest that the production of auditory hallucinations in schizophrenia is associated with increased activity in a network of cortical areas specialised for language.	INST PSYCHIAT, DEPT PSYCHOL MED, GENET SECT, LONDON SE5 8AF, ENGLAND	University of London; King's College London	MCGUIRE, PK (corresponding author), KINGS COLL HOSP, DEPT NUCL MED, DE CRESPIGNY PK, LONDON SE5 8AF, ENGLAND.		Murray, Robin M/F-8658-2012	Murray, Robin M/0000-0003-0829-0519; McGuire, Philip/0000-0003-4381-0532	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANNETT M, 1970, BRIT J PSYCHOL, V61, P303, DOI 10.1111/j.2044-8295.1970.tb01248.x; BARTA PE, 1990, AM J PSYCHIAT, V39, P784; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BOGERTS B, 1985, ARCH GEN PSYCHIAT, V43, P36; CLEGHORN JM, 1992, AM J PSYCHIAT, V149, P1062; COSTA DC, 1986, NUCL MED COMMUN, V7, P647; DAVID AS, 1993, NEUROPSYCHOLOGY SCHI, P269; DEMONET JF, 1992, BRAIN, V115, P1753, DOI 10.1093/brain/115.6.1753; FALKAI P, 1986, EUR ARCH PSY CLIN N, V236, P154, DOI 10.1007/BF00380943; FRISTON KJ, 1993, J CEREBR BLOOD F MET, V13, P5, DOI 10.1038/jcbfm.1993.4; FRITH CD, 1988, BRIT J PSYCHIAT, V153, P437, DOI 10.1192/bjp.153.4.437; FRITH CD, 1991, P ROY SOC B-BIOL SCI, V244, P241, DOI 10.1098/rspb.1991.0077; GROSSMAN M, 1993, J CEREB BLOOD FLO S1, V13, pS525; HOWARD D, 1992, BRAIN, V115, P1769, DOI 10.1093/brain/115.6.1769; LAGER AC, 1985, PSYCHIAT RES, V16, P27, DOI 10.1016/0165-1781(85)90025-3; LIDDLE PF, 1992, BRIT J PSYCHIAT, V160, P179, DOI 10.1192/bjp.160.2.179; MUSALEK M, 1989, COMPR PSYCHIAT, V30, P99, DOI 10.1016/0010-440X(89)90123-5; NIE NH, 1975, STATISTICAL PACKAGE; PANDYA DN, CEREBRAL CORTEX, V4; PAULESU E, 1993, NATURE, V362, P342, DOI 10.1038/362342a0; PENFIELD W, 1963, BRAIN, V86, P595, DOI 10.1093/brain/86.4.595; PETERSEN SE, 1988, NATURE, V331, P585, DOI 10.1038/331585a0; PRICE C, 1993, J CEREB BLOOD FLO S1, V13, pS501; ROBERTS GW, 1990, BIOL PSYCHIAT, V28, P127, DOI 10.1016/0006-3223(90)90630-K; SUDDATH RL, 1990, NEW ENGL J MED, V322, P789, DOI 10.1056/NEJM199003223221201; TALAIRACH J, 1988, COPLANOR STEREOTAXIC; TAYLOR DC, 1975, PSYCHOL MED, V5, P249, DOI 10.1017/S0033291700056609; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; [No title captured]	29	330	336	0	23	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 18	1993	342	8873					703	706		10.1016/0140-6736(93)91707-S	http://dx.doi.org/10.1016/0140-6736(93)91707-S			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX469	8103821				2022-12-28	WOS:A1993LX46900008
J	CROW, TJ				CROW, TJ			SEXUAL SELECTION, MACHIAVELLIAN INTELLIGENCE, AND THE ORIGINS OF PSYCHOSIS	LANCET			English	Review							STRUCTURAL BRAIN CHANGES; SCHIZOPHRENIA; ASYMMETRY; AGE; POSTMORTEM; SIBLINGS; ONSET; RATIO; AREA	According to Darwin's theory of sexual selection some features that differentiate the two sexes evolve by a process of ''male competition'' and ''female choice''. The sex difference in age of onset of psychotic illness in man may relate to a sexual dimorphism in cerebral organisation (the male brain being more lateralised or asymmetrical than the female brain), a difference consistent with,a role for sexual selection in the evolution of the human brain. Differing criteria (reflected in a cross-culturally stable difference in mean age at marriage) in males and females for selecting personality characteristics in a mate may generate diversity in the balance of growth between the hemispheres, and this could maintain the high and relatively constant rates of psychosis in human populations.			CROW, TJ (corresponding author), NORTHWICK PK HOSP & CLIN RES CTR,CLIN RES CTR,DIV PSYCHIAT,HARROW HA1 3UJ,MIDDX,ENGLAND.							Annett M., 1985, LEFT RIGHT HAND BRAI; BEAR D, 1986, ARCH NEUROL-CHICAGO, V43, P598, DOI 10.1001/archneur.1986.00520060060019; Bolk L., 1926, PROBLEM MENSCHWERDUN; BROWN R, 1986, ARCH GEN PSYCHIAT, V43, P36; BRUTON CJ, 1990, PSYCHOL MED, V20, P285, DOI 10.1017/S0033291700017608; BUSS DM, 1985, AM SCI, V73, P47; Byrne R., 1988, MACHIAVELLIAN INTELL; Crichton-Browne J., 1879, BRAIN, V2, P42, DOI DOI 10.1093/BRAIN/2.1.42; CROW T, 1987, COGNITIVE NEUROCHEMI, P372; CROW TJ, 1986, PSYCHIAT RES, V18, P107, DOI 10.1016/0165-1781(86)90023-5; CROW TJ, 1990, SCHIZOPHRENIA BULL, V16, P433, DOI 10.1093/schbul/16.3.433; CROW TJ, 1992, SCHIZOPHR RES, V6, P152, DOI 10.1016/0920-9964(92)90230-3; CROW TJ, 1989, ARCH GEN PSYCHIAT, V46, P1145; CROW TJ, 1991, BRIT J PSYCHIAT, V159, P76, DOI 10.1192/S0007125000296530; CROW TJ, 1991, NEGATIVE VERSUS POSI, P424; DANIEL DG, 1991, BIOL PSYCHIAT, V30, P887, DOI 10.1016/0006-3223(91)90003-5; Darwin C., 1981, DESCENT MAN SELECTIO; DAVIES K, 1991, NATURE, V349, P15, DOI 10.1038/349015a0; FALKAI P, 1992, SCHIZOPHR RES, V7, P23, DOI 10.1016/0920-9964(92)90070-L; GOTTESMAN II, 1991, SCHIZOPHRENIA GENETI; HARVEY I, 1990, PSYCHIAT RES-NEUROIM, V35, P61, DOI 10.1016/0925-4927(90)90009-U; JABLENSKY A, 1992, PSYCHOL MED S20, V22, P1; JOHNSTONE EC, 1989, PSYCHOL MED, V19, P91, DOI 10.1017/S0033291700011053; Kretschmer Ernst, 1921, KORPERBAU CHARAKTER; LEVY J, 1977, EVOLUTION LATERALIZA, V299, P264; LEWINE RRJ, 1991, SCHIZOPHRENIA LIFE C, P195; MCGLONE J, 1980, BEHAV BRAIN SCI, V3, P215, DOI 10.1017/S0140525X00004398; NETLEY C, 1982, CORTEX, V18, P377, DOI 10.1016/S0010-9452(82)80036-1; Netley C T, 1986, Birth Defects Orig Artic Ser, V22, P293; OFFORD DR, 1974, BRIT J PSYCHIAT, V125, P12, DOI 10.1192/bjp.125.1.12; PAKKENBERG B, 1987, BRIT J PSYCHIAT, V151, P744, DOI 10.1192/bjp.151.6.744; PEARLSON GD, 1989, ARCH GEN PSYCHIAT, V46, P690; PENROSE LS, 1991, EUR ARCH PSY CLIN N, V240, P315, DOI 10.1007/BF02279760; Rosenthal D., 1970, GENETIC THEORY ABNOR; ZIPURSKY RB, 1992, ARCH GEN PSYCHIAT, V49, P195; 1989, UN DEMOGRAPHIC YB 19	36	155	155	0	28	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 4	1993	342	8871					594	598		10.1016/0140-6736(93)91415-I	http://dx.doi.org/10.1016/0140-6736(93)91415-I			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LV963	8102725				2022-12-28	WOS:A1993LV96300015
J	JAMES, A				JAMES, A			PAINLESS HUMAN RIGHT	LANCET			English	Editorial Material																		BONICA JJ, 1985, ADV PAIN RES THER, V9, P589; STJERNSWARD J, 1993, J PAIN SYMPTOM MANAG, V8, P340, DOI 10.1016/0885-3924(93)90050-6; ZENZ M, 1993, LANCET, V341, P1075, DOI 10.1016/0140-6736(93)92425-S; 1990, CANCER PAIN RELIEF P; 1986, CANCER PAIN RELIEF	5	7	7	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 4	1993	342	8871					567	568		10.1016/0140-6736(93)91403-9	http://dx.doi.org/10.1016/0140-6736(93)91403-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV963	8102713				2022-12-28	WOS:A1993LV96300003
J	PELTOLA, H				PELTOLA, H			EARLY MENINGOCOCCAL DISEASE - ADVISING THE PUBLIC AND THE PROFESSION	LANCET			English	Editorial Material							TUMOR NECROSIS FACTOR; MENINGITIS				PELTOLA, H (corresponding author), UNIV HELSINKI,CHILDRENS HOSP,SF-00100 HELSINKI 10,FINLAND.							BEGG N, 1992, BRIT MED J, V305, P133, DOI 10.1136/bmj.305.6846.133; CARTWRIGHT K, 1992, BRIT MED J, V305, P774, DOI 10.1136/bmj.305.6856.774; FRIEDLAND J, 1990, LANCET, V335, P300, DOI 10.1016/0140-6736(90)90128-R; KILPI T, 1991, LANCET, V338, P406, DOI 10.1016/0140-6736(91)91032-P; MCGOWAN JE, 1992, J INFECT DIS, V165, P1, DOI 10.1093/infdis/165.1.1; PELTOLA H, 1983, REV INFECT DIS, V5, P71; SORENSEN HT, 1992, BRIT MED J, V305, P774, DOI 10.1136/bmj.305.6856.774-a; TARLOW MJ, 1992, LANCET, V340, P1481, DOI 10.1016/0140-6736(92)92678-9; THOMSON AP, 1993, ARCH DIS CHILD, V69, P166, DOI 10.1136/adc.69.1.166; WAAGE A, 1987, LANCET, V1, P355; 1985, LANCET, V2, P594	11	28	28	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 28	1993	342	8870					509	510		10.1016/0140-6736(93)91642-Y	http://dx.doi.org/10.1016/0140-6736(93)91642-Y			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU582	8102663				2022-12-28	WOS:A1993LU58200005
J	WALSH, D				WALSH, D			DYSPNEA IN ADVANCED CANCER	LANCET			English	Editorial Material											WALSH, D (corresponding author), CLEVELAND CLIN EDUC FDN,PALLAT CARE PROGRAM,CLEVELAND,OH 44106, USA.			Walsh, (Thomas) Declan/0000-0002-9310-1729				Bruera E, 1990, J Pain Symptom Manage, V5, P341, DOI 10.1016/0885-3924(90)90027-H; BRUERA E, 1993, LANCET, V342, P13, DOI 10.1016/0140-6736(93)91880-U; COOKE N, 1988, SYMPTOM CONTROL, P157; Curtis E B, 1991, J Palliat Care, V7, P25; KRECH RL, 1991, J PAIN SYMPTOM MANAG, V6, P360, DOI 10.1016/0885-3924(91)90027-2; NELSON K, 1991, CANCER B, V4, P423; RESTRICK LJ, 1992, LANCET, V339, P850; REUBEN DB, 1986, CHEST, V89, P234, DOI 10.1378/chest.89.2.234; VENTAFRIDDA V, 1990, CHEST, V6, P1544; WALSH TD, 1984, RECENT RESULTS CANC, V89, P115	10	15	15	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 21	1993	342	8869					450	451		10.1016/0140-6736(93)91588-D	http://dx.doi.org/10.1016/0140-6736(93)91588-D			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU075	8102424				2022-12-28	WOS:A1993LU07500005
J	COSTA, A				COSTA, A			TAMOXIFEN TRIAL IN HEALTHY WOMEN AT RISK OF BREAST-CANCER	LANCET			English	Letter											COSTA, A (corresponding author), AMBULATORIO LEGA ITALIANA LOTTA CONTRO TUMON,CTR OPERAT,I-20146 MILAN,ITALY.								0	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 14	1993	342	8868					444	444		10.1016/0140-6736(93)92864-P	http://dx.doi.org/10.1016/0140-6736(93)92864-P			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR900	8101951				2022-12-28	WOS:A1993LR90000067
J	GOLDACRE, M; SEAGROATT, V; HAWTON, K				GOLDACRE, M; SEAGROATT, V; HAWTON, K			SUICIDE AFTER-DISCHARGE FROM PSYCHIATRIC INPATIENT CARE	LANCET			English	Article							IOWA RECORD-LINKAGE; MORTALITY	People with a history of psychiatric disorder are at higher risk of suicide than people without such a history. The policy of reducing inpatient care in psychiatry has probably meant that some of the risk of suicide has shifted from the hospital to the community setting. We have quantified the risk of suicide within a year of psychiatric discharge in a population-based study in the Oxford health region, UK. We calculated suicide rates per 1000 person-years at risk (time from discharge to death, subsequent readmission, or the end of the study) and the standardised mortality ratio (SMR) for suicide, taking the value among the general population as 1. Among male patients the SMR for suicide (defined by coroner's verdict of suicide) in the first 28 days after discharge from inpatient care was 213 (95% CI 137-317); the equivalent SMR for female patients was 134 (67-240). The result was similar when we defined suicide more broadly as a suicide, open, or misadventure verdict. The suicide rate in the first 28 days after discharge was 7.1 (4.1-12) times higher for male patients and 3.0 (1.5-6.0) times higher for female patients than the rate during the remaining 48 weeks of the first year after discharge. Most of the patients studied (both those who committed suicide and those who did not) had been psychiatric inpatients for only a short time. The findings confirm that there is significant clustering of suicide soon after discharge from psychiatric care. Skilled support after discharge for high-risk patients in the community is essential. Audit of suicides that occur soon after discharge may help identify the patients at highest risk and thereby reduce the number of avoidable deaths.	UNIV OXFORD,WARNEFORD HOSP,DEPT PSYCHIAT,OXFORD OX3 7J,ENGLAND	University of Oxford	GOLDACRE, M (corresponding author), UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,HLTH CARE EPIDEMIOL UNIT,OLD RD,OXFORD OX3 7LF,ENGLAND.							Acheson E.D., 1967, MED RECORD LINKAGE; BAKER RJ, 1978, GLIM SYSTEM; BARRACLOUGH B, 1974, BRIT J PSYCHIAT, V125, P355, DOI 10.1192/bjp.125.4.355; BLACK DW, 1985, JAMA-J AM MED ASSOC, V253, P58, DOI 10.1001/jama.253.1.58; BLACK DW, 1989, SUICIDE LIFE-THREAT, V19, P78; Charlton J., 1992, Population Trends, P10; COLEMAN M, 1986, INT J EPIDEMIOL, V15, P134, DOI 10.1093/ije/15.1.134; GILL LE, 1987, TXB MED RECORD LINKA, P39; HAWTON K, 1992, BMJ-BRIT MED J, V304, P1000, DOI 10.1136/bmj.304.6833.1000; HAWTON K, 1987, BRIT J PSYCHIAT, V150, P145, DOI 10.1192/bjp.150.2.145; HENDERSON J, 1992, J EPIDEMIOL COMMUN H, V46, P297, DOI 10.1136/jech.46.3.297; HOFFMANN H, 1987, SOC PSYCH PSYCH EPID, V22, P93, DOI 10.1007/BF00584011; MILES CP, 1977, J NERV MENT DIS, V164, P231, DOI 10.1097/00005053-197704000-00002; MONK M, 1987, EPIDEMIOL REV, V9, P51, DOI 10.1093/oxfordjournals.epirev.a036308; ODEGARD O, 1952, ACTA PSYCH NEUROL, V27, P353, DOI 10.1111/j.1600-0447.1952.tb04667.x; PIERCE J, 1964, ARCH GEN PSYCHIAT, V10, P43; POUNDER DJ, 1992, BRIT MED J, V305, P472, DOI 10.1136/bmj.305.6851.472; ROY A, 1983, COMPR PSYCHIAT, V24, P487, DOI 10.1016/0010-440X(83)90040-8; ROY A, 1984, CAN J PSYCHIAT, V29, P319, DOI 10.1177/070674378402900408; SCHNEIDMAN ES, 1981, SUICIDE LIFE-THREAT, V11, P325; SEAGROATT V, 1991, BRIT MED J, V303, P1431, DOI 10.1136/bmj.303.6815.1431; SURTEES J, 1992, BRIT MED J, V305, P716, DOI 10.1136/bmj.305.6855.716-a; 1992, LANCET, V340, P700; 1992, HLTH NATION STRATEGY; 1982, STEERING GROUP HLTH	25	297	300	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 31	1993	342	8866					283	286		10.1016/0140-6736(93)91822-4	http://dx.doi.org/10.1016/0140-6736(93)91822-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ163	8101307				2022-12-28	WOS:A1993LQ16300015
J	ELDER, GH; HUNTER, PR; CODD, GA				ELDER, GH; HUNTER, PR; CODD, GA			HAZARDOUS FRESH-WATER CYANOBACTERIA (BLUE-GREEN-ALGAE)	LANCET			English	Article							DIARRHEA		COUNTESS CHESTER HOSP,PUBL HLTH LAB SERV LAB,CHESTER,ENGLAND; UNIV DUNDEE,DEPT BIOL SCI,DUNDEE DD1 4HN,SCOTLAND	University of Dundee	ELDER, GH (corresponding author), UNIV WALES COLL MED,DEPT MED BIOCHEM,CARDIFF CF4 4XN,S GLAM,WALES.		Hunter, Paul/N-9021-2019; Hunter, Paul/A-7172-2008	Hunter, Paul/0000-0002-5608-6144; Hunter, Paul/0000-0002-5608-6144				BEASLEY VR, 1989, VET CLIN N AM-FOOD A, V5, P345, DOI 10.1016/S0749-0720(15)30980-4; BENDALL RP, 1993, LANCET, V341, P590, DOI 10.1016/0140-6736(93)90352-H; CODD GA, 1992, NATURE, V359, P110, DOI 10.1038/359110b0; CODD GA, 1991, PHLS MICROBIOL, V8, P79; EDWARDS C, 1992, TOXICON, V30, P1165, DOI 10.1016/0041-0101(92)90432-5; FALCONER IR, 1991, ENVIRON TOXIC WATER, V6, P177, DOI 10.1002/tox.2530060207; GUNN GJ, 1992, VET REC, V130, P301, DOI 10.1136/vr.130.14.301; HUNTER PR, 1992, J MED MICROBIOL, V36, P301, DOI 10.1099/00222615-36-5-301; LONG EG, 1990, J CLIN MICROBIOL, V28, P1101, DOI 10.1128/JCM.28.6.1101-1104.1990; MACKINTOSH C, 1990, FEBS LETT, V264, P187, DOI 10.1016/0014-5793(90)80245-E; MATSUSHIMA R, 1990, BIOCHEM BIOPH RES CO, V171, P867, DOI 10.1016/0006-291X(90)91226-I; NISHIWAKIMATSUSHIMA R, 1992, J CANCER RES CLIN, V118, P420, DOI 10.1007/BF01629424; SHLIM DR, 1991, AM J TROP MED HYG, V45, P383, DOI 10.4269/ajtmh.1991.45.383; SOONG FS, 1992, MED J AUSTRALIA, V156, P67; TURNER PC, 1990, BRIT MED J, V300, P1440, DOI 10.1136/bmj.300.6737.1440; 1990, WATER QUALITY SERIES, V2	16	27	27	1	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 12	1993	341	8859					1519	1520		10.1016/0140-6736(93)90643-U	http://dx.doi.org/10.1016/0140-6736(93)90643-U			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LG242	8099388				2022-12-28	WOS:A1993LG24200012
J	HACKETT, R				HACKETT, R			RESEARCH OR REVELATION	LANCET			English	Editorial Material																			0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 12	1993	341	8859					1522	1523		10.1016/0140-6736(93)90646-X	http://dx.doi.org/10.1016/0140-6736(93)90646-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LG242	8099390				2022-12-28	WOS:A1993LG24200014
J	SCOTT, M; GROTH, D; FOSTER, D; TORCHIA, M; YANG, SL; DEARMOND, SJ; PRUSINER, SB				SCOTT, M; GROTH, D; FOSTER, D; TORCHIA, M; YANG, SL; DEARMOND, SJ; PRUSINER, SB			PROPAGATION OF PRIONS WITH ARTIFICIAL PROPERTIES IN TRANSGENIC MICE EXPRESSING CHIMERIC PRP GENES	CELL			English	Article							SCRAPIE AGENT; SECONDARY STRUCTURE; MOUSE SCRAPIE; PROTEINS; HAMSTERS; TRANSMISSION; PURIFICATION; INFECTIVITY; STRAINS; ASSAY	Transgenic mice expressing chimeric prion protein (PrP) genes derived from Syrian hamster (SHa) and mouse (Mo) PrP genes were constructed. One SHa/MoPrP gene, designated MH2M PrP, contains five amino acid substitutions encoded by SHaPrP, while another construct, designated MHM2 PrP, has two substitutions. Transgenic (Tg) (MH2M PrP) mice were susceptible to both Syrian hamster and mouse prions, whereas three lines expressing MHM2 PrP were resistant to Syrian hamster prions. The brains of Tg(MH2M PrP) mice dying of scrapie contained chimeric PrP(Sc) and prions with an artificial host range favoring propagation in mice that express the corresponding chimeric PrP and were also transmissible, at reduced efficiency, to nontransgenic mice and hamsters. Our findings provide genetic evidence for homophilic interactions between PrP(Sc) in the inoculum and PrP(c) synthesized by the host.	UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	SCOTT, M (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT NEUROL,SAN FRANCISCO,CA 94143, USA.				NIA NIH HHS [AG08967, AG02132] Funding Source: Medline; NINDS NIH HHS [NS14069] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS014069, P01NS014069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R35AG008967, P01AG002132] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARRY RA, 1986, J INFECT DIS, V154, P518, DOI 10.1093/infdis/154.3.518; BAZAN JF, 1987, PROTEIN ENG, V1, P125, DOI 10.1093/protein/1.2.125; BRUCE ME, 1987, J GEN VIROL, V68, P79, DOI 10.1099/0022-1317-68-1-79; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; CARLSON GA, 1986, CELL, V46, P503, DOI 10.1016/0092-8674(86)90875-5; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; CHANDLER RL, 1961, LANCET, V1, P1378; Dickinson A. G., 1976, Slow virus diseases of animals and man,, P209; Dickinson A. G., 1979, Slow transmissible diseases of the nervous system. Volume 1., P367; DICKINSON AG, 1988, CIBA F SYMP, V135, P63; GABIZON R, 1988, P NATL ACAD SCI USA, V85, P6617, DOI 10.1073/pnas.85.18.6617; GABIZON R, 1987, P NATL ACAD SCI USA, V84, P4017, DOI 10.1073/pnas.84.12.4017; GASSET M, 1993, P NATL ACAD SCI USA, V90, P1, DOI 10.1073/pnas.90.1.1; GASSET M, 1992, P NATL ACAD SCI USA, V89, P10940, DOI 10.1073/pnas.89.22.10940; HECKER R, 1992, GENE DEV, V6, P1213, DOI 10.1101/gad.6.7.1213; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; KIMBERLIN RH, 1978, J GEN VIROL, V39, P487, DOI 10.1099/0022-1317-39-3-487; KIMBERLIN RH, 1987, J GEN VIROL, V68, P1875, DOI 10.1099/0022-1317-68-7-1875; KIMBERLIN RH, 1989, J GEN VIROL, V70, P2017, DOI 10.1099/0022-1317-70-8-2017; LOWENSTEIN DH, 1990, MOL CELL BIOL, V10, P1153, DOI 10.1128/MCB.10.3.1153; MARSH RF, 1975, J INFECT DIS, V131, P104, DOI 10.1093/infdis/131.2.104; MARSH RF, 1977, FED PROC, V37, P2076; PATTISON IH, 1968, RES VET SCI, V9, P408; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1982, BIOCHEMISTRY-US, V21, P6942, DOI 10.1021/bi00269a050; PRUSINER SB, 1982, ANN NEUROL, V11, P353, DOI 10.1002/ana.410110406; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; PRUSINER SB, 1980, BIOCHEMISTRY-US, V19, P4883, DOI 10.1021/bi00562a028; ROGERS M, 1991, J IMMUNOL, V147, P3568; Sambrook J., 1989, MOL CLONING LAB MANU, P17; SCOTT M, 1989, CELL, V59, P847, DOI 10.1016/0092-8674(89)90608-9; SCOTT MR, 1992, PROTEIN SCI, V1, P986, DOI 10.1002/pro.5560010804; SERBAN D, 1990, NEUROLOGY, V40, P110, DOI 10.1212/WNL.40.1.110; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; TARABOULOS A, 1990, P NATL ACAD SCI USA, V87, P8262, DOI 10.1073/pnas.87.21.8262; TARABOULOS A, 1992, P NATL ACAD SCI USA, V89, P7620, DOI 10.1073/pnas.89.16.7620; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	38	285	301	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 4	1993	73	5					979	988		10.1016/0092-8674(93)90275-U	http://dx.doi.org/10.1016/0092-8674(93)90275-U			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LF061	8098995	Bronze			2022-12-28	WOS:A1993LF06100013
J	WAGNER, JJ; TERMAN, GW; CHAVKIN, C				WAGNER, JJ; TERMAN, GW; CHAVKIN, C			ENDOGENOUS DYNORPHINS INHIBIT EXCITATORY NEUROTRANSMISSION AND BLOCK LTP INDUCTION IN THE HIPPOCAMPUS	NATURE			English	Article							GUINEA-PIG; RAT HIPPOCAMPUS; PERFORANT PATH; MOSSY FIBERS; AGED RATS; RECEPTOR; PEPTIDES; MEMORY; IMMUNOREACTIVITY; TRANSMISSION	ALTHOUGH anatomical and neurochemical studies suggest that endogenous opioids act as neurotransmitters1-7, their roles in normal and pathophysiological regulation of synaptic transmission are not defined. Here we examine the actions of prodynorphin-derived opioid peptides in the guinea-pig hippocampus and show that physiological stimulation of the dynorphin-containing dentate granule cells can release endogenous dynorphins, which then activate kappa1 opioid receptors present in the molecular layer of the dentate gyrus. Activation of kappa1 receptors by either pharmacologically applied agonist or endogenously released peptide reduces excitatory transmission in the dentate gyrus, as shown by a reduction in the excitatory postsynaptic currents evoked by stimulation of the perforant path, a principal excitatory afferent. In addition, released dynorphin peptides were found to block the induction of long-term potentiation (LTP) at the granule cell-perforant path synapse. The results indicate that endogenous dynorphins function in this hippocampal circuit, as retrograde, inhibitory neurotransmitters.	UNIV WASHINGTON,DEPT PHARMACOL,SJ-30,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT ANESTHESIOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle			Wagner, John J/U-9056-2018; Chavkin, Charles/G-2797-2010	Wagner, John J/0000-0002-2552-3727; 	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004123] Funding Source: NIH RePORTER; NIDA NIH HHS [R01 DA004123-11A1, R01 DA004123-13, R01 DA004123-14, R01 DA004123-12, R01 DA004123, R01 DA004123-15] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; BRAMHAM CR, 1991, BRAIN RES, V567, P42, DOI 10.1016/0006-8993(91)91433-2; CHAVKIN C, 1983, P NATL ACAD SCI-BIOL, V80, P7669, DOI 10.1073/pnas.80.24.7669; CHAVKIN C, 1985, J NEUROSCI, V5, P808; COLLIER TJ, 1984, BRAIN RES, V310, P384, DOI 10.1016/0006-8993(84)90166-5; CRONIN J, 1992, BRAIN RES, V573, P305, DOI 10.1016/0006-8993(92)90777-7; DECKER MW, 1991, SYNAPSE, V7, P151, DOI 10.1002/syn.890070209; EVANS CJ, 1985, J NEUROSCI, V5, P3423; GALL C, 1981, J COMP NEUROL, V198, P335, DOI 10.1002/cne.901980211; GALLAGHER M, 1985, BEHAV NEURAL BIOL, V44, P374, DOI 10.1016/S0163-1047(85)90688-0; HOUSER CR, 1990, J NEUROSCI, V10, P267; JAN LY, 1982, J PHYSIOL-LONDON, V327, P219, DOI 10.1113/jphysiol.1982.sp014228; JIANG HK, 1989, P NATL ACAD SCI USA, V86, P2948, DOI 10.1073/pnas.86.8.2948; JONES LS, 1991, BRAIN RES, V564, P336, DOI 10.1016/0006-8993(91)91473-E; LAHTI RA, 1985, EUR J PHARMACOL, V109, P281, DOI 10.1016/0014-2999(85)90431-5; LUNDBERG JM, 1986, NEUROSCI LETT, V63, P96, DOI 10.1016/0304-3940(86)90020-0; LYNCH G, 1984, SCIENCE, V224, P1057, DOI 10.1126/science.6144182; MADISON DV, 1991, REV NEUROSCI, V14, P379; MARTINEZ JL, 1990, NIDA RES MG, V97, P48; MCGINTY JF, 1983, P NATL ACAD SCI-BIOL, V80, P589, DOI 10.1073/pnas.80.2.589; MCLEAN S, 1987, J COMP NEUROL, V255, P497, DOI 10.1002/cne.902550403; NOCK B, 1990, J PHARMACOL EXP THER, V254, P412; PORTOGHESE PS, 1987, LIFE SCI, V40, P1287, DOI 10.1016/0024-3205(87)90585-6; SINGH L, 1990, EUR J PHARMACOL, V191, P477, DOI 10.1016/0014-2999(90)94183-X; SLOVITER RS, 1992, NEUROSCI LETT, V137, P91, DOI 10.1016/0304-3940(92)90306-R; TORTELLA FC, 1988, TRENDS PHARMACOL SCI, V9, P366, DOI 10.1016/0165-6147(88)90256-8; WAGNER JJ, 1991, J NEUROCHEM, V57, P333, DOI 10.1111/j.1471-4159.1991.tb02132.x; WAGNER JJ, 1992, J NEUROSCI, V12, P132; WEISSKOPF MG, 1993, NATURE, V362, P423, DOI 10.1038/362423a0; XIE CW, 1991, J PHARMACOL EXP THER, V256, P289; ZUKIN RS, 1988, P NATL ACAD SCI USA, V85, P4061, DOI 10.1073/pnas.85.11.4061	31	235	237	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 3	1993	363	6428					451	454		10.1038/363451a0	http://dx.doi.org/10.1038/363451a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LE938	8099201	Green Accepted			2022-12-28	WOS:A1993LE93800059
J	JORGENSEN, JOL; CHRISTIANSEN, JS				JORGENSEN, JOL; CHRISTIANSEN, JS			GROWTH-HORMONE THERAPY - BRAVE NEW SENESCENCE - GH IN ADULTS	LANCET			English	Note											JORGENSEN, JOL (corresponding author), AARHUS KOMMUNE HOSP,DEPT MED M ENDOCRINOL & DIABET,DK-8000 AARHUS,DENMARK.		Jorgensen, Jens Otto Lunde/O-8003-2019					BOWERS CY, 1992, J CLIN ENDOCR METAB, V74, P292, DOI 10.1210/jc.74.2.292; CORPAS E, 1993, J CLIN ENDOCR METAB, V76, P134, DOI 10.1210/jc.76.1.134; CUNEO RC, 1992, CLIN ENDOCRINOL, V37, P387, DOI 10.1111/j.1365-2265.1992.tb02347.x; JORGENSEN JOL, 1989, LANCET, V1, P1221; RUDMAN D, 1990, NEW ENGL J MED, V323, P1, DOI 10.1056/NEJM199007053230101; RUDMAN D, 1985, J AM GERIATR SOC, V33, P800, DOI 10.1111/j.1532-5415.1985.tb04195.x; ZIEGLER TR, 1992, J CLIN ENDOCR METAB, V74, P865, DOI 10.1210/jc.74.4.865	7	15	15	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 15	1993	341	8855					1247	1248						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LC497	8098396				2022-12-28	WOS:A1993LC49700008
J	GALLOWAY, J				GALLOWAY, J			DENTAL IMPRESSIONS	LANCET			English	Editorial Material											GALLOWAY, J (corresponding author), NUFFIELD FDN,LONDON,ENGLAND.							ED TRAINING PERSONNE	1	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 9	1993	342	8876					881	882		10.1016/0140-6736(93)91941-E	http://dx.doi.org/10.1016/0140-6736(93)91941-E			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA963	8105162				2022-12-28	WOS:A1993MA96300005
J	KETLEY, D; WOODS, KL				KETLEY, D; WOODS, KL			IMPACT OF CLINICAL-TRIALS ON CLINICAL-PRACTICE - EXAMPLE OF THROMBOLYSIS FOR ACUTE MYOCARDIAL-INFARCTION	LANCET			English	Article							INFLUENCE MEDICAL-PRACTICE; THERAPY	Little is known about incorporation of new knowledge from randomised clinical trials into clinical practice. Thrombolytic therapy was shown to reduce the mortality of acute myocardial infarction in several large trials published during 1986-88. To examine the effect of these data on clinical practice, we analysed the supply of thrombolytic drugs in a representative English region (population 4.7 million) in 1987-92. During the study period there were over 10 000 hospital admissions per year in the region for acute myocardial infarction. From a very low initial level, thrombolytic drug use rose slowly for several years after publication of the trial results and reached a plateau in 1991-92. Rates of use per 1000 patients admitted with myocardial infarction varied almost six-fold between districts in 1989-90 and over two-fold in 1991-92. Level of use attained by districts in the latter period was strongly associated with the extent of their previous participation in multicentre trials of thrombolysis (p = 0.003); we estimate that 35-50% of patients admitted with acute myocardial infarction were receiving thrombolytics. The full potential of thrombolytic treatment has still not been achieved in routine care and the limiting factors need to be defined.	LEICESTER ROYAL INFIRM, DEPT PHARMACOL & THERAPEUT, CLIN SCI BLDG, LEICESTER LE2 7LX, ENGLAND; LEICESTER ROYAL INFIRM, DEPT PHARM, LEICESTER LE2 7LX, ENGLAND	University of Leicester; University of Leicester								[Anonymous], 1987, Lancet, V2, P871; [Anonymous], 1988, LANCET, V2, P349; BIRKHEAD JS, 1992, BMJ-BRIT MED J, V305, P445, DOI 10.1136/bmj.305.6851.445; BOISSEL JP, 1989, CONTROL CLIN TRIALS, V10, pS120; BOISSEL JP, 1990, ARCH MAL COEUR VAISS, V83, P1777; BRAUNWALD E, 1990, CIRCULATION, V82, P1510, DOI 10.1161/01.CIR.82.4.1510; BURRELL CJ, 1990, BMJ-BRIT MED J, V300, P237, DOI 10.1136/bmj.300.6719.237; CHAMBERLAIN DA, 1988, LANCET, V1, P545; COLLINS R, 1991, BRIT HEART J, V66, P250; FINEBERG HV, 1987, B CANCER, V74, P333; FRIEDMAN L, 1983, CONTROL CLIN TRIALS, V4, P513, DOI 10.1016/0197-2456(83)90032-6; GRAY D, 1993, LANCET, V341, P654, DOI 10.1016/0140-6736(93)90420-L; Haigh R, 1991, Health Trends, V23, P154; HENDRA TJ, 1992, BMJ-BRIT MED J, V304, P423, DOI 10.1136/bmj.304.6824.423; HLATKY MA, 1988, AM J CARDIOL, V61, P510, DOI 10.1016/0002-9149(88)90755-2; LAMAS GA, 1992, NEW ENGL J MED, V327, P241, DOI 10.1056/NEJM199207233270405; PFEFFER MA, 1991, JAMA-J AM MED ASSOC, V266, P528, DOI 10.1001/jama.266.4.528; WILCOX RG, 1988, LANCET, V2, P525; 1986, LANCET, V1, P398; 1987, LANCET, V1, P502	20	204	204	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 9	1993	342	8876					891	894		10.1016/0140-6736(93)91945-I	http://dx.doi.org/10.1016/0140-6736(93)91945-I			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA963	8105166				2022-12-28	WOS:A1993MA96300009
J	ROZGA, J; PODESTA, L; LEPAGE, E; HOFFMAN, A; MORSIANI, E; SHER, L; WOOLF, GM; MAKOWKA, L; DEMETRIOU, AA				ROZGA, J; PODESTA, L; LEPAGE, E; HOFFMAN, A; MORSIANI, E; SHER, L; WOOLF, GM; MAKOWKA, L; DEMETRIOU, AA			CONTROL OF CEREBRAL EDEMA BY TOTAL HEPATECTOMY AND EXTRACORPOREAL LIVER SUPPORT IN FULMINANT HEPATIC-FAILURE	LANCET			English	Note								Keeping a patient with fulminant hepatic failure (FHF) alive until a donor liver is available for transplantation can be a problem. We describe an 18-year-old woman with paracetamol-induced FHF, who was treated by total hepatectomy, hypothermia, plasma exchange, and extracorporeal liver support. The patient was anhepatic for 14 h. The liver-support system consisted of plasma separation and perfusion through a charcoal filter and a hollow-fibre module seeded with matrix-attached porcine hepatocytes. With artificial liver treatment there was reversal of severe neurological dysfunction, normalisation of intracranial pressure, and decreased serum ammonia. The patient underwent emergency transplantation with an ABO-incompatible liver, followed by transplantation with a compatible organ eight days later. The patient has fully recovered and is neurologically intact.	CEDARS SINAI MED CTR,LIVER SUPPORT UNIT,8700 BEVERLY BLVD,LOS ANGELES,CA 90048	Cedars Sinai Medical Center					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038763] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38763-08] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		NEUZIL DF, 1993, SURGERY, V113, P340; OGRADY JG, 1988, GASTROENTEROLOGY, V94, P1186, DOI 10.1016/0016-5085(88)90011-X; RINGE B, 1993, TRANSPLANT P, V25, P1090; ROZGA J, 1993, HEPATOLOGY, V17, P258, DOI 10.1016/0270-9139(93)90086-3; ROZGA J, 1993, ANN SURG, V217, P502, DOI 10.1097/00000658-199305010-00010; SO SKS, 1993, TRANSPLANT P, V25, P1962	6	126	131	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 9	1993	342	8876					898	899		10.1016/0140-6736(93)91947-K	http://dx.doi.org/10.1016/0140-6736(93)91947-K			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA963	8105168				2022-12-28	WOS:A1993MA96300011
J	EDWARDS, R				EDWARDS, R			COMPETING IN DRUG SAFETY	LANCET			English	Editorial Material											EDWARDS, R (corresponding author), WHO,COLLABORATING CTR INT DRUG MONITORING,UPPSALA,SWEDEN.							WALLER PC, 1992, BRIT MED J, V304, P1470, DOI 10.1136/bmj.304.6840.1470	1	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 11	1993	342	8872					631	632		10.1016/0140-6736(93)91755-B	http://dx.doi.org/10.1016/0140-6736(93)91755-B			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX272	8103142				2022-12-28	WOS:A1993LX27200006
J	DIXON, M				DIXON, M			ACID, ULCERS, AND HELICOBACTER-PYLORI	LANCET			English	Editorial Material							HELICOBACTER-PYLORI				DIXON, M (corresponding author), UNIV LEEDS,ACAD UNIT PATHOL SCI,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND.							CARD WI, 1960, CLIN SCI, V19, P147; DIXON MF, 1991, J GASTROEN HEPATOL, V6, P125, DOI 10.1111/j.1440-1746.1991.tb01451.x; DIXON MF, 1992, IRISH J MED SCI S10, V161, P11; ELOMAR E, 1993, GUT, V34, P1060, DOI 10.1136/gut.34.8.1060; ELOMAR E, 1993, GASTROENTEROLOGY, V104, pA75; Kramling H J, 1987, Adv Exp Med Biol, V216A, P427; MCCOLL KEL, 1993, GUT, V34, P762, DOI 10.1136/gut.34.6.762; MITCHELL HM, 1992, J INFECT DIS, V166, P149, DOI 10.1093/infdis/166.1.149; MOSS SF, 1993, GUT, V34, P888, DOI 10.1136/gut.34.7.888; MOSS SF, 1992, LANCET, V340, P930, DOI 10.1016/0140-6736(92)92816-X; MULHOLLAND G, 1993, GUT, V34, P757, DOI 10.1136/gut.34.6.757; SIPPONEN P, 1989, GUT, V30, P922, DOI 10.1136/gut.30.7.922; WYATT JI, 1987, J CLIN PATHOL, V40, P841, DOI 10.1136/jcp.40.8.841; WYATT JI, 1990, J CLIN PATHOL, V43, P981, DOI 10.1136/jcp.43.12.981; 1992, GUT, V34, P604	15	34	34	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 14	1993	342	8868					384	385						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR900	8101896				2022-12-28	WOS:A1993LR90000004
J	MORENO, S; BARAIAETXABURU, J; BOUZA, E; PARRAS, F; PEREZTASCON, M; MIRALLES, P; VICENTE, T; ALBERDI, JC; COSIN, J; LOPEZGAY, D				MORENO, S; BARAIAETXABURU, J; BOUZA, E; PARRAS, F; PEREZTASCON, M; MIRALLES, P; VICENTE, T; ALBERDI, JC; COSIN, J; LOPEZGAY, D			RISK FOR DEVELOPING TUBERCULOSIS AMONG ANERGIC PATIENTS INFECTED WITH HIV	ANNALS OF INTERNAL MEDICINE			English	Article						HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS; TUBERCULOSIS; HYPERSENSITIVITY, DELAYED; TUBERCULIN TEST; SKIN TESTS	HUMAN-IMMUNODEFICIENCY-VIRUS; AIDS; EPIDEMIC; SPAIN	Objective: To assess the risk for development of tuberculosis among anergic pa Design: Retrospective cohort study. Setting: Tertiary referral center. Patients: All HIV-infected patients who had a base-line positive protein purified derivative test (PPD) and delayed-type hypersensitivity skin tests. Measurements: Development of active tuberculosis. Results: Of 374 patients, 108 (29%) had positive results of PPD tests, 154 (41%) had negative results of PPD tests but no skin anergy, and 112 (30%) were anergic. Conversion of the PPD to positive was observed in 10 of 67 (15%) patients with previously negative results of PPD tests and no anergy and in 3 of 36 (8%) anergic patients who were retested during the follow-up period (mean, 26 months). The risk for active tuberculosis to develop in patients not receiving isoniazid chemoprophylaxis was similar in patients with a positive PPD test result (10.4 cases per 100 person-years) and in anergic patients (12.4 cases per 100 person-years) and higher in both groups than in nonanergic patients with a negative PPD test result (5.4 cases per 100 person-years). Tuberculosis was more frequent among intravenous drug abusers with no previous isoniazid treatment (63 of 290, 22%) than among homosexual men (0 of 29) or patients in other HIV transmission categories (0 of 31). Preventive therapy with isoniazid reduced tuberculosis development (4% as compared with 31 %; P = 0.008). Among 15 anergic patients who had CD4 counts measured within 3 months of tuberculosis development, only 1 (7%) had more than 500 CD4 cells/mm3. Conclusions: Anergic HIV-infected patients are at high risk for development of tuberculosis. Anergic HIV-infected patients, in addition to HIV-infected patients with positive results of PPD tests, should be offered preventive therapy if they live in areas with a high prevalence of tuberculosis, at least when the CD4 count decreases to less than 500 CD4 cells/mm3.	CONSEJERIA SALUD COMUNIDAD AUTONOMA, MADRID, SPAIN		MORENO, S (corresponding author), HOSP GREGORIO MARANON, SERV MICROBIOL CLIN, DR ESQUERDO 46, E-28007 MADRID, SPAIN.		Bouza, Emilio/D-8661-2014	Bouza, Emilio/0000-0001-6967-9267				AYUELA PD, 1990, REV CLIN ESP, V186, P365; BARNES PF, 1991, NEW ENGL J MED, V325, P1884; BERENGUER J, 1992, NEW ENGL J MED, V326, P668, DOI 10.1056/NEJM199203053261004; BOUZA E, 1988, EUR J CLIN MICROBIOL, V7, P785, DOI 10.1007/BF01975050; COLEBUNDERS RL, 1989, AM REV RESPIR DIS, V139, P1082, DOI 10.1164/ajrccm/139.5.1082; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DEVENDRA W, 1991, 7 P INT C AIDS FLOR; DIPERRI G, 1989, LANCET, V2, P1502; DIPERRI G, 1991, NEW ENGL J MED, V325, P1882; GUELAR A, 1991, 31ST INT C ANT AG CH; JORDAN TJ, 1991, JAMA-J AM MED ASSOC, V265, P2987, DOI 10.1001/jama.265.22.2987; PITCHENIK AE, 1990, ANN INTERN MED, V113, P89, DOI 10.7326/0003-4819-113-2-89; PITCHENIK AE, 1987, AM REV RESPIR DIS, V135, P875, DOI 10.1164/arrd.1987.135.4.875; RIEDER HL, 1989, JAMA-J AM MED ASSOC, V262, P385, DOI 10.1001/jama.262.3.385; Rothman K, 1986, MODERN EPIDEMIOLOGY; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; THEUER CP, 1990, J INFECT DIS, V162, P8, DOI 10.1093/infdis/162.1.8; 1991, MMWR MORB MORTAL WKL, V40, P27; 1989, MMWR MORB MORTAL WKL, V38, P236; 1989, MMWR MORB MORTAL WKL, V38, P243; 1991, VIGILANCIA EPIDEMIOL	21	171	173	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1993	119	3					194	198		10.7326/0003-4819-119-3-199308010-00003	http://dx.doi.org/10.7326/0003-4819-119-3-199308010-00003			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU903	8100693				2022-12-28	WOS:A1993LU90300003
J	SHAPER, AG				SHAPER, AG			WHATS NEW IN ENDOMYOCARDIAL FIBROSIS	LANCET			English	Editorial Material											SHAPER, AG (corresponding author), ROYAL FREE HOSP,SCH MED,LONDON,ENGLAND.							VALIATHAN MS, 1993, ENDOMYOCARDIAL FIBRO, P302	1	14	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 31	1993	342	8866					255	256		10.1016/0140-6736(93)91813-2	http://dx.doi.org/10.1016/0140-6736(93)91813-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ163	8101298				2022-12-28	WOS:A1993LQ16300006
J	HEPBURN, NC; SIDDIQUE, I; HOWIE, AF; BECKETT, GJ; HAYES, PC				HEPBURN, NC; SIDDIQUE, I; HOWIE, AF; BECKETT, GJ; HAYES, PC			HEPATOTOXICITY OF SODIUM STIBOGLUCONATE IN LEISHMANIASIS	LANCET			English	Letter									ROYAL EDINBURGH & ASSOCIATED HOSP,DEPT MED,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND; ROYAL EDINBURGH & ASSOCIATED HOSP,DEPT CLIN BIOCHEM,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND	Royal Infirmary of Edinburgh; Royal Infirmary of Edinburgh	HEPBURN, NC (corresponding author), ROYAL EDINBURGH & ASSOCIATED HOSP,DEPT DERMATOL,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND.		Siddique, Imran/ACG-3403-2022	Siddique, Imran/0000-0002-5060-7906				BALLOU WR, 1987, LANCET, V2, P13; BECKETT GJ, 1993, ADV CLIN CHEM, V30, P279; CHUNGE CN, 1990, T ROY SOC TROP MED H, V84, P221, DOI 10.1016/0035-9203(90)90263-E; HAYES JD, 1983, CLIN CHIM ACTA, V134, P107, DOI 10.1016/0009-8981(83)90189-4; HAYES PC, 1989, CLIN CHEM ENZYM COMM, V2, P23; HEPBURN NC, 1993, BRIT J DERMATOL, V128, P63, DOI 10.1111/j.1365-2133.1993.tb00149.x; RENNER E, 1984, HEPATOLOGY, V4, P38, DOI 10.1002/hep.1840040107	7	20	20	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 24	1993	342	8865					238	239		10.1016/0140-6736(93)92327-P	http://dx.doi.org/10.1016/0140-6736(93)92327-P			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN622	8100955				2022-12-28	WOS:A1993LN62200037
J	MANCHESTER, D				MANCHESTER, D			NEUROLEPTICS, LEARNING-DISABILITY, AND THE COMMUNITY - SOME HISTORY AND MYSTERY	BRITISH MEDICAL JOURNAL			English	Article							PSYCHOACTIVE DRUG-USE; MENTALLY-HANDICAPPED PATIENTS; RESIDENTIAL FACILITIES; PSYCHOTROPIC-DRUGS; RETARDATION; PSYCHOPHARMACOLOGY; DETERMINANTS; INSTITUTION; HOSPITALS; BEHAVIORS	Recent papers have again highlighted the consistently high use of neuroleptic agents among people with a learning disability, despite the lack of good evidence to support their role in this population for behaviour management and despite the risks of such medication. Evidence suggests, however, that prescribing habits have remained relatively unchanged; the reasons for this are poorly understood. Given the lack of understanding about the factors contributing to such drug use, and the possibility that use of neuroleptics will increase as people with learning disabilities move into the community, there seems a clear need for clinical guidelines to cover the prescribing and monitoring of neuroleptics within this group. Such guidelines should also ensure that reviews, using reliable measures of treatment efficacy, are carried out regularly.			MANCHESTER, D (corresponding author), CLIFTON HOSP,YORK CLIN PSYCHOL SERV,YORK YO3 6RD,ENGLAND.							AGRAN M, 1985, PSYCHOPHARMACOL BULL, V21, P285; AMAN MG, 1989, TREATMENT PSYCHIAT D, P71; Aman MG, 1983, TREATMENT ISSUES INN, P455; BALLINGER BR, 1991, BRIT J PSYCHIAT, V158, P251, DOI 10.1192/bjp.158.2.251; BIRD F, 1989, AM J MENT RETARD, V94, P37; BRIGGS R, 1989, AM J MENT RETARD, V93, P633; BURGIO LD, 1985, J APPL BEHAV ANAL, V18, P45, DOI 10.1901/jaba.1985.18-45; CHADSEYRUSCH J, 1989, AM J MENT RETARD, V93, P607; CLARKE DJ, 1990, J MENT DEFIC RES, V34, P385; DAVIS VJ, 1982, DRUGS MENTAL RETARDA; DEB S, 1991, BRIT J PSYCHIAT, V159, P826, DOI 10.1192/bjp.159.6.826; DUKER PC, 1986, AM J MENT RETARD, V91, P51; FAN TW, 1991, BRIT J PSYCHIAT, V158, P282, DOI 10.1192/bjp.158.2.282; FELCE D, 1991, RES DEV DISABIL, V12, P315, DOI 10.1016/0891-4222(91)90015-K; GARDNER WI, 1989, HDB BEHAVIOUR MODIFI, P225; GUALTIERI CT, 1985, PSYCHOPHARMACOL BULL, V21, P304; HANCOCK RD, 1991, AM J MENT RETARD, V96, P137; HARRISONREID P, 1984, ASPECTS PSYCHOPHARMA; HARVEY JR, 1979, MENT RETARD      APR, P71; HEATONWARD A, 1977, BRIT J PSYCHIAT, V130, P525, DOI 10.1192/bjp.130.6.525; HILL BK, 1985, PSYCHOPHARMACOL BULL, V21, P279; HOLDEN C, 1987, SCIENCE, V235, P1566, DOI 10.1126/science.2881355; INTAGLIATA J, 1985, PSYCHOPHARMACOL BULL, V21, P268; JACOBSON JW, 1990, AM J MENT RETARD, V94, P596; JAMES DH, 1983, BRIT J PSYCHIAT, V142, P163, DOI 10.1192/bjp.142.2.163; KEPPEL JM, 1988, TREATMENTS PSYCHIATR, P68; LINAKER OM, 1990, BRIT J PSYCHIAT, V156, P525, DOI 10.1192/bjp.156.4.525; MARTIN JE, 1985, APPL RES MENT RETARD, V6, P33, DOI 10.1016/S0270-3092(85)80020-5; MATSON JL, 1978, BEHAV MODIF, V2, P61, DOI 10.1177/014544557821004; MEADOWS G, 1991, BRIT J PSYCHIAT, V158, P103, DOI 10.1192/bjp.158.1.103; MOUCHKA S, 1985, PSYCHOPHARMACOL BULL, V21, P262; PARKER G, 1991, MED J AUSTRALIA, V155, P68, DOI 10.5694/j.1326-5377.1991.tb142125.x; RINCK C, 1989, AM J MENT RETARD, V93, P657; RYAN M, 1991, Australia and New Zealand Journal of Developmental Disabilities, V17, P177; SACHDEV PS, 1991, MED J AUSTRALIA, V155, P75, DOI 10.5694/j.1326-5377.1991.tb142129.x; SHRIQUI CL, 1990, CAN J PSYCHIAT, V35, P576, DOI 10.1177/070674379003500702; THINN K, 1990, J MENT DEFIC RES, V34, P397; WHITMAN TL, 1990, HDB BEHAV MODIFICATI, P9; WRESSELL SE, 1990, BRIT J PSYCHIAT, V157, P101, DOI 10.1192/bjp.157.1.101; ZAHARIA ES, 1991, MENT RETARD, V29, P191	40	20	20	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 17	1993	307	6897					184	187		10.1136/bmj.307.6897.184	http://dx.doi.org/10.1136/bmj.307.6897.184			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LN184	8102074	Green Published, Bronze			2022-12-28	WOS:A1993LN18400027
J	ROBERTS, JW; HOEG, JM; MOURADIAN, MM; LINFANTE, I; CHASE, TN				ROBERTS, JW; HOEG, JM; MOURADIAN, MM; LINFANTE, I; CHASE, TN			IATROGENIC HYPERLIPEMIA WITH G(M1) GANGLIOSIDE	LANCET			English	Letter									NHLBI,MOLEC DIS BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	ROBERTS, JW (corresponding author), NINCDS,EXPTL THERAPEUT BRANCH,BETHESDA,MD 20892, USA.							GEISLER FH, 1991, NEW ENGL J MED, V324, P1829, DOI 10.1056/NEJM199106273242601; SCHNEIDER JS, 1992, SCIENCE, V256, P843, DOI 10.1126/science.1350379	2	9	10	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 10	1993	342	8863					115	115		10.1016/0140-6736(93)91316-E	http://dx.doi.org/10.1016/0140-6736(93)91316-E			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LL789	8100881				2022-12-28	WOS:A1993LL78900041
J	SCHWARTZ, DH; GORSE, G; CLEMENTS, ML; BELSHE, R; IZU, A; DULIEGE, AM; BERMAN, P; TWADDELL, T; STABLEIN, D; SPOSTO, R; SILICIANO, R; MATTHEWS, T				SCHWARTZ, DH; GORSE, G; CLEMENTS, ML; BELSHE, R; IZU, A; DULIEGE, AM; BERMAN, P; TWADDELL, T; STABLEIN, D; SPOSTO, R; SILICIANO, R; MATTHEWS, T			INDUCTION OF HIV-1-NEUTRALIZING AND SYNCYTIUM-INHIBITING ANTIBODIES IN UNINFECTED RECIPIENTS OF HIV-1(IIIB) RGP120-SUBUNIT VACCINE	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HEPATITIS-B VACCINATION; HIV-1; GLYCOPROTEIN; SPREAD; SAFETY; GP160; AGE	A recombinant human immunodeficiency virus 1 IIIB(HIV-1IIIB) gp120 subunit vaccine (IIIB-rgp120/HIV-1, Genentech) was tested for safety and immunogenicity in a randomised, double-blind, placebo-controlled phase-I trial. HIV-1-seronegative adult volunteers received three 100 mug or 300 mug doses of IIIB-rgp120/HIV-1 in alum adjuvant (10 vaccinees in each group), or alum adjuvant alone (8 vaccinees), at 0, 4, and 32 weeks by intramuscular injection. The three injections were well tolerated in both vaccine groups. Antibodies that neutralised homologous HIV-1IIIB were induced in 9 of 10 recipients after three 300 mug doses, and 6 of these 9 sera also neutralised heterologous HIV-1SF2. A dose response was evident, since three 100 mug injections induced lower titres of HIV-1IIIB neutralising antibodies and in fewer recipients (5 of 9) than the higher dose, with no neutralisation of HIV-1SF2. Similarly, syncytia-inhibiting, CD4-rgp120-blocking, and HIV-1IIIB V3-binding antibodies were induced in a dose dependent manner. Response to the 300 mug per dose vaccination occurred in a larger proportion of volunteers and at higher mean titres than seen in previous human trials with other recombinant envelope subunit vaccines or live vaccinia-env priming followed by envelope subunit boosting.	GENENTECH INC,S SAN FRANCISCO,CA; EMMES CORP,POTOMAC,MD; ST LOUIS UNIV,MED CTR,DEPT INFECT DIS,ST LOUIS,MO 63103; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; DUKE UNIV,MED CTR,DEPT SURG,DURHAM,NC 27710	Roche Holding; Genentech; Emmes Corporation; Saint Louis University; Johns Hopkins University; Duke University	SCHWARTZ, DH (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,CTR IMMUNIZAT RES,624 N BROADWAY,125 HAMPTON HOUSE,BALTIMORE,MD 21205, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI005064, N01AI005061] Funding Source: NIH RePORTER; NIAID NIH HHS [NIAID N01-AI-05064, NIAID N01-AI-05061] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON RM, 1991, NATURE, V352, P581, DOI 10.1038/352581a0; BERMAN PW, 1992, J VIROL, V66, P4464, DOI 10.1128/JVI.66.7.4464-4469.1992; BERMAN PW, 1990, NATURE, V345, P622, DOI 10.1038/345622a0; BEYER WEP, 1989, VACCINE, V7, P385, DOI 10.1016/0264-410X(89)90150-3; COONEY EL, 1991, LANCET, V337, P567, DOI 10.1016/0140-6736(91)91636-9; DENIS F, 1984, J INFECT DIS, V149, P1019, DOI 10.1093/infdis/149.6.1019; DOLIN R, 1991, ANN INTERN MED, V114, P119, DOI 10.7326/0003-4819-114-2-119; GORSE GJ, 1992, VACCINE, V10, P383, DOI 10.1016/0264-410X(92)90068-U; GRAHAM BS, 1992, J INFECT DIS, V166, P244, DOI 10.1093/infdis/166.2.244; POTTS M, 1991, LANCET, V338, P608, DOI 10.1016/0140-6736(91)90614-U; POWERS DC, 1990, GERIATRIC SURGERY CO, P173; SHAW FE, 1989, VACCINE, V7, P425, DOI 10.1016/0264-410X(89)90157-6; TORRE D, 1984, LANCET, V2, P866	13	121	125	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 10	1993	342	8863					69	73		10.1016/0140-6736(93)91283-R	http://dx.doi.org/10.1016/0140-6736(93)91283-R			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LL789	8100910				2022-12-28	WOS:A1993LL78900007
J	VENTO, S; DIPERRI, G; GAROFANO, T; CONCIA, E; BASSETTI, D				VENTO, S; DIPERRI, G; GAROFANO, T; CONCIA, E; BASSETTI, D			PNEUMOCYSTIS-CARINII PNEUMONIA DURING PRIMARY HIV-1 INFECTION	LANCET			English	Note							IMMUNODEFICIENCY VIRUS-INFECTION; ILLNESS	3 patients with severe CD4 lymphocytopenia (62-91 cells/muL) and inverted CD4/CD8 ratios (0.13-0.15) developed Pneumocystis carinii pneumonia during symptomatic, primary HIV-1 infection. Within four months of symptom onset, their CD4 counts and CD4/CD8 ratios returned to normal. Twenty-nine to forty-eight months after acquiring HIV-1 infection, they show no signs or symptoms of progression to AIDS. Pneumocystis carinii pneumonia can occur, therefore, in primary HIV-1 infection, and profound CD4 lymphocytopenia can revert to normal without antiretroviral therapy.	UNIV VERONA,DEPT INFECT DIS,I-37100 VERONA,ITALY; A PUGLIESE HOSP,INFECT DIS UNIT,CATANZARO,ITALY; UNIV GENOA,DEPT INFECT DIS 1,I-16126 GENOA,ITALY	University of Verona; University of Genoa			Vento, Sandro/I-1662-2017	Vento, Sandro/0000-0003-0084-4062				CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; GAINES H, 1988, BRIT MED J, V297, P1363, DOI 10.1136/bmj.297.6660.1363; GAINES H, 1990, AIDS, V4, P995, DOI 10.1097/00002030-199010000-00008; PEDERSEN C, 1989, BRIT MED J, V299, P154, DOI 10.1136/bmj.299.6692.154; PEDERSEN C, 1987, J INFECT DIS, V156, P529, DOI 10.1093/infdis/156.3.529-a; SCHECHTER MT, 1990, AIDS, V4, P185, DOI 10.1097/00002030-199003000-00002; TINDALL B, 1988, ARCH INTERN MED, V148, P945, DOI 10.1001/archinte.148.4.945; TINDALL B, 1991, AIDS, V5, P1, DOI 10.1097/00002030-199101000-00001; TINDALL B, 1989, AIDS, V3, P747, DOI 10.1097/00002030-198911000-00010; [No title captured]	10	50	52	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 3	1993	342	8862					24	25		10.1016/0140-6736(93)91884-O	http://dx.doi.org/10.1016/0140-6736(93)91884-O			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK985	8100292				2022-12-28	WOS:A1993LK98500013
J	LAURENCE, J				LAURENCE, J			T-CELL SUBSETS IN HEALTH, INFECTIOUS-DISEASE, AND IDIOPATHIC CD4+ T-LYMPHOCYTOPENIA	ANNALS OF INTERNAL MEDICINE			English	Review						T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES; CD4-CD8 RATIO; LYMPHOPENIA; IMMUNOCOMPROMISED HOST	COMMON VARIABLE IMMUNODEFICIENCY; MULTICENTER AIDS COHORT; HIV-INFECTION; MONOCLONAL-ANTIBODIES; VIRUS-INFECTION; SUBPOPULATIONS; POPULATION; HELPER; HYPOGAMMAGLOBULINEMIA; MONONUCLEOSIS	Purpose: To update our knowledge about normal absolute values for CD4+ and CD8+ peripheral T-lymphocyte subsets and to show how these values are influenced by infectious disease. These data are discussed in the context of a newly identified syndrome, idiopathic CD4+ T lymphocytopenia and severe unexplained human immunodeficiency virus (HIV)-negative immune suppression (ICL/SUHIS). Data Identification: Studies done after 1978, when T-lymphocyte subset analysis using monoclonal antibodies was introduced, identified from a MEDLARS computer search and from personal files. Study Selection: All English-language articles that included the number of patients studied; the criteria for patient selection; and the means, ranges, and standard deviations for absolute counts of peripheral T-cell subsets. Results of Data Analysis: The effects of certain bacterial, viral, parasitic, and fungal infections; analytic variance; and biologic factors on T-lymphocyte subsets must be considered in assessing such values in health and disease. Quantitative T-cell abnormalities secondary to advanced HIV infection may be dissociated from physiologic changes, congenital disorders, and most other conditions by documentation of absolute CD4 counts of less than 400/mm3, a progressive depletion of CD4 cells, and a CD4:CD8 ratio of less than 1.0. Designation of ICL/SUHIS as a new syndrome, dependent solely on CD4 cell count, raises the possibility that persons with an extraordinary diversity of conditions, including those with stable, ''physiologic'' CD4 lymphopenia, will be given the diagnosis. Conclusions: Persons with a CD4 count of less than 300 to 400/mm3, a progressive decline in absolute CD4 count, and a CD4:CD8 ratio of less than 1.0 should be aggressively investigated for HIV infection as well as for other causes of immune deficiency, regardless of intercurrent infections. The search for potential novel infectious causes in syndromes such as ICL/SUHIS may be most productive among such a subset of all persons with CD4 counts less than normal levels.			LAURENCE, J (corresponding author), CORNELL UNIV, MED CTR,COLL MED,DEPT MED,DIV HEMATOL ONCOL, 411 E 69TH ST, NEW YORK, NY 10021 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033322, R01AI029119] Funding Source: NIH RePORTER; NIAID NIH HHS [AI33322, AI-29119] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALEDORT LM, 1993, NEW ENGL J MED, V328, P441, DOI 10.1056/NEJM199302113280614; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; BAST RC, 1983, CLIN IMMUNOL IMMUNOP, V28, P101, DOI 10.1016/0090-1229(83)90193-9; BECK JS, 1985, CLIN EXP IMMUNOL, V60, P49; BLOEMENA E, 1990, CLIN EXP IMMUNOL, V80, P460; BLUMBERG RS, 1985, SEMIN HEMATOL, V22, P81; BOFILL M, 1992, CLIN EXP IMMUNOL, V88, P243, DOI 10.1111/j.1365-2249.1992.tb03068.x; BUSCH MP, 1992, TRANSFUSION, V32, P800, DOI 10.1046/j.1537-2995.1992.32993110749.x; CARNEY WP, 1981, J IMMUNOL, V126, P2114; CHUNG HT, 1986, CELL IMMUNOL, V101, P571, DOI 10.1016/0008-8749(86)90167-X; COLLIER AC, 1992, INFECT MED S, V1, P11; CUNNINGHAMRUNDLES C, 1989, J CLIN IMMUNOL, V9, P22, DOI 10.1007/BF00917124; CUTHBERT RJG, 1992, BRIT J HAEMATOL, V80, P364, DOI 10.1111/j.1365-2141.1992.tb08146.x; DEWAELE M, 1981, NEW ENGL J MED, V304, P460; DUNCAN RA, 1993, NEW ENGL J MED, V328, P393, DOI 10.1056/NEJM199302113280604; EIBL MM, 1984, NEW ENGL J MED, V310, P198; FAHEY JL, 1984, AM J MED, V76, P95, DOI 10.1016/0002-9343(84)90756-3; FERNANDEZ-CRUZ E, 1988, Clinical and Experimental Immunology, V72, P190; FERRANTE A, 1987, CLIN EXP IMMUNOL, V70, P158; FREITAS AA, 1993, IMMUNOL TODAY, V14, P25, DOI 10.1016/0167-5699(93)90320-K; GATENBY PA, 1989, LANCET, V1, P1027, DOI 10.1016/S0140-6736(89)92677-9; GELMAN R, 1993, CLIN IMMUNOL IMMUNOP, V66, P150, DOI 10.1006/clin.1993.1019; GIORGI JV, 1989, CLIN IMMUNOL IMMUNOP, V52, P10, DOI 10.1016/0090-1229(89)90188-8; GIORGI JV, 1990, CLIN IMMUNOL IMMUNOP, V55, P173, DOI 10.1016/0090-1229(90)90096-9; GOMEZ E, 1991, BLOOD, V77, P1399; GRATAMA JW, 1988, CLIN EXP IMMUNOL, V74, P190; HO DD, 1993, NEW ENGL J MED, V328, P380, DOI 10.1056/NEJM199302113280602; HUANG YQ, 1992, AIDS, P1139; HUMINER D, 1987, REV INFECT DIS, V9, P1102; JACOBS JL, 1991, NEW ENGL J MED, V324, P246, DOI 10.1056/NEJM199101243240407; JONES JF, 1991, REV INFECT DIS, V13, pS26; JOWITT SN, 1991, LANCET, V337, P500, DOI 10.1016/0140-6736(91)93445-F; LANDMANN RMA, 1984, CLIN EXP IMMUNOL, V58, P127; LAURENCE J, 1989, J CLIN INVEST, V83, P1843, DOI 10.1172/JCI114090; LAURENCE J, 1992, LANCET, V340, P273, DOI 10.1016/0140-6736(92)92359-N; LAURENCE J, 1992, AIDS OTHER MANIFESTA, P77; LAURENCE J, 1992, AIDS READ, V2, P104; LEBRANCHU Y, 1991, CLIN IMMUNOL IMMUNOP, V61, P83, DOI 10.1016/S0090-1229(06)80009-7; LEVI FA, 1988, CLIN EXP IMMUNOL, V71, P329; LIFSON JD, 1985, CLIN IMMUNOL IMMUNOP, V36, P151, DOI 10.1016/0090-1229(85)90116-3; LIN RY, 1988, INT ARCH ALLER A IMM, V87, P263, DOI 10.1159/000234683; LUFT BJ, 1984, J INFECT DIS, V150, P761, DOI 10.1093/infdis/150.5.761; MALONE JL, 1990, J ACQ IMMUN DEF SYND, V3, P144; MIOTTI PG, 1992, J INFECT DIS, V165, P1116, DOI 10.1093/infdis/165.6.1116; NAGEL JE, 1981, J IMMUNOL, V127, P2086; NAGEL JE, 1983, IMMUNOL COMMUN, V12, P223, DOI 10.3109/08820138309066871; NOVICK DM, 1989, J PHARMACOL EXP THER, V250, P606; PALENICEK J, 1992, J ACQ IMMUN DEF SYND, V5, P1204; PANKHURST C, 1989, LANCET, V1, P672; PRINCE HE, 1992, CLIN IMMUNOL IMMUNOP, V65, P201, DOI 10.1016/0090-1229(92)90147-G; REICHERT T, 1991, CLIN IMMUNOL IMMUNOP, V60, P190, DOI 10.1016/0090-1229(91)90063-G; REICHERT TA, 1993, LANCET, V341, P636, DOI 10.1016/0140-6736(93)90402-3; REINHERZ EL, 1980, J IMMUNOL, V125, P1269; ROOS MTL, 1992, J INFECT DIS, V165, P427, DOI 10.1093/infdis/165.3.427; SELIGMANN M, 1991, LANCET, V337, P57, DOI 10.1016/0140-6736(91)93382-J; SHERIDAN JF, 1982, J IMMUNOL, V129, P326; SMITH DK, 1993, NEW ENGL J MED, V328, P373, DOI 10.1056/NEJM199302113280601; SPICKETT GP, 1988, CLIN EXP IMMUNOL, V74, P177; SPIRA TJ, 1993, NEW ENGL J MED, V328, P386, DOI 10.1056/NEJM199302113280603; SPIRA TJ, 1992, J CELL BIOCH E, V16, pA56; STATLAND BE, 1978, DIFFERENTIAL LEUKOCY, P23; STEIN DS, 1992, J INFECT DIS, V165, P352, DOI 10.1093/infdis/165.2.352; SYRJALA H, 1991, CLIN EXP IMMUNOL, V83, P326; TAYLOR JMG, 1989, J ACQ IMMUN DEF SYND, V2, P114; THOMAS HC, 1982, HEPATOLOGY, V2, P202; TOLLERUD DJ, 1989, J CLIN IMMUNOL, V9, P214, DOI 10.1007/BF00916817; TOLLERUD DJ, 1989, AM REV RESPIR DIS, V139, P1446, DOI 10.1164/ajrccm/139.6.1446; TOLLERUD DJ, 1990, CLIN IMMUNOL IMMUNOP, V56, P88, DOI 10.1016/0090-1229(90)90172-M; VANROOD Y, 1991, CLIN EXP IMMUNOL, V86, P349; VERMUND SH, 1993, NEW ENGL J MED, V328, P442, DOI 10.1056/NEJM199302113280615; VUILLIER F, 1988, CLIN EXP IMMUNOL, V71, P8; WEBSTER ADB, 1986, LANCET, V1, P581; WILFERT CM, 1991, HOSP PRACT, V26, P55; WILLIAMS RC, 1983, AM J MED, V75, P807, DOI 10.1016/0002-9343(83)90412-6; WRIGHT JJ, 1990, BLOOD, V76, P2046; YAGI MJ, 1991, J INFECT DIS, V164, P183, DOI 10.1093/infdis/164.1.183; YAMAGUCHI S, 1988, CLIN EXP IMMUNOL, V74, P1; 1991, LANCET, V337, P1108; 1992, WHO WKLY EPIDEM REC, V42, P309; 1991, LANCET, V337, P1107	80	124	133	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1993	119	1					55	62		10.7326/0003-4819-119-1-199307010-00010	http://dx.doi.org/10.7326/0003-4819-119-1-199307010-00010			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ266	8098929				2022-12-28	WOS:A1993LJ26600010
J	HULTGREN, SJ; ABRAHAM, S; CAPARON, M; FALK, P; STGEME, JW; NORMARK, S				HULTGREN, SJ; ABRAHAM, S; CAPARON, M; FALK, P; STGEME, JW; NORMARK, S			PILUS AND NONPILUS BACTERIAL ADHESINS - ASSEMBLY AND FUNCTION IN CELL RECOGNITION	CELL			English	Review							UROPATHOGENIC ESCHERICHIA-COLI; NONTYPABLE HAEMOPHILUS-INFLUENZAE; TYPE-2 FIMBRIAL LECTIN; PEPTIC-ULCER DISEASE; NUCLEOTIDE-SEQUENCE; CAMPYLOBACTER-PYLORI; DYNAMIC HISTOLOGY; ANTRAL EPITHELIUM; RECEPTOR-BINDING; MOUSE STOMACH				HULTGREN, SJ (corresponding author), WASHINGTON UNIV, SCH MED, DEPT MOLEC MICROBIOL, ST LOUIS, MO 63110 USA.							ALLEN BL, 1991, J BACTERIOL, V173, P916, DOI 10.1128/jb.173.2.916-920.1991; BARENKAMP SJ, 1990, PEDIATR INFECT DIS J, V9, P333, DOI 10.1097/00006454-199005000-00006; BARENKAMP SJ, 1992, INFECT IMMUN, V60, P1302, DOI 10.1128/IAI.60.4.1302-1313.1992; BJORK S, 1987, J BIOL CHEM, V262, P6758; BOCK K, 1985, J BIOL CHEM, V260, P8545; CAPARON MG, 1991, METHOD ENZYMOL, V204, P556; CAPARON MG, 1992, J BACTERIOL, V174, P5693, DOI 10.1128/JB.174.17.5693-5701.1992; CLARKE CA, 1955, BRIT MED J, V2, P643, DOI 10.1136/bmj.2.4940.643; CLAUSEN H, 1989, VOX SANG, V56, P1, DOI 10.1111/j.1423-0410.1989.tb03040.x; DEGRAAF FK, 1986, ADV MICROB PHYSIOL, V28, P65; DEGRAAF FK, 1981, INFECT IMMUN, V33, P877, DOI 10.1128/IAI.33.3.877-883.1981; DODSON KW, 1993, P NATL ACAD SCI USA, V90, P3670, DOI 10.1073/pnas.90.8.3670; EDEN CS, 1984, INFECT IMMUN, V44, P672; FALK P, 1993, P NATL ACAD SCI USA, V90, P2035, DOI 10.1073/pnas.90.5.2035; GOETZ MB, 1987, INFECT IMMUN, V55, P534, DOI 10.1128/IAI.55.3.534-540.1987; GOETZ MB, 1987, J INFECT DIS, V156, P229, DOI 10.1093/infdis/156.1.229; GONG MF, 1992, J MOL BIOL, V228, P735, DOI 10.1016/0022-2836(92)90860-M; GOODWIN CS, 1989, INT J SYST BACTERIOL, V39, P397, DOI 10.1099/00207713-39-4-397; GORDON JR, 1990, IMMUNOL TODAY, V11, P458, DOI 10.1016/0167-5699(90)90176-A; GRAHAM DY, 1988, J INFECT DIS, V157, P777, DOI 10.1093/infdis/157.4.777; GRAHAM DY, 1989, GASTROENTEROLOGY, V96, P615, DOI 10.1016/S0016-5085(89)80057-5; HANSKI E, 1992, P NATL ACAD SCI USA, V89, P6172, DOI 10.1073/pnas.89.13.6172; HANSKI E, 1992, INFECT IMMUN, V60, P5119, DOI 10.1128/IAI.60.12.5119-5125.1992; Hansson G C, 1988, Adv Exp Med Biol, V228, P465; HAZELL SL, 1986, J INFECT DIS, V153, P658, DOI 10.1093/infdis/153.4.658; HEDEGAARD L, 1989, GENE, V85, P115, DOI 10.1016/0378-1119(89)90471-X; HOEPELMAN AIM, 1992, INFECT IMMUN, V60, P1729, DOI 10.1128/IAI.60.5.1729-1733.1992; HOLGERSSON J, 1988, BIOCHIMIE, V70, P1565, DOI 10.1016/0300-9084(88)90292-1; HOLMGREN A, 1989, NATURE, V342, P248, DOI 10.1038/342248a0; HOLMGREN A, 1992, EMBO J, V11, P1617, DOI 10.1002/j.1460-2075.1992.tb05207.x; HULL RA, 1981, INFECT IMMUN, V33, P933, DOI 10.1128/IAI.33.3.933-938.1981; HULL RA, 1984, INFECT IMMUN, V43, P1064, DOI 10.1128/IAI.43.3.1064-1067.1984; Hultgren SJ, 1991, CURR OPIN GENET DEV, V1, P313, DOI 10.1016/S0959-437X(05)80293-X; HULTGREN SJ, 1991, ANNU REV MICROBIOL, V45, P383, DOI 10.1146/annurev.micro.45.1.383; HULTGREN SJ, 1989, P NATL ACAD SCI USA, V86, P4357, DOI 10.1073/pnas.86.12.4357; HULTGREN SJ, 1993, IN PRESS ADV PROT CH; JACOBDUBUISSON F, 1993, EMBO J, V12, P837, DOI 10.1002/j.1460-2075.1993.tb05724.x; JONES CH, 1992, INFECT IMMUN, V60, P4445, DOI 10.1128/IAI.60.11.4445-4451.1992; KAR S, 1990, INFECT IMMUN, V58, P903, DOI 10.1128/IAI.58.4.903-908.1990; KEITH BR, 1990, INFECT IMMUN, V58, P3448, DOI 10.1128/IAI.58.10.3448-3454.1990; KIHLBERG J, 1989, J AM CHEM SOC, V111, P6364, DOI 10.1021/ja00198a056; KIMURA A, 1990, INFECT IMMUN, V58, P7, DOI 10.1128/IAI.58.1.7-16.1990; KLEMM P, 1987, MOL GEN GENET, V208, P439, DOI 10.1007/BF00328136; KLEMM P, 1990, MOL GEN GENET, V220, P334; KUEHN MJ, 1992, NATURE, V356, P252, DOI 10.1038/356252a0; KUEHN MJ, 1991, P NATL ACAD SCI USA, V88, P10586, DOI 10.1073/pnas.88.23.10586; KUPPER TS, 1990, J INVEST DERMATOL, V94, pS146, DOI 10.1111/1523-1747.ep12876130; LEE ER, 1985, AM J ANAT, V172, P205, DOI 10.1002/aja.1001720304; LEE ER, 1985, AM J ANAT, V172, P225, DOI 10.1002/aja.1001720305; LEE ER, 1985, AM J ANAT, V172, P241, DOI 10.1002/aja.1001720306; LEFFLER H, 1980, FEMS MICROBIOL LETT, V8, P127, DOI 10.1111/j.1574-6968.1980.tb05064.x; LINDBERG F, 1987, NATURE, V328, P84, DOI 10.1038/328084a0; LINDBERG F, 1989, J BACTERIOL, V171, P6052, DOI 10.1128/jb.171.11.6052-6058.1989; LINDBERG F, 1986, P NATL ACAD SCI USA, V83, P1891, DOI 10.1073/pnas.83.6.1891; LUND B, 1988, MOL MICROBIOL, V2, P255, DOI 10.1111/j.1365-2958.1988.tb00027.x; MARKLUND BI, 1992, MOL MICROBIOL, V6, P2225, DOI 10.1111/j.1365-2958.1992.tb01399.x; MOOI FR, 1986, NUCLEIC ACIDS RES, V14, P2443, DOI 10.1093/nar/14.6.2443; Morimoto RI, 1990, STRESS PROTEINS BIOL; MUCHMORE EA, 1987, FASEB J, V1, P229, DOI 10.1096/fasebj.1.3.3623000; MURAMATSU T, 1988, J CELL BIOCHEM, V36, P1, DOI 10.1002/jcb.240360102; NOMURA A, 1991, NEW ENGL J MED, V325, P1132, DOI 10.1056/NEJM199110173251604; NORGREN M, 1987, MOL MICROBIOL, V1, P169, DOI 10.1111/j.1365-2958.1987.tb00509.x; NORGREN M, 1984, EMBO J, V3, P1159, DOI 10.1002/j.1460-2075.1984.tb01945.x; Normark S., 1986, Microbial lectins and agglutinins, P113; OKADA N, 1993, IN PRESS MOL MICROBI; OTA H, 1991, HISTOCHEM J, V23, P22, DOI 10.1007/BF01886504; PLOS K, 1990, J INFECT DIS, V161, P518, DOI 10.1093/infdis/161.3.518; READ RC, 1991, J INFECT DIS, V163, P549, DOI 10.1093/infdis/163.3.549; RELMAN DA, 1989, P NATL ACAD SCI USA, V86, P2637, DOI 10.1073/pnas.86.8.2637; REN R, 1992, CELL, V66, P296; RIOUX CR, 1990, J BACTERIOL, V172, P6217, DOI 10.1128/jb.172.11.6217-6222.1990; ROOSENDAAL B, 1989, NUCLEIC ACIDS RES, V17, P1263, DOI 10.1093/nar/17.3.1263; RUSSELL PW, 1992, J BACTERIOL, V174, P5923, DOI 10.1128/jb.174.18.5923-5935.1992; SANDBERG AL, 1986, INFECT IMMUN, V54, P472, DOI 10.1128/IAI.54.2.472-476.1986; SANDBERG AL, 1988, INFECT IMMUN, V56, P267, DOI 10.1128/IAI.56.1.267-269.1988; SCHEFFER J, 1986, IMMUNOLOGY, V59, P541; SCHEFFER J, 1985, INFECT IMMUN, V50, P271, DOI 10.1128/IAI.50.1.271-278.1985; SCHIFFERLI DM, 1991, J BACTERIOL, V173, P1230, DOI 10.1128/jb.173.3.1230-1240.1991; SIMONS LH, 1991, MICROB PATHOGENESIS, V11, P325, DOI 10.1016/0882-4010(91)90018-6; SIPPONEN P, 1989, SCAND J GASTROENTERO, V24, P581, DOI 10.3109/00365528909093093; SLONIM LN, 1992, EMBO J, V11, P4747, DOI 10.1002/j.1460-2075.1992.tb05580.x; STEINMAN R, 1989, BIOESSAYS, V10, P145, DOI 10.1002/bies.950100503; STGEME JW, 1990, INFECT IMMUN, V58, P4036, DOI 10.1128/IAI.58.12.4036-4044.1990; STGEME JW, 1993, IN PRESS P NATL ACAD; STROMBERG N, 1990, EMBO J, V9, P2001, DOI 10.1002/j.1460-2075.1990.tb08328.x; STROMBERG N, 1991, P NATL ACAD SCI USA, V88, P9340, DOI 10.1073/pnas.88.20.9340; TEWARI R, 1993, J BIOL CHEM, V268, P3009; TORRESPINEDO R, 1984, BIOCHEM BIOPH RES CO, V125, P546, DOI 10.1016/0006-291X(84)90574-6; TURK DC, 1984, J MED MICROBIOL, V18, P1, DOI 10.1099/00222615-18-1-1; VANDIE I, 1988, J BACTERIOL, V170, P5870, DOI 10.1128/jb.170.12.5870-5876.1988; WASSERMAN SI, 1989, ANN ALLERGY, V63, P546; WESTERLUND B, 1991, MOL MICROBIOL, V5, P2965, DOI 10.1111/j.1365-2958.1991.tb01856.x; WYATT JI, 1988, J PATHOL, V154, P113, DOI 10.1002/path.1711540203	93	338	346	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 4	1993	73	5					887	901		10.1016/0092-8674(93)90269-V	http://dx.doi.org/10.1016/0092-8674(93)90269-V			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LF061	8098994	Bronze			2022-12-28	WOS:A1993LF06100007
J	HARRISON, LC; HONEYMAN, MC; DEAIZPURUA, HJ; SCHMIDLI, RS; COLMAN, PG; TAIT, BD; CRAM, DS				HARRISON, LC; HONEYMAN, MC; DEAIZPURUA, HJ; SCHMIDLI, RS; COLMAN, PG; TAIT, BD; CRAM, DS			INVERSE RELATION BETWEEN HUMORAL AND CELLULAR-IMMUNITY TO GLUTAMIC-ACID DECARBOXYLASE IN SUBJECTS AT RISK OF INSULIN-DEPENDENT DIABETES	LANCET			English	Article							PANCREATIC-ISLETS; LYMPHOCYTE-T; HLA-DR3; CELLS	Glutamic acid decarboxylase (GAD) in pancreatic beta cells is an autoantigen in insulin-dependent diabetes (IDD). We measured immunity to GAD in 31 first-degree relatives of IDD patients judged to be at risk of developing IDD themselves because of the presence of islet-cell antibodies. We found that in most of the subjects GAD autoimmunity was either predominantly humoral or predominantly cellular. High concentrations of circulating autoantibodies that precipitate native GAD activity were associated with low proliferation of peripheral-blood T cells to recombinant GAD; conversely, low concentrations of autoantibody to GAD were associated with high T-cell proliferation to GAD. Although T-cell proliferation was measured in the presence of autologous serum, GAD autoantibodies did not have a blocking effect in vitro. This dichotomy of the immune response to GAD defined heterogeneity within at-risk relatives and could have prognostic importance. We postulate that, if GAD is a pathogenetic autoantigen, sensitisation to beta-cell GAD is more likely to lead to IDD when the immune response deviates towards the expansion of autoreactive T cells rather than towards generation of autoantibodies. This idea is consistent with evidence that beta-cell destruction is mediated by T cells and that high concentrations of GAD antibodies are associated with slower progression to clinical disease.			HARRISON, LC (corresponding author), ROYAL MELBOURNE HOSP, WALTER & ELIZA HALL INST MED RES, BURNET CLIN RES UNIT, PARKVILLE, VIC 3050, AUSTRALIA.			Colman, Peter/0000-0001-8718-6175				ALBERS RW, 1959, J BIOL CHEM, V234, P926; ATKINSON MA, 1992, LANCET, V339, P458, DOI 10.1016/0140-6736(92)91061-C; BONIFACIO E, 1990, LANCET, V335, P147, DOI 10.1016/0140-6736(90)90013-U; BRUSERUD O, 1985, DIABETOLOGIA, V28, P420, DOI 10.1007/BF00280884; CAMPBELL IL, 1991, J CLIN INVEST, V87, P739, DOI 10.1172/JCI115055; CRAM DS, 1991, BIOCHEM BIOPH RES CO, V176, P1239, DOI 10.1016/0006-291X(91)90418-7; DEAIZPURUA HJ, 1992, P NATL ACAD SCI USA, V89, P9841, DOI 10.1073/pnas.89.20.9841; DEAIZPURUA HJ, 1992, J AUTOIMMUN, V5, P759, DOI 10.1016/0896-8411(92)90191-R; DEAIZPURUA HJ, 1992, DIABETES, V41, P1182, DOI 10.2337/diabetes.41.9.1182; DESCHAMPS I, 1988, DIABETOLOGIA, V31, P896; GENOVESE S, 1992, DIABETOLOGIA, V35, P385, DOI 10.1007/BF00401207; GIANANI R, 1992, DIABETES, V41, P347, DOI 10.2337/diabetes.41.3.347; HARRISON LC, 1992, J CLIN INVEST, V89, P1161, DOI 10.1172/JCI115698; HARRISON LC, 1992, IMMUNOL TODAY, V13, P348, DOI 10.1016/0167-5699(92)90170-C; HARRISON LC, 1991, DIABETES, V40, P1128, DOI 10.2337/diabetes.40.9.1128; HARRISON LC, 1990, ADV ENDOCRINOL METAB, V1, P35; HONEYMAN MC, 1993, J EXP MED, V177, P535, DOI 10.1084/jem.177.2.535; KARLSEN AE, 1992, DIABETES, V41, P1355, DOI 10.2337/diabetes.41.10.1355; KAUFMAN DL, 1992, J CLIN INVEST, V89, P283, DOI 10.1172/JCI115573; MARTINO GV, 1991, J AUTOIMMUN, V4, P915, DOI 10.1016/0896-8411(91)90054-G; OKADA Y, 1976, SCIENCE, V194, P620, DOI 10.1126/science.185693; PARISH CR, 1972, TRANSPLANT REV-DENMA, V13, P35; PFEIFFER C, 1991, IMMUNOL REV, V123, P65, DOI 10.1111/j.1600-065X.1991.tb00606.x; RASANEN L, 1988, CLIN EXP IMMUNOL, V71, P470; ROBERTS E, 1950, J BIOL CHEM, V187, P55; ROWLEY MJ, 1992, DIABETES, V41, P548, DOI 10.2337/diabetes.41.4.548; SCHMNIDLI RS, 1992, P AUST DIABETES SOC, V36; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STREET NE, 1991, FASEB J, V5, P171, DOI 10.1096/fasebj.5.2.1825981; TAIT BD, 1991, BAILLIERE CLIN ENDOC, V5, P211, DOI 10.1016/S0950-351X(05)80124-7; YAMASHITA K, IN PRESS BIOCH BIOPH	31	261	263	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 29	1993	341	8857					1365	1369		10.1016/0140-6736(93)90940-I	http://dx.doi.org/10.1016/0140-6736(93)90940-I			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE180	8098789				2022-12-28	WOS:A1993LE18000003
J	SHARPE, RM; SKAKKEBAEK, NE				SHARPE, RM; SKAKKEBAEK, NE			ARE ESTROGENS INVOLVED IN FALLING SPERM COUNTS AND DISORDERS OF THE MALE REPRODUCTIVE-TRACT	LANCET			English	Article							MULLERIAN INHIBITING SUBSTANCE; TESTICULAR CANCER; ETHINYL ESTRADIOL; SERTOLI CELLS; EXPOSURE; DIETHYLSTILBESTROL; MAMMALS; TESTIS; RISK; CRYPTORCHIDISM	The incidence of disorders of development of the male reproductive tract has more than doubled in the past 30-50 years while sperm counts have declined by about half. Similar abnormalities occur in the sons of women exposed to diethylstilbestrol (DES) during pregnancy and can be induced in animals by brief exposure to exogenous oestrogen/DES during pregnancy. We argue that the increasing incidence of reproductive abnormalities in the human male may be related to increased oestrogen exposure in utero, and identify mechanisms by which this exposure could occur.	UNIV COPENHAGEN,DEPT GROWTH & REPROD,DK-1168 COPENHAGEN,DENMARK	University of Copenhagen	SHARPE, RM (corresponding author), CTR REPROD BIOL,MRC,REPROD BIOL UNIT,37 CHALMERS ST,EDINBURGH EH3 9EW,SCOTLAND.		Sharpe, Richard M/D-2725-2013	Sharpe, Richard M/0000-0003-1686-8085				ADLERCREUTZ H, 1990, ANN NY ACAD SCI, V595, P281, DOI 10.1111/j.1749-6632.1990.tb34302.x; ARAI Y, 1983, INT REV CYTOL, V84, P235, DOI 10.1016/S0074-7696(08)61019-0; BEHRINGER RR, 1990, NATURE, V345, P167, DOI 10.1038/345167a0; BERNSTEIN L, 1986, J NATL CANCER I, V76, P1035; BROWN LM, 1992, CANCER RES, V46, P4812; CARLSEN E, 1992, BRIT MED J, V305, P609, DOI 10.1136/bmj.305.6854.609; Colborn T., 1992, CHEM INDUCED ALTERAT; COOKE S, 1992, BIOL REPROD, V46, P146; CORTES D, 1987, INT J ANDROL, V10, P589, DOI 10.1111/j.1365-2605.1987.tb00358.x; DEGRAAFF WE, 1992, LAB INVEST, V66, P166; DEPUE RH, 1984, INT J EPIDEMIOL, V13, P311, DOI 10.1093/ije/13.3.311; FIELD B, 1990, SEMIN REPROD ENDOCR, V8, P44, DOI 10.1055/s-2007-1021422; FOREST MG, 1982, ASPECTS MALE INFERTI, P1; GIWERCMAN A, 1992, INT J ANDROL, V15, P373, DOI 10.1111/j.1365-2605.1992.tb01351.x; HAMON M, 1990, J DAIRY RES, V57, P419, DOI 10.1017/S0022029900027072; HIROBE S, 1992, ENDOCRINOLOGY, V131, P854, DOI 10.1210/en.131.2.854; HUTSON JM, 1990, OXFORD REV REPROD, P1; JACKSON MB, 1988, HORM RES, V30, P153, DOI 10.1159/000181052; KALDAS RS, 1989, REPROD TOXICOL, V3, P81, DOI 10.1016/0890-6238(89)90042-7; KURODA T, 1990, ENDOCRINOLOGY, V127, P1825, DOI 10.1210/endo-127-4-1825; LAMMING GE, 1984, COMMISSION EUROPEAN, V913, P4; MABLY TA, 1992, TOXICOL APPL PHARM, V114, P118, DOI 10.1016/0041-008X(92)90103-Y; McLachlan J. A., 1985, ESTROGENS ENV; MOSS AR, 1986, AM J EPIDEMIOL, V124, P39, DOI 10.1093/oxfordjournals.aje.a114369; ORTH JM, 1988, ENDOCRINOLOGY, V122, P787, DOI 10.1210/endo-122-3-787; OSTERLIND A, 1986, BRIT J CANCER, V53, P501, DOI 10.1038/bjc.1986.79; PRENER A, 1992, CANCER CAUSE CONTROL, V3, P265, DOI 10.1007/BF00124260; RUSSELL LD, 1984, J REPROD FERTIL, V70, P635, DOI 10.1530/jrf.0.0700635; SAGER D, 1991, ENVIRON TOXICOL CHEM, V10, P737, DOI 10.1897/1552-8618(1991)10[737:EPETPS]2.0.CO;2; SHARPE RM, 1993, J ENDOCRINOL, V137, P357; SHEEHAN DM, 1979, ENDOCRINOLOGY, V104, P1442, DOI 10.1210/endo-104-5-1442; SKAKKEBAEK N E, 1987, International Journal of Andrology, V10, P1; STILLMAN RJ, 1982, AM J OBSTET GYNECOL, V142, P905, DOI 10.1016/S0002-9378(16)32540-6; VERDEAL K, 1979, J FOOD PROTECT, V7, P577; WALKER AH, 1990, BRIT J CANCER, V62, P599, DOI 10.1038/bjc.1990.337; YASUDA Y, 1985, TERATOLOGY, V32, P113, DOI 10.1002/tera.1420320115; YASUDA Y, 1985, TERATOLOGY, V32, P210	37	1475	1555	1	74	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 29	1993	341	8857					1392	1395		10.1016/0140-6736(93)90953-E	http://dx.doi.org/10.1016/0140-6736(93)90953-E			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE180	8098802				2022-12-28	WOS:A1993LE18000016
J	FILOS, KS; GOUDAS, LC; PATRONI, O; TASSOUDIS, V				FILOS, KS; GOUDAS, LC; PATRONI, O; TASSOUDIS, V			ANALGESIA WITH EPIDURAL NIMODIPINE	LANCET			English	Letter							ANTAGONISTS				FILOS, KS (corresponding author), UNIV PATRAS,SCH MED,DEPT ANAESTHESIOL & CRIT CARE MED,GR-26500 PATRAI,GREECE.			Goudas, Leonidas C./0000-0002-3614-3455				KAVALIERS M, 1987, BRAIN RES, V408, P403, DOI 10.1016/0006-8993(87)90415-X; LEHMANN KA, 1989, ANAESTHESIST, V38, P110; LEWIS PJ, 1988, NEUROSURGERY, V22, P492; LJUNGGREN B, 1984, J NEUROSURG, V61, P864, DOI 10.3171/jns.1984.61.5.0864; VONBORMANN B, 1985, ANAESTHESIST, V34, P429	5	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 23	1993	342	8878					1047	1047		10.1016/0140-6736(93)92899-5	http://dx.doi.org/10.1016/0140-6736(93)92899-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD066	8105273				2022-12-28	WOS:A1993MD06600028
J	TAKAHASHI, H; SNOW, BJ; BHATT, MH; PEPPARD, R; EISEN, A; CALNE, DB				TAKAHASHI, H; SNOW, BJ; BHATT, MH; PEPPARD, R; EISEN, A; CALNE, DB			EVIDENCE FOR A DOPAMINERGIC DEFICIT IN SPORADIC AMYOTROPHIC-LATERAL-SCLEROSIS ON POSITRON EMISSION SCANNING	LANCET			English	Article							ALZHEIMERS-DISEASE; PARKINSONS-DISEASE; HYPOTHESIS; DEMENTIA; DISORDERS; GUAM	Although rare, the chronic neurodegenerative disorders amyotrophic lateral sclerosis (ALS) and idiopathic parkinsonism coexist to a greater degree than expected by chance. This suggests that patients with ALS may have subclinical lesions of the nigrostriatal dopaminergic pathway. To study this hypothesis, we did positron emission tomography with 6-fluorodopa on 16 patients with sporadic ALS and without extrapyramidal disease, and compared the results with age-matched controls. We found a significant progressive fall in 6-fluorodopa uptake with time since diagnosis, and reduced dopaminergic function in 3 patients with ALS of long duration. This supports the hypothesis that ALS and IP may share pathogenesis and, perhaps, aetiology.	UNIV BRITISH COLUMBIA,CTR NEURODEGENERAT DISORDERS,VANCOUVER V6T 1W5,BC,CANADA; UBC,TRIUMF,PET PROGRAM,VANCOUVER,BC,CANADA	University of British Columbia; University of British Columbia				Bhatt, Mohit/0000-0002-5233-3371; Eisen, Andrew/0000-0002-1447-2725				APPEL SH, 1981, ANN NEUROL, V10, P499, DOI 10.1002/ana.410100602; BURROW JNC, 1992, AUST NZ J MED, V22, P469; CALNE DB, 1986, LANCET, V2, P1067, DOI 10.1016/S0140-6736(86)90469-1; CALNE DB, 1992, ANN NEUROL, V32, P799, DOI 10.1002/ana.410320615; EISEN A, 1993, MUSCLE NERVE, V16, P27, DOI 10.1002/mus.880160107; EISEN A, 1992, CAN J NEUROL SCI, V19, P117, DOI 10.1017/S0317167100041482; FAHN S, 1992, ANN NEUROL, V32, P804, DOI 10.1002/ana.410320616; HAMMERSTAD J P, 1991, Neurology, V41, P192; HANSEN L, 1990, NEUROLOGY, V40, P1; HEATHFIELD MT, 1990, NEUROSCI LETT, V110, P216; HUDSON AJ, 1981, BRAIN, V104, P217, DOI 10.1093/brain/104.2.217; JELLINGER K, 1989, PARKINSONISM AGING, P35; MARTIN WRW, 1989, ANN NEUROL, V26, P535, DOI 10.1002/ana.410260407; Mendell J R, 1971, Trans Am Neurol Assoc, V96, P284; PATE BD, 1993, ANN NEUROL, V34, P331, DOI 10.1002/ana.410340306; RODGERSJOHNSON P, 1986, NEUROLOGY, V36, P7, DOI 10.1212/WNL.36.1.7; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; ROWLAND LP, 1991, AMYOTROPH LATERAL SC, P3; SNOW BJ, 1993, ANN NEUROL, V34, P324, DOI 10.1002/ana.410340304; SNOW BJ, 1990, ARCH NEUROL-CHICAGO, V47, P870, DOI 10.1001/archneur.1990.00530080052010	20	84	88	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 23	1993	342	8878					1016	1018		10.1016/0140-6736(93)92878-W	http://dx.doi.org/10.1016/0140-6736(93)92878-W			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD066	8105264				2022-12-28	WOS:A1993MD06600009
J	ROYSTON, D				ROYSTON, D			INHALATIONAL AGENTS FOR PULMONARY-HYPERTENSION	LANCET			English	Editorial Material							VASODILATION; SURVIVAL				ROYSTON, D (corresponding author), HAREFIELD HOSP,DEPT ANAESTHESIA,HAREFIELD,MIDDX,ENGLAND.							BIHARI D, 1987, NEW ENGL J MED, V317, P397, DOI 10.1056/NEJM198708133170701; CHANG JK, 1992, J APPL PHYSIOL, V73, P188, DOI 10.1152/jappl.1992.73.1.188; COSTARDJACKLE A, 1992, J AM COLL CARDIOL, V19, P48, DOI 10.1016/0735-1097(92)90050-W; Feneck R O, 1993, J Cardiothorac Vasc Anesth, V7, P21, DOI 10.1016/1053-0770(93)90107-V; HOLCROFT JW, 1986, ANN SURG, V203, P371, DOI 10.1097/00000658-198604000-00006; RICH S, 1992, NEW ENGL J MED, V327, P76, DOI 10.1056/NEJM199207093270203; ROSSAINT R, 1993, NEW ENGL J MED, V328, P399, DOI 10.1056/NEJM199302113280605; WEIR EK, 1989, AM REV RESPIR DIS, V140, P1623, DOI 10.1164/ajrccm/140.6.1623	8	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 16	1993	342	8877					941	942		10.1016/0140-6736(93)91996-Y	http://dx.doi.org/10.1016/0140-6736(93)91996-Y			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MC005	8105208				2022-12-28	WOS:A1993MC00500003
J	MORRISON, PJ				MORRISON, PJ			TRINUCLEOTIDE REPEAT REPEAT REPEAT	LANCET			English	Editorial Material											MORRISON, PJ (corresponding author), NO IRELAND GENET SERV,BELFAST,NORTH IRELAND.							BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; MANDEL JL, 1993, NAT GENET, V4, P8, DOI 10.1038/ng0593-8; NELSON DL, 1993, NAT GENET, V4, P107, DOI 10.1038/ng0693-107; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; REIK W, 1993, J MED GENET, V30, P175; SCHALLING M, 1993, NAT GENET, V4, P135, DOI 10.1038/ng0693-135; SHAW DJ, 1993, J MED GENET, V30, P189, DOI 10.1136/jmg.30.3.189; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; 1993, CELL, V72, P971	10	9	9	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 14	1993	342	8868					385	386						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR900	8101897				2022-12-28	WOS:A1993LR90000005
J	ROTHWELL, PM				ROTHWELL, PM			PHYSIOLOGICAL SCORING SYSTEMS AND AUDIT	LANCET			English	Letter											ROTHWELL, PM (corresponding author), WESTERN GEN HOSP,DEPT CLIN NEUROSCI,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.		Rothwell, Peter/ABE-5913-2020	Rothwell, Peter/0000-0001-9739-9211; Bersten, Andrew/0000-0001-9908-394X				BOYD, 1993, LANCET, V341, P1573; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; ROTHWELL PM, 1993, ANAESTHESIA, V48, P373, DOI 10.1111/j.1365-2044.1993.tb07006.x	3	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 31	1993	342	8866					306	306		10.1016/0140-6736(93)91854-F	http://dx.doi.org/10.1016/0140-6736(93)91854-F			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ163	8101332				2022-12-28	WOS:A1993LQ16300049
J	HELD, KR				HELD, KR			TURNERS-SYNDROME AND CHROMOSOME-Y	LANCET			English	Editorial Material							MOSAICISM				HELD, KR (corresponding author), INST HUMAN GENET & ANTHROPOL,HAMBURG,GERMANY.							BIANCHI DW, 1993, AM J MED GENET, V46, P542, DOI 10.1002/ajmg.1320460517; COOPER C, 1991, J MED GENET, V28, P6, DOI 10.1136/jmg.28.1.6; DELACHAPELLE A, 1990, PRINCIPLES PRACTICE, P273; HASSOLD T, 1988, AM J HUM GENET, V42, P534; HELD KR, 1992, HUM GENET, V88, P288; HOOK EB, 1983, HUM GENET, V64, P24, DOI 10.1007/BF00289473; KOCOVA M, 1993, LANCET, V342, P140, DOI 10.1016/0140-6736(93)91345-M; OSTRER H, 1989, AM J MED GENET, V34, P294, DOI 10.1002/ajmg.1320340235; WITT M, 1993, J MED GENET, V30, P304, DOI 10.1136/jmg.30.4.304	9	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 17	1993	342	8864					128	129		10.1016/0140-6736(93)91337-L	http://dx.doi.org/10.1016/0140-6736(93)91337-L			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN042	8101248				2022-12-28	WOS:A1993LN04200003
J	AUGARTEN, A; KEREM, BS; YAHAV, Y; NOIMAN, S; RIVLIN, Y; TAL, A; BLAU, H; BENTUR, L; SZEINBERG, A; KEREM, E; GAZIT, E				AUGARTEN, A; KEREM, BS; YAHAV, Y; NOIMAN, S; RIVLIN, Y; TAL, A; BLAU, H; BENTUR, L; SZEINBERG, A; KEREM, E; GAZIT, E			MILD CYSTIC-FIBROSIS AND NORMAL OR BORDERLINE SWEAT TEST IN PATIENTS WITH THE 3849+10 KB C-]T MUTATION	LANCET			English	Note							DELTA-F508; DISEASE; GENE	Different mutations in the cystic fibrosis (CF) gene appear to contribute to heterogeneity of the CF phenotype. We investigated 15 patients with CF who have the 3849+10 kb C-->T mutation. All were Ashkenazi Jews. Their clinical features were compared with those of CF patients with the DELTAF508/DELTAF508, W1282X/W1282X, W1282X/DELTAF508 mutations, which are known to be associated with a severe disease. Patients with the 3849+10 kb mutation were older, had been diagnosed as having CF at a more advanced age, and were in a better nutritional state. Sweat chloride values were normal (below 60 mmol/L) in 5 3849+10 kb patients (33%). 4 of these patients and 6 others (total 66%) had normal pancreatic function. However, age-adjusted pulmonary function did not differ between the two groups. None of the patients with 3849+10 kb C-->T had had meconium ileus or had liver disease or diabetes mellitus. We conclude that this mutation is associated with a mild type of CF.	CHAIM SHEBA MED CTR,TISSUE TYPING LAB,IL-52621 TEL HASHOMER,ISRAEL; SOROKA MED CTR,DEPT PAEDIAT,IL-84101 BEER SHEVA,ISRAEL; BEILINSON MED CTR,DEPT PAEDIAT,IL-49100 PETAH TIQWA,ISRAEL; CHAIM SHEBA MED CTR,DEPT PAEDIAT,IL-52621 TEL HASHOMER,ISRAEL; HEBREW UNIV JERUSALEM,INST LIFE SCI,DEPT GENET,JERUSALEM,ISRAEL; SHAARE ZEDEK MED CTR,DEPT PAEDIAT,IL-91000 JERUSALEM,ISRAEL; CARMEL HOSP,DEPT PAEDIAT,HAIFA,ISRAEL; RAMBAM MED CTR,DEPT PAEDIAT,HAIFA,ISRAEL	Chaim Sheba Medical Center; Ben Gurion University; Soroka Medical Center; Rabin Medical Center; Chaim Sheba Medical Center; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Shaare Zedek Medical Center; Clalit Health Services; Carmel Medical Center; Rambam Health Care Campus; Technion Israel Institute of Technology			Tal, Asher/B-4286-2012	Tal, Asher/0000-0002-5670-8804				ABELIOVICH D, 1992, AM J HUM GENET, V51, P951; GIBSON LE, 1959, PEDIATRICS, V23, P545; Highsmith W.E.B.L., 1991, PEDIATR PULM S, V6, p22A; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KEREM E, 1990, NEW ENGL J MED, V323, P1517, DOI 10.1056/NEJM199011293232203; SANTIS G, 1990, LANCET, V335, P1426, DOI 10.1016/0140-6736(90)91448-J; SHOSHANI T, 1992, AM J HUM GENET, V50, P222; STRONG TV, 1991, NEW ENGL J MED, V325, P1630, DOI 10.1056/NEJM199112053252307; TSUI LC, 1985, SCIENCE, V230, P145; VEEZE HJ, 1992, PEDIATR PULM S, V8, P239	10	114	116	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 3	1993	342	8862					25	26		10.1016/0140-6736(93)91885-P	http://dx.doi.org/10.1016/0140-6736(93)91885-P			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK985	8100293				2022-12-28	WOS:A1993LK98500014
J	TARBELL, NJ; GELBER, RD; WEINSTEIN, HJ; MAUCH, P				TARBELL, NJ; GELBER, RD; WEINSTEIN, HJ; MAUCH, P			SEX-DIFFERENCES IN RISK OF 2ND MALIGNANT-TUMORS AFTER HODGKINS-DISEASE IN CHILDHOOD	LANCET			English	Article							CANCER; COMPLICATIONS; IRRADIATION; THERAPY; CHEMOTHERAPY; CHILDREN; LEUKEMIA; LYMPHOMA	There have been reports of a high incidence of second malignant disorders in survivors of Hodgkin's disease. We studied the cumulative incidence of second tumours in 191 children, who were 16 years or younger at diagnosis, with stage IA-IVB Hodgkin's disease, treated at the Joint Center for Radiation Therapy, Boston, between 1969 and 1988. The 10-year actuarial survival was 89 (SE 2)%. The median follow-up time was 11 (range 3-21) years from diagnosis. 109 children were initially treated with radiotherapy alone, 61 received chemotherapy and radiotherapy, and 21 received chemotherapy alone. Second tumours arose in 15 patients 6-20 years after the diagnosis of Hodgkin's disease. The estimated cumulative incidence of second malignant disorders at 1 5 years was 12 (4)% overall. 10 of the second tumours arose among 66 female patients, compared with 5 among 125 male patients (cumulative incidence 24 [9] vs 5 [3]%). The relative risk of a second tumour for female compared with male patients was 4.5 (95% CI 1.4-15.1; p=0.013). For male patients, the observed incidence of second tumours was 18 times that expected for the normal population (95% CI 6-42), whereas for female patients it was 57 times that expected (27-105). 13 of the second malignant disorders were solid tumours, including 4 breast cancers. Thus, the risk of a child treated for Hodgkin's disease developing a second tumour is higher for girls than for boys. The cumulative incidence of second cancers increases from 10 years after treatment. These findings emphasise the importance of continued surveillance in patients treated for Hodgkin's disease.	HARVARD UNIV,SCH PUBL HLTH,DANA FARBER CANC INST,DEPT BIOSTAT,DIV BIOSTAT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV PEDIAT ONCOL,BOSTON,MA 02115; CHILDRENS HOSP MED CTR,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard T.H. Chan School of Public Health; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	TARBELL, NJ (corresponding author), JOINT CTR RADIAT THERAPY,DEPT RADIAT ONCOL,300 LONGWOOD AVE,BOSTON,MA 02115, USA.				NCI NIH HHS [CA 06516] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006516] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOICE J, 1992, NEW ENGL J MED, V326, P782; COLEMAN CN, 1977, NEW ENGL J MED, V297, P1249, DOI 10.1056/NEJM197712082972303; COX DR, 1972, J R STAT SOC B, V34, P187; COX DR, 1984, ANAL SURVIVAL DATA, P112; DEVITA VT, 1980, ANN INTERN MED, V92, P587, DOI 10.7326/0003-4819-92-5-587; DONALDSON SS, 1987, J CLIN ONCOL, V5, P742, DOI 10.1200/JCO.1987.5.5.742; GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951; Greenwood M., 1926, REPORTS PUBLIC HLTH, V33, P1; Henry-Amar M, 1992, Ann Oncol, V3 Suppl 4, P117; HORNING SJ, 1981, NEW ENGL J MED, V304, P1377, DOI 10.1056/NEJM198106043042301; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI, P169; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kaplan HS, 1980, HODGKINS DISEASE, P281; KUSHNER BH, 1988, CANCER-AM CANCER SOC, V62, P1364, DOI 10.1002/1097-0142(19881001)62:7<1364::AID-CNCR2820620721>3.0.CO;2-T; LI FP, 1983, CANCER, V51, P521, DOI 10.1002/1097-0142(19830201)51:3<521::AID-CNCR2820510325>3.0.CO;2-U; MAUCH P, 1978, CANCER-AM CANCER SOC, V42, P1039, DOI 10.1002/1097-0142(197809)42:3<1039::AID-CNCR2820420302>3.0.CO;2-R; MAUCH P, 1988, J CLIN ONCOL, V6, P1576, DOI 10.1200/JCO.1988.6.10.1576; MAUCH PM, 1983, CANCER-AM CANCER SOC, V51, P925, DOI 10.1002/1097-0142(19830301)51:5<925::AID-CNCR2820510527>3.0.CO;2-O; MEADOWS AT, 1989, MED PEDIATR ONCOL, V17, P477; MEFFERD JM, 1989, INT J RADIAT ONCOL, V16, P679, DOI 10.1016/0360-3016(89)90485-9; MILLER AB, 1989, NEW ENGL J MED, V321, P1285, DOI 10.1056/NEJM198911093211902; RODRIGUEZ M, IN PRESS ANN ONCOL; SHERINS RJ, 1973, ANN INTERN MED, V79, P216, DOI 10.7326/0003-4819-79-2-216; TARBELL NJ, 1990, INT J RADIAT ONCOL, V18, P275, DOI 10.1016/0360-3016(90)90089-3; TUCKER MA, 1988, NEW ENGL J MED, V318, P76, DOI 10.1056/NEJM198801143180203; VALAGUSSA P, 1986, J CLIN ONCOL, V4, P830, DOI 10.1200/JCO.1986.4.6.830; VANLEEUWEN FE, 1989, J CLIN ONCOL, V7, P1046, DOI 10.1200/JCO.1989.7.8.1046; VANRIJSWIJK REN, 1987, J CLIN ONCOL, V5, P1624, DOI 10.1200/JCO.1987.5.10.1624; 1981, NCI MONOGR, V57; [No title captured]	30	56	57	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 5	1993	341	8858					1428	1430		10.1016/0140-6736(93)90880-P	http://dx.doi.org/10.1016/0140-6736(93)90880-P			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF841	8099139				2022-12-28	WOS:A1993LF84100002
J	GOODMAN, BT; CHAMBERS, TL				GOODMAN, BT; CHAMBERS, TL			PEDIATRICS - BRONCHODILATORS FOR BRONCHIOLITIS	LANCET			English	Editorial Material							WHEEZY BRONCHITIS; SALBUTAMOL; CHILDREN; INFANTS				GOODMAN, BT (corresponding author), SOUTHMEAD GEN HOSP,DEPT PAEDIAT,BRISTOL BS10 5NB,AVON,ENGLAND.							HO L, 1991, ARCH DIS CHILD, V66, P1061, DOI 10.1136/adc.66.9.1061; KLASSEN TP, 1991, J PEDIATR-US, V118, P807, DOI 10.1016/S0022-3476(05)80051-4; LENNEY W, 1978, ARCH DIS CHILD, V53, P707, DOI 10.1136/adc.53.9.707; LOWELL DI, 1987, PEDIATRICS, V79, P939; RUTTER N, 1975, ARCH DIS CHILD, V50, P719, DOI 10.1136/adc.50.9.719; SANCHEZ I, 1993, J PEDIATR-US, V122, P145, DOI 10.1016/S0022-3476(05)83508-5; SCHUH S, 1990, J PEDIATR-US, V117, P633, DOI 10.1016/S0022-3476(05)80706-1; STERN RC, 1992, NELSON TXB PEDIATRIC, P1076; STOKES GM, 1983, ARCH DIS CHILD, V58, P279, DOI 10.1136/adc.58.4.279; WANG EEL, 1992, ARCH DIS CHILD, V67, P289, DOI 10.1136/adc.67.3.289	10	24	23	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 29	1993	341	8857					1380	1380						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE180	8098798				2022-12-28	WOS:A1993LE18000012
J	PUOTI, C; PANNULLO, A; ANNOVAZZI, G; FILIPPI, T; MAGRINI, A				PUOTI, C; PANNULLO, A; ANNOVAZZI, G; FILIPPI, T; MAGRINI, A			URSODEOXYCHOLIC ACID AND CHRONIC HEPATITIS-C INFECTION	LANCET			English	Letter							BILE-SALTS				PUOTI, C (corresponding author), MARINO GEN HOSP,LIVER UNIT,I-00141 ROME,ITALY.							CROSIGNANI A, 1991, HEPATOLOGY, V13, P339, DOI 10.1016/0270-9139(91)92450-M; GALLE PR, 1990, HEPATOLOGY, V12, P486, DOI 10.1002/hep.1840120307; HEUMAN DM, 1991, GASTROENTEROLOGY, V100, P203, DOI 10.1016/0016-5085(91)90602-H	3	10	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 29	1993	341	8857					1413	1414		10.1016/0140-6736(93)90981-L	http://dx.doi.org/10.1016/0140-6736(93)90981-L			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE180	8098817				2022-12-28	WOS:A1993LE18000036
J	LOBO, RA				LOBO, RA			HORMONE REPLACEMENT THERAPY - ESTROGEN REPLACEMENT AFTER TREATMENT FOR BREAST-CANCER	LANCET			English	Editorial Material							ESTROGEN; WOMEN				LOBO, RA (corresponding author), UNIV SO CALIF,SCH MED,DIV REPROD ENDOCRINOL & INFERTIL,LOS ANGELES,CA 90033, USA.							BERGKVIST L, 1989, AM J EPIDEMIOL, V130, P221, DOI 10.1093/oxfordjournals.aje.a115328; DARBRE PD, 1990, J STEROID BIOCHEM, V37, P753, DOI 10.1016/0960-0760(90)90416-I; EDEN JA, 1992, MED J AUSTRALIA, V157, P247, DOI 10.5694/j.1326-5377.1992.tb137129.x; EDEN JA, 1992, MED J AUSTRALIA, V157, P175, DOI 10.5694/j.1326-5377.1992.tb137081.x; LOBO RA, 1991, J CLIN ENDOCR METAB, V73, P925, DOI 10.1210/jcem-73-5-925; ROSEN PP, 1989, J CLIN ONCOL, V7, P355, DOI 10.1200/JCO.1989.7.3.355; Spicer D, 1990, Oncology (Williston Park), V4, P49; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; STOLL BA, 1989, EUR J CANCER CLIN ON, V25, P1909, DOI 10.1016/0277-5379(89)90372-6; VASSILOPOULOUSELLIN R, 1992, AM J MED SCI, V304, P145, DOI 10.1097/00000441-199209000-00001; 1991, TECHNICAL B AM COLLE, V158	11	23	23	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 22	1993	341	8856					1313	1314		10.1016/0140-6736(93)90820-7	http://dx.doi.org/10.1016/0140-6736(93)90820-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD253	8098453				2022-12-28	WOS:A1993LD25300008
J	MASKELL, K; MINTZER, IM; CALLANDER, BA				MASKELL, K; MINTZER, IM; CALLANDER, BA			BASIC SCIENCE OF CLIMATE-CHANGE	LANCET			English	Article									UNIV MARYLAND,STOCKHOLM ENVIRONM INST,COLL PK,MD 20742; UNIV MARYLAND,CTR GLOBAL CHANGE,COLL PK,MD 20742	University System of Maryland; University of Maryland College Park; University System of Maryland; University of Maryland College Park	MASKELL, K (corresponding author), METEOROL OFF,HADLEY CTR,INTERGOVT PANEL CLIMATE CHANGE TECH SUPPORT UNIT,BRACKNELL RG12 2SY,ENGLAND.							DANSGAARD W, 1993, NATURE, V364, P218, DOI 10.1038/364218a0; Houghton J.T., 1992, CLIMATE CHANGE 1992; Intergovernmental Panel on Climate Change, 1990, IPCC 1 ASS REP POL S, P63; MURPHY JM, 1992, 32 HADL CTR CLIM RES; Tegart W.J. McG., 1990, CLIMATE CHANGE IPCC	5	16	19	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 23	1993	342	8878					1027	1031		10.1016/0140-6736(93)92883-U	http://dx.doi.org/10.1016/0140-6736(93)92883-U			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD066	8105268				2022-12-28	WOS:A1993MD06600014
J	FAYAD, IM; HASHEM, M; DUGGAN, C; REFAT, M; BAKIR, M; FONTAINE, O; SANTOSHAM, M				FAYAD, IM; HASHEM, M; DUGGAN, C; REFAT, M; BAKIR, M; FONTAINE, O; SANTOSHAM, M			COMPARATIVE EFFICACY OF RICE-BASED AND GLUCOSE-BASED ORAL REHYDRATION SALTS PLUS EARLY REINTRODUCTION OF FOOD	LANCET			English	Article							ACUTE DIARRHEA; ELECTROLYTE SOLUTION; THERAPY	The use of oral rehydration salts (ORS) to restore fluid balance in children with diarrhoea is universally accepted. However, there is uncertainty about whether glucose-based ORS or ORS based on precooked rice powder is more effective. In a randomised trial we compared the two types of ORS in children who were given food immediately after completion of rehydration. 460 boys aged 3-18 months, admitted to hospital with acute diarrhoea and signs of dehydration, were randomly assigned to groups receiving rice-based and glucose-based ORS solution (230 to each group). After full rehydration (4-12 h), a weaning food consisting of rice and mixed vegetables was given until the diarrhoea stopped. Continuing losses of liquid stool and vomitus were replaced with the assigned ORS solution. There were no differences between the groups during the rehydration phase in stool volume, volume of ORS solution taken, duration of rehydration phase, or weight gain. However, after initiation of feeding, the glucose-based ORS group had significantly lower stool volumes than the rice-based ORS group (142 [95% CI 117-173] vs 96 [77-120] g/kg); they also took a smaller amount of ORS solution (153 [127-185] vs 111 [90-136] mL/kg) and had a shorter duration of diarrhoea (55 [SD 35] vs 44 [35] h). Glucose-based ORS solution was more effective than rice-based ORS solution for the treatment of diarrhoea in children when feeding with a rice-based diet was started soon after correction of dehydration. These results support the continued recommendation of glucose-based ORS solution as standard therapy for treatment of children with acute diarrhoea and emphasise the importance of resuming feeding as soon as dehydration has been corrected.	JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT INT HLTH, 615 N WOLFE ST, BALTIMORE, MD 21205 USA; CAIRO UNIV, HOSP ABU EL REECHE, DEPT GASTROENTEROL, CAIRO, EGYPT; WHO, DIARRHOEAL DIS CONTROL PROGRAMME, CH-1211 GENEVA 27, SWITZERLAND	Johns Hopkins University; Egyptian Knowledge Bank (EKB); Cairo University; World Health Organization								ALAM AN, 1987, ARCH DIS CHILD, V62, P440, DOI 10.1136/adc.62.5.440; AVERY ME, 1990, NEW ENGL J MED, V323, P891, DOI 10.1056/NEJM199009273231307; BHAN MK, 1987, J PEDIATR GASTR NUTR, V6, P392, DOI 10.1097/00005176-198705000-00016; BROWN KH, 1984, PEDIATRICS, V73, P119; DUTTA P, 1988, INDIAN J MED RES, V87, P229; ELMOUGI M, 1988, J PEDIATR GASTROENTE, V7, P76; GARDNER MJ, 1989, STATISTICS CNFIDENCE; GORE SM, 1992, BMJ-BRIT MED J, V304, P287, DOI 10.1136/bmj.304.6822.287; HIRSCHHORN N, 1968, NEW ENGL J MED, V279, P176, DOI 10.1056/NEJM196807252790402; KHINMAUNGU, 1985, BMJ-BRIT MED J, V290, P587; Mahalanabis D, 1974, J Trop Pediatr Environ Child Health, V20, P82; MOHAN M, 1988, INDIAN J MED RES, V87, P234; MOLLA AM, 1989, LANCET, V2, P429; MOLLA AM, 1989, J PEDIATR GASTR NUTR, V8, P81, DOI 10.1097/00005176-198901000-00015; MOLLA AM, 1985, B WORLD HEALTH ORGAN, V63, P751; PATRA FC, 1982, ARCH DIS CHILD, V57, P12; PIERCE NF, 1968, GASTROENTEROLOGY, V55, P333; POCOCK SJ, 1987, CLIN TRIALS PRACTICA, P123; RAHAMAN MM, 1979, LANCET, V2, P809; RICHARDS L, 1993, PEDIATR INFECT DIS J, V12, P5, DOI 10.1097/00006454-199301000-00003; SACK DA, 1978, LANCET, V2, P280; Santosham M, 1987, Pediatr Rev, V8, P273, DOI 10.1542/pir.8-9-273; SANTOSHAM M, 1985, PEDIATRICS, V76, P292; SANTOSHAM M, 1990, J PEDIATR-US, V116, P868, DOI 10.1016/S0022-3476(05)80642-0	24	37	37	1	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 25	1993	342	8874					772	775		10.1016/0140-6736(93)91540-3	http://dx.doi.org/10.1016/0140-6736(93)91540-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LY868	8103876	hybrid			2022-12-28	WOS:A1993LY86800009
J	DEBELLO, WM; BETZ, H; AUGUSTINE, GJ				DEBELLO, WM; BETZ, H; AUGUSTINE, GJ			SYNAPTOTAGMIN AND NEUROTRANSMITTER RELEASE	CELL			English	Review							SQUID GIANT SYNAPSE; TRANSMITTER RELEASE; VESICLE EXOCYTOSIS; NERVE-TERMINALS; SECRETION; PROTEIN; ACETYLCHOLINE		MAX PLANCK INST BRAIN RES, DEPT NEUROCHEM, D-60496 FRANKFURT 71, GERMANY	Max Planck Society	DEBELLO, WM (corresponding author), DUKE UNIV, MED CTR, DEPT NEUROBIOL, DURHAM, NC 27710 USA.		Augustine, George James/J-9228-2013					ADLER EM, 1991, J NEUROSCI, V11, P1496; AUGUSTINE GJ, 1991, ANN NY ACAD SCI, V635, P365, DOI 10.1111/j.1749-6632.1991.tb36505.x; AUGUSTINE GJ, 1984, J PHYSIOL-LONDON, V346, P257, DOI 10.1113/jphysiol.1984.sp015020; AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; AUGUSTINE GJ, 1986, J PHYSIOL-LONDON, V381, P619, DOI 10.1113/jphysiol.1986.sp016347; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DIANTONIO A, 1993, CELL, V73, P1281, DOI 10.1016/0092-8674(93)90356-U; DODGE FA, 1967, J PHYSIOL-LONDON, V193, P419, DOI 10.1113/jphysiol.1967.sp008367; ELFERINK LA, 1993, CELL, V72, P153, DOI 10.1016/0092-8674(93)90059-Y; HEUSER JE, 1979, J CELL BIOL, V81, P275, DOI 10.1083/jcb.81.2.275; Katz B., 1969, SHERRINGTON LECT; LEVEQUE C, 1992, P NATL ACAD SCI USA, V89, P3625, DOI 10.1073/pnas.89.8.3625; LITTLETON JT, 1993, CELL, V74, P1125, DOI 10.1016/0092-8674(93)90733-7; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; MATTHEW WD, 1981, J CELL BIOL, V91, P257, DOI 10.1083/jcb.91.1.257; MILEDI R, 1973, PROC R SOC SER B-BIO, V183, P421, DOI 10.1098/rspb.1973.0026; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; PARSEGIAN VA, 1977, SOC NEUROSCI S, V2, P161; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; PETRENKO AG, 1991, NATURE, V353, P65, DOI 10.1038/353065a0; POPOV SV, 1993, CELL, V73, P1247, DOI 10.1016/0092-8674(93)90352-Q; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SHOJIKASAI Y, 1992, SCIENCE, V256, P1820, DOI 10.1126/science.256.5065.1820; SILINSKY EM, 1985, PHARMACOL REV, V37, P81; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; TORRITARELLI F, 1985, J CELL BIOL, V101, P1386, DOI 10.1083/jcb.101.4.1386; WENDLAND B, 1991, NEURON, V6, P993, DOI 10.1016/0896-6273(91)90239-V	30	119	119	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 24	1993	74	6					947	950		10.1016/0092-8674(93)90716-4	http://dx.doi.org/10.1016/0092-8674(93)90716-4			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LY493	8104706				2022-12-28	WOS:A1993LY49300001
J	SUNG, JJY; CHUNG, SCS; LAI, CW; CHAN, FKL; LEUNG, JWC; YUNG, MY; KASSIANIDES, C; LI, AKC				SUNG, JJY; CHUNG, SCS; LAI, CW; CHAN, FKL; LEUNG, JWC; YUNG, MY; KASSIANIDES, C; LI, AKC			OCTREOTIDE INFUSION OR EMERGENCY SCLEROTHERAPY FOR VARICEAL HEMORRHAGE	LANCET			English	Article							BLEEDING ESOPHAGEAL-VARICES; CONTROLLED TRIAL; SOMATOSTATIN; CIRRHOSIS; MANAGEMENT; HEMORRHAGE	To compare octreotide with injection sclerotherapy in the treatment of acute variceal haemorrhage, patients admitted with gastrointestinal bleeding and oesophageal varices confirmed by endoscopy were randomised to receive either emergency sclerotherapy with 3% sodium tetradecyl sulphate or octreotide (50 mug intravenous bolus plus 50 mug per h intravenous infusion for 48 h). At the end of the study period (48 h), the octreotide group also had sclerotherapy to obliterate the varices. 100 patients were recruited. Demographic features including the aetiology of portal hypertension and the Child-Pugh's grading of the two groups were similar. Bleeding was initially controlled in 90% of patients by emergency sclerotherapy and in 84% by octreotide infusion (95% confidence interval 0-19.5, p=0.55). There were no significant differences between the two groups in early (within 48 h of randomisation) rebleeding (16% vs 14%), blood transfusion (3 units vs 3.5), hospital stay (5 days vs 6 days), or hospital mortality (27% vs 20%). No notable side-effects were associated with octreotide. We conclude that octreotide infusion and emergency sclerotherapy are equally effective in controlling variceal haemorrhage.	CHINESE UNIV HONG KONG,PRINCE WALES HOSP,DEPT SURG,SHA TIN,HONG KONG	Chinese University of Hong Kong; Prince of Wales Hospital	SUNG, JJY (corresponding author), CHINESE UNIV HONG KONG,PRINCE WALES HOSP,DEPT MED,SHA TIN,HONG KONG.		Sung, Joseph J. Y./R-3203-2018; Chan, Francis K. L./F-4851-2010	Sung, Joseph J. Y./0000-0003-3125-5199; Chan, Francis K. L./0000-0001-7388-2436				AVGERINOS A, 1991, J HEPATOL, V13, P78, DOI 10.1016/0168-8278(91)90867-B; BURROUGHS AK, 1990, GASTROENTEROLOGY, V99, P1388, DOI 10.1016/0016-5085(90)91166-4; FRANCO D, 1977, LANCET, V1, P218; GILBERT DA, 1981, GASTROINTEST ENDOSC, V27, P94; JENKINS SA, 1989, BRIT J SURG, V76, P49, DOI 10.1002/bjs.1800760115; JENKINS SA, 1985, BRIT MED J, V290, P270; LIN HC, 1992, GASTROENTEROLOGY, V103, P229, DOI 10.1016/0016-5085(92)91117-M; MASTAI R, 1986, Journal of Hepatology, V3, pS53; MCCORMICK PA, 1990, EUR J GASTROEN HEPAT, V2, P489; SHIELDS R, 1992, J HEPATOL, V16, P128, DOI 10.1016/S0168-8278(05)80105-9; SILVAIN C, 1991, HEPATOLOGY, V14, P1449; SONNENBERG GE, 1981, GASTROENTEROLOGY, V80, P526; TERBLANCHE J, 1989, NEW ENGL J MED, V320, P1393, DOI 10.1056/NEJM198905253202107; WALKER S, 1990, HEPATO-GASTROENTEROL, V37, P538	14	171	173	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 11	1993	342	8872					637	641		10.1016/0140-6736(93)91758-E	http://dx.doi.org/10.1016/0140-6736(93)91758-E			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX272	8103145				2022-12-28	WOS:A1993LX27200009
J	MERTENS, TE				MERTENS, TE			ESTIMATING THE EFFECTS OF MISCLASSIFICATION	LANCET			English	Article							RELATIVE RISK; CORRELATED EXPOSURES; BIAS		WHO,GLOBAL PROGRAMME AIDS,CH-1211 GENEVA 27,SWITZERLAND	World Health Organization				Mertens, Thierry Eric/0000-0002-1593-6608				[Anonymous], 1988, BMJ, V297, P319; BENNETT KJ, 1987, JAMA-J AM MED ASSOC, V257, P2451, DOI 10.1001/jama.257.18.2451; COPELAND KT, 1977, AM J EPIDEMIOL, V105, P488, DOI 10.1093/oxfordjournals.aje.a112408; CURTIS V, 1993, B WORLD HEALTH ORGAN, V71, P20; DEKLERK NH, 1989, INT J EPIDEMIOL, V18, P705, DOI 10.1093/ije/18.3.705; DUFFY SW, 1989, STAT MED, V8, P1529, DOI 10.1002/sim.4780081213; FINK AJ, 1989, J ROY SOC MED, V82, P695, DOI 10.1177/014107688908201132; FULLER WA, 1978, J AM STAT ASSOC, V73, P99, DOI 10.2307/2286529; GREENLAND S, 1985, AM J EPIDEMIOL, V122, P495, DOI 10.1093/oxfordjournals.aje.a114131; LILIENFELD AM, 1958, J NATL CANCER I, V27, P713; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MERTENS TE, 1990, TROP MED PARASITOL, V41, P79; PHILLIPS AN, 1992, STAT MED, V11, P953, DOI 10.1002/sim.4780110712; PHILLIPS AN, 1991, J CLIN EPIDEMIOL, V44, P1223, DOI 10.1016/0895-4356(91)90155-3; SILVERMAN WA, 1985, HUMAN EXPT GUIDED ST; SMITH GD, 1992, LANCET, V340, P709; SURICK I, 1989, 5 INT C AIDS MONTR; TZONOU A, 1986, REV EPIDEMIOL SANTE, V34, P10	18	62	63	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 14	1993	342	8868					418	421		10.1016/0140-6736(93)92820-J	http://dx.doi.org/10.1016/0140-6736(93)92820-J			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR900	8101908				2022-12-28	WOS:A1993LR90000016
J	SHANAHAN, F				SHANAHAN, F			PATHOGENESIS OF ULCERATIVE-COLITIS	LANCET			English	Article							INFLAMMATORY BOWEL-DISEASE; T-CELLS; CIGARETTE-SMOKING; MONOZYGOTIC TWINS; EPITHELIAL-CELLS; CROHNS-DISEASE; MESSENGER-RNA; SUBSTANCE-P; MUCOSA; AUTOANTIBODIES		UNIV CALIF LOS ANGELES, DEPT MED, DIV GASTROENTEROL, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles			Shanahan, Fergus/ABF-2390-2020	Shanahan, Fergus/0000-0003-0467-0936				BIRKENMELER E H, 1992, Gastroenterology, V102, pA596; BLUMBERG RS, 1990, GASTROENTEROLOGY, V98, P792, DOI 10.1016/0016-5085(90)90305-K; CANTRELL M, 1990, J AUTOIMMUN, V3, P307, DOI 10.1016/0896-8411(90)90149-M; CHOY MY, 1990, GUT, V31, P1365, DOI 10.1136/gut.31.12.1365; COMINELLI F, 1992, Gastroenterology, V102, pA609; COPE GF, 1992, GUT, V33, P721, DOI 10.1136/gut.33.6.721; DAS KM, 1987, J IMMUNOL, V139, P77; DAS KM, 1992, GUT, V33, P48, DOI 10.1136/gut.33.1.48; DRAKE CG, 1992, J CLIN IMMUNOL, V12, P149, DOI 10.1007/BF00918083; EKBOM A, 1991, DIGEST DIS SCI, V36, P97, DOI 10.1007/BF01300095; GIBSON PR, 1988, GUT, V29, P1076, DOI 10.1136/gut.29.8.1076; GIBSON PR, 1988, GUT, V29, P516, DOI 10.1136/gut.29.4.516; HALSTENSEN TS, 1990, GASTROENTEROLOGY, V98, P1264, DOI 10.1016/0016-5085(90)90343-Y; HAMMER RE, 1990, CELL, V63, P1099, DOI 10.1016/0092-8674(90)90512-D; HELGELAND L, 1992, GUT, V33, P1358, DOI 10.1136/gut.33.10.1358; ISAACS KL, 1992, GASTROENTEROLOGY, V103, P1587, DOI 10.1016/0016-5085(92)91182-4; JENKINS D, 1990, GUT, V31, P426, DOI 10.1136/gut.31.4.426; KAULFERSCH W, 1988, GASTROENTEROLOGY, V95, P364, DOI 10.1016/0016-5085(88)90492-1; KISHIMOTO TK, 1991, J NIH RES, V3, P75; KOIZUMI M, 1992, GASTROENTEROLOGY, V103, P840, DOI 10.1016/0016-5085(92)90015-Q; LOWES JR, 1990, SPRINGER SEMIN IMMUN, V12, P251; MACDONALD TT, 1988, J EXP MED, V167, P1341, DOI 10.1084/jem.167.4.1341; MADDEN MV, 1990, GUT, V31, P247, DOI 10.1136/gut.31.3.247; MANTYH CR, 1988, P NATL ACAD SCI USA, V85, P3235, DOI 10.1073/pnas.85.9.3235; MATSUURA T, 1993, GASTROENTEROLOGY, V104, P448, DOI 10.1016/0016-5085(93)90413-7; MAYER L, 1990, J CLIN INVEST, V86, P1255, DOI 10.1172/JCI114832; MULLIN GE, 1992, GASTROENTEROLOGY, V102, P1620, DOI 10.1016/0016-5085(92)91722-G; NORTH CS, 1991, ANN INTERN MED, V114, P381, DOI 10.7326/0003-4819-114-5-381; OKAZAKI K, 1993, GASTROENTEROLOGY, V104, P384, DOI 10.1016/0016-5085(93)90405-2; OSBORNE MJ, 1992, J ROY SOC MED, V85, P214; PARKOS CA, 1991, J CLIN INVEST, V88, P1605, DOI 10.1172/JCI115473; PAYAN DG, 1989, ANNU REV MED, V40, P341; PODOLSKY DK, 1991, NEW ENGL J MED, V325, P1008, DOI 10.1056/NEJM199110033251406; PODOLSKY DK, 1991, NEW ENGL J MED, V325, P928, DOI 10.1056/NEJM199109263251306; SARTOR RB, 1990, CAN J GASTROENTEROL, V4, P271; SAVERYMUTTU SH, 1985, EUR J CLIN INVEST, V15, P60, DOI 10.1111/j.1365-2362.1985.tb00145.x; SCHREIBER S, 1991, GASTROENTEROLOGY, V101, P1020, DOI 10.1016/0016-5085(91)90729-5; SCHREIBER S, 1992, GASTROENTEROL CLIN N, V21, P451; SHANAHAN F, 1992, GASTROENTEROLOGY, V103, P456, DOI 10.1016/0016-5085(92)90834-L; SHANAHAN F, 1992, CURR OPIN GASTROEN, V8, P988, DOI 10.1097/00001574-199212000-00016; SHANAHAN F, 1988, DIGEST DIS SCI, V33, pS41, DOI 10.1007/BF01538130; SHANAHAN F, 1992, CURRENT TOPICS GASTR, P77; SNOOK J, 1990, GUT, V31, P961, DOI 10.1136/gut.31.9.961; STERNBERG EM, 1992, ANN INTERN MED, V117, P854, DOI 10.7326/0003-4819-117-10-854; TYSK C, 1991, GASTROENTEROLOGY, V100, P419, DOI 10.1016/0016-5085(91)90211-3; VIDRICH A, 1991, Gastroenterology, V100, pA623; YANG H, IN PRESS INFLAMMATOR	47	89	92	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 14	1993	342	8868					407	411		10.1016/0140-6736(93)92818-E	http://dx.doi.org/10.1016/0140-6736(93)92818-E			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR900	8101906				2022-12-28	WOS:A1993LR90000014
J	HIEU, DT; TAN, TT; TAN, DN; NGUYET, PT; THAN, P; VINH, DQ				HIEU, DT; TAN, TT; TAN, DN; NGUYET, PT; THAN, P; VINH, DQ			31,781 CASES OF NONSURGICAL FEMALE STERILIZATION WITH QUINACRINE PELLETS IN VIETNAM	LANCET			English	Article							TUBAL-STERILIZATION; COMPLICATIONS; EFFICACY; SAFETY; RISK	The quinacrine method of non-surgical female sterilisation involves transcervical intrauterine insertion of 252 mg quinacrine as pellets during the proliferative phase of the menstrual cycle; the drug causes inflammation and fibrosis of the proximal fallopian tube. We have carried out a field trial of 31 781 cases in twenty-four provinces of Vietnam from Jan 2, 1989, until October, 1992. There were 818 pregnancies after the procedure, of which 80 were carried to term. Some women received only one dose of quinacrine; the majority received two doses with an interval of one month. Cumulative life-table pregnancy rates per 100 women at 1 year (for studies of at least 50 cases followed for 12 months) were 2.63 (SE 0.17) among 9461 women who received two doses and 5.15 (0.48) among 2225 who received only one dose. Failure rates (pregnancies) were strongly affected by the skill of the doctor or midwife. There were no deaths and only 8 serious complications were reported (0.03%); by contrast, in a similar series of women undergoing surgical sterilisation, 30 deaths and between 540 and 1812 serious complications would be expected. All reported side-effects were minor and of short duration. There were 19 ectopic pregnancies and the incidence was 0.89 per 1000 woman-years of use. There was one birth defect (anencephaly), in a fetus conceived 2.5 months after quinacrine insertions; however, we believe it is not related to the procedure. An estimated 242 maternal deaths will be averted by these 31 781 sterilisations. This method is safe and acceptably effective for female sterilisation.	MATERN & CHILD HLTH FAMILY PLANNING CTR,THAIBINH PROV,VIETNAM; MATERN & CHILD HLTH FAMILY PLANNING CTR,NAMHA PROV,VIETNAM; MYVAN HOSP,GYNAECOL OBSTET SECTOR,HAIHUNG PROV,VIETNAM; MATERN & CHILD HLTH FAMILY PLANNING CTR,NGHEAN PROV,VIETNAM		HIEU, DT (corresponding author), MINIST HLTH,DEPT MATERNAL & CHILD HLTH FAMILY PLANNING,138A GIANGVO,HANOI,VIETNAM.							AGOESTINA T, 1992, Advances in Contraception, V8, P141, DOI 10.1007/BF01849751; Bhatt R V, 1991, Asia Oceania J Obstet Gynaecol, V17, P297; BHATT RV, 1980, FERTIL STERIL, V33, P666; BHIWANDIWALA PP, 1982, AM J OBSTET GYNECOL, V14, P319; Blake D.A., 1983, FEMALE TRANSCERVICAL, P71; Chaturachinda K, 1980, Int J Gynaecol Obstet, V18, P414; CIAK J, 1967, SCIENCE, V156, P655, DOI 10.1126/science.156.3775.655; DESTEFANO F, 1983, OBSTET GYNECOL, V61, P153; Dubin N.H., 1983, FEMALE TRANSCERVICAL, P60; EL-KADY A A, 1991, Advances in Contraception, V7, P1, DOI 10.1007/BF01850712; FRANKS AL, 1990, AM J OBSTET GYNECOL, V163, P1120, DOI 10.1016/0002-9378(90)90668-W; KESSEL E, 1985, FERTIL STERIL, V44, P293; KESSEL E, 1982, FERTIL STERIL, V37, P725; LAYDE PM, 1983, OBSTET GYNECOL, V62, P180; MERCHANT R N, 1986, Advances in Contraception, V2, P79, DOI 10.1007/BF01849300; MERCHANT RN, IN PRESS INT J FERTI; MISHELL DR, 1988, MANAGEMENT COMMON PR, P638; MUMFORD SD, 1992, AM J OBSTET GYNECOL, V167, P1203, DOI 10.1016/S0002-9378(11)91689-5; MUMFORD SD, 1992, FERTIL STERIL, V57, P1151; PETERSON HB, 1983, INT J GYNECOL OBSTET, V21, P139, DOI 10.1016/0020-7292(83)90051-6; ROSENBERG MJ, 1982, INT J GYNECOL OBSTET, V20, P283, DOI 10.1016/0020-7292(82)90057-1; ROSS JA, 1991, 29 POP COUNC WORK PA; STECK EA, 1972, CHEMOTHERAPY PROTOZO, V3; ZIPPER J, 1987, Advances in Contraception, V3, P255, DOI 10.1007/BF01849399; Zipper J, 1980, Int J Gynaecol Obstet, V18, P275; 1991, MATERNAL MORTALITY R, P37; 1990, VIETNAM POPULATION C; 1990, VIETNAM PROGRAMME RE; 1982, COLLABORATIVE STUDY	29	98	99	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 24	1993	342	8865					213	217		10.1016/0140-6736(93)92302-A	http://dx.doi.org/10.1016/0140-6736(93)92302-A			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN622	8100933				2022-12-28	WOS:A1993LN62200015
J	BORGSTEIN, J; SADA, E; CORTES, R				BORGSTEIN, J; SADA, E; CORTES, R			CIPROFLOXACIN FOR RHINOSCLEROMA AND OZENA	LANCET			English	Letter									NATL INST RESP DIS,DEPT INFECT DIS,14080 MEXICO CITY,DF,MEXICO		BORGSTEIN, J (corresponding author), NATL INST RESP DIS,DEPT OTOLARYNGOL,14080 MEXICO CITY,DF,MEXICO.							GAMEA AM, 1988, J LARYNGOL OTOL, V102, P319, DOI 10.1017/S0022215100104840; LENIS A, 1988, SOUTHERN MED J, V81, P1580, DOI 10.1097/00007611-198812000-00029; MAHER AI, 1990, LARYNGOSCOPE, V100, P783; SANDERS CC, 1987, AM J MED, V82, P2; TOPPOZADA HH, 1986, J LARYNGOL OTOL, V100, P809, DOI 10.1017/S0022215100100118; ZAPATA A, 1986, ANAL SOC MEX ORL, V7, P100	6	15	17	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 10	1993	342	8863					122	122		10.1016/0140-6736(93)91329-K	http://dx.doi.org/10.1016/0140-6736(93)91329-K			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LL789	8100894				2022-12-28	WOS:A1993LL78900056
J	HILGARTNER, MW; BUCKLEY, JD; OPERSKALSKI, EA; PIKE, MC; MOSLEY, JW				HILGARTNER, MW; BUCKLEY, JD; OPERSKALSKI, EA; PIKE, MC; MOSLEY, JW			PURITY OF FACTOR-VIII CONCENTRATES AND SERIAL CD4 COUNTS	LANCET			English	Note							INFECTED HEMOPHILIACS	Whether expensive high-purity factor VIII concentrates are required to slow CD4 decline in HIV-infected haemophiliacs is controversial. We examined CD4 counts among such cases treated with intermediate-purity and high-purity factor VIII. 36 subjects treated with high-purity concentrate for 6 months or more had a smaller decline in CD4 than 72 matched controls on intermediate-purity concentrate (two-sided p=0.08). In a more complex analysis with 226 subjects, CD4 counts declined 3% less per 6 months with high-purity material than with intermediate product (p=0.04). Thus concentrate purity may affect rate of CD4 change.	CORNELL UNIV,NEW YORK HOSP CTR,NEW YORK,NY 10021; UNIV SO CALIF,SCH MED,LOS ANGELES,CA 90033	Cornell University; University of Southern California					NHLBI NIH HHS [N01-HB-9-7074, N01-HB-4-7003] Funding Source: Medline; DIVISION OF BLOOD DISEASES AND RESOURCES [N01HB047003, N01HB097074] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF BLOOD DISEASES AND RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CASH JD, 1991, BRIT MED J, V303, P633, DOI 10.1136/bmj.303.6803.633; DEBIASI R, 1991, BLOOD, V78, P1919; FLETCHER MA, 1992, BLOOD, V80, P831; FLETCHER MA, 1989, CLIN IMMUNOL IMMUNOP, V52, P38, DOI 10.1016/0090-1229(89)90191-8; GOLDSMITH JM, 1991, THROMB HAEMOSTASIS, V66, P415; GOMPERTS E D, 1992, Transfusion Medicine Reviews, V6, P44, DOI 10.1016/S0887-7963(92)70155-2; LAIRD NM, 1992, BIOMETRICS, V38, P963; MANNUCCI PM, 1992, THROMB HAEMOSTASIS, V67, P310; MAYNE EE, 1992, BRIT MED J, V304, P319, DOI 10.1136/bmj.304.6822.319-b; MENITOVE JE, 1983, NEW ENGL J MED, V308, P83, DOI 10.1056/NEJM198301133080206	10	40	40	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 29	1993	341	8857					1373	1374		10.1016/0140-6736(93)90943-B	http://dx.doi.org/10.1016/0140-6736(93)90943-B			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE180	8098792				2022-12-28	WOS:A1993LE18000006
J	BARNETT, AH; BAIN, SC				BARNETT, AH; BAIN, SC			MICROALBUMINURIA AND INSULIN-RESISTANCE IN DIABETES-MELLITUS	LANCET			English	Editorial Material							DISEASE		BIRMINGHAM HEARTLANDS HOSP,BIRMINGHAM,ENGLAND	Heart of England NHS Foundation Trust; University of Birmingham	BARNETT, AH (corresponding author), UNIV BIRMINGHAM,DEPT MED,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.							BORCHJOHNSEN K, 1985, DIABETOLOGIA, V28, P590, DOI 10.1007/BF00281993; GROOP L, 1993, DIABETOLOGIA, V36, P642, DOI 10.1007/BF00404074; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; YIP J, 1993, LANCET, V341, P369, DOI 10.1016/0140-6736(93)90167-F; YUDKIN JS, 1988, LANCET, V2, P530	5	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 9	1993	342	8876					880	881		10.1016/0140-6736(93)91940-N	http://dx.doi.org/10.1016/0140-6736(93)91940-N			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA963	8105161				2022-12-28	WOS:A1993MA96300004
J	KUMAR, L				KUMAR, L			EPIPODOPHYLLOTOXINS AND SECONDARY LEUKEMIA	LANCET			English	Editorial Material							LEUKEMIA; ETOPOSIDE; CISPLATIN; RADIATION; RISK				KUMAR, L (corresponding author), ALL INDIA INST MED SCI,INST ROTARY CANC HOSP,NEW DELHI 110016,INDIA.							AMYLON MD, 1992, BLOOD S, V80, pA206; BAJORIN DF, 1993, J NATL CANCER I, V85, P60, DOI 10.1093/jnci/85.1.60; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; HAWKINS MM, 1992, BRIT MED J, V304, P951, DOI 10.1136/bmj.304.6832.951; LEVINE EG, 1992, SEMIN ONCOL, V19, P47; NICHOLS CR, 1993, J NATL CANCER I, V85, P36, DOI 10.1093/jnci/85.1.36; PEDERSENBJERGAARD J, 1991, LANCET, V338, P359, DOI 10.1016/0140-6736(91)90490-G; PUI CH, 1991, NEW ENGL J MED, V325, P1682, DOI 10.1056/NEJM199112123252402; RATAIN MJ, 1987, BLOOD, V70, P1412; THACHUK DC, 1992, CELL, V71, P691; WHITLOCK JA, 1991, CANCER, V68, P600, DOI 10.1002/1097-0142(19910801)68:3<600::AID-CNCR2820680326>3.0.CO;2-F; WINICK NJ, 1993, J CLIN ONCOL, V11, P209, DOI 10.1200/JCO.1993.11.2.209	12	31	32	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 2	1993	342	8875					819	820		10.1016/0140-6736(93)92692-M	http://dx.doi.org/10.1016/0140-6736(93)92692-M			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA025	8104269				2022-12-28	WOS:A1993MA02500006
J	PALMER, CR				PALMER, CR			PROBABILITY OF RECURRENCE OF EXTREME DATA - AN AID TO DECISION-MAKING	LANCET			English	Article								Those, such as public health specialists, who have to assess routinely collected data often find it difficult to decide whether or not extreme results are a matter of chance. I describe here a simple method of measuring one's ''degree of surprise'' for noticeable patterns in ranked data, classified by time and place, to help detect significant departures from random variation. A table of exact probability values is the key to this approach. Designed primarily for reviewing post-hoc data, the method is relevant to published ''league tables'' of performance indicators. The table has to be used cautiously and the method is intended as a preliminary screen where data are limited or as a supplement to traditional analyses where there is more. Areas of application include public health, audit, and health services management and performance monitoring.			PALMER, CR (corresponding author), UNIV CAMBRIDGE,INST PUBL HLTH,DEPT COMMUNITY MED,ROBINSON WAY,CAMBRIDGE CB2 2SR,ENGLAND.							AGRESTI A, 1992, STAT SCI, V7, P131, DOI DOI 10.1214/SS/1177011454; Fisher RA, 1934, STAT METHODS RES WOR, V5; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; MEHTA CR, 1983, J AM STAT ASSOC, V78, P427, DOI 10.2307/2288652; Siegel S., 1988, NONPARAMETRIC STAT B; 1991, STATXACT STATISTICAL; 1993, LANCET, V341, P1183	7	6	6	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 2	1993	342	8875					845	847		10.1016/0140-6736(93)92699-T	http://dx.doi.org/10.1016/0140-6736(93)92699-T			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA025	8104276				2022-12-28	WOS:A1993MA02500013
J	DALEY, CL				DALEY, CL			TUBERCULOSIS RECURRENCE IN AFRICA - TRUE RELAPSE OR REINFECTION	LANCET			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS				DALEY, CL (corresponding author), SAN FRANCISCO GEN HOSP, DIV PULM & CRIT CARE MED, SAN FRANCISCO, CA 94110 USA.		Daley, Charles L./AAC-3231-2021					ALLEN S, 1992, AM REV RESPIR DIS, V146, P1439, DOI 10.1164/ajrccm/146.6.1439; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DECOCK KM, 1992, JAMA-J AM MED ASSOC, V268, P1581, DOI 10.1001/jama.1992.03490120095035; HAWKEN M, 1993, LANCET, V342, P332, DOI 10.1016/0140-6736(93)91474-Z; MUKADI Y, 1991, 7 P INT C AIDS FLOR; PERRIENS JH, 1991, AM REV RESPIR DIS, V144, P750, DOI 10.1164/ajrccm/144.4.750; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SMALL PM, 1993, NEW ENGL J MED, V328, P1137, DOI 10.1056/NEJM199304223281601; SMALL PM, 1991, NEW ENGL J MED, V324, P289, DOI 10.1056/NEJM199101313240503	9	23	23	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 25	1993	342	8874					756	757		10.1016/0140-6736(93)91535-T	http://dx.doi.org/10.1016/0140-6736(93)91535-T			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LY868	8103871				2022-12-28	WOS:A1993LY86800004
J	JUDSON, IR; THREADGILL, MD				JUDSON, IR; THREADGILL, MD			POLY(ADP-RIBOSYLATION) AS TARGET FOR CANCER-CHEMOTHERAPY	LANCET			English	Editorial Material							INHIBITORS; SYNTHETASE		UNIV BATH,SCH PHARM & PHARMACOL,BATH BA2 7AY,AVON,ENGLAND	University of Bath	JUDSON, IR (corresponding author), INST CANC RES,SUTTON SM2 5PX,SURREY,ENGLAND.		Threadgill, Michael/C-3925-2009					ALDERSON T, 1990, BIOL REV, V65, P623, DOI 10.1111/j.1469-185X.1990.tb01240.x; ALDERSON T, 1993, BIOL REV, V68, P265, DOI 10.1111/j.1469-185X.1993.tb00997.x; BANASIK M, 1992, J BIOL CHEM, V267, P1569; PURNELL MR, 1980, BIOCHEM J, V185, P775, DOI 10.1042/bj1850775; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; SUTO MJ, 1991, ANTI-CANCER DRUG DES, V7, P107; SWINNEN LJ, 1989, CANCER RES, V49, P1383; TSENG A, 1987, P NATL ACAD SCI USA, V84, P1107, DOI 10.1073/pnas.84.4.1107; UEDA K, 1985, ANNU REV BIOCHEM, V54, P73, DOI 10.1146/annurev.biochem.54.1.73	9	14	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 11	1993	342	8872					632	632		10.1016/0140-6736(93)91756-C	http://dx.doi.org/10.1016/0140-6736(93)91756-C			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX272	8103143				2022-12-28	WOS:A1993LX27200007
J	BLASI, J; CHAPMAN, ER; LINK, E; BINZ, T; YAMASAKI, S; DECAMILLI, P; SUDHOF, TC; NIEMANN, H; JAHN, R				BLASI, J; CHAPMAN, ER; LINK, E; BINZ, T; YAMASAKI, S; DECAMILLI, P; SUDHOF, TC; NIEMANN, H; JAHN, R			BOTULINUM NEUROTOXIN-A SELECTIVELY CLEAVES THE SYNAPTIC PROTEIN SNAP-25	NATURE			English	Article							SYNAPTOSOMAL-ASSOCIATED PROTEIN; MOTOR-NERVE TERMINALS; MEMBRANE-PROTEIN; CLOSTRIDIAL NEUROTOXINS; SECRETORY PATHWAY; VESICLES; IDENTIFICATION; SYNAPTOBREVIN; EXOCYTOSIS; RECEPTOR	NEUROTRANSMITTER release is potently blocked by a group of structurally related toxin proteins produced by Clostridium botulinum1. Botulinum neurotoxin type B (BoNT/B) and tetanus toxin (TeTx) are zinc-dependent proteases that specifically cleave synaptobrevin (VAMP), a membrane protein of synaptic vesicles2,3. Here we report that inhibition of transmitter release from synaptosomes caused by botulinum neurotoxin A (BoNT/A) is associated with the selective proteolysis of the synaptic protein SNAP-25. Furthermore, isolated or recombinant L chain of BoNT/A cleaves SNAP-25 in vitro. Cleavage occurred near the carboxyterminus and was sensitive to divalent cation chelators. In addition, a glutamate residue in the BoNT/A L chain, presumably required to stabilize a water molecule in the zinc-containing catalytic centre, was required for proteolytic activity. These findings demonstrate that BoNT/A acts as a zinc-dependent protease that selectively cleaves SNAP-25. Thus, a second component of the putative fusion complex mediating synaptic vesicle exocytosis is targeted by a clostridial neurotoxin.	FED RES CTR VIRUS DIS ANIM,INST MICROBIOL,W-7400 TUBINGEN,GERMANY; UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED CTR,DALLAS,TX 75235; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510; UNIV BARCELONA,SCH MED,DEPT CELL BIOL & PATHOL,BARCELONA 7,SPAIN	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; Yale University; Yale University; Yale University; University of Barcelona			Blasi, Juan/K-7943-2014	Blasi, Juan/0000-0002-0482-9444; Jahn, Reinhard/0000-0003-1542-3498; Chapman, Edwin/0000-0001-9787-8140				BARNSTABLE CJ, 1985, DEV BRAIN RES, V20, P286, DOI 10.1016/0165-3806(85)90116-6; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BINZ T, 1990, J BIOL CHEM, V265, P9153; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; BUCKLEY K, 1985, J CELL BIOL, V100, P1284, DOI 10.1083/jcb.100.4.1284; CATSICAS S, 1991, P NATL ACAD SCI USA, V88, P785, DOI 10.1073/pnas.88.3.785; CHAPMAN ER, 1992, J BIOL CHEM, V267, P25233; DREYER F, 1987, N-S ARCH PHARMACOL, V335, P1, DOI 10.1007/BF00165027; GANSEL M, 1987, PFLUG ARCH EUR J PHY, V409, P533, DOI 10.1007/BF00583812; HESS DT, 1992, J NEUROSCI, V12, P4634; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINK E, 1992, BIOCHEM BIOPH RES CO, V189, P1017, DOI 10.1016/0006-291X(92)92305-H; MATTEOLI M, 1991, J CELL BIOL, V115, P625, DOI 10.1083/jcb.115.3.625; NICHOLLS DG, 1986, NATURE, V321, P772, DOI 10.1038/321772a0; OLMSTEDT JB, 1987, METHOD ENZYMOL, V134, P467; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; SUGII S, 1975, INFECT IMMUN, V12, P1262, DOI 10.1128/IAI.12.6.1262-1270.1975; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; VALLEE BL, 1990, P NATL ACAD SCI USA, V87, P220, DOI 10.1073/pnas.87.1.220; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0; [No title captured]	30	960	998	2	87	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 9	1993	365	6442					160	163		10.1038/365160a0	http://dx.doi.org/10.1038/365160a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LW442	8103915				2022-12-28	WOS:A1993LW44200048
J	LEON, DA				LEON, DA			FAILED OR MISLEADING ADJUSTMENT FOR CONFOUNDING	LANCET			English	Article							HEART-DISEASE; AIR-POLLUTION; LUNG-CANCER; MORTALITY; SMOKING; AGE				LEON, DA (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,LONDON WC1E 7HT,ENGLAND.		Leon, David A/G-2195-2010	Leon, David A/0000-0001-9747-1762				BRESLOW NE, 1980, IARC SCI PUBL, V32, P100; DESWIET M, 1992, BRIT MED J, V304, P23, DOI 10.1136/bmj.304.6818.23; DOLL R, 1978, J EPIDEMIOL COMMUN H, V32, P303, DOI 10.1136/jech.32.4.303; GREENBERG ER, 1988, NEW ENGL J MED, V318, P612, DOI 10.1056/NEJM198803103181006; KAPLAN GA, 1990, BRIT MED J, V301, P1121, DOI 10.1136/bmj.301.6761.1121; Kiely J L, 1991, Paediatr Perinat Epidemiol, V5, P243, DOI 10.1111/j.1365-3016.1991.tb00707.x; KOHLMEIER L, 1992, BMJ-BRIT MED J, V305, P986, DOI 10.1136/bmj.305.6860.986; LAW CM, 1993, BRIT MED J, V306, P24, DOI 10.1136/bmj.306.6869.24; MALLOY MH, 1988, AM J EPIDEMIOL, V128, P46, DOI 10.1093/oxfordjournals.aje.a114957; MOSER KA, 1988, BRIT MED J, V296, P1221, DOI 10.1136/bmj.296.6631.1221; SCHIMMEL H, 1976, J OCCUP ENVIRON MED, V18, P316, DOI 10.1097/00043764-197605000-00006; SCHWARTZ J, 1990, AM J EPIDEMIOL, V131, P185, DOI 10.1093/oxfordjournals.aje.a115473; SIDNEY S, 1987, AM J PUBLIC HEALTH, V77, P317, DOI 10.2105/AJPH.77.3.317; SMITH GD, 1990, J EPIDEMIOL COMMUN H, V44, P257, DOI 10.1136/jech.44.4.257; SMITH GD, 1991, SOC SCI MED, V32, P1297, DOI 10.1016/0277-9536(91)90046-F; WILLETT WC, 1987, NEW ENGL J MED, V317, P1303, DOI 10.1056/NEJM198711193172102	16	45	45	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 21	1993	342	8869					479	481		10.1016/0140-6736(93)91599-H	http://dx.doi.org/10.1016/0140-6736(93)91599-H			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU075	8102435				2022-12-28	WOS:A1993LU07500016
J	KUIPERS, EJ; PENA, AS; VANKAMP, G; UYTERLINDE, AM; PALS, G; PELS, NFM; KURZPOHLMANN, E; MEUWISSEN, SGM				KUIPERS, EJ; PENA, AS; VANKAMP, G; UYTERLINDE, AM; PALS, G; PELS, NFM; KURZPOHLMANN, E; MEUWISSEN, SGM			SEROCONVERSION FOR HELICOBACTER-PYLORI	LANCET			English	Article							CAMPYLOBACTER-PYLORIDIS; GASTRIC-CARCINOMA; DUODENAL-ULCER; INFECTION; ERADICATION; ANTIBODY; RISK; SEROLOGY; CHILDREN; HUMANS	The prevalence of Helicobacter pylori antibodies increases with age, but it is unknown whether this is due to a constant rate of infection in different age groups, or whether most infection occurs in childhood. Follow-up data on infection rates and the course of infection in an untreated population are scarce. We measured H pylori IgG antibody concentrations in patients who were seen at our endoscopy unit between 1979 and 1983. 115 of 164 eligible patients (70%) participated in the study. H pylori IgG antibody concentrations were measured in two serum samples taken with a mean interval of 11.5 years. 56 patients tested positive at the first visit. During follow-up, 2 patients became infected (annual infection rate 0.30%, 95% CI 0.04-1.08%). Evidence of infection disappeared in 6 patients: after gastric surgery in 3 and due to an unknown cause in the remaining 3 patients. A non-significant decrease of infection was shown in different age cohorts during follow-up. Antibody concentrations did not increase with age. These results strongly support the concept of dominant infection rates in childhood. Elimination of infection may occur in a few patients without eradication therapy.	FREE UNIV AMSTERDAM HOSP,DEPT CLIN CHEM,1081 HV AMSTERDAM,NETHERLANDS; FREE UNIV AMSTERDAM HOSP,DEPT PATHOL,1081 HV AMSTERDAM,NETHERLANDS; FREE UNIV AMSTERDAM HOSP,DEPT HUMAN GENET,1081 HV AMSTERDAM,NETHERLANDS	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	KUIPERS, EJ (corresponding author), FREE UNIV AMSTERDAM HOSP,DEPT GASTROENTEROL,DE BOELELAAN 1117,1081 HV AMSTERDAM,NETHERLANDS.		Kuipers, Ernst J/H-3293-2019; Pals, Gerard/A-5198-2011	Kuipers, Ernst J/0000-0002-0633-3098; Pals, Gerard/0000-0003-4091-7115				FORMAN D, 1991, BRIT MED J, V302, P1302, DOI 10.1136/bmj.302.6788.1302; GEORGE LL, 1990, MED J AUSTRALIA, V153, P145, DOI 10.5694/j.1326-5377.1990.tb136833.x; GOODWIN CS, 1987, J INFECT DIS, V155, P488, DOI 10.1093/infdis/155.3.488; HO SA, 1991, J CLIN MICROBIOL, V29, P2543, DOI 10.1128/JCM.29.11.2543-2549.1991; JONES DM, 1986, J MED MICROBIOL, V22, P57, DOI 10.1099/00222615-22-1-57; KARNES WE, 1991, GASTROENTEROLOGY, V101, P167, DOI 10.1016/0016-5085(91)90474-Y; KOSUNEN TU, 1992, LANCET, V339, P893, DOI 10.1016/0140-6736(92)90929-W; KUIPERS EJ, 1993, SCAND J GASTROENTERO, V28, P433, DOI 10.3109/00365529309098245; KUIPERS EJ, IN PRESS SCAND J GAS; LOFFELD RJLF, 1992, GUT, V33, P1680, DOI 10.1136/gut.33.12.1680; MEYER B, 1991, GUT, V32, P347, DOI 10.1136/gut.32.4.347; NOMURA A, 1991, NEW ENGL J MED, V325, P1132, DOI 10.1056/NEJM199110173251604; ODERDA G, 1992, GUT, V33, P1328, DOI 10.1136/gut.33.10.1328; PARSONNET J, 1992, GASTROENTEROLOGY, V102, P41, DOI 10.1016/0016-5085(92)91782-Y; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; PENA AS, 1989, DIGESTION, V44, P131, DOI 10.1159/000199902; PEREZPEREZ GI, 1988, ANN INTERN MED, V109, P11, DOI 10.7326/0003-4819-109-1-11; RAUWS EAJ, 1990, LANCET, V335, P1233, DOI 10.1016/0140-6736(90)91301-P; SIERRA R, 1992, CANCER EPIDEM BIOMAR, V1, P449; SOBALA GM, 1991, LANCET, V338, P94, DOI 10.1016/0140-6736(91)90085-4; STEER HW, 1987, SERODIAGN IMMUNOTHER, V1, P253; VANZANTEN SV, 1992, GASTROENTEROLOGY, V102, pA184; VEENENDAAL RA, 1991, GUT, V32, P1291, DOI 10.1136/gut.32.11.1291; VEENENDAAL RA, 1992, GUT, V33, P452, DOI 10.1136/gut.33.4.452	24	208	209	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 7	1993	342	8867					328	331		10.1016/0140-6736(93)91473-Y	http://dx.doi.org/10.1016/0140-6736(93)91473-Y			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ868	8101585				2022-12-28	WOS:A1993LQ86800011
J	ABRAMS, MJ; MURRER, BA				ABRAMS, MJ; MURRER, BA			METAL-COMPOUNDS IN THERAPY AND DIAGNOSIS	SCIENCE			English	Article							COLLOIDAL BISMUTH SUBCITRATE; GALLIUM NITRATE; NITRIC-OXIDE; SODIUM-NITROPRUSSIDE; ANTITUMOR-ACTIVITY; CANCER; COMPLEXES; BONE; PHARMACOLOGY; ENHANCEMENT	There is increasing interest in the use of metal-containing compounds in medicine. This review describes several therapeutic applications, such as the use of platinum complexes in cancer chemotherapy, gold compounds in the treatment of arthritis, gallium in hypercalcemia, bismuth in anti-ulcer medication, and sodium nitroprusside in hypertension. The use of metal radionuclides in diagnosis and radiotherapy and the role of paramagnetic metal complexes as contrast agents in magnetic resonance imaging are also discussed.	JOHNSON MATTHEY TECHNOL CTR, READING RG4 9NH, ENGLAND		ABRAMS, MJ (corresponding author), JOHNSON MATTHEY INC, BIOMED RES WORLDWIDE, W CHESTER, PA 19380 USA.							ADAMSON RH, 1975, CANCER CHEMOTH REP 1, V59, P599; ALBERT A, 1985, SELECTIVE TOXICITY, P206; ANGHILERI LJ, 1987, ANTICANCER RES, V7, P1205; ASATO E, 1991, INORG CHEM, V30, P4210, DOI 10.1021/ic00022a023; BOCKMAN RS, 1986, CALCIFIED TISSUE INT, V39, P376, DOI 10.1007/BF02555174; CLARKE MJ, 1987, COORDIN CHEM REV, V78, P253, DOI 10.1016/0010-8545(87)85029-4; CLEARE MJ, 1978, BIOCHIMIE, V60, P835, DOI 10.1016/S0300-9084(78)80568-9; DIZIO JP, 1992, J NUCL MED, V33, P558; DOERR RJ, 1991, ANN SURG, V214, P118, DOI 10.1097/00000658-199108000-00005; EDWARDS CL, 1969, J NUCL MED, V10, P103; FERNANDEZHERLIHY L, 1991, ANN INTERN MED, V114, P993, DOI 10.7326/0003-4819-114-11-993_3; FLITNEY FW, 1992, BRIT J PHARMACOL, V107, P842, DOI 10.1111/j.1476-5381.1992.tb14534.x; FOGELMAN I, 1987, BONE SCANNING CLIN P, P31; FOSTER BJ, 1986, CANCER TREAT REP, V70, P1311; FRANCIS MD, 1987, BONE SCANNING CLIN P, P7; FRITZBERG AR, 1986, J NUCL MED, V27, P111; GIANDOMENICO C, 1985, SELECTIVE TOXICITY, P93; GROOTVELD M, 1990, FREE RADICAL RES COM, V10, P199, DOI 10.3109/10715769009149889; HALL DWR, 1989, SCAND J GASTROENTERO, V24, P3, DOI 10.3109/00365528909091043; HAMM B, 1992, RADIOLOGY, V182, P167, DOI 10.1148/radiology.182.1.1309218; HARRAP KR, 1985, SELECTIVE TOXICITY, P391; HERRMANN WA, 1991, INORG CHEM, V30, P2579, DOI 10.1021/ic00012a001; HOWARDLOCK HE, 1987, COMPREHENSIVE COORDI, V6; Howell S. B., 1991, PLATINUM OTHER METAL; JACKSON GE, 1990, POLYHEDRON, V9, P163, DOI 10.1016/S0277-5387(00)80565-3; KATSUKI S, 1977, J CYCLIC NUCL PROT, V3, P23; Kelland L, 1992, PLATINUM MET REV, V36, P178; KOENIG SH, 1988, ISRAEL J CHEM, V28, P345; KOWALUK EA, 1992, J PHARMACOL EXP THER, V262, P916; LINDER K E, 1992, Journal of Nuclear Medicine, V33, P919; MARKS GS, 1991, CAN J PHYSIOL PHARM, V69, P889, DOI 10.1139/y91-135; MATHER SJ, 1989, EUR J NUCL MED, V5, P307; MAXON HR, 1990, RADIOLOGY, V176, P155, DOI 10.1148/radiology.176.1.1693784; MONCADA S, 1991, PHARMACOL REV, V43, P109; MORROW JR, 1992, J AM CHEM SOC, V114, P1903, DOI 10.1021/ja00031a067; NOWOTNIK DP, 1992, DRUG NEWS PERSPECT, V5, P175; PIL PM, 1992, SCIENCE, V256, P234, DOI 10.1126/science.1566071; PREWETT EJ, 1991, ALIMENT PHARM THERAP, V5, P481; RASEY JS, 1982, EUR J CANCER CLIN ON, V18, P661, DOI 10.1016/0277-5379(82)90212-7; ROBINSON RG, 1987, NUCL MED BIOL, V14, P219, DOI 10.1016/0883-2897(87)90045-6; ROSENBERG B, 1965, NATURE, V205, P698, DOI 10.1038/205698a0; RUCKI R, 1977, ANAL PROFILES DRUG S, P489; RUEGG CL, 1990, CANCER RES, V50, P4221; Sadler P J, 1991, ADV INORG CHEM RAD, P1; SINGH A, 1989, J NUCL MED, V30, P1814; SNYDER RM, 1987, SEMIN ARTHRITIS RHEU, V17, P71, DOI 10.1016/0049-0172(87)90017-5; Steigman J, 1992, CHEM TECHNETIUM MED; SUNDQUIST WI, 1990, COORDIN CHEM REV, V100, P293, DOI 10.1016/0010-8545(90)85013-I; TIMMERBOSSCHA H, 1992, BRIT J CANCER, V66, P227, DOI 10.1038/bjc.1992.249; TWEEDLE MF, 1992, INVEST RADIOL, V27, pS2; WAGSTAFF AJ, 1988, DRUGS, V36, P132, DOI 10.2165/00003495-198836020-00002; WARRELL RP, 1983, CANCER, V51, P1982, DOI 10.1002/1097-0142(19830601)51:11<1982::AID-CNCR2820511104>3.0.CO;2-L; WARRELL RP, 1984, J CLIN INVEST, V73, P1487, DOI 10.1172/JCI111353; WARREN JR, 1983, LANCET, V1, P1273; WEINMANN HJ, 1984, AM J ROENTGENOL, V142, P619, DOI 10.2214/ajr.142.3.619	55	248	257	2	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 6	1993	261	5122					725	730		10.1126/science.8102010	http://dx.doi.org/10.1126/science.8102010			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ730	8102010				2022-12-28	WOS:A1993LQ73000029
J	FOWKES, FGR; LOWE, GDO; HOUSLEY, E; RATTRAY, A; RUMLEY, A; ELTON, RA; MACGREGOR, IR; DAWES, J				FOWKES, FGR; LOWE, GDO; HOUSLEY, E; RATTRAY, A; RUMLEY, A; ELTON, RA; MACGREGOR, IR; DAWES, J			CROSS-LINKED FIBRIN DEGRADATION PRODUCTS, PROGRESSION OF PERIPHERAL ARTERIAL-DISEASE, AND RISK OF CORONARY HEART-DISEASE	LANCET			English	Note							MYOCARDIAL-INFARCTION	Haemostatic and rheological factors may predict cardiovascular disease. We studied patients with intermittent claudication to see if the progression of peripheral arterial disease and the risks of coronary events could be predicted by baseline packed cell volume, plasma fibrinogen, blood and plasma viscosites, von Willebrand factor antigen, cross-linked fibrin degradation products (XLFDP), urinary fibrinopeptide A, and plasma leucocyte elastase. In 617 patients with claudication followed up for one year, baseline XLFDP was related most strongly to coronary events, relative risk 4.4 (95% CI 1.3-19.0) between top and bottom quintiles. Plasma fibrinogen was the strongest independent predictor of death from coronary disease. XLFDP was the only factor, in addition to age and cigarette smoking, that was independently associated (p = 0.008) with deterioration in peripheral arterial disease. We conclude that, in patients with peripheral arterial disease, plasma concentration of XLFDP, a measure of ongoing fibrin formation and degradation, is a strong predictor of both disease progression and future coronary risk. These results accord with the hypothesis that fibrin formation contributes to progression of coronary and peripheral atherosclerosis.	UNIV GLASGOW,GLASGOW ROYAL INFIRM,DEPT MED,HAEMOSTASIS & THROMBOSIS UNIT,GLASGOW,SCOTLAND; UNIV EDINBURGH,DEPT PUBL HLTH SCI,MED STAT UNIT,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND; SCOTTISH NATL BLOOD TRANSFUS SERV,NATL SCI LAB,EDINBURGH,SCOTLAND; MRC,SCOTTISH NATL BLOOD TRANSFUS SERV,BLOOD COMPONENTS ASSAY GRP,EDINBURGH,SCOTLAND	University of Glasgow; University of Edinburgh	FOWKES, FGR (corresponding author), UNIV EDINBURGH,DEPT PUBL HLTH SCI,WOLFSON UNIT PREVENT PERIFERAL VASC DIS,TEVIOT PL,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND.							ALZAHRANI H, 1992, CLIN HEMORHEOL, V12, P867; BANERJEE AK, 1992, THROMB HAEMOSTASIS, V68, P261; FOWKES FGR, 1988, J EPIDEMIOL COMMUN H, V42, P128, DOI 10.1136/jech.42.2.128; HAMSTEN A, 1987, LANCET, V2, P3; LOWE GDO, IN PRESS CIRCULATION; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; MEADE TW, 1991, LANCET, V337, P850; NIEUWENHUIZEN W, 1991, BLOOD COAGULATION HA, P151; SMITH EB, 1990, ARTERIOSCLEROSIS, V10, P263, DOI 10.1161/01.ATV.10.2.263; SMITH FB, IN PRESS ATHEROSCLER; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804; YARNELL JWG, 1991, CIRCULATION, V83, P836, DOI 10.1161/01.CIR.83.3.836; 1976, PUBLIC HLTH EUROPE	13	214	217	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 10	1993	342	8863					84	86		10.1016/0140-6736(93)91288-W	http://dx.doi.org/10.1016/0140-6736(93)91288-W			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LL789	8100915				2022-12-28	WOS:A1993LL78900012
J	LANGUINO, LR; PLESCIA, J; DUPERRAY, A; BRIAN, AA; PLOW, EF; GELTOSKY, JE; ALTIERI, DC				LANGUINO, LR; PLESCIA, J; DUPERRAY, A; BRIAN, AA; PLOW, EF; GELTOSKY, JE; ALTIERI, DC			FIBRINOGEN MEDIATES LEUKOCYTE ADHESION TO VASCULAR ENDOTHELIUM THROUGH AN ICAM-1-DEPENDENT PATHWAY	CELL			English	Article							GLYCOPROTEIN-IIB-IIIA; POLYMORPHONUCLEAR LEUKOCYTES; MONOCLONAL-ANTIBODIES; NEUTROPHIL ADHESION; SURFACE-RECEPTOR; CROSS-LINKING; CELL-LINES; ICAM-1; MOLECULE; BINDING	Leukocyte traffic in immune-inflammatory responses requires regulated adhesion of leukocyte subsets to vascular endothelium. We show that fibrinogen or normal human plasma enhances by 2- to 5-fold the adhesion of cells of myeloid and lymphoid lineage to endothelium. This mechanism is mediated by fibrinogen binding to complementary membrane receptors on leukocytes and endothelial cells. Using an affinity chromatography purification strategy, genetically engineered transfectants, and direct binding studies to the isolated recombinant protein, we identified a novel hematopoietic fibrinogen receptor participating in this adhesion pathway as intercellular adhesion molecule 1 (ICAM-1). Accordingly, a new model can be proposed, in which fibrinogen binding to a variety of vascular cell receptors mediates a specific pathway of cell to cell adhesion by bridging together leukocytes and endothelial cells.	SCRIPPS RES INST, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; RW JOHNSON PHARMACEUT RES INST, SAN DIEGO, CA 92121 USA; INSERM, U217, DBMS, HEMATOL LAB, F-38041 GRENOBLE, FRANCE; UNIV CALIF SAN DIEGO, DEPT CHEM, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR CANC, LA JOLLA, CA 92093 USA	Scripps Research Institute; Johnson & Johnson; Johnson & Johnson USA; Institut National de la Sante et de la Recherche Medicale (Inserm); University of California System; University of California San Diego; University of California System; University of California San Diego	LANGUINO, LR (corresponding author), SCRIPPS RES INST, COMM VASC BIOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Duperray, Alain/E-8428-2012	Duperray, Alain/0000-0002-2719-252X; Languino, Lucia/0000-0001-9011-7031	NHLBI NIH HHS [HL-43773] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043773] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIERI DC, 1993, J BIOL CHEM, V268, P1847; ALTIERI DC, 1988, J CELL BIOL, V107, P1893, DOI 10.1083/jcb.107.5.1893; BEEKHUIZEN H, 1990, J IMMUNOL, V145, P510; BERENDT AR, 1992, CELL, V68, P71, DOI 10.1016/0092-8674(92)90207-S; BEVILACQUA MP, 1985, J CLIN INVEST, V76, P2003, DOI 10.1172/JCI112200; BINI A, 1989, ARTERIOSCLEROSIS, V9, P109, DOI 10.1161/01.ATV.9.1.109; BURTON J, 1990, P NATL ACAD SCI USA, V87, P7329, DOI 10.1073/pnas.87.18.7329; CARLOS TM, 1990, IMMUNOL REV, V114, P5, DOI 10.1111/j.1600-065X.1990.tb00559.x; CERDAN C, 1989, CELL IMMUNOL, V123, P344, DOI 10.1016/0008-8749(89)90295-5; CHARO IF, 1987, J BIOL CHEM, V262, P9935; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; CHEUNG AL, 1991, J CLIN INVEST, V87, P2236, DOI 10.1172/JCI115259; CLARK EA, 1986, HUM IMMUNOL, V16, P100, DOI 10.1016/0198-8859(86)90039-X; DEJANA E, 1985, J CLIN INVEST, V75, P11, DOI 10.1172/JCI111661; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; DUSTIN ML, 1986, J IMMUNOL, V137, P245; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; GERRITY RG, 1981, AM J PATHOL, V103, P181; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; GUSTAFSON EJ, 1989, J CELL BIOL, V109, P377, DOI 10.1083/jcb.109.1.377; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JOHNSTON SC, 1990, J IMMUNOL, V145, P1181; JONASSON L, 1986, ARTERIOSCLEROSIS, V6, P131, DOI 10.1161/01.ATV.6.2.131; KATSUDA S, 1992, AM J PATHOL, V140, P907; KIRCHHOFER D, 1990, J BIOL CHEM, V265, P615; KUHLMAN P, 1991, J IMMUNOL, V146, P1773; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LEVESQUE JP, 1990, J BIOL CHEM, V265, P328; LEVESQUE JP, 1986, P NATL ACAD SCI USA, V83, P6494, DOI 10.1073/pnas.83.17.6494; MARKS RM, 1989, NATURE, V339, P314, DOI 10.1038/339314a0; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MCEVER RP, 1991, THROMB HAEMOSTASIS, V65, P223; OCKENHOUSE CF, 1992, CELL, V68, P63, DOI 10.1016/0092-8674(92)90206-R; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; PHILLIPS DR, 1988, BLOOD, V71, P831; POBER JS, 1986, J IMMUNOL, V137, P1893; POSTON RN, 1992, AM J PATHOL, V140, P665; PYTELA R, 1985, P NATL ACAD SCI USA, V82, P5766, DOI 10.1073/pnas.82.17.5766; ROSENSTEIN Y, 1991, NATURE, V354, P233, DOI 10.1038/354233a0; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SIMMONS D, 1988, NATURE, V331, P624, DOI 10.1038/331624a0; SMITH EB, 1979, LANCET, V2, P812; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAUNTON DE, 1989, CELL, V56, P849, DOI 10.1016/0092-8674(89)90689-2; TREZZINI C, 1988, BIOCHEM BIOPH RES CO, V156, P477, DOI 10.1016/S0006-291X(88)80866-0; TSUCHIYA S, 1980, INT J CANCER, V26, P171, DOI 10.1002/ijc.2910260208; VERCELLOTTI GM, 1991, J IMMUNOL, V146, P730; VOGEL BE, 1990, J BIOL CHEM, V265, P5934; WRIGHT SD, 1988, P NATL ACAD SCI USA, V85, P7734, DOI 10.1073/pnas.85.20.7734	53	305	313	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 2	1993	73	7					1423	1434		10.1016/0092-8674(93)90367-Y	http://dx.doi.org/10.1016/0092-8674(93)90367-Y			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LL209	8100742				2022-12-28	WOS:A1993LL20900016
J	GREEN, AR				GREEN, AR			ONCOLOGY - CHROMOSOMAL DELETIONS IN HEMATOLOGICAL MALIGNANCIES	LANCET			English	Editorial Material							LEUKEMIA				GREEN, AR (corresponding author), UNIV CAMBRIDGE,CAMBRIDGE,ENGLAND.			Green, Anthony/0000-0002-9795-0218				AHUJA HG, 1991, BLOOD, V78, P3259; BOULTWOOD J, 1991, P NATL ACAD SCI USA, V88, P6176, DOI 10.1073/pnas.88.14.6176; BROWN AG, 1993, NAT GENET, V3, P67, DOI 10.1038/ng0193-67; DIAZ MO, 1990, NEW ENGL J MED, V322, P77, DOI 10.1056/NEJM199001113220202; GAIDANO G, 1992, BLOOD, V80, P1781, DOI 10.1182/blood.V80.7.1781.bloodjournal8071781; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HU GY, 1992, BRIT J HAEMATOL, V81, P489, DOI 10.1111/j.1365-2141.1992.tb02979.x; JONVEAUX P, 1991, ONCOGENE, V6, P2243; MUFTI GJ, 1992, LEUKEMIA RES, V16, P35, DOI 10.1016/0145-2126(92)90097-Q; RIDGE SA, 1990, P NATL ACAD SCI USA, V87, P1377, DOI 10.1073/pnas.87.4.1377; SANDBERG AA, 1990, CHROMOSOMES HUMAN CA; VANDENBERGHE H, 1974, NATURE, V251, P437, DOI 10.1038/251437a0; WARRINGTON JA, 1992, GENOMICS, V13, P803, DOI 10.1016/0888-7543(92)90156-M; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156	14	4	4	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 19	1993	341	8860					1567	1568		10.1016/0140-6736(93)90704-K	http://dx.doi.org/10.1016/0140-6736(93)90704-K			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH550	8099647				2022-12-28	WOS:A1993LH55000011
J	MISSOURIS, CG; BUCKENHAM, T; VALLANCE, PJT; MACGREGOR, GA				MISSOURIS, CG; BUCKENHAM, T; VALLANCE, PJT; MACGREGOR, GA			RENAL-ARTERY STENOSIS MASQUERADING AS CONGESTIVE-HEART-FAILURE	LANCET			English	Article									ST GEORGE HOSP,SCH MED,DEPT MED,BLOOD PRESSURE UNIT,CRANMER TERRACE,LONDON SW17 0RE,ENGLAND; ST GEORGE HOSP,SCH MED,DEPT RADIOL,LONDON SW17 0RE,ENGLAND; ST GEORGE HOSP,SCH MED,DEPT CLIN PHARMACOL,LONDON SW17 0RE,ENGLAND	St Georges University London; St Georges University London; St Georges University London								GAVRAS H, 1973, SCIENCE, V180, P1369, DOI 10.1126/science.180.4093.1369; PICKERING TG, 1988, LANCET, V2, P551	2	49	51	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 12	1993	341	8859					1521	1522		10.1016/0140-6736(93)90645-W	http://dx.doi.org/10.1016/0140-6736(93)90645-W			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LG242	8099389				2022-12-28	WOS:A1993LG24200013
J	LOWDELL, M; BOTTAZZO, GF				LOWDELL, M; BOTTAZZO, GF			IMMUNOLOGY - AUTOIMMUNITY AND INSULIN-DEPENDENT DIABETES	LANCET			English	Editorial Material							SUBSETS; CELLS; TH1				LOWDELL, M (corresponding author), LONDON HOSP,COLL MED,DEPT IMMUNOL,LONDON E1 1BB,ENGLAND.		Lowdell, Mark W/G-4359-2011					ABBAS AK, 1991, IMMUNOL REV, V123, P5, DOI 10.1111/j.1600-065X.1991.tb00603.x; BAEKKESKOV S, 1990, NATURE, V347, P151, DOI 10.1038/347151a0; BOSI E, IN PRESS DIABETES CA; BOTTAZZO GF, 1963, DIABETES, V42, P778; GAJEWSKI TF, 1991, J IMMUNOL, V146, P1750; NERUP J, 1969, CLIN EXP IMMUNOL, V3, P55; POWRIE F, 1990, J EXP MED, V172, P1701, DOI 10.1084/jem.172.6.1701; ROMAGNANI S, 1991, IMMUNOL TODAY, V12, P256, DOI 10.1016/0167-5699(91)90120-I; SOLIMENA M, 1990, NEW ENGL J MED, V322, P1555, DOI 10.1056/NEJM199005313222202	9	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 29	1993	341	8857					1378	1379		10.1016/0140-6736(93)90947-F	http://dx.doi.org/10.1016/0140-6736(93)90947-F			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE180	8098796				2022-12-28	WOS:A1993LE18000010
J	TENCATE, JW				TENCATE, JW			THROMBOLYSIS - THROMBOLYTIC TREATMENT OF PULMONARY-EMBOLISM	LANCET			English	Editorial Material											TENCATE, JW (corresponding author), UNIV AMSTERDAM HOSP,DEPT HAEMATOL,AMSTERDAM,NETHERLANDS.							CARSON JL, 1992, NEW ENGL J MED, V326, P1240, DOI 10.1056/NEJM199205073261902; GOLDHABER SZ, 1993, LANCET, V341, P507, DOI 10.1016/0140-6736(93)90274-K; HUISMAN MV, 1989, CHEST, V95, P498, DOI 10.1378/chest.95.3.498; HULL RD, 1992, NEW ENGL J MED, V326, P975, DOI 10.1056/NEJM199204093261502; KRUIT WHJ, 1991, J INTERN MED, V230, P333, DOI 10.1111/j.1365-2796.1991.tb00453.x; PRADONI P, 1992, LANCET, V339, P441	6	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 22	1993	341	8856					1315	1316		10.1016/0140-6736(93)90822-X	http://dx.doi.org/10.1016/0140-6736(93)90822-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD253	8098455				2022-12-28	WOS:A1993LD25300010
J	HABUCHI, T; TAKAHASHI, R; YAMADA, H; KAKEHI, Y; SUGIYAMA, T; YOSHIDA, O				HABUCHI, T; TAKAHASHI, R; YAMADA, H; KAKEHI, Y; SUGIYAMA, T; YOSHIDA, O			METACHRONOUS MULTIFOCAL DEVELOPMENT OF UROTHELIAL CANCERS BY INTRALUMINAL SEEDING	LANCET			English	Note							BLADDER-CANCER; CLONAL ORIGIN; P53 MUTATIONS	To investigate the clonal origin of multifocal urothelial tumours, we analysed the p53 tumour-suppressor gene in 3 cases with bladder tumours developing after treatment for a renal pelvic or ureteral tumour and in 1 case with a ureteral tumour after treatment for a bladder tumour. For each case, identical p53 gene mutations were detected in all primary and recurrent tumours. The results suggest that heterotopic recurrence by intraluminal seeding from the original tumour is common in urothelial cancer. The data also support the view that multifocal urothelial tumours are derived from a single progenitor cell.	KYOTO UNIV,FAC MED,DEPT UROL,KYOTO 606,JAPAN; KYOTO UNIV,FAC MED,DEPT PATHOL,KYOTO 606,JAPAN	Kyoto University; Kyoto University								HABUCHI T, 1993, CANCER RES, V53, P3795; HARRIS AL, 1992, NEW ENGL J MED, V326, P759, DOI 10.1056/NEJM199203123261108; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LUNEC J, 1992, LANCET, V339, P439, DOI 10.1016/0140-6736(92)90135-P; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; SIDRANSKY D, 1992, NEW ENGL J MED, V326, P737, DOI 10.1056/NEJM199203123261104; SPRUCK CH, 1993, CANCER RES, V53, P1162	8	170	171	2	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 30	1993	342	8879					1087	1088		10.1016/0140-6736(93)92066-3	http://dx.doi.org/10.1016/0140-6736(93)92066-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME822	8105314				2022-12-28	WOS:A1993ME82200012
J	MACFARLANE, A; CHAMBERLAIN, G				MACFARLANE, A; CHAMBERLAIN, G			WHAT IS HAPPENING TO CESAREAN-SECTION RATES	LANCET			English	Editorial Material							CESAREAN-SECTION		ROYAL COLL OBSTETRICIANS & GYNAECOL,LONDON,ENGLAND		MACFARLANE, A (corresponding author), NATL PERINATAL EPIDEMIOL UNIT,OXFORD,ENGLAND.							Campbell R., 1990, POLITICS MATERNITY C; ENKIN MW, 1993, PREGNANCY CHILDBIRTH; LOMAS J, 1991, JAMA-J AM MED ASSOC, V265, P2202, DOI 10.1001/jama.265.17.2202; MACFARLANE A, 1988, BRIT MED J, V297, P852; Nair C, 1991, Health Rep, V3, P203; NOTZON FC, 1990, JAMA-J AM MED ASSOC, V263, P3286, DOI 10.1001/jama.263.24.3286; NOTZON FC, 1987, NEW ENGL J MED, V316, P386, DOI 10.1056/NEJM198702123160706; Notzon FC, 1991, ACTA OBSTET GYN SCAN, V70, P451, DOI 10.3109/00016349109007159; SAVAGE W, 1993, CAESAREAN BIRTH BRIT; STAFFORD RS, 1990, AM J PUBLIC HEALTH, V80, P313, DOI 10.2105/AJPH.80.3.313; Stephenson P A, 1993, Paediatr Perinat Epidemiol, V7, P45, DOI 10.1111/j.1365-3016.1993.tb00600.x; 1993, MMWR, V42, P285	12	36	36	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 23	1993	342	8878					1005	1006		10.1016/0140-6736(93)92874-S	http://dx.doi.org/10.1016/0140-6736(93)92874-S			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD066	8105260				2022-12-28	WOS:A1993MD06600005
J	DICKINSON, CJ				DICKINSON, CJ			FAINTING PRECIPITATED BY COLLAPSE-FIRING OF VENOUS BARORECEPTORS	LANCET			English	Article							TRANSPLANT RECIPIENT; VASOVAGAL SYNCOPE; HEMORRHAGE; HEART; RABBITS	I propose that fainting (vaso-vagal syncope) is caused by the sudden invagination of the walls of underfilled atria and great veins when their intraluminal pressure no longer exceeds intrathoracic pressure, leading to anomalous collapse-firing of veno-atrial stretch receptors. Impulses there from cause reflex systemic vasodilation and bradycardia, probably through a brainstem relay path involving opioids and possibly the A5 area of the medulla. The inappropriate increase of afferent atriovenous baroreceptor-nerve activity leads, by a vicious circle, to a sudden collapse of systemic arterial pressure. Activation of ventricular receptors is neither a probable nor a necessary cause of syncope, though it might be part of the response.			DICKINSON, CJ (corresponding author), ST BARTHOLOMEWS HOSP,COLL MED,WOLFSON INST PREVENT MED,CHARTERHOUSE SQ,LONDON EC1M 6BQ,ENGLAND.							ABBOUD FM, 1993, NEW ENGL J MED, V328, P1117, DOI 10.1056/NEJM199304153281510; AVIADO DM, 1951, AM J PHYSIOL, V165, P261, DOI 10.1152/ajplegacy.1951.165.2.261; Bainbridge FA, 1915, J PHYSIOL-LONDON, V50, P65; BARCROFT H, 1945, J PHYSIOL-LONDON, V104, P161, DOI 10.1113/jphysiol.1945.sp004113; BARER GR, 1958, J PHYSIOL-LONDON, V143, P1; BEARN AG, 1951, J PHYSIOL-LONDON, V115, P442, DOI 10.1113/jphysiol.1951.sp004680; BURKE SL, 1988, J PHYSIOL-LONDON, V402, P9, DOI 10.1113/jphysiol.1988.sp017191; COLERIDGE JCG, 1955, J PHYSIOL-LONDON, V128, P310, DOI 10.1113/jphysiol.1955.sp005308; DALY I. de BURGH, 1927, JOUR PHYSIOL, V62, P330; DEWARDENER HE, 1951, CLIN SCI, V10, P209; DICKINSON CJ, 1991, NEUROGENIC HYPERTENS, P65; EDIS A J, 1970, Circulation Research, V27, P1091; EVANS RG, 1989, J PHYSIOL-LONDON, V409, P1; HAINSWORTH R, 1991, PHYSIOL REV, V71, P617, DOI 10.1152/physrev.1991.71.3.617; Heymans C., 1958, REFLEXOGENIC AREAS C; KAPPAGODA CT, 1972, J PHYSIOL-LONDON, V220, P177, DOI 10.1113/jphysiol.1972.sp009700; KARIM F, 1992, J PHYSIOL-LONDON, V456, P529, DOI 10.1113/jphysiol.1992.sp019351; LANDGREN S, 1952, ACTA PHYSIOL SCAND, V26, P1; LINDEN RJ, 1982, ATRIAL RECEPTORS, P120; OBERG B, 1970, Acta Physiologica Scandinavica, V80, P395, DOI 10.1111/j.1748-1716.1970.tb04803.x; OBERG B, 1972, ACTA PHYSIOL SCAND, V85, P164, DOI 10.1111/j.1748-1716.1972.tb05247.x; PAINTAL AS, 1963, J PHYSIOL-LONDON, V169, P116, DOI 10.1113/jphysiol.1963.sp007244; PATHAK CL, 1966, AM HEART J, V72, P577, DOI 10.1016/0002-8703(66)90339-5; Popper K., 1959, LOGIC SCI DISCOVERY; RUDAS L, 1992, CAN J CARDIOL, V8, P403; SASSA K, 1920, J PHYSIOL-LONDON, V54, P230; SCHERRER U, 1990, NEW ENGL J MED, V322, P602, DOI 10.1056/NEJM199003013220906; SHARPEYSCHAFER EP, 1952, VISCERAL CIRCULATION, P268; STANEK KA, 1984, AM J PHYSIOL, V246, pH44, DOI 10.1152/ajpheart.1984.246.1.H44; VANLIESHOUT JJ, 1991, CLIN SCI, V81, P575, DOI 10.1042/cs0810575; WALLIN BG, 1982, J AUTONOM NERV SYST, V6, P287	31	48	56	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 16	1993	342	8877					970	972		10.1016/0140-6736(93)92008-H	http://dx.doi.org/10.1016/0140-6736(93)92008-H			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MC005	8105220				2022-12-28	WOS:A1993MC00500015
J	DOLMAN, KM; GANS, ROB; VERVAAT, TJ; ZEVENBERGEN, G; MAINGAY, D; NIKKELS, RE; DONKER, AJM; BORNE, AEGKV; GOLDSCHMEDING, R				DOLMAN, KM; GANS, ROB; VERVAAT, TJ; ZEVENBERGEN, G; MAINGAY, D; NIKKELS, RE; DONKER, AJM; BORNE, AEGKV; GOLDSCHMEDING, R			VASCULITIS AND ANTINEUTROPHIL CYTOPLASMIC AUTOANTIBODIES ASSOCIATED WITH PROPYLTHIOURACIL THERAPY	LANCET			English	Note							CUTANEOUS VASCULITIS; NEUTROPHIL	Vasculitis is a rare complication of propylthiouracil therapy. Antineutrophil cytoplasmic antibodies (ANCA) have been described in association with several vasculitic disorders. We report detection of ANCA against human neutrophil elastase, proteinase 3, and myeloperoxidase in serum from six patients who developed evidence of vasculitis during propylthiouracil treatment of hyperthyroidism. On withdrawal of the drug ANCA concentrations fell and clinical symptoms resolved completely.	NETHERLANDS RED CROSS, BLOOD TRANSFUS SERV,CENT LAB,PUBLICAT SECRETARIAT, POB 9406, 1006 AK AMSTERDAM, NETHERLANDS; UNIV AMSTERDAM, EXPTL & CLIN IMMUNOL LAB, AMSTERDAM, NETHERLANDS; FREE UNIV AMSTERDAM HOSP, DEPT NEPHROL, AMSTERDAM, NETHERLANDS; ST LUCAS HOSP, DEPT INTERNAL MED, AMSTERDAM, NETHERLANDS; WESTFIES GASTLUIS, DEPT INTERNAL MED, HOORN, NETHERLANDS; GOOI NOORD HOSP, DEPT INTERNAL MED, BLARICUM, NETHERLANDS; DE WEVER HOSP, DEPT INTERNAL MED, HEARTEN, NETHERLANDS; UNIV AMSTERDAM, ACAD MED CTR, DEPT HEMATOL, 1105 AZ AMSTERDAM, NETHERLANDS; UNIV AMSTERDAM, ACAD MED CTR, DEPT PATHOL, 1105 AZ AMSTERDAM, NETHERLANDS	University of Amsterdam; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Sint Lucas Andreas Hospital; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam			Goldschmeding, Roel/I-1723-2014	Gans, Reinold/0000-0001-5481-2387				CARRASCO MD, 1987, ARCH INTERN MED, V147, P1677, DOI 10.1001/archinte.147.9.1677; COOPER DS, 1984, NEW ENGL J MED, V311, P1353, DOI 10.1056/NEJM198411223112106; FALK RJ, 1990, P NATL ACAD SCI USA, V87, P4115, DOI 10.1073/pnas.87.11.4115; GALLICCHIO MC, 1991, CLIN EXP IMMUNOL, V84, P232; GRISWOLD WR, 1978, WESTERN J MED, V128, P543; KALLENBERG CGM, 1991, IMMUNOL TODAY, V12, P61, DOI 10.1016/0167-5699(91)90159-Q; NASSBERGER L, 1990, CLIN EXP IMMUNOL, V81, P380; TERVAERT JWC, 1990, THESIS U GRONINGEN N; VANDEWIEL BA, 1992, CLIN EXP IMMUNOL, V90, P409; VASILY DB, 1980, JAMA-J AM MED ASSOC, V243, P458, DOI 10.1001/jama.243.5.458	10	277	304	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 11	1993	342	8872					651	652		10.1016/0140-6736(93)91761-A	http://dx.doi.org/10.1016/0140-6736(93)91761-A			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX272	8103148				2022-12-28	WOS:A1993LX27200012
J	REMUZZI, G; BENIGNI, A				REMUZZI, G; BENIGNI, A			ENDOTHELINS IN THE CONTROL OF CARDIOVASCULAR AND RENAL-FUNCTION	LANCET			English	Review							PLASMA ENDOTHELIN; VASCULAR-RESPONSES; URINARY-EXCRETION; RAT; CYCLOSPORINE; CELLS; RECEPTOR; VASOCONSTRICTION; ATHEROSCLEROSIS; TRANSPLANTATION		OSPED RIUNITI BERGAMO,MARIO NEGRI INST PHARMACOL RES,I-24100 BERGAMO,ITALY; OSPED RIUNITI BERGAMO,DIV NEPHROL & DIALYSIS,I-24100 BERGAMO,ITALY	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Ospedali Riuniti di Bergamo; Ospedali Riuniti di Bergamo			Ariela, Benigni/ABH-3492-2020; Remuzzi, Giuseppe/V-9766-2017	Ariela, Benigni/0000-0002-4721-5485; Remuzzi, Giuseppe/0000-0002-6194-3446				ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; BADR KF, 1989, J CLIN INVEST, V83, P336, DOI 10.1172/JCI113880; BENIGNI A, 1991, AM J PHYSIOL, V260, pF331, DOI 10.1152/ajprenal.1991.260.3.F331; BENIGNI A, 1991, TRANSPLANTATION, V52, P175; BENIGNI A, 1993, 12TH INT C NEPHR SCI; CERNACEK P, 1989, BIOCHEM BIOPH RES CO, V161, P562, DOI 10.1016/0006-291X(89)92636-3; DAVENPORT AP, 1989, J CARDIOVASC PHAR S5, V13, P166; DENUCCI G, 1988, P NATL ACAD SCI USA, V85, P9797; EZRA D, 1989, AM J PHYSIOL, V257, pH339, DOI 10.1152/ajpheart.1989.257.1.H339; FOGO A, 1992, KIDNEY INT, V42, P770, DOI 10.1038/ki.1992.346; GOETZ KL, 1988, AM J PHYSIOL, V255, pR1064, DOI 10.1152/ajpregu.1988.255.6.R1064; HU RJ, 1988, EUR J PHARMACOL, V158, P177; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; ISHIMURA E, 1991, Journal of the American Society of Nephrology, V2, P546; KAWAGUCHI H, 1990, 13TH INT SOC HYPT SC; KOYAMA H, 1989, LANCET, V1, P991; LARIVIERE R, 1993, HYPERTENSION, V21, P294, DOI 10.1161/01.HYP.21.3.294; LERMAN A, 1991, NEW ENGL J MED, V325, P997, DOI 10.1056/NEJM199110033251404; LIPPTON HL, 1989, J APPL PHYSIOL, V66, P1008, DOI 10.1152/jappl.1989.66.2.1008; LIU JJ, 1989, BIOCHEM BIOPH RES CO, V164, P1220, DOI 10.1016/0006-291X(89)91799-3; LUSCHER TF, 1987, HYPERTENSION, V9, P157, DOI 10.1161/01.HYP.9.2.157; MILLER WL, 1989, J CLIN INVEST, V83, P317, DOI 10.1172/JCI113876; MIYAUCHI T, 1989, LANCET, V2, P53, DOI 10.1016/S0140-6736(89)90303-6; MORAVEC CS, 1989, BIOCHEM BIOPH RES CO, V159, P14, DOI 10.1016/0006-291X(89)92397-8; NAMBI P, 1990, EUR J PHARMACOL, V187, P113, DOI 10.1016/0014-2999(90)90346-8; NAYLER WG, 1989, BIOCHEM BIOPH RES CO, V163, P1270, DOI 10.1016/0006-291X(89)91115-7; OHTA K, 1991, KIDNEY INT, V39, P307, DOI 10.1038/ki.1991.38; ORISIO S, 1993, KIDNEY INT, V43, P354, DOI 10.1038/ki.1993.53; PERICO N, 1990, J AM SOC NEPHROL, V1, P76; PERICO N, 1992, TRANSPLANTATION, V54, P56, DOI 10.1097/00007890-199207000-00009; PERICO N, 1991, J AM SOC NEPHROL, V2, P57; PERNOW J, 1988, ACTA PHYSIOL SCAND, V134, P573, DOI 10.1111/j.1365-201X.1988.tb10642.x; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SHICHIRI M, 1990, HYPERTENSION, V15, P493, DOI 10.1161/01.HYP.15.5.493; SHIMOKAWA H, 1989, CIRC RES, V64, P900, DOI 10.1161/01.RES.64.5.900; Simonson M S, 1993, Curr Opin Nephrol Hypertens, V2, P51, DOI 10.1097/00041552-199301000-00008; SIMONSON MS, 1992, J LAB CLIN MED, V119, P622; SOKOLOVSKY M, 1992, J BIOL CHEM, V267, P20551; STEWART DJ, 1991, ANN INTERN MED, V114, P464, DOI 10.7326/0003-4819-114-6-464; STEWART JT, 1991, BRIT HEART J, V66, P7; SUZUKI N, 1990, BIOCHEM BIOPH RES CO, V169, P809, DOI 10.1016/0006-291X(90)90403-A; TAKAGI M, 1989, AM J PHYSIOL, V257, pE833, DOI 10.1152/ajpendo.1989.257.6.E833; TOMITA K, 1990, J CLIN INVEST, V85, P2014, DOI 10.1172/JCI114667; VIERHAPPER H, 1990, CIRCULATION, V81, P1415, DOI 10.1161/01.CIR.81.4.1415; VIGNE P, 1989, FEBS LETT, V249, P143, DOI 10.1016/0014-5793(89)80611-8; WAGNER OF, 1992, J BIOL CHEM, V267, P16066; WARNER TD, 1993, NATURE, V362, P497, DOI 10.1038/362497a0; WATANABE T, 1990, NATURE, V344, P114, DOI 10.1038/344114a0; WATSCHINGER B, 1991, TRANSPLANTATION, V52, P743, DOI 10.1097/00007890-199110000-00035; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; ZEIDEL ML, 1989, AM J PHYSIOL, V257, pC1101, DOI 10.1152/ajpcell.1989.257.6.C1101; ZOJA C, 1991, LAB INVEST, V64, P16	52	108	113	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 4	1993	342	8871					589	593		10.1016/0140-6736(93)91414-H	http://dx.doi.org/10.1016/0140-6736(93)91414-H			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV963	8102724				2022-12-28	WOS:A1993LV96300014
J	GOODWIN, CS				GOODWIN, CS			GASTRIC-CANCER AND HELICOBACTER-PYLORI - THE WHISPERING KILLER	LANCET			English	Editorial Material							INFECTION; STOMACH				GOODWIN, CS (corresponding author), UNITED ARAB EMIRATES UNIV, FAC MED, DEPT MED MICROBIOL, AL AIN, U ARAB EMIRATES.							BARKER DJP, 1990, BRIT J CANCER, V61, P575, DOI 10.1038/bjc.1990.129; FORMAN D, 1993, LANCET, V341, P1359; GOODWIN CS, 1992, CURR OPIN GASTROEN, V8, P122; GRAHAM DY, 1993, NEW ENGL J MED, V328, P349, DOI 10.1056/NEJM199302043280512; HALLISSEY MT, 1990, BRIT MED J, V301, P513, DOI 10.1136/bmj.301.6751.513; HENTSCHEL E, 1993, NEW ENGL J MED, V328, P308, DOI 10.1056/NEJM199302043280503; Logan Robert P. H., 1993, P307; Mitchell Hazel M., 1993, P95; NEWELL DG, 1991, J CLIN PATHOL, V44, P385, DOI 10.1136/jcp.44.5.385; PARSONNET J, 1993, GASTROENTEROL CLIN N, V22, P89; QIN DX, 1993, CANCER, V71, P216, DOI 10.1002/1097-0142(19930101)71:1<216::AID-CNCR2820710133>3.0.CO;2-#; RECAVARRENARCE S, 1991, SCAND J GASTROENTERO, V26, P51, DOI 10.3109/00365529109093208; SEDGWICK DM, 1991, BRIT MED J, V302, P1305, DOI 10.1136/bmj.302.6788.1305; Sipponen Pentti, 1993, P37; SOBALA GM, 1991, CARCINOGENESIS, V12, P193, DOI 10.1093/carcin/12.2.193	15	18	18	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 28	1993	342	8870					507	508		10.1016/0140-6736(93)91640-8	http://dx.doi.org/10.1016/0140-6736(93)91640-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU582	8102661				2022-12-28	WOS:A1993LU58200003
J	MATUSCHKA, FR; SPIELMAN, A				MATUSCHKA, FR; SPIELMAN, A			RISK OF INFECTION FROM AND TREATMENT OF TICK BITE	LANCET			English	Article							LYME-DISEASE SPIROCHETE; BORRELIA-BURGDORFERI; IXODES-DAMMINI; BABESIA-MICROTI; TRANSMISSION; ATTACHMENT; DURATION		HARVARD UNIV,SCH PUBL HLTH,DEPT TROP PUBL HLTH,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health	MATUSCHKA, FR (corresponding author), FREE UNIV BERLIN,UNIV KLINIKUM RUDOLF VIRCHOW,INST PATHOL,D-12249 BERLIN,GERMANY.							MAGID D, 1992, NEW ENGL J MED, V327, P534, DOI 10.1056/NEJM199208203270806; MATUSCHKA FR, 1992, PARASITOL RES, V78, P695, DOI 10.1007/BF00931523; MATUSCHKA FR, 1992, NEW ENGL J MED, V327, P542, DOI 10.1056/NEJM199208203270807; MATUSCHKA FR, 1992, WOOD TICKS LYME DISE; PIESMAN J, 1991, J INFECT DIS, V163, P895, DOI 10.1093/infdis/163.4.895; PIESMAN J, 1986, INT J PARASITOL, V16, P381, DOI 10.1016/0020-7519(86)90118-9; PIESMAN J, 1987, J CLIN MICROBIOL, V25, P557, DOI 10.1128/JCM.25.3.557-558.1987; PIESMAN J, 1986, ACTA TROP, V43, P263; SHAPIRO ED, 1992, NEW ENGL J MED, V327, P1769, DOI 10.1056/NEJM199212173272501; SHIH CM, 1992, J INFECT DIS, V166, P827, DOI 10.1093/infdis/166.4.827	10	17	18	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 28	1993	342	8870					529	530		10.1016/0140-6736(93)91650-B	http://dx.doi.org/10.1016/0140-6736(93)91650-B			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU582	8102671				2022-12-28	WOS:A1993LU58200013
J	BERNUAU, J; BENHAMOU, JP				BERNUAU, J; BENHAMOU, JP			CLASSIFYING ACUTE LIVER-FAILURE	LANCET			English	Editorial Material							FULMINANT; HEPATITIS				BERNUAU, J (corresponding author), HOP BEAUJON,INSERM,U24,SERV HEPATOL,CLICHY,FRANCE.							BERNUAU J, 1986, HEPATOLOGY, V6, P648, DOI 10.1002/hep.1840060417; BERNUAU J, 1991, HEPATOLOGY, V14, pA49; BERNUAU J, 1986, SEMIN LIVER DIS, V6, P97, DOI 10.1055/s-2008-1040593; OGRADY JG, 1993, LANCET, V342, P273; OGRADY JG, 1989, GASTROENTEROLOGY, V97, P439, DOI 10.1016/0016-5085(89)90081-4; Trey C, 1970, Prog Liver Dis, V3, P282	6	47	49	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 31	1993	342	8866					252	253		10.1016/0140-6736(93)91809-Z	http://dx.doi.org/10.1016/0140-6736(93)91809-Z			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ163	8101294				2022-12-28	WOS:A1993LQ16300002
J	WANG, PH				WANG, PH			TIGHT GLUCOSE CONTROL AND DIABETIC COMPLICATIONS	LANCET			English	Editorial Material											WANG, PH (corresponding author), HARVARD UNIV, SCH MED, JOSLIN DIABET CTR, BOSTON, MA 02115 USA.							DCCT Res Grp, 1988, DIABETES CARE, V11, P567; KLEIN R, 1992, DIABETES CARE, V15, P1875, DOI 10.2337/diacare.15.12.1875; Prospective U. K., 1991, DIABETOLOGIA, V34, P877; REAVEN GM, 1991, DIABETES CARE, V14, P33, DOI 10.2337/diacare.14.4.33; SAWIN CT, 1993, P ENDOC SOC, P230; WANG PH, 1993, LANCET, V341, P1306, DOI 10.1016/0140-6736(93)90816-Y	6	20	20	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 17	1993	342	8864					129	129		10.1016/0140-6736(93)91338-M	http://dx.doi.org/10.1016/0140-6736(93)91338-M			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN042	8101249				2022-12-28	WOS:A1993LN04200004
J	GROHMANN, GS; GLASS, RI; PEREIRA, HG; MONROE, SS; HIGHTOWER, AW; WEBER, R; BRYAN, RT				GROHMANN, GS; GLASS, RI; PEREIRA, HG; MONROE, SS; HIGHTOWER, AW; WEBER, R; BRYAN, RT			ENTERIC VIRUSES AND DIARRHEA IN HIV-INFECTED PATIENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; IMMUNE-DEFICIENCY SYNDROME; DOUBLE-STRANDED-RNA; AIDS PATIENTS; GASTROINTESTINAL MANIFESTATIONS; CAMPYLOBACTER-JEJUNI; HOMOSEXUAL MEN; GASTROENTERITIS; ENTEROCYTOZOON; ADENOVIRUSES	Background. Diarrhea occurs frequently among persons with the acquired immunodeficiency syndrome, but the cause often remains unknown. We used a group of diagnostic assays to determine which viruses were etiologic agents of diarrhea in a group of persons infected with the human immunodeficiency virus (HIV). Methods. Stool and serum specimens were obtained from HIV-infected patients enrolled in a longitudinal study in Atlanta. Fecal specimens from patients with diarrhea and from control patients without diarrhea were screened by electron microscopy, polyacrylamide-gel electrophoresis, and enzyme immunoassays for rotaviruses, enteric adenoviruses, caliciviruses, picobirnaviruses, and astroviruses. Paired serum samples were tested for antibody responses to Norwalk virus and picobirnavirus. Results. Viruses were detected in 35 percent of 109 fecal specimens from patients with diarrhea but in only 12 percent of 113 specimens from those without diarrhea (P<0.001). Specimens from patients with diarrhea were more likely than those from patients without diarrhea to have astrovirus (12 percent vs. 2 percent, P = 0.003); picobirnavirus (9 percent vs. 2 percent, P = 0.017); caliciviruses, including small round structured viruses (6 percent vs. 1 percent, P = 0.062); and adenoviruses (9 percent vs. 3 percent, P = 0.047). They were also more likely to have a mixed viral infection (6 percent vs. 0 percent, P = 0.006). With the use of polyacrylamide-gel electrophoresis to analyze concentrated RNA extracts from stool, picobirnavirus was detected in fecal specimens from 6 of the 65 patients with diarrhea and was associated with prolonged viral shedding and chronic diarrhea. No rotaviruses, enteric adenoviruses, or instances of seroconversion to positivity for Norwalk virus were observed. Conclusions. Novel enteric viruses such as astrovirus and picobirnavirus may be more important etiologic agents of diarrhea in HIV-infected patients than previously recognized and may be more common than either bacterial or parasitic enteropathogens.	CTR DIS CONTROL, NATL CTR INFECT DIS, DIV VIRAL & RICKETTSIAL DIS, ATLANTA, GA 30333 USA; CTR DIS CONTROL, NATL CTR INFECT DIS, DIV PARASIT DIS, PARASIT DIS BRANCH, ATLANTA, GA 30333 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA			Weber, Rainer/D-5175-2012	Monroe, Stephan/0000-0002-5424-716X	NIAID NIH HHS [YO2-AI-90002-02] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARTLETT JG, 1992, CLIN INFECT DIS, V15, P726, DOI 10.1093/clind/15.4.726; BRIDGER JC, 1987, CIBA F SYMP, V128, P5; BRYAN RT, 1991, PROGR CLIN PARASITOL, V1, P1; CALI A, 1990, J PROTOZOOL, V37, P145, DOI 10.1111/j.1550-7408.1990.tb05885.x; CELUM CL, 1987, J INFECT DIS, V156, P998, DOI 10.1093/infdis/156.6.998; COLEBUNDERS R, 1987, AM J GASTROENTEROL, V82, P859; COOPER DA, 1985, LANCET, V1, P537; CRUZ JR, 1992, J CLIN MICROBIOL, V30, P1140, DOI 10.1128/JCM.30.5.1140-1144.1992; CUNNINGHAM AL, 1988, J INFECT DIS, V158, P386, DOI 10.1093/infdis/158.2.386; DESPORTES I, 1985, J PROTOZOOL, V32, P250; DWORKIN B, 1985, AM J GASTROENTEROL, V80, P774; DWORKIN B, 1986, AM J MED, V80, P965, DOI 10.1016/0002-9343(86)90646-7; GARY GW, 1985, J CLIN MICROBIOL, V22, P274, DOI 10.1128/JCM.22.2.274-278.1985; GATTI MSV, 1989, RES VET SCI, V47, P397, DOI 10.1016/S0034-5288(18)31269-4; GRAY JR, 1989, AM J GASTROENTEROL, V84, P1521; GROHMANN G, 1991, J CLIN MICROBIOL, V29, P544, DOI 10.1128/JCM.29.3.544-550.1991; HERRMANN JE, 1991, NEW ENGL J MED, V324, P1757, DOI 10.1056/NEJM199106203242501; HIERHOLZER JC, 1988, J INFECT DIS, V158, P804, DOI 10.1093/infdis/158.4.804; HIERHOLZER JC, 1988, ARCH VIROL, V103, P99, DOI 10.1007/BF01319812; HORSBURGH CR, 1991, NEW ENGL J MED, V324, P1332, DOI 10.1056/NEJM199105093241906; JACOBS JL, 1985, ANN INTERN MED, V102, P186, DOI 10.7326/0003-4819-102-2-186; JANOFF EN, 1988, GASTROENTEROL CLIN N, V17, P451; JANOFF EN, 1987, J CLIN MICROBIOL, V25, P967, DOI 10.1128/JCM.25.6.967-975.1987; JANOFF EN, 1991, GASTROENTEROLOGY, V100, P976, DOI 10.1016/0016-5085(91)90272-M; JIANG X, 1990, Science (Washington D C), V250, P1580; KALJOT KT, 1989, GASTROENTEROLOGY, V97, P1031, DOI 10.1016/0016-5085(89)91516-3; KAPIKIAN AZ, 1980, MANUAL CLIN IMMUNOLO, P70; KOTLER DP, 1984, ANN INTERN MED, V101, P421, DOI 10.7326/0003-4819-101-4-421; LAMBDEN PR, 1993, SCIENCE, V259, P516, DOI 10.1126/science.8380940; LANE HC, 1983, NEW ENGL J MED, V309, P453, DOI 10.1056/NEJM198308253090803; LANE HC, 1985, NEW ENGL J MED, V313, P79, DOI 10.1056/NEJM198507113130204; LAUGHON BE, 1988, GASTROENTEROLOGY, V94, P984, DOI 10.1016/0016-5085(88)90557-4; LeBaron C W, 1990, MMWR Recomm Rep, V39, P1; LEW JF, 1991, J INFECT DIS, V164, P673, DOI 10.1093/infdis/164.4.673; MALEBRANCHE R, 1983, LANCET, V2, P873; MODIGLIANI R, 1985, GUT, V26, P179, DOI 10.1136/gut.26.2.179; MOE CL, 1991, J CLIN MICROBIOL, V29, P2390, DOI 10.1128/JCM.29.11.2390-2395.1991; MONROE SS, 1991, J MED VIROL, V33, P193, DOI 10.1002/jmv.1890330310; MONROE SS, 1993, J VIROL, V67, P3611, DOI 10.1128/JVI.67.6.3611-3614.1993; NELSON JA, 1988, LANCET, V1, P259; PEREIRA HG, 1988, J GEN VIROL, V69, P2749, DOI 10.1099/0022-1317-69-11-2749; PEREIRA HG, 1989, MEM I OSWALDO CRUZ, V84, P137, DOI 10.1590/S0074-02761989000100025; PEREIRA HG, 1988, LANCET, V2, P103; PERLMAN DM, 1988, ANN INTERN MED, V108, P540, DOI 10.7326/0003-4819-108-4-540; SAULSBURY FT, 1980, J PEDIATR-US, V97, P61, DOI 10.1016/S0022-3476(80)80131-4; SMITH PD, 1992, ANN INTERN MED, V116, P63, DOI 10.7326/0003-4819-116-1-63; SMITH PD, 1988, ANN INTERN MED, V108, P328, DOI 10.7326/0003-4819-108-3-328; SMITH PD, 1988, GASTROENTEROL CLIN N, V17, P587; SOAVE R, 1987, REV INFECT DIS, V9, P663; THEA DM, IN PRESS T R SOC TRO; VANOPDENBOSCH E, 1989, VET REC, V125, P610; VANOPDENBOSCH E, 1990, VLAAMS DIERGENEESKD, V59, P1; WEBER R, 1992, NEW ENGL J MED, V326, P161, DOI 10.1056/NEJM199201163260304; WILLCOCKS MM, 1992, ARCH VIROL, V124, P279, DOI 10.1007/BF01309809; XI J, 1992, J CLIN MICROBIOL, V30, P2529, DOI 10.1128/JCM.30.10.2529-2534.1992; YOLKEN RH, 1982, NEW ENGL J MED, V306, P1009, DOI 10.1056/NEJM198204293061701; 1986, MMWR MROB MORTAL WKL, V35, P334	57	230	236	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 1	1993	329	1					14	20		10.1056/NEJM199307013290103	http://dx.doi.org/10.1056/NEJM199307013290103			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ338	8099429				2022-12-28	WOS:A1993LJ33800003
J	LOCKWOOD, CM; THIRU, S; ISAACS, JD; HALE, G; WALDMANN, H				LOCKWOOD, CM; THIRU, S; ISAACS, JD; HALE, G; WALDMANN, H			LONG-TERM REMISSION OF INTRACTABLE SYSTEMIC VASCULITIS WITH MONOCLONAL-ANTIBODY THERAPY	LANCET			English	Note							RESPONSES	Monoclonal antibodies that target T cells offer an alternative to conventional immunosuppressive drugs in the management of autoimmune disease. ''Humanisation'' of such monoclonal antibodies makes their clinical use less likely to be prone to the risk of cross-species sensitisation than treatment with rodent antibodies. We describe humanised monoclonal antibody therapy in four patients with severe systemic vasculitis unresponsive to immunosuppressive drugs. Substantial and sustained benefit was seen in three of the four patients, although one of these three patients developed anti-idiotypic antibodies that had to be removed by plasma exchange.	UNIV CAMBRIDGE,DEPT PATHOL,DIV HISTOPATHOL,CAMBRIDGE,ENGLAND; UNIV CAMBRIDGE,DEPT PATHOL,DIV IMMUNOL,CAMBRIDGE,ENGLAND	University of Cambridge; University of Cambridge	LOCKWOOD, CM (corresponding author), UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT MED,CAMBRIDGE CB2 2SP,ENGLAND.		waldmann, herman/W-8051-2019	Isaacs, John/0000-0002-6103-7056; Waldmann, Herman/0000-0001-7519-6720; Hale, Geoff/0000-0001-9473-423X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		CHEN ZH, 1992, EUR J IMMUNOL, V22, P805, DOI 10.1002/eji.1830220326; COBBOLD SP, 1990, J IMMUNOL METHODS, V127, P19, DOI 10.1016/0022-1759(90)90335-S; HOM JT, 1988, EUR J IMMUNOL, V18, P881, DOI 10.1002/eji.1830180608; ISAACS JD, 1992, LANCET, V340, P748, DOI 10.1016/0140-6736(92)92294-P; MATHIESON PW, 1990, NEW ENGL J MED, V323, P250, DOI 10.1056/NEJM199007263230407; MATHIESON PW, 1992, NEW ENGL J MED, V340, P748; SAMPAIO EP, 1992, J EXP MED, V175, P1729, DOI 10.1084/jem.175.6.1729; WALDMANN H, 1989, ANNU REV IMMUNOL, V7, P407, DOI 10.1146/annurev.iy.07.040189.002203; WOFSY D, 1985, J IMMUNOL, V134, P852	9	181	184	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 26	1993	341	8861					1620	1622		10.1016/0140-6736(93)90759-A	http://dx.doi.org/10.1016/0140-6736(93)90759-A			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ727	8099991				2022-12-28	WOS:A1993LJ72700005
J	VISCOLI, CM; LACHS, MS; HORWITZ, RI				VISCOLI, CM; LACHS, MS; HORWITZ, RI			BLADDER-CANCER AND COFFEE-DRINKING - A SUMMARY OF CASE-CONTROL RESEARCH	LANCET			English	Article							LOWER URINARY-TRACT; RISK-FACTORS; ARTIFICIAL SWEETENERS; EARLY PRECURSORS; TOBACCO SMOKING; DIETARY FACTORS; COLLEGE MEN; OCCUPATION; EPIDEMIOLOGY; CONSUMPTION	An association between coffee drinking and cancer of the lower urinary tract (LUT) was first suggested 20 years ago and has been the subject of many epidemiological studies. We have undertaken a critical review and statistical summary of 35 case-control studies of this association published between 1971 and 1992. Predefined methodological criteria were applied to the available reports. Studies were classified as either meeting the criteria (core studies) or failing to satisfy at least one of the requirements for design or analysis (non-core studies). The summarised data from the 8 core studies showed no evidence of an increase in risk of LUT cancer with coffee drinking in men or women after adjustment for the effects of cigarette smoking (odds ratio 1.07 [95% CI 1.00-1.14] for men, 0.91 [0.81-1.03] for women). The measures of association from the non-core studies were higher on average than those from the core studies, although the inclusion of these data in an overall summarised estimate did not substantially change the findings from the core analysis. We conclude that the best available data do not suggest a clinically important association between the regular use of coffee and development of cancer of the LUT in men or women.	YALE UNIV, SCH MED,DEPT INTERNAL MED,ROOM IE-61 SHM,POB 3333, NEW HAVEN, CT 06510 USA	Yale University								AKDAS A, 1990, EUR UROL, V17, P23; BRAVO MP, 1987, NEOPLASMA, V34, P633; BROSS IDJ, 1973, PREV MED, V2, P445, DOI 10.1016/0091-7435(73)90040-6; CARTWRIGHT RA, 1981, CARCINOGENESIS, V2, P343, DOI 10.1093/carcin/2.4.343; CICCONE G, 1988, CANCER LETT, V41, P45, DOI 10.1016/0304-3835(88)90053-5; CLAUDE J, 1986, AM J EPIDEMIOL, V124, P578, DOI 10.1093/oxfordjournals.aje.a114430; CLAVEL J, 1991, INT J CANCER, V47, P207, DOI 10.1002/ijc.2910470208; COLE P, 1971, NEW ENGL J MED, V284, P129, DOI 10.1056/NEJM197101212840304; COLE P, 1971, LANCET, V1, P1335; DAVANZO B, 1992, EUR J CANCER, V28A, P1480, DOI 10.1016/0959-8049(92)90548-G; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DUNHAM LJ, 1968, J NATL CANCER I, V41, P683; FRAUMENI JF, 1971, LANCET, V2, P1204; GONZALES CA, 1988, AM J IND MED, V14, P673, DOI 10.1002/ajim.4700140607; GONZALEZ CA, 1985, CANCER, V55, P2031, DOI 10.1002/1097-0142(19850501)55:9<2031::AID-CNCR2820550934>3.0.CO;2-I; HARTGE P, 1983, J NATL CANCER I, V70, P1021; HOWE GR, 1980, JNCI-J NATL CANCER I, V64, P701; HOWE GR, 1977, LANCET, V2, P578, DOI 10.1016/S0140-6736(77)91428-3; ISCOVICH J, 1987, INT J CANCER, V40, P734, DOI 10.1002/ijc.2910400604; JACOBSEN BK, 1986, J NATL CANCER I, V76, P823; JENSEN OM, 1986, INT J CANCER, V37, P651, DOI 10.1002/ijc.2910370503; JENSEN OM, 1983, INT J CANCER, V32, P577; KABAT GC, 1986, CANCER-AM CANCER SOC, V57, P362, DOI 10.1002/1097-0142(19860115)57:2<362::AID-CNCR2820570229>3.0.CO;2-F; KANTOR AF, 1985, INT J CANCER, V35, P703, DOI 10.1002/ijc.2910350602; KANTOR AF, 1988, CANCER RES, V48, P3853; KUNZE E, 1992, CANCER-AM CANCER SOC, V69, P1776, DOI 10.1002/1097-0142(19920401)69:7<1776::AID-CNCR2820690721>3.0.CO;2-P; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; LAVECCHIA C, 1989, NUTR CANCER, V12, P93, DOI 10.1080/01635588909514006; MARRETT LD, 1983, AM J EPIDEMIOL, V117, P113, DOI 10.1093/oxfordjournals.aje.a113522; METTLIN C, 1979, AM J EPIDEMIOL, V110, P255, DOI 10.1093/oxfordjournals.aje.a112810; MILLER AB, 1977, CANCER RES, V37, P2939; MILLER CT, 1978, J CHRON DIS, V31, P51, DOI 10.1016/0021-9681(78)90080-2; MILLS PK, 1991, AM J EPIDEMIOL, V133, P230, DOI 10.1093/oxfordjournals.aje.a115867; MOMMSEN S, 1982, EUR J CANCER CLIN ON, V18, P1205, DOI 10.1016/0277-5379(82)90103-1; MOMMSEN S, 1983, EUR J CANCER CLIN ON, V19, P725, DOI 10.1016/0277-5379(83)90005-6; MORGAN RW, 1974, CAN MED ASSOC J, V111, P1067; MORRISON AS, 1982, JNCI-J NATL CANCER I, V68, P91; MORRISON AS, 1980, NEW ENGL J MED, V302, P537, DOI 10.1056/NEJM198003063021001; NAJEM GR, 1982, INT J EPIDEMIOL, V11, P212, DOI 10.1093/ije/11.3.212; NOMURA A, 1986, JNCI-J NATL CANCER I, V76, P587, DOI 10.1093/jnci/76.4.587; Ohno Y, 1985, Natl Cancer Inst Monogr, V69, P229; PIPER JM, 1986, AM J EPIDEMIOL, V123, P1033, DOI 10.1093/oxfordjournals.aje.a114331; REBELAKOS A, 1985, JNCI-J NATL CANCER I, V75, P455; RISCH HA, 1988, AM J EPIDEMIOL, V127, P1179, DOI 10.1093/oxfordjournals.aje.a114911; SCHULTE PA, 1986, CANCER, V58, P2156, DOI 10.1002/1097-0142(19861101)58:9<2156::AID-CNCR2820580933>3.0.CO;2-Y; SIMON D, 1975, J NATL CANCER I, V54, P587; SLATTERY ML, 1988, CANCER, V61, P402, DOI 10.1002/1097-0142(19880115)61:2<402::AID-CNCR2820610233>3.0.CO;2-U; SLATTERY ML, 1988, INT J CANCER, V42, P17, DOI 10.1002/ijc.2910420105; SNOWDON DA, 1984, AM J PUBLIC HEALTH, V74, P820, DOI 10.2105/AJPH.74.8.820; SULLIVAN JW, 1982, J UROLOGY, V128, P281, DOI 10.1016/S0022-5347(17)52886-4; VINEIS P, 1984, INT J CANCER, V34, P165, DOI 10.1002/ijc.2910340205; WHITTEMORE AS, 1984, J UROLOGY, V132, P1256, DOI 10.1016/S0022-5347(17)50118-4; WHITTEMORE AS, 1985, JNCI-J NATL CANCER I, V74, P43; WYNDER EL, 1977, CANCER-AM CANCER SOC, V40, P1246, DOI 10.1002/1097-0142(197709)40:3<1246::AID-CNCR2820400340>3.0.CO;2-5; WYNDER EL, 1977, CANCER RES, V37, P4608; WYNDER EL, 1985, ENVIRON RES, V37, P475, DOI 10.1016/0013-9351(85)90129-X; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7	57	41	41	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 5	1993	341	8858					1432	1437		10.1016/0140-6736(93)90881-G	http://dx.doi.org/10.1016/0140-6736(93)90881-G			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF841	8099140	hybrid			2022-12-28	WOS:A1993LF84100003
J	MULLEN, M; MULLEN, B; CAREY, M				MULLEN, M; MULLEN, B; CAREY, M			THE ASSOCIATION BETWEEN BETA-AGONIST USE AND DEATH FROM ASTHMA - A METAANALYTIC INTEGRATION OF CASE-CONTROL STUDIES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							PRESCRIBED FENOTEROL; ZEALAND	Objectives.-The purpose of this investigation was to provide an empirical summary of the evidence regarding the association between beta-agonist use and death from asthma. This effort integrated the results of case-control studies that examined the use of beta-agonists among asthmatic patients who died and the use of beta-agonists among asthmatic patients who did not die. The possible moderating effects of patient sample age and mode of delivery (oral, metered-dose inhaler, and nebulizer) were also examined. Data Sources.-An on-line computer search (using MEDLINE) was conducted using the key words beta-agonist and asthma. This search was supplemented by ancestry and descendency approach searches. Studies that were available as of April 1992 were eligible for inclusion in this integration. Study Selection.-Studies were included if they reported the precise numbers of cases and controls who did and did not use a beta-agonist. A total of six case-control studies comprising 15 separate tests of the relation between beta-agonist use and death from asthma and data for 364 cases and 1388 controls were included. Data Extraction.-The 2 (case vs control) X 2 (did vs did not use beta-agonist) designs allowed for direct derivation of a chi2 statistic that tested the association between beta-agonist use and death from asthma. Mode of delivery and average age of sample were also coded. Data Synthesis.-Statistical integration revealed a significant, although extremely weak, relation between beta-agonist use and death from asthma (z=3.996; P=.000075; mean r=.055). This relation emerged only when beta-agonists were administered with a nebulizer (z=4.481; P=.0000038; mean r=.103). There was no association between beta-agonist use and death when beta-agonists were administered by metered-dose inhaler (z=1.194; P=.11; mean r=.031) or orally (z=1.247; P=.1; mean r=.031). Adults were more likely than adolescents to evidence the association between beta-agonist use and death. Conclusions.-These results document the extremely small magnitude of the relation between beta-agonist use and death from asthma. Furthermore, these results specify that the weak relation between beta-agonist use and death from asthma may really be restricted to the delivery of beta-agonists with a nebulizer. These findings suggest that the headlines that followed the report by Spitzer et al (1992) were misleading.	SYRACUSE UNIV, COLL LIBERAL ARTS & SCI, DEPT PSYCHOL, SYRACUSE, NY 13244 USA	Syracuse University	MULLEN, M (corresponding author), AMER LUNG ASSOC CENT NEW YORK, POB 6409, SYRACUSE, NY 13217 USA.							Cohen J, 1977, STATISTICAL POWER AN; CRANE J, 1989, LANCET, V1, P917; FISHER RA, 1932, STATISTICAL METHODS; Glass G.V., 1976, ED RES, V5, P3, DOI [DOI 10.3102/0013189X005010003, 10.2307/1174772ISSN0536-1036]; GRAINGER J, 1991, THORAX, V46, P105, DOI 10.1136/thx.46.2.105; INMAN WHW, 1969, LANCET, V2, P279; LYONS S, 1992, AIR CURRENTS     MAY, P4; MILLER BD, 1989, AM J DIS CHILD, V143, P1294, DOI 10.1001/archpedi.1989.02150230052022; MULLEN B, 1990, NUTRITION, V6, P270; MULLEN B, 1985, BASIC METAANALYSIS P; PEARCE N, 1990, THORAX, V45, P170, DOI 10.1136/thx.45.3.170; PEARCE N, 1991, CLIN EXP ALLERGY, V21, P401, DOI 10.1111/j.1365-2222.1991.tb01679.x; Pearson K, 1933, ANN EUGENIC, V5, P337; ROSENTHAL R, 1992, METAANALYTIC PROCEDU; SACKS HS, 1987, NEW ENGL J MED, V316, P450, DOI 10.1056/NEJM198702193160806; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; STRUNK R C, 1985, Journal of the American Medical Association, V254, P1193, DOI 10.1001/jama.254.9.1193; Thorndike RL, 1933, J EDUC PSYCHOL, V24, P543, DOI 10.1037/h0070255; WIGAL J K, 1990, Pediatric Asthma Allergy and Immunology, V4, P17, DOI 10.1089/pai.1990.4.17; YELLOWLEES PM, 1989, CHEST, V95, P1298, DOI 10.1378/chest.95.6.1298	20	86	86	1	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 20	1993	270	15					1842	1845		10.1001/jama.270.15.1842	http://dx.doi.org/10.1001/jama.270.15.1842			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB464	8105113				2022-12-28	WOS:A1993MB46400028
J	ELLIS, SJ				ELLIS, SJ			FUNCTIONAL MAGNETIC-RESONANCE - NEUROLOGICAL ENLIGHTENMENT	LANCET			English	Editorial Material							POSITRON EMISSION TOMOGRAPHY; BRAIN				ELLIS, SJ (corresponding author), UNIV OXFORD, DEPT CLIN NEUROL, OXFORD, ENGLAND.			Ellis, Simon/0000-0002-9131-6427				FRACKOWIAK RSJ, 1989, SEMIN NEUROL, V9, P275, DOI 10.1055/s-2008-1041334; GRASBY PM, 1993, BRAIN, V116, P1, DOI 10.1093/brain/116.1.1; JAMIESON DG, 1989, COMPUT MED IMAG GRAP, V13, P61, DOI 10.1016/0895-6111(89)90079-7; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; Poeck K, 1984, Adv Neurol, V42, P71; SMITH FW, 1988, J CEREBRAL BLOOD FLO, V8, pS166; WEISSLEDER R, 1992, Magnetic Resonance Quarterly, V8, P55	7	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 9	1993	342	8876					882	882		10.1016/0140-6736(93)91942-F	http://dx.doi.org/10.1016/0140-6736(93)91942-F			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA963	8105163				2022-12-28	WOS:A1993MA96300006
J	HAYNES, WG; NOON, JP; WALKER, BR; WEBB, DJ				HAYNES, WG; NOON, JP; WALKER, BR; WEBB, DJ			L-NMMA INCREASES BLOOD-PRESSURE IN MAN	LANCET			English	Letter							NITRIC-OXIDE				HAYNES, WG (corresponding author), UNIV EDINBURGH,WESTERN GEN HOSP,DEPT MED,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.		Haynes, William G/D-5374-2013	Haynes, William G/0000-0003-1004-6136				CALVER A, 1992, J HYPERTENS, V10, P1025; MONCADA S, 1991, PHARMACOL REV, V43, P109; PETROS A, 1991, LANCET, V338, P1557, DOI 10.1016/0140-6736(91)92376-D; VALLANCE P, 1992, LANCET, V339, P572	4	61	61	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 9	1993	342	8876					931	932		10.1016/0140-6736(93)91981-Q	http://dx.doi.org/10.1016/0140-6736(93)91981-Q			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA963	8105193				2022-12-28	WOS:A1993MA96300047
J	POIRIER, J; DAVIGNON, J; BOUTHILLIER, D; KOGAN, S; BERTRAND, P; GAUTHIER, S				POIRIER, J; DAVIGNON, J; BOUTHILLIER, D; KOGAN, S; BERTRAND, P; GAUTHIER, S			APOLIPOPROTEIN-E POLYMORPHISM AND ALZHEIMERS-DISEASE	LANCET			English	Article							RAT SCIATIC-NERVE; CHOLESTEROL TRANSPORT; IMMUNOREACTIVITY; PROTEIN; CORTEX; LOCUS	Apolipoprotein E (apoE) is associated with Alzheimer's neurofibrillary tangles and beta-amyloid protein in senile plaques. It also appears to play an important part in the redistribution of lipids that follows deafferentation and neurodegeneration in the brain. The gene for apoE is on chromosome 19, within the genomic region previously associated with late-onset familial Alzheimer's disease (AD). We have studied apoE phenotype expression and the corresponding allele frequencies (epsilon2, epsilon3, epsilon4) in 91 patients with sporadic AD and 74 controls. There was a significant association between epsilon4 and sporadic AD (epsilon4 frequency 0.380 in AD and 0.122 in controls, p <0.01). Analysis of epsilon4 allele frequency as a function of age revealed a bimodal distribution, with peaks at 65 and 75 years. In bearers of epsilon4 in whom AD develops this tended to happen earlier in life than in those with epsilon3 or epsilon2. The epsilon4/AD association was more pronounced in women. Octogenarians with AD had an epsilon4 allele frequency that was 3 times higher than one reported, in a different study, in healthy octogenarians. ApoE may be an important susceptibility factor in the aetiopathology of sporadic AD.	MCGILL UNIV,DEPT PSYCHIAT,MONTREAL H3A 2T5,QUEBEC,CANADA; CLIN RES INST MONTREAL,MONTREAL H2W 1R7,QUEBEC,CANADA; UNIV MONTREAL,MONTREAL H3C 3J7,QUEBEC,CANADA	McGill University; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal	POIRIER, J (corresponding author), DOUGLAS HOSP,RES CTR,MCGILL CTR STUDIES AGING,6575 LASALLE BLVD,VERDUN H4H 1R3,PQ,CANADA.				NIA NIH HHS [AG-10003] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG010003] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BOUTHILLIER D, 1983, J LIPID RES, V24, P1060; BOYLES JK, 1989, J CLIN INVEST, V83, P1015, DOI 10.1172/JCI113943; CUMMING AM, 1984, CLIN GENET, V25, P310; DAVIES CA, 1987, J NEUROL SCI, V78, P151, DOI 10.1016/0022-510X(87)90057-8; Davignon J, 1988, Trans Am Clin Climatol Assoc, V99, P100; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; GUIBILEI F, 1989, ACTA NEUROL SCAND, V81, P84; HALLMAN DM, 1991, AM J HUM GENET, V49, P338; HONER WG, 1992, NEUROBIOL AGING, V13, P375, DOI 10.1016/0197-4580(92)90111-A; LEBLANC AC, 1990, J NEUROSCI RES, V25, P162, DOI 10.1002/jnr.490250203; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MASLIAH E, 1989, NEUROSCI LETT, V103, P234, DOI 10.1016/0304-3940(89)90582-X; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MUCJKLE TJ, 1985, LANCET, V1, P1191; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; POIRIER J, 1991, MOL BRAIN RES, V11, P97, DOI 10.1016/0169-328X(91)90111-A; POIRIER J, 1993, NEUROSCIENCE, V55, P81, DOI 10.1016/0306-4522(93)90456-P; POIRIER J, 1991, BASIC THERAPEUTIC ST, P191; RANSMAYR G, 1989, NEUROSCIENCE, V32, P701, DOI 10.1016/0306-4522(89)90291-1; SCHELLENBERG GD, 1992, SCIENCE, V258, P668, DOI 10.1126/science.1411576; SCHELLENBERG GD, 1992, ANN NEUROL, V31, P223, DOI 10.1002/ana.410310214; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C; WISNIEWSKI T, 1993, BIOCHEM BIOPH RES CO, V192, P359, DOI 10.1006/bbrc.1993.1423; YAMADA N, 1980, BIOCHEM BIOPH RES CO, V94, P710, DOI 10.1016/0006-291X(80)91290-5	25	1143	1177	4	53	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 18	1993	342	8873					697	699		10.1016/0140-6736(93)91705-Q	http://dx.doi.org/10.1016/0140-6736(93)91705-Q			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX469	8103819				2022-12-28	WOS:A1993LX46900006
J	SCOTT, J				SCOTT, J			APOLIPOPROTEIN-E AND ALZHEIMERS-DISEASE	LANCET			English	Editorial Material							PRECURSOR PROTEIN GENE; MUTATION				SCOTT, J (corresponding author), ROYAL POSTGRAD MED SCH,DEPT MED,LONDON W12 0HS,ENGLAND.							CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; SAUNDERS AM, 1993, NEUROLOGY, V43, P1462; SCHELLENBERG GD, 1992, SCIENCE, V258, P668, DOI 10.1126/science.1411576; SOUTAR AK, 1992, P NATL ACAD SCI USA, V89, P7389, DOI 10.1073/pnas.89.16.7389; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977	9	42	42	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 18	1993	342	8873					696	696		10.1016/0140-6736(93)91704-P	http://dx.doi.org/10.1016/0140-6736(93)91704-P			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX469	8103818				2022-12-28	WOS:A1993LX46900005
J	WILLIAMS, GT; SMITH, CA				WILLIAMS, GT; SMITH, CA			MOLECULAR REGULATION OF APOPTOSIS - GENETIC-CONTROLS ON CELL-DEATH	CELL			English	Review							CAENORHABDITIS-ELEGANS; C-MYC; BCL-2; INDUCTION; SURVIVAL; PROTEIN		UNIV BIRMINGHAM,SCH MED,DEPT ANAT,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Birmingham	WILLIAMS, GT (corresponding author), UNIV KEELE,DEPT BIOL SCI,KEELE ST5 5BG,STAFFS,ENGLAND.		Williams, Gwyn/GQY-7555-2022	Williams, Gwyn/0000-0003-4556-9930				BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; GOLSTEIN P, 1991, IMMUNOL REV, V121, P29, DOI 10.1111/j.1600-065X.1991.tb00822.x; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HENDERSON S, 1993, IN PRESS P NATL ACAD; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; LEVINE B, 1993, NATURE, V361, P739, DOI 10.1038/361739a0; MAPARA MY, 1993, EUR J IMMUNOL, V23, P702, DOI 10.1002/eji.1830230320; NEILAN JG, 1993, J VIROL, V67, P4391, DOI 10.1128/JVI.67.7.4391-4394.1993; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PEARSON GR, 1987, VIROLOGY, V160, P151, DOI 10.1016/0042-6822(87)90055-9; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAHELU M, 1993, J IMMUNOL, V150, P4856; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SMITH CA, 1993, IN PRESS APOPTOSIS M; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; WILLIAMS G T, 1992, Trends in Cell Biology, V2, P263, DOI 10.1016/0962-8924(92)90198-V; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	30	947	1004	0	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 10	1993	74	5					777	779		10.1016/0092-8674(93)90457-2	http://dx.doi.org/10.1016/0092-8674(93)90457-2			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LX292	8104100				2022-12-28	WOS:A1993LX29200003
J	LABIB, M; HOWELL, P				LABIB, M; HOWELL, P			DESIGN OF PATHOLOGY REQUEST FORMS	LANCET			English	Letter											LABIB, M (corresponding author), RUSSELLS HALL HOSP,DEPT CLIN BIOCHEM,DUDLEY DY1 2HQ,W MIDLANDS,ENGLAND.							DURANDKALESKI, 1993, LANCET, V342, P150	1	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 4	1993	342	8871					620	620		10.1016/0140-6736(93)91448-U	http://dx.doi.org/10.1016/0140-6736(93)91448-U			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV963	8102749				2022-12-28	WOS:A1993LV96300055
J	BUTTERFIELD, J				BUTTERFIELD, J			THE CIRCULATION IN DIABETES, FROM HL523 TO THE NO ERA	LANCET			English	Article								In 1955, F R Barany, a Swedish research physician interested in diabetes, summarised his dissertation (Acta Med Scand 1955; suppl 1304: 127) with the words ''The ultimate cause of the various abnormal vascular reactions in diabetes might be assumed to be the cause of diabetic neuropathy in which autonomic pathways are the first to be destroyed...''. That diabetes might involve a microcirculatory disease affecting the autonomic nervous system may be more relevant to the following reminiscence about the agent HL523 than I realised.										BEESON MF, 1971, HORM METAB RES, V3, P188, DOI 10.1055/s-0028-1094154; BLAZQUEZ E, 1970, DIABETOLOGIA, V6, P447, DOI 10.1007/BF01212081; BUCKLE AL, 1971, HORM METAB RES, V3, P76, DOI 10.1055/s-0028-1095031; BUTTERFIELD WJ, 1969, LANCET, V2, P381; BUTTERFIELD WJ, 1969, DIABETOLOGIA, V5, P204; MALAISSE W J, 1970, Hormone and Metabolic Research, V2, P21; MALASISSE W J, 1969, Hormone and Metabolic Research, V1, P258; SCHLESS GL, 1970, LANCET, V1, P780; SCHLESS GL, 1970, ANN INTERN MED, V72, P803, DOI 10.7326/0003-4819-72-5-803_5; WALDER CE, 1991, BRIT J PHARMACOL, V102, P967, DOI 10.1111/j.1476-5381.1991.tb12285.x	10	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 28	1993	342	8870					533	536		10.1016/0140-6736(93)91652-3	http://dx.doi.org/10.1016/0140-6736(93)91652-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU582	8102673				2022-12-28	WOS:A1993LU58200015
J	DALBAGNI, G; PRESTI, J; REUTER, V; FAIR, WR; CORDONCARDO, C				DALBAGNI, G; PRESTI, J; REUTER, V; FAIR, WR; CORDONCARDO, C			GENETIC ALTERATIONS IN BLADDER-CANCER	LANCET			English	Note							ALTERED EXPRESSION; ALLELOTYPE; CARCINOMA	To see whether genetic alterations follow a sequence of events leading to bladder cancer progression, 60 paired bladder tumours and normal tissues were analysed with polymorphic DNA markers, correlating loss of heterozygosity (LOH) at candidate tumour suppressor gene sites with pathological indices of poor clinical outcome. Distinct genotypic patterns were associated with early and late stages of bladder cancer. 9q deletions were observed in all superficial papillary tumours (Ta) and almost all tumours invading the lamina propria (T1), suggesting that this event associates with the development of superficial bladder tumours. However, 3p, 5q, and 17p deletions were absent in the Ta tumours but were identified in invasive bladder cancers. Two genetic pathways characterise the evolution of superficial bladder tumours. 9qLOH was detected in most Ta tumours, but in only 43% of muscle invasive neoplasms. Our hypothesis is that certain chromosomal abnormalities have a defined role in bladder tumour development, whereas others correlate with pathological indices of poor clinical outcome.	MEM SLOAN KETTERING CANC CTR,DEPT PATHOL,1275 YORK AVE,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,DEPT SURG,UROL SERV,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center					NCI NIH HHS [NCI CA-47538] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA047538, R01CA047538] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CORDONCARDO C, 1992, J NATL CANCER I, V84, P1251, DOI 10.1093/jnci/84.16.1251; DEVILEE P, 1991, ONCOGENE, V6, P1705; FARNDON PA, 1992, LANCET, V339, P581, DOI 10.1016/0140-6736(92)90868-4; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KOSS L, 1992, DIAGNOSTIC CYTOLOGY, P934; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LOGOTHETIS CJ, 1992, J NATL CANCER I, V84, P1256, DOI 10.1093/jnci/84.16.1256; PRESTI JC, 1991, CANCER RES, V51, P5405; TYRKUS M, 1992, J UROLOGY, V148, P44, DOI 10.1016/S0022-5347(17)36504-7; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047	10	220	221	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 21	1993	342	8869					469	471		10.1016/0140-6736(93)91595-D	http://dx.doi.org/10.1016/0140-6736(93)91595-D			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU075	8102431				2022-12-28	WOS:A1993LU07500012
J	BLATT, SP; HENDRIX, CW; BUTZIN, CA; FREEMAN, TM; WARD, WW; HENSLEY, RE; MELCHER, GP; DONOVAN, DJ; BOSWELL, RN				BLATT, SP; HENDRIX, CW; BUTZIN, CA; FREEMAN, TM; WARD, WW; HENSLEY, RE; MELCHER, GP; DONOVAN, DJ; BOSWELL, RN			DELAYED-TYPE HYPERSENSITIVITY SKIN TESTING PREDICTS PROGRESSION TO AIDS IN HIV-INFECTED PATIENTS	ANNALS OF INTERNAL MEDICINE			English	Article						HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS; ACQUIRED IMMUNODEFICIENCY SYNDROME; HYPERSENSITIVITY, DELAYED; SKIN TESTS; IMMUNITY, CELLULAR	HUMAN-IMMUNODEFICIENCY-VIRUS; CELL-MEDIATED-IMMUNITY; PNEUMOCYSTIS-CARINII PNEUMONIA; ACQUIRED-IMMUNODEFICIENCY; HOMOSEXUAL MEN; T-HELPER; BETA-2-MICROGLOBULIN LEVEL; CUTANEOUS HYPERSENSITIVITY; LYMPHOCYTE COUNT; KAPOSIS SARCOMA	Objective: To evaluate the prognostic significance of cutaneous delayed-type h Design: Cohort study. Setting: United States Air Force (USAF) Medical Center. Patients: Consecutive sample of 889 HIV-infected USAF personnel or dependents undergoing their first staging evaluation from 1985 through August 1990 in the USAF HIV Natural History Study. Measurements: All patients were evaluated with DTH skin testing including purified protein derivative and four control skin test antigens: mumps, candida, tetanus toxoid, and trichophyton. In addition, all patients underwent CD4+ T-cell surface marker determinations. The relation between DTH skin test response at first evaluation and progression to Walter Reed stage 6 (presence of an AIDS-defining opportunistic infection) was evaluated using Kaplan-Meier survival analysis. Results: Patients with more than 400 CD4+ T cells/mm3 are more likely than those having fewer than 400 CD4+ T cells per mm3 to respond to at least one (94% compared with 67%, P < 0.001) or at least two (86% compared with 45%, P < 0.001) DTH skin tests. Mean CD4 counts are lower for anergic compared with nonanergic patients and for patients responding to a single control skin test compared with those responding to two or more skin tests (P < 0.05). The DTH skin test response at first evaluation was also found to predict progression to AIDS; the relative risk at 5 years of follow-up was 2.5 (95% CI, 1.2 to 5.2) for anergy compared with a single positive skin test and 3.0 (CI, 1.4 to 6.2) for a single compared with two or more skin test responses. The DTH skin test response at first evaluation was a predictor of progression (P < 0.001) when controlling for initial CD4 count and Walter Reed stage in a Cox proportional hazards regression analysis. Conclusions: The DTH skin test response, a functional measure of cellular immunity, is an independent predictor of progression to AIDS in persons with HIV.			BLATT, SP (corresponding author), WILFORD HALL USAF MED CTR, CTR AIDS RES,SW FDN BIOMED RES,PSMI-H, 2200 BERGQUIST DR, STE 1, LACKLAND AFB, TX 78236 USA.		Hendrix, Craig W/G-4182-2014	Hendrix, Craig W/0000-0002-5696-8665				AHMED AR, 1983, ARCH DERMATOL, V119, P934, DOI 10.1001/archderm.119.11.934; ANDERSON RE, 1990, ARCH INTERN MED, V150, P73, DOI 10.1001/archinte.150.1.73; ANDERSON RE, 1991, AIDS, V5, P213, DOI 10.1097/00002030-199102000-00013; CANESSA PA, 1989, CHEST, V96, P1215, DOI 10.1378/chest.96.5.1215; FAHEY JL, 1984, AM J MED, V76, P95, DOI 10.1016/0002-9343(84)90756-3; FAIRSHTER RD, 1980, J ALLERGY CLIN IMMUN, V66, P452, DOI 10.1016/0091-6749(80)90005-6; FRENCH MAH, 1990, CLIN IMMUNOL IMMUNOP, V55, P86, DOI 10.1016/0090-1229(90)90070-7; GORDON EH, 1983, J ALLERGY CLIN IMMUN, V72, P487, DOI 10.1016/0091-6749(83)90586-9; GOTTLIEB MS, 1981, NEW ENGL J MED, V305, P1425, DOI 10.1056/NEJM198112103052401; GRAHAM NMH, 1992, JAMA-J AM MED ASSOC, V267, P369, DOI 10.1001/jama.267.3.369; HOFMANN B, 1990, AIDS, V4, P207, DOI 10.1097/00002030-199003000-00005; HUEBNER RE, 1992, JAMA-J AM MED ASSOC, V267, P409, DOI 10.1001/jama.267.3.409; KLATZMANN D, 1984, SCIENCE, V225, P59, DOI 10.1126/science.6328660; KNIKER WT, 1984, ANN ALLERGY, V52, P75; LAMBIN P, 1988, CLIN CHEM, V34, P1367; LANE HC, 1983, NEW ENGL J MED, V309, P453, DOI 10.1056/NEJM198308253090803; LEVY JA, 1989, JAMA-J AM MED ASSOC, V261, P2997, DOI 10.1001/jama.261.20.2997; LUCEY DR, 1991, J ACQ IMMUN DEF SYND, V4, P24; LUCEY DR, 1991, J INFECT DIS, V164, P631, DOI 10.1093/infdis/164.4.631; MALONE JL, 1990, J ACQ IMMUN DEF SYND, V3, P144; MARKOWITZ N, 1990, American Review of Respiratory Disease, V141, pA617; MASUR H, 1981, NEW ENGL J MED, V305, P1431, DOI 10.1056/NEJM198112103052402; MORRIS DL, 1979, CANCER RES, V39, P219; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; MUNOZ A, 1988, J ACQ IMMUN DEF SYND, V1, P396; PITCHENIK AE, 1983, ANN INTERN MED, V98, P277, DOI 10.7326/0003-4819-98-3-277; POLK BF, 1987, NEW ENGL J MED, V316, P61, DOI 10.1056/NEJM198701083160201; REDFIELD RR, 1986, NEW ENGL J MED, V314, P131, DOI 10.1056/NEJM198601093140232; RENZULLO PO, 1990, J ACQ IMMUN DEF SYND, V3, P266; REUBEN JM, 1984, ANN ALLERGY, V53, P390; ROBERT CF, 1989, NEW ENGL J MED, V321, P1268; SCHROFF RW, 1983, CLIN IMMUNOL IMMUNOP, V27, P300, DOI 10.1016/0090-1229(83)90083-1; SELWYN PA, 1992, JAMA-J AM MED ASSOC, V268, P504, DOI 10.1001/jama.268.4.504; SIEGAL FP, 1981, NEW ENGL J MED, V305, P1439, DOI 10.1056/NEJM198112103052403; STIMPSON PG, 1976, SOUTHERN MED J, V69, P424, DOI 10.1097/00007611-197604000-00013; YARCHOAN R, 1989, SCIENCE, V245, P412, DOI 10.1126/science.2502840; 1991, MMWR, V40, P27; 1990, MMWR, V39, P645; 1990, MMWR, V39, P638	39	120	120	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1993	119	3					177	184		10.7326/0003-4819-119-3-199308010-00001	http://dx.doi.org/10.7326/0003-4819-119-3-199308010-00001			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU903	8100691				2022-12-28	WOS:A1993LU90300001
J	HAMMOND, MF; EVANS, ME; LYE, M				HAMMOND, MF; EVANS, ME; LYE, M			ANTIDEPRESSANTS AND OLD-PEOPLE	LANCET			English	Letter							DEPRESSION				HAMMOND, MF (corresponding author), UNIV LIVERPOOL,ROYAL LIVERPOOL UNIV HOSP,DEPT GERIATR MED,POB 147,LIVERPOOL L69 3BX,ENGLAND.							ALEXOPOULOUS GS, 1992, INT J GERIATR PSYCH, V7, P305, DOI 10.1002/gps.930070502; BALDWIN RC, 1986, BRIT J PSYCHIAT, V149, P574, DOI 10.1192/bjp.149.5.574; EVANS ME, IN PRESS INT J GER P; MURPHY E, 1988, BRIT J PSYCHIAT, V152, P347, DOI 10.1192/bjp.152.3.347; TALLIS, 1993, LANCET, V341, P1444; 1993, BRIT J PSYCHIAT, V163, P175	6	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 24	1993	342	8865					244	244		10.1016/0140-6736(93)92338-T	http://dx.doi.org/10.1016/0140-6736(93)92338-T			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LN622	8100966				2022-12-28	WOS:A1993LN62200048
J	JOHNSON, N; SUTTON, J; THORNTON, JG; LILFORD, RJ; JOHNSON, VA; PEEL, KR				JOHNSON, N; SUTTON, J; THORNTON, JG; LILFORD, RJ; JOHNSON, VA; PEEL, KR			DECISION-ANALYSIS FOR BEST MANAGEMENT OF MILDLY DYSKARYOTIC SMEAR	LANCET			English	Article							CERVICAL INTRAEPITHELIAL NEOPLASIA; LOOP DIATHERMY EXCISION; TERM FOLLOW-UP; COLPOSCOPIC ASSESSMENT; CANCER; ATYPIA; DYSPLASIA; CYTOLOGY; BEHAVIOR; RISK	Should a woman with a mildly dyskaryotic cervical smear be referred for colposcopy or should the smear be repeated? One way to answer this question is to use decision analysis and compare the expected mortality and cost of each policy. Data for each component of the question were obtained from published work worldwide and were supplemented with an audit of mildly dyskaryotic smears in West Yorkshire, UK. 2 out of 1000 women with an initial mildly dyskaryotic smear will develop cancer if a conservative repeat smear policy is adopted in association with five-yearly cervical screening. This number can be reduced to 1.6 per 1000 if cervical screening is offered every three years. A policy of immediate referral for colposcopy is also associated with a subsequent cancer rate of 1.6 per 1000. Therefore, repeating the smear is almost as effective as an immediate referral to a colposcopy unit. Even if a five-yearly cervical screening programme is adopted, 2500 women with a mildly dyskaryotic smear will need to be referred for immediate colposcopy to save 1 additional cancer. A conservative policy is not financially cheaper: an average of six additional smears is required to save each colposcopy referral. Sensitivity analysis shows that the excess cost of the conservative policy increases exponentially as the risk of a subsequent cytological abnormality exceeds 60%. Local cytopathology laboratories should audit their recurrent dyskaryosis rate associated with borderline, mild, and moderate dyskaryosis before accepting the U-tum in the national recommendations.	GEN INFIRM,DEPT GYNAECOL & OBSTET,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND; UNIV LEEDS,INST EPIDEMIOL & HLTH SCI RES,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND	Leeds General Infirmary; University of Leeds	JOHNSON, N (corresponding author), LEEDS GEN INFIRM,DEPT OBSTET & GYNAECOL,OBSTET & GYNAECOL UNIT,CLARENDON WING,BELMONT GROVE,LEEDS LS2 9NS,ENGLAND.		Johnson, Victoria/GVU-7127-2022; Thornton, Jim/B-8336-2008	Thornton, Jim/0000-0001-9764-6876				CAMPION MJ, 1986, LANCET, V2, P237; CHOMET J, 1987, BRIT MED J, V294, P1326, DOI 10.1136/bmj.294.6583.1326; Christopherson W M, 1969, Obstet Gynecol Surv, V24, P842, DOI 10.1097/00006254-196907001-00014; EVANS DMD, 1986, J CLIN PATHOL, V39, P933, DOI 10.1136/jcp.39.9.933; GILES JA, 1988, BRIT MED J, V296, P1099, DOI 10.1136/bmj.296.6629.1099; HILLIER C, 1990, BRIT MED J, V301, P343, DOI 10.1136/bmj.301.6747.343-a; HULKA BS, 1968, AM J OBSTET GYNECOL, V101, P190, DOI 10.1016/0002-9378(68)90187-7; ISMAIL SM, 1990, BRIT MED J, V301, P343; ISMAIL SM, 1989, BRIT MED J, V298, P707, DOI 10.1136/bmj.298.6675.707; JORDAN JA, 1985, BRIT J OBSTET GYNAEC, V82, P394; KATAJA V, 1989, EUR J EPIDEMIOL, V5, P1, DOI 10.1007/BF00145037; KERN G, 1969, EPITHEL ARCH GYNAKOL, V207, P342; KINLEN LJ, 1978, LANCET, V2, P463; KITCHENER HC, 1987, BRIT MED J, V294, P1313, DOI 10.1136/bmj.294.6583.1313; KOSS LG, 1963, CANCER, V16, P1160, DOI 10.1002/1097-0142(196309)16:9<1160::AID-CNCR2820160910>3.0.CO;2-4; KOSS LG, 1979, DIAGNOSTIC CYTOLOGY, P294; KOTTMEIER HL, 1973, PROBLEMS OBSTETRICS, V6; LILFORD RJ, 1990, BAILLIERES CLIN OBST, V4; LOPES A, 1990, BRIT J OBSTET GYNAEC, V97, P175, DOI 10.1111/j.1471-0528.1990.tb01744.x; LUESLEY D, 1990, BRIT MED J, V301, P343, DOI 10.1136/bmj.301.6747.343-b; LUESLEY DM, 1990, BRIT MED J, V300, P1690, DOI 10.1136/bmj.300.6741.1690; MCINDOE WA, 1984, OBSTET GYNECOL, V64, P451; MCKAY DG, 1959, OBSTET GYNECOL, V13, P2; MITCHELL H, 1986, LANCET, V1, P573; NASIELL K, 1983, OBSTET GYNECOL, V61, P609; NASIELL K, 1986, OBSTET GYNECOL, V67, P665, DOI 10.1097/00006250-198605000-00012; PEARSON SE, 1989, BRIT J OBSTET GYNAEC, V96, P486, DOI 10.1111/j.1471-0528.1989.tb02429.x; RICHART RM, 1969, AM J OBSTET GYNECOL, V105, P386, DOI 10.1016/0002-9378(69)90268-3; ROBERTSON JH, 1988, BRIT MED J, V297, P18, DOI 10.1136/bmj.297.6640.18; SANTA UV, 1971, OBSTET GYNECOL, V38, P811; SEDLIS A, 1970, AM J OBSTET GYNECOL, V107, P1065, DOI 10.1016/0002-9378(70)90630-7; SOUTTER WP, 1986, BRIT J OBSTET GYNAEC, V93, P70, DOI 10.1111/j.1471-0528.1986.tb07816.x; STERN E, 1964, CANCER, V17, P508, DOI 10.1002/1097-0142(196404)17:4<508::AID-CNCR2820170412>3.0.CO;2-S; THORNTON JG, 1992, BRIT MED J, V304, P1099, DOI 10.1136/bmj.304.6834.1099; VANOORTMARSSEN GJ, 1992, BRIT MED J, V305, P449, DOI 10.1136/bmj.305.6851.449; WALKER EM, 1986, LANCET, V2, P672; 1986, BMJ, V293, P659	37	45	45	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 10	1993	342	8863					91	96		10.1016/0140-6736(93)91290-3	http://dx.doi.org/10.1016/0140-6736(93)91290-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LL789	8100917				2022-12-28	WOS:A1993LL78900014
J	DAVENPORT, A; JONES, SR; GOEL, S; ASTLEY, JP; HARTOG, M				DAVENPORT, A; JONES, SR; GOEL, S; ASTLEY, JP; HARTOG, M			DIFFERENTIATION OF ACUTE FROM CHRONIC RENAL IMPAIRMENT BY DETECTION OF CARBAMYLATED HEMOGLOBIN	LANCET			English	Article							HEMOGLOBIN; CYANATE; UREMIA; UREA	Detection of carbamylated haemoglobin, measured as valine hydantoin per g haemoglobin (VH/g Hb), may be useful in differentiating between patients with acute or chronic renal failure. To assess this test, we measured carbamylated haemoglobin prospectively in 42 consecutive patients referred to the regional renal unit with a serum creatinine in excess of 500 mumol/L and a provisional diagnosis of acute renal failure (ARF). Patients were subsequently classed on clinical criteria as having ARF (20) or acute on chronic renal failure (AonCRF, 22). 24 patients with stable chronic renal failure (CRF), matched for degree of renal impairment, were also studied. Standard biochemical tests and haemoglobin were similar among the three groups. Patients with ARF of 10 or less days duration had a lower median (interquartile range [IQR]) carbamylated haemoglobin concentration than those with a longer duration of ARF (29 [27-35] vs 72 [60-83] mug VH/g Hb; p < 0.01). Carbamylated haemoglobin concentration was lower in the ARF group than in the AonCRF or CRF groups (42 [31-67], 116 [83-119], and 148 [122-210] mug VH/g Hb, respectively; p < 0.001). All patients with a degree of acute and potentially, reversible renal failure (ARF and AonCRF) had a carbamylated haemoglobin concentration below 190 mug VH/g Hb (sensitivity 100%, positive predictive value 62% for this cut-off). When the ratio of carbamylated haemoglobin to serum creatinine was calculated, to correct for degree of renal failure, a value of less than 0.2 had a 100% sensitivity and 80% positive predictive value for dividing patients with potentially reversible renal failure from those with CRF. Measurement of carbamylated haemoglobin was useful in identifying patients with acute and potentially reversible forms of renal failure. This test could be of clinical value in deciding which patients require urgent referral for further management and treatment in hospitals without specialist neuphrological care.	SOUTHMEAD GEN HOSP,DEPT CLIN CHEM,BRISTOL BS10 5NB,AVON,ENGLAND; UNIV BRISTOL,SOUTHMEAD HOSP,DEPT MED,BRISTOL BS10 5NB,AVON,ENGLAND	Southmead Hospital; Southmead Hospital; University of Bristol	DAVENPORT, A (corresponding author), SOUTHMEAD GEN HOSP,DEPT RENAL MED,BRISTOL BS10 5NB,AVON,ENGLAND.							BASTL CP, 1980, CONTEMP ISS NEPHROL, V6, P17; BUNN HF, 1981, DIABETES, V30, P613; CASSIDY MJD, 1990, BRIT MED J, V301, P329, DOI 10.1136/bmj.301.6747.329; DELGRECO F, 1981, ANN CLIN LAB SCI, V11, P283; DIRNHUBER P, 1948, BIOCHEM J, V42, P628, DOI 10.1042/bj0420628; FEEST TG, 1993, BMJ-BRIT MED J, V306, P481, DOI 10.1136/bmj.306.6876.481; FLUCKIGER R, 1981, NEW ENGL J MED, V304, P823, DOI 10.1056/NEJM198104023041406; JENSEN M, 1973, J BIOL CHEM, V248, P8057; KANIS JA, 1987, OXFORD TXB MED, V1; KWAN JTC, 1990, CLIN CHEM, V36, P607; KWAN JTC, 1991, NEPHROL DIAL TRANSPL, V6, P38, DOI 10.1093/ndt/6.1.38; KWAN JTC, 1992, 29TH C EUR DIAL TRAN; LEE CK, 1973, J BIOL CHEM, V248, P5861; LEE JA, 1991, LANCET, V338, P1438, DOI 10.1016/0140-6736(91)92733-I; MARSHALL WJ, 1988, ILLUSTRATED TXB CLIN, P6; MUEHRCKE RC, 1969, ACUTE RENAL FAILURE; OLIVER DO, 1987, OXFORD TXB MED, V2; SMITH WGJ, 1988, CLIN CHIM ACTA, V178, P297, DOI 10.1016/0009-8981(88)90238-0; STARK GR, 1960, J BIOL CHEM, V235, P3177	19	47	48	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 26	1993	341	8861					1614	1617		10.1016/0140-6736(93)90757-8	http://dx.doi.org/10.1016/0140-6736(93)90757-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ727	8099989				2022-12-28	WOS:A1993LJ72700003
J	VANDERHULST, RRWJ; VANKREEL, BK; VONMEYENFELDT, MF; BRUMMER, RJM; ARENDS, JW; DEUTZ, NEP; SOETERS, PB				VANDERHULST, RRWJ; VANKREEL, BK; VONMEYENFELDT, MF; BRUMMER, RJM; ARENDS, JW; DEUTZ, NEP; SOETERS, PB			GLUTAMINE AND THE PRESERVATION OF GUT INTEGRITY	LANCET			English	Article							NITROGEN-BALANCE; PERMEABILITY; SURGERY; MUSCLE; FALL	Parenteral glutamine dipeptide improves nitrogen balance in postoperative patients on total parenteral nutrition (TPM). Animal studies show that the structure and function of the gut is preserved by glutamine. It is not known if this is the case in human beings. 20 patients admitted to hospital for total parenteral nutrition were randomly allocated to receive parenteral nutrition enriched with glycyl-L-glutamine (Gln TPN), or standard parenteral nutrition (STPN). Mucosal biopsy specimens were taken from the second part of the duodenum before starting parenteral nutrition, and after two weeks. The ratio between the urine concentrations of lactulose and mannitol after enteral administration was used to measure intestinal permeability. After two weeks of parenteral nutrition in the GlnTPN group, intestinal permeability was unchanged, whereas permeability in the STPN group increased. Villus height was unaltered in the GlnTPN group but in the STPN group it decreased. The addition of glutamine to parenteral nutrition prevents deterioration of gut permeability and preserves mucosal structure.	ACAD ZIEKENHUIS,DEPT GASTROENTEROL,6202 AZ MAASTRICHT,NETHERLANDS; ACAD ZIEKENHUIS,DEPT PATHOL,6202 AZ MAASTRICHT,NETHERLANDS; ACAD ZIEKENHUIS,DEPT CLIN CHEM,6202 AZ MAASTRICHT,NETHERLANDS	Maastricht University; Maastricht University; Maastricht University	VANDERHULST, RRWJ (corresponding author), ACAD ZIEKENHUIS,DEPT SURG,POB 5800,6202 AZ MAASTRICHT,NETHERLANDS.		Deutz, Nicolaas E/J-5200-2012; Brummer, Robert JM/A-3137-2009	Brummer, Robert JM/0000-0002-0362-0008; Deutz, Nicolaas/0000-0001-5845-6447				ADIBI SA, 1987, DIPEPTIDES NEW SUBST; EBERTS TJ, 1979, CLIN CHEM, V25, P1440; EPSTEIN MD, 1991, ARCH SURG-CHICAGO, V126, P198; HAMMARQVIST F, 1989, ANN SURG, V209, P455, DOI 10.1097/00000658-198904000-00011; HOLLANDER D, 1992, SCAND J GASTROENTERO, V27, P721, DOI 10.3109/00365529209011172; LO CW, 1989, NUTR REV, V47, P193, DOI 10.1111/j.1753-4887.1989.tb02837.x; MENZIES IS, 1979, LANCET, V2, P1107; SHIPPEE RL, 1992, CLIN CHEM, V38, P343; SOUBA WW, 1990, J SURG RES, V48, P383, DOI 10.1016/0022-4804(90)90080-L; STEHLE P, 1989, LANCET, V1, P231; TAMADA H, 1992, JPEN-PARENTER ENTER, V16, P110, DOI 10.1177/0148607192016002110; VANEIJK HMH, 1988, CLIN CHEM, V34, P2510; WALSER M, 1991, AM J CLIN NUTR, V53, P1337, DOI 10.1093/ajcn/53.6.1337; WILMORE DW, 1988, SURGERY, V104, P917; ZIEGLER TR, 1992, ANN INTERN MED, V116, P821, DOI 10.7326/0003-4819-116-10-821	15	470	483	1	21	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 29	1993	341	8857					1363	1365		10.1016/0140-6736(93)90939-E	http://dx.doi.org/10.1016/0140-6736(93)90939-E			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE180	8098788				2022-12-28	WOS:A1993LE18000002
J	MAYATEPEK, E; BECKER, K; GANA, L; HOFFMANN, GF; LEICHSENRING, M				MAYATEPEK, E; BECKER, K; GANA, L; HOFFMANN, GF; LEICHSENRING, M			LEUKOTRIENES IN THE PATHOPHYSIOLOGY OF KWASHIORKOR	LANCET			English	Article							CYSTEINYL LEUKOTRIENES; PATHOGENESIS; METABOLISM	The actions of cysteinyl leukotrienes include production of oedema. We investigated whether these mediators might be involved in the oedematous malnutrition syndrome kwashiorkor. The capacity of leukotriene (LT) synthesis by stimulated whole blood and urinary LTE4 excretion was measured in 12 children with kwashiorkor, and compared with that in 24 marasmic and 12 control children. Urinary LTE4 excretion was significantly higher in patients with kwashiorkor than in controls (118 8 [SD 28.5] vs 31.1 [19.3] nmol/mol creatinine; p<0.01). Whole blood LTE4 synthesis was increased in kwashiorkor patients by a factor of 3.5 (p<0.01). In marasmic children, LTE4 excretion and synthesis did not differ from those in controls. Although glutathione, known to participate in LTC4 synthesis, was subnormal in erythrocytes of all malnourished patients, whole-blood LTC4 synthesis was higher in kwashiorkor patients than in controls (28.1 [5.01 ng/mL; p<0.05), and close to control values (9.8 [1.51 ng/mL) in marasmic children. LTB4 synthesis, however, was greatly reduced in kwashiorkor patients (11.5 [2.4] vs 46.5 [6.4] ng/mL; p<0.01). Inability to synthesise the immunoregulator LTB4 may lead to inefficient chemoattraction of phagocytes and an inadequate inflammatory response in kwashiorkor. The increased endogenous cysteinyl LT generation in kwashiorkor suggests that these lipid mediators are involved in the pathophysiology of the syndrome, particularly in oedema formation.	UNIV HEIDELBERG, CHILDRENS HOSP, DIV TROP PAEDIAT, NEUENHEIMER FELD 150, D-69120 HEIDELBERG, GERMANY; SPECIALIST HOSP, MALDUGURI, NIGERIA	Ruprecht Karls University Heidelberg								ALANKO J, 1991, PROSTAGLANDINS, V42, P279, DOI 10.1016/0090-6980(91)90116-W; ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; [Anonymous], 1970, LANCET, V2, P302; ANTOINE C, 1991, BIOCHIM BIOPHYS ACTA, V1075, P162, DOI 10.1016/0304-4165(91)90247-E; BEUTLER E, 1988, COENZYMES COFACTORS, V3, P291; CHANDRA RK, 1983, LANCET, V1, P688; DAHLEN SE, 1981, P NATL ACAD SCI-BIOL, V78, P3887, DOI 10.1073/pnas.78.6.3887; FORDHUTCHINSON AW, 1985, FED PROC, V44, P25; GOLDEN MHN, 1987, P NUTR SOC, V46, P53, DOI 10.1079/PNS19870008; HUBER M, 1990, EUR J BIOCHEM, V194, P309, DOI 10.1111/j.1432-1033.1990.tb19458.x; KEPPLER D, 1988, ANN NY ACAD SCI, V524, P68, DOI 10.1111/j.1749-6632.1988.tb38531.x; LEICHSENRING M, 1992, LIPID SOLUBLE ANTIOX, P507; MAYATEPEK E, 1993, J CLIN INVEST, V91, P881, DOI 10.1172/JCI116309; MURPHY RC, 1979, P NATL ACAD SCI USA, V76, P4275, DOI 10.1073/pnas.76.9.4275; PACEASCIAK CR, 1986, BIOCHEM BIOPH RES CO, V140, P857, DOI 10.1016/0006-291X(86)90713-8; Paul K., 1993, European Journal of Pediatrics, V152, P282; ROLAPLESZCZYNSKI M, 1986, PROSTAG LEUKOTR ESS, V23, P207, DOI 10.1016/0262-1746(86)90187-3; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; STUART HC, 1987, TXB PEDIAT, P6; TAYLOR GW, 1989, LANCET, V1, P584; WATERLOW JC, 1984, T ROY SOC TROP MED H, V78, P436, DOI 10.1016/0035-9203(84)90053-1; Williams C D, 1933, Arch Dis Child, V8, P423; WILLIAMS Cicely D., 1935, Lancet, P1151	23	36	38	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 16	1993	342	8877					958	960		10.1016/0140-6736(93)92003-C	http://dx.doi.org/10.1016/0140-6736(93)92003-C			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MC005	8105215				2022-12-28	WOS:A1993MC00500010
J	COLLEE, JG				COLLEE, JG			BSE - STOCKTAKING 1993	LANCET			English	Review							CREUTZFELDT-JAKOB DISEASE; BOVINE SPONGIFORM ENCEPHALOPATHY; RISK-FACTORS; ENGLAND; WALES; EPIDEMIOLOGY				COLLEE, JG (corresponding author), UNIV EDINBURGH,SCH MED,DEPT MED MICROBIOL,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND.							[Anonymous], 1989, REPORT WORKING PARTY; BANISSISABOURDY C, 1992, BIOELECTROCH BIOENER, V28, P127, DOI 10.1016/0302-4598(92)80008-5; BOBOWICK AR, 1973, AM J EPIDEMIOL, V98, P381, DOI 10.1093/oxfordjournals.aje.a121567; BROWN P, 1993, LANCET, V341, P127, DOI 10.1016/0140-6736(93)90001-W; BROWN P, 1987, NEUROLOGY, V37, P895, DOI 10.1212/WNL.37.6.895; BROWN P, 1992, LANCET, V340, P24, DOI 10.1016/0140-6736(92)92431-E; Brugere H., 1991, Bulletin de l'Academie Veterinaire de France, V64, P139; COLLEE JG, 1991, MED LAB SCI, V48, P296; COLLINGE J, 1993, LANCET, V341, P627; COLLINGE J, 1990, LANCET, V336, P7, DOI 10.1016/0140-6736(90)91518-F; COUSENS SN, 1990, J NEUROL NEUROSUR PS, V53, P459, DOI 10.1136/jnnp.53.6.459; DAVANIPOUR Z, 1985, NEUROLOGY, V35, P1483, DOI 10.1212/WNL.35.10.1483; DAVANIPOUR Z, 1985, AM J EPIDEMIOL, V122, P443, DOI 10.1093/oxfordjournals.aje.a114125; DAVIES PTG, 1993, LANCET, V342, P680, DOI 10.1016/0140-6736(93)91787-M; DEALLER S, 1991, LANCET, V337, P173, DOI 10.1016/0140-6736(91)90834-C; DEALLER S F, 1990, Food Microbiology (London), V7, P253, DOI 10.1016/0740-0020(90)90032-D; HARDY J, 1993, LANCET, V341, P626; HARRIESJONES R, 1988, J NEUROL NEUROSUR PS, V51, P1113, DOI 10.1136/jnnp.51.9.1113; HARRISON PJ, 1992, BMJ-BRIT MED J, V304, P929, DOI 10.1136/bmj.304.6832.929; HORNSBY M, 1993, TIMES           0311, P1; JACKSON M, 1993, LANCET, V341, P626, DOI 10.1016/0140-6736(93)90383-R; Kimberlin R H, 1992, Rev Sci Tech, V11, P347; KIMBERLIN RH, 1990, TOPLEY WILSONS PRINC, V4, P671; KONDO K, 1982, ANN NEUROL, V11, P377, DOI 10.1002/ana.410110410; MASTERS CL, 1979, ANN NEUROL, V5, P177, DOI 10.1002/ana.410050212; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1987, ANNU REV MED, V38, P381, DOI 10.1146/annurev.me.38.020187.002121; SAWCER SJ, 1993, LANCET, V341, P642, DOI 10.1016/0140-6736(93)90414-C; TAYLOR DM, 1992, MED LAB SCI, V49, P334; WILESMITH JW, 1988, VET REC, V123, P638; WILESMITH JW, 1991, VIROLOGY, V2, P239; WILL RG, 1986, J NEUROL NEUROSUR PS, V49, P749, DOI 10.1136/jnnp.49.7.749; WILL RG, 1991, J NEUROL NEUROSUR PS, V54, P761, DOI 10.1136/jnnp.54.9.761; 1989, CONSULTATIVE COMMITT; 1990, LANCET, V336, P21	35	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 25	1993	342	8874					790	793		10.1016/0140-6736(93)91546-X	http://dx.doi.org/10.1016/0140-6736(93)91546-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LY868	8103881				2022-12-28	WOS:A1993LY86800015
J	TERPSTRA, OT				TERPSTRA, OT			AUXILIARY LIVER GRAFTING - A NEW CONCEPT IN LIVER-TRANSPLANTATION	LANCET			English	Editorial Material							DISEASE				TERPSTRA, OT (corresponding author), LEIDEN UNIV HOSP,DEPT SURG,2333 AA LEIDEN,NETHERLANDS.							BROELSCH CE, 1990, ANN SURG, V212, P368, DOI 10.1097/00000658-199009000-00015; GUBERNATIS G, 1991, WORLD J SURG, V15, P660, DOI 10.1007/BF01789221; METSELAAR HJ, 1990, LANCET, V335, P1156, DOI 10.1016/0140-6736(90)91158-7; REUVERS CB, 1985, TRANSPLANTATION, V39, P113, DOI 10.1097/00007890-198502000-00001; STAMPFL DA, 1990, GASTROENTEROLOGY, V99, P1834, DOI 10.1016/0016-5085(90)90497-O; TERPSTRA OT, 1988, NEW ENGL J MED, V319, P1507, DOI 10.1056/NEJM198812083192303; TERPSTRA OT, 1988, TRANSPLANTATION, V45, P1003, DOI 10.1097/00007890-198806000-00001	7	29	29	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 25	1993	342	8874					758	758		10.1016/0140-6736(93)91537-V	http://dx.doi.org/10.1016/0140-6736(93)91537-V			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LY868	8103873				2022-12-28	WOS:A1993LY86800006
J	COX, TM				COX, TM			GAUCHERS-DISEASE - A BRAND LEADER	LANCET			English	Editorial Material							GLUCOCEREBROSIDASE				COX, TM (corresponding author), UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT MED,CAMBRIDGE CB2 2QQ,ENGLAND.							ACHORD DT, 1978, CELL, V15, P269, DOI 10.1016/0092-8674(78)90102-2; BARTON NW, 1991, NEW ENGL J MED, V324, P1464, DOI 10.1056/NEJM199105233242104; DEDUVE C, 1964, FED PROC, V23, P1045; FRATANTONI JC, 1968, SCIENCE, V163, P570; MISTRY PK, 1992, Q J MED, V84, P541; MOULLIER P, 1993, NAT GENET, V4, P154, DOI 10.1038/ng0693-154; OHASHI T, 1992, P NATL ACAD SCI USA, V89, P11332, DOI 10.1073/pnas.89.23.11332; SATO Y, 1993, J CLIN INVEST, V91, P1909, DOI 10.1172/JCI116409; ZIMRAN A, 1993, BLOOD, V82, P1107	9	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 18	1993	342	8873					694	695		10.1016/0140-6736(93)91703-O	http://dx.doi.org/10.1016/0140-6736(93)91703-O			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX469	8103817				2022-12-28	WOS:A1993LX46900004
J	HORWICH, AL; LOW, KB; FENTON, WA; HIRSHFIELD, IN; FURTAK, K				HORWICH, AL; LOW, KB; FENTON, WA; HIRSHFIELD, IN; FURTAK, K			FOLDING IN-VIVO OF BACTERIAL CYTOPLASMIC PROTEINS - ROLE OF GROEL	CELL			English	Article							RIBULOSE BISPHOSPHATE CARBOXYLASE; ESCHERICHIA-COLI K-12; HEAT-SHOCK PROTEINS; ORNITHINE TRANSCARBAMYLASE; MOLECULAR CHAPERONE; YEAST MITOCHONDRIA; HSP60; GENE; DNAK; MUTAGENESIS	A general role for chaperonin ring structures in mediating folding of newly translated proteins has been suggested. Here we have directly examined the role of the E. coli chaperonin GroEL in the bacterial cytoplasm by production of temperature-sensitive lethal mutations in this essential gene. After shift to nonpermissive temperature, the rate of general translation in the mutant cells was reduced, but, more specifically, a defined group of cytoplasmic proteins - including citrate synthase, ketoglutarate dehydrogenase, and polynucleotide phosphorylase - were translated but failed to reach native form. Similarly, a monomeric test protein, maltose-binding protein, devoid of its signal domain, was translated but failed to fold to its native conformation. We conclude that GroEL indeed is a machine at the distal end of the pathway of transfer of genetic information, assisting a large and specific set of newly translated cytoplasmic proteins to reach their native tertiary structures.	YALE UNIV, SCH MED, DEPT THERAPEUT RADIOL, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, HOWARD HUGHES MED INST, NEW HAVEN, CT 06510 USA; ST JOHNS UNIV, DEPT BIOL SCI, JAMAICA, NY 11439 USA	Yale University; Howard Hughes Medical Institute; Yale University; Saint John's University	HORWICH, AL (corresponding author), YALE UNIV, SCH MED, DEPT GENET, NEW HAVEN, CT 06510 USA.							Bachmann B.J., 1987, ESCHERICHIA COLI SAL, P1190; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; BUSBY S, 1982, J MOL BIOL, V154, P197, DOI 10.1016/0022-2836(82)90060-2; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CHENG MY, 1990, NATURE, V348, P455, DOI 10.1038/348455a0; COHEN SN, 1973, P NATL ACAD SCI USA, V70, P3240, DOI 10.1073/pnas.70.11.3240; DONNELLY CE, 1992, J BACTERIOL, V174, P3133, DOI 10.1128/jb.174.10.3133-3139.1992; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FAYET O, 1986, MOL GEN GENET, V202, P435, DOI 10.1007/BF00333274; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; GAO YI, 1993, MOL CELL BIOL, V13, P2478, DOI 10.1128/MCB.13.4.2478; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GEORGOPOULOS C P, 1974, Journal of Supramolecular Structure, V2, P349, DOI 10.1002/jss.400020224; GEORGOPOULOS CP, 1973, J MOL BIOL, V76, P45, DOI 10.1016/0022-2836(73)90080-6; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GRAGEROV A, 1992, P NATL ACAD SCI USA, V89, P10341, DOI 10.1073/pnas.89.21.10341; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HARLOW E, 1988, ANTIBODIES LABORATOR; HARTL FU, 1992, ANNU REV BIOPH BIOM, V21, P293, DOI 10.1146/annurev.bb.21.060192.001453; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HOOGENRAAD NJ, 1980, ANAL BIOCHEM, V101, P97, DOI 10.1016/0003-2697(80)90045-7; HORWICH A, 1980, J VIROL, V36, P125, DOI 10.1128/JVI.36.1.125-132.1980; HORWICH AL, 1986, CELL, V44, P451, DOI 10.1016/0092-8674(86)90466-6; HORWICH AL, 1993, PHILOS T R SOC B, V339, P313, DOI 10.1098/rstb.1993.0030; KALOUSEK F, 1978, J BIOL CHEM, V253, P3939; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KUSUKAWA N, 1989, EMBO J, V8, P3517, DOI 10.1002/j.1460-2075.1989.tb08517.x; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LEE SC, 1992, J BIOL CHEM, V267, P2849; LOW B, 1971, J BACTERIOL, V108, P742, DOI 10.1128/JB.108.2.742-750.1971; LOW B, 1973, J BACTERIOL, V113, P798, DOI 10.1128/JB.113.2.798-812.1973; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1992, SCIENCE, V258, P995, DOI 10.1126/science.1359644; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; SCHELLHORN HE, 1991, J BACTERIOL, V173, P6192, DOI 10.1128/jb.173.19.6192-6198.1991; STERNBERG N, 1973, J MOL BIOL, V76, P45; STRAUS D, 1990, GENE DEV, V4, P2202, DOI 10.1101/gad.4.12a.2202; STRAUS DB, 1988, GENE DEV, V2, P1851, DOI 10.1101/gad.2.12b.1851; URSIC D, 1991, MOL CELL BIOL, V11, P2629, DOI 10.1128/MCB.11.5.2629; VANBOGELEN RA, 1992, ELECTROPHORESIS, V13, P1014, DOI 10.1002/elps.11501301203; VANDYK TK, 1989, NATURE, V342, P451, DOI 10.1038/342451a0; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; WANG Z, 1992, PROTEIN SCI, V1, P522; WOODCOCK DM, 1989, NUCLEIC ACIDS RES, V17, P3469, DOI 10.1093/nar/17.9.3469; WYNN RM, 1992, J BIOL CHEM, V267, P12400; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0; ZHENG XX, 1993, J BIOL CHEM, V268, P7489	56	299	304	0	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 10	1993	74	5					909	917		10.1016/0092-8674(93)90470-B	http://dx.doi.org/10.1016/0092-8674(93)90470-B			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LX292	8104102				2022-12-28	WOS:A1993LX29200016
J	WEISSKOPF, MG; ZALUTSKY, RA; NICOLL, RA				WEISSKOPF, MG; ZALUTSKY, RA; NICOLL, RA			THE OPIOID PEPTIDE DYNORPHIN MEDIATES HETEROSYNAPTIC DEPRESSION OF HIPPOCAMPAL MOSSY FIBER SYNAPSES AND MODULATES LONG-TERM POTENTIATION (VOL 362, PG 423, 1993)	NATURE			English	Correction, Addition																		DERRICK BE, 1991, BRAIN RES BULL, V27, P219, DOI 10.1016/0361-9230(91)90071-Q; KUPFERMANN I, 1991, PHYSIOL REV, V71, P683, DOI 10.1152/physrev.1991.71.3.683; WEISSKOPF MG, 1993, NATURE, V362, P423, DOI 10.1038/362423a0	3	35	35	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 9	1993	365	6442					188	188		10.1038/365188a0	http://dx.doi.org/10.1038/365188a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LW442	8103916	Bronze			2022-12-28	WOS:A1993LW44200056
J	PRAYITNO, SW; ADDY, M; WADE, WG				PRAYITNO, SW; ADDY, M; WADE, WG			DOES GINGIVITIS LEAD TO PERIODONTITIS IN YOUNG-ADULTS	LANCET			English	Note								It has been assumed that poor oral hygiene predisposes to gingivitis with progression to periodontitis and tooth loss. However, a high prevalence of gingivitis occurs in some populations in which severe periodontitis is rare. To assess whether gingivitis is a reliable predictor of periodontitis, we compared the periodontal health of tea pickers and university students aged between 18 and 30 in Indonesia. Oral hygiene and gingival health was significantly better in students than in tea pickers. However, the prevalence and the severity of chronic periodontitis were similar in the two groups. Our findings suggest that gingivitis is a poor predictor of periodontitis in subjects younger than 30 years. Attempts to prevent periodontitis in young adults through antigingivitis measures. such as plaque control may be unsuccessful.	DENT SCH, DEPT PERIODONTOL, JAKARTA, INDONESIA; UNIV WALES COLL MED, SCH DENT, DEPT PERIODONTOL, CARDIFF CF4 4XY, WALES	Cardiff University				Wade, William/0000-0003-2685-826X				Addy M, 1988, Community Dent Health, V5, P345; BAELUM V, 1986, J PERIODONTAL RES, V21, P221, DOI 10.1111/j.1600-0765.1986.tb01454.x; CUTRESS TW, 1982, COMMUNITY DENT ORAL, V10, P193, DOI 10.1111/j.1600-0528.1982.tb00378.x; LOE H, 1965, J PERIODONTOL, V36, P177, DOI 10.1902/jop.1965.36.3.177; LOVDAL A., 1958, JOUR AMER DENTAL ASSOC, V56, P21; MARSHALLDAY CD, 1955, J PERIODONTOL, V26, P185; PAPAPANOU PN, 1988, J CLIN PERIODONTOL, V15, P469, DOI 10.1111/j.1600-051X.1988.tb01602.x; PRAYITNO SW, 1990, THESIS U WALES CARDI; Sheiham A, 1969, Dent Pract Dent Rec, V19, P232; SILNESS J, 1964, Acta Odontol Scand, V22, P121, DOI 10.3109/00016356408993968	10	20	20	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 21	1993	342	8869					471	472		10.1016/0140-6736(93)91596-E	http://dx.doi.org/10.1016/0140-6736(93)91596-E			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU075	8102432				2022-12-28	WOS:A1993LU07500013
J	BOTKER, HE; MOLLER, N; OVESEN, P; MENGEL, A; SCHMITZ, O; ORSKOV, H; BAGGER, JP				BOTKER, HE; MOLLER, N; OVESEN, P; MENGEL, A; SCHMITZ, O; ORSKOV, H; BAGGER, JP			INSULIN-RESISTANCE IN MICROVASCULAR ANGINA (SYNDROME-X)	LANCET			English	Article							NORMAL CORONARY-ARTERIES; ESSENTIAL-HYPERTENSION; MUSCLE; DISEASE; DISORDER; OBESITY; NIDDM	Patients with microvascular angina (syndrome X) may be insulin resistant. We designed a study to establish whether this is the case. 11 patients with microvascular angina were compared with 9 matched subjects with noncardiac chest pain. Patients and controls were evaluated by coronary sinus catheterisation, and by isotopic measurement of glucose turnover, indirect calorimetry, and forearm technique during a 3 h baseline period after overnight fast and during a 2 h hyperinsulinaemic euglycaemic clamp. Pace-induced increase in coronary sinus blood flow was less in patients than in controls, whereas forearm blood flow did not differ between groups. Baseline measures of glucose metabolism were normal. During the clamp, glucose production and lipolysis were equally suppressed in both groups. Mean (SE) total insulin-induced glucose uptake was significantly impaired in patients compared with controls (3.9 [0.7] vs 6.4 [0.7] mg/kg per min; p < 0.01), and insulin-stimulated glucose uptake in the forearm was significantly reduced in patients (0.88 [0-101 vs 1.6 [0.301 mmol/L; p < 0.001). Reduced oxidative and nonoxidative metabolism accounted for the defect in overall glucose uptake in patients. No correlation between changes in coronary sinus blood flow and total body glucose uptake was seen. We found that microvascular angina was associated with substantial insulin resistance. Whether this relation is causal or coincidental is as yet unsettled.	AARHUS UNIV,INST EXPTL CLIN RES,DK-8000 AARHUS,DENMARK; AARHUS UNIV HOSP,AARHUS KOMMUNEHOSP,DEPT MED ENDOCRINOL & DIABET M,DK-8000 AARHUS,DENMARK	Aarhus University; Aarhus University	BOTKER, HE (corresponding author), UNIV HOSP AARHUS,SKEJBY HOSP,DEPT CARDIOL,DK-8200 AARHUS N,DENMARK.		Moller, Niels/E-5091-2011	Moller, Niels/0000-0001-5627-7322; Botker, Hans Erik/0000-0001-6358-8962				BAGGER JP, 1985, CARDIOVASC RES, V19, P27, DOI 10.1093/cvr/19.1.27; BARON AD, 1990, J CLIN ENDOCR METAB, V70, P1525, DOI 10.1210/jcem-70-6-1525; BRESSLER P, 1992, DIABETES S1, V41, pA24; CANNON RO, 1990, AM J MED, V88, P217, DOI 10.1016/0002-9343(90)90145-4; CANNON RO, 1992, CIRCULATION, V85, P883, DOI 10.1161/01.CIR.85.3.883; CANNON RO, 1988, AM J CARDIOL, V61, P1338, DOI 10.1016/0002-9149(88)91180-0; CANNON RO, 1990, CIRCULATION, V82, P2011, DOI 10.1161/01.CIR.82.6.2011; DEAN JD, 1991, LANCET, V337, P456; DEFRONZO RA, 1991, DIABETES CARE, V14, P173, DOI 10.2337/diacare.14.3.173; DEFRONZO RA, 1979, AM J PHYSIOL, V237, pE214; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; DETEJADA IS, 1989, NEW ENGL J MED, V320, P1025, DOI 10.1056/NEJM198904203201601; FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605; FISHER BM, 1986, DIABETOLOGIA, V29, P706, DOI 10.1007/BF00870280; HOTHERNIELSEN O, 1987, DIABETOLOGIA, V30, P834; KEMP HG, 1973, AM J CARDIOL, V32, P375, DOI 10.1016/S0002-9149(73)80150-X; KOIVISTO V A, 1986, Diabetes Metabolism Reviews, V1, P445; LILLIOJA S, 1987, J CLIN INVEST, V80, P415, DOI 10.1172/JCI113088; MOLLER N, 1990, J CLIN ENDOCR METAB, V70, P1179, DOI 10.1210/jcem-70-4-1179; OPERK D, 1989, CIRCULATION, V80, P1610; PANZA JA, 1990, NEW ENGL J MED, V323, P22, DOI 10.1056/NEJM199007053230105; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; RICHARDSON PJ, 1974, LANCET, V2, P677; SAX FL, 1987, NEW ENGL J MED, V317, P1366, DOI 10.1056/NEJM198711263172202; STALDER M, 1982, DIABETOLOGIA, V21, P544; STEELE R, 1959, ANN NY ACAD SCI, V82, P420, DOI 10.1111/j.1749-6632.1959.tb44923.x	26	88	92	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 17	1993	342	8864					136	140						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN042	8101255				2022-12-28	WOS:A1993LN04200010
J	CLARK, SG; CHISHOLM, AD; HORVITZ, HR				CLARK, SG; CHISHOLM, AD; HORVITZ, HR			CONTROL OF CELL FATES IN THE CENTRAL BODY REGION OF C-ELEGANS BY THE HOMEOBOX GENE LIN-39	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; POST-EMBRYONIC DEVELOPMENT; PATTERN-FORMATION; DROSOPHILA; EXPRESSION; SEQUENCES; SYSTEM; SPECIFICATION; LINEAGES; CLUSTER	Cells in the mid-body region of the nematode C. elegans develop differently from their anterior or posterior homologs. The gene lin-39 is required for mid-body region-specific development. In lin-39 mutants, midbody cells express fates characteristic of more anterior or posterior homologs, and the migration of a neuroblast through the mid-body is defective. lin-39 acts cell autonomously in these mid-body cells and in the migrating neuroblast. lin-39 encodes a protein with an Antennapedia class homeodomain, most similar to those of the Drosophila homeotic genes Deformed and Sex combs reduced, and is located in a homeotic gene cluster with two other regional homeotic genes, mab-5 and egl-5. lin-39 and mab-5 function combinatorially in 2 ectodermal cells and have redundant functions in gonad development.	MIT,DEPT BIOL,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)				Chisholm, Andrew/0000-0001-5091-0537	NIGMS NIH HHS [GM24943, GM24663] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024663, R01GM024663, R01GM024943] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AROIAN RV, 1993, MOL CELL BIOL, V13, P626, DOI 10.1128/MCB.13.1.626; AUSTIN J, 1987, CELL, V51, P589, DOI 10.1016/0092-8674(87)90128-0; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; BRENNER S, 1974, GENETICS, V77, P71; BURGLIN TR, 1991, NATURE, V351, P703, DOI 10.1038/351703a0; BURGLIN TR, 1993, IN PRESS GUIDEBOOK H; CHALFIE M, 1983, SCIENCE, V221, P61, DOI 10.1126/science.6857263; CHISHOLM A, 1991, DEVELOPMENT, V111, P921; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CLARK SG, 1992, THESIS MIT CAMBRIDGE; COSTA M, 1988, CELL, V55, P747, DOI 10.1016/0092-8674(88)90131-6; COULONDRE C, 1977, J MOL BIOL, V117, P577, DOI 10.1016/0022-2836(77)90059-6; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; COULSON A, 1988, NATURE, V335, P184, DOI 10.1038/335184a0; ELLIS H, 1985, THESIS MIT CAMBRIDGE; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; FERGUSON EL, 1987, NATURE, V326, P259, DOI 10.1038/326259a0; FIELDS C, 1990, NUCLEIC ACIDS RES, V18, P1509, DOI 10.1093/nar/18.6.1509; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; FIXSEN W, 1985, COLD SPRING HARB SYM, V50, P99, DOI 10.1101/SQB.1985.050.01.014; HEDGECOCK EM, 1983, SCIENCE, V220, P1277, DOI 10.1126/science.6857247; HIRSH D, 1976, DEV BIOL, V49, P200, DOI 10.1016/0012-1606(76)90267-0; HODGKIN J, 1979, GENETICS, V91, P67; HODGKIN J, 1988, NEMATODE CAENORHABDI, P491; KAMB A, 1989, P NATL ACAD SCI USA, V86, P4372, DOI 10.1073/pnas.86.12.4372; KENYON C, 1986, CELL, V46, P477, DOI 10.1016/0092-8674(86)90668-9; KENYON C, 1991, SCIENCE, V253, P516, DOI 10.1126/science.1677487; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; LEMOTTE PK, 1989, EMBO J, V8, P219, DOI 10.1002/j.1460-2075.1989.tb03367.x; LI C, 1990, NEURON, V4, P681, DOI 10.1016/0896-6273(90)90195-L; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; PRIESS JR, 1986, DEV BIOL, V117, P156, DOI 10.1016/0012-1606(86)90358-1; REGULSKI M, 1987, EMBO J, V6, P767, DOI 10.1002/j.1460-2075.1987.tb04819.x; ROSENBLUTH RE, 1985, GENETICS, V109, P493; SALSER SJ, 1992, NATURE, V355, P255, DOI 10.1038/355255a0; SCHALLER D, 1990, NUCLEIC ACIDS RES, V18, P2033, DOI 10.1093/nar/18.8.2033; STERNBERG PW, 1986, CELL, V44, P761, DOI 10.1016/0092-8674(86)90842-1; STROEHER VL, 1986, MOL CELL BIOL, V6, P4667, DOI 10.1128/MCB.6.12.4667; STRUHL G, 1982, P NATL ACAD SCI-BIOL, V79, P7380, DOI 10.1073/pnas.79.23.7380; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; SULSTON JE, 1980, DEV BIOL, V78, P542, DOI 10.1016/0012-1606(80)90352-8; WANG BB, 1993, CELL, V74, P29, DOI 10.1016/0092-8674(93)90292-X; White J., 1988, NEMATODE CAENORHABDI, V17, P81; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; White T.J., 1990, PCR PROTOCOLS GUIDE, V18, P315	50	216	232	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 16	1993	74	1					43	55		10.1016/0092-8674(93)90293-Y	http://dx.doi.org/10.1016/0092-8674(93)90293-Y			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LN625	8101475				2022-12-28	WOS:A1993LN62500006
J	DAY, CP; JAMES, OFW; BUTLER, TJ; CAMPBELL, RWF				DAY, CP; JAMES, OFW; BUTLER, TJ; CAMPBELL, RWF			QT PROLONGATION AND SUDDEN CARDIAC DEATH IN PATIENTS WITH ALCOHOLIC LIVER-DISEASE	LANCET			English	Article							MYOCARDIAL-INFARCTION; CIRRHOSIS; CARDIOMYOPATHY; CONSUMPTION; DISPERSION	Cardiovascular death is the most important cause of mortality in alcoholics, yet alcohol may protect against ischaemic heart disease. This could be explained if deaths were a consequence of alcohol-related arrhythmias rather than of coronary atheroma. In many conditions, abnormalities of the QT interval are markers of arrhythmia and for risk of sudden death. We examined the relation between QT intervals and mortality in patients with alcoholic liver disease. Simultaneous 12-lead electrocardiographic recordings were obtained from 69 patients with histologically proven alcoholic liver disease (without evidence of structural heart disease), and from 40 healthy non-drinking controls matched for age and sex. Patients were abstinent for at least 7 days before investigation to exclude acute effects of alcohol. QT intervals were corrected for rate with Bazett's and cube root formulae to define QT(c) and QT(cub), respectively. Unlike QT(c), QT(cub) was independent of rate. Patients were followed for up to four years. For those who died, the cause was determined from case records and postmortem reports. Maximum QT intervals were longer in alcoholics than in controls (QT(cub) 450 vs 439, p = 0.016). This difference was not explained by variations in electrolytes. QT intervals were prolonged in the 14 patients who died compared with survivors (QT(cub) 471 vs 446, p = 0.007). This difference was mainly due to the long QT intervals in the 6 patients with sudden cardiac deaths (QT(cub) 493). The only other factor independently associated with death was sex. QT interval prolongation occurs in some patients with alcoholic liver disease and is associated with an adverse prognosis, especially sudden cardiac death. QT measurement should be included in the initial assessment of alcoholic patients, particularly in those considered for liver transplantation.	UNIV NEWCASTLE UPON TYNE, SCH MED, DEPT MED, NEWCASTLE UPON TYNE NE2 4HH, ENGLAND; UNIV NEWCASTLE UPON TYNE, SCH MED, DEPT MED STAT, NEWCASTLE UPON TYNE NE2 4HH, ENGLAND	Newcastle University - UK; Newcastle University - UK	DAY, CP (corresponding author), UNIV NEWCASTLE UPON TYNE, SCH MED, DEPT ACAD CARDIOL, NEWCASTLE UPON TYNE NE2 4HH, ENGLAND.		Day, Christopher/Z-3305-2019					AHMED SS, 1984, J AM COLL CARDIOL, V3, P696, DOI 10.1016/S0735-1097(84)80245-4; AHNVE S, 1980, ACTA MED SCAND, V208, P55; ALGRA A, 1991, CIRCULATION, V83, P1888, DOI 10.1161/01.CIR.83.6.1888; ASHLEY MJ, 1980, J STUD ALCOHOL, V41, P1040, DOI 10.15288/jsa.1980.41.1040; Bazett HC, 1920, HEART-J STUD CIRC, V7, P353; Child CG., 1964, LIVER PORTAL HYPERTE; COHEN EJ, 1988, AM J CARDIOL, V62, P971, DOI 10.1016/0002-9149(88)90906-X; COWAN JC, 1988, AM J CARDIOL, V61, P83, DOI 10.1016/0002-9149(88)91309-4; DAY CP, 1991, HEPATOLOGY, V14, P798, DOI 10.1002/hep.1840140509; DAY CP, 1992, BRIT HEART J, V67, P39; DAY CP, 1991, EUR HEART J, V12, P423, DOI 10.1093/oxfordjournals.eurheartj.a059911; DYER AR, 1977, CIRCULATION, V56, P1067, DOI 10.1161/01.CIR.56.6.1067; ETTINGER PO, 1978, AM HEART J, V95, P555, DOI 10.1016/0002-8703(78)90296-X; EVANS W, 1959, BRIT HEART J, V31, P445; GREENSPON AJ, 1979, NEW ENGL J MED, V301, P1049, DOI 10.1056/NEJM197911083011906; HAYES PC, 1990, LANCET, V336, P153, DOI 10.1016/0140-6736(90)91668-Z; JACKMAN WM, 1988, PROG CARDIOVASC DIS, V31, P115, DOI 10.1016/0033-0620(88)90014-X; KELBAEK H, 1984, AM J CARDIOL, V54, P852, DOI 10.1016/S0002-9149(84)80220-9; KINO M, 1981, BRIT HEART J, V46, P545; KOIDE T, 1981, JPN HEART J, V22, P151; KOIDE T, 1972, JPN HEART J, V13, P418; KOSKINEN P, 1987, BRIT HEART J, V57, P468, DOI 10.1136/hrt.57.5.468; KRAMER K, 1968, ANN INTERN MED, V69, P273, DOI 10.7326/0003-4819-69-2-273; KRASNER N, 1977, BRIT MED J, V1, P1497, DOI 10.1136/bmj.1.6075.1497; KUO CS, 1983, CARDIOVASC RES, V17, P152, DOI 10.1093/cvr/17.3.152; LEFKOWITCH JH, 1983, HUM PATHOL, V14, P457, DOI 10.1016/S0046-8177(83)80293-7; PANOS RJ, 1988, PACE, V11, P423, DOI 10.1111/j.1540-8159.1988.tb06002.x; SCHLICHTING P, 1983, HEPATOLOGY, V3, P889; SCHWARTZ PJ, 1975, AM HEART J, V89, P378, DOI 10.1016/0002-8703(75)90089-7; TURNER TB, 1981, JOHNS HOPKINS MED J, V148, P53	30	178	182	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 5	1993	341	8858					1423	1428						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF841	8099138				2022-12-28	WOS:A1993LF84100001
J	ANTINORI, A; AMMASSARI, A; MURRI, R; TUMBARELLO, M; ORTONA, L; SCERRATI, M; ROSELLI, R; CEFARO, GA				ANTINORI, A; AMMASSARI, A; MURRI, R; TUMBARELLO, M; ORTONA, L; SCERRATI, M; ROSELLI, R; CEFARO, GA			PRIMARY CENTRAL-NERVOUS-SYSTEM LYMPHOMA AND BRAIN BIOPSY IN AIDS	LANCET			English	Letter									UNIV CATTOLICA SACRO CUORE, INST NEUROSURG, I-00168 ROME, ITALY; UNIV CATTOLICA SACRO CUORE, DEPT RADIOTHERAPY, I-00168 ROME, ITALY	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	ANTINORI, A (corresponding author), UNIV CATTOLICA SACRO CUORE, INFECT DIS CLIN, I-00168 ROME, ITALY.		Tumbarello, Mario/A-8549-2019; Antinori, Andrea/K-7125-2016	Tumbarello, Mario/0000-0002-9519-8552; Antinori, Andrea/0000-0003-2121-4684; Murri, Rita/0000-0001-9468-5458; Ammassari, Adriana/0000-0002-0284-0340				BAUMGARTNER JE, 1990, J NEUROSURG, V73, P206, DOI 10.3171/jns.1990.73.2.0206; CHAPPELL ET, 1992, NEUROSURGERY, V30, P825, DOI 10.1227/00006123-199206000-00001; GALETTO G, 1993, JAMA-J AM MED ASSOC, V269, P92, DOI 10.1001/jama.269.1.92; 1992, LANCET, V340, P1135	4	16	16	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 29	1993	341	8857					1411	1412		10.1016/0140-6736(93)90977-O	http://dx.doi.org/10.1016/0140-6736(93)90977-O			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE180	8098815				2022-12-28	WOS:A1993LE18000032
J	GOUGEON, ML; MONTAGNIER, L				GOUGEON, ML; MONTAGNIER, L			APOPTOSIS IN AIDS	SCIENCE			English	Editorial Material							MATURE T-CELLS; DEATH; RECEPTOR; SUPERANTIGEN; MECHANISMS; ANTIGEN; VIRUS				GOUGEON, ML (corresponding author), INST PASTEUR, DEPT AIDS & RETROVIRUSES, 28 RUE DR ROUX, F-75724 PARIS, FRANCE.							ARENDS MJ, 1990, AM J PATHOL, V136, P593; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; BANDA NK, 1992, J EXP MED, V176, P1099, DOI 10.1084/jem.176.4.1099; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; CHOI YW, 1991, NATURE, V350, P203, DOI 10.1038/350203a0; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; COLE BC, 1991, IMMUNOL TODAY, V12, P271, DOI 10.1016/0167-5699(91)90125-D; DUVALL E, 1986, IMMUNOL TODAY, V7, P115, DOI 10.1016/0167-5699(86)90152-0; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; GOUGEON ML, 1993, AIDS RES HUM RETROV, V9, P287, DOI 10.1089/aid.1993.9.287; GOUGEON ML, IN PRESS AIDS RES HU; GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331; HABESHAW J, 1992, IMMUNOL TODAY, V13, P207, DOI 10.1016/0167-5699(92)90155-Z; KAZIKI H, 1989, J IMMUNOL, V43, P1790; LAURENTCRAWFORD AG, 1991, VIROLOGY, V185, P829, DOI 10.1016/0042-6822(91)90554-O; LAURENTCRAWFORD AG, IN PRESS AIDS RES HU; LEMAITRE M, 1992, INFECT IMMUN, V60, P742; LO SC, 1989, AM J TROP MED HYG, V41, P601, DOI 10.4269/ajtmh.1989.41.601; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; MONTAGNIER L, IN PRESS NEW CONCEPT; NEWELL MK, 1990, NATURE, V347, P286, DOI 10.1038/347286a0; PAU X, COMMUNICATION; RUSSELL JH, 1991, P NATL ACAD SCI USA, V88, P2151, DOI 10.1073/pnas.88.6.2151; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112	26	341	359	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 28	1993	260	5112					1269	1270		10.1126/science.8098552	http://dx.doi.org/10.1126/science.8098552			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LE025	8098552				2022-12-28	WOS:A1993LE02500031
J	COELHO, HLL; TEIXEIRA, AC; SANTOS, AP; FORTE, EB; MORAIS, SM; LAVECCHIA, C; TOGNONI, G; HERXHEIMER, A				COELHO, HLL; TEIXEIRA, AC; SANTOS, AP; FORTE, EB; MORAIS, SM; LAVECCHIA, C; TOGNONI, G; HERXHEIMER, A			MISOPROSTOL AND ILLEGAL ABORTION IN FORTALEZA, BRAZIL	LANCET			English	Article								Misoprostol, a prostaglandin E1 analogue indicated for ulcer treatment, has been widely used as an abortifacient by women in Brazil, where abortion is legal only in cases of rape or incest, or to save the woman's life. Because misoprostol is an inefficient abortifacient, many women who use it have incomplete abortions and need uterine evacuation. We reviewed the records of women admitted to the main obstetric hospital of Fortaleza, capital of Ceara state, Brazil, between January, 1990, and July, 1992, for uterine evacuation after induced abortion. The number of incomplete abortions induced by misoprostol increased substantially during the first half of 1990, and declined thereafter. Of the 593 cases in 1991, 75% were related to misoprostol, 10% to the use of other specified drugs, and 6% to unspecified drugs. For the remaining 9% the procedure used was not recorded; these included 3% in whom abortion had been induced by a clandestine abortionist. The number of uterine evacuations per month fell from 89 in August, 1990, to 62 in July, 1991, when sales of misoprostol in Ceara state were suspended. The fall continued after the sale of misoprostol ceased, to about 20 cases in December, 1991 numbers remained around this level until June, 1992, sustained by clandestine sales. The lack of access to contraception is the main reason for the large numbers of unplanned pregnancies and is a major public health issue for Brazilian women. The prohibition of abortion creates a void in which misuse of medicines is one extra complication, mainly because of the poor control of drug marketing.	FED UNIV CEARA,DEPT PHARM,PREVENCAO USO INDEVIDO MEDICAMENTOS GRP,FORTALEZA,BRAZIL; UNIV MILAN,IST BIOMETRIA & STAT MED,I-20122 MILAN,ITALY; COCHRANE CTR,NHS RES & DEV PROGRAMME,OXFORD,ENGLAND	Universidade Federal do Ceara; University of Milan; Cochrane Centre	COELHO, HLL (corresponding author), MARIO NEGRI INST PHARMACOL RES,VIA ERITREA 62,I-20157 MILAN,ITALY.			La Vecchia, Carlo/0000-0003-1441-897X; Araujo Teixeira, Ana Claudia de/0000-0003-2851-5260				BAIRD DT, 1992, LANCET, V339, P313, DOI 10.1016/0140-6736(92)91392-L; COELHO HLL, 1991, LANCET, V338, P247, DOI 10.1016/0140-6736(91)90379-4; COELHO HLL, 1991, CIENCIA HOJE, V13, P60; FONSECA W, 1991, LANCET, V338, P1594, DOI 10.1016/0140-6736(91)92414-W; FONSECA W, 1991, LANCET, V338, P56, DOI 10.1016/0140-6736(91)90046-R; LAGUARDIA K, 1990, OBSTET GYNECOL, V75, P28; MUMFORD SD, 1984, AM J OBSTET GYNECOL, V149, P639, DOI 10.1016/0002-9378(84)90249-7; NORMAN JE, 1991, LANCET, V338, P1233, DOI 10.1016/0140-6736(91)92102-8; PAUMGARTTEN FJR, 1992, RISK ASSESSMENT PREN, P163; PINOTTI JA, 1989, INT J GYNECOL OBSTET, V3, P97; RABE T, 1987, GEBURTSH FRAUENHEILK, V47, P324, DOI 10.1055/s-2008-1035830; Schonhofar P S, 1991, Lancet, V337, P1534, DOI 10.1016/0140-6736(91)93212-R; SCHOR N, 1990, REV SAUDE PUBL, V24, P1444	13	77	82	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 15	1993	341	8855					1261	1263		10.1016/0140-6736(93)91157-H	http://dx.doi.org/10.1016/0140-6736(93)91157-H			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LC497	8098403				2022-12-28	WOS:A1993LC49700015
J	KOJIMA, T; SASAI, M; KOBAYASHI, Y				KOJIMA, T; SASAI, M; KOBAYASHI, Y			INCREASED SOLUBLE ICAM-1 IN TRACHEAL ASPIRATES OF INFANTS WITH BRONCHOPULMONARY DYSPLASIA	LANCET			English	Note							ADHESION MOLECULE-1 ICAM-1; CIRCULATING ICAM-1	Raised concentrations of soluble intercellular adhesion molecule 1 (sICAM-1) in tracheal aspirates from premature infants may predict development of bronchopulmonary dysplasia (BPD). We measured sICAM-1 in tracheal aspirates and serum samples from 15 newborn babies (9 with BPD, 6 without BPD) at 2-4, 6-7, and 12-14 days of age. sICAM-1 concentrations in tracheal aspirates were significantly raised at 6-7 and 12-14 days of age in infants who later developed BPD compared with infants who did not develop BPD. Serum samples from the two groups did not differ significantly in sICAM-1. Raised sICAM-1 in tracheal aspirate was a good predictor of lung injury in infants who later developed BPD.			KOJIMA, T (corresponding author), KANSAI MED UNIV,DEPT PAEDIAT,FUMIZONOCHO 1,MORIGUCHI,OSAKA 570,JAPAN.							CLEMENT A, 1988, PEDIATR RES, V23, P470, DOI 10.1203/00006450-198805000-00007; DUSTIN ML, 1986, J IMMUNOL, V137, P245; JACOBSON W, 1992, EUR J PEDIATR, V151, P204, DOI 10.1007/BF01954385; KUSTER H, 1993, LANCET, V341, P506, DOI 10.1016/0140-6736(93)90272-I; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; NORTHWAY WH, 1992, PEDIATRICS, V89, P969; OGDEN BE, 1984, AM REV RESPIR DIS, V130, P817; ROTHLEIN R, 1991, J IMMUNOL, V147, P3788; SETH R, 1991, LANCET, V338, P83, DOI 10.1016/0140-6736(91)90077-3; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851	10	36	36	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 23	1993	342	8878					1023	1024		10.1016/0140-6736(93)92880-3	http://dx.doi.org/10.1016/0140-6736(93)92880-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD066	8105265				2022-12-28	WOS:A1993MD06600011
J	WANG, Q; GREEN, E; BARNICOAT, A; GARRETT, D; MULLARKEY, M; BOBROW, M; MATHEW, CG				WANG, Q; GREEN, E; BARNICOAT, A; GARRETT, D; MULLARKEY, M; BOBROW, M; MATHEW, CG			CYTOGENETIC VERSUS DNA DIAGNOSIS IN ROUTINE REFERRALS FOR FRAGILE-X SYNDROME	LANCET			English	Note							INSTABILITY	The molecular cloning of the gene that causes the fragile X syndrome, and the demonstration that the causative mutation is an expansion of an unstable trinucleotide repeat, suggests that cytogenetic testing could be replaced by a molecular test. We compared the two methods in 525 routine referrals. 12 cases were positive in both tests. 1 case that had a negative DNA test for the fragile site at Xq27.3 (FRAXA), but a positive cytogenetic result, was shown to be caused by a mutation at the FRAXE locus on chromosome Xq28. DNA analysis is a sensitive, reliable, and cost-effective diagnostic alternative.	UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,DIV MED & MOLEC GENET,8TH FLOOR GUYS TOWER,LONDON SE1 9RT,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London			Mathew, Christopher G/G-3434-2015	Mathew, Christopher G/0000-0003-4178-1838				FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; JACKY PB, 1991, AM J MED GENET, V38, P400, DOI 10.1002/ajmg.1320380249; KNIGHT SJL, 1993, CELL, V74, P127, DOI 10.1016/0092-8674(93)90300-F; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; SHERMAN SL, 1984, ANN HUM GENET, V48, P21, DOI 10.1111/j.1469-1809.1984.tb00830.x; Sutherland Grant R., 1992, Human Molecular Genetics, V1, P111, DOI 10.1093/hmg/1.2.111; VERHEIJ C, 1993, NATURE, V363, P722, DOI 10.1038/363722a0; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179	9	24	25	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 23	1993	342	8878					1025	1026		10.1016/0140-6736(93)92882-T	http://dx.doi.org/10.1016/0140-6736(93)92882-T			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD066	8105267				2022-12-28	WOS:A1993MD06600013
J	WEINER, TM; LIU, ET; CRAVEN, RJ; CANCE, WG				WEINER, TM; LIU, ET; CRAVEN, RJ; CANCE, WG			EXPRESSION OF FOCAL ADHESION KINASE GENE AND INVASIVE CANCER	LANCET			English	Note							PROTEIN-TYROSINE KINASE; PHOSPHORYLATION; INTEGRINS	The focal adhesion kinase (FAK) gene produces a tyrosine kinase that localises to contact points between cells and extracellular matrix. It is believed to be an important signal molecule in cell adhesion. We have isolated a human homologue of the FAK gene from primary sarcomas and looked for FAK mRNA in 49 human tissue samples, including paired normal and neoplastic samples. We found increased levels of FAK in 1 of 8 adenomatous tissues, in 17 of 20 invasive tumours, and in all 15 metastatic tumours. There was no detectable FAK mRNA in 6 normal tissue samples. These observations suggest that FAK overexpression may accompany changes in signal pathways involved in tumour cell invasion.	UNIV N CAROLINA,SCH MED,DEPT SURG,3010 OLD CLIN BLDG,CB 7210,CHAPEL HILL,NC 27599; UNIV N CAROLINA,SCH MED,DEPT MED,CHAPEL HILL,NC 27599; UNIV N CAROLINA,SCH MED,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine			Liu, Edison/C-4141-2008		NCI NIH HHS [1-P50-CA-58223-01, CA-09688, KO8-CA-01635] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009688, P50CA058223] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; TIERNEY RP, 1990, SURG GYNECOL OBSTET, V171, P81; WEINER TM, IN PRESS ANN SURG ON; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	10	308	321	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 23	1993	342	8878					1024	1025		10.1016/0140-6736(93)92881-S	http://dx.doi.org/10.1016/0140-6736(93)92881-S			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD066	8105266				2022-12-28	WOS:A1993MD06600012
J	BOGREN, HG; BUONOCORE, MH				BOGREN, HG; BUONOCORE, MH			MEASUREMENT OF CORONARY-ARTERY FLOW RESERVE BY MAGNETIC-RESONANCE VELOCITY MAPPING IN THE AORTA	LANCET			English	Note							BLOOD-FLOW	Coronary artery flow occurs predominantly in diastole via retrograde flow in the ascending aorta, some of which supplies the coronary arteries while the remainder recirculates in the ascending aorta. We used magnetic resonance velocity mapping to measure global coronary artery diastolic flow in the ascending aorta. In eight normal subjects and in four patients with possible ischaemic heart disease but with normal perfusion scans, the mean coronary flow reserve (CFR) was 269 ml/min. CFR was zero in seven patients with coronary artery disease. We have shown that CFR can be measured non-invasively with this technique.			BOGREN, HG (corresponding author), UNIV CALIF DAVIS,SACRAMENTO MED CTR,DEPT RADIOL,TICON 11 BLDG,SACRAMENTO,CA 95817, USA.							BOGREN HG, 1989, AM HEART J, V117, P1214, DOI 10.1016/0002-8703(89)90399-2; BUONOCORE MH, 1992, MAGNET RESON MED, V26, P141, DOI 10.1002/mrm.1910260115; GOULD KL, 1988, CIRCULATION, V78, P237, DOI 10.1161/01.CIR.78.2.237; HOFFMAN JIE, 1984, CIRCULATION, V70, P153, DOI 10.1161/01.CIR.70.2.153; LENTNER C, 1990, GEIGY SCI TABLES, V5, P124; VOGEL RA, 1984, ARCH INTERN MED, V144, P1773, DOI 10.1001/archinte.144.9.1773; WILSON RF, 1988, PROG CARDIOVASC DIS, V31, P95, DOI 10.1016/0033-0620(88)90013-8	7	13	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 9	1993	342	8876					899	900		10.1016/0140-6736(93)91948-L	http://dx.doi.org/10.1016/0140-6736(93)91948-L			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA963	8105169				2022-12-28	WOS:A1993MA96300012
J	DRUCKER, E				DRUCKER, E			MOLECULAR EPIDEMIOLOGY MEETS THE 4TH WORLD	LANCET			English	Editorial Material											DRUCKER, E (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,MONTEFIORE MED CTR,DEPT EPIDEMIOL & SOCIAL MED,BRONX,NY 10461, USA.							BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; Dubos Rene, 1987, WHITE PLAGUE TUBERCU; MAUER M, 1990, YOUNG BLACK MEN CRIM; 1988, TRUBERCULOSIS NEW YO; 1992, TUBERCULOSIS NEW YOR	5	6	6	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 2	1993	342	8875					817	818		10.1016/0140-6736(93)92689-Q	http://dx.doi.org/10.1016/0140-6736(93)92689-Q			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA025	8104266				2022-12-28	WOS:A1993MA02500003
J	ADINOLFI, M; DAVIES, A; SHARIF, S; SOOTHILL, P; RODECK, C				ADINOLFI, M; DAVIES, A; SHARIF, S; SOOTHILL, P; RODECK, C			DETECTION OF TRISOMY-18 AND Y-DERIVED SEQUENCES IN FETAL NUCLEATED CELLS OBTAINED BY TRANSCERVICAL FLUSHING	LANCET			English	Note							DIAGNOSIS; INSITU	A Procedure which combines the collection of fetal cells by transcervical flushing and in situ hybridisation techniques on nuclei in interphase was used to detect trisomy 18 in a fetus at 12 weeks of gestation. Using a primed in situ labelling method, we could also detect Y-specific sequences in a small percentage of transcervically flushed cells obtained at 8-12 weeks from pregnant women with male fetuses. This approach seems to be suitable for prenatal diagnosis of major chromosomal abnormalities and other selected inherited disorders very early in gestation.	UCL, SCH MED, LONDON WC1, ENGLAND	University of London; University College London; UCL Medical School	ADINOLFI, M (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP, DIV MED & MOLEC GENET, 7TH FLOOR, GUYS HOSP TOWER, LONDON SE1 9RT, ENGLAND.		Soothill, Peter/D-2814-2009					ADINOLFI M, 1992, NAT GENET, V1, P316, DOI 10.1038/ng0892-316; ADINOLFI M, 1992, ADV GENOME BIOL, V1, P301; CREMER T, 1986, HUM GENET, V74, P346, DOI 10.1007/BF00280484; GRIFFITHJONES MD, 1992, BRIT J OBSTET GYNAEC, V99, P508, DOI 10.1111/j.1471-0528.1992.tb13792.x; KOCH J, 1992, CYTOGENET CELL GENET, V60, P1, DOI 10.1159/000133281; MORRIS N, 1992, BRIT J OBSTET GYNAEC, V99, P446, DOI 10.1111/j.1471-0528.1992.tb13777.x; RHINE SA, 1977, BIRTH DEFECTS-ORIG, V12, P231; SHETTLES LB, 1971, NATURE, V230, P52, DOI 10.1038/230052b0	8	52	54	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 14	1993	342	8868					403	404		10.1016/0140-6736(93)92816-C	http://dx.doi.org/10.1016/0140-6736(93)92816-C			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR900	8101904				2022-12-28	WOS:A1993LR90000012
J	SHARP, D				SHARP, D			GODDESS LANCED THROUGH THE HART	LANCET			English	Editorial Material																			0	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 7	1993	342	8867					320	320		10.1016/0140-6736(93)91470-7	http://dx.doi.org/10.1016/0140-6736(93)91470-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ868	8101581				2022-12-28	WOS:A1993LQ86800008
J	DANCHIN, N				DANCHIN, N			IS MYOCARDIAL REVASCULARIZATION FOR TIGHT CORONARY STENOSES ALWAYS NECESSARY	LANCET			English	Editorial Material							LEFT-VENTRICULAR FUNCTION; 10-YEAR FOLLOW-UP; ARTERY DISEASE; ANGIOGRAPHIC PROGRESSION; ANGINA-PECTORIS; MEDICAL THERAPY; TOTAL OCCLUSION; INFARCTION; ANGIOPLASTY; SURGERY				DANCHIN, N (corresponding author), CHU NANCY BRABOIS,SERV CARDIOL A,F-54500 VANDOEUVRE NANCY,FRANCE.		Danchin, Nicolas/AAN-8291-2020					ALDERMAN EL, 1990, CIRCULATION, V82, P1629, DOI 10.1161/01.CIR.82.5.1629; AMBROSE JA, 1988, J AM COLL CARDIOL, V12, P56, DOI 10.1016/0735-1097(88)90356-7; BISSETT JK, 1990, AM J CARDIOL, V66, P1293, DOI 10.1016/0002-9149(90)91156-Z; CAMPEAU L, 1983, CIRCULATION S2, V68, P7; CRIBIER A, 1985, ARCH MAL COEUR VAISS, V78, P353; DANCHIN N, 1989, AM J CARDIOL, V63, P660, DOI 10.1016/0002-9149(89)90247-6; DANCHIN N, 1989, EUR HEART J        S, V10, pG54; DEWOOD MA, 1980, NEW ENGL J MED, V303, P897, DOI 10.1056/NEJM198010163031601; EPSTEIN SE, 1988, AM J CARDIOL, V61, P866, DOI 10.1016/0002-9149(88)91081-8; GRONDIN CM, 1984, CIRCULATION, V70, P208; HARTZ AJ, 1992, AM J CARDIOL, V70, P179, DOI 10.1016/0002-9149(92)91272-6; HERMANS WRM, 1991, AM HEART J, V122, P171, DOI 10.1016/0002-8703(91)90775-D; HESS OM, 1988, CIRCULATION, V77, P967, DOI 10.1161/01.CIR.77.5.967; HWANG MH, 1990, J AM COLL CARDIOL, V16, P1066, DOI 10.1016/0735-1097(90)90533-U; JUILLIERE Y, 1990, AM J CARDIOL, V65, P277, DOI 10.1016/0002-9149(90)90287-B; JUILLIERE Y, 1991, AM J CARDIOL, V68, P7, DOI 10.1016/0002-9149(91)90701-L; KRONCKE GM, 1988, CIRCULATION, V78, P144; LITTLE WC, 1988, CIRCULATION, V78, P1157, DOI 10.1161/01.CIR.78.5.1157; MOISE A, 1984, AM J CARDIOL, V54, P1176, DOI 10.1016/S0002-9149(84)80063-6; PARISI AF, 1992, NEW ENGL J MED, V326, P10, DOI 10.1056/NEJM199201023260102; RENTROP KP, 1988, AM J CARDIOL, V61, P677, DOI 10.1016/0002-9149(88)91048-X; ROGERS WJ, 1990, CIRCULATION, V82, P1647, DOI 10.1161/01.CIR.82.5.1647; VARNAUSKAS E, 1988, NEW ENGL J MED, V319, P332, DOI 10.1056/NEJM198808113190603; 1992, CIRCULATION, V86, P121; 1993, LANCET, V341, P573	25	21	22	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 24	1993	342	8865					224	225		10.1016/0140-6736(93)92305-D	http://dx.doi.org/10.1016/0140-6736(93)92305-D			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN622	8100936				2022-12-28	WOS:A1993LN62200018
J	CARSWELL, W				CARSWELL, W			HIV IN SOUTH-AFRICA	LANCET			English	Editorial Material																			0	4	4	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 17	1993	342	8864					132	132		10.1016/0140-6736(93)91342-J	http://dx.doi.org/10.1016/0140-6736(93)91342-J			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN042	8101253				2022-12-28	WOS:A1993LN04200008
J	ROSANO, GMC; SARREL, PM; POOLEWILSON, PA; COLLINS, P				ROSANO, GMC; SARREL, PM; POOLEWILSON, PA; COLLINS, P			BENEFICIAL EFFECT OF ESTROGEN ON EXERCISE-INDUCED MYOCARDIAL-ISCHEMIA IN WOMEN WITH CORONARY-ARTERY DISEASE	LANCET			English	Article							FOLLOW-UP; ESTROGEN; 17-BETA-ESTRADIOL; ATHEROSCLEROSIS; MENOPAUSE; RESPONSES; RABBIT	Oestradiol-17beta causes relaxation of isolated coronary arteries. and increases blood flow in several vascular beds in human beings and animals. Oestrogen replacement therapy is associated with a lower incidence of cardiovascular disease, but the acute effects of oestradiol-17beta on myocardial ischaemia are unknown. We have studied the acute effect of sublingual oestradiol-17beta on exercise-induced myocardial ischaemia in eleven women (mean age 58 [SD 8] years) with coronary artery disease. The women did two treadmill exercise tests on separate days; 40 min before the test they took sublingual oestradiol-17beta (1 mg) or placebo, in random order. Plasma oestradiol-17beta concentrations were confirmed to be higher after sublingual oestradiol-17beta than after placebo (2531 [1192] vs 155 [1.68] pmol/L, p<0.001). Oestradiol-17beta increased both time to 1 mm ST depression (456 [214] vs 579 [191] s, p<0.004; difference of medians 92 [95% CI 46-254]) and total exercise time (569 [249] vs 658 [193] s, p<0.01; difference 54 [10-212]). Acute administration of oestradiol-17beta therefore has a beneficial effect on myocardial ischaemia in women with coronary artery disease. This effect may be due to a direct coronary-relaxing effect, to peripheral vasodilation, or to a combination of these mechanisms. Oestradiol-17beta may prove to be a useful adjunct to the treatment of angina in postmenopausal women with coronary heart disease.	NATL HEART & LUNG INST,DOVEHOUSE ST,LONDON SW3 6LY,ENGLAND; ROYAL BROMPTON NATL HEART & LUNG HOSP,LONDON SW3 6LY,ENGLAND	Imperial College London; Imperial College London			Rosano, Giuseppe M. C./K-8718-2018	Rosano, Giuseppe M. C./0000-0003-4023-2263				ADAMS MR, 1990, OVARIAN SECRETIONS C, P151; BRASS LM, 1990, J CARDIOVASC TECHNOL, V9, P68; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; CHELSKY R, 1990, CIRCULATION, V82, P126; COLDITZ GA, 1987, NEW ENGL J MED, V316, P1105, DOI 10.1056/NEJM198704303161801; COLLINS P, 1993, LANCET, V341, P1264, DOI 10.1016/0140-6736(93)91158-I; DANAHY DT, 1977, CIRCULATION, V55, P381, DOI 10.1161/01.CIR.55.2.381; GANGAR KF, 1991, LANCET, V338, P839; GINSBURG J, 1989, BRIT MED J, V298, P1488, DOI 10.1136/bmj.298.6686.1488; GISCLARD V, 1988, J PHARMACOL EXP THER, V244, P19; GODSLAND IF, 1987, AM HEART J, V114, P1467, DOI 10.1016/0002-8703(87)90552-7; GRUCHOW HW, 1988, AM HEART J, V115, P954, DOI 10.1016/0002-8703(88)90063-4; JIANG C, 1992, BRIT J PHARMACOL, V106, P739, DOI 10.1111/j.1476-5381.1992.tb14403.x; JIANG CW, 1992, AM J PHYSIOL, V263, pH271, DOI 10.1152/ajpheart.1992.263.1.H271; JIANG CW, 1991, BRIT J PHARMACOL, V104, P1033, DOI 10.1111/j.1476-5381.1991.tb12545.x; MAGNESS RR, 1989, AM J PHYSIOL, V256, pE536, DOI 10.1152/ajpendo.1989.256.4.E536; ROSANO GMC, 1992, CIRCULATION, V86, P537; SARREL P, 1989, CIRCULATION FEMALE C, P117; SARREL PM, 1990, MATURITAS, V12, P287, DOI 10.1016/0378-5122(90)90008-T; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; SULLIVAN JM, 1988, ANN INTERN MED, V108, P358, DOI 10.7326/0003-4819-108-3-358; WILLIAMS JK, 1992, J AM COLL CARDIOL, V20, P452, DOI 10.1016/0735-1097(92)90116-5; WILLIAMS JK, 1990, CIRCULATION, V81, P1680, DOI 10.1161/01.CIR.81.5.1680	23	415	420	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 17	1993	342	8864					133	136		10.1016/0140-6736(93)91343-K	http://dx.doi.org/10.1016/0140-6736(93)91343-K			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN042	8101254				2022-12-28	WOS:A1993LN04200009
J	BOTT, J; CARROLL, MP; CONWAY, JH; KEILTY, SEJ; WARD, EM; BROWN, AM; PAUL, EA; ELLIOTT, MW; GODFREY, RC; WEDZICHA, JA; MOXHAM, J				BOTT, J; CARROLL, MP; CONWAY, JH; KEILTY, SEJ; WARD, EM; BROWN, AM; PAUL, EA; ELLIOTT, MW; GODFREY, RC; WEDZICHA, JA; MOXHAM, J			RANDOMIZED CONTROLLED TRIAL OF NASAL VENTILATION IN ACUTE VENTILATORY FAILURE DUE TO CHRONIC OBSTRUCTIVE AIRWAYS DISEASE	LANCET			English	Article							POSITIVE PRESSURE VENTILATION; NONINVASIVE MECHANICAL VENTILATION; ACUTE RESPIRATORY-FAILURE	Acute exacerbations of chronic obstructive airways disease (COAD) are a common cause of admission to hospital, and have a high mortality. Nasal intermittent positive pressure ventilation (NIPPV) has been used successfully in patients with respiratory failure due to neuromuscular and skeletal disorders, but the outcome of treatment in patients with COAD is less well known. We carried out a prospective randomised controlled trial of conventional treatment versus conventional treatment plus NIPPV, in 60 patients with acute ventilatory failure due to exacerbations of COAD. For the NIPPV group there was a rise in pH, compared with a fall in the controls (mean difference of change between the groups 0.046 [95% Cl 0.06-0.02, p < 0.001]), and a larger fall in PaCO2 (mean difference in change between the groups 1.2 kPa [95% Cl 0.45 to 2.03, p < 0.011]). Median visual analogue scores over the first 3 days of admission showed less breathlessness in the NIPPV group (2.3 cm [range 0.1-5.5]) than in the control group (4.5 cm [range 0.9-8.8]) (p < 0.025). Survival rates at 30 days were compared for intention-to-treat and efficacy populations. In the efficacy mortality comparison, mortality in the NIPPV group was reduced: 1/26 vs 9/30 (relative risk = 0.13, Cl = 0.02-0.95, p = 0.014). This effect was less in the intention-to-treat analysis: 3/30 vs 9/30 (relative risk = 0.33, Cl = 0.10-1.11, p = 0.106). In patients with acute ventilatory failure due to COAD who received NIPPV there was a significant rise in pH, a reduction in PaCO2 and breathlessness, and reduced mortality.	KINGS COLL, SCH MED & DENT, DEPT THORAC MED, BESSEMER RD, LONDON SE5 9JP, ENGLAND; SOUTHAMPTON GEN HOSP, SOUTHAMPTON SO9 4XY, HANTS, ENGLAND; LONDON CHEST HOSP, LONDON, ENGLAND	University of London; King's College London; University of Southampton; University of London; Queen Mary University London				Conway, Joy/0000-0001-6464-1526				AHMED AH, 1992, THORAX, V47, pP858; BOTT J, 1991, THORAX, V46, P457, DOI 10.1136/thx.46.6.457; CHEVROLET JC, 1991, CHEST, V100, P775, DOI 10.1378/chest.100.3.775; ELLIOTT MW, 1990, BRIT MED J, V300, P358, DOI 10.1136/bmj.300.6721.358; ELLIS ER, 1988, CHEST, V94, P811, DOI 10.1378/chest.94.4.811; HODSON ME, 1991, EUR RESPIR J, V4, P524; JEFFREY AA, 1992, THORAX, V47, P34, DOI 10.1136/thx.47.1.34; KERBY GR, 1987, AM REV RESPIR DIS, V135, P738; KETTEL LJ, 1971, J AMER MED ASSOC, V217, P1503, DOI 10.1001/jama.217.11.1503	9	600	616	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 19	1993	341	8860					1555	1557		10.1016/0140-6736(93)90696-E	http://dx.doi.org/10.1016/0140-6736(93)90696-E			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH550	8099639				2022-12-28	WOS:A1993LH55000003
J	HILLIS, WS; MACINTYRE, PD				HILLIS, WS; MACINTYRE, PD			DRUG-REACTIONS - SUMATRIPTAN AND CHEST PAIN	LANCET			English	Editorial Material											HILLIS, WS (corresponding author), WESTERN INFIRM & ASSOCIATED HOSP,GARDINER INST,DEPT MED & THERAPEUT,GLASGOW G11 6NT,SCOTLAND.							CURTIN T, 1992, BRIT MED J, V305, P713, DOI 10.1136/bmj.305.6855.713-d; INMAN W, 1992, BRIT MED J, V305, P714, DOI 10.1136/bmj.305.6855.714; KASKI JC, 1991, J AM COLL CARDIOL, V17, P627, DOI 10.1016/S0735-1097(10)80175-5; MACINTYRE PD, 1992, BRIT J CLIN PHARMACO, V34, P541; MACINTYRE PD, 1993, CIRCULATION, V87, P401, DOI 10.1161/01.CIR.87.2.401; MCFADDEN EP, 1991, NEW ENGL J MED, V324, P6348; OTTERVANGER JP, 1993, LANCET, V341, P861, DOI 10.1016/0140-6736(93)93064-8; TANSEY MJB, 1993, J NEUROL SCI, V114, P109, DOI 10.1016/0022-510X(93)90057-6; WILLETT F, 1992, BRIT MED J, V304, P1415, DOI 10.1136/bmj.304.6839.1415	9	49	49	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 19	1993	341	8860					1564	1565		10.1016/0140-6736(93)90700-Q	http://dx.doi.org/10.1016/0140-6736(93)90700-Q			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH550	8099643				2022-12-28	WOS:A1993LH55000007
J	RIDKER, PM; HEBERT, PR; FUSTER, V; HENNEKENS, CH				RIDKER, PM; HEBERT, PR; FUSTER, V; HENNEKENS, CH			ARE BOTH ASPIRIN AND HEPARIN JUSTIFIED AS ADJUNCTS TO THROMBOLYTIC THERAPY FOR ACUTE MYOCARDIAL-INFARCTION	LANCET			English	Review							TISSUE PLASMINOGEN-ACTIVATOR; ENTERIC-COATED ASPIRIN; LOW-DOSE ASPIRIN; INTRAVENOUS HEPARIN; INHIBITION		BRIGHAM & WOMENS HOSP, DEPT MED, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT PREVENT MED, BOSTON, MA 02115 USA; MASSACHUSETTS GEN HOSP, DEPT MED, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School			Fuster, Valentin/H-4319-2015	Fuster, Valentin/0000-0002-9043-9986				[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1990, Lancet, V336, P65; BLEICH SD, 1990, AM J CARDIOL, V66, P1412, DOI 10.1016/0002-9149(90)90525-6; COL J, 1992, CIRCULATION, V86, P259; DEBONO DP, 1992, BRIT HEART J, V67, P122; GUNNAR RM, 1990, J AM COLL CARDIOL, V16, P249, DOI 10.1016/0735-1097(90)90575-A; HSIA J, 1990, NEW ENGL J MED, V323, P1433, DOI 10.1056/NEJM199011223232101; HUNT D, 1992, LANCET, V339, P753; JAKUBOWSKI JA, 1985, BRIT J HAEMATOL, V60, P635, DOI 10.1111/j.1365-2141.1985.tb07467.x; LAMAS GA, 1992, NEW ENGL J MED, V327, P241, DOI 10.1056/NEJM199207233270405; OCONNOR C, 1992, AM HEART ASS ANAHEIM; PATRIGNANI P, 1982, J CLIN INVEST, V69, P1366, DOI 10.1172/JCI110576; REILLY IAG, 1987, BLOOD, V69, P180; SOBEL BE, 1992, AM J CARDIOL, V70, P385, DOI 10.1016/0002-9149(92)90624-8; TAVAZZI L, 1989, LANCET, V2, P182; THOMPSON PL, 1991, CIRCULATION, V83, P1534, DOI 10.1161/01.CIR.83.5.1534; TOPOL EJ, 1989, CIRCULATION, V79, P281, DOI 10.1161/01.CIR.79.2.281; TOPOL EJ, 1992, J AM COLL CARDIOL, V19, P1123, DOI 10.1016/0735-1097(92)90312-B; VANAGS D, 1990, THROMB RES, V59, P995, DOI 10.1016/0049-3848(90)90123-T; VANDEWERF F, 1990, LANCET, V336, P71; 1991, UPDATE, V2, P1	21	46	46	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 19	1993	341	8860					1574	1577		10.1016/0140-6736(93)90707-N	http://dx.doi.org/10.1016/0140-6736(93)90707-N			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH550	8099650				2022-12-28	WOS:A1993LH55000014
J	SCOTT, J				SCOTT, J			LIPID-METABOLISM - NATURE, NURTURE, AND HYPERCHOLESTEROLEMIA	LANCET			English	Editorial Material											SCOTT, J (corresponding author), ROYAL POSTGRAD MED SCH,LONDON W12 0HS,ENGLAND.							BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; DUELAND S, 1992, J BIOL CHEM, V267, P22695; Hobbs Helen H., 1992, Human Mutation, V1, P445, DOI 10.1002/humu.1380010602; HOBBS HH, 1989, J CLIN INVEST, V84, P656, DOI 10.1172/JCI114212; MITSURU E, 1991, ARTERIOSCL THROMB, V11, P1349; SEED M, 1990, NEW ENGL J MED, V322, P1494, DOI 10.1056/NEJM199005243222104; ZAMBON A, 1993, LANCET, V341, P1119, DOI 10.1016/0140-6736(93)93129-O	7	1	1	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 22	1993	341	8856					1312	1313		10.1016/0140-6736(93)90819-3	http://dx.doi.org/10.1016/0140-6736(93)90819-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD253	8098452				2022-12-28	WOS:A1993LD25300007
J	COLLINS, P; ROSANO, GMC; JIANG, CW; LINDSAY, D; SARREL, PM; POOLEWILSON, PA				COLLINS, P; ROSANO, GMC; JIANG, CW; LINDSAY, D; SARREL, PM; POOLEWILSON, PA			CARDIOVASCULAR PROTECTION BY ESTROGEN - A CALCIUM-ANTAGONIST EFFECT	LANCET			English	Article							CORONARY ATHEROSCLEROSIS; ESTROGEN; ARTERY; PROGRESSION; NIFEDIPINE; THERAPY; DISEASE; TRIAL	During their Premenopausal years, women have a lower risk than men of getting cardiovascular disease. This protection continues after the menopause if women receive oestrogen replacement. Based on new experimental evidence we propose that some of the cardiovascular benefits of oestrogen replacement therapy may be due to a long-term calcium antagonist effect of oestrogen.	YALE UNIV,SCH MED,NEW HAVEN,CT 06520	Yale University	COLLINS, P (corresponding author), NATL HEART & LUNG INST,DEPT CARDIAC MED,DOVEHOUSE ST,LONDON SW3 6LY,ENGLAND.		Rosano, Giuseppe M. C./K-8718-2018	Rosano, Giuseppe M. C./0000-0003-4023-2263				ADAMS MR, 1990, OVARIAN SECRETIONS C, P151; BRASS LM, 1990, J CARDIOVASC TECHNOL, V9, P68; CHELSKY R, 1990, CIRCULATION, V82, P111; COLLINS P, 1993, CIRCULATION, V87, P80, DOI 10.1161/01.CIR.87.1.80; GANGAR KF, 1991, LANCET, V338, P839; GRUCHOW HW, 1988, AM HEART J, V115, P954, DOI 10.1016/0002-8703(88)90063-4; HENRY PD, 1981, J CLIN INVEST, V68, P1366, DOI 10.1172/JCI110384; JIANG C, 1992, BRIT J PHARMACOL, V106, P739, DOI 10.1111/j.1476-5381.1992.tb14403.x; JIANG CW, 1992, AM J PHYSIOL, V263, pH271, DOI 10.1152/ajpheart.1992.263.1.H271; JIANG CW, 1991, BRIT J PHARMACOL, V104, P1033, DOI 10.1111/j.1476-5381.1991.tb12545.x; LICHTLEN PR, 1990, LANCET, V335, P1109, DOI 10.1016/0140-6736(90)91121-P; MAGNESS RR, 1989, AM J PHYSIOL, V256, pE536, DOI 10.1152/ajpendo.1989.256.4.E536; OPIE LH, 1987, DRUGS HEART, P34; SARREL P, 1989, CIRCULATION FEMALE C, P117; SARREL PM, 1990, MATURITAS, V12, P287, DOI 10.1016/0378-5122(90)90008-T; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; STICE SL, 1987, BIOL REPROD, V36, P361, DOI 10.1095/biolreprod36.2.361; SULLIVAN JM, 1988, ANN INTERN MED, V108, P358, DOI 10.7326/0003-4819-108-3-358; VANBUREN G, 1992, AM J OBSTET GYNECOL, V16, P828; WATERS D, 1990, CIRCULATION, V82, P1940, DOI 10.1161/01.CIR.82.6.1940; WILLIAMS JK, 1990, CIRCULATION, V81, P1680, DOI 10.1161/01.CIR.81.5.1680	21	262	268	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 15	1993	341	8855					1264	1265		10.1016/0140-6736(93)91158-I	http://dx.doi.org/10.1016/0140-6736(93)91158-I			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LC497	8098404				2022-12-28	WOS:A1993LC49700016
J	EPSTEIN, PR; SHARP, D				EPSTEIN, PR; SHARP, D			MEDICINE IN A WARMER WORLD	LANCET			English	Editorial Material											EPSTEIN, PR (corresponding author), HARVARD UNIV,CAMBRIDGE HOSP,SCH MED,DEPT MED,CAMBRIDGE,MA 02138, USA.							Chivian E., 1993, CRITICAL CONDITION H; Houghton J.T., 1992, CLIMATE CHANGE 1992; McMichael A J, 1993, PLANETARY OVERLOAD G; MEEHL GA, 1993, SCIENCE, V260, P1101, DOI 10.1126/science.260.5111.1101; SIEGENTHALER U, 1993, NATURE, V365, P119, DOI 10.1038/365119a0; 1993, NATURE, V364, P203; 1993, MMWR, V42, P565; 1993, MMWR, V42, P558	8	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 23	1993	342	8878					1003	1004						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD066	8105258				2022-12-28	WOS:A1993MD06600003
J	WALMRATH, D; SCHNEIDER, T; PILCH, J; GRIMMINGER, F; SEEGER, W				WALMRATH, D; SCHNEIDER, T; PILCH, J; GRIMMINGER, F; SEEGER, W			AEROSOLIZED PROSTACYCLIN IN ADULT-RESPIRATORY-DISTRESS-SYNDROME	LANCET			English	Note							INHALED NITRIC-OXIDE; PULMONARY-HYPERTENSION	We studied the effects of aerosolised prostacyclin (PGI2) in three patients with acute severe adult respiratory distress syndrome. 17-50 ng/kg per min, nebulised into the afferent limb of the ventilator circuit, decreased mean pulmonary artery pressure (SEM) from 40.3 (13.5) to 32.0 (3.8) mm Hg (pulmonary vascular resistance fell by 30%); systemic arterial pressure decreased slightly from 76.8 (2.2) to 74.5 (6.1) mm Hg. Concomitantly, the ratio of arterial oxygen partial pressure to the fraction of inspired oxygen increased from 120 (19) to 173 (18), mainly due to redistribution of blood flow from shunt areas to regions of normal ventilation-perfusion. All effects were reversed on drug withdrawal.	UNIV GIESSEN,DEPT INTERNAL MED,KLIN STR 36,W-6300 GIESSEN,GERMANY	Justus Liebig University Giessen				Grimminger, Friedrich/0000-0001-8725-6276; Seeger, Werner/0000-0003-1946-0894				BIHARI D, 1987, NEW ENGL J MED, V317, P397, DOI 10.1056/NEJM198708133170701; FROSTELL C, 1991, CIRCULATION, V83, P2038, DOI 10.1161/01.CIR.83.6.2038; HARDY CC, 1988, J APPL PHYSIOL, V64, P1567, DOI 10.1152/jappl.1988.64.4.1567; HIGENBOTTAM T, 1987, AM REV RESPIR DIS, V136, P782, DOI 10.1164/ajrccm/136.3.782; KINSELLA JP, 1992, LANCET, V340, P819, DOI 10.1016/0140-6736(92)92687-B; MELOT C, 1989, AM REV RESPIR DIS, V139, P106, DOI 10.1164/ajrccm/139.1.106; PEPKEZABA J, 1991, LANCET, V338, P1173, DOI 10.1016/0140-6736(91)92033-X; RADERMACHER P, 1990, INTENS CARE MED, V16, P227, DOI 10.1007/BF01705156; ROSSAINT R, 1993, NEW ENGL J MED, V328, P399, DOI 10.1056/NEJM199302113280605; WAGNER PD, 1974, J APPL PHYSIOL, V36, P588, DOI 10.1152/jappl.1974.36.5.588	10	232	239	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 16	1993	342	8877					961	962		10.1016/0140-6736(93)92004-D	http://dx.doi.org/10.1016/0140-6736(93)92004-D			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MC005	8105216				2022-12-28	WOS:A1993MC00500011
J	CALIN, A				CALIN, A			HLA-B27, THE ARTHRITOGENIC PEPTIDE, AND THE EFFECTOR T-CELL	LANCET			English	Editorial Material							ANKYLOSING-SPONDYLITIS				CALIN, A (corresponding author), ROYAL NATL HOSP RHEUMAT DIS,BATH,AVON,ENGLAND.							BENJAMIN R, 1990, IMMUNOL TODAY, V11, P137, DOI 10.1016/0167-5699(90)90051-A; BREWERTON DA, 1973, LANCET, V1, P904; GAY S, 1993, ANN RHEUM DIS, V52, pS39, DOI 10.1136/ard.52.Suppl_1.S39; MONACO JJ, 1992, IMMUNOL TODAY, V13, P173, DOI 10.1016/0167-5699(92)90122-N	4	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 11	1993	342	8872					629	629		10.1016/0140-6736(93)91752-8	http://dx.doi.org/10.1016/0140-6736(93)91752-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX272	8103139				2022-12-28	WOS:A1993LX27200003
J	CALNE, RY				CALNE, RY			RESECTION OF LARGE LIVER-TUMORS - LESSONS FROM TRANSPLANTATION SURGERY	LANCET			English	Editorial Material											CALNE, RY (corresponding author), UNIV CAMBRIDGE,SCH CLIN,DEPT SURG,CAMBRIDGE,ENGLAND.							FORTNER JG, 1974, ANN SURG, V180, P644; PICHLMAYR R, 1990, BRIT J SURG, V77, P21, DOI 10.1002/bjs.1800770107; YANAGA K, 1993, SURGERY, V113, P637	3	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 14	1993	342	8868					386	386						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR900	8101898				2022-12-28	WOS:A1993LR90000006
J	ROS, E; NAVARRO, S; BRU, C; GILABERT, R; BIANCHI, L; BRUGUERA, M				ROS, E; NAVARRO, S; BRU, C; GILABERT, R; BIANCHI, L; BRUGUERA, M			URSODEOXYCHOLIC ACID TREATMENT OF PRIMARY HEPATOLITHIASIS IN CAROLIS SYNDROME	LANCET			English	Note							INTRAHEPATIC CHOLESTEROL STONES; DISSOLUTION THERAPY; GALLSTONES; DISEASE	Congenital cystic dilation of the intrahepatic bile ducts (Caroli's syndrome) is a rare cause of chronic cholestasis and hepatolithiasis in young adults. Long-term prognosis is poor even with surgical drainage. We treated twelve patients who had Caroli's syndrome and intrahepatic stones with ursodeoxycholic acid (UDCA), 10-20 mg/kg daily. The duodenal bile of these patients contained cholesterol crystals, which suggests that the stones were cholesterol rich. UDCA led to sustained clinical remission, return to normal liver function, and dissolution of intrahepatic stones on ultrasound in all patients (nine partial, three complete) after 48 (range 12-114) months' follow-up. Litholytic therapy is indicated for intrahepatic stones in Caroli's syndrome.	HOSP CLIN BARCELONA,DEPT RADIOL,E-08036 BARCELONA,SPAIN; HOSP CLIN BARCELONA,LIVER UNIT,E-08036 BARCELONA,SPAIN	University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona	ROS, E (corresponding author), HOSP CLIN BARCELONA,GASTROENTEROL SERV,C VILLARROEL 170,E-08036 BARCELONA,SPAIN.		Navarro, Samuel/AAD-2021-2020	Navarro, Samuel/0000-0001-5016-5653; Ros, Emilio/0000-0002-2573-1294				BENHAMOU JP, 1987, DISEASES LIVER, P1461; CAROLI J, 1958, Sem Hop, V34, P488; DAYTON MT, 1983, AM J SURG, V145, P41, DOI 10.1016/0002-9610(83)90164-2; DECAESTECKER JS, 1991, GUT, V32, P1061, DOI 10.1136/gut.32.9.1061; HEUMAN DM, 1991, HEPATOLOGY, V14, P920, DOI 10.1002/hep.1840140527; OKUDA K, 1984, INTRAHEPATIC CALCULI; ROS E, 1986, GASTROENTEROLOGY, V91, P703, DOI 10.1016/0016-5085(86)90642-6; SCHILLIO Y, 1992, DIGEST DIS SCI, V37, P1460, DOI 10.1007/BF01296020; SEDAGHAT A, 1980, NEW ENGL J MED, V302, P1274, DOI 10.1056/NEJM198006053022302; STRICHARTZ SD, 1991, GASTROENTEROLOGY, V100, P228, DOI 10.1016/0016-5085(91)90605-K	10	72	77	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 14	1993	342	8868					404	406		10.1016/0140-6736(93)92817-D	http://dx.doi.org/10.1016/0140-6736(93)92817-D			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR900	8101905				2022-12-28	WOS:A1993LR90000013
J	VANDERWAALS, FW; MOHRS, J; FOETS, M				VANDERWAALS, FW; MOHRS, J; FOETS, M			SEX-DIFFERENCES AMONG RECIPIENTS OF BENZODIAZEPINES IN DUTCH GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article							SEDATIVE DRUG-USE; PREVALENCE; DURATION	Objective-To analyse sex differences among recipients of benzodiazepines in Dutch general practice. Design-Study of consultations and associated interventions as recorded in the Dutch national survey of general practice. Setting-Practices of 45 general practitioners monitored during 1 April to 30 June 1987. Subjects-61249 patients (29035 (47.4%) men in the age groups 19-44, 45-64, and 65 years and over. Main outcome measures-Symptoms among recipients of repeat as well as new benzodiazepine prescriptions stratified by sex and age. Results-Prescriptions for benzodiazepines were found to be significantly more common among women than among men, (a) after correcting for the sex distribution of the total patient population, and (b) in the two oldest age groups after correcting for the number of consultations. Of all prescriptions for benzodiazepines, 89% (6055/6777) were repeats and 70% (4759/6777) requests. Only 9% (439/4759) of these were authorised by the general practitioner, the rest being issued by the general practitioner's assistant after he or she had referred to the diagnosis in the patient's record. In contrast, only three (1%) of the 492 first time recipients of benzodiazepines had requested a prescription and were not seen by the general practitioner. Women (43/96; 45%) aged 45-64 years received their first prescription for benzodiazepines almost twice as often as men (15/63; 24%) without symptoms or a diagnosis being an indication (female to male relative risk 1.88 (95% confidence interval 1.15 to 3.08)). Conclusions-The sex difference among first time recipients of benzodiazepines seems to be due to general practitioners being less stringent when prescribing this drug for women. The difference continues in repeat prescriptions, physicians failing to check adequately the need for these.	NETHERLANDS INST PRIMARY HLTH CARE,3500 BN UTRECHT,NETHERLANDS; UNIV AMSTERDAM,FAC MED,DEPT GEN PRACTICE,1105 AZ AMSTERDAM,NETHERLANDS	University of Amsterdam	VANDERWAALS, FW (corresponding author), UNIV AMSTERDAM,FAC MED,1105 AZ AMSTERDAM,NETHERLANDS.							BALTER MB, 1974, NEW ENGL J MED, V290, P769, DOI 10.1056/NEJM197404042901404; BALTER MB, 1984, CURR MED RES OPIN, V8, P5; Bensing JM, 1991, HUISARTS WETENSCHAP, V34, P51; BLIJENBERGRUIS B, 1986, TIJDSCHRIFT SOCIALE, V64, P491; CATALAN J, 1988, BRIT J PSYCHIAT, V152, P399, DOI 10.1192/bjp.152.3.399; HAAFKENS J, 1992, CONT DRUG PROBLE FAL, P505; HERINGS RMC, 1989, EFFECTEN CHRONISCH G; Lamberts H., 1987, ICPC INT CLASSIFICAT; MELLINGER GD, 1984, CURR MED RES OPIN, V8, P21, DOI 10.1185/03007998409109542; MELLINGER GD, 1984, JAMA-J AM MED ASSOC, V251, P375, DOI 10.1001/jama.251.3.375; MORGAN K, 1988, BRIT MED J, V296, P601, DOI 10.1136/bmj.296.6622.601; NIJLAND A, 1991, THESIS RIJKS U GRONI; NOLAN L, 1988, EUR J CLIN PHARMACOL, V35, P225, DOI 10.1007/BF00558257; POST D, 1988, PHARM WEEKBLAD, V123, P522; RODRIGO EK, 1988, BMJ-BRIT MED J, V296, P603, DOI 10.1136/bmj.296.6622.603; SWINKELS H, 1990, HUISARTS WET, V33, P504; TIMMERMANS AJG, 1983, MED CONTACT, V38, P1331; VANASSELT JW, 1989, SLAAPVERWEKKEND ONDE; VANDENBREKEL EJG, 1987, MAANDBERICHTEN GEZON, V3, P5; VANDERVELDEN J, 1989, INT CLASSIFICATION P; WOODS JH, 1987, PHARMACOL REV, V39, P251; 1993, VADEMECUM GEZONDHEID; 1989, DIAGNOSE INFORMATIE; 1989, VODEMECUM GEZONDHEID	24	80	82	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 7	1993	307	6900					363	366		10.1136/bmj.307.6900.363	http://dx.doi.org/10.1136/bmj.307.6900.363			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR768	8104066	Green Published, Bronze			2022-12-28	WOS:A1993LR76800022
J	WOLF, AR				WOLF, AR			TREAT THE BABIES, NOT THEIR STRESS RESPONSES	LANCET			English	Editorial Material							ANESTHESIA; SUFENTANIL; FENTANYL; SURGERY; PAIN				WOLF, AR (corresponding author), ROYAL HOSP SICK CHILDREN,DEPT ANAESTHESIA,GLASGOW G3 8SJ,SCOTLAND.							ANAND KJS, 1992, NEW ENGL J MED, V326, P1, DOI 10.1056/NEJM199201023260101; ANAND KJS, 1987, LANCET, V1, P243; ARNOLD JH, 1990, ANESTHESIOLOGY, V73, P1136, DOI 10.1097/00000542-199012000-00011; GREELEY WJ, 1988, ANESTH ANALG, V67, P86; ROGERS MC, 1992, NEW ENGL J MED, V326, P55, DOI 10.1056/NEJM199201023260109; SCHULZE S, 1988, SURGERY, V103, P321; WOLF AR, 1992, BRIT J ANAESTH, V70, P654	7	18	19	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 7	1993	342	8867					319	320		10.1016/0140-6736(93)91468-2	http://dx.doi.org/10.1016/0140-6736(93)91468-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ868	8101580				2022-12-28	WOS:A1993LQ86800006
J	COOPER, DA; GATELL, JM; KROON, S; CLUMECK, N; MILLARD, J; GOEBEL, FD; BRUUN, JN; STINGL, G; MELVILLE, RL; GONZALEZLAHOZ, J; STEVENS, JW; FIDDIAN, AP				COOPER, DA; GATELL, JM; KROON, S; CLUMECK, N; MILLARD, J; GOEBEL, FD; BRUUN, JN; STINGL, G; MELVILLE, RL; GONZALEZLAHOZ, J; STEVENS, JW; FIDDIAN, AP			ZIDOVUDINE IN PERSONS WITH ASYMPTOMATIC HIV-INFECTION AND CD4+ CELL COUNTS GREATER-THAN 400 PER CUBIC MILLIMETER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; AIDS; SURVIVAL; EFFICACY; TYPE-1; AZT	Background. Zidovudine therapy is of benefit in the treatment of symptomatic and asymptomatic human immunodeficiency virus (HIV) infection in persons with CD4+ cen counts of less than 500 per cubic millimeter. The efficacy, safety, and duration of benefit of zidovudine in those with 500 or more CD4+ cells per cubic millimeter are uncertain. Methods. In a double-blind, placebo-controlled trial, 993 patients with asymptomatic HIV infection and CD4+ cell counts above 400 per cubic millimeter were randomly assigned to receive zidovudine (500 mg twice daily) or placebo for three years. The primary end point was progression of disease, as defined by the development of Centers for Disease Control and Prevention (CDC) group IV disease (including recurrent oral candidiasis, hairy leukoplakia, or progressive diarrhea) or two CD4+ cell counts below 350 per cubic millimeter. This outcome measure was changed from the original end point of the acquired immunodeficiency syndrome (AIDS) or advanced AIDS-related complex to reflect changes in recommendations for management. The study was terminated after the first interim analysis. Results. Disease progression was significantly less frequent in the zidovudine group (relative risk, 0.56; 95 percent confidence interval, 0.43 to 0.75; P<0.001 by the log-rank test). The probability of disease progression at two years was 0.19 with zidovudine, as compared with 0.34 with placebo (95 percent confidence interval for the difference, -0.21 to -0.08). Progression to CDC group IV disease was reduced by half in the zidovudine recipients (relative risk, 0.49; P = 0.049) and decline in CD4+ cell counts to below 350 per cubic millimeter was reduced by 40 percent (relative risk, 0.60; P<0.001). The inclusion of early HIV disease events (oral candidiasis, oral hairy leukoplakia, and herpes zoster) as end points confirmed the effects of zidovudine on the progression of clinical disease (relative risk, 0.55; 95 percent confidence interval, 0.37 to 0.84; P = 0.004). The median duration of treatment was 94 weeks. Severe hematologic or clinical side effects were rare. Conclusions. Treatment with zidovudine benefits HIV-infected persons with CD4+ cell counts above 400 per cubic millimeter. Despite the use of doses larger than those now generally prescribed, zidovudine was well tolerated for up to three years by most of our patients.	HOSP CLIN BARCELONA,BARCELONA,SPAIN; BISPEBJERG UNIV HOSP,COPENHAGEN,DENMARK; INST SALUD CARLOS III,MADRID,SPAIN; HOP UNIV ST PIERRE,B-1000 BRUSSELS,BELGIUM; UNIV MUNICH,MED POLYCLIN,W-8000 MUNICH 2,GERMANY; UNIV VIENNA,SCH MED,A-1010 VIENNA,AUSTRIA; WELLCOME RES LABS,BECKENHAM BR3 3BS,KENT,ENGLAND; UNIV OSLO,ULLEVAL HOSP,OSLO 1,NORWAY; PRINCE WALES HOSP,ALBION ST CTR,SYDNEY,NSW,AUSTRALIA	University of Barcelona; Hospital Clinic de Barcelona; University of Copenhagen; Bispebjerg Hospital; Instituto de Salud Carlos III; Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of Munich; University of Vienna; GlaxoSmithKline; Wellcome Research Laboratories; University of Oslo	COOPER, DA (corresponding author), UNIV NEW S WALES,ST VINCENTS HOSP,NATL CTR HIV EPIDEMIOL & CLIN RES,2ND FLOOR,376 VICTORIA ST,SYDNEY,NSW 2010,AUSTRALIA.			Stevens, John/0000-0002-9867-7209				ABOULKER JP, 1993, LANCET, V341, P889, DOI 10.1016/0140-6736(93)93096-J; BUIRA E, 1992, J ACQ IMMUN DEF SYND, V5, P737; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FISCHL MA, 1990, NEW ENGL J MED, V323, P1009, DOI 10.1056/NEJM199010113231501; FRIEDLAND GH, 1990, NEW ENGL J MED, V322, P1000, DOI 10.1056/NEJM199004053221409; GAZZARD BG, 1992, BRIT MED J, V304, P456, DOI 10.1136/bmj.304.6825.456; GRAHAM NMH, 1992, NEW ENGL J MED, V326, P1037, DOI 10.1056/NEJM199204163261601; HAMILTON JD, 1992, NEW ENGL J MED, V326, P437, DOI 10.1056/NEJM199202133260703; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; LANGE JMA, 1992, 3RD EUR C CLIN ASP H; RICHMAN DD, 1990, J ACQ IMMUN DEF SYND, V3, P743; SWANSON CE, 1990, AIDS, V4, P749, DOI 10.1097/00002030-199008000-00006; SWART AM, 1990, BRIT MED J, V301, P825, DOI 10.1136/bmj.301.6756.825; VELLA S, 1992, JAMA-J AM MED ASSOC, V267, P1232, DOI 10.1001/jama.267.9.1232; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; 1987, MMWR MORB MORTAL S1, V36, pS1; 1992, BMJ, V304, P13	19	212	212	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 29	1993	329	5					297	303		10.1056/NEJM199307293290501	http://dx.doi.org/10.1056/NEJM199307293290501			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN621	8100611	Green Published, Green Submitted			2022-12-28	WOS:A1993LN62100001
J	CHARLTON, BG				CHARLTON, BG			MANAGEMENT OF SCIENCE	LANCET			English	Editorial Material								Another phase of the UK's National Health Service reforms is becoming visible, at least in outline-namely, the management of scientific knowledge in medicine. The strategy has several promising aspects but also contains serious threats, which require debate before new practices harden into dogma.			CHARLTON, BG (corresponding author), UNIV NEWCASTLE UPON TYNE,SCH MED,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND.							CHARLTON BG, 1993, MED AUDIT NEWS, V3, P51; DOWNIE RS, 1992, MAKING DOCTOR MED ED; GRIFFITHS R, 1983, REPORT NHS MANAGEMEN; 1992, 1ST STEPS NHS; 1992, HLTH NATION	5	10	10	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 10	1993	342	8863					99	100		10.1016/0140-6736(93)91292-T	http://dx.doi.org/10.1016/0140-6736(93)91292-T			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LL789	8100919				2022-12-28	WOS:A1993LL78900016
J	JURKOVIC, D; JAUNIAUX, E; CAMPBELL, S; PANDYA, P; CARDY, DL; NICOLAIDES, KH				JURKOVIC, D; JAUNIAUX, E; CAMPBELL, S; PANDYA, P; CARDY, DL; NICOLAIDES, KH			COELOCENTESIS - A NEW TECHNIQUE FOR EARLY PRENATAL-DIAGNOSIS	LANCET			English	Note							AMNIOCENTESIS	Chorionic villus sampling and amniocentesis have disadvantages. In 100 women undergoing termination of pregnancy, coelomic fluid was successfully aspirated in 96% of cases at 6-10 weeks' gestation, 42% at 11, and 10% at 12 weeks. Cytogenetic analysis always failed with coelomic fluid, but fetal sexing was always successful with fluorescence in-situ hybridisation and polymerase chain reaction, and the results agreed with those obtained from chorionic villi and amniotic fluid in all cases. Coelocentesis may be suitable for prenatal diagnosis in the first trimester.	KINGS COLL,SCH MED & DENT,HARRIS BIRTHRIGHT RES CTR FETAL MED,LONDON SE5 8RX,ENGLAND; CYOCELL LTD,LEWKNOR,OXON,ENGLAND	University of London; King's College London	JURKOVIC, D (corresponding author), KINGS COLL,SCH MED & DENT,DEPT OBSTET & GYNAECOL,LONDON SE5 8RX,ENGLAND.			Nicolaides, Kypros/0000-0003-1266-0711				[Anonymous], 1991, LANCET, V337, P1491; BYRNE D, 1991, ULTRASOUND OBST GYN, V1, P235, DOI 10.1046/j.1469-0705.1991.01040235.x; FIRTH HV, 1991, LANCET, V337, P762, DOI 10.1016/0140-6736(91)91374-4; JAUNIAUX E, 1991, OBSTET GYNECOL, V78, P1124; JORGENSEN FS, 1992, PRENATAL DIAG, V12, P277, DOI 10.1002/pd.1970120407; RODECK CH, 1993, LANCET, V341, P468, DOI 10.1016/0140-6736(93)90213-Z; TABOR A, 1986, LANCET, V1, P1287; WARBURTON PE, 1991, GENOMICS, V11, P324, DOI 10.1016/0888-7543(91)90139-6	8	58	61	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 26	1993	341	8861					1623	1624		10.1016/0140-6736(93)90761-5	http://dx.doi.org/10.1016/0140-6736(93)90761-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ727	8099993				2022-12-28	WOS:A1993LJ72700007
J	MACKIE, RM; MCHENRY, P; HOLE, D				MACKIE, RM; MCHENRY, P; HOLE, D			ACCELERATED DETECTION WITH PROSPECTIVE SURVEILLANCE FOR CUTANEOUS MALIGNANT-MELANOMA IN HIGH-RISK GROUPS	LANCET			English	Article							MELANOCYTIC NEVI; NUMBER	In 1983 a classification scheme was proposed for patients with atypical naevi, according to their personal and family history of melanoma and atypical naevi. To assess the predictive value of these features we undertook prospective surveillance of patients at high risk of primary melanoma. We followed up 116 patients each with 3 or more clinically atypical naevi for at least 5 years. Patients are examined and naevi are photographed every 3-6 months; lesions showing disturbing change are excised for histopathology. Among 85 patients with no personal or family history of melanoma, 5 invasive (level 2 or deeper) melanomas developed during 583 person-years of follow up. The expected number of invasive melanomas in this population would be 0.054; the increased risk is significant (p < 0.001; relative risk 92 [95% CI 30-216]). There was a similarly increased risk of new melanoma also among 24 patients with atypical naevi plus a history of previous melanoma (observed 2, expected 0.022, p < 0.001; relative risk 91 [11-328]). By comparison, no second melanoma developed among 25 patients with previous melanoma but a normal naevus pattern during 213 person-years of similarly intensive follow-up. The risk of melanoma was highest among 7 patients with atypical naevi and a family history of melanoma (observed 6, expected 0.009, p < 0.001; relative risk 444 [121-1138]). The median thickness of surveillance-detected melanomas was 0.75 mm (range 0.40-1.05 mm) in this group. This study shows the value of clinical follow-up of high-risk patients to detect early thin melanomas.			MACKIE, RM (corresponding author), UNIV GLASGOW,DEPT DERMATOL,ROBERTSON BLDG,GLASGOW G12 8QQ,SCOTLAND.							BRESLOW NE, 1987, STATISTICAL METHODS, V11; GALLAGHER RP, 1990, ARCH DERMATOL, V126, P770, DOI 10.1001/archderm.126.6.770; GOLDGAR DE, 1991, J NATL CANCER I, V83, P1726, DOI 10.1093/jnci/83.23.1726; GROB JJ, 1990, CANCER, V66, P387, DOI 10.1002/1097-0142(19900715)66:2<387::AID-CNCR2820660232>3.0.CO;2-J; HOLLY EA, 1987, J AM ACAD DERMATOL, V17, P459, DOI 10.1016/S0190-9622(87)70230-8; MACKIE R, 1992, LANCET, V339, P971, DOI 10.1016/0140-6736(92)91539-K; MACKIE RM, 1989, LANCET, V2, P487; MILTON GW, 1984, RISK FACTORS MULTIPL, P353; OSTERLIND A, 1988, INT J CANCER, V42, P200, DOI 10.1002/ijc.2910420210; POPE DJ, 1992, ARCH DERMATOL, V128, P1201, DOI 10.1001/archderm.128.9.1201	10	85	85	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 26	1993	341	8861					1618	1620		10.1016/0140-6736(93)90758-9	http://dx.doi.org/10.1016/0140-6736(93)90758-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ727	8099990				2022-12-28	WOS:A1993LJ72700004
J	AGARD, DA				AGARD, DA			TO FOLD OR NOT TO FOLD	SCIENCE			English	Editorial Material							ALPHA-LYTIC PROTEASE; CLASS-I; PROTEINS; SUBTILISIN		UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,STRUCT BIOL UNIT,SAN FRANCISCO,CA 94143	Howard Hughes Medical Institute; University of California System; University of California San Francisco	AGARD, DA (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.							Anfinsen C B, 1975, Adv Protein Chem, V29, P205, DOI 10.1016/S0065-3233(08)60413-1; BAKER D, 1992, NATURE, V356, P263, DOI 10.1038/356263a0; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; EDER J, 1993, BIOCHEMISTRY-US, V32, P18, DOI 10.1021/bi00052a004; FLAJNIK MF, 1991, IMMUNOGENETICS, V33, P295, DOI 10.1007/BF00216688; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; Georgopoulos C, 1990, Semin Cell Biol, V1, P19; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GETHING MJ, UNPUB; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; SABIL HR, 1993, CURR BIOL, V3, P265; SILEN JL, 1989, NATURE, V341, P462, DOI 10.1038/341462a0; SILEN JL, 1988, GENE, V69, P237, DOI 10.1016/0378-1119(88)90434-9; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WELLS JA, 1983, NUCLEIC ACIDS RES, V11, P7911, DOI 10.1093/nar/11.22.7911; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0	27	94	100	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 25	1993	260	5116					1903	1904		10.1126/science.8100365	http://dx.doi.org/10.1126/science.8100365			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LJ349	8100365				2022-12-28	WOS:A1993LJ34900031
J	GIAID, A; MICHEL, RP; STEWART, DJ; SHEPPARD, M; CORRIN, B; HAMID, Q				GIAID, A; MICHEL, RP; STEWART, DJ; SHEPPARD, M; CORRIN, B; HAMID, Q			EXPRESSION OF ENDOTHELIN-1 IN LUNGS OF PATIENTS WITH CRYPTOGENIC FIBROSING ALVEOLITIS	LANCET			English	Article							IDIOPATHIC PULMONARY FIBROSIS; LOWER RESPIRATORY-TRACT; SMOOTH-MUSCLE CELLS; FIBROBLAST INTERACTIONS; CHRONIC INFLAMMATION; UNKNOWN CAUSE; C-FOS; VASOCONSTRICTOR; MITOGENESIS; DISEASES	The vasoconstrictor and mitogenic peptide endothelin-1 (ET-1) is believed to play a part in fibrosis and collagen production. We examined expression of ET-1 in lung tissue from 52 patients with interstitial lung fibrosis, of whom 45 had cryptogenic fibrosing alveolitis (CFA), 10 had CFA and concomitant pulmonary hypertension, and 7 had non-specific focal fibrosis. 17 normal unused donor lungs were studied as controls. Immunohistochemistry and in-situ hybridisation were done with polyclonal antisera to ET-1 and its precursor big ET-1, and complementary RNA probes for preproET-1. Normal lung tissue and that from patients with focal fibrosis expressed very little ET-1. By contrast, there was striking expression of ET-1 in lung tissue from patients with CFA. Immunostains for ET-1 and big ET-1 and expression of ET-1 mRNA were most prominent in airway epithelium and type II pneumocytes, particularly those lining areas of young granulation tissue. ET-1-like immunoreactivity and mRNA were also present in pulmonary vascular endothelial cells, particularly in specimens from patients with pulmonary hypertension. In all patients, there was a significant correlation between ET-1 -like immunoreactivity and histological parameters of disease activity (r = 0.78, 95% Cl 0-65-0.87, p < 0.001). These findings suggest a possible role for cell-specific expression of ET-1 in the pathogenesis of CFA and associated pulmonary hypertension.	MCGILL UNIV,MONTREAL GEN HOSP,DEPT MED,MONTREAL H3G 1A4,QUEBEC,CANADA; MCGILL UNIV,ROYAL VICTORIA HOSP,DEPT PATHOL,MONTREAL H3A 1A1,QUEBEC,CANADA; MCGILL UNIV,ROYAL VICTORIA HOSP,DEPT MED,MONTREAL H3A 1A1,QUEBEC,CANADA; BROMPTON HOSP,NATL HEART & LUNG INST,DEPT LUNG PATHOL,LONDON SW3 6HP,ENGLAND	McGill University; McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; Imperial College London; Royal Brompton Hospital	GIAID, A (corresponding author), MCGILL UNIV,MONTREAL GEN HOSP,DEPT PATHOL,1650 CEDAR AVE,MONTREAL H3G 1A4,QUEBEC,CANADA.		Sheppard, Mary N/AAB-3364-2019	Sheppard, Mary N/0000-0003-2724-3881				ADAMSON IYR, 1990, AM J PATHOL, V137, P385; ADAMSON IYR, 1991, EXP LUNG RES, V17, P821, DOI 10.3109/01902149109062880; CHERNIACK RM, 1991, AM REV RESPIR DIS, V143, P680, DOI 10.1164/ajrccm/143.3.680; CORRIN B, 1985, J PATHOL, V147, P107, DOI 10.1002/path.1711470206; CROUCH E, 1990, AM J PHYSIOL, V259, pL159, DOI 10.1152/ajplung.1990.259.4.L159; CRYSTAL RG, 1984, NEW ENGL J MED, V310, P235, DOI 10.1056/NEJM198401263100406; CRYSTAL RG, 1984, NEW ENGL J MED, V310, P154, DOI 10.1056/NEJM198401193100304; ENDO T, 1992, BIOCHEM BIOPH RES CO, V186, P1594, DOI 10.1016/S0006-291X(05)81590-6; GIAID A, 1991, AM J RESP CELL MOL, V4, P50, DOI 10.1165/ajrcmb/4.1.50; GIAID A, 1992, American Review of Respiratory Disease, V145, pA717; HORI S, 1992, ENDOCRINOLOGY, V130, P1885, DOI 10.1210/en.130.4.1885; HYDE DM, 1992, AM REV RESPIR DIS, V146, P1042, DOI 10.1164/ajrccm/146.4.1042; KAHALEH MB, 1991, ARTHRITIS RHEUM, V34, P978, DOI 10.1002/art.1780340807; KANSE SM, 1991, LIFE SCI, V48, P1379, DOI 10.1016/0024-3205(91)90434-D; KHALIL N, 1991, AM J RESP CELL MOL, V5, P155, DOI 10.1165/ajrcmb/5.2.155; KOMURO I, 1988, FEBS LETT, V238, P249, DOI 10.1016/0014-5793(88)80489-7; MASAKI T, 1991, CIRCULATION, V84, P1457, DOI 10.1161/01.CIR.84.4.1457; MULDOON LL, 1989, J BIOL CHEM, V264, P8529; NASH JRG, 1993, HISTOPATHOLOGY, V22, P343, DOI 10.1111/j.1365-2559.1993.tb00133.x; PANOS RJ, 1991, IMMUNOLOGICALLY MEDI, P1; Reeves JT, 1984, PULMONARY HYPERTENSI, P1; SHINMI O, 1989, BIOCHEM BIOPH RES CO, V162, P340, DOI 10.1016/0006-291X(89)92001-9; SIMONSON MS, 1992, J LAB CLIN MED, V119, P622; SIMONSON MS, 1989, J CLIN INVEST, V83, P708, DOI 10.1172/JCI113935; Sokal R. R., 1981, BIOMETRY; SPRINGALL DR, 1991, LANCET, V337, P697, DOI 10.1016/0140-6736(91)90279-X; TAKUWA N, 1989, J BIOL CHEM, V264, P7856; VITTORI E, 1992, AM REV RESPIR DIS, V146, P1320, DOI 10.1164/ajrccm/146.5_Pt_1.1320; YAMANE K, 1991, ARTHRITIS RHEUM, V34, P243, DOI 10.1002/art.1780340220; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; 1990, AM REV RESPIR DIS, V141, pS166	31	238	243	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 19	1993	341	8860					1550	1554						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH550	8099638				2022-12-28	WOS:A1993LH55000002
J	HERTOG, MGL; FESKENS, EJM; HOLLMAN, PCH; KATAN, MB; KROMHOUT, D				HERTOG, MGL; FESKENS, EJM; HOLLMAN, PCH; KATAN, MB; KROMHOUT, D			DIETARY ANTIOXIDANT FLAVONOIDS AND RISK OF CORONARY HEART-DISEASE - THE ZUTPHEN ELDERLY STUDY	LANCET			English	Article							DENSITY-LIPOPROTEIN; QUERCETIN; CHOLESTEROL; INHIBITION	Flavonoids are polyphenolic antioxidants naturally present in vegetables, fruits, and beverages such as tea and wine. In vitro, flavonoids inhibit oxidation of low-density lipoprotein and reduce thrombotic tendency, but their effects on atherosclerotic complications in human beings are unknown. We measured the content in various foods of the flavonoids quercetin, kaempferol, myricetin, apigenin, and luteolin. We then assessed the flavonoid intake of 805 men aged 65-84 years in 1985 by a cross-check dietary history; the men were then followed up for 5 years. Mean baseline flavonoid intake was 25.9 mg daily. The major sources of intake were tea (61%), onions (13%), and apples (10%). Between 1985 and 1990, 43 men died of coronary heart disease. Fatal or non-fatal myocardial infarction occurred in 38 of 693 men with no history of myocardial infarction at baseline. Flavonoid intake (analysed in tertiles) was significantly inversely associated with mortality from coronary heart disease (p for trend = 0.015) and showed an inverse relation with incidence of myocardial infarction, which was of borderline significance (p for trend = 0 08). The relative risk of coronary heart disease mortality in the highest versus the lowest tertile of flavonoid intake was 0.42 (95% Cl 0.20-0.88). After adjustment for age, body-mass index, smoking, serum total and high-density-lipoprotein cholesterol, blood pressure, physical activity, coffee consumption, and intake of energy, vitamin C, vitamin E, beta-carotene, and dietary fibre, the risk was still significant (0.32 [0.15-0.71]). Intakes of tea, onions, and apples were also inversely related to coronary heart disease mortality, but these associations were weaker. Flavonoids in regularly consumed foods may reduce the risk of death from coronary heart disease in elderly men.	AGR UNIV WAGENINGEN,6700 HB WAGENINGEN,NETHERLANDS; STATE INST QUAL CONTROL AGR PROD,WAGENINGEN,NETHERLANDS	Wageningen University & Research	HERTOG, MGL (corresponding author), NATL INST PUBL HLTH & ENVIRONM PROTECT,DEPT CHRON DIS & ENVIRONM EPIDEMIOL,POB 1,3720 BA BILTHOVEN,NETHERLANDS.		Ibrahim, Essam Hassan/G-1960-2018; Feskens, Edith/ABI-1446-2020; Kromhout, Daan/A-8566-2014; Hollman, Peter C.H./I-7446-2013; Feskens, Edith JM/A-3757-2012	Ibrahim, Essam Hassan/0000-0003-0130-2257; Feskens, Edith/0000-0001-5819-2488; Hollman, Peter C.H./0000-0002-7510-6809; 				BLOEMBERG BPM, 1989, AM J EPIDEMIOL, V130, P1047, DOI 10.1093/oxfordjournals.aje.a115405; CASPERSEN CJ, 1991, AM J EPIDEMIOL, V133, P1078, DOI 10.1093/oxfordjournals.aje.a115821; CONNEY AH, 1992, PREV MED, V21, P361, DOI 10.1016/0091-7435(92)90043-H; DEWHALLEY CV, 1990, BIOCHEM PHARMACOL, V39, P1743, DOI 10.1016/0006-2952(90)90120-A; FRANKEL EN, 1993, LANCET, V341, P454, DOI 10.1016/0140-6736(93)90206-V; GUGLER R, 1975, EUR J CLIN PHARMACOL, V9, P229, DOI 10.1007/BF00614022; HERTOG MGL, 1993, NUTR CANCER, V20, P21, DOI 10.1080/01635589309514267; HERTOG MGL, 1992, J AGR FOOD CHEM, V40, P1591, DOI 10.1021/jf00021a023; HERTOG MGL, 1992, J AGR FOOD CHEM, V40, P2379, DOI 10.1021/jf00024a011; HERTOG MGL, 1993, J AGR FOOD CHEM, V41, P1242, DOI 10.1021/jf00032a015; HUSAIN SR, 1987, PHYTOCHEMISTRY, V26, P2489, DOI 10.1016/s0031-9422(00)83860-1; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KATIYAR SK, 1992, NUTR CANCER, V18, P73, DOI 10.1080/01635589209514207; KEYS A, 1967, ACTA MED SCAND, P1; KLELIJNEN J, 1992, LANCET, V340, P1136; Kuhnau J, 1976, World Rev Nutr Diet, V24, P117; LAUGHTON MJ, 1991, BIOCHEM PHARMACOL, V42, P1673, DOI 10.1016/0006-2952(91)90501-U; NEGRESALVAYRE A, 1992, FREE RADICAL BIO MED, V12, P101, DOI 10.1016/0891-5849(92)90002-X; Robak J, 1998, BIOCHEM PHARMACOL, V37, P83; Rose G, 1968, CARDIOVASCULAR SURVE; SIEDEL J, 1981, J CLIN CHEM CLIN BIO, V19, P838; SORATA Y, 1984, BIOCHIM BIOPHYS ACTA, V799, P313, DOI 10.1016/0304-4165(84)90276-9; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; TAKAHAMA U, 1985, PHYTOCHEMISTRY, V24, P1443, DOI 10.1016/S0031-9422(00)81040-7; UENO I, 1983, JPN J EXP MED, V53, P41; VANBUCHEM FSP, 1967, ACTA MED SCAND  S460, P191; WARNICK GR, 1982, CLIN CHEM, V28, P1379; WILSON PWF, 1989, ARCH INTERN MED, V149, P1169, DOI 10.1001/archinte.149.5.1169; 1985, UCV TABEL UITGEBREID	29	3468	3615	7	512	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 23	1993	342	8878					1007	1011		10.1016/0140-6736(93)92876-U	http://dx.doi.org/10.1016/0140-6736(93)92876-U			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD066	8105262				2022-12-28	WOS:A1993MD06600007
J	YOUNG, ID				YOUNG, ID			DIAGNOSING FRAGILE-X SYNDROME	LANCET			English	Editorial Material											YOUNG, ID (corresponding author), CITY HOSP NOTTINGHAM,DEPT CLIN GENET,NOTTINGHAM NG5 1PD,ENGLAND.							BONTHRON D, 1993, LANCET, V341, P769, DOI 10.1016/0140-6736(93)90552-R; BRADLEY DM, 1993, BRIT MED J, V306, P357, DOI 10.1136/bmj.306.6874.357; BUNDEY S, 1993, LANCET, V341, P770; JACOBS PA, 1993, J MED GENET, V30, P454, DOI 10.1136/jmg.30.6.454; MULLEY JC, 1992, J MED GENET, V29, P368, DOI 10.1136/jmg.29.6.368; PALOMAKI GE, 1993, LANCET, V341, P373, DOI 10.1016/0140-6736(93)90176-H; TURNER G, 1992, LANCET, V339, P1210, DOI 10.1016/0140-6736(92)91142-U	7	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 23	1993	342	8878					1004	1005		10.1016/0140-6736(93)92873-R	http://dx.doi.org/10.1016/0140-6736(93)92873-R			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD066	8105259				2022-12-28	WOS:A1993MD06600004
J	MOMBAERTS, P; MIZOGUCHI, E; GRUSBY, MJ; GLIMCHER, LH; BHAN, AK; TONEGAWA, S				MOMBAERTS, P; MIZOGUCHI, E; GRUSBY, MJ; GLIMCHER, LH; BHAN, AK; TONEGAWA, S			SPONTANEOUS DEVELOPMENT OF INFLAMMATORY BOWEL-DISEASE IN T-CELL RECEPTOR MUTANT MICE	CELL			English	Article							MONOCLONAL-ANTIBODIES; TARGETED DISRUPTION; GENE; MOUSE; LYMPHOCYTES	We describe the spontaneous development of inflammatory bowel disease (IBD) in several immunodeficient mouse strains created via gene targeting in embryonic stem cells. Chronic colitis was observed in T cell receptor (TCR) alpha mutant, TCR beta mutant, TCR beta x delta double mutant, or class II major histocompatibility complex (MHC) mutant mice, but not in recombination-activating gene RAG-1 mutant mice or nude mice kept in the same specific pathogen-free animal facility. This clinical pattern suggests that the disease requires the presence of B lymphocytes and the absence of class II HC-restricted CD4+ alphabeta T cells. IBD in the mutant mice has some of the features of the human disease ulcerative colitis. Based on these results, we suggest that dysfunction of the mucosal immune system may underly the pathogenesis of some types of IBD in humans.	HARVARD UNIV, MASSACHUSETTS GEN HOSP, SCH MED, DEPT PATHOL, BOSTON, MA 02114 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT CANC BIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; MASSACHUSETTS GEN HOSP, CTR STUDY INFLAMMATORY BOWEL DIS, BOSTON, MA 02114 USA; NEW ENGLAND REG PRIMATE RES CTR, BOSTON, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	MOMBAERTS, P (corresponding author), MIT, HOWARD HUGHES MED INST, CTR CANC RES, DEPT BIOL, CAMBRIDGE, MA 02139 USA.							CERFBENSUSSAN N, 1983, J IMMUNOL, V130, P2615; CHEN JZ, 1993, INT IMMUNOL, V5, P647, DOI 10.1093/intimm/5.6.647; GRUSBY MJ, 1991, SCIENCE, V253, P1417, DOI 10.1126/science.1910207; ITOHARA S, 1989, P NATL ACAD SCI USA, V86, P5094, DOI 10.1073/pnas.86.13.5094; ITOHARA S, 1993, CELL, V72, P337, DOI 10.1016/0092-8674(93)90112-4; JUNG S, 1993, SCIENCE, V259, P984, DOI 10.1126/science.8438159; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; KUSUGAMI K, 1991, GASTROENTEROLOGY, V101, P1594, DOI 10.1016/0016-5085(91)90397-4; Leiter EH, 1990, ROLE MICROORGANISMS, P39; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; MOMBAERTS P, 1991, P NATL ACAD SCI USA, V88, P3084, DOI 10.1073/pnas.88.8.3084; MOMBAERTS P, 1993, NATURE, V365, P53, DOI 10.1038/365053a0; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; NITSCHKE L, 1993, P NATL ACAD SCI USA, V90, P1887, DOI 10.1073/pnas.90.5.1887; PODOLSKY DK, 1991, NEW ENGL J MED, V325, P1008, DOI 10.1056/NEJM199110033251406; PODOLSKY DK, 1991, NEW ENGL J MED, V325, P928, DOI 10.1056/NEJM199109263251306; POZZILLI P, 1993, IMMUNOL TODAY, V14, P193, DOI 10.1016/0167-5699(93)90160-M; ROCHA B, 1992, IMMUNOL TODAY, V13, P449, DOI 10.1016/0167-5699(92)90074-H; ROES J, 1993, J EXP MED, V177, P45, DOI 10.1084/jem.177.1.45; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0	24	631	651	1	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 22	1993	75	2					275	282		10.1016/0092-8674(93)80069-Q	http://dx.doi.org/10.1016/0092-8674(93)80069-Q			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MD885	8104709				2022-12-28	WOS:A1993MD88500009
J	MILLER, FH; HARRISON, A				MILLER, FH; HARRISON, A			MALPRACTICE LIABILITY AND PHYSICIAN AUTONOMY	LANCET			English	Editorial Material									KINGS FUND INST,LONDON NW1 7NF,ENGLAND; BOSTON UNIV,SCH MED,BOSTON,MA 02215	Boston University	MILLER, FH (corresponding author), BOSTON UNIV,SCH LAW,765 COMMONWEALTH AVE,BOSTON,MA 02215, USA.							EICHHORN JH, 1986, JAMA-J AM MED ASSOC, V256, P1017; Field M, 1991, CLIN PRACTICE GUIDEL; ROGERS D, 1993, WALL STREET J   0615	3	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 16	1993	342	8877					973	975		10.1016/0140-6736(93)92009-I	http://dx.doi.org/10.1016/0140-6736(93)92009-I			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MC005	8105221	hybrid			2022-12-28	WOS:A1993MC00500016
J	WEALE, A; WARWICK, D; DURANT, N				WEALE, A; WARWICK, D; DURANT, N			IS THERE HEMOSTATIC INTERACTION BETWEEN LOW-MOLECULAR-WEIGHT HEPARIN AND NONSTEROIDAL ANALGESICS AFTER TOTAL HIP-REPLACEMENT	LANCET			English	Letter									AVON ORTHOPAED CTR,BRISTOL BS10 5NB,ENGLAND; MUSGROVE PK HOSP,DEPT PHARM,TAUNTON,ENGLAND	Musgrove Park Hospital	WEALE, A (corresponding author), MUSGROVE PK HOSP,DEPT ORTHOPAED SURG,TAUNTON,ENGLAND.		warwick, david/I-1061-2019	warwick, david/0000-0003-3030-442X				Greer IA, 1990, PHARMACOTHERAPY S, V10, P71; LEIZOROVICZ A, 1992, BMJ-BRIT MED J, V305, P913, DOI 10.1136/bmj.305.6859.913; YETT HS, 1978, NEW ENGL J MED, V298, P1092	3	8	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 16	1993	342	8877					995	995		10.1016/0140-6736(93)92044-T	http://dx.doi.org/10.1016/0140-6736(93)92044-T			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MC005	8105247				2022-12-28	WOS:A1993MC00500057
J	KEIRSE, MJNC				KEIRSE, MJNC			FREQUENT PRENATAL ULTRASOUND - TIME TO THINK AGAIN	LANCET			English	Editorial Material							RANDOMIZED CONTROLLED TRIAL; PREGNANCY				KEIRSE, MJNC (corresponding author), LEIDEN UNIV HOSP, DEPT OBSTET GYNAECOL & REPROD, 2333 AA LEIDEN, NETHERLANDS.							BAKKETEIG LS, 1984, LANCET, V2, P207; EWIGMAN B, 1990, OBSTET GYNECOL, V76, P189; KEIRSE MJN, 1981, FETAL GROWTH RETARDA, P37; KEIRSE MJNC, 1984, CLIN OBSTET GYNAECOL, V11, P415; NEILSON JP, 1993, REV UPDATE SOFTWARE, V3889; NEILSON JP, 1993, REV UPDATE SOFTWARE, V3872; ROBINSON D, 1952, AM J OBSTET GYNECOL, V63, P1330; SALVESEN KA, 1992, LANCET, V339, P85, DOI 10.1016/0140-6736(92)90998-I; SALVESEN KA, 1993, BRIT MED J, V307, P159, DOI 10.1136/bmj.307.6897.159; WALDENSTROM U, 1988, LANCET, V2, P585; WILCOX AJ, 1981, AM J OBSTET GYNECOL, V139, P863, DOI 10.1016/0002-9378(81)90950-9	11	7	7	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 9	1993	342	8876					878	879						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA963	8105159				2022-12-28	WOS:A1993MA96300002
J	TEARE, JP; SHERMAN, D; GREENFIELD, SM; SIMPSON, J; BRAY, G; CATTERALL, AP; MURRAYLYON, IM; PETERS, TJ; WILLIAMS, R; THOMPSON, RPH				TEARE, JP; SHERMAN, D; GREENFIELD, SM; SIMPSON, J; BRAY, G; CATTERALL, AP; MURRAYLYON, IM; PETERS, TJ; WILLIAMS, R; THOMPSON, RPH			COMPARISON OF SERUM PROCOLLAGEN-III PEPTIDE CONCENTRATIONS AND PGA INDEX FOR ASSESSMENT OF HEPATIC-FIBROSIS	LANCET			English	Article							PRIMARY BILIARY-CIRRHOSIS; APOLIPOPROTEIN-A-I; CHRONIC ACTIVE HEPATITIS; ALCOHOLIC LIVER-DISEASE; LIPOPROTEIN ABNORMALITIES; LAMININ; INJURY	In early hepatic fibrosis, increased amounts of type III collagen are deposited. Persistently high serUM concentrations of aminoterminal type III procollagen propeptide (PIIIP) correlate with the activity of the fibrogenic process. Another index for the detection of fibrosis, the PGA index, combines the prothrombin time, gamma-glutamyl transpeptidase activity, and serum apolipoprotein A1 concentration (the latter falls with progressive fibrosis). We compared PIIIP measurements and PGA index in patients with various histological forms of alcoholic liver disease (104), primary biliary cirrhosis (38), and chronic B virus hepatitis (2 7), and in healthy age-matched controls (30). The ability of each test to identify correctly patients with fibrosis or cirrhosis was assessed with receiver operating curves. The PGA index was much higher in all groups of patients with alcoholic liver disease than in controls (p<0.0001). PIIIP concentrations were also substantially higher than in controls (p<0.05 for fatty liver, p<0.0001 for all other groups), especially in the group with alcoholic hepatitis and cirrhosis. For the detection of cirrhosis the PGA was 91% sensitive and 81% specific and the PIIIP concentration was 94% sensitive and 81% specific. The two tests combined had 85% sensitivity, but 93% specificity. Among patients with primary biliary cirrhosis, both PGA index and PIIIP concentration correlated well with the severity of the disease, determined by the Mayo score (r=0.72 and 0.66 respectively). The combined tests were 96% sensitive for the detection of fibrosis. All patients with chronic B virus hepatitis had raised PGA and PIIIP values in comparison with controls (p<0.0001) but there were no differences between subgroups. Substantially raised PIIIP concentrations thus identify the subgroup of alcoholic patients with both hepatitis and cirrhosis. The combination of PGA index and PIIIP concentration may be useful for targeting treatment with antifibrotic drugs and to reduce the need for liver biopsy.	UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT CLIN BIOCHEM,LONDON WC2R 2LS,ENGLAND; CHARING CROSS HOSP,DEPT GASTROENTEROL,LONDON W6 8RP,ENGLAND	University of London; King's College London; Imperial College London	TEARE, JP (corresponding author), ST THOMAS HOSP,RAYNE INST,GASTROINTESTINAL LAB,LONDON SE1 7EH,ENGLAND.		Simpson, Julie A/P-7299-2014	teare, Julian/0000-0003-3551-9139; opoku, anita/0000-0001-7243-8157				ALTMAN D, 1991, PRACTICAL STAT MED R, P408; ANNONI G, 1989, HEPATOLOGY, V9, P693, DOI 10.1002/hep.1840090506; CAMARGO CA, 1985, JAMA-J AM MED ASSOC, V253, P2854; CLEMENT B, 1991, J HEPATOL         S3, V13, P541; CORDOVA C, 1984, CLIN CHIM ACTA, V137, P61, DOI 10.1016/0009-8981(84)90312-7; DICKSON ER, 1989, HEPATOLOGY, V10, P1, DOI 10.1002/hep.1840100102; DUHAMEL G, 1984, HEPATOLOGY, V4, P577, DOI 10.1002/hep.1840040401; FEELY J, 1992, BRIT MED J, V304, P545, DOI 10.1136/bmj.304.6826.545; JAHN CE, 1985, GASTROENTEROLOGY, V89, P1266, DOI 10.1016/0016-5085(85)90642-0; LOTTERER E, 1992, J HEPATOL, V14, P71, DOI 10.1016/0168-8278(92)90133-A; MARTH E, 1982, ANN NUTR METAB, V26, P56, DOI 10.1159/000176544; NAKANO M, 1982, GASTROENTEROLOGY, V83, P777; PIERARD D, 1982, CONNECTIVE TISSUE NO, P217; POYNARD T, 1986, HEPATOLOGY, V6, P1391, DOI 10.1002/hep.1840060628; POYNARD T, 1991, GASTROENTEROLOGY, V100, P1397; PUGH RNH, 1973, BRIT J SURG, V60, P640; RAEDSCH R, 1982, Z GASTROENTEROL, V20, P738; RAGLAND JB, 1978, SCAND J CLIN LAB INV, V38, P208, DOI 10.3109/00365517809104927; ROHDE H, 1979, EUR J CLIN INVEST, V9, P451, DOI 10.1111/j.1365-2362.1979.tb00912.x; SABESIN SM, 1985, GASTROENTEROLOGY, V89, P1426, DOI 10.1016/0016-5085(85)90665-1; SCHUPPAN D, 1991, J HEPATOL, V13, pS17, DOI 10.1016/0168-8278(91)90004-U; TORRESSALINAS M, 1986, GASTROENTEROLOGY, V90, P1241, DOI 10.1016/0016-5085(86)90391-4; WEIGAND K, 1984, HEPATOLOGY, V4, P835, DOI 10.1002/hep.1840040506	23	93	99	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 9	1993	342	8876					895	898		10.1016/0140-6736(93)91946-J	http://dx.doi.org/10.1016/0140-6736(93)91946-J			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA963	8105167				2022-12-28	WOS:A1993MA96300010
J	RUPPERT, J; SIDNEY, J; CELIS, E; KUBO, RT; GREY, HM; SETTE, A				RUPPERT, J; SIDNEY, J; CELIS, E; KUBO, RT; GREY, HM; SETTE, A			PROMINENT ROLE OF SECONDARY ANCHOR RESIDUES IN PEPTIDE BINDING TO HLA-A2.1 MOLECULES	CELL			English	Article							HISTOCOMPATIBILITY COMPLEX MHC; CLASS-I MOLECULES; VIRAL PEPTIDES; T-CELLS; ANTIGENS; MOTIFS; RECOGNITION; SELECTION; HLA-AW68	The functional determinants of histocompatibility leukocyte antigen (HLA)-A2.1-peptide interactions have been detailed by the use of quantitative molecular binding assays and a chemically synthesized library of naturally occurring epitopes. The importance of hydrophobic anchor residues in position 2 and the C-terminus minus was confirmed. These anchors are necessary, but not sufficient, for high affinity binding, as the predictions based solely on these anchors are only about 30% accurate. Prominent roles for several other positions (1, 3, and 7) were also demonstrated. The location of these residues within the peptides matches secondary A2.1 pockets previously demonstrated by X-ray crystallography. From a functional standpoint, similar dominant negative effects on binding were observed for charged residues in both nonamers and decamers, while positive effects differed between nonamers and decamers. An extended motif taking into account secondary anchors increased the predictability of A2.1-binding epitopes to a level of 70%, underscoring the practical usefulness of extended motifs.			RUPPERT, J (corresponding author), CYTEL CORP,3525 JOHN HOPKINS COURT,SAN DIEGO,CA 92121, USA.		Sette, Alessandro/AFO-8916-2022					BJORKMAN PJ, 1990, ANNU REV BIOCHEM, V59, P253, DOI 10.1146/annurev.bi.59.070190.001345; BOEHNCKE WH, 1993, J IMMUNOL, V150, P331; BUUS S, 1987, SCIENCE, V235, P1353, DOI 10.1126/science.2435001; CHEN BP, 1989, NATURE, V337, P743, DOI 10.1038/337743a0; CORR M, 1992, J EXP MED, V176, P1681, DOI 10.1084/jem.176.6.1681; ELLIOTT T, 1991, NATURE, V351, P402, DOI 10.1038/351402a0; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GUO HC, 1992, NATURE, V360, P364, DOI 10.1038/360364a0; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; JAMESON SC, 1992, EUR J IMMUNOL, V22, P2663, DOI 10.1002/eji.1830221028; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; LATRON F, 1992, SCIENCE, V257, P964, DOI 10.1126/science.1380181; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; PARHAM P, 1992, NATURE, V360, P300, DOI 10.1038/360300a0; PARKER KC, 1992, J IMMUNOL, V149, P3580; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; ROTZSCHKE O, 1991, IMMUNOL TODAY, V12, P447, DOI 10.1016/0167-5699(91)90018-O; SAPER MA, 1991, J MOL BIOL, V219, P27; SCHAEFFER EB, 1989, P NATL ACAD SCI USA, V86, P4649, DOI 10.1073/pnas.86.12.4649; SCHUMACHER TNM, 1991, NATURE, V350, P703, DOI 10.1038/350703a0; SETTE A, 1992, J IMMUNOL, V148, P844; SETTE A, 1993, IN PRESS J IMMUNOL; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; Travers Paul J., 1992, Current Biology, V2, P679, DOI 10.1016/0960-9822(92)90141-V	26	628	714	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 10	1993	74	5					929	937		10.1016/0092-8674(93)90472-3	http://dx.doi.org/10.1016/0092-8674(93)90472-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LX292	8104103				2022-12-28	WOS:A1993LX29200018
J	MITCHISON, TJ				MITCHISON, TJ			LOCALIZATION OF AN EXCHANGEABLE GTP-BINDING SITE AT THE PLUS END OF MICROTUBULES	SCIENCE			English	Article							MECHANISM; DYNAMICS; TUBULINS; INVITRO	Microtubule polarity arises from the head-to-tall orientation of alpha-beta tubulin heterodimers in the microtubule lattice. The identity of the polypeptide at each end of the microtubule is unknown, but structural models predict that the beta-tubulin end contains an exchangeable guanosine triphosphate (GTP) binding site. When GTP-coated fluorescent beads were incubated with microtubules, they bound specifically to plus ends, suggesting that tubulin is oriented in microtubules with beta-tubulin toward the plus end.			MITCHISON, TJ (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA.				NIGMS NIH HHS [GM-39565] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM039565, R01GM039565] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMOS LA, 1974, J CELL SCI, V14, P523; BEESE L, 1987, J MOL BIOL, V194, P257, DOI 10.1016/0022-2836(87)90373-1; BERGEN LG, 1980, J CELL BIOL, V84, P151, DOI 10.1083/jcb.84.1.151; BURNS RG, 1991, CELL MOTIL CYTOSKEL, V20, P181, DOI 10.1002/cm.970200302; CAPLOW M, 1990, J BIOL CHEM, V265, P8935; CARLIER MF, 1989, INT REV CYTOL, V115, P139; GELFAND VI, 1991, ANNU REV CELL BIOL, V7, P93, DOI 10.1146/annurev.cb.07.110191.000521; HYMAN A, 1991, METHOD ENZYMOL, V196, P478; HYMAN AA, 1991, J CELL SCI, P125; JACKSON RJ, 1973, BIOCHEM BIOPH RES CO, V51, P428, DOI 10.1016/0006-291X(73)91275-8; Kirschner M W, 1978, Int Rev Cytol, V54, P1, DOI 10.1016/S0074-7696(08)60164-3; MANDELKOW E, 1989, CELL MOVEMENT, V2, P23; MANDELKOW EM, 1985, J MOL BIOL, V181, P123, DOI 10.1016/0022-2836(85)90330-4; NATH JP, 1985, BIOCHEMISTRY-US, V24, P1555, DOI 10.1021/bi00327a040; Oakley B R, 1992, Trends Cell Biol, V2, P1, DOI 10.1016/0962-8924(92)90125-7; VALLEE RB, 1990, ANNU REV BIOCHEM, V59, P909, DOI 10.1146/annurev.biochem.59.1.909; WALKER RA, 1989, J CELL BIOL, V108, P931, DOI 10.1083/jcb.108.3.931; WEISENBERG RC, 1968, BIOCHEMISTRY-US, V7, P4466, DOI 10.1021/bi00852a043	18	138	141	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 20	1993	261	5124					1044	1047		10.1126/science.8102497	http://dx.doi.org/10.1126/science.8102497			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LT747	8102497				2022-12-28	WOS:A1993LT74700034
J	HUGHES, GRV				HUGHES, GRV			THE ANTIPHOSPHOLIPID SYNDROME - 10 YEARS ON	LANCET			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS; ANTICARDIOLIPIN ANTIBODIES; ANTI-CARDIOLIPIN; ASSOCIATION; DISEASE; THROMBOSIS; INFARCTION; ANTICOAGULANT; PREVALENCE				HUGHES, GRV (corresponding author), ST THOMAS HOSP,LUPUS ARTHRIT RES UNIT,LONDON SE1 7EH,ENGLAND.							ALARCONSEGOVIA D, 1989, MEDICINE, V68, P353, DOI 10.1097/00005792-198911000-00003; AMIGO MC, 1992, J RHEUMATOL, V19, P1181; ASHERSON RA, 1993, J RHEUMATOL, V20, P284; ASHERSON RA, 1986, CLIN RHEUMATOL, V5, P102, DOI 10.1007/BF02030977; ASHERSON RA, 1989, MEDICINE, V68, P366, DOI 10.1097/00005792-198911000-00004; ASHERSON RA, 1991, ANN RHEUM DIS, V50, P805, DOI 10.1136/ard.50.11.805; ASHERSON RA, 1989, BRIT J DERMATOL, V120, P215; ASHERSON RA, 1987, ANN RHEUM DIS, V46, P605, DOI 10.1136/ard.46.8.605; ASHERSON RA, 1992, J RHEUMATOL, V19, P508; ASHERSON RA, 1987, SEMIN ARTHRITIS RHEU, V16, P253, DOI 10.1016/0049-0172(87)90003-5; ASHERSON RA, 1986, J RHEUMATOL, V12, P416; ASHERSON RA, 1989, ANN RHEUM DIS, V16, P378; BEVERS EM, 1992, LUPUS, V1, P51, DOI 10.1177/096120339200100201; BUCHANAN NMM, 1992, AM J REPROD IMMUNOL, V28, P192, DOI 10.1111/j.1600-0897.1992.tb00789.x; CERVERA R, 1991, LUPUS, V1, P43, DOI 10.1177/096120339100100108; DERUE GJ, 1985, J OBSTET GYNAECOL, V5, P207, DOI 10.3109/01443618509067758; GALLI M, 1990, LANCET, V335, P1544, DOI 10.1016/0140-6736(90)91374-J; GHARAVI AE, 1992, LUPUS S1, V1, P150; GLUCK I, 1985, ARCH INTERN MED, V145, P1389; HAMSTEN A, 1986, LANCET, V1, P113; HARRIS EN, 1984, CLIN EXP RHEUMATOL, V2, P47; HARRIS EN, 1985, J CLIN LAB IMMUNOL, V17, P155; HARRIS EN, 1987, CLIN EXP IMMUNOL, V68, P215; HARRIS EN, 1985, BRIT J HAEMATOL, V59, P231, DOI 10.1111/j.1365-2141.1985.tb02989.x; HARRIS EN, 1983, LANCET, V2, P1211; HARRIS EN, 1991, PHOSPHOLIPID BINDING; HAYSLETT JP, 1992, AM J REPROD IMMUNOL, V28, P199, DOI 10.1111/j.1600-0897.1992.tb00791.x; HERRANZ MT, IN PRESS ARTHRITIS R; HUGHES GRV, 1983, BRIT MED J, V287, P1088, DOI 10.1136/bmj.287.6399.1088; HUGHES GRV, 1986, J RHEUMATOL, V13, P486; HUGHES GRV, 1984, CLIN EXP DERMATOL, V9, P535, DOI 10.1111/j.1365-2230.1984.tb00856.x; HUNT JE, 1993, P NATL ACAD SCI USA, V90, P2141, DOI 10.1073/pnas.90.6.2141; ICHIKAWA K, 1993, ARTHRITIS RHEUM, V35, pS69; KANT KS, 1981, MEDICINE, V60, P71, DOI 10.1097/00005792-198103000-00001; KHAMASHTA MA, 1993, J CLIN PATHOL, V46, P104, DOI 10.1136/jcp.46.2.104; KHAMASHTA MA, 1990, LANCET, V335, P1541, DOI 10.1016/0140-6736(90)91373-I; KINKAIDSMITH P, 1988, Q J MED, V69, P795; MACKWORTHYOUNG CG, 1984, EUR J RHEUMATOL INFL, V7, P71; MCNEIL HP, 1990, P NATL ACAD SCI USA, V87, P4120, DOI 10.1073/pnas.87.11.4120; MONTALBAN J, 1991, STROKE, V22, P751; NENCINI P, 1992, STROKE, V23, P189, DOI 10.1161/01.STR.23.2.189; PELLETIER S, 1992, ARTHRITIS RHEUM, V35, pS238; VAARALA O, 1993, LANCET, V341, P923, DOI 10.1016/0140-6736(93)91213-6; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; XU QB, 1993, LANCET, V341, P255, DOI 10.1016/0140-6736(93)92613-X	45	612	631	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 7	1993	342	8867					341	344		10.1016/0140-6736(93)91477-4	http://dx.doi.org/10.1016/0140-6736(93)91477-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ868	8101587				2022-12-28	WOS:A1993LQ86800015
J	BLACKWELL, AL; THOMAS, PD; WAREHAM, K; EMERY, SJ				BLACKWELL, AL; THOMAS, PD; WAREHAM, K; EMERY, SJ			HEALTH GAINS FROM SCREENING FOR INFECTION OF THE LOWER GENITAL-TRACT IN WOMEN ATTENDING FOR TERMINATION OF PREGNANCY	LANCET			English	Article							PELVIC INFLAMMATORY DISEASE; CHLAMYDIA-TRACHOMATIS INFECTION; 1ST TRIMESTER ABORTION; NON-SPECIFIC VAGINITIS; THERAPEUTIC-ABORTION; BACTERIAL VAGINOSIS; DOUBLE-BLIND; METRONIDAZOLE; FLORA	Infection of the upper genital tract after abortion is well recognised, but routine screening for infection before termination is rare, and few centres are aware of the prevalence of post-abortion complications in their population. We undertook a study to assess the prevalence and sequelae of genital-tract infection in patients undergoing termination of pregnancy and to estimate the costs and potential benefits of introducing screening and prophylaxis for the most commonly found organisms. The study in Swansea, UK, was of 401 consecutive patients attending for termination of pregnancy; only 1 patient refused to take part. Immediately before the termination procedure vaginal and cervical swabs were taken for microscopic examination and culture of Trichomonas vaginalis, Neisseria gonorrhoeae, and candida species. We sought Chlamydia trachomatis by enzyme-linked immunosorbent assay. 112 (28%) women had the typical bacterial flora of anaerobic (bacterial) vaginosis, 95 (24%) had candidal infection, 32 (8%) chlamydial infection, 3 (0.75%) trichomonas infection, and 1 (0.25%) gonorrhoea. Postoperative follow-up of 30 of the women with chlamydial infection showed that pelvic infection developed in 19 (63%), of whom 7 were readmitted to hospital. 9 male partners of women with chlamydial (plus gonococcal in 1 case) infection were examined; 8 were symptom-free, 3 had C trachomatis infection, and 1 N gonorrhoeae. Estimated costs of hospital admissions for complications of chlamydial infection were more than double the costs of providing a routine chlamydia screening programme and prophylactic treatment. Screening for chlamydial infection before termination of pregnancy is essential. Prophylactic treatment for both chlamydial infection and anaerobic vaginosis should also be considered. Male partners of women infected with chlamydia are often symptom-free, but they must be traced to avoid reinfections.	SINGLETON HOSP TRUST,PUBL HLTH LAB SERV,SWANSEA SA2 8QA,WALES; SINGLETON HOSP TRUST,DEPT OBSTET & GYNAECOL,SWANSEA SA2 8QA,WALES; MORRISTON HOSP,SCH POSTGRAD STUDIES MED & HLTH CARE,SWANSEA,W GLAM,WALES	Singleton Hospital; Singleton Hospital; Morriston Hospital; Swansea University	BLACKWELL, AL (corresponding author), SINGLETON HOSP TRUST,DEPT GENITOURINARY MED,SWANSEA SA2 8QA,WALES.							BLACKWELL A, 1982, BRIT J VENER DIS, V58, P387; BLACKWELL AL, 1983, LANCET, V2, P1379; CATES W, 1990, EPIDEMIOL REV, V12, P199, DOI 10.1093/oxfordjournals.epirev.a036054; DUTHIE SJ, 1987, GENITOURIN MED, V63, P183; FISH ANJ, 1989, EUR J OBSTET GYN R B, V31, P67, DOI 10.1016/0028-2243(89)90027-0; GUIJON F, 1992, INT J GYNECOL OBSTET, V37, P185, DOI 10.1016/0020-7292(92)90379-W; HEISTERBERG L, 1985, OBSTET GYNECOL, V65, P371; HILLIER SL, 1992, OBSTET GYNECOL, V79, P369, DOI 10.1097/00006250-199203000-00008; HILLIER SL, 1992, AM J OBSTET GYNECOL, V166, P938, DOI 10.1016/0002-9378(92)91368-K; LARSSON PG, 1989, ACTA OBSTET GYN SCAN, V68, P217, DOI 10.3109/00016348909020992; LARSSON PG, 1992, AM J OBSTET GYNECOL, V166, P100, DOI 10.1016/0002-9378(92)91838-2; MARTIUS J, 1990, ARCH GYNECOL OBSTET, V247, P1, DOI 10.1007/BF02390649; MAZULLI T, 1990, J CLIN MICROBIOL, V28, P1506; MOLLER BR, 1982, OBSTET GYNECOL, V59, P210; MORTON K, 1990, EUR J OBSTET GYN R B, V37, P231, DOI 10.1016/0028-2243(90)90029-Z; PETERSON HB, 1990, MED CLIN N AM, V74, P1603, DOI 10.1016/S0025-7125(16)30497-7; QVIGSTAD E, 1983, BRIT J VENER DIS, V59, P189; RIDGWAY GL, 1983, BRIT MED J, V286, P1478, DOI 10.1136/bmj.286.6376.1478-a; SCHULTZ R, 1991, BRIT MED J, V303, P1369, DOI 10.1136/bmj.303.6814.1369; SHIOOTZ H, 1985, ANN CLIN RES, V17, P60; SKJELDESTAD FE, 1988, ACTA OBSTET GYN SCAN, V67, P525, DOI 10.3109/00016348809029864; SPIEGEL CA, 1989, CLIN LAB MED, V9, P525, DOI 10.1016/S0272-2712(18)30616-4; THIN RN, 1989, GENITOURIN MED, V65, P157; VEJTORP M, 1988, BRIT J OBSTET GYNAEC, V95, P920, DOI 10.1111/j.1471-0528.1988.tb06581.x; WESTROM L, 1987, CONTRACEPTION, V36, P111, DOI 10.1016/0010-7824(87)90064-3; WOOD SM, 1989, LANCET, V2, P928; 1991, SEX TRANSM DIS, V18, P46; 1991, REPORT RCOG WORKING	28	112	114	1	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 24	1993	342	8865					206	210		10.1016/0140-6736(93)92299-9	http://dx.doi.org/10.1016/0140-6736(93)92299-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN622	8100930				2022-12-28	WOS:A1993LN62200012
J	ROBINSON, MHE; BERRY, DP; VELLACOTT, KD; MOSHAKIS, V; HARDCASTLE, JD				ROBINSON, MHE; BERRY, DP; VELLACOTT, KD; MOSHAKIS, V; HARDCASTLE, JD			SCREENING FOR COLORECTAL-CANCER	LANCET			English	Letter							CONTROLLED TRIAL		GEORGE ELLIOT HOSP,DEPT SURG,NUNEATON,WARWICK,ENGLAND; ROYAL GWENT HOSP,DEPT SURG,NEWPORT NPT-2VB,GWENT,WALES; UNIV HOSP WALES,DEPT SURG,CARDIFF,WALES	Royal Gwent Hospital; Cardiff University	ROBINSON, MHE (corresponding author), UNIV NOTTINGHAM HOSP,DEPT SURG,NOTTINGHAM NG7 2UH,ENGLAND.							ATKIN, 1993, LANCET, V341, P736; ATKIN, 1993, LANCET, V341, P1667; FOLEY DP, 1987, GUT, V28, pA1367; HARDCASTLE JD, 1989, LANCET, V1, P1160; HOFF G, 1985, SCAND J GASTROENTERO, V20, P351, DOI 10.3109/00365528509091663; KEWENTER J, 1988, CANCER, V62, P645, DOI 10.1002/1097-0142(19880801)62:3<645::AID-CNCR2820620333>3.0.CO;2-#; KRONBORG O, 1987, SCAND J GASTROENTERO, V22, P677, DOI 10.3109/00365528709011142; ROBINSON MHE, 1993, GUT, V34, pS40	8	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 24	1993	342	8865					241	241		10.1016/0140-6736(93)92332-N	http://dx.doi.org/10.1016/0140-6736(93)92332-N			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN622	8100960				2022-12-28	WOS:A1993LN62200042
J	BRYCE, J; CUTTS, F; NAIMOLI, JF; BEESLEY, M				BRYCE, J; CUTTS, F; NAIMOLI, JF; BEESLEY, M			WHAT HAVE TEACHERS LEARNT	LANCET			English	Editorial Material							HEALTH PERSONNEL		SAVE CHILDREN FUND,LONDON,ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED,LONDON WC1E 7HT,ENGLAND	Save the Children; University of London; London School of Hygiene & Tropical Medicine	BRYCE, J (corresponding author), CTR DIS CONTROL & PREVENT,INT HLTH PROGRAM OFF,DIV TECH SUPPORT,SOCIAL & BEHAV SCI BRANCH,F-03,ATLANTA,GA 30333, USA.							BOSSERT TJ, 1990, SOC SCI MED, V30, P1015, DOI 10.1016/0277-9536(90)90148-L; BRYCE J, 1992, HEALTH POLICY PLANN, V7, P155, DOI 10.1093/heapol/7.2.155; BRYCE J, 1990, 116TH AM PUBL HLTH A; CASSELS A, 1991, HDB FACILITATORS; FOSTER SO, 1990, JAMA-J AM MED ASSOC, V263, P3303, DOI 10.1001/jama.263.24.3303; FULOP T, 1986, WHO CHRON, V40, P194; FULOP T, 1986, WHO CHRON, V40, P222; KANLISI N, 1991, TROP DOCT, V21, P98, DOI 10.1177/004947559102100303; Laing R., 1989, Health Policy and Planning, V4, P229, DOI 10.1093/heapol/4.3.229; Lynton R. P., 1978, TRAINING DEV; MBURU FM, 1979, SOC SCI MED-MED SOC, V13, P577, DOI 10.1016/0271-7123(79)90100-7; Simmonds S, 1989, Health Policy Plan, V4, P187, DOI 10.1093/heapol/4.3.187; 1989, UN DEV PROGRAM, P12	13	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 17	1993	342	8864					160	161		10.1016/0140-6736(93)91352-M	http://dx.doi.org/10.1016/0140-6736(93)91352-M			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LN042	8101261				2022-12-28	WOS:A1993LN04200018
J	BUNKER, CB; REAVLEY, C; OSHAUGHNESSY, DJ; DOWD, PM				BUNKER, CB; REAVLEY, C; OSHAUGHNESSY, DJ; DOWD, PM			CALCITONIN-GENE-RELATED PEPTIDE IN TREATMENT OF SEVERE PERIPHERAL VASCULAR INSUFFICIENCY IN RAYNAUDS-PHENOMENON	LANCET			English	Article							CONGESTIVE-HEART-FAILURE; HUMAN-SKIN; BLOOD-FLOW; NEUROPEPTIDES; VASODILATOR; HISTAMINE	Calcitonin gene-related peptide (CGRP) is a potent vasodilator that may be involved in the regulation of the peripheral circulation and in its response to cold. There is evidence that CGRP in digital cutaneous perivascular nerves is deficient in Raynaud's phenomenon. Our pilot study of intravenous CGRP suggested that this substance is beneficial in patients with Raynaud's phenomenon; here we have extended our studies. Ten patients with severe Raynaud's phenomenon secondary to connective tissue disease were randomly assigned to groups receving intravenous CGRP (0.6 mug/min for 3 h per day on 5 days) or saline. Hand and digital blood flow and skin temperature were measured by thermocouple and laser doppler flowmetry. Blood flow was significantly (p < 0.05) increased by CGRP in both hands (median blood flow after infusion as percentage of baseline reading 179 [range 100-355]%) and fingers (149 [100-161]%); saline had no effect (hands 102 [84-123]%, fingers 96 [81-113]%). Hand temperature was increased more by CGRP than by saline (2.8 [1.5-4.0] vs 1.0 [-1.0 to 2.5]-degrees-C, p < 0.05). Digital temperature increased after CGRP but the difference between the treatment groups in temperature rise was not significant, perhaps because saline caused increases in some patients. All ulcers healed in four of five CGRP-treated patients but in no saline-treated patients. Thus intravenous CGRP effectively dilates the compromised digital cutaneous vasculature in severe Raynaud's phenomenon.	UNIV COLL & MIDDLESEX SCH MED,MIDDLESEX HOSP,DEPT DERMATOL,LONDON W1N 8AA,ENGLAND; CELLTECH LTD,SLOUGH,ENGLAND	University of London; University College London; Celltech Group Ltd				Bunker, Christopher/0000-0002-6693-7483				Allen EV, 1932, AM J MED SCI, V183, P187, DOI 10.1097/00000441-193202000-00004; ANAND IS, 1991, J AM COLL CARDIOL, V17, P208, DOI 10.1016/0735-1097(91)90729-S; BRAIN SD, 1988, NATURE, V335, P73, DOI 10.1038/335073a0; BULL HA, 1989, J INVEST DERMATOL, V92, P409; BUNKER CB, 1991, J INVEST DERMATOL, V96, P314, DOI 10.1111/1523-1747.ep12465175; BUNKER CB, 1990, LANCET, V336, P1530, DOI 10.1016/0140-6736(90)93307-B; BUNKER CB, 1992, THESIS U CAMBRIDGE; COFFMAN JD, 1989, RAYNAUDS PHENOMENON, P127; DALSGAARD CJ, 1989, HISTOCHEMISTRY, V91, P35, DOI 10.1007/BF00501907; DIPETTE DJ, 1987, HYPERTENSION, V9, P142; DOWD PM, 1986, BRIT J DERMATOL, V114, P527, DOI 10.1111/j.1365-2133.1986.tb04059.x; EMESON RB, 1989, NATURE, V341, P76, DOI 10.1038/341076a0; FRANCOCERECEDA A, 1987, CIRC RES, V60, P393, DOI 10.1161/01.RES.60.3.393; GENNARI C, 1990, CARDIOVASC RES, V24, P239, DOI 10.1093/cvr/24.3.239; GENNARI C, 1985, CALCIFIED TISSUE INT, V37, P581, DOI 10.1007/BF02554909; HOLLOWAY GA, 1977, J INVEST DERMATOL, V69, P306, DOI 10.1111/1523-1747.ep12507665; HOWDEN CW, 1988, CLIN SCI, V74, P413, DOI 10.1042/cs0740413; JOHNSTON FG, 1990, LANCET, V335, P869, DOI 10.1016/0140-6736(90)90473-I; MACDONALD NJ, 1989, BRIT J CLIN PHARMACO, V28, P257, DOI 10.1111/j.1365-2125.1989.tb05424.x; MCEWAN J, 1986, CIRCULATION, V74, P1243, DOI 10.1161/01.CIR.74.6.1243; OHALLORAN DJ, 1991, BMJ-BRIT MED J, V302, P739, DOI 10.1136/bmj.302.6779.739; PIOTROWSKI W, 1986, BRIT J DERMATOL, V114, P37, DOI 10.1111/j.1365-2133.1986.tb02777.x; Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee, 1980, ARTHRITIS RHEUM, V23, P581; RADEMAKER M, 1989, BRIT MED J, V298, P561, DOI 10.1136/bmj.298.6673.561; SHAWKET S, 1989, LANCET, V2, P1354; SHEKHAR YC, 1991, AM J CARDIOL, V67, P732, DOI 10.1016/0002-9149(91)90531-O; STRUTHERS AD, 1986, CLIN SCI, V70, P389, DOI 10.1042/cs0700389; THOM SM, 1987, BRIT J CLIN PHARMACO, V24, P139, DOI 10.1111/j.1365-2125.1987.tb03154.x; UREN NG, 1990, EUR HEART J SUPPL, V11, P1070; WALLENGREN J, 1987, ACTA DERM-VENEREOL, V67, P185	30	57	58	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 10	1993	342	8863					80	83		10.1016/0140-6736(93)91286-U	http://dx.doi.org/10.1016/0140-6736(93)91286-U			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LL789	8100913				2022-12-28	WOS:A1993LL78900010
J	SHANN, F				SHANN, F			AUSTRALIAN VIEW OF PEDIATRIC INTENSIVE-CARE IN BRITAIN	LANCET			English	Editorial Material											SHANN, F (corresponding author), ROYAL CHILDRENS HOSP,PAEDIAT INTENS CARE UNIT,PARKVILLE,VIC 3052,AUSTRALIA.		Shann, Frank/C-9510-2011					EDGE WE, 1992, CRIT CARE MED, V20, pS38; FARLEY DE, 1992, MED CARE, V30, P77, DOI 10.1097/00005650-199201000-00009; POLLACK MM, 1988, CRIT CARE MED, V16, P11, DOI 10.1097/00003246-198801000-00003; POLLACK MM, 1991, CRIT CARE MED, V19, P150, DOI 10.1097/00003246-199102000-00007; RAMSEY CB, 1993, TXB PEDIATRIC CRITIC, P1108; REYNOLDS HN, 1988, JAMA-J AM MED ASSOC, V260, P3446, DOI 10.1001/jama.260.23.3446; YEH TS, 1992, CRIT CARE CLIN, V8, P23, DOI 10.1016/S0749-0704(18)30265-3; 1987, REPORT WORKING PARTY; 1982, MANAGEMENT SERIOUSLY	9	19	19	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 10	1993	342	8863					68	68		10.1016/0140-6736(93)91282-Q	http://dx.doi.org/10.1016/0140-6736(93)91282-Q			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LL789	8100909				2022-12-28	WOS:A1993LL78900006
J	DIANTONIO, A; PARFITT, KD; SCHWARZ, TL				DIANTONIO, A; PARFITT, KD; SCHWARZ, TL			SYNAPTIC TRANSMISSION PERSISTS IN SYNAPTOTAGMIN MUTANTS OF DROSOPHILA	CELL			English	Article							BINDING; PROTEIN; P65; MELANOGASTER; SECRETION; DOMAIN; CELLS; LOCUS; GAP	Synaptotagmin is one of the major integral membrane proteins of synaptic vesicles. It has been postulated to dock vesicles to their release sites, to act as the Ca2+ sensor for the release process, and to be a fusion protein during exocytosis. To clarify the function of this protein, we have undertaken a genetic analysis of the synaptotagmin gene in Drosophila. We have identified five lethal alleles of synaptotagmin, at least one of which lacks detectable protein. Surprisingly, however, many embryos homozygous for this null allele hatch and, as larvae, crawl, feed, and respond to stimuli. Electrophysiological recordings in embryonic cultures confirmed that synaptic transmission persists in the null allele. Therefore, synaptotagmin is not absolutely required for the regulated exocytosis of synaptic vesicles. The lethality of synaptotagmin in late first instar larvae is probably due to a perturbation of transmission that leaves the main apparatus for vesicle docking and fusion intact.			DIANTONIO, A (corresponding author), STANFORD UNIV,MED CTR,DEPT MOLEC & CELLULAR PHYSIOL,STANFORD,CA 94305, USA.			DiAntonio, Aaron/0000-0002-7262-0968	NIGMS NIH HHS [5T32 GM07365] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007365] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHBURNER M, 1989, DROSOPHILA LABORATOR; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BROADIE KS, 1993, J NEUROSCI, V13, P144; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; COUTEAUX R, 1973, ARCH ITAL BIOL, V3, P231; ELFERINK LA, 1993, CELL, V72, P153, DOI 10.1016/0092-8674(93)90059-Y; GEPPERT M, 1991, J BIOL CHEM, V266, P13548; GERST JE, 1992, P NATL ACAD SCI USA, V89, P4338, DOI 10.1073/pnas.89.10.4338; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; JAN LY, 1976, J PHYSIOL-LONDON, V262, P189, DOI 10.1113/jphysiol.1976.sp011592; JESSELL TM, 1993, CELL 72 NEURON S, V10, P1; JOHANSEN J, 1989, J NEUROSCI, V9, P710; JOHNSTON PA, 1991, NEURON, V7, P101, DOI 10.1016/0896-6273(91)90078-E; LEVEQUE C, 1992, P NATL ACAD SCI USA, V89, P3625, DOI 10.1073/pnas.89.8.3625; Marty A., 1983, SINGLE CHANNEL RECOR, P107; MOCHLYROSEN D, 1992, BIOCHEMISTRY-US, V31, P8120, DOI 10.1021/bi00150a003; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; PERIN MS, 1991, J BIOL CHEM, V266, P615; PERIN MS, 1991, J BIOL CHEM, V266, P623; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; PETRENKO AG, 1991, NATURE, V353, P65, DOI 10.1038/353065a0; ROBINOW S, 1988, DEV BIOL, V126, P294, DOI 10.1016/0012-1606(88)90139-X; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SCHWARZ TL, 1990, NEURON, V2, P119; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SHIRATAKI K, 1993, MOL CELL BIOL, V13, P2061; SHOJIKASAI Y, 1992, SCIENCE, V256, P1820, DOI 10.1126/science.256.5065.1820; SORSA V, 1988, CHROMOSOMA MAPS DROS; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WENDLAND B, 1991, NEURON, V6, P993, DOI 10.1016/0896-6273(91)90239-V	33	236	239	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 2	1993	73	7					1281	1290		10.1016/0092-8674(93)90356-U	http://dx.doi.org/10.1016/0092-8674(93)90356-U			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology	LL209	8100740	Bronze			2022-12-28	WOS:A1993LL20900005
J	STLOUIS, ME; KAMENGA, M; BROWN, C; NELSON, AM; MANZILA, T; BATTER, V; BEHETS, F; KABAGABO, U; RYDER, RW; OXTOBY, M; QUINN, TC; HEYWARD, WL				STLOUIS, ME; KAMENGA, M; BROWN, C; NELSON, AM; MANZILA, T; BATTER, V; BEHETS, F; KABAGABO, U; RYDER, RW; OXTOBY, M; QUINN, TC; HEYWARD, WL			RISK FOR PERINATAL HIV-1 TRANSMISSION ACCORDING TO MATERNAL IMMUNOLOGICAL, VIROLOGICAL, AND PLACENTAL FACTORS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ACQUIRED IMMUNODEFICIENCY; SEROPOSITIVE MOTHERS; PREGNANT-WOMEN; INFECTION; TYPE-1; INFANTS; CELLS; AIDS; CHORIOAMNIONITIS	Objective.-To evaluate how maternal and obstetric factors interact to influence mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission. Design.-Prospective, observational cohort study of children born to HIV-infected women to determine child's HIV infection status. The analysis then compared peripartum maternal, placental, and obstetric variables between HIV-1 transmitter and nontransmitter women. Setting.-Two large maternity wards in Kinshasa, Zaire. Participants.-Consecutive sample of 324 HIV-1-infected women at delivery, with 254 HIV-seronegative women followed up as control subjects. Principal Outcome Measures.-HIV infection status of children, to classify each woman as an HIV-1 transmitter or nontransmitter. Results.-The highest transmission risk (TR) was associated with maternal p24 antigenemia (TR, 71 %; relative risk [RR], 3.0; 95% confidence interval [CI], 1.7 to 5.2) and maternal CD8+ lymphocyte counts of at least 1.80 X 10(9)/L (1800/muL) (TR, 50%; RR, 2.2; 95% CI, 1.2 to 4.2). Among women with CD8+ lymphocyte counts of less than 1.80 X 10(9)/L, CD4+ lymphocyte counts of less than 0.60 x 10(9)/L were a risk factor (TR, 29%; RR, 2.2; 95% CI, 1.2 to 4.2). In women with neither high CD8+ nor low CD4+ lymphocyte counts, placental membrane inflammation was associated with perinatal transmission (TR, 40%; RR, 4.2; 95% CI, 1.3 to 13.7). In women with neither p24 antigenemia, high CD8+ or low CD4+ lymphocyte counts, nor placental membrane inflammation, the transmission risk was only 7%. Additional correlates of transmission included maternal anemia and fever, but not maternal sexually transmitted diseases. Conclusions.-Identifiable subgroups of HIV-1-infected women based on maternal and placental characteristics had between a 7% and 71% risk of perinatal HIV-1 transmission. Not only the overall rate of transmission but the impact of different risk factors for transmission appear to vary over the course of HIV infection.	PROJET SIDA, KINSHASA, DEM REP CONGO; NIAID, BETHESDA, MD 20892 USA; ARMED FORCES INST PATHOL, WASHINGTON, DC 20306 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); United States Department of Defense	STLOUIS, ME (corresponding author), CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, DIV HIV AIDS, 1600 CLIFTON RD, MAILSTOP E-50, ATLANTA, GA 30333 USA.		Quinn, Thomas/A-2494-2010					ALIMENTI A, 1992, J INFECT DIS, V166, P1146, DOI 10.1093/infdis/166.5.1146; BELL SJD, 1992, CLIN IMMUNOL IMMUNOP, V64, P254, DOI 10.1016/0090-1229(92)90208-6; Blanc W A, 1981, Monogr Pathol, P67; BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; BLANCHE S, 1990, AM J DIS CHILD, V144, P1210, DOI 10.1001/archpedi.1990.02150350042021; BLANCO JD, 1983, J INFECT DIS, V147, P650, DOI 10.1093/infdis/147.4.650; BROWN C, 1991, AIDS, V5, P89, DOI 10.1097/00002030-199101000-00013; BRYSON YJ, 1992, NEW ENGL J MED, V327, P1246, DOI 10.1056/NEJM199210223271718; BURGARD M, 1992, NEW ENGL J MED, V327, P1192, DOI 10.1056/NEJM199210223271702; CAMERON DW, 1989, LANCET, V2, P403; CHANDWANI S, 1991, J INFECT DIS, V163, P1134, DOI 10.1093/infdis/163.5.1134; CLERICI M, 1992, P NATL ACAD SCI USA, V89, P8424, DOI 10.1073/pnas.89.18.8424; CLIFFORD SH, 1954, J PEDIATR-US, V44, P1, DOI 10.1016/S0022-3476(54)80085-0; COLEBUNDERS R, 1987, LANCET, V1, P492; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; DINSMOOR MJ, 1992, AM J OBSTET GYNECOL, V167, P1575, DOI 10.1016/0002-9378(92)91743-T; EHRNST A, 1991, LANCET, V338, P203, DOI 10.1016/0140-6736(91)90347-R; FOX H, 1978, PATHOLOGY PLACENTA, P286; GOEDERT JJ, 1991, LANCET, V338, P1471, DOI 10.1016/0140-6736(91)92297-F; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; GOEDERT JJ, 1989, LANCET, V2, P1351; GUZICK DS, 1985, OBSTET GYNECOL, V65, P11; HALSEY NA, 1990, JAMA-J AM MED ASSOC, V264, P2088, DOI 10.1001/jama.264.16.2088; HANDSFIELD HH, 1973, JAMA-J AM MED ASSOC, V225, P697; HERZENBERG LA, 1979, P NATL ACAD SCI USA, V76, P1453, DOI 10.1073/pnas.76.3.1453; HILLIER SL, 1988, NEW ENGL J MED, V319, P972, DOI 10.1056/NEJM198810133191503; HIRA SK, 1990, J PEDIATR-US, V117, P421, DOI 10.1016/S0022-3476(05)81084-4; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HUNZIKER RD, 1984, J IMMUNOL, V133, P667; HUTTO C, 1991, J PEDIATR-US, V118, P347, DOI 10.1016/S0022-3476(05)82145-6; JAUNIAUX E, 1988, PLACENTA, V9, P633, DOI 10.1016/0143-4004(88)90007-0; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; LANG W, 1989, J ACQ IMMUN DEF SYND, V2, P63; LEWIS SH, 1990, LANCET, V335, P565, DOI 10.1016/0140-6736(90)90349-A; MARTIN AW, 1992, HUM PATHOL, V23, P411, DOI 10.1016/0046-8177(92)90088-K; MAYERS MM, 1991, PEDIATRICS, V88, P1248; MERCER BM, 1992, AM J OBSTET GYNECOL, V166, P794, DOI 10.1016/0002-9378(92)91336-9; MIOTTI PG, 1992, J INFECT DIS, V165, P1116, DOI 10.1093/infdis/165.6.1116; MUSHER DM, 1990, ANN INTERN MED, V113, P872, DOI 10.7326/0003-4819-113-11-872; NELSON AM, 1991, MAR ANN M US CAN AC; NEWELL ML, 1992, LANCET, V339, P1007; OU CY, 1990, AIDS RES HUM RETROV, V6, P1323, DOI 10.1089/aid.1990.6.1323; OXTOBY MJ, 1990, PEDIATR INFECT DIS J, V9, P609; POLLACK H, 1990, 30TH INT C ANT AG CH; PRINCE HE, 1991, J ACQ IMMUN DEF SYND, V4, P1227; QUINN TC, 1993, J INFECT DIS, V167, P1193, DOI 10.1093/infdis/167.5.1193; QUINN TC, 1987, JAMA-J AM MED ASSOC, V257, P2617, DOI 10.1001/jama.257.19.2617; ROGERS MF, 1989, NEW ENGL J MED, V320, P1649, DOI 10.1056/NEJM198906223202503; ROSSI P, 1989, P NATL ACAD SCI USA, V86, P8055, DOI 10.1073/pnas.86.20.8055; RYDER RW, 1989, NEW ENGL J MED, V320, P1637, DOI 10.1056/NEJM198906223202501; SEAGE GR, 1989, AM J PUBLIC HEALTH, V79, P1638, DOI 10.2105/AJPH.79.12.1638; SIEGAL FP, 1981, NEW ENGL J MED, V305, P1439, DOI 10.1056/NEJM198112103052403; STEIN DS, 1992, J INFECT DIS, V165, P352, DOI 10.1093/infdis/165.2.352; TAYLOR JMG, 1989, J ACQ IMMUN DEF SYND, V2, P114; VANDEPERRE P, 1991, NEW ENGL J MED, V325, P593, DOI 10.1056/NEJM199108293250901; VORHERR H, 1975, AM J OBSTET GYNECOL, V123, P67, DOI 10.1016/0002-9378(75)90951-5; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; 1990, BMDP STATISTICAL SOF; 1985, SAS PROCEDURES GUIDE	59	246	251	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 9	1993	269	22					2853	2859		10.1001/jama.269.22.2853	http://dx.doi.org/10.1001/jama.269.22.2853			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE936	8098783				2022-12-28	WOS:A1993LE93600020
J	HAUSSINGER, D; ROTH, E; LANG, F; GEROK, W				HAUSSINGER, D; ROTH, E; LANG, F; GEROK, W			CELLULAR HYDRATION STATE - AN IMPORTANT DETERMINANT OF PROTEIN CATABOLISM IN HEALTH AND DISEASE	LANCET			English	Article							RAT SKELETAL-MUSCLE; GLUTAMINE; INJURY; NUTRITION; TURNOVER; PLASMA; SEPSIS; WATER	There is evidence that cellular hydration state is an important factor controlling cellular protein turnover, protein synthesis and protein degradation are affected in opposite directions by cell swelling and shrinking. An increase in cellular hydration (swelling) acts as an anabolic proliferative signal, whereas cell shrinkage is catabolic and antiproliferative. The cellular hydration state is mainly determined by the activity of ion and substrate transport systems in the plasma membrane. Hormones, substrates, and oxidative stress can change the cellular hydration state within minutes, thereby affecting protein turnover. We postulate that a decrease in cellular hydration in liver and skeletal muscle triggers the protein catabolic states that accompany various diseases.	UNIV VIENNA,CHIRURG KLIN,A-1010 VIENNA,AUSTRIA; UNIV TUBINGEN,INST PHYSIOL,W-7400 TUBINGEN 1,GERMANY	University of Vienna; Eberhard Karls University of Tubingen	HAUSSINGER, D (corresponding author), UNIV FREIBURG,MED KLIN,HUGSTETTERSTR 55,W-7800 FREIBURG,GERMANY.							BERGSTROM J, 1974, J APPL PHYSIOL, V36, P693, DOI 10.1152/jappl.1974.36.6.693; BERGSTROM JP, 1987, ACTA CHIR SCAND, V153, P261; CUNNINGHAM JN, 1971, J CLIN INVEST, V50, P49, DOI 10.1172/JCI106483; ELWYN DH, 1975, ANN SURG, V182, P76, DOI 10.1097/00000658-197507000-00015; FURST P, 1990, JPEN-PARENTER ENTER, V14, pS118, DOI 10.1177/014860719001400417; HALLBRUCKER C, 1993, EUR J BIOCHEM, V211, P449, DOI 10.1111/j.1432-1033.1993.tb17570.x; HAUSSINGER D, 1992, TRENDS PHARMACOL SCI, V13, P371, DOI 10.1016/0165-6147(92)90114-L; HAUSSINGER D, 1991, BIOCHIM BIOPHYS ACTA, V1071, P331, DOI 10.1016/0304-4157(91)90001-D; HAUSSINGER D, 1990, EUR J BIOCHEM, V188, P689, DOI 10.1111/j.1432-1033.1990.tb15451.x; HAUSSINGER D, 1991, FEBS LETT, V283, P470; JAMES JH, 1990, METABOLISM, V39, P335, DOI 10.1016/0026-0495(90)90245-8; JEPSON MM, 1988, AM J PHYSIOL, V255, pE155; KARNER J, 1981, J PARENT EUR NUTR, V5, P102; MACLENNAN PA, 1988, FEBS LETT, V237, P133, DOI 10.1016/0014-5793(88)80186-8; MORTIMORE GE, 1987, ANNU REV NUTR, V7, P539, DOI 10.1146/annurev.nu.07.070187.002543; RENNIE MJ, 1986, LANCET, V2, P1008; RENNIE MJ, 1985, BRIT MED BULL, V41, P257, DOI 10.1093/oxfordjournals.bmb.a072060; ROTH E, 1990, JPEN-PARENTER ENTER, V14, pS130, DOI 10.1177/014860719001400419; Roth E, 1982, Clin Nutr, V1, P25, DOI 10.1016/0261-5614(82)90004-8; ROTH E, 1985, CLIN CHEM, V31, P1305; ROTH E, 1984, ADV HEPATIC ENCEPHAL, P527; SMITH R, 1983, TRENDS BIOCHEM SCI, V4, P142; STOLL B, 1992, BIOCHEM J, V287, P217, DOI 10.1042/bj2870217; TRACEY KJ, 1986, J EXP MED, V164, P1368, DOI 10.1084/jem.164.4.1368; VONDAHL S, 1991, BIOCHEM J, V280, P105; WATFORD M, 1989, TRENDS BIOCHEM SCI, V14, P1, DOI 10.1016/0968-0004(89)90074-1; WILKINSON HW, 1976, METABOLISM RESPONSE	27	360	365	3	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 22	1993	341	8856					1330	1332		10.1016/0140-6736(93)90828-5	http://dx.doi.org/10.1016/0140-6736(93)90828-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD253	8098459				2022-12-28	WOS:A1993LD25300015
J	WHITE, D; WALLWORK, J				WHITE, D; WALLWORK, J			XENOGRAFTING - PROBABILITY, POSSIBILITY, OR PIPE DREAM	LANCET			English	Editorial Material											WHITE, D (corresponding author), UNIV CAMBRIDGE,IMUTRAN LABS,CAMBRIDGE,ENGLAND.							CALNE RY, 1979, LANCET, V2, P1033; CARY N, 1993, TRANSPLANT P, V25, P400; COOPER DKC, 1993, LANCET, V342, P682, DOI 10.1016/0140-6736(93)91791-J; DALMASSO AP, 1991, TRANSPLANTATION, V52, P530, DOI 10.1097/00007890-199109000-00029; GORE SM, 1989, BRIT MED J, V299, P1193, DOI 10.1136/bmj.299.6709.1193; HASAN RIR, 1993, TRANSPLANT P, V25, P421; JAMES A, 1993, LANCET, V342, P45; KEMP E, 1982, TRANSPLANT P, V14, P116; OGLESBY TJ, 1992, J EXP MED, V175, P1547, DOI 10.1084/jem.175.6.1547; REEMTSMA K, 1964, ANN SURG, V160, P384, DOI 10.1097/00000658-196409000-00006	10	42	43	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 9	1993	342	8876					879	880		10.1016/0140-6736(93)91939-J	http://dx.doi.org/10.1016/0140-6736(93)91939-J			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA963	8105160				2022-12-28	WOS:A1993MA96300003
J	BRITTON, J				BRITTON, J			TOLERANCE TO BETA-AGONISTS IN ASTHMA THERAPY	LANCET			English	Editorial Material							HYPERRESPONSIVENESS; SALBUTAMOL				BRITTON, J (corresponding author), CITY HOSP NOTTINGHAM,RESP MED UNIT,NOTTINGHAM NG5 1PD,ENGLAND.		Britton, John R/G-9705-2011					CHEUNG D, 1992, NEW ENGL J MED, V327, P1198, DOI 10.1056/NEJM199210223271703; HARVEY JE, 1982, THORAX, V37, P280, DOI 10.1136/thx.37.4.280; OCONNOR BJ, 1992, NEW ENGL J MED, V327, P1204, DOI 10.1056/NEJM199210223271704; REISMAN RE, 1970, J ALLERGY, V46, P162, DOI 10.1016/0021-8707(70)90095-X; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; TAYLOR DR, 1993, THORAX, V48, P134, DOI 10.1136/thx.48.2.134; TAYLOR IK, 1993, RESP MED, V87, P261, DOI 10.1016/0954-6111(93)90022-R; VANSCHAYCK CP, 1990, J ALLERGY CLIN IMMUN, V86, P793, DOI 10.1016/S0091-6749(05)80185-X; VANSCHAYCK CP, 1991, BRIT MED J, V303, P1426, DOI 10.1136/bmj.303.6815.1426; VATHENEN AS, 1988, LANCET, V1, P554; WAHEDNA I, IN PRESS AM REV RESP; 1991, GUIDELINES DIAGNOSIS; 1993, BMJ, V306, P776	13	6	6	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 2	1993	342	8875					818	819		10.1016/0140-6736(93)92691-L	http://dx.doi.org/10.1016/0140-6736(93)92691-L			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA025	8104268				2022-12-28	WOS:A1993MA02500005
J	TAN, K; BETTERIDGE, DJ; MARMOT, MG; TALMUD, P; HUMPHRIES, SE; YUDKIN, JS				TAN, K; BETTERIDGE, DJ; MARMOT, MG; TALMUD, P; HUMPHRIES, SE; YUDKIN, JS			HYPERTRIGLYCERIDEMIA AND VASCULAR RISK - REPORT OF A MEETING OF PHYSICIANS AND SCIENTISTS, UNIVERSITY-COLLEGE-LONDON MEDICAL-SCHOOL	LANCET			English	Discussion							CORONARY HEART-DISEASE; LOW-DENSITY-LIPOPROTEIN; PLASMINOGEN-ACTIVATOR INHIBITOR-1; PLASMA FACTOR-VII; MYOCARDIAL-INFARCTION; ARTERY DISEASE; INSULIN RESISTANCE; HEPATIC LIPASE; MEN; CHOLESTEROL		UCL, SCH MED,DEPT MED,G BLOCK,ARCHWAY WING, ARCHWAY WING, LONDON N19 3UA, ENGLAND; UNIV LONDON UNIV COLL, MIDDLESEX HOSP, SCH MED, DEPT MED, LONDON WC1E 6BT, ENGLAND; UNIV LONDON UNIV COLL, DEPT EPIDEMIOL & PUBL HLTH, LONDON WC1E 6BT, ENGLAND; UNIV LONDON UNIV COLL, RAYNE INST, DIV CARDIOVAS GERIATR, LONDON WC1E 6BT, ENGLAND	University of London; University College London; UCL Medical School; University of London; University College London; UCL Medical School; University of London; University College London; University of London; King's College London; University College London			Talmud, Philippa J/C-4402-2008; Yudkin, John S/C-1988-2008; Marmot, M G/Y-3920-2019	Marmot, M G/0000-0002-2431-6419; Talmud, Philippa/0000-0002-5560-1933	Medical Research Council [G8802774] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		[Anonymous], 1992, NUTR METAB CARDIOVAS, V2, P113; ASSMANN G, 1992, AM J CARDIOL, V70, P733, DOI 10.1016/0002-9149(92)90550-I; ASSMANN G, 1991, AM J CARDIOL, V68, pA30, DOI 10.1016/0002-9149(91)90858-I; AUSTIN MA, 1988, AM J HUM GENET, V43, P838; AUSTIN MA, 1990, CIRCULATION, V82, P495, DOI 10.1161/01.CIR.82.2.495; BABIRAK SP, 1992, ARTERIOSCLER THROMB, V12, P1176, DOI 10.1161/01.ATV.12.10.1176; BAINTON D, 1992, BRIT HEART J, V68, P60; BETTERIDGE DJ, 1993, POSTGRAD MED J, V69, P359, DOI 10.1136/pgmj.69.811.359; CARLSON LA, 1988, ACTA MED SCAND, V223, P405; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; DAWSON S, 1991, ARTERIOSCLER THROMB, V11, P183, DOI 10.1161/01.ATV.11.1.183; DEGRAAF J, 1991, ARTERIOSCLER THROMB, V11, P298, DOI 10.1161/01.ATV.11.2.298; FONTBONNE A, 1989, DIABETOLOGIA, V32, P300, DOI 10.1007/BF00265546; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; GOTTO AM, 1991, AM J CARDIOL, V68, pA11, DOI 10.1016/0002-9149(91)90853-D; GRAY RP, 1993, BRIT HEART J, V69, P228; GRAY RP, IN PRESS BR HEART J; GREEN F, 1991, ARTERIOSCLER THROMB, V11, P540, DOI 10.1161/01.ATV.11.3.540; HALL WH, 1993, JAMA-J AM MED ASSOC, V269, P505; HAMSTEN A, 1987, LANCET, V2, P3; HAMSTEN A, 1985, NEW ENGL J MED, V313, P1557, DOI 10.1056/NEJM198512193132501; HENNEY AM, 1992, 13TH ISTH C AMST, V94, P43; HULLEY SB, 1980, NEW ENGL J MED, V302, P1383, DOI 10.1056/NEJM198006193022503; ITO Y, 1990, SCIENCE, V249, P790, DOI 10.1126/science.2167514; JOHANSSON J, 1991, ATHEROSCLEROSIS, V86, P111, DOI 10.1016/0021-9150(91)90207-J; KARPE F, 1993, ARTERIOSCLER THROMB, V13, P11, DOI 10.1161/01.ATV.13.1.11; KRAUSS RM, 1982, J LIPID RES, V23, P97; KRAUSS RM, 1987, LANCET, V2, P62; KRAUSS RM, 1991, CURR OPIN LIPIDOL, V2, P248; Mahley Jr RWRS, 1989, METABOLIC BASIS INHE, P1195; MANNINEN V, 1992, CIRCULATION, V85, P37, DOI 10.1161/01.CIR.85.1.37; MCKEIGUE PM, 1991, LANCET, V337, P382, DOI 10.1016/0140-6736(91)91164-P; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; MEILAHN E, 1992, 32ND ANN C CARD DIS; MENSINK RP, 1987, LANCET, V1, P122, DOI 10.1016/S0140-6736(87)91965-9; MILLER GJ, 1986, ATHEROSCLEROSIS, V60, P269, DOI 10.1016/0021-9150(86)90174-7; MILLER GJ, 1991, ATHEROSCLEROSIS, V86, P163, DOI 10.1016/0021-9150(91)90212-L; MILLER GJ, 1985, BRIT J HAEMATOL, V59, P249, DOI 10.1111/j.1365-2141.1985.tb02991.x; ORDOVAS JM, 1991, ATHEROSCLEROSIS, V87, P75, DOI 10.1016/0021-9150(91)90234-T; PATSCH JR, 1987, J CLIN INVEST, V80, P341, DOI 10.1172/JCI113078; PETO R, 1985, CIRCULATION, V72, P451; PHILLIPS AN, 1991, J CLIN EPIDEMIOL, V44, P1223, DOI 10.1016/0895-4356(91)90155-3; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; SMITH GD, 1993, BMJ-BRIT MED J, V306, P1367, DOI 10.1136/bmj.306.6889.1367; STIKORAHM A, 1990, ARTERIOSCLEROSIS, V10, P1067, DOI 10.1161/01.ATV.10.6.1067; TAN KCB, 1992, DIABETOLOGIA S1, V35, P168; TAN KCB, 1993, ATHEROSCLEROSIS, V98, P118; WILSON DE, 1990, J CLIN INVEST, V86, P735, DOI 10.1172/JCI114770; WOJCIECHOWSKI AP, 1991, NATURE, V349, P161, DOI 10.1038/349161a0; YUDKIN JS, 1993, BMJ-BRIT MED J, V306, P1313, DOI 10.1136/bmj.306.6888.1313; ZILVERSMIT DB, 1979, CIRCULATION, V60, P473, DOI 10.1161/01.CIR.60.3.473	51	41	40	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 25	1993	342	8874					781	787		10.1016/0140-6736(93)91544-V	http://dx.doi.org/10.1016/0140-6736(93)91544-V			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LY868	8103879				2022-12-28	WOS:A1993LY86800013
J	MANSFIELD, S; SINGH, S				MANSFIELD, S; SINGH, S			WHO SHOULD FILL THE CARE GAP IN HIV DISEASE	LANCET			English	Editorial Material							GENERAL-PRACTITIONER; INFECTION; AIDS; ATTITUDES		ROYAL FREE HOSP,SCH MED,DEPT PUBL HLTH & PRIMARY CARE,ROWLAND HILL ST,LONDON NW3 2PF,ENGLAND; WESTMINSTER MED SCH & HOSP,LONDON SW1P 2AP,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Imperial College London								ANDERSON P, 1988, BRIT MED J, V296, P535, DOI 10.1136/bmj.296.6621.535; BARTON S, 1992, BRIT MED J, V305, P902, DOI 10.1136/bmj.305.6859.902; BOYTON R, 1988, BRIT MED J, V296, P538, DOI 10.1136/bmj.296.6621.538; HASLAR J, 1984, CONTINUING CARE MANA; HIGGINSON I, 1991, HLTH TRENDS, V23, P59; KING E, 1992, HIV PREVENTION GAY M; KING MB, 1988, BRIT MED J, V297, P182, DOI 10.1136/bmj.297.6642.182; LANDE R, 1989, ROLE GP CARE PEOPLE; MANSFIELD S, 1992, INT J STD AIDS, V3, P248, DOI 10.1177/095646249200300403; MANSFIELD SJ, 1989, J ROY COLL GEN PRACT, V39, P104; MILNE RIG, 1988, BMJ, V296, P280; PINCHING AJ, 1989, AIDS S1, V3, P209; SHAPIRO J, 1991, BR J GEN PRACT, V41, P401; Singh S, 1991, Health Trends, V23, P55; SINGH S, 1990, IN PRESS BR J GEN PR; SMITS A, 1990, BRIT MED J, V300, P241, DOI 10.1136/bmj.300.6719.241; STRANG J, 1992, BMJ, V304, P1129; WADSWORTH E, 1992, BRIT J GEN PRACT, V42, P107; 1992 REPORT MINISTER; 1992, C REPORT ROLE GENERA	20	16	17	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 18	1993	342	8873					726	728						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX469	8103828				2022-12-28	WOS:A1993LX46900015
J	MICHAEL, AE; GREGORY, L; WALKER, SM; ANTONIW, JW; SHAW, RW; EDWARDS, CRW; COOKE, BA				MICHAEL, AE; GREGORY, L; WALKER, SM; ANTONIW, JW; SHAW, RW; EDWARDS, CRW; COOKE, BA			OVARIAN 11-BETA-HYDROXYSTEROID DEHYDROGENASE - POTENTIAL PREDICTOR OF CONCEPTION BY IN-VITRO FERTILIZATION AND EMBRYO-TRANSFER	LANCET			English	Note							FLUID	Cortisol is converted to the inactive glucocorticoid, cortisone, in several tissues by 11beta-hydroxysteroid dehydrogenase (11betaHSD). We have recently measured 11betaHSD activity in cultured human granulosa-lutein cells recovered from patients undergoing in-vitro fertilisation and embryo transfer (IVF-ET). We now report an association between the outcome of IVF-ET and 11betaHSD activity in these cells. Of the 64 patients studied, 32 had detectable 11betaHSD activity and none became pregnant; whereas 76% of the remaining ''11betaHSD-negative'' patients achieved pregnancies. Hence 11betaHSD activity may predict the outcome of IVF-ET.	ROYAL FREE HOSP,SCH MED,DEPT BIOCHEM,ROWLAND HILL ST,LONDON NW3 2PF,ENGLAND; UNIV HOSP WALES,ACAD DEPT OBSTET & GYNAECOL,FERTIL UNIT,CARDIFF,WALES; UNIV EDINBURGH,WESTERN GEN HOSP,DEPT MED,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Cardiff University; University of Edinburgh								ANDERSEN CY, 1990, J CLIN ENDOCR METAB, V71, P1375, DOI 10.1210/jcem-71-5-1375; BENEDIKTSSON R, 1992, J ENDOCRINOL, V135, P53, DOI 10.1677/joe.0.1350053; FATEH M, 1989, FERTIL STERIL, V51, P538; LAKSHMI V, 1985, ENDOCRINOLOGY, V116, P552, DOI 10.1210/endo-116-2-552; MICHAEL AE, 1993, CLIN ENDOCRINOL, V38, P641, DOI 10.1111/j.1365-2265.1993.tb02147.x; MURPHY BEP, 1981, J STEROID BIOCHEM, V14, P811; TANNIN GM, 1991, J BIOL CHEM, V266, P16653	7	63	65	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 18	1993	342	8873					711	712		10.1016/0140-6736(93)91710-4	http://dx.doi.org/10.1016/0140-6736(93)91710-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX469	8103824				2022-12-28	WOS:A1993LX46900011
J	SEREMETIS, SV; ALEDORT, LM; BERGMAN, GE; BONA, R; BRAY, G; BRETTLER, D; EYSTER, ME; KESSLER, C; LAU, TS; LUSHER, J; RICKLES, F				SEREMETIS, SV; ALEDORT, LM; BERGMAN, GE; BONA, R; BRAY, G; BRETTLER, D; EYSTER, ME; KESSLER, C; LAU, TS; LUSHER, J; RICKLES, F			3-YEAR RANDOMIZED STUDY OF HIGH-PURITY OR INTERMEDIATE-PURITY FACTOR-VIII CONCENTRATES IN SYMPTOM-FREE HIV-SEROPOSITIVE HEMOPHILIACS - EFFECTS ON IMMUNE STATUS	LANCET			English	Article							INFECTED HEMOPHILIACS; VIRUS; CELLS; ACTIVATION; COMPONENT	The availability of monoclonal-antibody-purified factor VIII (FVIII) concentrates allows us to test the hypothesis, based on in vitro observations, that their use in HIV seropositive haemophiliacs would result in a difference in the rate of deterioration of immune function. We designed a multicentre, prospective, randomised, controlled study of symptom-free HIV-infected patients with haemophilia A who were assigned to receive either an intermediate-purity or monoclonal-antibody-purified product. All had CD4 lymphocyte counts of 100-600/muL, were negative for hepatitis B surface antigen, had not received any antiretroviral or immunomodulating drugs before study entry, and had previously received replacement therapy with intermediate purity FVIII concentrates. Use of antiretroviral therapy was permitted. 60 patients were recruited and 30 were assigned to each group. 35 completed the 3 year study, 20 in the monoclonal arm and 15 in the intermediate-purity arm. Among those completing the study, there were no differences between the two groups in the occurrence of AIDS-defining diagnoses (1 in each group). There were, however, striking and significant differences in terms of changes in absolute CD4 counts. The group receiving monoclonal-antibody-purified concentrates had essentially stable counts while a significant drop was observed in the group receiving intermediate-purity FVIII. These differences were independent of the use of antiretroviral therapy. These observations support the use of high-purity concentrates in the treatment of symptom-free HIV-positive patients with haemophilia A, and they should be taken into account along with cost, by doctors making therapeutic decisions.	ARMOUR PHARMACEUT CO,COLLEGEVILLE,PA; UNIV CONNECTICUT,SCH MED,FARMINGTON,CT 06032; GEORGE WASHINGTON UNIV,MED CTR,WASHINGTON,DC 20037; MED CTR CENT MASSACHUSETTS,WORCESTER,MA; PENN STATE UNIV,MILTON S HERSHEY MED CTR,MED CTR,HERSHEY,PA 17033; WAYNE STATE UNIV,SCH MED,DETROIT,MI 48201	University of Connecticut; George Washington University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Wayne State University	SEREMETIS, SV (corresponding author), CUNY MT SINAI SCH MED,NEW YORK,NY 10029, USA.			, M. Elaine Eyster/0000-0001-8248-6793				ABOULKER JP, 1993, LANCET, V341, P889, DOI 10.1016/0140-6736(93)93096-J; BRETTLER DB, 1989, BLOOD, V73, P1859; BRETTLER DB, 1989, BLOOD, V73, P2067; DEBIASI R, 1991, BLOOD, V78, P1918; EIBL MM, 1987, BLOOD, V69, P1153; EYSTER ME, 1987, ANN INTERN MED, V107, P1, DOI 10.7326/0003-4819-107-1-1; FLEISS JL, 1986, DESIGN ANAL CLIN EXP, P220; FUKUTAKE K, 1990, 19TH INT C WORLD FED; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; GOLDSMITH JM, 1991, THROMB HAEMOSTASIS, V66, P415; HILGARTNER MW, 1993, LANCET, V341, P1373, DOI 10.1016/0140-6736(93)90943-B; MADHOK R, 1991, BRIT J HAEMATOL, V79, P235, DOI 10.1111/j.1365-2141.1991.tb04527.x; MANNUCCI PM, 1990, RES CLIN LAB, V20, P227; MANNUCCI PM, 1992, THROMB HAEMOSTASIS, V67, P310; MARGOLICK JB, 1987, J IMMUNOL, V138, P1719; OBRIEN PC, 1978, BIOMETRICS, V34, P243, DOI 10.2307/2530014; SCHREIBER AB, 1988, SEMIN HEMATOL, V25, P27; SCHULMAN S, 1989, BIOTECHNOLOGY PROMIS, V8, P21; SEREMENTIS SV, 1990, BLOOD S, V76, pA408; THROPE R, 1989, BRIT J HAEMATOL, V71, P387; VERMOTDESROCHES C, 1992, BRIT J HAEMATOL, V80, P370, DOI 10.1111/j.1365-2141.1992.tb08147.x; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; 1993, MMWR, V41, P1	23	79	79	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 18	1993	342	8873					700	703		10.1016/0140-6736(93)91706-R	http://dx.doi.org/10.1016/0140-6736(93)91706-R			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX469	8103820				2022-12-28	WOS:A1993LX46900007
J	CORTELLARO, M; COFRANCESCO, E; BOSCHETTI, C				CORTELLARO, M; COFRANCESCO, E; BOSCHETTI, C			CARDIOLIPIN ANTIBODIES IN SURVIVORS OF MYOCARDIAL-INFARCTION	LANCET			English	Editorial Material							ANTIPHOSPHOLIPID ANTIBODIES				CORTELLARO, M (corresponding author), UNIV MILAN,IST MED INTERNA MALATTIE INFETT & IMMUNOPATOL,I-20122 MILAN,ITALY.							CORTELLARO M, 1992, LANCET, V339, P929, DOI 10.1016/0140-6736(92)90966-7; HAMSTEN A, 1986, LANCET, V1, P113; PHADKE KV, 1993, BRIT HEART J, V69, P391; SLETNES KE, 1992, LANCET, V339, P451, DOI 10.1016/0140-6736(92)91057-F; TRIPLETT DA, 1993, ARCH PATHOL LAB MED, V117, P78	5	2	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 24	1993	342	8865					192	192		10.1016/0140-6736(93)92294-4	http://dx.doi.org/10.1016/0140-6736(93)92294-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN622	8100926				2022-12-28	WOS:A1993LN62200007
J	GUILLOU, PJ				GUILLOU, PJ			BIOLOGICAL VARIATION IN THE DEVELOPMENT OF SEPSIS AFTER SURGERY OR TRAUMA	LANCET			English	Article							SEVERELY INJURED PATIENTS; HUMAN-MONOCYTES; GAMMA; INFECTION; MECHANISMS; EXPRESSION; DEATH				GUILLOU, PJ (corresponding author), IMPERIAL COLL SCI TECHNOL & MED,ST MARYS HOSP,SCH MED,ACAD SURG UNIT,LONDON W2 1NY,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAIGRIE RJ, 1992, BRIT J SURG, V79, P757, DOI 10.1002/bjs.1800790813; BAKER CC, 1980, AM J SURG, V140, P144, DOI 10.1016/0002-9610(80)90431-6; BUCKLE AM, 1989, J IMMUNOL, V143, P2295; BUFFONE V, 1984, ARCH SURG-CHICAGO, V119, P39; CAINZOS M, 1989, BRIT J SURG, V76, P169, DOI 10.1002/bjs.1800760222; Carey PD, 1992, BRIT J SURG, V79, P1223; CHRISTOU NV, 1982, SURGERY, V92, P786; CHRISTOU NV, 1989, ANN SURG, V210, P69, DOI 10.1097/00000658-198907000-00011; CRUICKSHANK AM, 1990, CLIN SCI, V79, P161, DOI 10.1042/cs0790161; DOHERTY GM, 1992, CYTOKINE, V4, P55, DOI 10.1016/1043-4666(92)90037-R; DUIGNAN JP, 1986, BRIT J SURG, V73, P238, DOI 10.1002/bjs.1800730328; FAIST E, 1988, ARCH SURG-CHICAGO, V123, P287; FELICIANO DV, 1987, ARCH SURG-CHICAGO, V122, P679; FIFE D, 1988, AM J SURG, V155, P278, DOI 10.1016/S0002-9610(88)80713-X; GREEN DR, 1988, IMMUNOL TODAY, V9, P253, DOI 10.1016/0167-5699(88)91300-X; HERSHMAN MJ, 1990, BRIT J SURG, V77, P204, DOI 10.1002/bjs.1800770225; HERSHMAN MJ, 1988, INJURY, V19, P263, DOI 10.1016/0020-1383(88)90042-3; KINNAERT P, 1989, WORLD J SURG, V13, P478, DOI 10.1007/BF01660762; LENNARD TWJ, 1985, BRIT J SURG, V72, P771, DOI 10.1002/bjs.1800721002; MARSHALL J, 1990, ARCH SURG-CHICAGO, V125, P17; MILLERGRAZIANO CL, 1988, ARCH SURG-CHICAGO, V123, P293; MOORE FA, 1990, SURGERY, V103, P667; PARREN PWHI, 1992, J CLIN INVEST, V90, P1537, DOI 10.1172/JCI116022; POLK HC, 1992, AM J SURG, V163, P191, DOI 10.1016/0002-9610(92)90099-D; POLK HC, 1986, ANN SURG, V204, P282; PULLICINO EA, 1990, LYMPHOKINE RES, V9, P321; SALMON JE, 1992, J CLIN INVEST, V89, P1274, DOI 10.1172/JCI115712; SANTAMARIA P, 1989, J IMMUNOL, V143, P913; SEDMAN PC, 1988, BRIT J SURG, V75, P976, DOI 10.1002/bjs.1800751012; SOLOMKIN JS, 1985, ARCH SURG-CHICAGO, V120, P93; UTOH J, 1988, BRIT J SURG, V75, P682, DOI 10.1002/bjs.1800750719; WAKEFIELD CH, 1993, ARCH SURG-CHICAGO, V128, P390; WAKEFIELD CH, 1993, BRIT J SURG, V80, P205, DOI 10.1002/bjs.1800800224; WAKEFIELD CH, 1992, BRIT J SURG, V79, P1225; WAYDHAS C, 1992, ARCH SURG-CHICAGO, V127, P460; WINDSOR ACJ, 1993, BRIT J SURG, V80, P10, DOI 10.1002/bjs.1800800106	36	96	97	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 24	1993	342	8865					217	220		10.1016/0140-6736(93)92303-B	http://dx.doi.org/10.1016/0140-6736(93)92303-B			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN622	8100934				2022-12-28	WOS:A1993LN62200016
J	GRISSO, JA				GRISSO, JA			MAKING COMPARISONS	LANCET			English	Article							POST-MENOPAUSAL WOMEN; HIV-INFECTION; POPULATIONS; RISK				GRISSO, JA (corresponding author), UNIV PENN,CTR CLIN EPIDEMIOL & BIOSTAT,317R NURSING EDUC BLDG 6095,PHILADELPHIA,PA 19104, USA.							BONGAARTS J, 1989, AIDS, V3, P373, DOI 10.1097/00002030-198906000-00006; COBB LA, 1959, NEW ENGL J MED, V260, P1115, DOI 10.1056/NEJM195905282602204; Fletcher RH, 1988, CLIN EPIDEMIOLOGY ES, V2nd; HARDY AM, 1985, JAMA-J AM MED ASSOC, V253, P215, DOI 10.1001/jama.253.2.215; HENDERSON DK, 1990, ANN INTERN MED, V113, P740, DOI 10.7326/0003-4819-113-10-740; JAFFE HW, 1983, ANN INTERN MED, V99, P145, DOI 10.7326/0003-4819-99-2-145; Kelsey JL, 1986, METHODS OBSERVATIONA; KREIGER N, 1982, AM J EPIDEMIOL, V116, P141, DOI 10.1093/oxfordjournals.aje.a113388; Lytle B W, 1991, Cardiovasc Clin, V21, P265; McGoon D C, 1987, Cardiovasc Clin, V17, pxvii; MERTENS TE, 1990, AIDS, V4, P57, DOI 10.1097/00002030-199001000-00008; Michael M, 1984, BIOMEDICAL BESTIARY; MURPHY ML, 1977, NEW ENGL J MED, V297, P621, DOI 10.1056/NEJM197709222971201; SACKS H, 1982, AM J MED, V72, P233, DOI 10.1016/0002-9343(82)90815-4; STROM BL, 1986, TRENDS PHARMACOL SCI, V7, P377, DOI 10.1016/0165-6147(86)90391-3; Strom BL, 1989, PHARMACOEPIDEM DR S, P13; WEN CP, 1983, J OCCUP ENVIRON MED, V25, P283; WILLIAMS AR, 1982, OBSTET GYNECOL, V60, P695; 1981, MMWR, V30, P305; 1981, MMWR, V30, P25	20	14	15	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 17	1993	342	8864					157	160		10.1016/0140-6736(93)91351-L	http://dx.doi.org/10.1016/0140-6736(93)91351-L			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN042	8101260	hybrid			2022-12-28	WOS:A1993LN04200017
J	MURRAY, LS; TEASDALE, GM; MURRAY, GD; JENNETT, B; MILLER, JD; PICKARD, JD; SHAW, MDM; ACHILLES, J; BAILEY, S; JONES, P; KELLY, D; LACEY, J				MURRAY, LS; TEASDALE, GM; MURRAY, GD; JENNETT, B; MILLER, JD; PICKARD, JD; SHAW, MDM; ACHILLES, J; BAILEY, S; JONES, P; KELLY, D; LACEY, J			DOES PREDICTION OF OUTCOME ALTER PATIENT-MANAGEMENT	LANCET			English	Article							SEVERE HEAD-INJURY; DECISIONS; JUDGMENT; SURVIVAL; SYSTEM	A patient's prognosis is a key factor for the clinicians involved in management. We set out to determine if provision of computer-based predictions of outcome after severe head injury resulted in measurable changes in patient management. In particular, we wondered whether introduction of the predictive system would alter the relation between severity of injury and ''intensity'' of management. 1025 patients admitted to four British neurosurgical units between 1986 and 1989 following a severe head injury, and who were either in coma for 6 h or had an operation for acute intracranial haematoma, were studied. Specified aspects of intensive management were recorded and all patients were followed up after six months. The study had three phases: a baseline period of at least one year before the introduction of computer-based outcome prediction, one year when predictions were provided at specified times, and a final six months when prediction was withdrawn. While predictions were being provided, there was an increase in the use of specified aspects of intensive care in patients predicted to have a good outcome, but a 39% reduction in the use of these same aspects of intensive care in patients predicted to have the worst outcome. There was no evidence that the provision of predictions affected overall outcome, length of stay, or the recording of explicit decisions to limit treatment. We have demonstrated that the introduction of a routine prediction service can alter patient management.	UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,WESSEX NEUROL CTR,SOUTHAMPTON S09 4XY,ENGLAND; WALTON HOSP,WALTON CTR NEUROL & NEUROSURG NHS TRUST,LIVERPOOL L9 1AE,MERSEYSIDE,ENGLAND; UNIV GLASGOW,WESTERN INFIRM,DEPT SURG,GLASGOW G11 6NT,SCOTLAND; UNIV EDINBURGH,WESTERN GEN HOSP,DEPT CLIN NEUROSCI,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND	University of Southampton; Walton Centre; University of Glasgow; University of Edinburgh	MURRAY, LS (corresponding author), UNIV GLASGOW,SO GEN HOSP,DEPT NEUROSURG,GLASGOW G51 4TF,SCOTLAND.			Murray, Gordon/0000-0001-9866-4734				ADAMS ID, 1986, BRIT MED J, V293, P800, DOI 10.1136/bmj.293.6550.800; BARLOW P, 1986, NEUROSURGERY, V19, P989, DOI 10.1227/00006123-198612000-00014; BARLOW P, 1987, MED APPL MICROCOMPUT, P105; CHANG RWS, 1989, CRIT CARE MED, V17, P1091, DOI 10.1097/00003246-198911000-00001; COHEN H, 1977, NEW ENGL J MED, V297, P1182; DAWES RM, 1989, SCIENCE, V243, P1668, DOI 10.1126/science.2648573; DEDOMBAL FT, 1987, J MED ETHICS, V13, P179, DOI 10.1136/jme.13.4.179; FELDMAN Z, 1991, LANCET, V337, P1451, DOI 10.1016/0140-6736(91)93137-X; GIBSON RM, 1989, LANCET, V2, P369; HARARI RJ, 1992, J NEUROSURG, V76, pA397; IMBUS SH, 1977, NEW ENGL J MED, V297, P308, DOI 10.1056/NEJM197708112970605; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1980, J NEUROL NEUROSUR PS, V43, P289, DOI 10.1136/jnnp.43.4.289; JENNETT B, 1976, LANCET, V1, P1031; JENNETT WB, 1984, BRIT MED J, V289, P1209; KAUFMANN MA, 1992, RESUSCITATION, V23, P199, DOI 10.1016/0300-9572(92)90003-U; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1990, MED DECIS MAKING, V10, P163, DOI 10.1177/0272989X9001000303; MURRAY GD, 1986, STAT MED, V5, P403, DOI 10.1002/sim.4780050504; Spiegelhalter D J, 1983, Stat Med, V2, P207, DOI 10.1002/sim.4780020215; STABLEIN DM, 1980, NEUROSURGERY, V6, P243; TITTERINGTON DM, 1981, J ROY STAT SOC A STA, V144, P145, DOI 10.2307/2981918; WELLWOOD J, 1992, ANN R COLL SURG ENGL, V74, P140; WYATT J, 1989, 6TH P WORLD C MED IN, P111	24	108	114	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 12	1993	341	8859					1487	1491		10.1016/0140-6736(93)90631-P	http://dx.doi.org/10.1016/0140-6736(93)90631-P			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LG242	8099377				2022-12-28	WOS:A1993LG24200001
J	ROBERTS, JM; REDMAN, CWG				ROBERTS, JM; REDMAN, CWG			PREECLAMPSIA - MORE THAN PREGNANCY-INDUCED HYPERTENSION	LANCET			English	Article							MATERNAL MORTALITY; REMOTE PROGNOSIS; PREECLAMPSIA; WOMEN		JOHN RADCLIFFE HOSP,NUFFIELD DEPT OBSTET & GYNAECOL,OXFORD OX3 9DU,ENGLAND	University of Oxford	ROBERTS, JM (corresponding author), UNIV PITTSBURGH,MAGEE WOMENS HOSP,DEPT OBSTET GYNECOL & REPROD SCI,FORBES AVE,PITTSBURGH,PA 15213, USA.		Roberts, James/AAI-3283-2020	Roberts, James/0000-0002-2671-3207				ASSALI NS, 1950, J CLIN INVEST, V29, P1354, DOI 10.1172/JCI102373; AUGENSEN K, 1984, ACTA OBSTET GYN SCAN, V63, P115, DOI 10.3109/00016348409154645; AUGUST P, 1990, AM J OBSTET GYNECOL, V163, P1612, DOI 10.1016/0002-9378(90)90639-O; BRANCH DW, 1992, PROSTAG LEUKOTR ESS, V45, P191, DOI 10.1016/0952-3278(92)90112-V; BRANCH DW, 1991, LANCET, V337, P943, DOI 10.1016/0140-6736(91)91572-C; Brosens I A, 1972, Obstet Gynecol Annu, V1, P177; CHESLEY LC, 1980, KIDNEY INT, V18, P234, DOI 10.1038/ki.1980.131; COMBS A, IN PRESS AM J OBSTET; COOPER DW, 1988, BRIT J OBSTET GYNAEC, V95, P644, DOI 10.1111/j.1471-0528.1988.tb06524.x; DEBOER K, 1989, AM J OBSTET GYNECOL, V160, P95, DOI 10.1016/0002-9378(89)90096-3; ENDRESEN MJ, 1992, AM J OBSTET GYNECOL, V167, P440, DOI 10.1016/S0002-9378(11)91426-4; FISHER KA, 1981, MEDICINE, V60, P267, DOI 10.1097/00005792-198107000-00002; FRIEDMAN SA, 1988, OBSTET GYNECOL, V71, P122; GALLERY EDM, 1980, PREGNANCY HYPERTENSI; GANT NF, 1973, J CLIN INVEST, V52, P2682, DOI 10.1172/JCI107462; GIFFORD RW, 1990, AM J OBSTET GYNECOL, V163, P1691; KAUNITZ AM, 1985, OBSTET GYNECOL, V65, P605; KHONG TY, 1986, BRIT J OBSTET GYNAEC, V93, P1049, DOI 10.1111/j.1471-0528.1986.tb07830.x; KITZMILL.JL, 1973, AM J OBSTET GYNECOL, V115, P248, DOI 10.1016/0002-9378(73)90293-7; MALEE MP, 1992, J CLIN ENDOCR METAB, V74, P1095, DOI 10.1210/jc.74.5.1095; RAMSEY E M, 1966, Carnegie Institution of Washington Publication, V38, P59; REDMAN CWG, 1978, BRIT MED J, V1, P467, DOI 10.1136/bmj.1.6111.467; Roberts J.M., 1989, MATERNAL FETAL MED P, P777; ROBERTS JM, 1989, AM J OBSTET GYNECOL, V161, P1200, DOI 10.1016/0002-9378(89)90665-0; ROBERTS JM, 1991, AM J HYPERTENS, V4, P700, DOI 10.1093/ajh/4.8.700; ROBERTS JM, 1992, AM J REPROD IMMUNOL, V27, P101, DOI 10.1111/j.1600-0897.1992.tb00735.x; SPARGO BH, 1976, HYPERTENS PREGNANCY, P129; TAYLOR RN, 1991, AM J OBSTET GYNECOL, V165, P1705, DOI 10.1016/0002-9378(91)90019-N; TAYLOR RN, 1990, J CLIN ENDOCR METAB, V71, P1675, DOI 10.1210/jcem-71-6-1675; TAYLOR RN, 1991, AM J OBSTET GYNECOL, V165, P895, DOI 10.1016/0002-9378(91)90435-T; TSUKIMORI K, 1992, OBSTET GYNECOL, V80, P229; Wallenburg HCS., 1988, HDB HYPERTENSION, P66; WEINER CP, 1982, AM J OBSTET GYNECOL, V142, P275, DOI 10.1016/0002-9378(82)90730-X; 1991, 1985 87 DEP HLTH REP, P17; 1957, 1952 54 MIN HLTH REP	35	1044	1065	1	35	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 5	1993	341	8858					1447	1451		10.1016/0140-6736(93)90889-O	http://dx.doi.org/10.1016/0140-6736(93)90889-O			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF841	8099148				2022-12-28	WOS:A1993LF84100011
J	CORRIS, PA; DARK, JH				CORRIS, PA; DARK, JH			ETIOLOGY OF ASTHMA - LESSONS FROM LUNG TRANSPLANTATION	LANCET			English	Article							NOCTURNAL ASTHMA; REACTIVITY	Asthma is thought to result from both genetic and environmental influences. The genetic component is most obviously seen in patients who are atopic and have allergic responses to common antigens. We have done lung transplants in two such patients; and we have also transplanted the lungs from two mildly asthmatic patients, whose death was unrelated to their asthma, into two patients with end-stage cystic fibrosis and primary pulmonary hypertension, respectively. The non-asthmatic recipients of asthmatic lungs developed asthma after transplantation; however, the asthmatic recipients of normal lungs have not developed asthma up to three years after transplantation. These observations support the notion that asthma is a ''local'' disease.	FREEMAN RD HOSP,DEPT CARDIOTHORAC SURG,NEWCASTLE TYNE NE7 7DN,TYNE & WEAR,ENGLAND	Newcastle Freeman Hospital	CORRIS, PA (corresponding author), FREEMAN RD HOSP,DEPT RESP MED,NEWCASTLE TYNE NE7 7DN,TYNE & WEAR,ENGLAND.							AGOSTI JM, 1988, NEW ENGL J MED, V319, P1623, DOI 10.1056/NEJM198812223192502; BELCHER HR, 1961, BR J DIS CHEST, V55, P77; BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; COE CI, 1986, CHEST, V90, P485, DOI 10.1378/chest.90.4.485; COOKSON WOCM, 1988, LANCET, V1, P86; COOKSON WOCM, 1989, LANCET, V1, P1292; DARK J, 1989, THORAX, V44, P689, DOI 10.1136/thx.44.9.689; FUNG JJ, 1985, HUM IMMUNOL, V4, P433; HOPKIN J, 1991, BRIT MED J, V302, P1222, DOI 10.1136/bmj.302.6787.1222; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; MORRISON JFJ, 1988, BRIT MED J, V296, P1427, DOI 10.1136/bmj.296.6634.1427	11	69	70	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 29	1993	341	8857					1369	1371		10.1016/0140-6736(93)90941-9	http://dx.doi.org/10.1016/0140-6736(93)90941-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE180	8098790				2022-12-28	WOS:A1993LE18000004
J	CROME, P; KALRA, L				CROME, P; KALRA, L			DO STROKE UNITS SAVE LIVES	LANCET			English	Letter									ORPINGTON HOSP,ORPINGTON STROKE UNIT,ORPINGTON BR6 9JU,KENT,ENGLAND		CROME, P (corresponding author), KINGS COLL,SCH MED & DENT,DEPT HLTH CARE ELDERLY,ORPINGTON BR6 9JU,KENT,ENGLAND.							KALRA L, 1993, J AM GERIATR SOC, V41, P396, DOI 10.1111/j.1532-5415.1993.tb06947.x; KALRA L, IN PRESS STROKE; LANGHORN, 1993, LANCET, V342, P395	3	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 16	1993	342	8877					992	992		10.1016/0140-6736(93)92039-V	http://dx.doi.org/10.1016/0140-6736(93)92039-V			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MC005	8105238				2022-12-28	WOS:A1993MC00500047
J	WRIGHT, EC				WRIGHT, EC			NONCOMPLIANCE - OR HOW MANY AUNTS HAS MATILDA	LANCET			English	Review							IMPROVING MEDICATION COMPLIANCE; THERAPY; ASTHMA; TRIAL; USAGE	The compliance of patients with medication prescribed for them is a challenge. It seems that one-third of patients comply adequately, one-third more-or-less, and one-third are non-compliant, so that compliance rates hover around 50%. This can be improved upon, but not by treating failure to comply as a deplorably aberrant behaviour. First we need to know more about compliance and non-compliance, and that means standardising methods of study and measuring, by questioning the patient, counting tablets, or looking at drug metabolites or markers in faeces, blood or urine. Doctors' prejudices and patients' perceptions alike have to be taken into account since strategies for improvement must include both educating the prescriber and counselling the patient.			WRIGHT, EC (corresponding author), LIFECARE NHS TRUST, CATERHAM CR3 5YA, SURREY, ENGLAND.							AZRIN NH, 1969, J APPL BEHAV ANAL, V2, P39, DOI 10.1901/jaba.1969.2-39; BARKIN RL, DRUG INTELL CLIN PHA, V18, P82; BECKER MH, 1975, MED CARE, V13, P10, DOI 10.1097/00005650-197501000-00002; BERGMAN AB, 1963, NEW ENGL J MED, V268, P1334, DOI 10.1056/NEJM196306132682404; BLACKWELL B, 1973, NEW ENGL J MED, V289, P249, DOI 10.1056/NEJM197308022890506; BOND WS, 1991, AM J HOSP PHARM, V48, P1978, DOI 10.1093/ajhp/48.9.1978; CRAMER JA, 1989, JAMA-J AM MED ASSOC, V261, P3273, DOI 10.1001/jama.261.22.3273; DAVIS MS, 1966, J MED EDUC, V41, P1037; DAVIS MS, 1968, MED CARE, V6, P115, DOI 10.1097/00005650-196803000-00003; DAVIS TME, 1988, PRACTICAL DIABETES, V5, P170; DIXON WM, 1957, LANCET, V2, P871; DROLET GJ, 1949, WHY PATIENTS TUBERCU, P1; ELLARD GA, 1980, BRIT J CLIN PHARMACO, V10, P369; ELLARD GA, 1974, LEPROSY REV, V45, P224; ELLARD JA, 1981, LEPROSY REV, V52, P201; EPSTEIN LH, 1984, HEALTH PSYCHOL, V3, P385, DOI 10.1037/0278-6133.3.4.385; GILBERT JR, 1980, CAN MED ASSOC J, V123, P119; GONG H, 1988, J ALLERGY CLIN IMMUN, V82, P5, DOI 10.1016/0091-6749(88)90043-7; GORDIS L, 1969, MED CARE, V7, P49, DOI 10.1097/00005650-196901000-00006; GREENBERG RN, CLIN THER, V6, P590; HAEFNER DP, 1970, PUBLIC HEALTH REP, V85, P478, DOI 10.2307/4593885; Haynes R. B., 1979, COMPLIANCE HLTH CARE; HAYNES RB, 1987, PATIENT EDUC COUNS, V10, P155, DOI 10.1016/0738-3991(87)90095-4; HAYNES RB, 1980, HYPERTENSION, V2, P757, DOI 10.1161/01.HYP.2.6.757; HERTROIJS AR, 1974, INT J LEPROSY, V42, P419; HOBBY GL, 1959, AM REV RESPIR DIS, V80, P415; HULKA BS, 1976, AM J PUBLIC HEALTH, V66, P847, DOI 10.2105/AJPH.66.9.847; JANK NK, 1984, HLTH ED Q, V11, P1; KEEN PJ, 1991, J ROY SOC MED, V84, P640; KINSMAN RA, 1980, J PSYCHOSOM RES, V24, P97, DOI 10.1016/0022-3999(80)90059-8; MAZZULLO JM, 1972, DRUG THER, V2, P11; MCCARTNEY JR, 1985, INT J PSYCHIAT MED, V15, P31, DOI 10.2190/HV5B-GCW5-9BCV-RYW5; MORISKY DE, 1983, AM J PUBLIC HEALTH, V73, P153, DOI 10.2105/AJPH.73.2.153; NAGY VT, 1984, MED CARE, V22, P912, DOI 10.1097/00005650-198410000-00004; NORELL SE, 1979, BRIT MED J, V2, P1031, DOI 10.1136/bmj.2.6197.1031; OLIVIERI NF, 1991, ARCH DIS CHILD, V66, P1399, DOI 10.1136/adc.66.12.1399; PULLAR T, 1989, CLIN PHARMACOL THER, V46, P163, DOI 10.1038/clpt.1989.121; Pullar T, 1990, PHARM J, V245, P213; RICHARDSON JL, 1990, J CLIN ONCOL, V8, P356, DOI 10.1200/JCO.1990.8.2.356; ROTH HP, 1970, CLIN PHARMACOL THER, V11, P228; RUDD P, 1989, CLIN PHARMACOL THER, V46, P169, DOI 10.1038/clpt.1989.122; Sackett DL, 1979, COMPLIANCE HLTH CARE; SCHWARTZ D, 1962, AM J PUBLIC HEALTH N, V52, P2018, DOI 10.2105/AJPH.52.12.2018; STANAWAY L, 1985, NEW ZEAL MED J, V98, P150; STEPHENSON BJ, 1993, IN PRESS JAMA; TAKAKI S, 1985, THER DRUG MONIT, V7, P87, DOI 10.1097/00007691-198503000-00015; TROSTLE J. A., 1988, COMPLIANCE EPILEPSY, P57; Walker R., 1992, PHARM J, V249, P605; WEINTRAUB M, 1973, JAMA-J AM MED ASSOC, V224, P481, DOI 10.1001/jama.224.4.481; YEE RD, 1974, AM J OPHTHALMOL, V78, P774, DOI 10.1016/0002-9394(74)90299-2	50	172	176	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 9	1993	342	8876					909	913		10.1016/0140-6736(93)91951-H	http://dx.doi.org/10.1016/0140-6736(93)91951-H			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA963	8105172				2022-12-28	WOS:A1993MA96300015
J	VAINIO, S; KARAVANOVA, I; JOWETT, A; THESLEFF, I				VAINIO, S; KARAVANOVA, I; JOWETT, A; THESLEFF, I			IDENTIFICATION OF BMP-4 AS A SIGNAL MEDIATING SECONDARY INDUCTION BETWEEN EPITHELIAL AND MESENCHYMAL TISSUES DURING EARLY TOOTH DEVELOPMENT	CELL			English	Article							BONE MORPHOGENETIC PROTEIN; GROWTH-FACTOR-BETA; HOMEOBOX GENE; EMBRYONIC-DEVELOPMENT; MOUSE EMBRYO; EXPRESSION PATTERNS; MESODERM INDUCTION; CELL-PROLIFERATION; DENTAL MESENCHYME; RNA EXPRESSION	Growth factor-mediated signaling has been implicated in the regulation of epithelial-mesenchymal interactions during organogenesis. Bone morphogenetic protein 4 (BMP-4), a member of the transforming growth factor beta superfamily, is expressed in the presumptive dental epithelium at the initiation of tooth development. Subsequently, epithelial signaling leads to mesenchymal induction of BMP-4 expression. To address the role of this factor, BMP-4-releasing agarose beads were added to dental mesenchyme in culture. These beads induced a translucent mesenchymal zone similar to that induced by dental epithelium. Moreover, three transcription factors (Msx-1, Msx-2, and Egr-1) whose expression is governed by epithelial signaling were induced in response to BMP-4. In addition, BMP-4 induced its own mesenchymal expression. These findings support the hypothesis that BMP-4 mediates epithelial-mesenchymal interactions during early tooth development.	UNIV HELSINKI,INST DENT,DEPT PEDODONT & ORTHODONT,SF-00014 HELSINKI,FINLAND	University of Helsinki				Vainio, Seppo/0000-0001-9319-3566	NIDCR NIH HHS [DE-09399] Funding Source: Medline	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALTABA ARI, 1989, NATURE, V341, P945; BEQUEKIRN C, 1992, INT J DEV BIOL, V36, P491; BESSHO K, 1990, J ORAL MAXIL SURG, V48, P162, DOI 10.1016/S0278-2391(10)80204-6; Bienz Mariann, 1992, Current Opinion in Cell Biology, V4, P955, DOI 10.1016/0955-0674(92)90124-U; CELESTE AJ, 1990, P NATL ACAD SCI USA, V87, P9843, DOI 10.1073/pnas.87.24.9843; CRICK F, 1970, NATURE, V225, P420, DOI 10.1038/225420a0; DOLLE P, 1992, DIFFERENTIATION, V49, P93, DOI 10.1111/j.1432-0436.1992.tb00773.x; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FRENZ DA, 1992, DEV BIOL, V153, P324, DOI 10.1016/0012-1606(92)90117-Y; GILBERT S, 1992, DEV BIOL; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; GROBSTEIN C, 1953, NATURE, V172, P869, DOI 10.1038/172869a0; GURDON JB, 1992, CELL, V68, P185, DOI 10.1016/0092-8674(92)90465-O; GURDON JB, 1992, CURR BIOL, V3, P1; HAYAMIZU TF, 1991, DEV BIOL, V145, P164, DOI 10.1016/0012-1606(91)90222-O; HAYEK A, 1987, BIOCHEM BIOPH RES CO, V147, P876, DOI 10.1016/0006-291X(87)91011-4; HEINE UI, 1987, J CELL BIOL, V105, P2861, DOI 10.1083/jcb.105.6.2861; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; INGHAM P, 1992, CURR BIOL, V9, P465; JALKANEN M, 1985, J CELL BIOL, V101, P976, DOI 10.1083/jcb.101.3.976; JESSELL TM, 1992, CELL, V68, P257, DOI 10.1016/0092-8674(92)90469-S; JONES CM, 1991, DEVELOPMENT, V111, P531; JONES CM, 1992, DEVELOPMENT, V115, P639; JOWETT AK, 1993, DEVELOPMENT, V117, P461; KARAVANOVA I, 1992, MECH DEVELOP, V39, P41, DOI 10.1016/0925-4773(92)90024-E; KAWAI T, 1989, J DENT RES, V68, P1069, DOI 10.1177/00220345890680060301; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; LEHNERT SA, 1988, DEVELOPMENT, V104, P263; LUMSDEN AGS, 1979, J BIOL BUCCALE, V7, P77; LUMSDEN AGS, 1988, DEVELOPMENT, V103, P155; LYONS KM, 1990, DEVELOPMENT, V109, P833; LYONS KM, 1991, TRENDS GENET, V7, P408, DOI 10.1016/0168-9525(91)90265-R; LYONS KM, 1989, GENE DEV, V3, P1657, DOI 10.1101/gad.3.11.1657; MACKENZIE A, 1991, DEVELOPMENT, V111, P269; MACKENZIE A, 1992, DEVELOPMENT, V115, P403; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MINA M, 1987, ARCH ORAL BIOL, V32, P123, DOI 10.1016/0003-9969(87)90055-0; MOON RT, 1992, CELL, V71, P709, DOI 10.1016/0092-8674(92)90545-N; NISWANDER L, 1993, NATURE, V361, P68, DOI 10.1038/361068a0; ORRURTREGER A, 1992, DEVELOPMENT, V115, P1045; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; PELTON RW, 1990, DEVELOPMENT, V110, P609; ROS MA, 1992, DEVELOPMENT, V116, P811; ROSEN V, 1992, TRENDS GENET, V8, P97, DOI 10.1016/0168-9525(92)90063-A; Ruch J V, 1987, Revis Biol Celular, V14, P1; RUNYAN RB, 1992, MOL REPROD DEV, V32, P152, DOI 10.1002/mrd.1080320211; SAXEN L, 1976, NATURE, V259, P662, DOI 10.1038/259662a0; SAXEN L, 1980, DEV MAMMALS, V4, P161; SCHREIBER AB, 1986, SCIENCE, V232, P1250, DOI 10.1126/science.2422759; SCOTT MP, 1992, CELL, V71, P551, DOI 10.1016/0092-8674(92)90588-4; SLACK JMW, 1993, NATURE, V361, P490, DOI 10.1038/361490a0; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; TESSAROLLO L, 1992, DEVELOPMENT, V115, P11; THESLEFF I, 1988, DEV BIOL, V129, P565, DOI 10.1016/0012-1606(88)90401-0; THESLEFF I, 1990, J BIOL BUCCALE, V18, P179; THESLEFF I, 1981, DIFFERENTIATION, V18, P75, DOI 10.1111/j.1432-0436.1981.tb01107.x; THESLEFF I, 1979, DEV BIOL, V70, P116, DOI 10.1016/0012-1606(79)90011-3; THESLEFF I, 1992, CHEM BIOL MINERALIZE, P369; TICKLE C, 1985, DEV BIOL, V109, P82, DOI 10.1016/0012-1606(85)90348-3; TREMML G, 1992, DEVELOPMENT, V116, P447; VAAHTOKARI A, 1991, DEVELOPMENT, V113, P985; VAINIO S, 1989, J CELL BIOL, V108, P1945, DOI 10.1083/jcb.108.5.1945; VAINIO S, 1992, DIFFERENTIATION, V50, P97, DOI 10.1111/j.1432-0436.1992.tb00490.x; VAINIO S, 1992, DEV DYNAM, V194, P105, DOI 10.1002/aja.1001940204; VAINIO S, 1992, THESIS U HELSINKI HE; VAINIO S, 1991, DEV BIOL, V147, P323; Wilkinson D. G., 1990, POSTIMPLANTATION MAM, P155; WILKINSON DG, 1989, DEVELOPMENT, V105, P131; Williams J, 1991, CURR OPIN CELL BIOL, V3, P925, DOI 10.1016/0955-0674(91)90108-B; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; WOZNEY JM, 1992, MOL REPROD DEV, V32, P160, DOI 10.1002/mrd.1080320212	71	819	847	1	35	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 8	1993	75	1					45	58		10.1016/S0092-8674(05)80083-2	http://dx.doi.org/10.1016/S0092-8674(05)80083-2			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MB667	8104708				2022-12-28	WOS:A1993MB66700007
J	TATE, JJT; DAWSON, JW; CHUNG, SCS; LAU, WY; LI, AKC				TATE, JJT; DAWSON, JW; CHUNG, SCS; LAU, WY; LI, AKC			LAPAROSCOPIC VERSUS OPEN APPENDECTOMY - PROSPECTIVE RANDOMIZED TRIAL	LANCET			English	Article							OPEN APPENDECTOMY; CHOLECYSTECTOMY; APPENDICITIS; SURGERY	Randomised assessment of new laparoscopic surgical techniques is difficult. Surgeons need time to become experienced with the methods and tend, when they have experience, to favour one or other approach. We have carried out a prospective randomised comparison of laparoscopic and conventional appendicectomy done by surgeons of comparable experience in patients with suspected acute appendicitis. Postoperative management decisions were made by surgeons other than the operating surgeon. 140 patients were randomly assigned to open (OA) or laparoscopic (LA) appendicectomy (70 each). The age, sex ratio, duration of symptoms, and proportion of patients with histologically confirmed appendicitis was similar in the two groups. Operating time was longer for LA than for OA (mean 70.3 [SD 21.9] vs 46.5 [25.9] min; p < 0.001). There were no major intraoperative complications in either group. 14 (20%) patients in the LA group required conversion to an open operation. No significant differences between the groups were found postoperatively for pain score, analgesic requirement, time to reintroduction of diet, or hospital stay. 46 LA patients and 42 OA patients attended follow-up 3 weeks after surgery. Similar proportions had returned to work (36 [79%] vs 31 [74%]). The frequency of wound complications and wound pain after leaving hospital was lower after LA but not significantly so. We conclude that the postoperative course after LA and conventional OA does not differ significantly.	CHINESE UNIV HONG KONG, PRINCE WALES HOSP, DEPT SURG, SHA TIN, HONG KONG	Chinese University of Hong Kong; Prince of Wales Hospital								ATTWOOD SEA, 1992, SURGERY, V112, P497; CHAMBERLAIN GVP, 1978, REPORT WORKING PARTY; CLARKE PJ, 1986, ANN ROY COLL SURG, V68, P68; CUSCHIERI A, 1991, AM J SURG, V161, P385, DOI 10.1016/0002-9610(91)90603-B; DAWSON JW, 1992, GUT, V33, pS16; GOODMAN GR, 1991, AM J SURG, V162, P576, DOI 10.1016/0002-9610(91)90112-Q; GOTZ F, 1990, SURG ENDOSC-ULTRAS, V4, P6, DOI 10.1007/BF00591402; HOFFMANN J, 1989, BRIT J SURG, V76, P774, DOI 10.1002/bjs.1800760803; LEAPE LL, 1980, ANN SURG, V191, P410, DOI 10.1097/00000658-198004000-00004; MCANENA OJ, 1992, BRIT J SURG, V79, P818, DOI 10.1002/bjs.1800790837; MCANENA OJ, 1991, LANCET, V338, P693, DOI 10.1016/0140-6736(91)91267-X; NEUGEBAUER E, 1991, BRIT J SURG, V78, P150, DOI 10.1002/bjs.1800780207; Nowzaradan Y, 1991, J Laparoendosc Surg, V1, P247; OLSEN JB, 1993, BRIT J SURG, V80, P922, DOI 10.1002/bjs.1800800744; Pier A, 1991, Surg Laparosc Endosc, V1, P8; Saye W B, 1991, Surg Laparosc Endosc, V1, P109; Schreiber J H, 1987, Surg Endosc, V1, P211; SEMM K, 1983, ENDOSCOPY, V15, P59, DOI 10.1055/s-2007-1021466; TATE JJT, 1993, BRIT J SURG, V80, P761, DOI 10.1002/bjs.1800800636; TATE JJT, 1993, BRIT J SURG, V80, P764, DOI 10.1002/bjs.1800800637; Valla J S, 1991, Surg Laparosc Endosc, V1, P166; WHEELER RA, 1991, BRIT J SURG, V78, P1283, DOI 10.1002/bjs.1800781103; 1991, NEW ENGL J MED, V213, P2	23	162	165	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 11	1993	342	8872					633	637		10.1016/0140-6736(93)91757-D	http://dx.doi.org/10.1016/0140-6736(93)91757-D			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX272	8103144				2022-12-28	WOS:A1993LX27200008
J	DETRUCHIS, P; FLAMENTSAILLOUR, M; URTIZBEREA, JA; HASSINE, D; CLAIR, B				DETRUCHIS, P; FLAMENTSAILLOUR, M; URTIZBEREA, JA; HASSINE, D; CLAIR, B			INEFFICACY OF CYTARABINE IN PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY IN AIDS	LANCET			English	Letter							LEUKOENCEPHALOPATHY		HOP RAY POINCARE,DEPT RADIOL,F-92380 GARCHES,FRANCE; HOP RAY POINCARE,DEPT INTENS CARE,F-92380 GARCHES,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Raymond-Poincare - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Raymond-Poincare - APHP	DETRUCHIS, P (corresponding author), HOP RAY POINCARE,DEPT INFECT DIS,F-92380 GARCHES,FRANCE.							BERGER JR, 1987, ANN INTERN MED, V107, P78, DOI 10.7326/0003-4819-107-1-78; CONWAY B, 1990, REV INFECT DIS, V12, P479; LINDMAN C, 1991, AIDS, V5, P1039; NICOLI F, 1992, LANCET, V339, P306, DOI 10.1016/0140-6736(92)91376-J; PORTEGIES P, 1991, LANCET, V337, P680, DOI 10.1016/0140-6736(91)92504-U	5	18	18	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 4	1993	342	8871					622	623		10.1016/0140-6736(93)91453-S	http://dx.doi.org/10.1016/0140-6736(93)91453-S			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV963	8102756				2022-12-28	WOS:A1993LV96300061
J	STEWART, TA; HULTGREN, B; HUANG, X; PITTSMEEK, S; HULLY, J; MACLACHLAN, NJ				STEWART, TA; HULTGREN, B; HUANG, X; PITTSMEEK, S; HULLY, J; MACLACHLAN, NJ			INDUCTION OF TYPE-I DIABETES BY INTERFERON-ALPHA IN TRANSGENIC MICE	SCIENCE			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS; PANCREATIC-ISLET CELLS; INTERLEUKIN-1 PRODUCTION; AUTOIMMUNE-DISEASE; CHRONIC HEPATITIS; BETA-INTERFERON; CYTO-TOXICITY; MELLITUS; INSULIN; THERAPY	Type I diabetes is an autoimmune disease involving an interaction between an epigenetic event (possibly a viral infection), the pancreatic beta cells, and the immune system in a genetically susceptible host. The possibility that the type I interferons could mediate this interaction was tested with transgenic mice in which the insulin-producing beta cells expressed an interferon-alpha. These mice developed a hypoinsulinemic diabetes associated with a mixed inflammation centered on the islets. The inflammation and the diabetes were prevented with a neutralizing antibody to the interferon-alpha. Thus, the expression of interferon-alpha by the beta cells could be causal in the development of type I diabetes, which suggests a therapeutic approach to this disease.	UNIV CALIF DAVIS,DEPT VET PATHOL,DAVIS,CA 95616	University of California System; University of California Davis	STEWART, TA (corresponding author), GENENTECH INC,DEPT ENDOCRINE RES,S SAN FRANCISCO,CA 94080, USA.							ALLISON J, 1992, EUR J IMMUNOL, V22, P1115, DOI 10.1002/eji.1830220503; APPELS B, 1989, J IMMUNOL, V142, P3803; BOHOSLAWEC O, 1986, J INTERFERON RES, V6, P207, DOI 10.1089/jir.1986.6.207; BURMAN P, 1986, J CLIN ENDOCR METAB, V63, P1086, DOI 10.1210/jcem-63-5-1086; CANDLER RV, 1985, J INTERFERON RES, V5, P179, DOI 10.1089/jir.1985.5.179; CHEN SA, 1988, J INTERFERON RES, V8, P597, DOI 10.1089/jir.1988.8.597; COLLINS AR, 1990, ADV EXP MED BIOL, V276, P497; CONLON KC, 1990, CANCER, V65, P2237, DOI 10.1002/1097-0142(19900515)65:10<2237::AID-CNCR2820651013>3.0.CO;2-5; CONTI P, 1988, INT J IMMUNOPHARMACO, V10, P907, DOI 10.1016/0192-0561(88)90035-5; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; DEMAEYER E, 1988, INTERFERONS OTHER RE, P39; EBERHARDT MS, 1985, DIABETES, V34, P1247, DOI 10.2337/diabetes.34.12.1247; EISENBARTH GS, 1986, NEW ENGL J MED, V314, P1360; ELLERMANNERIKSEN S, 1989, J GEN VIROL, V70, P2139, DOI 10.1099/0022-1317-70-8-2139; ERLICH HA, 1990, DIABETES, V39, P96, DOI 10.2337/diabetes.39.1.96; EVANS SS, 1987, J IMMUNOL, V138, P2451; FATTOVICH G, 1991, J MED VIROL, V34, P132, DOI 10.1002/jmv.1890340212; FINKELMAN FD, 1991, J EXP MED, V174, P1179, DOI 10.1084/jem.174.5.1179; FOULIS AK, 1987, J PATHOL, V152, P141, DOI 10.1002/path.1711520302; FOULIS AK, 1987, LANCET, V2, P1423; FRISK G, 1992, J INFECTION, V24, P13, DOI 10.1016/0163-4453(92)90814-M; FRISK G, 1985, J MED VIROL, V17, P219, DOI 10.1002/jmv.1890170303; GENDELMAN HE, 1992, J IMMUNOL, V148, P422; GEPTS W, 1985, DIABETIC PANCREAS, P337; GERRARD TL, 1987, J IMMUNOL, V138, P2535; GINGERICH RL, 1979, DIABETES, V28, P276, DOI 10.2337/diabetes.28.4.276; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HIGUCHI Y, 1992, J EXP MED, V176, P1719, DOI 10.1084/jem.176.6.1719; HOLAN V, 1991, J INTERFERON RES, V11, P319, DOI 10.1089/jir.1991.11.319; HORN GT, 1988, P NATL ACAD SCI USA, V85, P6012, DOI 10.1073/pnas.85.16.6012; KASAIAN MT, 1990, J EXP MED, V171, P245; KATO T, 1981, J GEN VIROL, V54, P293, DOI 10.1099/0022-1317-54-2-293; LI BL, 1990, CANCER RES, V50, P5328; MACCARI S, 1991, CLIN RHEUMATOL, V10, P452, DOI 10.1007/BF02206672; MACKAY P, 1986, J CLIN INVEST, V77, P916, DOI 10.1172/JCI112390; MAYET WJ, 1989, HEPATOLOGY, V10, P24, DOI 10.1002/hep.1840100106; OLMOS P, 1988, DIABETOLOGIA, V31, P747, DOI 10.1007/BF00274777; OZES ON, 1992, J INTERFERON RES, V12, P55, DOI 10.1089/jir.1992.12.55; PETERS M, 1986, J IMMUNOL, V137, P3163; PICARELLA DE, 1992, P NATL ACAD SCI USA, V89, P10036, DOI 10.1073/pnas.89.21.10036; PICHERT G, 1990, BRIT J CANCER, V62, P100, DOI 10.1038/bjc.1990.237; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; PUKEL C, 1987, DIABETES, V36, P1217, DOI 10.2337/diabetes.36.11.1217; Pyke D A, 1988, Adv Exp Med Biol, V246, P255; RHODES J, 1986, EUR J IMMUNOL, V16, P370, DOI 10.1002/eji.1830160410; RONNBLOM LE, 1991, ACTA ONCOL, V30, P537; RONNBLOM LE, 1990, J INTERN MED, V227, P207; SARVETNICK N, 1988, CELL, V52, P773, DOI 10.1016/0092-8674(88)90414-X; SARZOTTI M, 1989, NAT IMMUN CELL GROW, V8, P66; SAUTER NP, 1992, AM J MED, V92, P441, DOI 10.1016/0002-9343(92)90278-J; SCALZO S, 1990, EUR J CANCER, V26, P1152, DOI 10.1016/0277-5379(90)90275-X; SCHATTNER A, 1986, CLIN IMMUNOL IMMUNOP, V38, P327, DOI 10.1016/0090-1229(86)90242-4; SCHILLING PJ, 1991, CANCER, V68, P1536, DOI 10.1002/1097-0142(19911001)68:7<1536::AID-CNCR2820680713>3.0.CO;2-B; SCHWIZER RW, 1984, TRANSPLANTATION, V37, P539, DOI 10.1097/00007890-198406000-00002; SEMENZATO G, 1986, BLOOD, V68, P293; STAEHELIN T, 1981, P NATL ACAD SCI-BIOL, V78, P1848, DOI 10.1073/pnas.78.3.1848; STEWART T, UNPUB; TABATA Y, 1988, JPN J CANCER RES, V79, P636, DOI 10.1111/j.1349-7006.1988.tb00034.x; TANIGUCHI Y, 1992, INTERNAL MED, V31, P373, DOI 10.2169/internalmedicine.31.373; TODD JA, 1987, NATURE, V329, P599, DOI 10.1038/329599a0; TUVEMO T, 1988, DIABETES RES CLIN EX, V9, P125; VERHAGEN A, 1990, NAT IMMUN CELL GROW, V9, P325; VILCEK J, 1990, HDB EXPT PHARM, V95, P1	63	262	277	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 25	1993	260	5116					1942	1946		10.1126/science.8100367	http://dx.doi.org/10.1126/science.8100367			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LJ349	8100367				2022-12-28	WOS:A1993LJ34900043
J	THOMAS, DL; MAHLEY, RW; BADUR, S; PALAOGLU, KE; QUINN, TC				THOMAS, DL; MAHLEY, RW; BADUR, S; PALAOGLU, KE; QUINN, TC			EPIDEMIOLOGY OF HEPATITIS-E VIRUS-INFECTION IN TURKEY	LANCET			English	Note							NON-B HEPATITIS; TRANSMITTED NON-A; TRANSMISSION	The seroprevalence and risk factors for infection with hepatitis E virus (HEV) were analysed in five regions of Turkey, where one-third of acute hepatitis cases are non-A, non-B. Antibodies to HEV (anti-HEV) were found in 80 (5.9%) of 1350 subjects. Independent predictors of anti-HEV were age over 25 years, less than elementary education, antibodies to hepatitis C virus, and residence in the warmest region (Adana). Whereas none of 105 subjects in the second decade of life were HEV seropositive, 17 (3.7%) of 464 and 28 (9.1%) of 308 of those in the third and fourth decades of life, respectively, had anti-HEV (p < 0.001). These data demonstrate that in Turkey HEV is more prevalent in warmer regions and in adults, beginning in the third decade of life.	ISTANBUL FAC MED,DEPT MICROBIOL,ISTANBUL,TURKEY; NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20892; AMER BRISTOL HOSP,GLADSTONE RES INST,ISTANBUL,TURKEY	Istanbul University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Amerikan Hospital	THOMAS, DL (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DIV INFECT DIS,1155 ROSS BLDG,720 RUTLAND AVE,BALTIMORE,MD 21205, USA.							BABACAN F, 1990, J TURK MICROBIOL SOC, V20, P131; BADUR S, 1985, APR P INT C INF DIS; BALAYAN MS, 1983, INTERVIROLOGY, V20, P23, DOI 10.1159/000149370; BRADLEY DW, 1990, BRIT MED BULL, V46, P442, DOI 10.1093/oxfordjournals.bmb.a072409; BRADLEY DW, 1988, LANCET, V1, P819; GOLDSMITH R, 1992, LANCET, V339, P328, DOI 10.1016/0140-6736(92)91647-Q; KANE MA, 1984, JAMA-J AM MED ASSOC, V252, P3140, DOI 10.1001/jama.252.22.3140; KHUROO MS, 1980, AM J MED, V68, P818, DOI 10.1016/0002-9343(80)90200-4; SKIDMORE SJ, 1992, J MED VIROL, V37, P58, DOI 10.1002/jmv.1890370110; VELAZQUEZ O, 1990, JAMA-J AM MED ASSOC, V263, P3281, DOI 10.1001/jama.263.24.3281	10	79	81	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 19	1993	341	8860					1561	1562		10.1016/0140-6736(93)90698-G	http://dx.doi.org/10.1016/0140-6736(93)90698-G			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH550	8099641	hybrid			2022-12-28	WOS:A1993LH55000005
J	WYATT, J; VOGELSANG, H; HUBL, W; WALDHOER, T; LOCHS, H				WYATT, J; VOGELSANG, H; HUBL, W; WALDHOER, T; LOCHS, H			INTESTINAL PERMEABILITY AND THE PREDICTION OF RELAPSE IN CROHNS-DISEASE	LANCET			English	Article							INDEX	To see whether intestinal permeability (IP) predicted relapse in Crohn's disease, we measured IP in 72 patients with quiescent Crohn's disease using the lactulose-mannitol test. The permeability index (lactulose/mannitol) was significantly higher in patients than in controls (0.046 [SEM 0.005] vs 0.018 [SEM 0.002], respectively). Patients were followed for 1 year after the test. 26 of the 37 patients with raised permeability, but only 6 of the 35 with normal permeability relapsed within 1 year after the test (p<0.001). The sensitivity of the permeability test as a predictor for relapse was 81%. A significant correlation was found between the value of the permeability index and the probability of relapse (p<0.01). These results show that increases in intestinal permeability precede clinical relapses in Crohn's disease and so are an indicator of subclinical disease. The measurement of intestinal permeability may lead to a better understanding of the pathogenesis of Crohn's disease.	INST TUMOR BIOL, A-1090 VIENNA, AUSTRIA		WYATT, J (corresponding author), CLIN INTERNAL MED 4, DEPT GASTROENTEROL & HEPATOL, WAHRINGER GURTEL 18-20, A-1090 VIENNA, AUSTRIA.		Waldhoer, Thomas Johannes/I-1215-2019	Waldhoer, Thomas Johannes/0000-0003-2043-8299				Albert A., 1987, MULTIVARIATE INTERPR; ANDRE F, 1988, GUT, V29, P511, DOI 10.1136/gut.29.4.511; BEST WR, 1976, GASTROENTEROLOGY, V70, P439; BRIGNOLA C, 1986, GASTROENTEROLOGY, V91, P1490, DOI 10.1016/0016-5085(86)90206-4; CAMPBELL CA, 1982, J PEDIATR GASTR NUTR, V1, P193, DOI 10.1097/00005176-198201020-00007; Cox DR., 1970, ANAL BINARY DATA; DAMBOISE M, 1980, CLIN CHEM, V26, P1348; DELAHUNTY T, 1986, CLIN CHEM, V32, P1542; GROSS V, 1992, GASTROENTEROLOGY, V102, P514, DOI 10.1016/0016-5085(92)90098-J; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MALCHOW H, 1986, GASTROENTEROLOGY, V2, P249; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MURPHY MS, 1989, ARCH DIS CHILD, V64, P321, DOI 10.1136/adc.64.3.321	14	499	506	1	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 5	1993	341	8858					1437	1439		10.1016/0140-6736(93)90882-H	http://dx.doi.org/10.1016/0140-6736(93)90882-H			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF841	8099141				2022-12-28	WOS:A1993LF84100004
J	FEDER, G				FEDER, G			PARADIGM LOST - A CELEBRATION OF PARACELSUS ON HIS QUINCENTENARY	LANCET			English	Editorial Material									ROYAL LONDON HOSP,COLL MED,LONDON,ENGLAND	Barts Health NHS Trust; Royal London Hospital	FEDER, G (corresponding author), ST BARTHOLOMEWS HOSP,JOINT ACAD DEPT GEN PRACTICE & PRIMARY CARE,LONDON EC1M 6BQ,ENGLAND.			Feder, Gene/0000-0002-7890-3926				BUTTERFIELD J, 1991, LANCET, V338, P1576; Curry P, 1985, Hist Sci, V23, P299; Jackson M., 1989, PATHS CLEARING RADIC; JACOBI J, 1958, PARACELSUS SELECTED, P72; JACOBI J, 1958, PARACELSUS SELECTED, P57; Jung C.G., 1937, ALCHEMICAL STUDIES, P13; Merchant C., 1982, DEATH NATURE; OTS T, 1990, CULT MED PSYCHIAT, V14, P21, DOI 10.1007/BF00046703; PAGEL W, 1982, PARACELSUS; SHIRA V, 1989, STAYING ALIVE WOMEN; Webster Charles, 1982, PARACELSUS NEWTON MA	11	6	6	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 29	1993	341	8857					1396	1397		10.1016/0140-6736(93)90954-F	http://dx.doi.org/10.1016/0140-6736(93)90954-F			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LE180	8098803				2022-12-28	WOS:A1993LE18000017
J	EASTWOOD, R				EASTWOOD, R			MENTAL-ILLNESS - WEEDING OUT	LANCET			English	Editorial Material											EASTWOOD, R (corresponding author), CLARKE INST PSYCHIAT, TORONTO M5T 1R8, ONTARIO, CANADA.							Phelan M, 1993, PSYCHIATR B, V17, P86, DOI [10.1192/pb.17.2.86, DOI 10.1192/PB.17.2.86]	1	6	6	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 22	1993	341	8856					1316	1316		10.1016/0140-6736(93)90823-Y	http://dx.doi.org/10.1016/0140-6736(93)90823-Y			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD253	8098456				2022-12-28	WOS:A1993LD25300011
J	MOORJANI, S; ROY, M; TORRES, A; BETARD, C; GAGNE, C; LAMBERT, M; BRUN, D; DAVIGNON, J; LUPIEN, P				MOORJANI, S; ROY, M; TORRES, A; BETARD, C; GAGNE, C; LAMBERT, M; BRUN, D; DAVIGNON, J; LUPIEN, P			MUTATIONS OF LOW-DENSITY-LIPOPROTEIN-RECEPTOR GENE, VARIATION IN PLASMA-CHOLESTEROL, AND EXPRESSION OF CORONARY HEART-DISEASE IN HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA	LANCET			English	Article							LOCUS	Variation in plasma-cholesterol concentration and the expression of coronary heart disease in patients with homozygous familial hypercholesterolaemia (FH) is well documented, but the underlying reasons for variation are not clearly defined. Because FH is caused by mutations at the low-density-lipoprotein-gene locus, we compared plasma-cholesterol concentrations in 21 FH homozygotes with either the greater than 10 kb deletion (promoter region and exon 1) (11 subjects) or the exon 3 missense (trp66-->gly) mutation (1 0 subjects) of the low-density-lipoprotein gene. Subjects with the greater than 10 kb deletion had a higher mean plasma-cholesterol concentration than those with the exon 3 mutations (26.7 vs 16.1 mmol/L; p=0.000006), and there was no overlap in individual plasma-cholesterol concentrations between subjects in the two groups. Although the frequency of coronary heart disease was similar in the two groups, age-of-onset was earlier in subjects with the greater than 10 kb deletion (p=0.059). Also, coronary deaths were more frequent (p=0.044) and occurred at an earlier age (p=0.009) in subjects with the greater than 10 kb deletion. Our results provide evidence that there is less variation in plasma-cholesterol concentrations among FH homozygotes when they are subdivided into groups according to low-density-lipoprotein-receptor-gene defect. Furthermore, differences in plasma-cholesterol concentrations are reflected in the severity of coronary heart disease expression.	UNIV LAVAL,MED RES CTR,QUEBEC CITY G1K 7P4,QUEBEC,CANADA; CLIN RES INST MONTREAL,MONTREAL H2W 1R7,QUEBEC,CANADA; ST JUSTINE HOSP,MONTREAL,PQ,CANADA	Laval University; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; Centre Hospitalier Universitaire Sainte-Justine								BETARD C, 1992, HUM GENET, V88, P529, DOI 10.1007/BF00219339; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Goldstein J.L., 1989, METABOLIC BASIS INHE, P1215; GOLDSTEIN JL, 1982, MED CLIN N AM, V66, P335, DOI 10.1016/S0025-7125(16)31424-9; HOBBS HH, 1990, ANNU REV GENET, V24, P133, DOI 10.1146/annurev.ge.24.120190.001025; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; LEHRMAN MA, 1987, J BIOL CHEM, V262, P401; LEITERSDORF E, 1989, J CLIN INVEST, V84, P954, DOI 10.1172/JCI114258; LEITERSDORF E, 1990, J CLIN INVEST, V85, P1014, DOI 10.1172/JCI114531; MA YH, 1989, CLIN GENET, V36, P219; MEINER V, 1991, AM J HUM GENET, V49, P443; MOORJANI S, 1989, ARTERIOSCLEROSIS, V9, P211, DOI 10.1161/01.ATV.9.2.211; SPRECHER DL, 1985, METABOLISM, V34, P294, DOI 10.1016/0026-0495(85)90015-0; Thompson GR, 1989, ARTERIOSCLER, V9, P175; YAMAMOTO A, 1989, ARTERIOSCLEROSIS S, V9, P66	15	132	143	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 22	1993	341	8856					1303	1306		10.1016/0140-6736(93)90815-X	http://dx.doi.org/10.1016/0140-6736(93)90815-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD253	8098448				2022-12-28	WOS:A1993LD25300003
J	COHEN, ML; QUINTNER, JL				COHEN, ML; QUINTNER, JL			FIBROMYALGIA SYNDROME, A PROBLEM OF TAUTOLOGY	LANCET			English	Review							TENDER POINTS; PAIN MEASURES; FIBROSITIS; CLASSIFICATION; HYPERALGESIA; SCALE	Fibromyalgia syndrome is generally taken to denote a clinical state of widespread musculoskeletal pain, stiffness, and fatigue but its pathophysiology, physical and psychological, is unknown, and the nature of the diagnostically mandatory ''tender points'' remains obscure. Diagnostic criteria convey no pathophysiological insight and they have been ''validated'' via a circular argument in which the evidence on which the construct is based is taken as proof of its veracity. The concept of fibromyalgia syndrome is valid only in the sense that it includes all possibilities. An alternative approach to this very real clinical presentation is via secondary hyperalgesia.	ST VINCENTS HOSP, DEPT RHEUMATOL, SYDNEY, NSW 2010, AUSTRALIA; ST JOHN GOD HOSP, PERTH, WA, AUSTRALIA; UNIV NEW S WALES, SYDNEY, NSW, AUSTRALIA	St Vincents Hospital Sydney; St John of God Health Care; University of New South Wales Sydney								[Anonymous], 1979, Pain, V6, P249; ARROYO JF, IN PRESS J RHEUMATOL; BENNETT R M, 1989, Journal of Rheumatology, V16, P58; BOISSEVAIN MD, 1991, PAIN, V45, P227, DOI 10.1016/0304-3959(91)90047-2; BOISSEVAIN MD, 1991, PAIN, V45, P239, DOI 10.1016/0304-3959(91)90048-3; CAMPBELL SM, 1983, ARTHRITIS RHEUM, V26, P817, DOI 10.1002/art.1780260701; CHAPMAN CR, 1985, PAIN, V22, P1, DOI 10.1016/0304-3959(85)90145-9; CODERRE TJ, 1987, BRAIN RES, V404, P95, DOI 10.1016/0006-8993(87)91359-X; CSILLAG C, 1992, LANCET, V340, P663, DOI 10.1016/0140-6736(92)92190-Q; GRACELY RH, 1992, PAIN, V51, P175, DOI 10.1016/0304-3959(92)90259-E; HARDY JD, 1950, J CLIN INVEST, V29, P115, DOI 10.1172/JCI102227; HARRIS G, 1983, PAIN, V17, P369, DOI 10.1016/0304-3959(83)90168-9; HEFT MW, 1984, PAIN, V19, P153, DOI 10.1016/0304-3959(84)90835-2; KOLTZENBURG M, 1992, PAIN, V51, P207, DOI 10.1016/0304-3959(92)90262-A; Lewis T, 1936, CLIN SCI, V2, P373; Medawar PB, 1969, INDUCTION INTUITION; MERSKEY H, 1989, Journal of Rheumatology, V16, P72; PERRY F, 1988, PAIN, V34, P185, DOI 10.1016/0304-3959(88)90164-9; QUIMBY LG, 1988, J RHEUMATOL, V15, P1264; RANSOHOFF DF, 1978, NEW ENGL J MED, V299, P926, DOI 10.1056/NEJM197810262991705; ROLLMAN G B, 1989, Journal of Rheumatology, V16, P113; SCUDDS RA, 1987, J RHEUMATOL, V14, P563; SIMMS RW, 1988, J RHEUMATOL, V15, P1271; SMYTHE H A, 1977, Bulletin on the Rheumatic Diseases, V28, P928; SMYTHE HA, 1992, J RHEUMATOL, V19, P284; TREEDE RD, 1992, PROG NEUROBIOL, V38, P397, DOI 10.1016/0301-0082(92)90027-C; TUNKS E, 1988, PAIN, V34, P11, DOI 10.1016/0304-3959(88)90176-5; WOLFE F, 1990, ARTHRITIS RHEUM-US, V33, P160, DOI 10.1002/art.1780330203; YUNUS M, 1981, SEMIN ARTHRITIS RHEU, V11, P151, DOI 10.1016/0049-0172(81)90096-2	29	112	112	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 9	1993	342	8876					906	909		10.1016/0140-6736(93)91950-Q	http://dx.doi.org/10.1016/0140-6736(93)91950-Q			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA963	8105171				2022-12-28	WOS:A1993MA96300014
J	RAUSKOLB, C; PEIFER, M; WIESCHAUS, E				RAUSKOLB, C; PEIFER, M; WIESCHAUS, E			EXTRADENTICLE, A REGULATOR OF HOMEOTIC GENE ACTIVITY, IS A HOMOLOG OF THE HOMEOBOX-CONTAINING HUMAN PROTOONCOGENE PBX1	CELL			English	Article							CULTURED DROSOPHILA CELLS; BITHORAX COMPLEX; ULTRABITHORAX PROTEINS; DNA-BINDING; FUSHI-TARAZU; TRANSCRIPTIONAL ACTIVATION; SEGMENTAL IDENTITY; HOMOEOTIC GENES; PRE-B; SEQUENCE	Mutations in the Drosophila gene extradenticle (exd) cause homeotic transformations by altering the morphological consequences of homeotic selector gene activity. We have cloned and sequenced exd: it encodes a homeodomain protein with extensive identity (71%) to the human proto-oncoprotein Pbx1. exd is expressed during embryogenesis when the selector homeodomain proteins of the Antennapedia and bithorax complexes establish segmental identity. Maternally expressed exd is uniform and can suppress the segmental transformations of embryos lacking zygotic exd. While zygotic exd expression is also at first uniform, later expression is modulated by the homeotic selector genes. These studies support the view that exd acts with the selector homeodomain proteins as a DNA-binding transcription factor, thereby altering their regulation of downstream target genes.			RAUSKOLB, C (corresponding author), PRINCETON UNIV, DEPT MOLEC BIOL, PRINCETON, NJ 08544 USA.		Peifer, Mark/A-1152-2010	Peifer, Mark/0000-0003-1412-3987	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022780] Funding Source: NIH RePORTER; NICHD NIH HHS [5R01HD22780] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDREW DJ, 1992, NEW BIOL, V4, P5; AOTA S, 1988, NUCLEIC ACIDS RES, V16, pR315, DOI 10.1093/nar/16.suppl.r315; ASTELL CR, 1981, CELL, V27, P15, DOI 10.1016/0092-8674(81)90356-1; BEACHY PA, 1985, NATURE, V313, P545, DOI 10.1038/313545a0; BEACHY PA, 1988, CELL, V55, P1069, DOI 10.1016/0092-8674(88)90251-6; BOULET AM, 1991, DEVELOPMENT, V111, P393; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CARROLL SB, 1988, GENE DEV, V2, P350, DOI 10.1101/gad.2.3.350; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CELNIKER SE, 1989, GENE DEV, V3, P1424, DOI 10.1101/gad.3.9.1424; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; CHOU TB, 1992, GENETICS, V131, P643; DELORENZI M, 1990, DEVELOPMENT, V108, P323; DESPLAN C, 1988, CELL, V54, P1081, DOI 10.1016/0092-8674(88)90123-7; DRANGINIS AM, 1990, NATURE, V347, P682, DOI 10.1038/347682a0; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; DUNCAN I, 1987, ANNU REV GENET, V21, P285, DOI 10.1146/annurev.ge.21.120187.001441; FAINSOD A, 1986, P NATL ACAD SCI USA, V83, P9532, DOI 10.1073/pnas.83.24.9532; FALK DR, 1984, MUTAT RES, V126, P25, DOI 10.1016/0027-5107(84)90166-0; FIELD KG, 1988, SCIENCE, V239, P748, DOI 10.1126/science.3277277; FLEGEL WA, 1993, MECH DEVELOP, V41, P155, DOI 10.1016/0925-4773(93)90045-Y; Garcia-Bellido A, 1975, Ciba Found Symp, V0, P161; GIBSON G, 1988, DEVELOPMENT, V102, P657; GONZALEZREYES A, 1990, CELL, V61, P515, DOI 10.1016/0092-8674(90)90533-K; GOULD AP, 1990, NATURE, V348, P308, DOI 10.1038/348308a0; GOUTTE C, 1988, CELL, V52, P875, DOI 10.1016/0092-8674(88)90429-1; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; IRVINE KD, 1991, DEVELOPMENT, V111, P407; JOHNSON AD, 1985, CELL, V42, P237, DOI 10.1016/S0092-8674(85)80119-7; JOHNSON FB, 1990, GENE DEV, V4, P1044, DOI 10.1101/gad.4.6.1044; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KARCH F, 1990, GENE DEV, V4, P1573, DOI 10.1101/gad.4.9.1573; KATZEN AL, 1990, THESIS U CALIFORNIA; Kaufman T C, 1990, Adv Genet, V27, P309; KAUFMANN E, 1993, CHROMOSOMA, V102, P174, DOI 10.1007/BF00387732; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; KRUMLAUF R, 1992, BIOESSAYS, V14, P245, DOI 10.1002/bies.950140408; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LAMKA ML, 1992, DEVELOPMENT, V116, P841; LAWRENCE HJ, 1992, BLOOD, V80, P2445; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LEVINE M, 1988, CELL, V55, P537, DOI 10.1016/0092-8674(88)90209-7; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; MACIAS A, 1990, DEVELOPMENT, V110, P1197; MAHAFFEY JW, 1989, DEVELOPMENT, V105, P167; MALICKI J, 1990, CELL, V63, P961, DOI 10.1016/0092-8674(90)90499-5; MANIATIS T, 1978, CELL, V15, P687, DOI 10.1016/0092-8674(78)90036-3; MANN RS, 1990, CELL, V60, P597, DOI 10.1016/0092-8674(90)90663-Y; MARTIN KJ, 1991, BIOESSAYS, V13, P499, DOI 10.1002/bies.950131003; MCGINNIS N, 1990, CELL, V63, P969, DOI 10.1016/0092-8674(90)90500-E; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; MCGINNIS W, 1984, CELL, V37, P403, DOI 10.1016/0092-8674(84)90370-2; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; MULLER M, 1988, EMBO J, V7, P4299, DOI 10.1002/j.1460-2075.1988.tb03328.x; MULLINS MC, 1989, GENE DEV, V3, P729, DOI 10.1101/gad.3.5.729; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; ODENWALD WF, 1989, GENE DEV, V3, P158, DOI 10.1101/gad.3.2.158; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PEIFER M, 1990, GENE DEV, V4, P1209, DOI 10.1101/gad.4.7.1209; PIROTTA V, 1988, VECTORS SURVEY MOL C, P437; RAMIREZSOLIS R, 1993, CELL, V73, P279, DOI 10.1016/0092-8674(93)90229-J; REGULSKI M, 1991, GENE DEV, V5, P278, DOI 10.1101/gad.5.2.278; REUTER R, 1990, DEVELOPMENT, V110, P1031; SANCHEZ F, 1983, J MOL BIOL, V163, P533, DOI 10.1016/0022-2836(83)90111-0; SCOTT MP, 1984, P NATL ACAD SCI-BIOL, V81, P4115, DOI 10.1073/pnas.81.13.4115; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; STRUHL G, 1989, NATURE, V338, P741, DOI 10.1038/338741a0; STRUHL G, 1985, CELL, V43, P507, DOI 10.1016/0092-8674(85)90180-1; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THALI M, 1988, NATURE, V336, P598, DOI 10.1038/336598a0; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; WHITE RAH, 1984, CELL, V39, P163, DOI 10.1016/0092-8674(84)90202-2; WHITE RAH, 1985, EMBO J, V4, P2035, DOI 10.1002/j.1460-2075.1985.tb03889.x; WIESCHAUS E, 1986, ROUX ARCH DEV BIOL, V195, P63, DOI 10.1007/BF00444042; WINSLOW GM, 1989, CELL, V57, P1017, DOI 10.1016/0092-8674(89)90340-1; ZHAO JJ, 1993, GENE DEV, V7, P343, DOI 10.1101/gad.7.3.343	87	218	219	1	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 24	1993	74	6					1101	1112		10.1016/0092-8674(93)90731-5	http://dx.doi.org/10.1016/0092-8674(93)90731-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LY493	8104703				2022-12-28	WOS:A1993LY49300016
J	THOMPSON, GB; VANHEERDEN, JA; SARR, MG				THOMPSON, GB; VANHEERDEN, JA; SARR, MG			ADENOCARCINOMA OF THE STOMACH - ARE WE MAKING PROGRESS	LANCET			English	Article							EARLY GASTRIC-CARCINOMA; CURATIVE GASTRECTOMY; CANCER; SURVIVAL; LYMPHADENECTOMY; PROGNOSIS; RESECTION; METASTASIS; SURGERY; EXTENT				THOMPSON, GB (corresponding author), MAYO CLIN & MAYO FDN, DEPT SURG, 200 1ST ST SW, ROCHESTER, MN 55905 USA.							AKOH JA, 1992, BRIT J SURG, V79, P293, DOI 10.1002/bjs.1800790404; BEAHRS OH, 1992, MANUAL STAGING CANC, P63; BEHRNS KE, 1992, SURG CLIN N AM, V72, P433; CADY B, 1976, SURG CLIN N AM, V56, P599; CHOI TK, 1982, AM J SURG, V143, P748, DOI 10.1016/0002-9610(82)90051-4; COIT DG, 1990, SURGICAL TREATMENT D, P212; CORREA P, 1983, CANCER SURV, V2, P437; CZERNIAK B, 1989, CANCER, V64, P1467, DOI 10.1002/1097-0142(19891001)64:7<1467::AID-CNCR2820640718>3.0.CO;2-N; DENT DM, 1988, BRIT J SURG, V75, P110, DOI 10.1002/bjs.1800750206; DESIGAN G, 1986, AM J GASTROENTEROL, V81, P19; DUPONT JB, 1978, CANCER-AM CANCER SOC, V41, P941, DOI 10.1002/1097-0142(197803)41:3<941::AID-CNCR2820410323>3.0.CO;2-M; EL-DOMEIRI A A, 1972, Journal of Surgical Oncology, V4, P460, DOI 10.1002/jso.2930040509; ERIKSSON S, 1981, ACTA MED SCAND, V210, P481; FUJITA Y, 1983, JPN J SURG, V13, P184, DOI 10.1007/BF02469474; GILBERTSEN VA, 1969, CANCER-AM CANCER SOC, V23, P1305, DOI 10.1002/1097-0142(196906)23:6<1305::AID-CNCR2820230610>3.0.CO;2-0; HISAMICHI S, 1988, CANCER DETECT PREV, V11, P323; JAEHNE J, 1992, ARCH SURG-CHICAGO, V127, P290; KAJITANI T, 1981, JPN J SURG, V11, P127; Kodama Y, 1981, World J Surg, V5, P241; KODAMA Y, 1983, CANCER, V51, P320, DOI 10.1002/1097-0142(19830115)51:2<320::AID-CNCR2820510226>3.0.CO;2-#; KOGA S, 1980, AM J SURG, V140, P356, DOI 10.1016/0002-9610(80)90167-1; KORENAGA D, 1988, BRIT J SURG, V75, P12, DOI 10.1002/bjs.1800750106; KORENAGA D, 1988, CANCER, V62, P309, DOI 10.1002/1097-0142(19880715)62:2<309::AID-CNCR2820620214>3.0.CO;2-#; KRASNER N, 1986, DIGEST DIS SCI, V31, pS155; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; LAWRENCE W, 1958, CANCER, V11, P28, DOI 10.1002/1097-0142(195801/02)11:1<28::AID-CNCR2820110108>3.0.CO;2-7; MONSON JRT, 1991, CANCER, V68, P1863, DOI 10.1002/1097-0142(19911101)68:9<1863::AID-CNCR2820680902>3.0.CO;2-1; MOSNIER JF, 1991, GUT, V32, P1565, DOI 10.1136/gut.32.12.1565; Murakami T, 1979, World J Surg, V3, P685; OKUSA T, 1990, SURG GYNECOL OBSTET, V170, P488; PAPACHRISTOU DN, 1980, AM J SURG, V139, P711, DOI 10.1016/0002-9610(80)90369-4; PAPACHRISTOU DN, 1981, J SURG ONCOL, V18, P27, DOI 10.1002/jso.2930180105; PATERSON IM, 1987, BRIT J SURG, V74, P481, DOI 10.1002/bjs.1800740618; PREUSSER P, 1988, CANCER TREAT REV, V15, P257, DOI 10.1016/0305-7372(88)90025-4; ReMine W H, 1979, World J Surg, V3, P709; ROUKOS DH, 1990, J CANCER RES CLIN, V116, P307, DOI 10.1007/BF01612909; SASAKO M, 1992, JPN J CLIN ONCOL, V22, P41; SHIU MH, 1987, ARCH SURG-CHICAGO, V122, P1347; SILVERBER GE, CANCER, V38, P15; SMITH JW, 1991, ARCH SURG-CHICAGO, V126, P1469; Soga J, 1979, World J Surg, V3, P701; SUEHIRO S, 1984, AM J SURG, V148, P645, DOI 10.1016/0002-9610(84)90343-X; SUGIMACHI K, 1980, GANN, V71, P704; TSUKUMA H, 1983, INT J CANCER, V31, P421, DOI 10.1002/ijc.2910310405; WRIGHT PA, 1993, GUT, V34, P145, DOI 10.1136/gut.34.2.145; YAMAZAKI H, 1989, CANCER-AM CANCER SOC, V63, P613, DOI 10.1002/1097-0142(19890215)63:4<613::AID-CNCR2820630402>3.0.CO;2-0	46	75	77	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 18	1993	342	8873					713	718		10.1016/0140-6736(93)91711-T	http://dx.doi.org/10.1016/0140-6736(93)91711-T			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX469	8103825				2022-12-28	WOS:A1993LX46900012
J	FANG, FC; MCCLELLAND, M; GUINEY, DG; JACKSON, MM; HARTSTEIN, AI; MORTHLAND, VH; DAVIS, CE; MCPHERSON, DC; WELSH, J				FANG, FC; MCCLELLAND, M; GUINEY, DG; JACKSON, MM; HARTSTEIN, AI; MORTHLAND, VH; DAVIS, CE; MCPHERSON, DC; WELSH, J			VALUE OF MOLECULAR EPIDEMIOLOGIC ANALYSIS IN A NOSOCOMIAL METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS OUTBREAK	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PLASMID ANALYSIS; ARBITRARY PRIMERS; STRAINS; INFECTIONS; DNA; EPIDERMIDIS; EVOLUTION; MARKERS	Objective.-To evaluate two molecular epidemiologic methods used in the analysis of a nosocomial methicillin-resistant Staphylococcus aureus (MRSA) outbreak. Design.-Restriction endonuclease analysis of plasmid DNA (REAP) was used in the analysis of 45 MRSA isolates. After termination of the outbreak, isolates were retrospectively analyzed in a blind fashion using the newly described technique of arbitrarily primed polymerase chain reaction (AP-PCR). Molecular analyses were compared with epidemiologic and antimicrobial susceptibility data. Setting.-Tertiary care university hospital. Subjects.-Twenty-eight patients and 12 employees infected or colonized with MRSA during a 6-week period. Results.-A clonal relationship demonstrated among isolates from burn unit patients and staff was clearly distinguishable from MRSA isolates arising from other hospital wards. The combination of REAP and AP-PCR provided complementary information in several instances. Aggressive measures to isolate infected patients and eradicate colonization from patients and staff terminated the outbreak. Conclusions.-Although traditional epidemiologic methods retain their central role in modem hospital infection control, molecular epidemiologic analysis can significantly enhance the ability of infection control officers to analyze and terminate hospital epidemics. The combination of AP-PCR and REAP may prove to be a particularly informative means of tracking the nosocomial spread of microbial strains and their mobile genetic elements.	CALIF INST BIOL RES, LA JOLLA, CA USA; OREGON HLTH SCI UNIV, DEPT PATHOL, PORTLAND, OR 97201 USA; UNIV CALIF SAN DIEGO, MED CTR, DIV INFECT DIS, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, MED CTR, EPIDEMIOL UNIT, LA JOLLA, CA 92093 USA	Oregon Health & Science University; University of California System; University of California San Diego; University of California System; University of California San Diego			McClelland, Michael/A-8583-2011	Fang, Ferric/0000-0002-3243-110X; McClelland, Michael/0000-0003-1788-9347				[Anonymous], 1961, BMJ-BRIT MED J, V1, P113; ARCHER GL, 1983, J CLIN MICROBIOL, V18, P395, DOI 10.1128/JCM.18.2.395-399.1983; BENNER EJ, 1968, LANCET, V2, P741; BOYCE JM, 1991, INFECT CONT HOSP EP, V12, P46, DOI 10.2307/30147088; BOYCE JM, 1983, JAMA-J AM MED ASSOC, V249, P2803, DOI 10.1001/jama.249.20.2803; BRANGER C, 1987, J MED MICROBIOL, V24, P275, DOI 10.1099/00222615-24-3-275; BRANGER C, 1990, J CLIN MICROBIOL, V28, P150, DOI 10.1128/JCM.28.1.150-151.1990; BRAUDE AI, 1955, ANTIBIOT ANNU, P1133; BRUMFITT W, 1989, NEW ENGL J MED, V320, P1188, DOI 10.1056/NEJM198905043201806; Chambers H.F., 1988, CLIN MICROBIOL REV, V1, P173, DOI DOI 10.1128/CMR.1.2.173; COHEN ML, 1982, ANTIMICROB AGENTS CH, V21, P210, DOI 10.1128/AAC.21.2.210; CRISTINO JAGM, 1989, J HOSP INFECT, V13, P133, DOI 10.1016/0195-6701(89)90019-4; EISENSTEIN BI, 1990, J INFECT DIS, V161, P595, DOI 10.1093/infdis/161.4.595; FRENCH GL, 1990, J HOSP INFECT, V15, P117, DOI 10.1016/0195-6701(90)90120-D; HALL LMC, 1989, EPIDEMIOL INFECT, V103, P183, DOI 10.1017/S095026880003048X; HARTSTEIN AI, 1989, J CLIN MICROBIOL, V27, P1874, DOI 10.1128/JCM.27.8.1874-1879.1989; KOZARSKY PE, 1986, INFECT CONT HOSP EP, V7, P577, DOI 10.1017/S0195941700065413; KREISWIRTH B, 1993, SCIENCE, V259, P227, DOI 10.1126/science.8093647; LACEY RW, 1973, J MED MICROBIOL, V6, P511, DOI 10.1099/00222615-6-4-511; LOCKSLEY RM, 1982, ANN INTERN MED, V97, P317, DOI 10.7326/0003-4819-97-3-317; LUPSKI JR, 1987, REV INFECT DIS, V9, P357; LYON BR, 1987, MICROBIOL REV, V51, P88, DOI 10.1128/MMBR.51.1.88-134.1987; MCDONNELL RW, 1983, ANTIMICROB AGENTS CH, V23, P151, DOI 10.1128/AAC.23.1.151; MCMANUS AT, 1989, ARCH SURG-CHICAGO, V124, P1456; MUDER RR, 1991, ANN INTERN MED, V114, P107, DOI 10.7326/0003-4819-114-2-1-107; MULLIGAN ME, 1991, INFECT CONT HOSP EP, V12, P20, DOI 10.2307/30147085; PEACOCK JE, 1980, ANN INTERN MED, V93, P526, DOI 10.7326/0003-4819-93-4-526; PFALLER MA, 1991, DIAGN MICR INFEC DIS, V14, P209, DOI 10.1016/0732-8893(91)90034-D; PFALLER MA, 1991, MANUAL CLIN MICROBIO, P171; RALPH D, 1993, J BACTERIOL, V175, P973, DOI 10.1128/JB.175.4.973-981.1993; REBOLI AC, 1990, INFECT CONT HOSP EP, V11, P291, DOI 10.1086/646174; RHINEHART E, 1987, ARCH INTERN MED, V147, P521, DOI 10.1001/archinte.147.3.521; RUTALA WA, 1983, J CLIN MICROBIOL, V18, P683, DOI 10.1128/JCM.18.3.683-688.1983; Sambrook J, 1989, MOL CLONING LABORATO; SCHABERG DR, 1986, REV INFECT DIS, V8, P705; STEWART G T, 1963, Br Med J, V1, P308; WACHSMUTH K, 1986, REV INFECT DIS, V8, P682; WAKEFIELD DS, 1988, AM J INFECT CONTROL, V16, P185, DOI 10.1016/0196-6553(88)90058-2; WELSH J, 1992, INT J SYST BACTERIOL, V42, P370, DOI 10.1099/00207713-42-3-370; WELSH J, 1990, NUCLEIC ACIDS RES, V18, P7213, DOI 10.1093/nar/18.24.7213; Welsh John, 1993, P595; WILLIAMS JGK, 1990, NUCLEIC ACIDS RES, V18, P6531, DOI 10.1093/nar/18.22.6531	42	32	33	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	1993	270	11					1323	1328		10.1001/jama.270.11.1323	http://dx.doi.org/10.1001/jama.270.11.1323			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LW345	8103118				2022-12-28	WOS:A1993LW34500029
J	LAUPACIS, A; FEAGAN, B; WONG, C				LAUPACIS, A; FEAGAN, B; WONG, C			EFFECTIVENESS OF PERIOPERATIVE RECOMBINANT-HUMAN-ERYTHROPOIETIN IN ELECTIVE HIP-REPLACEMENT	LANCET			English	Letter											LAUPACIS, A (corresponding author), OTTAWA CIVIC HOSP,LOEB MED RES INST,CLIN EPIDEMIOL UNIT,OTTAWA K1Y 4E9,ONTARIO,CANADA.							FEINSTEIN AR, 1983, ANN INTERN MED, V99, P545; Neustein S M, 1993, J Cardiothorac Vasc Anesth, V7, P95, DOI 10.1016/1053-0770(93)90127-7; PERRETT, 1993, LANCET, V341, P1665	3	22	22	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 7	1993	342	8867					378	378		10.1016/0140-6736(93)91527-S	http://dx.doi.org/10.1016/0140-6736(93)91527-S			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ868	8101624				2022-12-28	WOS:A1993LQ86800067
J	JAMIL, S; KEER, JT; LUCAS, SB; DOCKRELL, HM; CHIANG, TJ; HUSSAIN, R; STOKER, NG				JAMIL, S; KEER, JT; LUCAS, SB; DOCKRELL, HM; CHIANG, TJ; HUSSAIN, R; STOKER, NG			USE OF POLYMERASE CHAIN-REACTION TO ASSESS EFFICACY OF LEPROSY CHEMOTHERAPY	LANCET			English	Article							MYCOBACTERIUM-LEPRAE; BIOPSIES; THERAPY; PCR	The assessment of chemotherapy efficacy in leprosy is difficult, since the only reliable method for determining whether the causative organism, Mycobacterium leprae, is viable depends on its growth in mouse foot pads. In an attempt to replace this expensive, time-consuming test, methods based on the polymerase chain reaction (PCR) have been developed. These methods depend on detection of DNA, which is more susceptible to degradation on cell death than are other cell components, so should be a more accurate indicator of viability. We have used a specific PCR assay to detect M leprae DNA in skin biopsy samples from leprosy patients. By use of limiting dilution PCR (LD-PCR), the concentration of M leprae DNA in the original sample could be measured. The DNA concentration was more closely correlated with the morphological index (derived from a staining technique that distinguishes morphologically intact and damaged bacteria) than with the number of bacteria visible (bacterial index, BI, which counts both alive and dead bacteria). In a longitudinal study of multibacillary patients on multi-drug therapy, skin biopsy samples were collected before treatment and 3, 6, 12, and 24 months after the start of therapy. While the BI showed little or no change during treatment, the number of genomes detected by PCR fell sharply, in parallel with the MI. We propose that PCR can be used as a rapid measure of M leprae viability and that this approach can be used for monitoring individual leprosy patients and for assessment of existing and new regimens. The method may be applicable to other infectious diseases in which culture of the causative organism is slow or impossible.	UNIV LONDON LONDON SCH HYG & TROP MED, DEPT CLIN SCI, KEPPEL ST, LONDON WC1E 7HT, ENGLAND; AGA KHAN UNIV, DEPT MICROBIOL, KARACHI, PAKISTAN; MARIE ADELAIDE LEPROSY CTR, KARACHL, PAKISTAN; UNIV LONDON UNIV COLL, SCH MED, DEPT HISTOPATHOL, LONDON WC1E 6BT, ENGLAND	University of London; London School of Hygiene & Tropical Medicine; Aga Khan University; University of London; University College London; UCL Medical School			Stoker, Neil G/L-8812-2016; Hussain, Rabia/E-9982-2015	Stoker, Neil G/0000-0001-7055-6184; Dockrell, Hazel/0000-0003-1869-9107				BANCROFT JD, 1984, MAUAL HISTOLOGICAL T, P207; BAOHONG J, 1987, International Journal of Leprosy and Other Mycobacterial Diseases, V55, P830; BECXBLEUMINCK M, 1989, INT J LEPROSY, V57, P540; COLSTON M J, 1987, International Journal of Leprosy and Other Mycobacterial Diseases, V55, P859; DEWIT MYL, 1991, J CLIN MICROBIOL, V29, P906, DOI 10.1128/JCM.29.5.906-910.1991; Grosset J H, 1986, Lepr Rev, V57 Suppl 3, P223; GROSSET JH, 1988, INT J LEPROSY, V56, P259; Haas M, 1993, Int J Antimicrob Agents, V2, P117, DOI 10.1016/0924-8579(93)90050-F; HARTSKEERL RA, 1989, J GEN MICROBIOL, V135, P2357; HONORE N, 1993, ANTIMICROB AGENTS CH, V37, P414, DOI 10.1128/AAC.37.3.414; Leiker D L, 1971, Lepr Rev, V42, P121; MCCULLAGH P, 1984, GENERALIZED LINEAR M, P1; MCRAE DH, 1971, INFECT IMMUN, V3, P116, DOI 10.1128/IAI.3.1.116-120.1971; REES RJW, 1985, LEPROSY, P31; Ridley D S, 1966, Int J Lepr Other Mycobact Dis, V34, P255; RIDLEY D. S., 1958, LEPROSY REV, V29, P45; RIDLEY D. S., 1955, TRANS ROY SOC TROP MED AND HYG, V49, P449, DOI 10.1016/0035-9203(55)90010-9; Ridley D S, 1967, Int J Lepr Other Mycobact Dis, V35, P184; Ridley M J, 1971, Lepr Rev, V42, P88; SHEPARD CC, 1974, AM J TROP MED HYG, V23, P1120, DOI 10.4269/ajtmh.1974.23.1120; Sheppard CC, 1985, LEPROSY, P269; VEGALOPEZ F, 1993, INFECT IMMUN, V61, P2145; Waters M F, 1974, Lepr Rev, V45, P288; WATERS M F, 1962, Int J Lepr, V30, P266; WILLIAMS DL, 1990, J INFECT DIS, V162, P193, DOI 10.1093/infdis/162.1.193; WILLIAMS DL, 1992, MOL CELL PROBE, V6, P401, DOI 10.1016/0890-8508(92)90034-U; WOODS SA, 1989, FEMS MICROBIOL LETT, V65, P305; WHO82 TECH REP, P675; 1987, INT J LEPROSY, V55, P864	29	37	40	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 31	1993	342	8866					264	268		10.1016/0140-6736(93)91816-5	http://dx.doi.org/10.1016/0140-6736(93)91816-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ163	8101301				2022-12-28	WOS:A1993LQ16300009
J	BRESTERS, D; MAUSERBUNSCHOTEN, EP; REESINK, HW; ROOSENDAAL, G; VANDERPOEL, CL; CHAMULEAU, RAFM; JANSEN, PLM; WEEGINK, CJ; CUYPERS, HTM; LELIE, PN; VANDENBERG, HM				BRESTERS, D; MAUSERBUNSCHOTEN, EP; REESINK, HW; ROOSENDAAL, G; VANDERPOEL, CL; CHAMULEAU, RAFM; JANSEN, PLM; WEEGINK, CJ; CUYPERS, HTM; LELIE, PN; VANDENBERG, HM			SEXUAL TRANSMISSION OF HEPATITIS-C VIRUS	LANCET			English	Note							SPOUSES; SEMEN	We tested 50 heterosexual partners of hepatitis C viraemic (HCV) individuals, using second generation HCV antibody assays and a validated polymerase chain reaction assay. In none of them were HCV antibodies or HCV-RNA detected. The median duration of the sexual relationship was 13 years. This study, with the most sensitive techniques for detection of HCV, indicates that the risk of sexual transmission of HCV is absent or very low.	NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,1105 AZ AMSTERDAM,NETHERLANDS; UNIV UTRECHT HOSP,VAN CREVELD CLIN,3511 GV UTRECHT,NETHERLANDS; PRINSENGRACHT HOSP,AMSTERDAM,NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam; Utrecht University; Utrecht University Medical Center	BRESTERS, D (corresponding author), RED CROSS BLOOD BANK,POB 9137,1006 AC AMSTERDAM,NETHERLANDS.		Jansen, Peter LM/I-4509-2013; Valente, Guido/B-9714-2013					AKAHANE Y, 1992, LANCET, V339, P1059, DOI 10.1016/0140-6736(92)90585-Q; BRETTLER DB, 1992, BLOOD, V80, P540; CYPERS HTM, 1992, J CLIN MICROBIOL, V30, P3220; HSU HH, 1991, HEPATOLOGY, V14, P763, DOI 10.1002/hep.1840140504; JENISON SA, 1987, J INFECT DIS, V156, P299, DOI 10.1093/infdis/156.2.299; KAO JH, 1992, J INFECT DIS, V166, P900, DOI 10.1093/infdis/166.4.900; KELLOGG DE, 1990, PCR PROTOCOLS GUIDE, P343; OSMOND DH, 1993, JAMA-J AM MED ASSOC, V269, P361, DOI 10.1001/jama.269.3.361; TERADA S, 1992, ANN INTERN MED, V117, P171, DOI 10.7326/0003-4819-117-2-171_2; Urdea M S, 1991, Nucleic Acids Symp Ser, P197; ZAAIJER HL, 1993, LANCET, V341, P722, DOI 10.1016/0140-6736(93)90488-3	11	189	189	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 24	1993	342	8865					210	211		10.1016/0140-6736(93)92300-I	http://dx.doi.org/10.1016/0140-6736(93)92300-I			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN622	8100931				2022-12-28	WOS:A1993LN62200013
J	MANGLA, B				MANGLA, B			LEPROSY VACCINE DEBATE IN INDIA RE-IGNITED	LANCET			English	Editorial Material																		1992, LANCET, V339, P446	1	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 24	1993	342	8865					233	233		10.1016/0140-6736(93)92314-J	http://dx.doi.org/10.1016/0140-6736(93)92314-J			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN622	8100944				2022-12-28	WOS:A1993LN62200026
J	LANDRY, SJ; ZEILSTRARYALLS, J; FAYET, O; GEORGOPOULOS, C; GIERASCH, LM				LANDRY, SJ; ZEILSTRARYALLS, J; FAYET, O; GEORGOPOULOS, C; GIERASCH, LM			CHARACTERIZATION OF A FUNCTIONALLY IMPORTANT MOBILE DOMAIN OF GROES	NATURE			English	Article							ESCHERICHIA-COLI; PROTEIN; CHAPERONIN; ATP	ALTHOUGH genetic1 and biochemical2,3 evidence has established that GroES is required for the full function of the molecular chaperone, GroEL, little is known about the molecular details of their interaction. GroES enhances the cooperativity of ATP binding and hydrolysis by GroEL (refs 4, 5) and is necessary for release and folding of several GroEL substrates6. Here we report that native GroES has a highly mobile and accessible polypeptide loop whose mobility and accessibility are lost upon formation of the GroES/GroEL complex. In addition, lesions present in eight independently isolated mutant groES alleles map in the mobile loop. Studies with synthetic peptides suggest that the loop binds in a hairpin conformation at a site on GroEL that is distinct from the substrate-binding site. Flexibility may be required in the mobile loops on the GroES seven-mer to allow them to bind simultaneously to sites on seven GroEL subunits, which may themselves be able to adopt different arrangements, and thus to modulate allosterically GroEL/substrate affinity.	UNIV TEXAS,SW MED CTR,DALLAS,TX 75235; UNIV GENEVA,DEPT BIOCHIM MED,CH-1211 GENEVA 4,SWITZERLAND; UNIV UTAH,MED CTR,SALT LAKE CITY,UT 84132	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Geneva; Utah System of Higher Education; University of Utah			Landry, Samuel/AAK-5778-2020; Gierasch, Lila M/D-1494-2009	Landry, Samuel/0000-0002-4082-0543; 				BERTSCH U, 1992, P NATL ACAD SCI USA, V89, P8696, DOI 10.1073/pnas.89.18.8696; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CREIGHTON TE, 1991, NATURE, V352, P17, DOI 10.1038/352017a0; GEORGOPOULOS CP, 1973, J MOL BIOL, V76, P45, DOI 10.1016/0022-2836(73)90080-6; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; HARTMAN DJ, 1992, P NATL ACAD SCI USA, V89, P3394, DOI 10.1073/pnas.89.8.3394; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; JAENICKE R, 1993, CURR OPIN STRUC BIOL, V3, P104, DOI 10.1016/0959-440X(93)90209-4; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; LANDRY SJ, 1992, NATURE, V355, P45; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LUBBEN TH, 1990, P NATL ACAD SCI USA, V87, P7683, DOI 10.1073/pnas.87.19.7683; MARION D, 1989, J MAGN RESON, V84, P425, DOI 10.1016/0022-2364(89)90391-0; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; NILSSON B, 1991, ANNU REV MICROBIOL, V45, P607; OHTAKA C, 1992, J BACTERIOL, V174, P1869, DOI 10.1128/jb.174.6.1869-1874.1992; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; TILLY K, 1982, J BACTERIOL, V149, P1082, DOI 10.1128/JB.149.3.1082-1088.1982; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; Wuthrich K., 1986, NMR PROTEINS NUCL AC	24	212	214	1	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 15	1993	364	6434					255	258		10.1038/364255a0	http://dx.doi.org/10.1038/364255a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM683	8100614				2022-12-28	WOS:A1993LM68300063
J	GURNEY, H; GRILL, V; MARTIN, TJ				GURNEY, H; GRILL, V; MARTIN, TJ			PARATHYROID HORMONE-RELATED PROTEIN AND RESPONSE TO PAMIDRONATE IN TUMOR-INDUCED HYPERCALCEMIA	LANCET			English	Article							MALIGNANCY-ASSOCIATED HYPERCALCEMIA; SERUM-CALCIUM; BISPHOSPHONATE; THRESHOLD; SINGLE	To find out if the concentration of parathyroid hormone-related protein (PTHrP) predicts the response of tumour-inducing hypercalcaemia (TIH) to pamidronate, we studied 44 patients. Pretreatment measurements of serum PTHrP, calcium and phosphate, nephrogenous cyclic AMP, tubular threshold for calcium and phosphate (TmP), and the presence of bone metastases were correlated with response to pamidronate. Response was considered good (normal calcium concentration corrected for albumin [CCa] for > 14 days), or poor (failure of CCa to fall, or a rise above normal less-than-or-equal-to 14 days). PTHrP correlated significantly with response (good vs poor, p = 0.02). Undetectable PTHrP (< 2 pmol/L) was associated with a good response in all seven treatments, PTHrP in the range 2-12 pmol/L was associated with good response in 10 of 14 treatments, while PTHrP greater-than-or-equal-to 12 pmol/L was associated with a poor response in all 11 treatments. Tubular threshold for calcium correlated with the fall in CCa by day 6 after treatment (p = 0.02). Urinary clearance estimations in poor responders suggested that there was an incomplete reversal of the renal tubular component of hypercalcaemia. Serum PTHrP correlates with response to pamidronate in the treatment of TIH; which may be associated with a renal tubular mechanism not significantly affected by currently available treatment. Drugs that inhibit tubular reabsorption of calcium or PTHrP secretion may help in patients who do not respond to pamidronate.	ST VINCENTS HOSP,DEPT MED,FITZROY,VIC 3065,AUSTRALIA; ST VINCENTS HOSP,INST MED RES,FITZROY,VIC 3065,AUSTRALIA	St Vincent's Hospital Melbourne; St Vincent's Hospital Melbourne; University of Sydney; Westmead Institute for Medical Research	GURNEY, H (corresponding author), WESTMEAD HOSP,DEPT MED ONCOL & PALLIAT CARE,WESTMEAD,NSW 2145,AUSTRALIA.		Gurney, Howard/ABF-6924-2020	Gurney, Howard/0000-0003-0217-5261				BILEZIKIAN JP, 1992, NEW ENGL J MED, V326, P1196; BROADUS AE, 1977, ADV CYCLIC NUCLEOTID, P509; FLEISCH H, 1982, BONE MINERAL RES ANN, P319; GOLDMAN ME, 1988, ENDOCRINOLOGY, V123, P2597, DOI 10.1210/endo-123-5-2597; GRILL V, 1991, J CLIN ENDOCR METAB, V73, P1309, DOI 10.1210/jcem-73-6-1309; GRILL V, 1992, J CLIN ENDOCR METAB, V74, P1468, DOI 10.1210/jc.74.6.1468; GURNEY H, 1989, LANCET, V2, P241; KLEEREKOPER M, 1974, CLIN CHEM, V20, P369; KUKREJA SC, 1988, J CLIN INVEST, V82, P1798, DOI 10.1172/JCI113794; MARTIN TJ, 1991, CRIT REV BIOCHEM MOL, V26, P377, DOI 10.3109/10409239109114073; MUNDY GR, 1982, METABOLISM, V31, P1247, DOI 10.1016/0026-0495(82)90012-9; Nordin B.E.C., 1976, CALCIUM PHOSPHATE MA; POWELL GJ, 1991, CANCER RES, V51, P3059; RALSTON SH, 1987, BONE MINER, V2, P227; RALSTON SH, 1989, LANCET, V2, P617; THIEBAUD D, 1988, J CLIN ONCOL, V6, P762, DOI 10.1200/JCO.1988.6.5.762; VANBREUKELEN FJM, 1982, CALCIFIED TISSUE INT, V34, P321, DOI 10.1007/BF02411261; WALTON RJ, 1975, LANCET, V2, P309, DOI 10.1016/S0140-6736(75)92736-1; WARRELL RP, 1988, J CLIN ONCOL, V6, P759, DOI 10.1200/JCO.1988.6.5.759; WIRSCHEL SS, 1985, J CLIN INVEST, V76, P1851; YATES AJP, 1987, AUST NZ J MED, V17, P387, DOI 10.1111/j.1445-5994.1987.tb00070.x	21	79	79	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 26	1993	341	8861					1611	1613		10.1016/0140-6736(93)90756-7	http://dx.doi.org/10.1016/0140-6736(93)90756-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ727	8099988				2022-12-28	WOS:A1993LJ72700002
J	MORINIERE, BJ; VANLOON, FPL; RHODES, PH; KLEINZABBAN, ML; FRANKSENAT, B; HERRINGTON, JE; PALLANSCH, MA; PATRIARCA, PA				MORINIERE, BJ; VANLOON, FPL; RHODES, PH; KLEINZABBAN, ML; FRANKSENAT, B; HERRINGTON, JE; PALLANSCH, MA; PATRIARCA, PA			IMMUNOGENICITY OF A SUPPLEMENTAL DOSE OF ORAL VERSUS INACTIVATED POLIOVIRUS VACCINE	LANCET			English	Article							COST-EFFECTIVENESS; ENHANCED-POTENCY; POLIOMYELITIS; IMMUNIZATION; STRATEGIES	In many developing countries, the immunogenicity of three doses of live, attenuated, oral poliovirus vaccine (OPV) is lower than that in industrialised countries. We evaluated serum neutralising antibody responses in 368 children aged 6 months and 346 children aged 9 months in Cote d'Ivoire who had previously received three doses of OPV at 2,3, and 4 months of age, and who were then randomised to receive a supplemental dose of OPV or enhanced-potency inactivated poliovirus vaccine (IPV) at the time of measles vaccination. Although both vaccines increased seroconversion to all three poliovirus types, antibody responses were greater in the IPV group. Among children with no detectable antibody at baseline, IPV was 2 to 14 times more likely than OPV to induce seroconversion (type 1, 80% vs 40% at 6 months [p < 0.001] and 81%vs 14% at 9 months [p < 0.001]; type 3, 76% vs 22% at 6 months [p < 0.001], and 67% vs 5% at 9 months [p < 0.001]). Among children with detectable antibody at baseline, IPV was 1-4 to 7 times more likely than OPV to elicit 4-fold or more rises in antibody titre (p < 0.01). Geometric mean titres (GMTs) to all three poliovirus types were also consistently higher among IPV recipients than in OPV recipients when measured 4-6 weeks and 13-17 months after vaccination. Administration of a supplemental dose of IPV or OPV, which requires no additional visits or changes in the existing immunisation schedule, might improve protection against paralytic poliomyelitis in communities with suboptimum seroconversion rates after three doses of OPV.	CTR DIS CONTROL, DIV IMMUNIZAT, ATLANTA, GA 30333 USA; CTR DIS CONTROL, INT HLTH PROGRAM OFF, ATLANTA, GA 30333 USA; CTR PROTECT MATERNELLE & INFANT KOUMASSI, ABIDJAN, COTE IVOIRE; CTR DIS CONTROL, DIV VIRAL & RICKETTSIAL DIS, ATLANTA, GA 30333 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA								CREESE AL, 1984, REV INFECT DIS, V6, pS404; CREESE AL, 1987, PAHO B, V21, P377; DEQUADROS CA, 1992, ANNU REV PUBL HEALTH, V13, P239, DOI 10.1146/annurev.publhealth.13.1.239; Finney D., 1964, STAT METHOD BIOL ASS, P524; Francis Thomas, 1957, EVALUATION 1954 FIEL; MCBEAN AM, 1988, AM J EPIDEMIOL, V128, P615, DOI 10.1093/oxfordjournals.aje.a115009; MORINIERE B, 1992, 32ND INT C ANT AG CH, P180; OTTEN MW, 1992, AM J EPIDEMIOL, V135, P381, DOI 10.1093/oxfordjournals.aje.a116299; PATRIARCA PA, 1988, LANCET, V1, P429; PATRIARCA PA, 1991, REV INFECT DIS, V13, P926; PATRIARCA PA, IN PRESS MEASLES POL; REICHLER MR, 1992, 32ND INT C ANT AG CH, P398; ROBERTSON SE, 1988, LANCET, V1, P897; SABIN AB, 1963, PEDIATRICS, V31, P623; SHEPARD DS, 1989, B WORLD HEALTH ORGAN, V67, P649; SIMOES EAF, 1985, AM J DIS CHILD, V139, P977, DOI 10.1001/archpedi.1985.02140120023021; Snedecor G. W, 1989, STAT METHODS, V8th; STREBEL PM, 1992, CLIN INFECT DIS, V14, P568, DOI 10.1093/clinids/14.2.568; SUTTER RW, 1991, LANCET, V338, P715, DOI 10.1016/0140-6736(91)91442-W; SUTTER RW, 1993, IN PRESS MEASLES POL; SWARTZ TA, 1989, EUR J EPIDEMIOL, V5, P143, DOI 10.1007/BF00156819; TULCHINSKY T, 1989, AM J PUBLIC HEALTH, V79, P1648, DOI 10.2105/AJPH.79.12.1648; WOOD DJ, 1991, WHO BS911660 EXP COM; WRIGHT PF, 1991, NEW ENGL J MED, V325, P1774, DOI 10.1056/NEJM199112193252504; 1988, TECHNICAL REPORT SER, V771; 1989, SAS STAT USERS GUIDE; 1992, EPIDEMIOL REC OL, V67, P113; 1992, 32ND INT C ANT AG CH, P263; 1992, MMWR, V41, P681; 1988, PROCEDURAL GUIDE POL, P22; 1992, EPI TECHNICAL SERIES, V1	31	65	67	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 19	1993	341	8860					1545	1550		10.1016/0140-6736(93)90693-B	http://dx.doi.org/10.1016/0140-6736(93)90693-B			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH550	8099637				2022-12-28	WOS:A1993LH55000001
J	BERAL, V				BERAL, V			BREAST-CANCER - MAMMOGRAPHIC SCREENING	LANCET			English	Editorial Material											BERAL, V (corresponding author), ICRF,CANC EPIDEMIOL UNIT,OXFORD,ENGLAND.							MILLER AB, 1992, CAN MED ASSOC J, V147, P1459; NYSTROM L, 1993, LANCET, V341, P973, DOI 10.1016/0140-6736(93)91067-V; PEETERS PHM, 1989, BRIT J CANCER, V59, P929, DOI 10.1038/bjc.1989.196; Shapiro S, 1985, Natl Cancer Inst Monogr, V67, P65; TABAR L, 1992, RADIOL CLIN N AM, V30, P187; [No title captured]	6	10	10	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 12	1993	341	8859					1509	1510		10.1016/0140-6736(93)90639-X	http://dx.doi.org/10.1016/0140-6736(93)90639-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LG242	8099384				2022-12-28	WOS:A1993LG24200008
J	LAMPETER, EF; HOMBERG, M; QUABECK, K; SCHAEFER, UW; WERNET, P; BERTRAMS, J; GROSSEWILDE, H; GRIES, FA; KOLB, H				LAMPETER, EF; HOMBERG, M; QUABECK, K; SCHAEFER, UW; WERNET, P; BERTRAMS, J; GROSSEWILDE, H; GRIES, FA; KOLB, H			TRANSFER OF INSULIN-DEPENDENT DIABETES BETWEEN HLA-IDENTICAL SIBLINGS BY BONE-MARROW TRANSPLANTATION	LANCET			English	Note							AUTOANTIBODIES; MELLITUS; MOUSE	Insulin-dependent diabetes was observed in a woman, aged 29, 4 years after transplantation of bone marrow from her HLA-identical brother with insulin-dependent diabetes. Both had classic symptoms and insulin dependency from onset. At diagnosis of diabetes the recipient was positive for high-titre islet cell antibodies (ICA) whereas she had been ICA negative before transplantation. Chromosomal analyses verified that all circulating leucocytes were of male donor type. These findings suggest transfer of insulin-dependent diabetes by bone marrow cells and confirm the immune nature of the disease.	UNIV ESSEN GESAMTHSCH,DEPT BONE MARROW TRANSPLANT,W-4300 ESSEN 1,GERMANY; UNIV DUSSELDORF,INST HAEMOSTASIS & BLOOD TRANSFUS,W-4000 DUSSELDORF 1,GERMANY; UNIV ESSEN GESAMTHSCH,INST IMMUNOL,W-4300 ESSEN 1,GERMANY; ELISABETH HOSP,DEPT LAB MED,ESSEN,GERMANY	University of Duisburg Essen; Heinrich Heine University Dusseldorf; University of Duisburg Essen	LAMPETER, EF (corresponding author), DIABET RES INST,HENNEKAMP 65,W-4000 DUSSELDORF 1,GERMANY.							BOHMER K, 1991, DIABETOLOGIA, V34, P830, DOI 10.1007/BF00408359; KUGLIN B, 1989, KLIN WOCHENSCHR, V67, P66, DOI 10.1007/BF01735654; NAKANO K, 1988, DIABETES, V37, P520, DOI 10.2337/diabetes.37.5.520; OLMOS P, 1988, DIABETOLOGIA, V31, P747, DOI 10.1007/BF00274777; SERREZE DV, 1990, DIABETOLOGIA, V33, P84, DOI 10.1007/BF00401045; SORG UR, 1992, EUR J IMMUNOGENET, V19, P391, DOI 10.1111/j.1744-313X.1992.tb00082.x; SUTHERLAND DER, 1989, DIABETES, V38, P85, DOI 10.2337/diab.38.1.S85; TARN AC, 1988, LANCET, V1, P845; WICKER LS, 1988, J EXP MED, V167, P1801, DOI 10.1084/jem.167.6.1801; [No title captured]	10	163	164	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 15	1993	341	8855					1243	1244		10.1016/0140-6736(93)91148-F	http://dx.doi.org/10.1016/0140-6736(93)91148-F			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LC497	8098394				2022-12-28	WOS:A1993LC49700006
J	LARKINS, R				LARKINS, R			TREATMENT OF GRAVES OPHTHALMOPATHY	LANCET			English	Editorial Material							EYE DISEASE; MANAGEMENT				LARKINS, R (corresponding author), ROYAL MELBOURNE HOSP,DEPT MED,PARKVILLE,VIC 3050,AUSTRALIA.							BAHN RS, 1990, J CLIN ENDOCR METAB, V71, P559, DOI 10.1210/jcem-71-3-559; BARTALENA L, 1983, J CLIN ENDOCR METAB, V56, P1139, DOI 10.1210/jcem-56-6-1139; DONALDSON SS, 1973, J CLIN ENDOCR METAB, V37, P276, DOI 10.1210/jcem-37-2-276; FELLS P, 1991, LANCET, V338, P29, DOI 10.1016/0140-6736(91)90014-G; WEETMAN AP, 1991, LANCET, V338, P25, DOI 10.1016/0140-6736(91)90013-F	5	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 16	1993	342	8877					941	941		10.1016/0140-6736(93)91995-X	http://dx.doi.org/10.1016/0140-6736(93)91995-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MC005	8105207				2022-12-28	WOS:A1993MC00500002
J	LOCKWOOD, APM				LOCKWOOD, APM			ALIENS AND INTERLOPERS AT SEA	LANCET			English	Editorial Material											LOCKWOOD, APM (corresponding author), UNIV SOUTHAMPTON,DEPT OCEANOG,SOUTHAMPTON SO9 5NH,HANTS,ENGLAND.							CARLTON JT, 1993, SCIENCE, V261, P78, DOI 10.1126/science.261.5117.78; CLARK RB, 1968, LANCET, V2, P770; CRAWFORD DW, 1993, TOXIC PHYTOPLANKTON, P389; ELSTON RA, 1986, DIS AQUAT ORGAN, V2, P49, DOI 10.3354/dao002049; Lockwood A.P.M., 1986, IFREMER Actes de Colloques, P421; PEARSON RCM, 1968, LANCET, P767; PERKINS FO, 1993, PATHOBIOLOGY MARINE, P255; RIGBY GR, 1993, TOXIC PHYTOPLANKTON, P169; THORP CH, 1980, NATURAL ENV RES CO C, V22, P76; TUBBS CR, 1980, NATURAL ENV RES CO C, V22, P1	10	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 16	1993	342	8877					942	944		10.1016/0140-6736(93)91998-2	http://dx.doi.org/10.1016/0140-6736(93)91998-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MC005	8105210				2022-12-28	WOS:A1993MC00500005
J	ROSCH, PJ				ROSCH, PJ			STRESSFUL LIFE EVENTS AND GRAVES-DISEASE	LANCET			English	Editorial Material											ROSCH, PJ (corresponding author), AMER INST STRESS,NEW YORK,NY, USA.							HADDEN DR, 1974, LANCET, V2, P577; MEANS JH, 1948, THYROID ITS DISEASES, P295; ORTHGOMER K, 1990, PSYCHOSOM MED, V52, P59, DOI 10.1097/00006842-199001000-00005; ROSCH PJ, 1992, LANCET, V339, P428; SONINO N, 1993, ACTA ENDOCRINOL-COP, V128, P293, DOI 10.1530/acta.0.1280293; UTIGER RD, 1991, NEW ENGL J MED, V325, P278, DOI 10.1056/NEJM199107253250410; WINSA B, 1991, LANCET, V338, P1475, DOI 10.1016/0140-6736(91)92298-G	7	12	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 4	1993	342	8871					566	567		10.1016/0140-6736(93)91402-8	http://dx.doi.org/10.1016/0140-6736(93)91402-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV963	8102712				2022-12-28	WOS:A1993LV96300002
J	HARRIES, AD				HARRIES, AD			MALARIA - KEEPING THE MOSQUITOS AT BAY	LANCET			English	Editorial Material							TREATED BED NETS; GAMBIAN CHILDREN; AFRICA				HARRIES, AD (corresponding author), UNIV MALAWI, DEPT MED, BLANTYRE, MALAWI.							ALONSO PL, 1991, LANCET, V337, P1499, DOI 10.1016/0140-6736(91)93194-E; GREENWOOD BM, 1988, LANCET, V1, P1121; GREENWOOD BM, 1993, T R SOC TROP MED S2, V87; SNOW RW, 1988, T ROY SOC TROP MED H, V82, P212, DOI 10.1016/0035-9203(88)90414-2; SNOW RW, 1992, LANCET, V340, P351, DOI 10.1016/0140-6736(92)91414-4; SNOW RW, 1988, T ROY SOC TROP MED H, V82, P838, DOI 10.1016/0035-9203(88)90011-9; SPENCER H C, 1987, Annals of Tropical Medicine and Parasitology, V81, P36; STURCHLER D, 1989, PARASITOL TODAY, V5, P39, DOI 10.1016/0169-4758(89)90188-9	8	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 28	1993	342	8870					506	507		10.1016/0140-6736(93)91639-4	http://dx.doi.org/10.1016/0140-6736(93)91639-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU582	8102660				2022-12-28	WOS:A1993LU58200002
J	BERTRAND, D; HARDING, T				BERTRAND, D; HARDING, T			EUROPEAN GUIDELINES ON PRISON HEALTH	LANCET			English	Editorial Material											BERTRAND, D (corresponding author), UNIV GENEVA,INST LEGAL MED,CH-1211 GENEVA 4,SWITZERLAND.							[Anonymous], 1991, Lancet, V337, P647; HARDING T, 1993, LANCET, V341, P24, DOI 10.1016/0140-6736(93)92488-F; HARDING TW, 1989, LANCET, V1, P1191; 1991, LANCET, V338, P1559; 1993, EUROPEAN COMMITTEE; 1993, WHO GUIDELINES HIV I	6	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 31	1993	342	8866					253	254		10.1016/0140-6736(93)91811-Y	http://dx.doi.org/10.1016/0140-6736(93)91811-Y			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ163	8101296				2022-12-28	WOS:A1993LQ16300004
J	COCKBURN, F; COOKE, RWI; GAMSU, HR; GREENOUGH, A; HOPKINS, A; MCINTOSH, N; OGSTON, SA; PARRY, GJ; SILVERMAN, M; SHAW, JCL; TARNOWMORDI, WO; WILKINSON, AR				COCKBURN, F; COOKE, RWI; GAMSU, HR; GREENOUGH, A; HOPKINS, A; MCINTOSH, N; OGSTON, SA; PARRY, GJ; SILVERMAN, M; SHAW, JCL; TARNOWMORDI, WO; WILKINSON, AR			THE CRIB (CLINICAL RISK INDEX FOR BABIES) SCORE - A TOOL FOR ASSESSING INITIAL NEONATAL RISK AND COMPARING PERFORMANCE OF NEONATAL INTENSIVE-CARE UNITS	LANCET			English	Article							BIRTH-WEIGHT INFANTS; PRETERM INFANTS; PREDICTION; MORTALITY; ULTRASOUND; SEVERITY; DELIVERY; SYSTEM; TIME	Assessment of different hospitals' performance in neonatal intensive care has tended to rely on risk of mortality adjusted only for birthweight. We have developed a neonatal scoring system, CRIB (clinical risk index for babies), to take account of other factors. Scores are given for birthweight, gestational age, maximum and minimum fraction of inspired oxygen and maximum base excess during the first 12 h, and presence of congenital malformations. CRIB was developed retrospectively in a cohort of 812 infants of birthweight 1500 g or less or gestational age less than 31 weeks treated in four UK tertiary hospitals between 1988 and 1990. The scoring system was then validated by comparing its value as a predictor of hospital death with that of birthweight in a separate cohort of 488 similar infants. The area under the receiver operating characteristic (ROC) curve for predicting death in this validation cohort (a measure of the predictor's accuracy) was significantly greater for CRIB than for birthweight alone (0.90 [SE 0.05] vs 0.78 [0.03], p=0.03). Both indices of initial risk were used to assess the performance of nine tertiary and four non-tertiary hospitals in the UK We looked at hospital mortality among the 1300 infants in the development and validation cohorts plus 248 other infants of birthweight 1500 g or less or gestational age less than 31 weeks. Without adjustment for initial risk, there was no clear difference in group mortality between the tertiary and non-tertiary hospitals. However, calculation of risk-adjusted mortality by means of CRIB showed that babies were twice as likely to die in the non-tertiary hospitals as in the tertiary hospitals (odds ratio 2.12 [95% CI 1.39-3.24]). Adjustment for birthweight alone also showed higher odds of death in non-tertiary hospitals (1.45 [1.01-2.11]). CRIB is a robust index of initial neonatal risk that is more accurate than birthweight and simple enough for routine use. International comparisons of staffing policy and organisation of neonatal intensive care units are needed to investigate the reasons for variations in performance.	UNIV DUNDEE, NINEWELLS HOSP & MED SCH, DEPT CHILD HLTH, DUNDEE DD1 9SY, SCOTLAND; LIVERPOOL MATERN HOSP, LIVERPOOL, ENGLAND; ROYAL HOSP SICK CHILDREN, GLASGOW G3 8SJ, SCOTLAND; SIMPSON MEM MATERN PAVIL, EDINBURGH, SCOTLAND; HAMMERSMITH HOSP, LONDON W12 0HS, ENGLAND; UNIV LONDON KINGS COLL HOSP, LONDON SE5 8RX, ENGLAND; UNIV COLL HOSP LONDON, WC1 LONDON, ENGLAND; JOHN RADCLIFFE HOSP, OXFORD OX3 9DU, ENGLAND	University of Dundee; University of Glasgow; Imperial College London; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; University College London Hospitals NHS Foundation Trust; University of Oxford			Valls, Adolfo/E-1358-2012; Parry, Gareth/CAF-6975-2022		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		[Anonymous], 1980, Lancet, V1, P461; BOYD O, 1993, LANCET, V341, P1573, DOI 10.1016/0140-6736(93)90706-M; COLE TJ, 1993, APPL STAT-J ROY ST C, V42, P261; COSTELLO AMD, 1988, DEV MED CHILD NEUROL, V30, P711; CROWLEY P, 1990, BRIT J OBSTET GYNAEC, V97, P11, DOI 10.1111/j.1471-0528.1990.tb01711.x; FARLEY DE, 1992, MED CARE, V30, P77, DOI 10.1097/00005650-199201000-00009; FIELD D, 1991, ARCH DIS CHILD-FETAL, V66, P408, DOI 10.1136/adc.66.4_Spec_No.408; GRAHAM M, 1987, LANCET, V2, P593; GRAY J E, 1992, Pediatric Research, V31, p249A; GREENLAND S, 1981, MED CARE, V19, P872, DOI 10.1097/00005650-198108000-00006; HANLEY JA, 1983, RADIOLOGY, V148, P839, DOI 10.1148/radiology.148.3.6878708; HORBAR JD, 1993, CRIT CARE MED, V21, P12, DOI 10.1097/00003246-199301000-00008; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; KINMOND S, 1993, BMJ-BRIT MED J, V306, P172, DOI 10.1136/bmj.306.6871.172; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; LEVENE MI, 1981, ARCH DIS CHILD, V56, P900, DOI 10.1136/adc.56.12.900; PANETH N, 1982, NEW ENGL J MED, V307, P149, DOI 10.1056/NEJM198207153070303; Patterson C C, 1988, Paediatr Perinat Epidemiol, V2, P221, DOI 10.1111/j.1365-3016.1988.tb00211.x; POLLACK MM, 1987, NEW ENGL J MED, V316, P134, DOI 10.1056/NEJM198701153160304; POLLACK MM, 1991, CRIT CARE MED, V19, P150, DOI 10.1097/00003246-199102000-00007; POLLACK MM, 1988, CRIT CARE MED, V16, P1110, DOI 10.1097/00003246-198811000-00006; RICHARDSON DK, 1993, PEDIATRICS, V91, P969; RICHARDSON DK, 1993, PEDIATRICS, V91, P617; ROWAN KM, 1992, THESIS U OXFORD OXFO; STILWELL J, 1988, J EPIDEMIOL COMMUN H, V42, P157, DOI 10.1136/jech.42.2.157; TARNOWMORDI W, 1990, BRIT MED J, V300, P1611, DOI 10.1136/bmj.300.6740.1611; 1992, OUTCOME MEASUREMENTS	28	649	673	2	16	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 24	1993	342	8865					193	198						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN622	8100927				2022-12-28	WOS:A1993LN62200009
J	BARLOW, DH				BARLOW, DH			MANAGING THE MENOPAUSE - FROM PUMPKINS TO HRT	LANCET			English	Editorial Material											BARLOW, DH (corresponding author), JOHN RADCLIFFE HOSP,NUFFIELD DEPT OBSTET & GYNAECOL,OXFORD OX3 9DU,ENGLAND.		Barlow, David/F-8738-2011					BARLOW DH, 1989, BRIT J OBSTET GYNAEC, V96, P1192, DOI 10.1111/j.1471-0528.1989.tb03195.x; BARLOW DH, 1992, BRIT MED BULL, V48, P356, DOI 10.1093/oxfordjournals.bmb.a072551; BUNGAY GT, 1980, BRIT MED J, V2, P181; CHAKRAVARTI S, 1977, BRIT J OBSTET GYNAEC, V84, P769, DOI 10.1111/j.1471-0528.1977.tb12491.x; GARNETT T, 1991, J ROY SOC MED, V84, P128, DOI 10.1177/014107689108400304; GATH D, 1990, HRT AND OSTEOPOROSIS, P35; OLDENHAVE A, 1993, AM J OBSTET GYNECOL, V168, P765, DOI 10.1016/S0002-9378(12)90816-9; OLDENHAVE A, 1993, AM J OBSTET GYNECOL, V168, P772, DOI 10.1016/S0002-9378(12)90817-0; SPECTOR TD, 1989, BRIT MED J, V299, P1434, DOI 10.1136/bmj.299.6713.1434	9	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 10	1993	342	8863					66	67		10.1016/0140-6736(93)91280-Y	http://dx.doi.org/10.1016/0140-6736(93)91280-Y			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LL789	8100907				2022-12-28	WOS:A1993LL78900004
J	TAMASHIRO, H; MASKILL, W; EMMANUEL, J; FAUQUEX, A; SATO, P; HEYMANN, D				TAMASHIRO, H; MASKILL, W; EMMANUEL, J; FAUQUEX, A; SATO, P; HEYMANN, D			REDUCING THE COST OF HIV ANTIBODY TESTING	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; POOLED SERA; DEVELOPING-COUNTRIES; ASSAYS; SALIVA; SEROPREVALENCE; SPECIFICITY; SENSITIVITY; PREVALENCE	Available tests to detect antibody to human immunodeficiency virus (HIV) have a range of applications, and injudicious selection and inappropriate use can add a significant financial burden to budgets for AIDS programmes in developing countries. There are several ways by which the cost of HIV antibody testing can be reduced; they include use of tests appropriate for existing laboratory capabilities; adoption of cost-effective testing strategies; pooling of serum samples before testing; and ensuring best possible purchase prices. Each approach can significantly reduce the cost of HIV antibody testing alone or in combination, which increases the potential sustainability of antibody testing programmes, even in settings of limited resources.	WHO,GLOBAL PROGRAMME AIDS,OFF COOPERAT NATL PROGRAMME,CH-1211 GENEVA 27,SWITZERLAND; FAIRFIELD HOSP,DEPT VIROL,MELBOURNE,AUSTRALIA	World Health Organization	TAMASHIRO, H (corresponding author), WHO,GLOBAL PROGRAMME AIDS,OFF RES,DIAGNOST UNIT,CH-1211 GENEVA 27,SWITZERLAND.		Tamashiro, Hidehiko/B-2403-2013					BEHETS F, 1990, AIDS, V4, P737, DOI 10.1097/00002030-199008000-00004; CAHOONYOUNG B, 1989, J CLIN MICROBIOL, V27, P1893, DOI 10.1128/JCM.27.8.1893-1895.1989; CONNELL JA, 1990, LANCET, V335, P1366, DOI 10.1016/0140-6736(90)91245-6; EMMANUEL JC, 1988, J CLIN PATHOL, V41, P582, DOI 10.1136/jcp.41.5.582; FROSNER GG, 1990, AIDS, V4, P73, DOI 10.1097/00002030-199001000-00010; JOHNSON AM, 1988, AIDS, V2, P369, DOI 10.1097/00002030-198810000-00006; KLINE RL, 1989, J CLIN MICROBIOL, V27, P1449, DOI 10.1128/JCM.27.7.1449-1452.1989; LILLO F, 1992, B WORLD HEALTH ORGAN, V70, P323; MAJOR CJ, 1991, J INFECT DIS, V163, P699, DOI 10.1093/infdis/163.4.699; MITCHELL SW, 1991, LANCET, V337, P1328, DOI 10.1016/0140-6736(91)92991-A; MONZON OT, 1992, AIDS, V6, P35; MORTIMER J, 1992, B WORLD HEALTH ORGAN, V70, P751; MORTIMER PP, 1991, LANCET, V337, P286; MORTIMER PP, 1991, REV MED VIROL, V1, P73; NKENGASONG J, 1992, ANN SOC BELG MED TR, V72, P129; PARRY JV, 1987, LANCET, V2, P72, DOI 10.1016/S0140-6736(87)92737-1; PARRY JV, 1989, AIDS, V3, P173, DOI 10.1097/00002030-198903000-00008; SCHOCHETMAN G, 1989, ANNU REV MICROBIOL, V43, P629; SPIELBERG F, 1989, LANCET, V1, P580; SPIELBERG FA, 1990, J CLIN MICROBIOL, V28, P303, DOI 10.1128/JCM.28.2.303-306.1990; SVENDSEN J, 1990, LANCET, V336, P1198, DOI 10.1016/0140-6736(90)92822-Y; TAMASHIRO H, 1991, 6TH INT C AIDS AFR D, P15; URASSA WK, 1992, J ACQ IMMUN DEF SYND, V5, P170; VANDERGROEN G, 1991, B WORLD HEALTH ORGAN, V69, P747; VANKERCKHOVEN I, 1991, B WORLD HEALTH ORGAN, V69, P753; WEISS SH, 1985, JAMA-J AM MED ASSOC, V253, P221, DOI 10.1001/jama.253.2.221; 1992, WHO WEEKLY EPIDEMIOL, V20, P145; WHO GPABMR894 DOC; WHO GPARESDIA901 DOC; 1990, WHO WEEKLY EPIDEMIOL, V37, P281; 1991, WHO WEEKLY EPIDEMIOL, V44, P326; WHO GPABMR901 DOC; WHO GPARESDIA916 DOC	33	64	64	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 10	1993	342	8863					87	90		10.1016/0140-6736(93)91289-X	http://dx.doi.org/10.1016/0140-6736(93)91289-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LL789	8100916				2022-12-28	WOS:A1993LL78900013
J	SISSONS, JGP				SISSONS, JGP			IMMUNOLOGY - SUPERANTIGENS AND INFECTIOUS-DISEASE	LANCET			English	Editorial Material											SISSONS, JGP (corresponding author), UNIV CAMBRIDGE,SCH CLIN,DEPT MED,CAMBRIDGE,ENGLAND.							ABE J, 1992, P NATL ACAD SCI USA, V89, P4066, DOI 10.1073/pnas.89.9.4066; BOWNESS P, 1992, J EXP MED, V176, P893, DOI 10.1084/jem.176.3.893; Cole B C, 1991, Curr Top Microbiol Immunol, V174, P107; IMBERTI L, 1991, SCIENCE, V254, P860, DOI 10.1126/science.1948066; JOHNSON HM, 1992, SCI AM, V266, P92, DOI 10.1038/scientificamerican0492-92; LAURENCE J, 1992, NATURE, V358, P255, DOI 10.1038/358255a0; MARRACK P, 1993, IMMUNOL REV, V131, P79, DOI 10.1111/j.1600-065X.1993.tb01531.x; MIETHKE T, 1992, J EXP MED, V175, P91, DOI 10.1084/jem.175.1.91; MOLLER G, 1993, IMMUNOL REV, V131, P1; PALIARD X, 1991, SCIENCE, V253, P325, DOI 10.1126/science.1857971; TAKEI S, 1993, J CLIN INVEST, V91, P602, DOI 10.1172/JCI116240; WINSLOW GM, 1992, CELL, V71, P719, DOI 10.1016/0092-8674(92)90549-R	12	11	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 26	1993	341	8861					1627	1629		10.1016/0140-6736(93)90765-9	http://dx.doi.org/10.1016/0140-6736(93)90765-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ727	8099997				2022-12-28	WOS:A1993LJ72700011
J	ZHUO, M; SMALL, SA; KANDEL, ER; HAWKINS, RD				ZHUO, M; SMALL, SA; KANDEL, ER; HAWKINS, RD			NITRIC-OXIDE AND CARBON-MONOXIDE PRODUCE ACTIVITY-DEPENDENT LONG-TERM SYNAPTIC ENHANCEMENT IN HIPPOCAMPUS	SCIENCE			English	Article							CYCLIC-GMP; CELLULAR MECHANISM; SENSORY NEURONS; RAT HIPPOCAMPUS; POTENTIATION; TRANSMISSION; MESSENGER; PROTOPORPHYRIN; INHIBITION; ACTIVATION	Nitric oxide (NO) and carbon monoxide (CO) may act as retrograde messages for long-term potentiation (LTP) in the hippocampus. Zinc protoporphyrin IX, an inhibitor of the enzyme that produces CO, blocked induction of LTP in the CA1 region of hippocampal slices. Application of either NO or CO to slices produced a rapid and long-lasting increase in the size of evoked synaptic potentials if, and only if, the application occurred at the same time as weak tetanic stimulation. This long-term enhancement was spatially restricted to synapses from active presynaptic fibers and appeared to involve mechanisms utilized by LTP, occluding the subsequent induction of LTP by strong tetanic stimulation. The enhancement by NO and CO was not blocked by an N-methyl-D-aspartate (NMDA) receptor blocker, suggesting that NO and CO act downstream from the NMDA receptor. Also, CO produced long-term enhancement when paired with low-frequency stimulation. These results are consistent with the hypothesis that NO and CO, either alone or in combination, serve as retrograde messages that produce activity-dependent presynaptic enhancement during LTP.	COLUMBIA UNIV COLL PHYS & SURG,NEW YORK STATE PSYCHIAT INST,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032; HOWARD HUGHES MED INST,NEW YORK,NY 10032	Columbia University; New York State Psychiatry Institute; Howard Hughes Medical Institute			Zhuo, Min/A-2072-2008	Zhuo, Min/0000-0001-9062-3241	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH045923, R37MH045923] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG008702] Funding Source: NIH RePORTER; NIA NIH HHS [AG08702] Funding Source: Medline; NIMH NIH HHS [MH45923] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDERSEN P, 1977, NATURE, V266, P736, DOI 10.1038/266736a0; ANIKSZTEJN L, 1991, NATURE, V349, P67, DOI 10.1038/349067a0; Bohme G. A., 1992, Society for Neuroscience Abstracts, V18, P640; BOHME GA, 1991, EUR J PHARMACOL, V199, P379, DOI 10.1016/0014-2999(91)90505-K; BONHOEFFER T, 1989, P NATL ACAD SCI USA, V86, P8113, DOI 10.1073/pnas.86.20.8113; BREDT DS, 1991, NEURON, V7, P615, DOI 10.1016/0896-6273(91)90374-9; BREEN CA, 1983, NATURE, V303, P716, DOI 10.1038/303716a0; CHAPMAN PF, 1992, NEUROREPORT, V3, P567, DOI 10.1097/00001756-199207000-00005; Chetkovich D. M., 1992, Society for Neuroscience Abstracts, V18, P761; CLARK GD, 1992, NEURON, V9, P1211, DOI 10.1016/0896-6273(92)90078-R; COLINO A, 1992, J NEUROSCI, V12, P180; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; EAST SJ, 1991, NEUROSCI LETT, V123, P17, DOI 10.1016/0304-3940(91)90147-L; EWING JF, 1992, MOL CELL NEUROSCI, V3, P559, DOI 10.1016/1044-7431(92)90068-D; GALLY JA, 1990, P NATL ACAD SCI USA, V87, P3547, DOI 10.1073/pnas.87.9.3547; GRIBKOFF VK, 1992, J NEUROPHYSIOL, V68, P639, DOI 10.1152/jn.1992.68.2.639; GROVER LM, 1990, NATURE, V347, P477, DOI 10.1038/347477a0; HALEY JE, 1992, NEURON, V8, P211, DOI 10.1016/0896-6273(92)90288-O; HAWKINS RD, 1983, SCIENCE, V219, P400, DOI 10.1126/science.6294833; HAWKINS RD, 1993, ANNU REV NEUROSCI, V16, P625, DOI 10.1146/annurev.ne.16.030193.003205; HAWKINS RD, 1990, SEMIN NEUROSCI, V2, P391; HUANG YY, 1993, J NEUROSCI, V13, P568; LI YG, 1992, SOC NEUR ABSTR, V18, P343; MACINTYRE I, 1991, P NATL ACAD SCI USA, V88, P2936, DOI 10.1073/pnas.88.7.2936; MAINES MD, 1981, BIOCHIM BIOPHYS ACTA, V673, P339, DOI 10.1016/0304-4165(81)90465-7; MARKS GS, 1991, TRENDS PHARMACOL SCI, V12, P185, DOI 10.1016/0165-6147(91)90544-3; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; ODELL TT, COMMUNICATION; QATO MK, 1985, BIOCHEM J, V226, P51, DOI 10.1042/bj2260051; SCHUMAN E M, 1991, Society for Neuroscience Abstracts, V17, P2; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SMALL SA, 1989, SCIENCE, V243, P1603, DOI 10.1126/science.2538924; STEVENS CF, IN PRESS NATURE; SWEATT JD, COMMUNICATION; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; WALTERS ET, 1983, SCIENCE, V219, P405, DOI 10.1126/science.6294834; WIGSTROM H, 1986, ACTA PHYSIOL SCAND, V126, P317, DOI 10.1111/j.1748-1716.1986.tb07822.x; WILLIAMS JH, 1989, NATURE, V341, P739, DOI 10.1038/341739a0; WOODY CD, 1978, BRAIN RES, V158, P373, DOI 10.1016/0006-8993(78)90682-0; ZHUO M, UNPUB	40	503	514	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 25	1993	260	5116					1946	1950		10.1126/science.8100368	http://dx.doi.org/10.1126/science.8100368			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LJ349	8100368				2022-12-28	WOS:A1993LJ34900044
J	VANDENBROECK, J; EECKELS, R; VUYLSTEKE, J				VANDENBROECK, J; EECKELS, R; VUYLSTEKE, J			INFLUENCE OF NUTRITIONAL-STATUS ON CHILD-MORTALITY IN RURAL ZAIRE	LANCET			English	Article							RISK; DEATH; MALNUTRITION; GUINEA; GROWTH; AGE	Although the association between nutritional status and mortality risk is obvious for extreme malnutrition, the issue is not so clear for mild to moderate undernutrition. We have investigated this association in children of 0-5 years in the rural area of Bwamanda, Zaire, where an integrated development project, with good medical facilities, has operated for 20 years. A random cluster sample of 5167 children was taken; newborn infants and immigrants were included at six quarterly survey rounds from October, 1989, until February, 1991. All surveys included clinical and anthropometric assessment of nutritional status. Deaths were recorded up to April, 1992; there were 246 deaths. Marasmus, kwashiorkor, and other causes of death were defined by the verbal autopsy method and checked against medical records kept at the central hospital and the peripheral dispensaries. As expected, we found an increased risk of death in severe malnutrition. When deaths directly attributed to marasmus or kwashiorkor were excluded, mild to moderate stunting or wasting were not associated with higher mortality in the short term (within 3 months of the previous study round) or in the long term (from 3-30 months after study entry). The commonest causes of death were malaria and anaemia. Extreme marasmus and kwashiorkor caused 16% of deaths, and are important causes of death even in this favoured area with an integrated development project. Nutritional interventions should be targeted more selectively so that children with moderate malnutrition can be protected from progression to marasmus or kwashiorkor.	INST TROP MED,ANTWERP,BELGIUM; CATHOLIC UNIV LEUVEN,DEPT PAEDIAT,B-3000 LOUVAIN,BELGIUM	Institute of Tropical Medicine (ITM); KU Leuven	VANDENBROECK, J (corresponding author), CATHOLIC UNIV LEUVEN,CTR HUMAN GENET,HERESTR 49,B-3000 LOUVAIN,BELGIUM.							ALAM N, 1989, AM J CLIN NUTR, V49, P884, DOI 10.1093/ajcn/49.5.884; BRIEND A, 1989, BRIT MED J, V298, P1607, DOI 10.1136/bmj.298.6688.1607; CHEN LC, 1980, AM J CLIN NUTR, V33, P1836, DOI 10.1093/ajcn/33.8.1836; HEYWOOD P, 1982, J FOOD NUTR, V39, P13; KALTER HD, 1991, INT J EPIDEMIOL, V20, P192; KATZ J, 1989, AM J EPIDEMIOL, V130, P1219, DOI 10.1093/oxfordjournals.aje.a115450; KIELMANN AA, 1978, LANCET, V1, P1247; LACKRITZ EM, 1992, LANCET, V340, P524, DOI 10.1016/0140-6736(92)91719-O; LINDSKOG U, 1988, ACTA PAEDIATR SCAND, V77, P260, DOI 10.1111/j.1651-2227.1988.tb10640.x; MORRIS JA, 1989, STAT CONFIDENCE, P50; SMEDMAN L, 1987, AM J CLIN NUTR, V46, P369, DOI 10.1093/ajcn/46.2.369; SNOW RW, 1992, LANCET, V340, P351, DOI 10.1016/0140-6736(92)91414-4; SOMMER A, 1975, AM J CLIN NUTR, V28, P287, DOI 10.1093/ajcn/28.3.287; SUZAWAL S, 1992, LANCET, V340, P528; VANLERBERGHE W, 1989, KASONGO CHILD MORTAL; VANLOON H, 1989, COMP ELEMENTARY EPID; VANLOON H, 1987, THESIS U LEUVEN BELG; Waterlow JC, 1992, PROTEIN ENERGY MALNU; 1976, MONTHLY VITAL STAT S, V25; 1986, B WORLD HEALTH ORGAN, V64, P707; 1988, SAS USERS GUIDE STAT	21	87	87	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 12	1993	341	8859					1491	1495		10.1016/0140-6736(93)90632-Q	http://dx.doi.org/10.1016/0140-6736(93)90632-Q			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LG242	8099378				2022-12-28	WOS:A1993LG24200002
J	FORMAN, D; COLEMAN, M; DEBACKER, G; EIDER, J; MOLLER, H; DAMOTTA, LC; ROY, P; ABID, L; DEBACKER, G; TJONNELAND, A; BOEING, H; HAUBRICH, T; WAHRENDORF, J; MANOUSOS, O; TULINIUS, H; OGMUNDSDOTTIR, H; PALLI, D; CIPRIANI, F; FUKAO, A; TSUGANE, S; MIYAJIMA, Y; ZATONSKI, W; TYCZYNSKI, J; CALHEIROS, J; ZAKELJ, MP; POTOCNIK, M; WEBB, P; KNIGHT, T; WILSON, A; KAYE, S; POTTER, J				FORMAN, D; COLEMAN, M; DEBACKER, G; EIDER, J; MOLLER, H; DAMOTTA, LC; ROY, P; ABID, L; DEBACKER, G; TJONNELAND, A; BOEING, H; HAUBRICH, T; WAHRENDORF, J; MANOUSOS, O; TULINIUS, H; OGMUNDSDOTTIR, H; PALLI, D; CIPRIANI, F; FUKAO, A; TSUGANE, S; MIYAJIMA, Y; ZATONSKI, W; TYCZYNSKI, J; CALHEIROS, J; ZAKELJ, MP; POTOCNIK, M; WEBB, P; KNIGHT, T; WILSON, A; KAYE, S; POTTER, J			AN INTERNATIONAL ASSOCIATION BETWEEN HELICOBACTER-PYLORI INFECTION AND GASTRIC-CANCER	LANCET			English	Article							ANTIBODY PREVALENCE; CARCINOMA; RISK	Gastric infection with Helicobacter pylori seems to be a risk factor for gastric cancer. We have conducted a multicentre epidemiological study to investigate this relation further. Our study was designed to look at the relation between the prevalence of H pylori infection and gastric cancer rates in 17 populations from 13 countries, chosen to reflect the global range of gastric cancer incidence. In each centre, about 50 males and 50 females in each of the two age groups 25-34 years and 55-64 years were selected at random from the local population and provided blood samples. Serum samples were assayed for the presence of IgG antibodies to H pylori in a single laboratory. Prevalence rates of H pylori seropositivity were related to local gastric cancer incidence and mortality rates using linear regression. There was a statistically significant relation between the prevalence of seropositivity and cumulative rates (0-74 years) for both gastric cancer incidence and mortality with regression coefficients of 2.68 (p=0.001) and 1.79 (p=0.002), respectively. Our findings are consistent with an approximately six-fold increased risk of gastric cancer in populations with 100% H pylori infection compared with populations that have no infection.	INST ONCOL, EPIDEMIOL UNIT, LJUBLJANA, SLOVENIA; BLOOD TRANSFUS CTR SLOVENIA, LJUBLJANA, SLOVENIA; UNIV MINNESOTA, DIV EPIDEMIOL, MINNEAPOLIS, MN 55455 USA; CTR STUDY & PREVENT CANC, EPIDEMIOL, FLORENCE, ITALY; TOHOKU UNIV, DEPT PUBL HLTH, SENDAI, MIYAGI 980, JAPAN; NATL CANC CTR, RES INST, ENVIRONM EPIDEMIOL SECT, TOKYO 104, JAPAN; YOKOTE HLTH CTR, AKITA, JAPAN; INST ONCOL, DEPT CANC CONTROL & EPIDEMIOL, PL-02034 WARSAW, POLAND; UNIV PORTO, INST BIOMED SCI ABEL SALAZER, EPIDEMIOL UNIT, OPORTO, PORTUGAL; DANISH CANC SOC, INST CANC EPIDEMIOL, DANISH CANC REGISTRY, COPENHAGEN, DENMARK; NATL SCH PUBL HLTH, LISBON, PORTUGAL; BOLOGHINE HOSP, REGISTRY DIGEST TRACT CANC, ALGIERS, ALGERIA; GERMAN CANC RES CTR, INST EPIDEMIOL & BIOMETRY, W-6900 HEIDELBERG 1, GERMANY; PHLS, CTR APPL MICROBIOL & RES, D G NEWELL, DEPT PATHOL, PORTON DOWN, ENGLAND; UNIV GEN HOSP CRETE, DEPT GASTROENTEROL, CRETEL, GREECE; INT AGCY RES CANC, DESCRIPT EPIDEMIOL UNIT, F-69372 LYON, FRANCE; STATE UNIV GHENT HOSP, DEPT HYG & SOCIAL MED, B-9000 GHENT, BELGIUM; UNIV KEELE, DEPT SURG, STOKE ON TRENT, ENGLAND; ICELAND CANC SOC, REYKJAVIK, ICELAND	Institute of Oncology - Slovenia; University of Minnesota System; University of Minnesota Twin Cities; Tohoku University; National Cancer Center - Japan; Maria Sklodowska-Curie National Research Institute of Oncology; Universidade do Porto; Danish Cancer Society; Helmholtz Association; German Cancer Research Center (DKFZ); World Health Organization; International Agency for Research on Cancer (IARC); Ghent University; Ghent University Hospital; Keele University	FORMAN, D (corresponding author), RADCLIFFE INFIRM, IMPERIAL CANC RES FUND, CANC EPIDEMIOL UNIT, GIBSON BLDG, OXFORD OX2 6HE, ENGLAND.		Ögmundsdóttir, Helga M/L-6970-2015; Tsugane, Shoichiro/A-2424-2015; De Backer, Guy/AAI-4607-2021; Webb, Penelope/D-5736-2013	Tsugane, Shoichiro/0000-0003-4105-2774; Webb, Penelope/0000-0003-0733-5930; Coleman, Michel/0000-0001-8940-3807; Roy, Pascal/0000-0003-3837-3198; Calheiros, Jose/0000-0002-2724-0675				CORREA P, 1990, CANCER-AM CANCER SOC, V66, P2569, DOI 10.1002/1097-0142(19901215)66:12<2569::AID-CNCR2820661220>3.0.CO;2-I; FORMAN D, 1990, INT J CANCER, V46, P608, DOI 10.1002/ijc.2910460410; FORMAN D, 1991, J NATL CANCER I, V83, P1702, DOI 10.1093/jnci/83.23.1702; FORMAN D, 1991, BRIT MED J, V302, P1302, DOI 10.1136/bmj.302.6788.1302; HOLCOMBE C, 1992, GUT, V33, P429, DOI 10.1136/gut.33.4.429; HOWSON CP, 1986, EPIDEMIOL REV, V8, P1; MUIR C, 1987, CANCER INCIDENCE 5 C, V5; NOMURA A, 1991, NEW ENGL J MED, V325, P1132, DOI 10.1056/NEJM199110173251604; PALLI D, 1993, CANCER EPIDEM BIOMAR, V2, P37; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; STEER HW, 1987, SERODIAG IMMUN INF D, V1, P23; TALLEY NJ, 1991, J CLIN MICROBIOL, V29, P1635, DOI 10.1128/JCM.29.8.1635-1639.1991; TAYLOR DN, 1991, EPIDEMIOL REV, V13, P42, DOI 10.1093/oxfordjournals.epirev.a036078	13	973	999	2	34	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 29	1993	341	8857					1359	1362						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE180	8098787				2022-12-28	WOS:A1993LE18000001
J	TUCKER, G				TUCKER, G			PHARMACOLOGY - DRUG DELIVERY - LYMPHING ALONG	LANCET			English	Editorial Material											TUCKER, G (corresponding author), UNIV SHEFFIELD,DEPT MED & PHARMACOL,SHEFFIELD S10 2TN,S YORKSHIRE,ENGLAND.							AUNGST BJ, 1992, PHARM RES-DORDR, V9, P1507, DOI 10.1023/A:1015831517800; BARNWELL SG, 1992, INT J PHARMACEUT, V88, P423, DOI 10.1016/0378-5173(92)90342-Y; BARNWELL SG, 1993, INT S RECENT ADV DRU; CHARMAN WNA, 1986, INT J PHARM, V34, P175, DOI 10.1016/0378-5173(86)90027-X; Muranishi S., 1991, ADV DRUG RES, P1; WHITE DG, 1991, INT J PHARM, V69, P169, DOI 10.1016/0378-5173(91)90221-9	6	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 22	1993	341	8856					1314	1315		10.1016/0140-6736(93)90821-W	http://dx.doi.org/10.1016/0140-6736(93)90821-W			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD253	8098454				2022-12-28	WOS:A1993LD25300009
J	CARSON, DA; RIBEIRO, JM				CARSON, DA; RIBEIRO, JM			APOPTOSIS AND DISEASE	LANCET			English	Review							CELL-DEATH; ENDONUCLEASE; PROGRESSION; EXPRESSION	The intercellular connections that characterise advanced forms of life would not be possible without a mechanism to remove individual cells that are no longer needed, or that function abnormally. Such physiological cell death, in the absence of inflammation, is achieved by apoptosis, a structurally distinct programmed cell death pathway. Defective regulation of programmed cell death may play a part in the aetiology of cancer, AIDS, autoimmune diseases, and degenerative diseases of the central nervous system. The pharmacological manipulation of apoptosis offers new possibilities for the prevention and treatment of these illnesses.			CARSON, DA (corresponding author), UNIV CALIF SAN DIEGO,SAM & ROSE STEIN INST RES AGING,LA JOLLA,CA 92093, USA.		Ribeiro, João Meireles/K-6555-2014	Ribeiro, João Meireles/0000-0002-6548-1402	NIGMS NIH HHS [GM232000] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARENDS MJ, 1990, AM J PATHOL, V136, P593; BANDA NK, 1992, J EXP MED, V38, P252; BEUTLER E, 1992, LANCET, V340, P952, DOI 10.1016/0140-6736(92)92826-2; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BRACH MA, 1992, BLOOD, V80, P2920; CARRERA CJ, 1991, ADV EXP MED BIOL, V309, P15; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; COHEN PL, 1992, IMMUNOL TODAY, V13, P427, DOI 10.1016/0167-5699(92)90066-G; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FINKE J, 1992, BLOOD, V80, P459; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; GOLSTEIN P, 1991, IMMUNOL REV, V121, P29, DOI 10.1111/j.1600-065X.1991.tb00822.x; GRANINGER WB, 1992, WIEN KLIN WOCHENSCHR, V104, P205; GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331; HICKMAN JA, 1992, CANCER METAST REV, V11, P121, DOI 10.1007/BF00048059; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KNIGHT CRL, 1991, BIOCHIM BIOPHYS ACTA, V1096, P312, DOI 10.1016/0925-4439(91)90067-J; KORSMEYER SJ, 1992, CANCER SURV, V15, P105; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MARTIN DP, 1992, J NEUROBIOL, V23, P1205, DOI 10.1002/neu.480230911; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; OREN M, 1992, CANCER METAST REV, V11, P141, DOI 10.1007/BF00048060; ORRENIUS S, 1989, TRENDS PHARMACOL SCI, V10, P281, DOI 10.1016/0165-6147(89)90029-1; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; ROSENBERG MB, 1988, SCIENCE, V242, P1575, DOI 10.1126/science.3201248; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; TERAI C, 1991, J CLIN INVEST, V87, P1710, DOI 10.1172/JCI115188; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	31	665	717	0	19	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 15	1993	341	8855					1251	1254		10.1016/0140-6736(93)91154-E	http://dx.doi.org/10.1016/0140-6736(93)91154-E			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LC497	8098400				2022-12-28	WOS:A1993LC49700012
